<units>
<unit type="BATCH">
<unit-content>
<bibrecord>
<item-info>
<status state="new" stage="S300" />
<itemidlist>
<ce:doi>10.1007/978-3-031-09518-4</ce:doi>
<itemid idtype="TPB-ID">20232000349315</itemid>
</itemidlist>
</item-info>
<head>
<citation-info>
<citation-type code="bk" />
<citation-language xml:lang="ENG" />
<abstract-language xml:lang="ENG" />
<author-keywords>
<author-keyword>systemic cancer effects</author-keyword>
<author-keyword>cachexia</author-keyword>
<author-keyword>cancer metabolism</author-keyword>
<author-keyword>Muscle wasting</author-keyword>
<author-keyword>tumour microenvironment</author-keyword>
<author-keyword>cancer metastasis</author-keyword>
<author-keyword>signaling in cachexia</author-keyword>
<author-keyword>chemotherapy</author-keyword>
<author-keyword>cancer-induced muscle wasting</author-keyword>
<author-keyword>skeletal muscle</author-keyword>
<author-keyword>cachexia treatment</author-keyword>
<author-keyword>cytokines</author-keyword>
<author-keyword>interleukin-6 IL-6</author-keyword>
<author-keyword>cachexia prevention</author-keyword>
<author-keyword>bone metastasis</author-keyword>
</author-keywords>
</citation-info>
<citation-title>
<titletext xml:lang="ENG" original="y">The Systemic Effects of Advanced Cancer A Textbook on Cancer-Associated Cachexia</titletext></citation-title>
<author-group seq="1">
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:degrees>Asst.Prof.</ce:degrees>
<ce:surname>Acharyya</ce:surname>
<ce:given-name>Swarnali</ce:given-name> 
</author>
<affiliation>
<organization>Columbia University Irving Medical Center</organization>
<state>New York</state>
<country iso-code="USA" />
<ce:source-text>Swarnali Acharyya is a cancer biologist who performed her postdoctoral training at the Memorial Sloan Kettering Cancer Center and joined Columbia University as an Assistant Professor in 2014. Her laboratory investigates how metastatic tumors induce systemic changes in distant organs, such as skeletal muscle, and how these changes cause a debilitating syndrome in advanced cancer patients known as cachexia. This textbook aims to provide readers with an understanding of the systemic regulation and crosstalk between tumors and distant organs and its impact on the prognosis and treatment of advanced cancer patients</ce:source-text>
</affiliation>
</author-group>
<abstracts>
<abstract xml:lang="ENG" original="y">
<publishercopyright>©Springer Nature Switzerland AG 2022</publishercopyright>
<ce:para>This textbook discusses the systemic consequences of cancer, covering a range of topics from tumor-promoting systemic effects to the development of cachexia, as summarized in the introductory chapter 1. Part I of this textbook focuses on tumor-promoting systemic effects and begins with a chapter on how tumor-derived extracellular vesicles and particles lay the foundation for future metastases (Chapter 2). Chapter 3 discusses how metastatic cells that have colonized the bone impact the local bone microenvironment, neighboring muscles, and host physiology. Chapter 4 summarizes the available strategies for targeting metastatic cancer and emphasizes the need to incorporate a systemic view of the disease. Following this overview of the systemic effects of cancer progression, Part II of the textbook discusses cancer-induced cachexia, a debilitating systemic effect of advanced cancer. Chapters 5-7 examine the key signaling pathways (interleukin-6/GP130, NF-kB, and muscle proteolysis) that drive the development of cancer cachexia. Chapters 8 and 9 in Part III of this textbook explore how toxicities from anti-cancer therapy are associated with the onset of cachexia in cancer patients, and provide insight into potential approaches to simultaneously target both cancer and cachexia. Chapters 10 and 11 (Part IV) conclude this textbook by outlining promising approaches for the diagnosis and treatment of cachexia as well as strategies to prevent the development of cachexia through exercise. An understanding of the systemic effects of cancer is essential for the design of effective anti-cancer and anti-cachexia treatment strategies. As such, this textbook provides key information for both students and scientists engaged in cancer research and oncology.</ce:para>
</abstract>
</abstracts>
<source type="book" country="USA">
<sourcetitle>The Systemic Effects of Advanced Cancer A Textbook on Cancer-Associated Cachexia</sourcetitle>
<sourcetitle-abbrev>The Systemic Effects of Advanced Cancer A Textbook on Cancer-Associated Cachexia</sourcetitle-abbrev>
<isbn type="print" length="13">9783031072727</isbn>
<isbn type="electronic" length="13">9783031095184</isbn>
<volisspag>
<page-information>
<pages>
<first-page>1</first-page>
<last-page>203</last-page>
</pages>
</page-information>
</volisspag>
<publicationyear first="2022" />
<publicationdate>
<year>2022</year>
<month>01</month>
<day>01</day>
</publicationdate>
<website type="item">
<ce:e-address type="url">https://link.springer.com</ce:e-address>
</website>
<publisher>
<publishername>Springer International Publishing</publishername>
</publisher>
</source>
<enhancement>
<classificationgroup>
<classifications type="ASJC">
<classification>
<classification-code>2700</classification-code>
<classification-code>2400</classification-code>
<classification-code>1300</classification-code>
</classification>
</classifications>
</classificationgroup>
</enhancement>
</head>
</bibrecord>
<bibrecord>
<item-info>
<status state="new" stage="S300" />
<itemidlist>
<ce:doi>10.1007/978-3-031-09518-4_1</ce:doi>
<itemid idtype="TPB-ID">20232000349315</itemid>
</itemidlist>
</item-info>
<head>
<citation-info>
<citation-type code="ch" />
<citation-language xml:lang="ENG" />
<abstract-language xml:lang="ENG" />
</citation-info>
<citation-title>
<titletext xml:lang="ENG" original="y">A Systemic View of Metastatic Disease: Inter-Organ Crosstalk and Therapeutic Implications</titletext>
</citation-title>
<author-group seq="1">
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Acharyya</ce:surname>
<ce:given-name>Swarnali</ce:given-name>
<ce:e-address>sa3141@cumc.columbia.edu</ce:e-address>
</author>
<affiliation>
<organization>Institute for Cancer Genetics</organization>
<organization>Department of Pathology and Cell Biology</organization>
<organization>Columbia University</organization>
<organization>Herbert Irving Comprehensive Cancer Center</organization>
<city>New York</city>
<country iso-code="USA" />
<ce:source-text>Institute for Cancer Genetics and Department of Pathology and Cell Biology, Columbia University, New York, NY, USA. Herbert Irving Comprehensive Cancer Center, New York, NY, USA</ce:source-text>
</affiliation>
</author-group>
<correspondence>
<person>
<ce:initials>S.</ce:initials>
<ce:surname>Acharyya</ce:surname>
<ce:given-name>Swarnali</ce:given-name>
<ce:e-address>sa3141@cumc.columbia.edu</ce:e-address>
</person>
<affiliation>
<organization>Institute for Cancer Genetics</organization>
<organization>Department of Pathology and Cell Biology</organization>
<organization>Columbia University</organization>
<organization>Herbert Irving Comprehensive Cancer Center</organization>
<city>New York</city>
<country iso-code="USA" />
<ce:source-text>Institute for Cancer Genetics and Department of Pathology and Cell Biology, Columbia University, New York, NY, USA. Herbert Irving Comprehensive Cancer Center, New York, NY, USA</ce:source-text>
</affiliation>
</correspondence>
<abstracts>
<abstract xml:lang="ENG" original="y">
<publishercopyright>© Springer Nature Switzerland AG 2022</publishercopyright>
<ce:para>As cancer progresses, the communication and crosstalk between cancer cells and the tumor microenvironment become a key determinant of successful cancer cell growth and survival. These interactions arise through either local contact-mediated signaling or the systemic release of soluble factors, extracellular vesicles and particles (EVP) by tumor cells. Systemic effects that are initiated early during cancer progression, when cancer cell growth is still confined to the primary tumor, establish the pre-metastatic niche (PMN). PMN formation lays the groundwork for cancer-cell colonization of distant organs by altering the extracellular matrix, immune-cell composition, and vascular permeability of distant organs. Tumors also independently reprogram host physiology and metabolism, which often results in a debilitating skeletal-muscle-wasting syndrome known as cachexia. Indeed, over 80% of advanced cancer patients develop cachexia and consequently suffer from reduced tolerance to anti-neoplastic therapies and premature death. This introductory chapter summarizes the various systemic effects of cancer that are detrimental to the host. The design of treatments that can prevent and/or reverse these systemic changes is ultimately expected to improve the quality of life and survival of cancer patients.</ce:para>
</abstract>
</abstracts>
<source type="book" country="USA">
<sourcetitle>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle>
<sourcetitle-abbrev>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle-abbrev>
<isbn type="print" length="13">9783031072727</isbn>
<isbn type="electronic" length="13">9783031095184</isbn>
<volisspag>
<page-information>
<pages>
<first-page>1</first-page>
<last-page>6</last-page>
</pages>
</page-information>
</volisspag>
<publicationyear first="2022" />
<publicationdate>
<year>2022</year>
<month>09</month>
<day>21</day>
</publicationdate>
<website type="item">
<ce:e-address type="url">https://link.springer.com/</ce:e-address>
</website>
<publisher>
<publishername>Springer International Publishing</publishername>
</publisher>
</source>
<enhancement>
<classificationgroup>
<classifications type="ASJC">
<classification>
<classification-code>2700</classification-code>
<classification-code>2400</classification-code>
<classification-code>1300</classification-code>
</classification>
</classifications>
</classificationgroup>
</enhancement>
</head>
<tail>
<bibliography refcount="9">
<reference seq="1">
<ref-info>
<ref-title>
<ref-titletext-english>Emerging biological principles of metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.W.</ce:initials>
<ce:surname>Lambert</ce:surname>
<ce:given-name>A.W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.R.</ce:initials>
<ce:surname>Pattabiraman</ce:surname>
<ce:given-name>D.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.A.</ce:initials>
<ce:surname>Weinberg</ce:surname>
<ce:given-name>R.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>168</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>670</first-page>
<last-page>691</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.cell.2016.11.037</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Lambert, A.W., Pattabiraman, D.R., Weinberg, R.A.:Emerging biological principles of metastasis. Cell.  168(4), 670–691 (2017). https://doi.org/10.1016/j.cell.2016.11.037</ref-fulltext>
<ce:source-text>Lambert, A.W., Pattabiraman, D.R., Weinberg, R.A.:Emerging biological principles of metastasis. Cell.  168(4), 670–691 (2017). https://doi.org/10.1016/j.cell.2016.11.037</ce:source-text>
</reference>
<reference seq="2">
<ref-info>
<ref-title>
<ref-titletext-english>Surviving at a distance:
organ-specific metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.C.</ce:initials>
<ce:surname>Obenauf</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> Trends Cancer</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>76</first-page>
<last-page>91</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.trecan.2015.07.009</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Obenauf, A.C., Massague, J.: Surviving at a distance: organ-specific metastasis. Trends Cancer. 1(1), 76–91 (2015). https://doi.org/10.1016/j.trecan.2015.07.009</ref-fulltext>
<ce:source-text>Obenauf, A.C., Massague, J.: Surviving at a distance: organ-specific metastasis. Trends Cancer. 1(1), 76–91 (2015). https://doi.org/10.1016/j.trecan.2015.07.009</ce:source-text>
</reference>
<reference seq="3">
<ref-info>
<ref-title>
<ref-titletext-english>Accessories to the crime: functions of cells recruited to the tumor microenvironment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Hanahan</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.M</ce:initials>
<ce:surname>Coussens</ce:surname>
<ce:given-name>L.M</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>309</first-page>
<last-page>322</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.ccr.2012.02.022</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Hanahan, D., Coussens, L.M.: Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 21(3), 309–322 (2012). https://doi.org/10.1016/j.ccr.2012.02.022</ref-fulltext>
<ce:source-text>Hanahan, D., Coussens, L.M.: Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 21(3), 309–322 (2012). https://doi.org/10.1016/j.ccr.2012.02.022</ce:source-text>
</reference>
<reference seq="4">
<ref-info>
<ref-title>
<ref-titletext-english> Extracellular vesicle- and particle-mediated communication shapes innate and adaptive immune responses</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.A.</ce:initials>
<ce:surname>Pelissier Vatter</ce:surname>
<ce:given-name>F.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Cioff</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.J.</ce:initials>
<ce:surname>Hanna</ce:surname>
<ce:given-name>S.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Exp. Med.</ref-sourcetitle>
<ref-publicationyear first="2021" />
<volisspag>
<volume-issue-number>
<vol-first>218</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1084/jem.20202579</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Pelissier Vatter, F.A., Cioffi, M., Hanna, S.J., Castarede, I., Caielli, S., Pascual, V., et al.: Extracellular vesicle- and particle-mediated communication shapes innate and adaptive immune responses. J. Exp. Med. 218(8) (2021). https://doi.org/10.1084/jem.20202579</ref-fulltext>
<ce:source-text>Pelissier Vatter, F.A., Cioffi, M., Hanna, S.J., Castarede, I., Caielli, S., Pascual, V., et al.: Extracellular vesicle- and particle-mediated communication shapes innate and adaptive immune responses. J. Exp. Med. 218(8) (2021). https://doi.org/10.1084/jem.20202579</ce:source-text>
</reference>
<reference seq="5">
<ref-info>
<ref-title>
<ref-titletext-english>Pre-metastatic niches: organ-specific homes for metastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Peinado</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>I.R.</ce:initials>
<ce:surname>Matei</ce:surname>
<ce:given-name>I.R.</ce:given-name>
</author>
<author seq="4">
<ce:initials>B.</ce:initials>
<ce:surname>Costa-Silva</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Hoshino</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>G.</ce:initials>
<ce:surname>Rodrigues</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>302</first-page>
<last-page>317</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/nrc.2017.6</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Peinado, H., Zhang, H., Matei, I.R., Costa-Silva, B., Hoshino, A., Rodrigues, G., et al.: Pre-metastatic niches: organ-specific homes for metastases. Nat. Rev. Cancer. 17(5), 302–317 (2017). https://doi.org/10.1038/nrc.2017.6</ref-fulltext>
<ce:source-text>Peinado, H., Zhang, H., Matei, I.R., Costa-Silva, B., Hoshino, A., Rodrigues, G., et al.: Pre-metastatic niches: organ-specific homes for metastases. Nat. Rev. Cancer. 17(5), 302–317 (2017). https://doi.org/10.1038/nrc.2017.6</ce:source-text>
</reference>
<reference seq="6">
<ref-info>
<ref-title>
<ref-titletext-english> Priming the ‘soil’ for breast cancer metastasis: the pre-metastatic niche</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Psaila</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.N.</ce:initials>
<ce:surname>Kaplan</ce:surname>
<ce:given-name>R.N.</ce:given-name>
</author>
<author seq="3">
<ce:initials>E.R.</ce:initials>
<ce:surname>Port</ce:surname>
<ce:given-name>E.R.</ce:given-name>
</author>
<author seq="4">
<ce:initials>D.</ce:initials>
<ce:surname>Lyden</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Breast Dis.</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>65</first-page>
<last-page>74</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.3233/bd-2007-26106</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Psaila, B., Kaplan, R.N., Port, E.R., Lyden, D.: Priming the ‘soil’ for breast cancer metastasis: the pre-metastatic niche. Breast Dis. 26, 65–74 (2006). https://doi.org/10.3233/bd-2007-26106</ref-fulltext>
<ce:source-text>Psaila, B., Kaplan, R.N., Port, E.R., Lyden, D.: Priming the ‘soil’ for breast cancer metastasis: the pre-metastatic niche. Breast Dis. 26, 65–74 (2006). https://doi.org/10.3233/bd-2007-26106</ce:source-text>
</reference>
<reference seq="7">
<ref-info>
<ref-title>
<ref-titletext-english>The metastatic niche: adapting the foreign soil</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Psaila</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Lyden</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>285</first-page>
<last-page>293</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/nrc2621</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Psaila, B., Lyden, D.: The metastatic niche: adapting the foreign soil. Nat. Rev. Cancer. 9(4), 285–293 (2009). https://doi.org/10.1038/nrc2621</ref-fulltext>
<ce:source-text>Psaila, B., Lyden, D.: The metastatic niche: adapting the foreign soil. Nat. Rev. Cancer. 9(4), 285–293 (2009). https://doi.org/10.1038/nrc2621</ce:source-text>
</reference>
<reference seq="8">
<ref-info>
<ref-title>
<ref-titletext-english> Precision oncology framework for investigation of exercise as treatment for cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.W.</ce:initials>
<ce:surname>Jones</ce:surname>
<ce:given-name>L.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol.</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
<iss-first>35</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4134</first-page>
<last-page>4137</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1200/JCO.2015.62.7687</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Jones, L.W.: Precision oncology framework for investigation of exercise as treatment for cancer. J. Clin. Oncol. 33(35), 4134–4137 (2015). https://doi.org/10.1200/JCO.2015.62.7687</ref-fulltext>
<ce:source-text>Jones, L.W.: Precision oncology framework for investigation of exercise as treatment for cancer. J. Clin. Oncol. 33(35), 4134–4137 (2015). https://doi.org/10.1200/JCO.2015.62.7687</ce:source-text>
</reference>
<reference seq="9">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia: rationale for the MENAC (Multimodal-Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.S.</ce:initials>
<ce:surname>Solheim</ce:surname>
<ce:given-name>T.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.J.A.</ce:initials>
<ce:surname>Laird</ce:surname>
<ce:given-name>B.J.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.R.</ce:initials>
<ce:surname>Balstad</ce:surname>
<ce:given-name>T.R.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Bye</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="5">
<ce:initials>G.</ce:initials>
<ce:surname>Stene</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="6">
<ce:initials>V.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>BMJ
Support. Palliat. Care.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>258</first-page>
<last-page>265</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1136/bmjspcare-2017-001440</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Solheim, T.S., Laird, B.J.A., Balstad, T.R., Bye, A., Stene, G., Baracos, V., et al.: Cancer cachexia: rationale for the MENAC (Multimodal-Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial. BMJ Support. Palliat. Care. 8(3), 258–265 (2018). https://doi.org/10.1136/bmjspcare-2017-001440</ref-fulltext>
<ce:source-text>Solheim, T.S., Laird, B.J.A., Balstad, T.R., Bye, A., Stene, G., Baracos, V., et al.: Cancer cachexia: rationale for the MENAC (Multimodal-Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial. BMJ Support. Palliat. Care. 8(3), 258–265 (2018). https://doi.org/10.1136/bmjspcare-2017-001440</ce:source-text>
</reference>
</bibliography>
</tail>
</bibrecord>
<bibrecord>
<item-info>
<status state="new" stage="S300" />
<itemidlist>
<ce:doi>10.1007/978-3-031-09518-4_2</ce:doi>
<itemid idtype="TPB-ID">20232000349315</itemid>
</itemidlist>
</item-info>
<head>
<citation-info>
<citation-type code="ch" />
<citation-language xml:lang="ENG" />
<abstract-language xml:lang="ENG" />
</citation-info>
<citation-title>
<titletext xml:lang="ENG" original="y">Systemic Regulation of Metastatic Disease by Extracellular Vesicles and Particles</titletext>
</citation-title>
<author-group seq="1">
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>Gang</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.M.</ce:initials>
<ce:surname>Kenific</ce:surname>
<ce:given-name>Candia M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>G.</ce:initials>
<ce:surname>Lieberman</ce:surname>
<ce:given-name>Grace</ce:given-name>
</author>
<author seq="4">
<ce:initials>H.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>Haiying</ce:given-name>
<ce:e-address>haz2005@med.cornell.edu</ce:e-address>
</author>
<author seq="5">
<ce:initials>D.</ce:initials>
<ce:surname>Lyden</ce:surname>
<ce:given-name>David</ce:given-name>
<ce:e-address>dcl2001@med.cornell.edu</ce:e-address>
</author>
<affiliation>
<organization>Children’s Cancer and Blood Foundation Laboratories</organization>
<organization>Departments of Pediatrics, and Cell and Developmental Biology</organization>
<organization>Drukier Institute for Children’s Health</organization>
<city>New York</city>
<country iso-code="USA" />
<ce:source-text>Children’s Cancer and Blood Foundation Laboratories, Departments of Pediatrics, and Cell and Developmental Biology, Drukier Institute for Children’s Health, Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA</ce:source-text>
</affiliation>
</author-group>
<correspondence>
<person>
<ce:initials>D.</ce:initials>
<ce:surname>Lyden</ce:surname>
<ce:given-name>David</ce:given-name>
<ce:e-address>dcl2001@med.cornell.edu</ce:e-address>
</person>
<affiliation>
<organization>Children’s Cancer and Blood Foundation Laboratories</organization>
<organization>Departments of Pediatrics, and Cell and Developmental Biology</organization>
<organization>Drukier Institute for Children’s Health</organization>
<city>New York</city>
<country iso-code="USA" />
<ce:source-text>Children’s Cancer and Blood Foundation Laboratories, Departments of Pediatrics, and Cell and Developmental Biology, Drukier Institute for Children’s Health, Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA</ce:source-text>
</affiliation>
</correspondence>
<abstracts>
<abstract xml:lang="ENG" original="y">
<publishercopyright>© Springer Nature Switzerland AG 2022</publishercopyright>
<ce:para>Cancer is a systemic disease that induces functional dysregulation in multiple tissues and organs. The great majority of cancer-related deaths are due to metastasis, a multistep process involving crosstalk between cancer cells and stromal cells and immune cells in pre-metastatic niches (PMNs) at distant organs. As message carriers, extracellular vesicles and particles (EVPs) derived from cancer cells can modulate the phenotype of recipient cells by transferring various biomolecules, including nucleic acids, proteins, metabolites and lipids, thereby contributing to PMN formation and metastasis. In this chapter, we highlight the roles of cancer cell-derived EVPs in metastasis progression, with a focus on PMN establishment.</ce:para>
</abstract>
</abstracts>
<source type="book" country="USA">
<sourcetitle>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle>
<sourcetitle-abbrev>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle-abbrev>
<isbn type="print" length="13">9783031072727</isbn>
<isbn type="electronic" length="13">9783031095184</isbn>
<volisspag>
<page-information>
<pages>
<first-page>9</first-page>
<last-page>39</last-page>
</pages>
</page-information>
</volisspag>
<publicationyear first="2022" />
<publicationdate>
<year>2022</year>
<month>09</month>
<day>21</day>
</publicationdate>
<website type="item">
<ce:e-address type="url">https://link.springer.com/</ce:e-address>
</website>
<publisher>
<publishername>Springer International Publishing</publishername>
</publisher>
</source>
<enhancement>
<classificationgroup>
<classifications type="ASJC">
<classification>
<classification-code>2700</classification-code>
<classification-code>2400</classification-code>
<classification-code>1300</classification-code>
</classification>
</classifications>
</classificationgroup>
</enhancement>
</head>
<tail>
<bibliography refcount="230">
<reference seq="1">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer: an old disease, a new disease or something in between? </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.R.</ce:initials>
<ce:surname>David</ce:surname>
<ce:given-name>A.R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.R.</ce:initials>
<ce:surname>Zimmerman</ce:surname>
<ce:given-name>M.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>728</first-page>
<last-page>733</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>David, A.R., Zimmerman, M.R.: Cancer: an old disease, a new disease or something in between? Nat. Rev. Cancer. 10, 728–733 (2010)</ref-fulltext>
<ce:source-text>David, A.R., Zimmerman, M.R.: Cancer: an old disease, a new disease or something in between? Nat. Rev. Cancer. 10, 728–733 (2010)</ce:source-text>
</reference>
<reference seq="2">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer statistics, 2020</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.L.</ce:initials>
<ce:surname>Siegel</ce:surname>
<ce:given-name>R.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.D.</ce:initials>
<ce:surname>Miller</ce:surname>
<ce:given-name>K.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Jemal</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>CA Cancer J. Clin.</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>70</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7</first-page>
<last-page>30</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Siegel, R.L., Miller, K.D., Jemal, A.: Cancer statistics, 2020. CA Cancer J. Clin. 70, 7–30 (2020)</ref-fulltext>
<ce:source-text>Siegel, R.L., Miller, K.D., Jemal, A.: Cancer statistics, 2020. CA Cancer J. Clin. 70, 7–30 (2020)</ce:source-text>
</reference>
<reference seq="3">
<ref-info>
<ref-title>
<ref-titletext-english>Emerging biological principles of metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.W.</ce:initials>
<ce:surname>Lambert</ce:surname>
<ce:given-name>A.W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.R.</ce:initials>
<ce:surname>Pattabiraman</ce:surname>
<ce:given-name>D.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.A.</ce:initials>
<ce:surname>Weinberg</ce:surname>
<ce:given-name>R.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>168</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>670</first-page>
<last-page>691</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lambert, A.W., Pattabiraman, D.R., Weinberg, R.A.: Emerging biological principles of metastasis. Cell. 168, 670–691 (2017)</ref-fulltext>
<ce:source-text>Lambert, A.W., Pattabiraman, D.R., Weinberg, R.A.: Emerging biological principles of metastasis. Cell. 168, 670–691 (2017)</ce:source-text>
</reference>
<reference seq="4">
<ref-info>
<ref-title>
<ref-titletext-english> Surviving at a distance: organ-specific metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.C.</ce:initials>
<ce:surname>Obenauf</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Massague</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Trends Cancer</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>76</first-page>
<last-page>91</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Obenauf, A.C., Massague, J.: Surviving at a distance: organ-specific metastasis. Trends Cancer. 1, 76–91 (2015)</ref-fulltext>
<ce:source-text>Obenauf, A.C., Massague, J.: Surviving at a distance: organ-specific metastasis. Trends Cancer. 1, 76–91 (2015)</ce:source-text>
</reference>
<reference seq="5">
<ref-info>
<ref-title>
<ref-titletext-english>Metastatic colonization by circulating tumour cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Massague</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.C.</ce:initials>
<ce:surname>Obenauf</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>529</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>298</first-page>
<last-page>306</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Massague, J., Obenauf, A.C.: Metastatic colonization by circulating tumour cells. Nature. 529, 298–306 (2016)</ref-fulltext>
<ce:source-text>Massague, J., Obenauf, A.C.: Metastatic colonization by circulating tumour cells. Nature. 529, 298–306 (2016)</ce:source-text>
</reference>
<reference seq="6">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor metastasis: molecular insights and evolving paradigms</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Valastyan</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.A.</ce:initials>
<ce:surname>Weinberg</ce:surname>
<ce:given-name>R.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>147</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>275</first-page>
<last-page>292</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Valastyan, S., Weinberg, R.A.: Tumor metastasis: molecular insights and evolving paradigms. Cell. 147, 275–292 (2011)</ref-fulltext>
<ce:source-text>Valastyan, S., Weinberg, R.A.: Tumor metastasis: molecular insights and evolving paradigms. Cell. 147, 275–292 (2011)</ce:source-text>
</reference>
<reference seq="7">
<ref-info>
<ref-title>
<ref-titletext-english>Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Peinado</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Med.</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>883</first-page>
<last-page>891</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Peinado, H., et al.: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 18, 883–891 (2012)</ref-fulltext>
<ce:source-text>Peinado, H., et al.: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 18, 883–891 (2012)</ce:source-text>
</reference>
<reference seq="8">
<ref-info>
<ref-title>
<ref-titletext-english>Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Costa-Silva</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Cell Biol.</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>816</first-page>
<last-page>826</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Costa-Silva, B., et al.: Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat. Cell Biol. 17, 816–826 (2015)</ref-fulltext>
<ce:source-text>Costa-Silva, B., et al.: Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat. Cell Biol. 17, 816–826 (2015)</ce:source-text>
</reference>
<reference seq="9">
<ref-info>
<ref-title>
<ref-titletext-english>Tumour exosome integrins determine organotropic metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Hoshino</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>527</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>329</first-page>
<last-page>335</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hoshino, A., et al.: Tumour exosome integrins determine organotropic metastasis. Nature. 527, 329–335 (2015)</ref-fulltext>
<ce:source-text>Hoshino, A., et al.: Tumour exosome integrins determine organotropic metastasis. Nature. 527, 329–335 (2015)</ce:source-text>
</reference>
<reference seq="10">
<ref-info>
<ref-title>
<ref-titletext-english>Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Rodrigues</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Cell Biol.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1403</first-page>
<last-page>1412</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rodrigues, G., et al.: Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. Nat. Cell Biol. 21, 1403–1412 (2019)</ref-fulltext>
<ce:source-text>Rodrigues, G., et al.: Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. Nat. Cell Biol. 21, 1403–1412 (2019)</ce:source-text>
</reference>
<reference seq="11">
<ref-info>
<ref-title>
<ref-titletext-english>The distribution of secondary growths in cancer of the breast</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Paget</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> Lancet.</ref-sourcetitle>
<ref-publicationyear first="1889" />
<volisspag>
<volume-issue-number>
<vol-first>133</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>571</first-page>
<last-page>573</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Paget, S.: The distribution of secondary growths in cancer of the breast. Lancet. 133, 571–573 (1889)</ref-fulltext>
<ce:source-text>Paget, S.: The distribution of secondary growths in cancer of the breast. Lancet. 133, 571–573 (1889)</ce:source-text>
</reference>
<reference seq="12">
<ref-info>
<ref-title>
<ref-titletext-english>Pre-metastatic niches: organspecific homes for metastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Peinado</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>302</first-page>
<last-page>317</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Peinado, H., et al.: Pre-metastatic niches: organspecific homes for metastases. Nat. Rev. Cancer. 17, 302–317 (2017)</ref-fulltext>
<ce:source-text>Peinado, H., et al.: Pre-metastatic niches: organspecific homes for metastases. Nat. Rev. Cancer. 17, 302–317 (2017)</ce:source-text>
</reference>
<reference seq="13">
<ref-info>
<ref-title>
<ref-titletext-english>VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.N.</ce:initials>
<ce:surname>Kaplan</ce:surname>
<ce:given-name>R.N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>438</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>820</first-page>
<last-page>827</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kaplan, R.N., et al.: VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 438, 820–827 (2005)</ref-fulltext>
<ce:source-text>Kaplan, R.N., et al.: VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 438, 820–827 (2005)</ce:source-text>
</reference>
<reference seq="14">
<ref-info>
<ref-title>
<ref-titletext-english>Exosome-mediated metastasis: communication from a distance</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Wortzel</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Dror</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.M.</ce:initials>
<ce:surname>Kenific</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>D.</ce:initials>
<ce:surname>Lyden</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Dev. Cell.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>49</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>347</first-page>
<last-page>360</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wortzel, I., Dror, S., Kenific, C.M., Lyden, D.: Exosome-mediated metastasis: communication from a distance. Dev. Cell. 49, 347–360 (2019)</ref-fulltext>
<ce:source-text>Wortzel, I., Dror, S., Kenific, C.M., Lyden, D.: Exosome-mediated metastasis: communication from a distance. Dev. Cell. 49, 347–360 (2019)</ce:source-text>
</reference>
<reference seq="15">
<ref-info>
<ref-title>
<ref-titletext-english> Breast cancer cells rely on environmental pyruvate to shape the metastatic niche</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Elia</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>568</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>117</first-page>
<last-page>121</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Elia, I., et al.: Breast cancer cells rely on environmental pyruvate to shape the metastatic niche. Nature. 568, 117–121 (2019)</ref-fulltext>
<ce:source-text>Elia, I., et al.: Breast cancer cells rely on environmental pyruvate to shape the metastatic niche. Nature. 568, 117–121 (2019)</ce:source-text>
</reference>
<reference seq="16">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor exosomal RNAs promote lung pre-metastatic niche formation by activating Alveolar epithelial TLR3 to recruit neutrophils</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>243</first-page>
<last-page>256</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Liu, Y., et al.: Tumor exosomal RNAs promote lung pre-metastatic niche formation by activating Alveolar epithelial TLR3 to recruit neutrophils. Cancer Cell. 30, 243–256 (2016)</ref-fulltext>
<ce:source-text>Liu, Y., et al.: Tumor exosomal RNAs promote lung pre-metastatic niche formation by activating Alveolar epithelial TLR3 to recruit neutrophils. Cancer Cell. 30, 243–256 (2016)</ce:source-text>
</reference>
<reference seq="17">
<ref-info>
<ref-title>
<ref-titletext-english>Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.Y.</ce:initials>
<ce:surname>Fong</ce:surname>
<ce:given-name>M.Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> Nat. Cell Biol. </ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>183</first-page>
<last-page>194</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fong, M.Y., et al.: Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat. Cell Biol. 17, 183–194 (2015)</ref-fulltext>
<ce:source-text>Fong, M.Y., et al.: Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat. Cell Biol. 17, 183–194 (2015)</ce:source-text>
</reference>
<reference seq="18">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.</ce:initials>
<ce:surname>Zhou</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>25</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>501</first-page>
<last-page>515</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhou, W., et al.: Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell. 25, 501–515 (2014)</ref-fulltext>
<ce:source-text>Zhou, W., et al.: Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell. 25, 501–515 (2014)</ce:source-text>
</reference>
<reference seq="19">
<ref-info>
<ref-title>
<ref-titletext-english>Extracellular vesicles and metastasis. Cold Spring Harb</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.E.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>S.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Perspect. Med.</ref-sourcetitle>
<ref-publicationyear first="2019" />
</ref-info>
<ref-fulltext>Wang, S.E.: Extracellular vesicles and metastasis. Cold Spring Harb. Perspect. Med. (2019)</ref-fulltext>
<ce:source-text>Wang, S.E.: Extracellular vesicles and metastasis. Cold Spring Harb. Perspect. Med. (2019)</ce:source-text>
</reference>
<reference seq="20">
<ref-info>
<ref-title>
<ref-titletext-english> Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Mathieu</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Martin-Jaular</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>G.</ce:initials>
<ce:surname>Lavieu</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Thery</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Cell Biol.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>9</first-page>
<last-page>17</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mathieu, M., Martin-Jaular, L., Lavieu, G., Thery, C.: Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat. Cell Biol. 21, 9–17 (2019)</ref-fulltext>
<ce:source-text>Mathieu, M., Martin-Jaular, L., Lavieu, G., Thery, C.: Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat. Cell Biol. 21, 9–17 (2019)</ce:source-text>
</reference>
<reference seq="21">
<ref-info>
<ref-title>
<ref-titletext-english>Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Cell Biol.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>332</first-page>
<last-page>343</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, H., et al.: Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation. Nat. Cell Biol. 20, 332–343 (2018)</ref-fulltext>
<ce:source-text>Zhang, H., et al.: Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation. Nat. Cell Biol. 20, 332–343 (2018)</ce:source-text>
</reference>
<reference seq="22">
<ref-info>
<ref-title>
<ref-titletext-english> Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Colombo</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Raposo</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Thery</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Annu. Rev. Cell Dev. Biol.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>255</first-page>
<last-page>289</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Colombo, M., Raposo, G., Thery, C.: Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu. Rev. Cell Dev. Biol. 30, 255–289 (2014)</ref-fulltext>
<ce:source-text>Colombo, M., Raposo, G., Thery, C.: Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu. Rev. Cell Dev. Biol. 30, 255–289 (2014)</ce:source-text>
</reference>
<reference seq="23">
<ref-info>
<ref-title>
<ref-titletext-english>Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Al-Nedawi</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Cell Biol.</ref-sourcetitle>
<ref-publicationyear first="2008" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>619</first-page>
<last-page>624</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Al-Nedawi, K., et al.: Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat. Cell Biol. 10, 619–624 (2008)</ref-fulltext>
<ce:source-text>Al-Nedawi, K., et al.: Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat. Cell Biol. 10, 619–624 (2008)</ce:source-text>
</reference>
<reference seq="24">
<ref-info>
<ref-title>
<ref-titletext-english>Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Di Vizio</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>69</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5601</first-page>
<last-page>5609</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Di Vizio, D., et al.: Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res. 69, 5601–5609 (2009)</ref-fulltext>
<ce:source-text>Di Vizio, D., et al.: Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res. 69, 5601–5609 (2009)</ce:source-text>
</reference>
<reference seq="25">
<ref-info>
<ref-title>
<ref-titletext-english>Transfer of functional cargo in exomeres</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Q.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>Q.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Rep.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>940</first-page>
<last-page>954</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, Q., et al.: Transfer of functional cargo in exomeres. Cell Rep. 27, 940–954 e946 (2019)</ref-fulltext>
<ce:source-text>Zhang, Q., et al.: Transfer of functional cargo in exomeres. Cell Rep. 27, 940–954 e946 (2019)</ce:source-text>
</reference>
<reference seq="26">
<ref-info>
<ref-title>
<ref-titletext-english>The Jeanne Manery-Fisher Memorial Lecture 1991. Maturation of reticulocytes: formation of exosomes as a mechanism for shedding membrane proteins</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.M.</ce:initials>
<ce:surname>Johnstone</ce:surname>
<ce:given-name>R.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochem. Cell Biol.</ref-sourcetitle>
<ref-publicationyear first="1992" />
<volisspag>
<volume-issue-number>
<vol-first>70</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>179</first-page>
<last-page>190</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Johnstone, R.M.: The Jeanne Manery-Fisher Memorial Lecture 1991. Maturation of reticulocytes: formation of exosomes as a mechanism for shedding membrane proteins. Biochem. Cell Biol. 70, 179–190 (1992)</ref-fulltext>
<ce:source-text>Johnstone, R.M.: The Jeanne Manery-Fisher Memorial Lecture 1991. Maturation of reticulocytes: formation of exosomes as a mechanism for shedding membrane proteins. Biochem. Cell Biol. 70, 179–190 (1992)</ce:source-text>
</reference>
<reference seq="27">
<ref-info>
<ref-title>
<ref-titletext-english>Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Harding</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Heuser</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Stahl</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell Biol.</ref-sourcetitle>
<ref-publicationyear first="1983" />
<volisspag>
<volume-issue-number>
<vol-first>97</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>329</first-page>
<last-page>339</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Harding, C., Heuser, J., Stahl, P.: Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J. Cell Biol. 97, 329–339 (1983)</ref-fulltext>
<ce:source-text>Harding, C., Heuser, J., Stahl, P.: Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J. Cell Biol. 97, 329–339 (1983)</ce:source-text>
</reference>
<reference seq="28">
<ref-info>
<ref-title>
<ref-titletext-english> Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.T.</ce:initials>
<ce:surname>Pan</ce:surname>
<ce:given-name>B.T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.M.</ce:initials>
<ce:surname>Johnstone</ce:surname>
<ce:given-name>R.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell.</ref-sourcetitle>
<ref-publicationyear first="1983" />
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>967</first-page>
<last-page>978</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pan, B.T., Johnstone, R.M.: Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell. 33, 967–978 (1983)</ref-fulltext>
<ce:source-text>Pan, B.T., Johnstone, R.M.: Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell. 33, 967–978 (1983)</ce:source-text>
</reference>
<reference seq="29">
<ref-info>
<ref-title>
<ref-titletext-english>High-resolution proteomic and lipidomic analysis of exosomes and microvesicles from different cell sources</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.A.</ce:initials>
<ce:surname>Haraszti</ce:surname>
<ce:given-name>R.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> J Extracell Vesicles.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>32570</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Haraszti, R.A., et al.: High-resolution proteomic and lipidomic analysis of exosomes and microvesicles from different cell sources. J Extracell Vesicles. 5, 32570 (2016)</ref-fulltext>
<ce:source-text>Haraszti, R.A., et al.: High-resolution proteomic and lipidomic analysis of exosomes and microvesicles from different cell sources. J Extracell Vesicles. 5, 32570 (2016)</ce:source-text>
</reference>
<reference seq="30">
<ref-info>
<ref-title>
<ref-titletext-english>T cell exosomes induce cholesterol accumulation in human monocytes via phosphatidylserine receptor</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Zakharova</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Svetlova</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.F.</ce:initials>
<ce:surname>Fomina</ce:surname>
<ce:given-name>A.F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Physiol.</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>212</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>174</first-page>
<last-page>181</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zakharova, L., Svetlova, M., Fomina, A.F.: T cell exosomes induce cholesterol accumulation in human monocytes via phosphatidylserine receptor. J. Cell. Physiol. 212, 174–181 (2007)</ref-fulltext>
<ce:source-text>Zakharova, L., Svetlova, M., Fomina, A.F.: T cell exosomes induce cholesterol accumulation in human monocytes via phosphatidylserine receptor. J. Cell. Physiol. 212, 174–181 (2007)</ce:source-text>
</reference>
<reference seq="31">
<ref-info>
<ref-title>
<ref-titletext-english>Adipocyte extracellular vesicles carry enzymes and fatty acids that stimulate mitochondrial metabolism and remodeling in tumor cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Clement</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>EMBO J.</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>39</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>e102525</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Clement, E., et al.: Adipocyte extracellular vesicles carry enzymes and fatty acids that stimulate mitochondrial metabolism and remodeling in tumor cells. EMBO J. 39, e102525 (2020)</ref-fulltext>
<ce:source-text>Clement, E., et al.: Adipocyte extracellular vesicles carry enzymes and fatty acids that stimulate mitochondrial metabolism and remodeling in tumor cells. EMBO J. 39, e102525 (2020)</ce:source-text>
</reference>
<reference seq="32">
<ref-info>
<ref-title>
<ref-titletext-english>The role of exosomes in cancer metastasis. Semin</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.B.</ce:initials>
<ce:surname>Steinbichler</ce:surname>
<ce:given-name>T.B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Dudas</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Riechelmann</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="4">
<ce:initials>I.I.</ce:initials>
<ce:surname>Skvortsova</ce:surname>
<ce:given-name>I.I.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Semin. Cancer Biol.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>44</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>170</first-page>
<last-page>181</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Steinbichler, T.B., Dudas, J., Riechelmann, H., Skvortsova, I.I.: The role of exosomes in cancer metastasis. Semin. Cancer Biol. 44, 170–181 (2017)</ref-fulltext>
<ce:source-text>Steinbichler, T.B., Dudas, J., Riechelmann, H., Skvortsova, I.I.: The role of exosomes in cancer metastasis. Semin. Cancer Biol. 44, 170–181 (2017)</ce:source-text>
</reference>
<reference seq="33">
<ref-info>
<ref-title>
<ref-titletext-english>Exosome-derived microRNAs in cancer metabolism: possible implications in cancer diagnostics and therapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Tomasetti</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>W.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:surname>Santarelli</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Neuzil</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Exp. Mol. Med.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>49</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>e285</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tomasetti, M., Lee, W., Santarelli, L., Neuzil, J.: Exosome-derived microRNAs in cancer metabolism: possible implications in cancer diagnostics and therapy. Exp. Mol. Med. 49, e285 (2017)</ref-fulltext>
<ce:source-text>Tomasetti, M., Lee, W., Santarelli, L., Neuzil, J.: Exosome-derived microRNAs in cancer metabolism: possible implications in cancer diagnostics and therapy. Exp. Mol. Med. 49, e285 (2017)</ce:source-text>
</reference>
<reference seq="34">
<ref-info>
<ref-title>
<ref-titletext-english>Decoding the biology of exosomes in metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Adem</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.F.</ce:initials>
<ce:surname>Vieira</ce:surname>
<ce:given-name>P.F.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.A.</ce:initials>
<ce:surname>Melo</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Trends Cancer.</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>20</first-page>
<last-page>30</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Adem, B., Vieira, P.F., Melo, S.A.: Decoding the biology of exosomes in metastasis. Trends Cancer. 6, 20–30 (2020)</ref-fulltext>
<ce:source-text>Adem, B., Vieira, P.F., Melo, S.A.: Decoding the biology of exosomes in metastasis. Trends Cancer. 6, 20–30 (2020)</ce:source-text>
</reference>
<reference seq="35">
<ref-info>
<ref-title>
<ref-titletext-english>The importance of exosomal PDL1 in tumour immune evasion</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Daassi</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.M.</ce:initials>
<ce:surname>Mahoney</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>G.J.</ce:initials>
<ce:surname>Freeman</ce:surname>
<ce:given-name>G.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Immunol.</ref-sourcetitle>
<ref-publicationyear first="2020" />
</ref-info>
<ref-fulltext>Daassi, D., Mahoney, K.M., Freeman, G.J.: The importance of exosomal PDL1 in tumour immune evasion. Nat. Rev. Immunol. (2020)</ref-fulltext>
<ce:source-text>Daassi, D., Mahoney, K.M., Freeman, G.J.: The importance of exosomal PDL1 in tumour immune evasion. Nat. Rev. Immunol. (2020)</ce:source-text>
</reference>
<reference seq="36">
<ref-info>
<ref-title>
<ref-titletext-english>Matrix metalloproteinases: regulators of the tumor microenvironment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Kessenbrock</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>V.</ce:initials>
<ce:surname>Plaks</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Z.</ce:initials>
<ce:surname>Werb</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell.</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>141</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>52</first-page>
<last-page>67</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kessenbrock, K., Plaks, V., Werb, Z.: Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 141, 52–67 (2010)</ref-fulltext>
<ce:source-text>Kessenbrock, K., Plaks, V., Werb, Z.: Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 141, 52–67 (2010)</ce:source-text>
</reference>
<reference seq="37">
<ref-info>
<ref-title>
<ref-titletext-english> Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Ginestra</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem.</ref-sourcetitle>
<ref-publicationyear first="1997" />
<volisspag>
<volume-issue-number>
<vol-first>272</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>17216</first-page>
<last-page>17222</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ginestra, A., et al.: Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. J. Biol. Chem. 272, 17216–17222 (1997)</ref-fulltext>
<ce:source-text>Ginestra, A., et al.: Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. J. Biol. Chem. 272, 17216–17222 (1997)</ce:source-text>
</reference>
<reference seq="38">
<ref-info>
<ref-title>
<ref-titletext-english> Selective localization of matrix metalloproteinase 9, beta1 integrins, and human lymphocyte antigen class I molecules on membrane vesicles shed by 8701-BC breast carcinoma cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.</ce:initials>
<ce:surname>Dolo</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="1998" />
<volisspag>
<volume-issue-number>
<vol-first>58</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4468</first-page>
<last-page>4474</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dolo, V., et al.: Selective localization of matrix metalloproteinase 9, beta1 integrins, and human lymphocyte antigen class I molecules on membrane vesicles shed by 8701-BC breast carcinoma cells. Cancer Res. 58, 4468–4474 (1998)</ref-fulltext>
<ce:source-text>Dolo, V., et al.: Selective localization of matrix metalloproteinase 9, beta1 integrins, and human lymphocyte antigen class I molecules on membrane vesicles shed by 8701-BC breast carcinoma cells. Cancer Res. 58, 4468–4474 (1998)</ce:source-text>
</reference>
<reference seq="39">
<ref-info>
<ref-title>
<ref-titletext-english>Hypoxia-induced matrix metalloproteinase-13 expression in exosomes from nasopharyngeal carcinoma enhances metastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Shan</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Death Dis.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>382</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shan, Y., et al.: Hypoxia-induced matrix metalloproteinase-13 expression in exosomes from nasopharyngeal carcinoma enhances metastases. Cell Death Dis. 9, 382 (2018)</ref-fulltext>
<ce:source-text>Shan, Y., et al.: Hypoxia-induced matrix metalloproteinase-13 expression in exosomes from nasopharyngeal carcinoma enhances metastases. Cell Death Dis. 9, 382 (2018)</ce:source-text>
</reference>
<reference seq="40">
<ref-info>
<ref-title>
<ref-titletext-english>Secretion of active membrane type 1 matrix metalloproteinase (MMP-14) into extracellular space in microvesicular exosomes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Hakulinen</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Sankkila</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Sugiyama</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="4">
<ce:initials>K.</ce:initials>
<ce:surname>Lehti</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Keski-Oja</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Biochem.</ref-sourcetitle>
<ref-publicationyear first="2008" />
<volisspag>
<volume-issue-number>
<vol-first>105</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1211</first-page>
<last-page>1218</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hakulinen, J., Sankkila, L., Sugiyama, N., Lehti, K., Keski-Oja, J.: Secretion of active membrane type 1 matrix metalloproteinase (MMP-14) into extracellular space in microvesicular exosomes. J. Cell. Biochem. 105, 1211–1218 (2008)</ref-fulltext>
<ce:source-text>Hakulinen, J., Sankkila, L., Sugiyama, N., Lehti, K., Keski-Oja, J.: Secretion of active membrane type 1 matrix metalloproteinase (MMP-14) into extracellular space in microvesicular exosomes. J. Cell. Biochem. 105, 1211–1218 (2008)</ce:source-text>
</reference>
<reference seq="41">
<ref-info>
<ref-title>
<ref-titletext-english>Host matrix modulation by tumor exosomes promotes motility and invasiveness</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.</ce:initials>
<ce:surname>Mu</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Rana</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Zoller</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Neoplasia.</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>875</first-page>
<last-page>887</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mu, W., Rana, S., Zoller, M.: Host matrix modulation by tumor exosomes promotes motility and invasiveness. Neoplasia. 15, 875–887 (2013)</ref-fulltext>
<ce:source-text>Mu, W., Rana, S., Zoller, M.: Host matrix modulation by tumor exosomes promotes motility and invasiveness. Neoplasia. 15, 875–887 (2013)</ce:source-text>
</reference>
<reference seq="42">
<ref-info>
<ref-title>
<ref-titletext-english>Extracellular vesicles secreted from cancer cell lines stimulate secretion of MMP-9, IL-6, TGF-beta1 and EMMPRIN</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S.</ce:initials>
<ce:surname>Redzic</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>PLoS One.</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>e71225</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Redzic, J.S., et al.: Extracellular vesicles secreted from cancer cell lines stimulate secretion of MMP-9, IL-6, TGF-beta1 and EMMPRIN. PLoS One. 8, e71225 (2013)</ref-fulltext>
<ce:source-text>Redzic, J.S., et al.: Extracellular vesicles secreted from cancer cell lines stimulate secretion of MMP-9, IL-6, TGF-beta1 and EMMPRIN. PLoS One. 8, e71225 (2013)</ce:source-text>
</reference>
<reference seq="43">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomes from bulk and stem cells from human prostate cancer have a differential microRNA content that contributes cooperatively over local and pre-metastatic niche</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.A.</ce:initials>
<ce:surname>Sanchez</ce:surname>
<ce:given-name>C.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3993</first-page>
<last-page>4008</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sanchez, C.A., et al.: Exosomes from bulk and stem cells from human prostate cancer have a differential microRNA content that contributes cooperatively over local and pre-metastatic niche. Oncotarget. 7, 3993–4008 (2016)</ref-fulltext>
<ce:source-text>Sanchez, C.A., et al.: Exosomes from bulk and stem cells from human prostate cancer have a differential microRNA content that contributes cooperatively over local and pre-metastatic niche. Oncotarget. 7, 3993–4008 (2016)</ce:source-text>
</reference>
<reference seq="44">
<ref-info>
<ref-title>
<ref-titletext-english>Oncogenic KIT-containing exosomes increase gastrointestinal stromal tumor cell invasion</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Atay</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>111</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>711</first-page>
<last-page>716</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Atay, S., et al.: Oncogenic KIT-containing exosomes increase gastrointestinal stromal tumor cell invasion. Proc. Natl. Acad. Sci. USA. 111, 711–716 (2014)</ref-fulltext>
<ce:source-text>Atay, S., et al.: Oncogenic KIT-containing exosomes increase gastrointestinal stromal tumor cell invasion. Proc. Natl. Acad. Sci. USA. 111, 711–716 (2014)</ce:source-text>
</reference>
<reference seq="45">
<ref-info>
<ref-title>
<ref-titletext-english>Alpha-smooth muscle actin expression upregulates fibroblast contractile activity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Hinz</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Celetta</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.J.</ce:initials>
<ce:surname>Tomasek</ce:surname>
<ce:given-name>J.J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>G.</ce:initials>
<ce:surname>Gabbiani</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="5">
<ce:initials>C.</ce:initials>
<ce:surname>Chaponnier</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Biol. Cell.</ref-sourcetitle>
<ref-publicationyear first="2001" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2730</first-page>
<last-page>2741</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hinz, B., Celetta, G., Tomasek, J.J., Gabbiani, G., Chaponnier, C.: Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. Mol. Biol. Cell. 12, 2730–2741 (2001)</ref-fulltext>
<ce:source-text>Hinz, B., Celetta, G., Tomasek, J.J., Gabbiani, G., Chaponnier, C.: Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. Mol. Biol. Cell. 12, 2730–2741 (2001)</ce:source-text>
</reference>
<reference seq="46">
<ref-info>
<ref-title>
<ref-titletext-english>The biology and function of fibroblasts in cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Kalluri</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>582</first-page>
<last-page>598</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kalluri, R.: The biology and function of fibroblasts in cancer. Nat. Rev. Cancer. 16, 582–598 (2016)</ref-fulltext>
<ce:source-text>Kalluri, R.: The biology and function of fibroblasts in cancer. Nat. Rev. Cancer. 16, 582–598 (2016)</ce:source-text>
</reference>
<reference seq="47">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer exosomes trigger fibroblast to myofibroblast differentiation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Webber</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Steadman</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.D.</ce:initials>
<ce:surname>Mason</ce:surname>
<ce:given-name>M.D.</ce:given-name>
</author>
<author seq="4">
<ce:initials>Z.</ce:initials>
<ce:surname>Tabi</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Clayton</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>70</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>9621</first-page>
<last-page>9630</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Webber, J., Steadman, R., Mason, M.D., Tabi, Z., Clayton, A.: Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res. 70, 9621–9630 (2010)</ref-fulltext>
<ce:source-text>Webber, J., Steadman, R., Mason, M.D., Tabi, Z., Clayton, A.: Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res. 70, 9621–9630 (2010)</ce:source-text>
</reference>
<reference seq="48">
<ref-info>
<ref-title>
<ref-titletext-english>Differentiation of tumourpromoting stromal myofibroblasts by cancer exosomes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.P.</ce:initials>
<ce:surname>Webber</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene.</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>34</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>290</first-page>
<last-page>302</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Webber, J.P., et al.: Differentiation of tumourpromoting stromal myofibroblasts by cancer exosomes. Oncogene. 34, 290–302 (2015)</ref-fulltext>
<ce:source-text>Webber, J.P., et al.: Differentiation of tumourpromoting stromal myofibroblasts by cancer exosomes. Oncogene. 34, 290–302 (2015)</ce:source-text>
</reference>
<reference seq="49">
<ref-info>
<ref-title>
<ref-titletext-english> Rab27a and Rab27b control different steps of the exosome secretion pathway</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Ostrowski</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Cell Biol.</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>19</first-page>
<last-page>30</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ostrowski, M., et al.: Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat. Cell Biol. 12, 19–30.; sup pp 11-13 (2010)</ref-fulltext>
<ce:source-text>Ostrowski, M., et al.: Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat. Cell Biol. 12, 19–30.; sup pp 11-13 (2010)</ce:source-text>
</reference>
<reference seq="50">
<ref-info>
<ref-title>
<ref-titletext-english>Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancerassociated fibroblasts</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Zhou</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Exp. Clin. Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>37</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>324</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhou, Y., et al.: Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancerassociated fibroblasts. J. Exp. Clin. Cancer Res. 37, 324 (2018)</ref-fulltext>
<ce:source-text>Zhou, Y., et al.: Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancerassociated fibroblasts. J. Exp. Clin. Cancer Res. 37, 324 (2018)</ce:source-text>
</reference>
<reference seq="51">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Paggetti</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Blood.</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>126</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1106</first-page>
<last-page>1117</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Paggetti, J., et al.: Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts. Blood. 126, 1106–1117 (2015)</ref-fulltext>
<ce:source-text>Paggetti, J., et al.: Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts. Blood. 126, 1106–1117 (2015)</ce:source-text>
</reference>
<reference seq="52">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer exosomes trigger mesenchymal stem cell differentiation into pro-angiogenic and pro-invasive myofibroblasts</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Chowdhury</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget.</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>715</first-page>
<last-page>731</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chowdhury, R., et al.: Cancer exosomes trigger mesenchymal stem cell differentiation into pro-angiogenic and pro-invasive myofibroblasts. Oncotarget. 6, 715–731 (2015)</ref-fulltext>
<ce:source-text>Chowdhury, R., et al.: Cancer exosomes trigger mesenchymal stem cell differentiation into pro-angiogenic and pro-invasive myofibroblasts. Oncotarget. 6, 715–731 (2015)</ce:source-text>
</reference>
<reference seq="53">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomes from ovarian cancer cells induce adipose tissue-derived mesenchymal stem cells to acquire the physical and functional characteristics of tumor-supporting myofibroblasts</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Cho</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Gynecol. Oncol.</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>123</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>379</first-page>
<last-page>386</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cho, J.A., et al.: Exosomes from ovarian cancer cells induce adipose tissue-derived mesenchymal stem cells to acquire the physical and functional characteristics of tumor-supporting myofibroblasts. Gynecol. Oncol. 123, 379–386 (2011)</ref-fulltext>
<ce:source-text>Cho, J.A., et al.: Exosomes from ovarian cancer cells induce adipose tissue-derived mesenchymal stem cells to acquire the physical and functional characteristics of tumor-supporting myofibroblasts. Gynecol. Oncol. 123, 379–386 (2011)</ce:source-text>
</reference>
<reference seq="54">
<ref-info>
<ref-title>
<ref-titletext-english>Natural innate and adaptive immunity to cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.D.</ce:initials>
<ce:surname>Vesely</ce:surname>
<ce:given-name>M.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.H.</ce:initials>
<ce:surname>Kershaw</ce:surname>
<ce:given-name>M.H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.D.</ce:initials>
<ce:surname>Schreiber</ce:surname>
<ce:given-name>R.D.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.J.</ce:initials>
<ce:surname>Smyth</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Annu. Rev. Immunol.</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>29</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>235</first-page>
<last-page>271</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vesely, M.D., Kershaw, M.H., Schreiber, R.D., Smyth, M.J.: Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29, 235–271 (2011)</ref-fulltext>
<ce:source-text>Vesely, M.D., Kershaw, M.H., Schreiber, R.D., Smyth, M.J.: Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29, 235–271 (2011)</ce:source-text>
</reference>
<reference seq="55">
<ref-info>
<ref-title>
<ref-titletext-english>Concise review: modulating cancer immunity with hematopoietic stem and progenitor cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.J.</ce:initials>
<ce:surname>Wildes</ce:surname>
<ce:given-name>T.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Stem Cells.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>37</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>166</first-page>
<last-page>175</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wildes, T.J., Flores, C.T., Mitchell, D.A.: Concise review: modulating cancer immunity with hematopoietic stem and progenitor cells. Stem Cells. 37, 166–175 (2019)</ref-fulltext>
<ce:source-text>Wildes, T.J., Flores, C.T., Mitchell, D.A.: Concise review: modulating cancer immunity with hematopoietic stem and progenitor cells. Stem Cells. 37, 166–175 (2019)</ce:source-text>
</reference>
<reference seq="56">
<ref-info>
<ref-title>
<ref-titletext-english>Roles of the immune system in cancer: from tumor initiation to metastatic progression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Gonzalez</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Hagerling</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Z.</ce:initials>
<ce:surname>Werb</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> Genes Dev.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1267</first-page>
<last-page>1284</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gonzalez, H., Hagerling, C., Werb, Z.: Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 32, 1267–1284 (2018)</ref-fulltext>
<ce:source-text>Gonzalez, H., Hagerling, C., Werb, Z.: Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 32, 1267–1284 (2018)</ce:source-text>
</reference>
<reference seq="57">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-cellintrinsic mechanisms shaping the tumor immune landscape</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.D.</ce:initials>
<ce:surname>Wellenstein</ce:surname>
<ce:given-name>M.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.E.</ce:initials>
<ce:surname>de Visser</ce:surname>
<ce:given-name>K.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Immunity.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>48</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>399</first-page>
<last-page>416</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wellenstein, M.D., de Visser, K.E.: Cancer-cellintrinsic mechanisms shaping the tumor immune landscape. Immunity. 48, 399–416 (2018)</ref-fulltext>
<ce:source-text>Wellenstein, M.D., de Visser, K.E.: Cancer-cellintrinsic mechanisms shaping the tumor immune landscape. Immunity. 48, 399–416 (2018)</ce:source-text>
</reference>
<reference seq="58">
<ref-info>
<ref-title>
<ref-titletext-english>Allele-specific HLA loss and immune escape in lung cancer evolution</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>McGranahan</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>171</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1259</first-page>
<last-page>1271</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>McGranahan, N., et al.: Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 171, 1259–1271 e1211 (2017)</ref-fulltext>
<ce:source-text>McGranahan, N., et al.: Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 171, 1259–1271 e1211 (2017)</ce:source-text>
</reference>
<reference seq="59">
<ref-info>
<ref-title>
<ref-titletext-english>TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.V.F.</ce:initials>
<ce:surname>Tauriello</ce:surname>
<ce:given-name>D.V.F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>554</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>538</first-page>
<last-page>543</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tauriello, D.V.F., et al.: TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 554, 538–543 (2018)</ref-fulltext>
<ce:source-text>Tauriello, D.V.F., et al.: TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 554, 538–543 (2018)</ce:source-text>
</reference>
<reference seq="60">
<ref-info>
<ref-title>
<ref-titletext-english>Inflammatory modulation of HSCs: viewing the HSC as a foundation for the immune response</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.Y.</ce:initials>
<ce:surname>King</ce:surname>
<ce:given-name>K.Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.A.</ce:initials>
<ce:surname>Goodell</ce:surname>
<ce:given-name>M.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Immunol. </ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>685</first-page>
<last-page>692</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>King, K.Y., Goodell, M.A.: Inflammatory modulation of HSCs: viewing the HSC as a foundation for the immune response. Nat. Rev. Immunol. 11, 685–692 (2011)</ref-fulltext>
<ce:source-text>King, K.Y., Goodell, M.A.: Inflammatory modulation of HSCs: viewing the HSC as a foundation for the immune response. Nat. Rev. Immunol. 11, 685–692 (2011)</ce:source-text>
</reference>
<reference seq="61">
<ref-info>
<ref-title>
<ref-titletext-english>An interferon-driven oxysterol-based defense against tumor-derived extracellular vesicles</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Ortiz</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>33</first-page>
<last-page>45</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ortiz, A., et al.: An interferon-driven oxysterol-based defense against tumor-derived extracellular vesicles. Cancer Cell. 35, 33–45 e36 (2019)</ref-fulltext>
<ce:source-text>Ortiz, A., et al.: An interferon-driven oxysterol-based defense against tumor-derived extracellular vesicles. Cancer Cell. 35, 33–45 e36 (2019)</ce:source-text>
</reference>
<reference seq="62">
<ref-info>
<ref-title>
<ref-titletext-english>Innate or adaptive immunity? The example of natural killer cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Vivier</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science.</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>331</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>44</first-page>
<last-page>49</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vivier, E., et al.: Innate or adaptive immunity? The example of natural killer cells. Science. 331, 44–49 (2011)</ref-fulltext>
<ce:source-text>Vivier, E., et al.: Innate or adaptive immunity? The example of natural killer cells. Science. 331, 44–49 (2011)</ce:source-text>
</reference>
<reference seq="63">
<ref-info>
<ref-title>
<ref-titletext-english>AML suppresses hematopoiesis by releasing exosomes that contain microRNAs targeting c-MYB</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.I.</ce:initials>
<ce:surname>Hornick</ce:surname>
<ce:given-name>N.I.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Signal.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Hornick, N.I., et al.: AML suppresses hematopoiesis by releasing exosomes that contain microRNAs targeting c-MYB. Sci. Signal. 9, ra88 (2016)</ref-fulltext>
<ce:source-text>Hornick, N.I., et al.: AML suppresses hematopoiesis by releasing exosomes that contain microRNAs targeting c-MYB. Sci. Signal. 9, ra88 (2016)</ce:source-text>
</reference>
<reference seq="64">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor exosomes inhibit differentiation of bone marrow dendritic cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Yu</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Immunol.</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>178</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>6867</first-page>
<last-page>6875</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yu, S., et al.: Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J. Immunol. 178, 6867–6875 (2007)</ref-fulltext>
<ce:source-text>Yu, S., et al.: Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J. Immunol. 178, 6867–6875 (2007)</ce:source-text>
</reference>
<reference seq="65">
<ref-info>
<ref-title>
<ref-titletext-english>Induction of myeloid-derived suppressor cells by tumor exosomes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Xiang</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> Int. J. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>124</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2621</first-page>
<last-page>2633</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xiang, X., et al.: Induction of myeloid-derived suppressor cells by tumor exosomes. Int. J. Cancer. 124, 2621–2633 (2009)</ref-fulltext>
<ce:source-text>Xiang, X., et al.: Induction of myeloid-derived suppressor cells by tumor exosomes. Int. J. Cancer. 124, 2621–2633 (2009)</ce:source-text>
</reference>
<reference seq="66">
<ref-info>
<ref-title>
<ref-titletext-english>Myeloid-derived suppressor cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.I.</ce:initials>
<ce:surname>Gabrilovich</ce:surname>
<ce:given-name>D.I.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Immunol. Res.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3</first-page>
<last-page>8</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gabrilovich, D.I.: Myeloid-derived suppressor cells. Cancer Immunol. Res. 5, 3–8 (2017)</ref-fulltext>
<ce:source-text>Gabrilovich, D.I.: Myeloid-derived suppressor cells. Cancer Immunol. Res. 5, 3–8 (2017)</ce:source-text>
</reference>
<reference seq="67">
<ref-info>
<ref-title>
<ref-titletext-english> Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3- dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Chalmin</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest.</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>120</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>457</first-page>
<last-page>471</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chalmin, F., et al.: Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3- dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J. Clin. Invest. 120, 457–471 (2010)</ref-fulltext>
<ce:source-text>Chalmin, F., et al.: Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3- dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J. Clin. Invest. 120, 457–471 (2010)</ce:source-text>
</reference>
<reference seq="68">
<ref-info>
<ref-title>
<ref-titletext-english>Melanoma extracellular vesicles generate immunosuppressive myeloid cells by upregulating PD-L1 via TLR4 signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.</ce:initials>
<ce:surname>Fleming</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>79</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4715</first-page>
<last-page>4728</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fleming, V., et al.: Melanoma extracellular vesicles generate immunosuppressive myeloid cells by upregulating PD-L1 via TLR4 signaling. Cancer Res. 79, 4715–4728 (2019)</ref-fulltext>
<ce:source-text>Fleming, V., et al.: Melanoma extracellular vesicles generate immunosuppressive myeloid cells by upregulating PD-L1 via TLR4 signaling. Cancer Res. 79, 4715–4728 (2019)</ce:source-text>
</reference>
<reference seq="69">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.</ce:initials>
<ce:surname>Huber</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>128</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5505</first-page>
<last-page>5516</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Huber, V., et al.: Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. J. Clin. Invest. 128, 5505–5516 (2018)</ref-fulltext>
<ce:source-text>Huber, V., et al.: Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. J. Clin. Invest. 128, 5505–5516 (2018)</ce:source-text>
</reference>
<reference seq="70">
<ref-info>
<ref-title>
<ref-titletext-english> Immunosuppressive effects of hypoxia-induced glioma exosomes through myeloid-derived suppressor cells via the miR-10a/ Rora and miR-21/Pten Pathways</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Guo</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>37</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4239</first-page>
<last-page>4259</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Guo, X., et al.: Immunosuppressive effects of hypoxia-induced glioma exosomes through myeloid-derived suppressor cells via the miR-10a/ Rora and miR-21/Pten Pathways. Oncogene. 37, 4239–4259 (2018)</ref-fulltext>
<ce:source-text>Guo, X., et al.: Immunosuppressive effects of hypoxia-induced glioma exosomes through myeloid-derived suppressor cells via the miR-10a/ Rora and miR-21/Pten Pathways. Oncogene. 37, 4239–4259 (2018)</ce:source-text>
</reference>
<reference seq="71">
<ref-info>
<ref-title>
<ref-titletext-english>Pathogen recognition and innate immunity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Akira</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Uematsu</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>O.</ce:initials>
<ce:surname>Takeuchi</ce:surname>
<ce:given-name>O.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell.</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>124</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>783</first-page>
<last-page>801</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Akira, S., Uematsu, S., Takeuchi, O.: Pathogen recognition and innate immunity. Cell. 124, 783–801 (2006)</ref-fulltext>
<ce:source-text>Akira, S., Uematsu, S., Takeuchi, O.: Pathogen recognition and innate immunity. Cell. 124, 783–801 (2006)</ce:source-text>
</reference>
<reference seq="72">
<ref-info>
<ref-title>
<ref-titletext-english>Macrophages and metabolism in the tumor microenvironment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Vitale</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Manic</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.M.</ce:initials>
<ce:surname>Coussens</ce:surname>
<ce:given-name>L.M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>G.</ce:initials>
<ce:surname>Kroemer</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="5">
<ce:initials>L.</ce:initials>
<ce:surname>Galluzzi</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>36</first-page>
<last-page>50</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vitale, I., Manic, G., Coussens, L.M., Kroemer, G., Galluzzi, L.: Macrophages and metabolism in the tumor microenvironment. Cell Metab. 30, 36–50 (2019)</ref-fulltext>
<ce:source-text>Vitale, I., Manic, G., Coussens, L.M., Kroemer, G., Galluzzi, L.: Macrophages and metabolism in the tumor microenvironment. Cell Metab. 30, 36–50 (2019)</ce:source-text>
</reference>
<reference seq="73">
<ref-info>
<ref-title>
<ref-titletext-english>MicroRNAs bind to toll-like receptors to induce prometastatic inflammatory response</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Fabbri</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA. </ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>109</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>E2110</first-page>
<last-page>E2116</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fabbri, M., et al.: MicroRNAs bind to toll-like receptors to induce prometastatic inflammatory response. Proc. Natl. Acad. Sci. USA. 109, E2110– E2116 (2012)</ref-fulltext>
<ce:source-text>Fabbri, M., et al.: MicroRNAs bind to toll-like receptors to induce prometastatic inflammatory response. Proc. Natl. Acad. Sci. USA. 109, E2110– E2116 (2012)</ce:source-text>
</reference>
<reference seq="74">
<ref-info>
<ref-title>
<ref-titletext-english>Epithelial ovarian cancer-secreted exosomal miR-222-3p induces polarization of tumor-associated macrophages</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Ying</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> Oncotarget.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>43076</first-page>
<last-page>43087</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ying, X., et al.: Epithelial ovarian cancer-secreted exosomal miR-222-3p induces polarization of tumor-associated macrophages. Oncotarget. 7, 43076–43087 (2016)</ref-fulltext>
<ce:source-text>Ying, X., et al.: Epithelial ovarian cancer-secreted exosomal miR-222-3p induces polarization of tumor-associated macrophages. Oncotarget. 7, 43076–43087 (2016)</ce:source-text>
</reference>
<reference seq="75">
<ref-info>
<ref-title>
<ref-titletext-english>Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Cooks</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>771</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cooks, T., et al.: Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246. Nat. Commun. 9, 771 (2018)</ref-fulltext>
<ce:source-text>Cooks, T., et al.: Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246. Nat. Commun. 9, 771 (2018)</ce:source-text>
</reference>
<reference seq="76">
<ref-info>
<ref-title>
<ref-titletext-english>Hypoxia-induced tumor exosomes promote M2-like macrophage polarization of infiltrating myeloid cells and microRNA-mediated metabolic shift</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.E.</ce:initials>
<ce:surname>Park</ce:surname>
<ce:given-name>J.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5158</first-page>
<last-page>5173</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Park, J.E., et al.: Hypoxia-induced tumor exosomes promote M2-like macrophage polarization of infiltrating myeloid cells and microRNA-mediated metabolic shift. Oncogene. 38, 5158–5173 (2019)</ref-fulltext>
<ce:source-text>Park, J.E., et al.: Hypoxia-induced tumor exosomes promote M2-like macrophage polarization of infiltrating myeloid cells and microRNA-mediated metabolic shift. Oncogene. 38, 5158–5173 (2019)</ce:source-text>
</reference>
<reference seq="77">
<ref-info>
<ref-title>
<ref-titletext-english> Cancer immunotherapy via dendritic cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Palucka</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Banchereau</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>265</first-page>
<last-page>277</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Palucka, K., Banchereau, J.: Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer. 12, 265–277 (2012)</ref-fulltext>
<ce:source-text>Palucka, K., Banchereau, J.: Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer. 12, 265–277 (2012)</ce:source-text>
</reference>
<reference seq="78">
<ref-info>
<ref-title>
<ref-titletext-english>EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Yu</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene.</ref-sourcetitle>
<ref-publicationyear first="2020" />
</ref-info>
<ref-fulltext>Yu, S., et al.: EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells. Oncogene. (2020)</ref-fulltext>
<ce:source-text>Yu, S., et al.: EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells. Oncogene. (2020)</ce:source-text>
</reference>
<reference seq="79">
<ref-info>
<ref-title>
<ref-titletext-english>Pancreatic cancer-derived exosomes transfer miRNAs to dendritic cells and inhibit RFXAP expression via miR-212-3p</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Ding</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget.</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>29877</first-page>
<last-page>29888</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ding, G., et al.: Pancreatic cancer-derived exosomes transfer miRNAs to dendritic cells and inhibit RFXAP expression via miR-212-3p. Oncotarget. 6, 29877–29888 (2015)</ref-fulltext>
<ce:source-text>Ding, G., et al.: Pancreatic cancer-derived exosomes transfer miRNAs to dendritic cells and inhibit RFXAP expression via miR-212-3p. Oncotarget. 6, 29877–29888 (2015)</ce:source-text>
</reference>
<reference seq="80">
<ref-info>
<ref-title>
<ref-titletext-english>Targeting natural killer cells in cancer immunotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Guillerey</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>N.D.</ce:initials>
<ce:surname>Huntington</ce:surname>
<ce:given-name>N.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.J.</ce:initials>
<ce:surname>Smyth</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Immunol.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1025</first-page>
<last-page>1036</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Guillerey, C., Huntington, N.D., Smyth, M.J.: Targeting natural killer cells in cancer immunotherapy. Nat. Immunol. 17, 1025–1036 (2016)</ref-fulltext>
<ce:source-text>Guillerey, C., Huntington, N.D., Smyth, M.J.: Targeting natural killer cells in cancer immunotherapy. Nat. Immunol. 17, 1025–1036 (2016)</ce:source-text>
</reference>
<reference seq="81">
<ref-info>
<ref-title>
<ref-titletext-english>The critical role of the tumor microenvironment in shaping natural killer cellmediated anti-tumor immunity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Baginska</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Immunol.</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>490</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baginska, J., et al.: The critical role of the tumor microenvironment in shaping natural killer cellmediated anti-tumor immunity. Front. Immunol. 4, 490 (2013)</ref-fulltext>
<ce:source-text>Baginska, J., et al.: The critical role of the tumor microenvironment in shaping natural killer cellmediated anti-tumor immunity. Front. Immunol. 4, 490 (2013)</ce:source-text>
</reference>
<reference seq="82">
<ref-info>
<ref-title>
<ref-titletext-english>Altered NKp30, NKp46, NKG2D, and DNAM-1 expression on circulating NK cells is associated with tumor progression in human gastric cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Han</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J Immunol Res.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>2018</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>6248590</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Han, B., et al.: Altered NKp30, NKp46, NKG2D, and DNAM-1 expression on circulating NK cells is associated with tumor progression in human gastric cancer. J Immunol Res. 2018, 6248590 (2018)</ref-fulltext>
<ce:source-text>Han, B., et al.: Altered NKp30, NKp46, NKG2D, and DNAM-1 expression on circulating NK cells is associated with tumor progression in human gastric cancer. J Immunol Res. 2018, 6248590 (2018)</ce:source-text>
</reference>
<reference seq="83">
<ref-info>
<ref-title>
<ref-titletext-english>TGF-beta inhibits the activation and functions of NK cells by repressing the mTOR pathway</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Viel</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Signal.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>ra19</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Viel, S., et al.: TGF-beta inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci. Signal. 9, ra19 (2016)</ref-fulltext>
<ce:source-text>Viel, S., et al.: TGF-beta inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci. Signal. 9, ra19 (2016)</ce:source-text>
</reference>
<reference seq="84">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived extracellular vesicles inhibit natural killer cell function in pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.G.</ce:initials>
<ce:surname>Zhao</ce:surname>
<ce:given-name>J.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancers.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Zhao, J.G., et al.: Tumor-derived extracellular vesicles inhibit natural killer cell function in pancreatic cancer. Cancers. 11 (2019) </ref-fulltext>
<ce:source-text>Zhao, J.G., et al.: Tumor-derived extracellular vesicles inhibit natural killer cell function in pancreatic cancer. Cancers. 11 (2019)</ce:source-text>
</reference>
<reference seq="85">
<ref-info>
<ref-title>
<ref-titletext-english>Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Lundholm</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>PLoS One.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>e108925</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lundholm, M., et al.: Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion. PLoS One. 9, e108925 (2014)</ref-fulltext>
<ce:source-text>Lundholm, M., et al.: Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion. PLoS One. 9, e108925 (2014)</ce:source-text>
</reference>
<reference seq="86">
<ref-info>
<ref-title>
<ref-titletext-english>Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Immunol.</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>176</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1375</first-page>
<last-page>1385</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Liu, C., et al.: Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J. Immunol. 176, 1375–1385 (2006)</ref-fulltext>
<ce:source-text>Liu, C., et al.: Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J. Immunol. 176, 1375–1385 (2006)</ce:source-text>
</reference>
<reference seq="87">
<ref-info>
<ref-title>
<ref-titletext-english>Neutrophils in cancer: neutral no more</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.B.</ce:initials>
<ce:surname>Coffelt</ce:surname>
<ce:given-name>S.B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.D.</ce:initials>
<ce:surname>Wellenstein</ce:surname>
<ce:given-name>M.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.E.</ce:initials>
<ce:surname>de Visser</ce:surname>
<ce:given-name>K.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>431</first-page>
<last-page>446</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Coffelt, S.B., Wellenstein, M.D., de Visser, K.E.: Neutrophils in cancer: neutral no more. Nat. Rev. Cancer. 16, 431–446 (2016)</ref-fulltext>
<ce:source-text>Coffelt, S.B., Wellenstein, M.D., de Visser, K.E.: Neutrophils in cancer: neutral no more. Nat. Rev. Cancer. 16, 431–446 (2016)</ce:source-text>
</reference>
<reference seq="88">
<ref-info>
<ref-title>
<ref-titletext-english>Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Kowanetz</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA.</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>107</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>21248</first-page>
<last-page>21255</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kowanetz, M., et al.: Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc. Natl. Acad. Sci. USA. 107, 21248–21255 (2010)</ref-fulltext>
<ce:source-text>Kowanetz, M., et al.: Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc. Natl. Acad. Sci. USA. 107, 21248–21255 (2010)</ce:source-text>
</reference>
<reference seq="89">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor entrained neutrophils inhibit seeding in the premetastatic lung</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Granot</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell.</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>300</first-page>
<last-page>314</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Granot, Z., et al.: Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell. 20, 300–314 (2011)</ref-fulltext>
<ce:source-text>Granot, Z., et al.: Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell. 20, 300–314 (2011)</ce:source-text>
</reference>
<reference seq="90">
<ref-info>
<ref-title>
<ref-titletext-english>Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following resection</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.W.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>Y.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Hepatol.</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>54</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>497</first-page>
<last-page>505</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Li, Y.W., et al.: Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following resection. J. Hepatol. 54, 497–505 (2011)</ref-fulltext>
<ce:source-text>Li, Y.W., et al.: Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following resection. J. Hepatol. 54, 497–505 (2011)</ce:source-text>
</reference>
<reference seq="91">
<ref-info>
<ref-title>
<ref-titletext-english>The prognostic value of tumorinfiltrating neutrophils in gastric adenocarcinoma after resection</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.J.</ce:initials>
<ce:surname>Zhao</ce:surname>
<ce:given-name>J.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>PLoS One.</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>e33655</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhao, J.J., et al.: The prognostic value of tumorinfiltrating neutrophils in gastric adenocarcinoma after resection. PLoS One. 7, e33655 (2012)</ref-fulltext>
<ce:source-text>Zhao, J.J., et al.: The prognostic value of tumorinfiltrating neutrophils in gastric adenocarcinoma after resection. PLoS One. 7, e33655 (2012)</ce:source-text>
</reference>
<reference seq="92">
<ref-info>
<ref-title>
<ref-titletext-english>Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.K.</ce:initials>
<ce:surname>Jensen</ce:surname>
<ce:given-name>H.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol.</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4709</first-page>
<last-page>4717</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Jensen, H.K., et al.: Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J. Clin. Oncol. 27, 4709–4717 (2009) </ref-fulltext>
<ce:source-text>Jensen, H.K., et al.: Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J. Clin. Oncol. 27, 4709–4717 (2009)</ce:source-text>
</reference>
<reference seq="93">
<ref-info>
<ref-title>
<ref-titletext-english>Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Schmidt</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>93</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>273</first-page>
<last-page>278</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Schmidt, H., et al.: Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br. J. Cancer. 93, 273–278 (2005) </ref-fulltext>
<ce:source-text>Schmidt, H., et al.: Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br. J. Cancer. 93, 273–278 (2005)</ce:source-text>
</reference>
<reference seq="94">
<ref-info>
<ref-title>
<ref-titletext-english> Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.J.</ce:initials>
<ce:surname>Casbon</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA.</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>112</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>E566</first-page>
<last-page>E575</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Casbon, A.J., et al.: Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils. Proc. Natl. Acad. Sci. USA. 112, E566–E575 (2015)</ref-fulltext>
<ce:source-text>Casbon, A.J., et al.: Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils. Proc. Natl. Acad. Sci. USA. 112, E566–E575 (2015)</ce:source-text>
</reference>
<reference seq="95">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.J.</ce:initials>
<ce:surname>Bayne</ce:surname>
<ce:given-name>L.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell.</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>822</first-page>
<last-page>835</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bayne, L.J., et al.: Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell. 21, 822–835 (2012)</ref-fulltext>
<ce:source-text>Bayne, L.J., et al.: Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell. 21, 822–835 (2012)</ce:source-text>
</reference>
<reference seq="96">
<ref-info>
<ref-title>
<ref-titletext-english>IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.B.</ce:initials>
<ce:surname>Coffelt</ce:surname>
<ce:given-name>S.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature.</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>522</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>345</first-page>
<last-page>348</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Coffelt, S.B., et al.: IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 522, 345–348 (2015) </ref-fulltext>
<ce:source-text>Coffelt, S.B., et al.: IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 522, 345–348 (2015)</ce:source-text>
</reference>
<reference seq="97">
<ref-info>
<ref-title>
<ref-titletext-english>CXCL1 is critical for premetastatic niche formation and metastasis in colorectal cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Sun</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Wei</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>B.</ce:initials>
<ce:surname>Cen</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="5">
<ce:initials>R.N.</ce:initials>
<ce:surname>DuBois</ce:surname>
<ce:given-name>R.N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>77</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3655</first-page>
<last-page>3665</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, D., Sun, H., Wei, J., Cen, B., DuBois, R.N.: CXCL1 is critical for premetastatic niche formation and metastasis in colorectal cancer. Cancer Res. 77, 3655–3665 (2017)</ref-fulltext>
<ce:source-text>Wang, D., Sun, H., Wei, J., Cen, B., DuBois, R.N.: CXCL1 is critical for premetastatic niche formation and metastasis in colorectal cancer. Cancer Res. 77, 3655–3665 (2017)</ce:source-text>
</reference>
<reference seq="98">
<ref-info>
<ref-title>
<ref-titletext-english>Tumour-associated neutrophils in patients with cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.E.</ce:initials>
<ce:surname>Shaul</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Z.G.</ce:initials>
<ce:surname>Fridlender</ce:surname>
<ce:given-name>Z.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Clin. Oncol.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>601</first-page>
<last-page>620</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shaul, M.E., Fridlender, Z.G.: Tumour-associated neutrophils in patients with cancer. Nat. Rev. Clin. Oncol. 16, 601–620 (2019)</ref-fulltext>
<ce:source-text>Shaul, M.E., Fridlender, Z.G.: Tumour-associated neutrophils in patients with cancer. Nat. Rev. Clin. Oncol. 16, 601–620 (2019)</ce:source-text>
</reference>
<reference seq="99">
<ref-info>
<ref-title>
<ref-titletext-english> Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Andzinski</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>138</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1982</first-page>
<last-page>1993</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Andzinski, L., et al.: Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human. Int. J. Cancer. 138, 1982–1993 (2016)</ref-fulltext>
<ce:source-text>Andzinski, L., et al.: Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human. Int. J. Cancer. 138, 1982–1993 (2016)</ce:source-text>
</reference>
<reference seq="100">
<ref-info>
<ref-title>
<ref-titletext-english>Polarization of tumorassociated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.G.</ce:initials>
<ce:surname>Fridlender</ce:surname>
<ce:given-name>Z.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell.</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>183</first-page>
<last-page>194</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fridlender, Z.G., et al.: Polarization of tumorassociated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell. 16, 183–194 (2009)</ref-fulltext>
<ce:source-text>Fridlender, Z.G., et al.: Polarization of tumorassociated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell. 16, 183–194 (2009)</ce:source-text>
</reference>
<reference seq="101">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived exosomes induce N2 polarization of neutrophils to promote gastric cancer cell migration</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>146</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, X., et al.: Tumor-derived exosomes induce N2 polarization of neutrophils to promote gastric cancer cell migration. Mol. Cancer. 17, 146 (2018)</ref-fulltext>
<ce:source-text>Zhang, X., et al.: Tumor-derived exosomes induce N2 polarization of neutrophils to promote gastric cancer cell migration. Mol. Cancer. 17, 146 (2018)</ce:source-text>
</reference>
<reference seq="102">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor stem-like cell-derived exosomal RNAs prime neutrophils for facilitating tumorigenesis of colon cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.L.</ce:initials>
<ce:surname>Hwang</ce:surname>
<ce:given-name>W.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.Y.</ce:initials>
<ce:surname>Lan</ce:surname>
<ce:given-name>H.Y.</ce:given-name>
</author>
<author seq="3">
<ce:initials>W.C.</ce:initials>
<ce:surname>Cheng</ce:surname>
<ce:given-name>W.C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.C.</ce:initials>
<ce:surname>Huang</ce:surname>
<ce:given-name>S.C.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.H.</ce:initials>
<ce:surname>Yang</ce:surname>
<ce:given-name>M.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Hematol. Oncol.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>10</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hwang, W.L., Lan, H.Y., Cheng, W.C., Huang, S.C., Yang, M.H.: Tumor stem-like cell-derived exosomal RNAs prime neutrophils for facilitating tumorigenesis of colon cancer. J. Hematol. Oncol. 12, 10 (2019)</ref-fulltext>
<ce:source-text>Hwang, W.L., Lan, H.Y., Cheng, W.C., Huang, S.C., Yang, M.H.: Tumor stem-like cell-derived exosomal RNAs prime neutrophils for facilitating tumorigenesis of colon cancer. J. Hematol. Oncol. 12, 10 (2019)</ce:source-text>
</reference>
<reference seq="103">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived exosomes induce the formation of neutrophil extracellular traps: implications for the establishment of cancerassociated thrombosis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.C.</ce:initials>
<ce:surname>Leal</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>6438</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Leal, A.C., et al.: Tumor-derived exosomes induce the formation of neutrophil extracellular traps: implications for the establishment of cancerassociated thrombosis. Sci. Rep. 7, 6438 (2017)</ref-fulltext>
<ce:source-text>Leal, A.C., et al.: Tumor-derived exosomes induce the formation of neutrophil extracellular traps: implications for the establishment of cancerassociated thrombosis. Sci. Rep. 7, 6438 (2017)</ce:source-text>
</reference>
<reference seq="104">
<ref-info>
<ref-title>
<ref-titletext-english>Neutrophil extracellular traps kill bacteria</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.</ce:initials>
<ce:surname>Brinkmann</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science.</ref-sourcetitle>
<ref-publicationyear first="2004" />
<volisspag>
<volume-issue-number>
<vol-first>303</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1532</first-page>
<last-page>1535</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Brinkmann, V., et al.: Neutrophil extracellular traps kill bacteria. Science. 303, 1532–1535 (2004)</ref-fulltext>
<ce:source-text>Brinkmann, V., et al.: Neutrophil extracellular traps kill bacteria. Science. 303, 1532–1535 (2004)</ce:source-text>
</reference>
<reference seq="105">
<ref-info>
<ref-title>
<ref-titletext-english>Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Demers</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA.</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>109</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>13076</first-page>
<last-page>13081</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Demers, M., et al.: Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc. Natl. Acad. Sci. USA. 109, 13076–13081 (2012)</ref-fulltext>
<ce:source-text>Demers, M., et al.: Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc. Natl. Acad. Sci. USA. 109, 13076–13081 (2012)</ce:source-text>
</reference>
<reference seq="106">
<ref-info>
<ref-title>
<ref-titletext-english> Cancer cells induce metastasissupporting neutrophil extracellular DNA traps</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Park</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Transl. Med.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Park, J., et al.: Cancer cells induce metastasissupporting neutrophil extracellular DNA traps. Sci. Transl. Med. 8, 361ra138 (2016)</ref-fulltext>
<ce:source-text>Park, J., et al.: Cancer cells induce metastasissupporting neutrophil extracellular DNA traps. Sci. Transl. Med. 8, 361ra138 (2016)</ce:source-text>
</reference>
<reference seq="107">
<ref-info>
<ref-title>
<ref-titletext-english>Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Cools-Lartigue</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest.</ref-sourcetitle>
<ref-publicationyear first="2013" />
</ref-info>
<ref-fulltext>Cools-Lartigue, J., et al.: Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J. Clin. Invest. (2013)</ref-fulltext>
<ce:source-text>Cools-Lartigue, J., et al.: Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J. Clin. Invest. (2013)</ce:source-text>
</reference>
<reference seq="108">
<ref-info>
<ref-title>
<ref-titletext-english>The origins of vertebrate adaptive immunity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.W.</ce:initials>
<ce:surname>Litman</ce:surname>
<ce:given-name>G.W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.P.</ce:initials>
<ce:surname>Rast</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.D.</ce:initials>
<ce:surname>Fugmann</ce:surname>
<ce:given-name>S.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Immunol.</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>543</first-page>
<last-page>553</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Litman, G.W., Rast, J.P., Fugmann, S.D.: The origins of vertebrate adaptive immunity. Nat. Rev. Immunol. 10, 543–553 (2010)</ref-fulltext>
<ce:source-text>Litman, G.W., Rast, J.P., Fugmann, S.D.: The origins of vertebrate adaptive immunity. Nat. Rev. Immunol. 10, 543–553 (2010)</ce:source-text>
</reference>
<reference seq="109">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived exosomes promote carcinogenesis of murine oral squamous cell carcinoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.M.</ce:initials>
<ce:surname>Razzo</ce:surname>
<ce:given-name>B.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Carcinogenesis.</ref-sourcetitle>
<ref-publicationyear first="2019" />
</ref-info>
<ref-fulltext>Razzo, B.M., et al.: Tumor-derived exosomes promote carcinogenesis of murine oral squamous cell carcinoma. Carcinogenesis. (2019)</ref-fulltext>
<ce:source-text>Razzo, B.M., et al.: Tumor-derived exosomes promote carcinogenesis of murine oral squamous cell carcinoma. Carcinogenesis. (2019)</ce:source-text>
</reference>
<reference seq="110">
<ref-info>
<ref-title>
<ref-titletext-english>14-3-3zeta delivered by hepatocellular carcinoma-derived exosomes impaired antitumor function of tumor-infiltrating T lymphocytes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Death Dis.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>159</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, X., et al.: 14-3-3zeta delivered by hepatocellular carcinoma-derived exosomes impaired antitumor function of tumor-infiltrating T lymphocytes. Cell Death Dis. 9, 159 (2018)</ref-fulltext>
<ce:source-text>Wang, X., et al.: 14-3-3zeta delivered by hepatocellular carcinoma-derived exosomes impaired antitumor function of tumor-infiltrating T lymphocytes. Cell Death Dis. 9, 159 (2018)</ce:source-text>
</reference>
<reference seq="111">
<ref-info>
<ref-title>
<ref-titletext-english>Brain tumor-initiating cells export tenascin-C associated with exosomes to suppress T cell activity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Mirzaei</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Onco. Targets. Ther.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>e1478647</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mirzaei, R., et al.: Brain tumor-initiating cells export tenascin-C associated with exosomes to suppress T cell activity. Onco. Targets. Ther. 7, e1478647 (2018)</ref-fulltext>
<ce:source-text>Mirzaei, R., et al.: Brain tumor-initiating cells export tenascin-C associated with exosomes to suppress T cell activity. Onco. Targets. Ther. 7, e1478647 (2018)</ce:source-text>
</reference>
<reference seq="112">
<ref-info>
<ref-title>
<ref-titletext-english>B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Griss</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4186</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Griss, J., et al.: B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nat. Commun. 10, 4186 (2019)</ref-fulltext>
<ce:source-text>Griss, J., et al.: B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nat. Commun. 10, 4186 (2019)</ce:source-text>
</reference>
<reference seq="113">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Garaud</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>JCI Insight.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Garaud, S., et al.: Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer. JCI Insight. 5 (2019)</ref-fulltext>
<ce:source-text>Garaud, S., et al.: Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer. JCI Insight. 5 (2019)</ce:source-text>
</reference>
<reference seq="114">
<ref-info>
<ref-title>
<ref-titletext-english>KRAS renaissance(s) in tumor infiltrating B cells in pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Q.</ce:initials>
<ce:surname>Meng</ce:surname>
<ce:given-name>Q.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Valentini</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Rao</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Maeurer</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Oncol.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>384</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Meng, Q., Valentini, D., Rao, M., Maeurer, M.: KRAS renaissance(s) in tumor infiltrating B cells in pancreatic cancer. Front. Oncol. 8, 384 (2018) </ref-fulltext>
<ce:source-text>Meng, Q., Valentini, D., Rao, M., Maeurer, M.: KRAS renaissance(s) in tumor infiltrating B cells in pancreatic cancer. Front. Oncol. 8, 384 (2018) </ce:source-text>
</reference>
<reference seq="115">
<ref-info>
<ref-title>
<ref-titletext-english>IL35-producing B cells promote the development of pancreatic neoplasia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Pylayeva-Gupta</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Discov.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>247</first-page>
<last-page>255</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pylayeva-Gupta, Y., et al.: IL35-producing B cells promote the development of pancreatic neoplasia. Cancer Discov. 6, 247–255 (2016)</ref-fulltext>
<ce:source-text>Pylayeva-Gupta, Y., et al.: IL35-producing B cells promote the development of pancreatic neoplasia. Cancer Discov. 6, 247–255 (2016)</ce:source-text>
</reference>
<reference seq="116">
<ref-info>
<ref-title>
<ref-titletext-english>PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Xiao</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Discov.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>546</first-page>
<last-page>559</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xiao, X., et al.: PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression. Cancer Discov. 6, 546–559 (2016)</ref-fulltext>
<ce:source-text>Xiao, X., et al.: PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression. Cancer Discov. 6, 546–559 (2016)</ce:source-text>
</reference>
<reference seq="117">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1(+) regulatory B cell expansion</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Ye</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> J. Immunother. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>145</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ye, L., et al.: Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1(+) regulatory B cell expansion. J. Immunother. Cancer. 6, 145 (2018)</ref-fulltext>
<ce:source-text>Ye, L., et al.: Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1(+) regulatory B cell expansion. J. Immunother. Cancer. 6, 145 (2018)</ce:source-text>
</reference>
<reference seq="118">
<ref-info>
<ref-title>
<ref-titletext-english>Therapeutics targeting angiogenesis: genetics and epigenetics, extracellular miRNAs and signaling networks (Review)</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Katoh</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Mol. Med.</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>763</first-page>
<last-page>767</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Katoh, M.: Therapeutics targeting angiogenesis: genetics and epigenetics, extracellular miRNAs and signaling networks (Review). Int. J. Mol. Med. 32, 763–767 (2013)</ref-fulltext>
<ce:source-text>Katoh, M.: Therapeutics targeting angiogenesis: genetics and epigenetics, extracellular miRNAs and signaling networks (Review). Int. J. Mol. Med. 32, 763–767 (2013)</ce:source-text>
</reference>
<reference seq="119">
<ref-info>
<ref-title>
<ref-titletext-english> Microenvironmental regulation of tumour angiogenesis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>De Palma</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Biziato</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.V.</ce:initials>
<ce:surname>Petrova</ce:surname>
<ce:given-name>T.V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>457</first-page>
<last-page>474</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>De Palma, M., Biziato, D., Petrova, T.V.: Microenvironmental regulation of tumour angiogenesis. Nat. Rev. Cancer. 17, 457–474 (2017)</ref-fulltext>
<ce:source-text>De Palma, M., Biziato, D., Petrova, T.V.: Microenvironmental regulation of tumour angiogenesis. Nat. Rev. Cancer. 17, 457–474 (2017)</ce:source-text>
</reference>
<reference seq="120">
<ref-info>
<ref-title>
<ref-titletext-english> Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Sawamiphak</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature.</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>465</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>487</first-page>
<last-page>491</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sawamiphak, S., et al.: Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature. 465, 487–491 (2010)</ref-fulltext>
<ce:source-text>Sawamiphak, S., et al.: Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature. 465, 487–491 (2010)</ce:source-text>
</reference>
<reference seq="121">
<ref-info>
<ref-title>
<ref-titletext-english>EPHB2 carried on small extracellular vesicles induces tumor angiogenesis via activation of ephrin reverse signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Sato</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>JCI Insight.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Sato, S., et al.: EPHB2 carried on small extracellular vesicles induces tumor angiogenesis via activation of ephrin reverse signaling. JCI Insight. 4 (2019)</ref-fulltext>
<ce:source-text>Sato, S., et al.: EPHB2 carried on small extracellular vesicles induces tumor angiogenesis via activation of ephrin reverse signaling. JCI Insight. 4 (2019)</ce:source-text>
</reference>
<reference seq="122">
<ref-info>
<ref-title>
<ref-titletext-english>Visualization of exosome-mediated miR-210 transfer from hypoxic tumor cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.O.</ce:initials>
<ce:surname>Jung</ce:surname>
<ce:given-name>K.O.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Youn</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.H.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>C.H.</ce:given-name>
</author>
<author seq="4">
<ce:initials>K.W.</ce:initials>
<ce:surname>Kang</ce:surname>
<ce:given-name>K.W.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.K.</ce:initials>
<ce:surname>Chung</ce:surname>
<ce:given-name>J.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>9899</first-page>
<last-page>9910</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Jung, K.O., Youn, H., Lee, C.H., Kang, K.W., Chung, J.K.: Visualization of exosome-mediated miR-210 transfer from hypoxic tumor cells. Oncotarget. 8, 9899–9910 (2017)</ref-fulltext>
<ce:source-text>Jung, K.O., Youn, H., Lee, C.H., Kang, K.W., Chung, J.K.: Visualization of exosome-mediated miR-210 transfer from hypoxic tumor cells. Oncotarget. 8, 9899–9910 (2017)</ce:source-text>
</reference>
<reference seq="123">
<ref-info>
<ref-title>
<ref-titletext-english>PTP1b is a physiologic regulator of vascular endothelial growth factor signaling in endothelial cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.A.</ce:initials>
<ce:surname>Lanahan</ce:surname>
<ce:given-name>A.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Circulation.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>130</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>902</first-page>
<last-page>909</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lanahan, A.A., et al.: PTP1b is a physiologic regulator of vascular endothelial growth factor signaling in endothelial cells. Circulation. 130, 902–909 (2014)</ref-fulltext>
<ce:source-text>Lanahan, A.A., et al.: PTP1b is a physiologic regulator of vascular endothelial growth factor signaling in endothelial cells. Circulation. 130, 902–909 (2014)</ce:source-text>
</reference>
<reference seq="124">
<ref-info>
<ref-title>
<ref-titletext-english> Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Umezu</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Blood.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>124</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3748</first-page>
<last-page>3757</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Umezu, T., et al.: Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood. 124, 3748–3757 (2014)</ref-fulltext>
<ce:source-text>Umezu, T., et al.: Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood. 124, 3748–3757 (2014)</ce:source-text>
</reference>
<reference seq="125">
<ref-info>
<ref-title>
<ref-titletext-english>piRNA-823 delivered by multiple myeloma-derived extracellular vesicles promoted tumorigenesis through re-educating endothelial cells in the tumor environment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.B.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>B.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5227</first-page>
<last-page>5238
</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Li, B.B., et al.: piRNA-823 delivered by multiple myeloma-derived extracellular vesicles promoted tumorigenesis through re-educating endothelial cells in the tumor environment. Oncogene. 38, 5227–5238 (2019)</ref-fulltext>
<ce:source-text>Li, B.B., et al.: piRNA-823 delivered by multiple myeloma-derived extracellular vesicles promoted tumorigenesis through re-educating endothelial cells in the tumor environment. Oncogene. 38, 5227–5238 (2019)</ce:source-text>
</reference>
<reference seq="126">
<ref-info>
<ref-title>
<ref-titletext-english>Glioblastoma stem-like cells secrete the pro-angiogenic VEGF-A factor in extracellular vesicles</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Treps</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Perret</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Edmond</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>D.</ce:initials>
<ce:surname>Ricard</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Gavard</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Extracell. Vesicles.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1359479</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Treps, L., Perret, R., Edmond, S., Ricard, D., Gavard, J.: Glioblastoma stem-like cells secrete the pro-angiogenic VEGF-A factor in extracellular vesicles. J. Extracell. Vesicles. 6, 1359479 (2017)</ref-fulltext>
<ce:source-text>Treps, L., Perret, R., Edmond, S., Ricard, D., Gavard, J.: Glioblastoma stem-like cells secrete the pro-angiogenic VEGF-A factor in extracellular vesicles. J. Extracell. Vesicles. 6, 1359479 (2017)</ce:source-text>
</reference>
<reference seq="127">
<ref-info>
<ref-title>
<ref-titletext-english> Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.Y.</ce:initials>
<ce:surname>Ko</ce:surname>
<ce:given-name>S.Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> Commun. Biol.</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>386</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ko, S.Y., et al.: Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake. Commun. Biol. 2, 386 (2019)</ref-fulltext>
<ce:source-text>Ko, S.Y., et al.: Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake. Commun. Biol. 2, 386 (2019)</ce:source-text>
</reference>
<reference seq="128">
<ref-info>
<ref-title>
<ref-titletext-english>Intravascular survival and extravasation of tumor cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Strilic</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>282</first-page>
<last-page>293</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Strilic, B., Offermanns, S.: Intravascular survival and extravasation of tumor cells. Cancer Cell. 32, 282–293 (2017)</ref-fulltext>
<ce:source-text>Strilic, B., Offermanns, S.: Intravascular survival and extravasation of tumor cells. Cancer Cell. 32, 282–293 (2017)</ce:source-text>
</reference>
<reference seq="129">
<ref-info>
<ref-title>
<ref-titletext-english> Circulating and disseminated tumour cells – mechanisms of immune surveillance and escape</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Mohme</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Riethdorf</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.</ce:initials>
<ce:surname>Pantel</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Clin. Oncol.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>155</first-page>
<last-page>167</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mohme, M., Riethdorf, S., Pantel, K.: Circulating and disseminated tumour cells – mechanisms of immune surveillance and escape. Nat. Rev. Clin. Oncol. 14, 155–167 (2017)</ref-fulltext>
<ce:source-text>Mohme, M., Riethdorf, S., Pantel, K.: Circulating and disseminated tumour cells – mechanisms of immune surveillance and escape. Nat. Rev. Clin. Oncol. 14, 155–167 (2017)</ce:source-text>
</reference>
<reference seq="130">
<ref-info>
<ref-title>
<ref-titletext-english> Extracellular vesicle-transported Semaphorin3A promotes vascular permeability in glioblastoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Treps</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2615</first-page>
<last-page>2623</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Treps, L., et al.: Extracellular vesicle-transported Semaphorin3A promotes vascular permeability in glioblastoma. Oncogene. 35, 2615–2623 (2016)</ref-fulltext>
<ce:source-text>Treps, L., et al.: Extracellular vesicle-transported Semaphorin3A promotes vascular permeability in glioblastoma. Oncogene. 35, 2615–2623 (2016)</ce:source-text>
</reference>
<reference seq="131">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Zeng</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5395</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zeng, Z., et al.: Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis. Nat. Commun. 9, 5395 (2018)</ref-fulltext>
<ce:source-text>Zeng, Z., et al.: Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis. Nat. Commun. 9, 5395 (2018)</ce:source-text>
</reference>
<reference seq="132">
<ref-info>
<ref-title>
<ref-titletext-english>Inhibition of vascular permeability factor/vascular endothelial growth factormediated angiogenesis by the Kruppel-like factor KLF2</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Bhattacharya</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem.</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>280</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>28848</first-page>
<last-page>28851</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bhattacharya, R., et al.: Inhibition of vascular permeability factor/vascular endothelial growth factormediated angiogenesis by the Kruppel-like factor KLF2. J. Biol. Chem. 280, 28848–28851 (2005)</ref-fulltext>
<ce:source-text>Bhattacharya, R., et al.: Inhibition of vascular permeability factor/vascular endothelial growth factormediated angiogenesis by the Kruppel-like factor KLF2. J. Biol. Chem. 280, 28848–28851 (2005)</ce:source-text>
</reference>
<reference seq="133">
<ref-info>
<ref-title>
<ref-titletext-english>Kruppel-like factor 4 regulates bloodtumor barrier permeability via ZO-1, occludin and claudin-5</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Ma</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Physiol.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>229</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>916</first-page>
<last-page>926</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ma, J., et al.: Kruppel-like factor 4 regulates bloodtumor barrier permeability via ZO-1, occludin and claudin-5. J. Cell. Physiol. 229, 916–926 (2014)</ref-fulltext>
<ce:source-text>Ma, J., et al.: Kruppel-like factor 4 regulates bloodtumor barrier permeability via ZO-1, occludin and claudin-5. J. Cell. Physiol. 229, 916–926 (2014)</ce:source-text>
</reference>
<reference seq="134">
<ref-info>
<ref-title>
<ref-titletext-english>Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.L.</ce:initials>
<ce:surname>Hsu</ce:surname>
<ce:given-name>Y.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene. </ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4929</first-page>
<last-page>4942</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hsu, Y.L., et al.: Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1. Oncogene. 36, 4929–4942 (2017)</ref-fulltext>
<ce:source-text>Hsu, Y.L., et al.: Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1. Oncogene. 36, 4929–4942 (2017)</ce:source-text>
</reference>
<reference seq="135">
<ref-info>
<ref-title>
<ref-titletext-english>Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Di Modica</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Lett.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>384</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>94</first-page>
<last-page>100</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Di Modica, M., et al.: Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers. Cancer Lett. 384, 94–100 (2017)</ref-fulltext>
<ce:source-text>Di Modica, M., et al.: Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers. Cancer Lett. 384, 94–100 (2017)</ce:source-text>
</reference>
<reference seq="136">
<ref-info>
<ref-title>
<ref-titletext-english>Hepatoma cell-secreted exosomal microRNA-103 increases vascular permeability and promotes metastasis by targeting junction proteins</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.H.</ce:initials>
<ce:surname>Fang</ce:surname>
<ce:given-name>J.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Hepatology.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>68</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1459</first-page>
<last-page>1475</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fang, J.H., et al.: Hepatoma cell-secreted exosomal microRNA-103 increases vascular permeability and promotes metastasis by targeting junction proteins. Hepatology. 68, 1459–1475 (2018)</ref-fulltext>
<ce:source-text>Fang, J.H., et al.: Hepatoma cell-secreted exosomal microRNA-103 increases vascular permeability and promotes metastasis by targeting junction proteins. Hepatology. 68, 1459–1475 (2018)</ce:source-text>
</reference>
<reference seq="137">
<ref-info>
<ref-title>
<ref-titletext-english> Circular RNA IARS (circ-IARS) secreted by pancreatic cancer cells and located within exosomes regulates endothelial monolayer permeability to promote tumor metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> J. Exp. Clin. Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>37</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Li, J., et al.: Circular RNA IARS (circ-IARS) secreted by pancreatic cancer cells and located within exosomes regulates endothelial monolayer permeability to promote tumor metastasis. J. Exp. Clin. Cancer Res. 37 (2018)</ref-fulltext>
<ce:source-text>Li, J., et al.: Circular RNA IARS (circ-IARS) secreted by pancreatic cancer cells and located within exosomes regulates endothelial monolayer permeability to promote tumor metastasis. J. Exp. Clin. Cancer Res. 37 (2018)</ce:source-text>
</reference>
<reference seq="138">
<ref-info>
<ref-title>
<ref-titletext-english>Natural RNA circles function as efficient microRNA sponges</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.B.</ce:initials>
<ce:surname>Hansen</ce:surname>
<ce:given-name>T.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature.</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>495</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>384</first-page>
<last-page>388</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hansen, T.B., et al.: Natural RNA circles function as efficient microRNA sponges. Nature. 495, 384–388 (2013)</ref-fulltext>
<ce:source-text>Hansen, T.B., et al.: Natural RNA circles function as efficient microRNA sponges. Nature. 495, 384–388 (2013)</ce:source-text>
</reference>
<reference seq="139">
<ref-info>
<ref-title>
<ref-titletext-english> Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.J.</ce:initials>
<ce:surname>Fidler</ce:surname>
<ce:given-name>I.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.L.</ce:initials>
<ce:surname>Nicolson</ce:surname>
<ce:given-name>G.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Natl. Cancer Inst.</ref-sourcetitle>
<ref-publicationyear first="1976" />
<volisspag>
<volume-issue-number>
<vol-first>57</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1199</first-page>
<last-page>1202</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fidler, I.J., Nicolson, G.L.: Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines. J. Natl. Cancer Inst. 57, 1199–1202 (1976)</ref-fulltext>
<ce:source-text>Fidler, I.J., Nicolson, G.L.: Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines. J. Natl. Cancer Inst. 57, 1199–1202 (1976)</ce:source-text>
</reference>
<reference seq="140">
<ref-info>
<ref-title>
<ref-titletext-english>Role of organ selectivity in the determination of metastatic patterns of B16 melanoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.R.</ce:initials>
<ce:surname>Hart</ce:surname>
<ce:given-name>I.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="1980" />
<volisspag>
<volume-issue-number>
<vol-first>40</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2281</first-page>
<last-page>2287</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hart, I.R., Fidler, I.J.: Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res. 40, 2281–2287 (1980)</ref-fulltext>
<ce:source-text>Hart, I.R., Fidler, I.J.: Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res. 40, 2281–2287 (1980)</ce:source-text>
</reference>
<reference seq="141">
<ref-info>
<ref-title>
<ref-titletext-english> Metastasis organotropism: redefining the congenial soil</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Gao</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Dev. Cell.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>49</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>375</first-page>
<last-page>391</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gao, Y., et al.: Metastasis organotropism: redefining the congenial soil. Dev. Cell. 49, 375–391 (2019)</ref-fulltext>
<ce:source-text>Gao, Y., et al.: Metastasis organotropism: redefining the congenial soil. Dev. Cell. 49, 375–391 (2019)</ce:source-text>
</reference>
<reference seq="142">
<ref-info>
<ref-title>
<ref-titletext-english>Metastasis: from dissemination to organ-specific colonization</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.X.</ce:initials>
<ce:surname>Nguyen</ce:surname>
<ce:given-name>D.X.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.D.</ce:initials>
<ce:surname>Bos</ce:surname>
<ce:given-name>P.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Massague</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>U265</first-page>
<last-page>U274</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nguyen, D.X., Bos, P.D., Massague, J.: Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer. 9, 274–U265 (2009)</ref-fulltext>
<ce:source-text>Nguyen, D.X., Bos, P.D., Massague, J.: Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer. 9, 274–U265 (2009)</ce:source-text>
</reference>
<reference seq="143">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.L.</ce:initials>
<ce:surname>Hood</ce:surname>
<ce:given-name>J.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.S.</ce:initials>
<ce:surname>San</ce:surname>
<ce:given-name>R.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.A.</ce:initials>
<ce:surname>Wickline</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>71</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3792</first-page>
<last-page>3801</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hood, J.L., San, R.S., Wickline, S.A.: Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res. 71, 3792–3801 (2011)</ref-fulltext>
<ce:source-text>Hood, J.L., San, R.S., Wickline, S.A.: Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res. 71, 3792–3801 (2011)</ce:source-text>
</reference>
<reference seq="144">
<ref-info>
<ref-title>
<ref-titletext-english>Molecular mechanism underlying lymphatic metastasis in pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Xiao</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biomed. Res. Int.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>2014</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>925845</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xiao, Z., et al.: Molecular mechanism underlying lymphatic metastasis in pancreatic cancer. Biomed. Res. Int. 2014, 925845 (2014)</ref-fulltext>
<ce:source-text>Xiao, Z., et al.: Molecular mechanism underlying lymphatic metastasis in pancreatic cancer. Biomed. Res. Int. 2014, 925845 (2014)</ce:source-text>
</reference>
<reference seq="145">
<ref-info>
<ref-title>
<ref-titletext-english>SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pucci</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>352</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>242</first-page>
<last-page>246</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pucci, F., et al.: SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions. Science. 352, 242–246 (2016)</ref-fulltext>
<ce:source-text>Pucci, F., et al.: SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions. Science. 352, 242–246 (2016)</ce:source-text>
</reference>
<reference seq="146">
<ref-info>
<ref-title>
<ref-titletext-english>Human melanoma-derived extracellular vesicles regulate dendritic cell maturation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.L.G.</ce:initials>
<ce:surname>Maus</ce:surname>
<ce:given-name>R.L.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Immunol.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>358</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Maus, R.L.G., et al.: Human melanoma-derived extracellular vesicles regulate dendritic cell maturation. Front. Immunol. 8, 358 (2017)</ref-fulltext>
<ce:source-text>Maus, R.L.G., et al.: Human melanoma-derived extracellular vesicles regulate dendritic cell maturation. Front. Immunol. 8, 358 (2017)</ce:source-text>
</reference>
<reference seq="147">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomal tumor microRNA modulates premetastatic organ cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Rana</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Malinowska</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Zoller</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Neoplasia.</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>281</first-page>
<last-page>295</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rana, S., Malinowska, K., Zoller, M.: Exosomal tumor microRNA modulates premetastatic organ cells. Neoplasia. 15, 281–295 (2013)</ref-fulltext>
<ce:source-text>Rana, S., Malinowska, K., Zoller, M.: Exosomal tumor microRNA modulates premetastatic organ cells. Neoplasia. 15, 281–295 (2013)</ce:source-text>
</reference>
<reference seq="148">
<ref-info>
<ref-title>
<ref-titletext-english> Lymphatic transport of exosomes as a rapid route of information dissemination to the lymph node</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Srinivasan</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>F.O.</ce:initials>
<ce:surname>Vannberg</ce:surname>
<ce:given-name>F.O.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.B.</ce:initials>
<ce:surname>Dixon</ce:surname>
<ce:given-name>J.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>24436</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Srinivasan, S., Vannberg, F.O., Dixon, J.B.: Lymphatic transport of exosomes as a rapid route of information dissemination to the lymph node. Sci. Rep. 6, 24436 (2016)</ref-fulltext>
<ce:source-text>Srinivasan, S., Vannberg, F.O., Dixon, J.B.: Lymphatic transport of exosomes as a rapid route of information dissemination to the lymph node. Sci. Rep. 6, 24436 (2016)</ce:source-text>
</reference>
<reference seq="149">
<ref-info>
<ref-title>
<ref-titletext-english> Exosomal long noncoding RNA LNMAT2 promotes lymphatic metastasis in bladder cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest.</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>130</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>404</first-page>
<last-page>421</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, C., et al.: Exosomal long noncoding RNA LNMAT2 promotes lymphatic metastasis in bladder cancer. J. Clin. Invest. 130, 404–421 (2020)</ref-fulltext>
<ce:source-text>Chen, C., et al.: Exosomal long noncoding RNA LNMAT2 promotes lymphatic metastasis in bladder cancer. J. Clin. Invest. 130, 404–421 (2020)</ce:source-text>
</reference>
<reference seq="150">
<ref-info>
<ref-title>
<ref-titletext-english> Colorectal cancer exosomes induce lymphatic network remodeling in lymph nodes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Sun</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>145</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1648</first-page>
<last-page>1659</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sun, B., et al.: Colorectal cancer exosomes induce lymphatic network remodeling in lymph nodes. Int. J. Cancer. 145, 1648–1659 (2019)</ref-fulltext>
<ce:source-text>Sun, B., et al.: Colorectal cancer exosomes induce lymphatic network remodeling in lymph nodes. Int. J. Cancer. 145, 1648–1659 (2019)</ce:source-text>
</reference>
<reference seq="151">
<ref-info>
<ref-title>
<ref-titletext-english>The lymphatic system: integral roles in immunity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.J.</ce:initials>
<ce:surname>Randolph</ce:surname>
<ce:given-name>G.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Ivanov</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>B.H.</ce:initials>
<ce:surname>Zinselmeyer</ce:surname>
<ce:given-name>B.H.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.P.</ce:initials>
<ce:surname>Scallan</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Annu. Rev. Immunol.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>31</first-page>
<last-page>52</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Randolph, G.J., Ivanov, S., Zinselmeyer, B.H., Scallan, J.P.: The lymphatic system: integral roles in immunity. Annu. Rev. Immunol. 35, 31–52 (2017)</ref-fulltext>
<ce:source-text>Randolph, G.J., Ivanov, S., Zinselmeyer, B.H., Scallan, J.P.: The lymphatic system: integral roles in immunity. Annu. Rev. Immunol. 35, 31–52 (2017)</ce:source-text>
</reference>
<reference seq="152">
<ref-info>
<ref-title>
<ref-titletext-english>Macrophage immunomodulation by breast cancer-derived exosomes requires toll-like receptor 2-mediated activation of NF-kappaB</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Chow</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5750</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chow, A., et al.: Macrophage immunomodulation by breast cancer-derived exosomes requires toll-like receptor 2-mediated activation of NF-kappaB. Sci. Rep. 4, 5750 (2014)</ref-fulltext>
<ce:source-text>Chow, A., et al.: Macrophage immunomodulation by breast cancer-derived exosomes requires toll-like receptor 2-mediated activation of NF-kappaB. Sci. Rep. 4, 5750 (2014)</ce:source-text>
</reference>
<reference seq="153">
<ref-info>
<ref-title>
<ref-titletext-english>Melanoma growth and lymph node metastasis is independent of host CD169 expression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.R.</ce:initials>
<ce:surname>Muhsin-Sharafaldine</ce:surname>
<ce:given-name>M.R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.C.</ce:initials>
<ce:surname>Saunderson</ce:surname>
<ce:given-name>S.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.C.</ce:initials>
<ce:surname>Dunn</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.D.</ce:initials>
<ce:surname>McLellan</ce:surname>
<ce:given-name>A.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochem. Biophys. Res. Commun.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>486</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>965</first-page>
<last-page>970</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Muhsin-Sharafaldine, M.R., Saunderson, S.C., Dunn, A.C., McLellan, A.D.: Melanoma growth and lymph node metastasis is independent of host CD169 expression. Biochem. Biophys. Res. Commun. 486, 965–970 (2017)</ref-fulltext>
<ce:source-text>Muhsin-Sharafaldine, M.R., Saunderson, S.C., Dunn, A.C., McLellan, A.D.: Melanoma growth and lymph node metastasis is independent of host CD169 expression. Biochem. Biophys. Res. Commun. 486, 965–970 (2017)</ce:source-text>
</reference>
<reference seq="154">
<ref-info>
<ref-title>
<ref-titletext-english> Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Skobe</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Med.</ref-sourcetitle>
<ref-publicationyear first="2001" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>192</first-page>
<last-page>198</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Skobe, M., et al.: Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 7, 192–198 (2001)</ref-fulltext>
<ce:source-text>Skobe, M., et al.: Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 7, 192–198 (2001)</ce:source-text>
</reference>
<reference seq="155">
<ref-info>
<ref-title>
<ref-titletext-english>VEGF-D promotes the metastatic spread of tumor cells via the lymphatics</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.A.</ce:initials>
<ce:surname>Stacker</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Med.</ref-sourcetitle>
<ref-publicationyear first="2001" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>186</first-page>
<last-page>191</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stacker, S.A., et al.: VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med. 7, 186–191 (2001)</ref-fulltext>
<ce:source-text>Stacker, S.A., et al.: VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med. 7, 186–191 (2001)</ce:source-text>
</reference>
<reference seq="156">
<ref-info>
<ref-title>
<ref-titletext-english> Lymphangiogenesis and lymphatic vessel remodelling in cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.A.</ce:initials>
<ce:surname>Stacker</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>159</first-page>
<last-page>172</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stacker, S.A., et al.: Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat. Rev. Cancer. 14, 159–172 (2014)</ref-fulltext>
<ce:source-text>Stacker, S.A., et al.: Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat. Rev. Cancer. 14, 159–172 (2014)</ce:source-text>
</reference>
<reference seq="157">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomes as a communication tool between the lymphatic system and bladder cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.J.</ce:initials>
<ce:surname>Park</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.J.</ce:initials>
<ce:surname>Hong</ce:surname>
<ce:given-name>Y.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Wu</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="4">
<ce:initials>P.M.</ce:initials>
<ce:surname>Kim</ce:surname>
<ce:given-name>P.M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>Y.K.</ce:initials>
<ce:surname>Hong</ce:surname>
<ce:given-name>Y.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. Neurourol. J.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>22</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>220</first-page>
<last-page>224</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Park, R.J., Hong, Y.J., Wu, Y., Kim, P.M., Hong, Y. K.: Exosomes as a communication tool between the lymphatic system and bladder cancer. Int. Neurourol. J. 22, 220–224 (2018)</ref-fulltext>
<ce:source-text>Park, R.J., Hong, Y.J., Wu, Y., Kim, P.M., Hong, Y. K.: Exosomes as a communication tool between the lymphatic system and bladder cancer. Int. Neurourol. J. 22, 220–224 (2018)</ce:source-text>
</reference>
<reference seq="158">
<ref-info>
<ref-title>
<ref-titletext-english>Cervical squamous cell carcinomasecreted exosomal miR-221-3p promotes lymphangiogenesis and lymphatic metastasis by targeting VASH1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.F.</ce:initials>
<ce:surname>Zhou</ce:surname>
<ce:given-name>C.F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1256</first-page>
<last-page>1268</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhou, C.F., et al.: Cervical squamous cell carcinomasecreted exosomal miR-221-3p promotes lymphangiogenesis and lymphatic metastasis by targeting VASH1. Oncogene. 38, 1256–1268 (2019)</ref-fulltext>
<ce:source-text>Zhou, C.F., et al.: Cervical squamous cell carcinomasecreted exosomal miR-221-3p promotes lymphangiogenesis and lymphatic metastasis by targeting VASH1. Oncogene. 38, 1256–1268 (2019)</ce:source-text>
</reference>
<reference seq="159">
<ref-info>
<ref-title>
<ref-titletext-english>Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.E.</ce:initials>
<ce:surname>Hautmann</ce:surname>
<ce:given-name>R.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.C.</ce:initials>
<ce:surname>de Petriconi</ce:surname>
<ce:given-name>R.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Pfeiffer</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>B.G.</ce:initials>
<ce:surname>Volkmer</ce:surname>
<ce:given-name>B.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. Urol.</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>61</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1039</first-page>
<last-page>1047</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hautmann, R.E., de Petriconi, R.C., Pfeiffer, C., Volkmer, B.G.: Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur. Urol. 61, 1039–1047 (2012)</ref-fulltext>
<ce:source-text>Hautmann, R.E., de Petriconi, R.C., Pfeiffer, C., Volkmer, B.G.: Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur. Urol. 61, 1039–1047 (2012)</ce:source-text>
</reference>
<reference seq="160">
<ref-info>
<ref-title>
<ref-titletext-english> CD97 promotion of gastric carcinoma lymphatic metastasis is exosome dependent</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Gastric Cancer.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>754</first-page>
<last-page>766</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Liu, D., et al.: CD97 promotion of gastric carcinoma lymphatic metastasis is exosome dependent. Gastric Cancer. 19, 754–766 (2016)</ref-fulltext>
<ce:source-text>Liu, D., et al.: CD97 promotion of gastric carcinoma lymphatic metastasis is exosome dependent. Gastric Cancer. 19, 754–766 (2016)</ce:source-text>
</reference>
<reference seq="161">
<ref-info>
<ref-title>
<ref-titletext-english>Sentinel-node biopsy or nodal observation in melanoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.L.</ce:initials>
<ce:surname>Morton</ce:surname>
<ce:given-name>D.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>N. Engl. J. Med.</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>355</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1307</first-page>
<last-page>1317</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Morton, D.L., et al.: Sentinel-node biopsy or nodal observation in melanoma. N. Engl. J. Med. 355, 1307–1317 (2006)</ref-fulltext>
<ce:source-text>Morton, D.L., et al.: Sentinel-node biopsy or nodal observation in melanoma. N. Engl. J. Med. 355, 1307–1317 (2006)</ce:source-text>
</reference>
<reference seq="162">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer volume of lymph node metastasis predicts progression in prostate cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Cheng</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Surg. Pathol.</ref-sourcetitle>
<ref-publicationyear first="1998" />
<volisspag>
<volume-issue-number>
<vol-first>22</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1491</first-page>
<last-page>1500</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cheng, L., et al.: Cancer volume of lymph node metastasis predicts progression in prostate cancer. Am. J. Surg. Pathol. 22, 1491–1500 (1998)</ref-fulltext>
<ce:source-text>Cheng, L., et al.: Cancer volume of lymph node metastasis predicts progression in prostate cancer. Am. J. Surg. Pathol. 22, 1491–1500 (1998)</ce:source-text>
</reference>
<reference seq="163">
<ref-info>
<ref-title>
<ref-titletext-english>Sulfisoxazole inhibits the secretion of small extracellular vesicles by targeting the endothelin receptor A</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.J.</ce:initials>
<ce:surname>Im</ce:surname>
<ce:given-name>E.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1387</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Im, E.J., et al.: Sulfisoxazole inhibits the secretion of small extracellular vesicles by targeting the endothelin receptor A. Nat. Commun. 10, 1387 (2019)</ref-fulltext>
<ce:source-text>Im, E.J., et al.: Sulfisoxazole inhibits the secretion of small extracellular vesicles by targeting the endothelin receptor A. Nat. Commun. 10, 1387 (2019)</ce:source-text>
</reference>
<reference seq="164">
<ref-info>
<ref-title>
<ref-titletext-english>The lung microenvironment: an important regulator of tumour growth and metastasis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.K.</ce:initials>
<ce:surname>Altorki</ce:surname>
<ce:given-name>N.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>9</first-page>
<last-page>31</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Altorki, N.K., et al.: The lung microenvironment: an important regulator of tumour growth and metastasis. Nat. Rev. Cancer. 19, 9–31 (2019)</ref-fulltext>
<ce:source-text>Altorki, N.K., et al.: The lung microenvironment: an important regulator of tumour growth and metastasis. Nat. Rev. Cancer. 19, 9–31 (2019)</ce:source-text>
</reference>
<reference seq="165">
<ref-info>
<ref-title>
<ref-titletext-english>Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.T.</ce:initials>
<ce:surname>Erler</ce:surname>
<ce:given-name>J.T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell.</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>35</first-page>
<last-page>44</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Erler, J.T., et al.: Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell. 15, 35–44 (2009)</ref-fulltext>
<ce:source-text>Erler, J.T., et al.: Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell. 15, 35–44 (2009)</ce:source-text>
</reference>
<reference seq="166">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived exosomal miR-1247- 3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Fang</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun. </ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>191</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fang, T., et al.: Tumor-derived exosomal miR-1247- 3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer. Nat. Commun. 9, 191 (2018)</ref-fulltext>
<ce:source-text>Fang, T., et al.: Tumor-derived exosomal miR-1247- 3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer. Nat. Commun. 9, 191 (2018)</ce:source-text>
</reference>
<reference seq="167">
<ref-info>
<ref-title>
<ref-titletext-english>The liver</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Trefts</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Gannon</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.H.</ce:initials>
<ce:surname>Wasserman</ce:surname>
<ce:given-name>D.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Biol.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>R1147</first-page>
<last-page>R1151</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Trefts, E., Gannon, M., Wasserman, D.H.: The liver. Curr. Biol. 27, R1147–R1151 (2017)</ref-fulltext>
<ce:source-text>Trefts, E., Gannon, M., Wasserman, D.H.: The liver. Curr. Biol. 27, R1147–R1151 (2017)</ce:source-text>
</reference>
<reference seq="168">
<ref-info>
<ref-title>
<ref-titletext-english>Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>15016</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, H., et al.: Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis. Nat. Commun. 8, 15016 (2017)</ref-fulltext>
<ce:source-text>Zhang, H., et al.: Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis. Nat. Commun. 8, 15016 (2017)</ce:source-text>
</reference>
<reference seq="169">
<ref-info>
<ref-title>
<ref-titletext-english>Colorectal cancer-derived small extracellular vesicles establish an inflammatory premetastatic niche in liver metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Shao</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Carcinogenesis.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>39</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1368</first-page>
<last-page>1379</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shao, Y., et al.: Colorectal cancer-derived small extracellular vesicles establish an inflammatory premetastatic niche in liver metastasis. Carcinogenesis. 39, 1368–1379 (2018)</ref-fulltext>
<ce:source-text>Shao, Y., et al.: Colorectal cancer-derived small extracellular vesicles establish an inflammatory premetastatic niche in liver metastasis. Carcinogenesis. 39, 1368–1379 (2018)</ce:source-text>
</reference>
<reference seq="170">
<ref-info>
<ref-title>
<ref-titletext-english>Metastasis to bone: causes, consequences and therapeutic opportunities</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.R.</ce:initials>
<ce:surname>Mundy</ce:surname>
<ce:given-name>G.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2002" />
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>584</first-page>
<last-page>593</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mundy, G.R.: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer. 2, 584–593 (2002)</ref-fulltext>
<ce:source-text>Mundy, G.R.: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer. 2, 584–593 (2002)</ce:source-text>
</reference>
<reference seq="171">
<ref-info>
<ref-title>
<ref-titletext-english>RANKL-RANK signaling regulates osteoblast differentiation and bone formation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Cao</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Bone Res. </ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>35</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cao, X.: RANKL-RANK signaling regulates osteoblast differentiation and bone formation. Bone Res. 6, 35 (2018)</ref-fulltext>
<ce:source-text>Cao, X.: RANKL-RANK signaling regulates osteoblast differentiation and bone formation. Bone Res. 6, 35 (2018)</ce:source-text>
</reference>
<reference seq="172">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomal release of L-plastin by breast cancer cells facilitates metastatic bone osteolysis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Tiedemann</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Transl. Oncol. </ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>462</first-page>
<last-page>474</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tiedemann, K., et al.: Exosomal release of L-plastin by breast cancer cells facilitates metastatic bone osteolysis. Transl. Oncol. 12, 462–474 (2019)</ref-fulltext>
<ce:source-text>Tiedemann, K., et al.: Exosomal release of L-plastin by breast cancer cells facilitates metastatic bone osteolysis. Transl. Oncol. 12, 462–474 (2019)</ce:source-text>
</reference>
<reference seq="173">
<ref-info>
<ref-title>
<ref-titletext-english>Breast cancer cell-derived exosomal miR-20a-5p promotes the proliferation and differentiation of osteoclasts by targeting SRCIN1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Guo</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Med.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5687</first-page>
<last-page>5701</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Guo, L., et al.: Breast cancer cell-derived exosomal miR-20a-5p promotes the proliferation and differentiation of osteoclasts by targeting SRCIN1. Cancer Med. 8, 5687–5701 (2019)</ref-fulltext>
<ce:source-text>Guo, L., et al.: Breast cancer cell-derived exosomal miR-20a-5p promotes the proliferation and differentiation of osteoclasts by targeting SRCIN1. Cancer Med. 8, 5687–5701 (2019)</ce:source-text>
</reference>
<reference seq="174">
<ref-info>
<ref-title>
<ref-titletext-english> Communication of prostate cancer cells with bone cells via extracellular vesicle RNA; a potential mechanism of metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Probert</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1751</first-page>
<last-page>1763</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Probert, C., et al.: Communication of prostate cancer cells with bone cells via extracellular vesicle RNA; a potential mechanism of metastasis. Oncogene. 38, 1751–1763 (2019)</ref-fulltext>
<ce:source-text>Probert, C., et al.: Communication of prostate cancer cells with bone cells via extracellular vesicle RNA; a potential mechanism of metastasis. Oncogene. 38, 1751–1763 (2019)</ce:source-text>
</reference>
<reference seq="175">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomal miR-141-3p regulates osteoblast activity to promote the osteoblastic metastasis of prostate cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Ye</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>94834</first-page>
<last-page>94849</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ye, Y., et al.: Exosomal miR-141-3p regulates osteoblast activity to promote the osteoblastic metastasis of prostate cancer. Oncotarget. 8, 94834–94849 (2017)</ref-fulltext>
<ce:source-text>Ye, Y., et al.: Exosomal miR-141-3p regulates osteoblast activity to promote the osteoblastic metastasis of prostate cancer. Oncotarget. 8, 94834–94849 (2017)</ce:source-text>
</reference>
<reference seq="176">
<ref-info>
<ref-title>
<ref-titletext-english>Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.L.</ce:initials>
<ce:surname>Lacey</ce:surname>
<ce:given-name>D.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Drug Discov.</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>401</first-page>
<last-page>419</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lacey, D.L., et al.: Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat. Rev. Drug Discov. 11, 401–419 (2012)</ref-fulltext>
<ce:source-text>Lacey, D.L., et al.: Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat. Rev. Drug Discov. 11, 401–419 (2012)</ce:source-text>
</reference>
<reference seq="177">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Hashimoto</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>115</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2204</first-page>
<last-page>2209</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hashimoto, K., et al.: Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A. Proc. Natl. Acad. Sci. USA. 115, 2204–2209 (2018)</ref-fulltext>
<ce:source-text>Hashimoto, K., et al.: Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A. Proc. Natl. Acad. Sci. USA. 115, 2204–2209 (2018)</ce:source-text>
</reference>
<reference seq="178">
<ref-info>
<ref-title>
<ref-titletext-english>Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Tominaga</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun.</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>6716</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tominaga, N., et al.: Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier. Nat. Commun. 6, 6716 (2015)</ref-fulltext>
<ce:source-text>Tominaga, N., et al.: Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier. Nat. Commun. 6, 6716 (2015)</ce:source-text>
</reference>
<reference seq="179">
<ref-info>
<ref-title>
<ref-titletext-english>Loss of XIST in breast cancer activates MSN-c-Met and reprograms microglia via exosomal miRNA to promote brain metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Xing</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first />
<iss-first />
</volume-issue-number>
<page-information>
<pages>
<first-page>4316</first-page>
<last-page>4330</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xing, F., et al.: Loss of XIST in breast cancer activates MSN-c-Met and reprograms microglia via exosomal miRNA to promote brain metastasis. Cancer Res. 78, 4316–4330 (2018)</ref-fulltext>
<ce:source-text>Xing, F., et al.: Loss of XIST in breast cancer activates MSN-c-Met and reprograms microglia via exosomal miRNA to promote brain metastasis. Cancer Res. 78, 4316–4330 (2018)</ce:source-text>
</reference>
<reference seq="180">
<ref-info>
<ref-title>
<ref-titletext-english>Melanoma-derived extracellular vesicles instigate proinflammatory signaling in the metastatic microenvironment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Gener Lahav</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer. </ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>145</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2521</first-page>
<last-page>2534</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gener Lahav, T., et al.: Melanoma-derived extracellular vesicles instigate proinflammatory signaling in the metastatic microenvironment. Int. J. Cancer. 145, 2521–2534 (2019)</ref-fulltext>
<ce:source-text>Gener Lahav, T., et al.: Melanoma-derived extracellular vesicles instigate proinflammatory signaling in the metastatic microenvironment. Int. J. Cancer. 145, 2521–2534 (2019)</ce:source-text>
</reference>
<reference seq="181">
<ref-info>
<ref-title>
<ref-titletext-english>Blood-brain barrier: from physiology to disease and back</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.D.</ce:initials>
<ce:surname>Sweeney</ce:surname>
<ce:given-name>M.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Z.</ce:initials>
<ce:surname>Zhao</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Montagne</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.R.</ce:initials>
<ce:surname>Nelson</ce:surname>
<ce:given-name>A.R.</ce:given-name>
</author>
<author seq="5">
<ce:initials>B.V.</ce:initials>
<ce:surname>Zlokovic</ce:surname>
<ce:given-name>B.V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Physiol. Rev.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>99</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>21</first-page>
<last-page>78</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sweeney, M.D., Zhao, Z., Montagne, A., Nelson, A. R., Zlokovic, B.V.: Blood-brain barrier: from physiology to disease and back. Physiol. Rev. 99, 21–78 (2019)</ref-fulltext>
<ce:source-text>Sweeney, M.D., Zhao, Z., Montagne, A., Nelson, A. R., Zlokovic, B.V.: Blood-brain barrier: from physiology to disease and back. Physiol. Rev. 99, 21–78 (2019)</ce:source-text>
</reference>
<reference seq="182">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived extracellular vesicles breach the intact blood-brain barrier via transcytosis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Morad</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>ACS Nano. </ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>13</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>13853</first-page>
<last-page>13865</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Morad, G., et al.: Tumor-derived extracellular vesicles breach the intact blood-brain barrier via transcytosis. ACS Nano. 13, 13853–13865 (2019)</ref-fulltext>
<ce:source-text>Morad, G., et al.: Tumor-derived extracellular vesicles breach the intact blood-brain barrier via transcytosis. ACS Nano. 13, 13853–13865 (2019)</ce:source-text>
</reference>
<reference seq="183">
<ref-info>
<ref-title>
<ref-titletext-english> Brain microvascular endothelial cell exosome-mediated S100A16 up-regulation confers small-cell lung cancer cell survival in brain</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.H.</ce:initials>
<ce:surname>Xu</ce:surname>
<ce:given-name>Z.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>FASEB
J.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1742</first-page>
<last-page>1757</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xu, Z.H., et al.: Brain microvascular endothelial cell exosome-mediated S100A16 up-regulation confers small-cell lung cancer cell survival in brain. FASEB J. 33, 1742–1757 (2019)</ref-fulltext>
<ce:source-text>Xu, Z.H., et al.: Brain microvascular endothelial cell exosome-mediated S100A16 up-regulation confers small-cell lung cancer cell survival in brain. FASEB J. 33, 1742–1757 (2019)</ce:source-text>
</reference>
<reference seq="184">
<ref-info>
<ref-title>
<ref-titletext-english>Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature.</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>527</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>100</first-page>
<last-page>104</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, L., et al.: Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature. 527, 100–104 (2015)</ref-fulltext>
<ce:source-text>Zhang, L., et al.: Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature. 527, 100–104 (2015)</ce:source-text>
</reference>
<reference seq="185">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD1 response</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature. </ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>560</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>382</first-page>
<last-page>386</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, G., et al.: Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD1 response. Nature. 560, 382–386 (2018)</ref-fulltext>
<ce:source-text>Chen, G., et al.: Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD1 response. Nature. 560, 382–386 (2018)</ce:source-text>
</reference>
<reference seq="186">
<ref-info>
<ref-title>
<ref-titletext-english>Astrocytes and Glioblastoma cells release exosomes carrying mtDNA</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Guescini</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Genedani</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>V.</ce:initials>
<ce:surname>Stocchi</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
<author seq="4">
<ce:initials>L.F.</ce:initials>
<ce:surname>Agnati</ce:surname>
<ce:given-name>L.F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Neural Transm. (Vienna).</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>117</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1</first-page>
<last-page>4</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Guescini, M., Genedani, S., Stocchi, V., Agnati, L.F.: Astrocytes and Glioblastoma cells release exosomes carrying mtDNA. J. Neural Transm. (Vienna). 117, 1–4 (2010)</ref-fulltext>
<ce:source-text>Guescini, M., Genedani, S., Stocchi, V., Agnati, L.F.: Astrocytes and Glioblastoma cells release exosomes carrying mtDNA. J. Neural Transm. (Vienna). 117, 1–4 (2010)</ce:source-text>
</reference>
<reference seq="187">
<ref-info>
<ref-title>
<ref-titletext-english>Double-stranded DNA in exosomes: a novel biomarker in cancer detection</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.K.</ce:initials>
<ce:surname>Thakur</ce:surname>
<ce:given-name>B.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Res.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>766</first-page>
<last-page>769</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Thakur, B.K., et al.: Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res. 24, 766–769 (2014)</ref-fulltext>
<ce:source-text>Thakur, B.K., et al.: Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res. 24, 766–769 (2014)</ce:source-text>
</reference>
<reference seq="188">
<ref-info>
<ref-title>
<ref-titletext-english>Exosome DNA: critical regulator of tumor immunity and a diagnostic biomarker</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Sharma</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Johnson</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Physiol.</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>235</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1921</first-page>
<last-page>1932</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sharma, A., Johnson, A.: Exosome DNA: critical regulator of tumor immunity and a diagnostic biomarker. J. Cell. Physiol. 235, 1921–1932 (2020)</ref-fulltext>
<ce:source-text>Sharma, A., Johnson, A.: Exosome DNA: critical regulator of tumor immunity and a diagnostic biomarker. J. Cell. Physiol. 235, 1921–1932 (2020)</ce:source-text>
</reference>
<reference seq="189">
<ref-info>
<ref-title>
<ref-titletext-english>DNA-containing exosomes derived from cancer cells treated with topotecan activate a STING-dependent pathway and reinforce antitumor immunity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Kitai</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Immunol.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>198</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1649</first-page>
<last-page>1659</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kitai, Y., et al.: DNA-containing exosomes derived from cancer cells treated with topotecan activate a STING-dependent pathway and reinforce antitumor immunity. J. Immunol. 198, 1649–1659 (2017)</ref-fulltext>
<ce:source-text>Kitai, Y., et al.: DNA-containing exosomes derived from cancer cells treated with topotecan activate a STING-dependent pathway and reinforce antitumor immunity. J. Immunol. 198, 1649–1659 (2017)</ce:source-text>
</reference>
<reference seq="190">
<ref-info>
<ref-title>
<ref-titletext-english> Dendritic cells but not macrophages sense tumor mitochondrial DNA for cross-priming through signal regulatory protein alpha signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.M.</ce:initials>
<ce:surname>Xu</ce:surname>
<ce:given-name>M.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Immunity. </ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>47</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>363</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xu, M.M., et al.: Dendritic cells but not macrophages sense tumor mitochondrial DNA for cross-priming through signal regulatory protein alpha signaling. Immunity. 47, 363-+ (2017)</ref-fulltext>
<ce:source-text>Xu, M.M., et al.: Dendritic cells but not macrophages sense tumor mitochondrial DNA for cross-priming through signal regulatory protein alpha signaling. Immunity. 47, 363-+ (2017)</ce:source-text>
</reference>
<reference seq="191">
<ref-info>
<ref-title>
<ref-titletext-english> Metabolomic profiling of extracellular vesicles and alternative normalization methods reveal enriched metabolites and strategies to study prostate cancer-related changes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Puhka</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Theranostics.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3824</first-page>
<last-page>3841</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Puhka, M., et al.: Metabolomic profiling of extracellular vesicles and alternative normalization methods reveal enriched metabolites and strategies to study prostate cancer-related changes. Theranostics. 7, 3824–3841 (2017)</ref-fulltext>
<ce:source-text>Puhka, M., et al.: Metabolomic profiling of extracellular vesicles and alternative normalization methods reveal enriched metabolites and strategies to study prostate cancer-related changes. Theranostics. 7, 3824–3841 (2017)</ce:source-text>
</reference>
<reference seq="192">
<ref-info>
<ref-title>
<ref-titletext-english>Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.P.</ce:initials>
<ce:surname>Lai</ce:surname>
<ce:given-name>C.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun.</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7029</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lai, C.P., et al.: Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters. Nat. Commun. 6, 7029 (2015)</ref-fulltext>
<ce:source-text>Lai, C.P., et al.: Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters. Nat. Commun. 6, 7029 (2015)</ce:source-text>
</reference>
<reference seq="193">
<ref-info>
<ref-title>
<ref-titletext-english>In vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Zomer</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell.</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>161</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1046</first-page>
<last-page>1057</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zomer, A., et al.: In vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior. Cell. 161, 1046–1057 (2015)</ref-fulltext>
<ce:source-text>Zomer, A., et al.: In vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior. Cell. 161, 1046–1057 (2015)</ce:source-text>
</reference>
<reference seq="194">
<ref-info>
<ref-title>
<ref-titletext-english> Studying extracellular vesicle transfer by a Cre-loxP method</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Zomer</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.C.</ce:initials>
<ce:surname>Steenbeek</ce:surname>
<ce:given-name>S.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Maynard</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>van Rheenen</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Protoc.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>87</first-page>
<last-page>101</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zomer, A., Steenbeek, S.C., Maynard, C., van Rheenen, J.: Studying extracellular vesicle transfer by a Cre-loxP method. Nat. Protoc. 11, 87–101 (2016)</ref-fulltext>
<ce:source-text>Zomer, A., Steenbeek, S.C., Maynard, C., van Rheenen, J.: Studying extracellular vesicle transfer by a Cre-loxP method. Nat. Protoc. 11, 87–101 (2016)</ce:source-text>
</reference>
<reference seq="195">
<ref-info>
<ref-title>
<ref-titletext-english>Studying the fate of tumor extracellular vesicles at high spatiotemporal resolution using the zebrafish embryo</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.</ce:initials>
<ce:surname>Hyenne</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Dev. Cell. </ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>48</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>554</first-page>
<last-page>572</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hyenne, V., et al.: Studying the fate of tumor extracellular vesicles at high spatiotemporal resolution using the zebrafish embryo. Dev. Cell. 48, 554–572 e557 (2019)</ref-fulltext>
<ce:source-text>Hyenne, V., et al.: Studying the fate of tumor extracellular vesicles at high spatiotemporal resolution using the zebrafish embryo. Dev. Cell. 48, 554–572 e557 (2019)</ce:source-text>
</reference>
<reference seq="196">
<ref-info>
<ref-title>
<ref-titletext-english> Cancer cachexia: mediators, signaling, and metabolic pathways</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.C.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.J.</ce:initials>
<ce:surname>Glass</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.C.</ce:initials>
<ce:surname>Guttridge</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab.</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>153</first-page>
<last-page>166</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fearon, K.C., Glass, D.J., Guttridge, D.C.: Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 16, 153–166 (2012)</ref-fulltext>
<ce:source-text>Fearon, K.C., Glass, D.J., Guttridge, D.C.: Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 16, 153–166 (2012)</ce:source-text>
</reference>
<reference seq="197">
<ref-info>
<ref-title>
<ref-titletext-english>Understanding cachexia as a cancer metabolism syndrome</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.E.</ce:initials>
<ce:surname>Porporato</ce:surname>
<ce:given-name>P.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogenesis.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Porporato, P.E.: Understanding cachexia as a cancer metabolism syndrome. Oncogenesis. 5 (2016)</ref-fulltext>
<ce:source-text>Porporato, P.E.: Understanding cachexia as a cancer metabolism syndrome. Oncogenesis. 5 (2016)</ce:source-text>
</reference>
<reference seq="198">
<ref-info>
<ref-title>
<ref-titletext-english>Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Med.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>770</first-page>
<last-page>781</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, G., et al.: Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle. Nat. Med. 24, 770–781 (2018)</ref-fulltext>
<ce:source-text>Wang, G., et al.: Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle. Nat. Med. 24, 770–781 (2018)</ce:source-text>
</reference>
<reference seq="199">
<ref-info>
<ref-title>
<ref-titletext-english> Cancer-associated cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Martin</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Korc</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>D.C.</ce:initials>
<ce:surname>Guttridge</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
<author seq="5">
<ce:initials>K.C.H.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.C.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Dis. Primers.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>17105</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baracos, V.E., Martin, L., Korc, M., Guttridge, D.C., Fearon, K.C.H.: Cancer-associated cachexia. Nat. Rev. Dis. Primers. 4, 17105 (2018)</ref-fulltext>
<ce:source-text>Baracos, V.E., Martin, L., Korc, M., Guttridge, D.C., Fearon, K.C.H.: Cancer-associated cachexia. Nat. Rev. Dis. Primers. 4, 17105 (2018)</ce:source-text>
</reference>
<reference seq="200">
<ref-info>
<ref-title>
<ref-titletext-english> Cancer-derived exosome miRNAs induce skeletal muscle wasting by Bcl-2-mediated apoptosis in colon cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Miao</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> Mol. Ther. Nucleic Acids.</ref-sourcetitle>
<ref-publicationyear first="2021" />
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>923</first-page>
<last-page>938</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Miao, C., et al.: Cancer-derived exosome miRNAs induce skeletal muscle wasting by Bcl-2-mediated apoptosis in colon cancer cachexia. Mol. Ther. Nucleic Acids. 24, 923–938 (2021)</ref-fulltext>
<ce:source-text>Miao, C., et al.: Cancer-derived exosome miRNAs induce skeletal muscle wasting by Bcl-2-mediated apoptosis in colon cancer cachexia. Mol. Ther. Nucleic Acids. 24, 923–938 (2021)</ce:source-text>
</reference>
<reference seq="201">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>589</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, G., et al.: Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90. Nat. Commun. 8, 589 (2017)</ref-fulltext>
<ce:source-text>Zhang, G., et al.: Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90. Nat. Commun. 8, 589 (2017)</ce:source-text>
</reference>
<reference seq="202">
<ref-info>
<ref-title>
<ref-titletext-english>Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.A.</ce:initials>
<ce:surname>He</ce:surname>
<ce:given-name>W.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>111</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4525</first-page>
<last-page>4529</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>He, W.A., et al.: Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7. Proc. Natl. Acad. Sci. USA. 111, 4525–4529 (2014)</ref-fulltext>
<ce:source-text>He, W.A., et al.: Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7. Proc. Natl. Acad. Sci. USA. 111, 4525–4529 (2014)</ce:source-text>
</reference>
<reference seq="203">
<ref-info>
<ref-title>
<ref-titletext-english>Pathogenesis of pancreatic cancer exosome-induced lipolysis in adipose tissue</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Sagar</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Gut.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>65</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1165</first-page>
<last-page>1174</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sagar, G., et al.: Pathogenesis of pancreatic cancer exosome-induced lipolysis in adipose tissue. Gut. 65, 1165–1174 (2016)</ref-fulltext>
<ce:source-text>Sagar, G., et al.: Pathogenesis of pancreatic cancer exosome-induced lipolysis in adipose tissue. Gut. 65, 1165–1174 (2016)</ce:source-text>
</reference>
<reference seq="204">
<ref-info>
<ref-title>
<ref-titletext-english>Reduced adipogenesis after lung tumor exosomes priming in human mesenchymal stem cells via TGFbeta signaling pathway</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>X.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Xu</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="5">
<ce:initials>R.C.</ce:initials>
<ce:surname>Zhao</ce:surname>
<ce:given-name>R.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cell. Biochem.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>435</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>59</first-page>
<last-page>66</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, S., Li, X., Xu, M., Wang, J., Zhao, R.C.: Reduced adipogenesis after lung tumor exosomes priming in human mesenchymal stem cells via TGFbeta signaling pathway. Mol. Cell. Biochem. 435, 59–66 (2017)</ref-fulltext>
<ce:source-text>Wang, S., Li, X., Xu, M., Wang, J., Zhao, R.C.: Reduced adipogenesis after lung tumor exosomes priming in human mesenchymal stem cells via TGFbeta signaling pathway. Mol. Cell. Biochem. 435, 59–66 (2017)</ce:source-text>
</reference>
<reference seq="205">
<ref-info>
<ref-title>
<ref-titletext-english>A switch from white to brown fat increases energy expenditure in cancer-associated cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Petruzzelli</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>433</first-page>
<last-page>447</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Petruzzelli, M., et al.: A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab. 20, 433–447 (2014)</ref-fulltext>
<ce:source-text>Petruzzelli, M., et al.: A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab. 20, 433–447 (2014)</ce:source-text>
</reference>
<reference seq="206">
<ref-info>
<ref-title>
<ref-titletext-english>Tumour-originated exosomal miR-155 triggers cancer-associated cachexia to promote tumour progression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Q.</ce:initials>
<ce:surname>Wu</ce:surname>
<ce:given-name>Q.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>155</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wu, Q., et al.: Tumour-originated exosomal miR-155 triggers cancer-associated cachexia to promote tumour progression. Mol. Cancer. 17, 155 (2018)</ref-fulltext>
<ce:source-text>Wu, Q., et al.: Tumour-originated exosomal miR-155 triggers cancer-associated cachexia to promote tumour progression. Mol. Cancer. 17, 155 (2018)</ce:source-text>
</reference>
<reference seq="207">
<ref-info>
<ref-title>
<ref-titletext-english>Colorectal cancer prompted adipose tissue browning and cancer cachexia through transferring exosomal miR-146b-5p</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.J.</ce:initials>
<ce:surname>Di</ce:surname>
<ce:given-name>W.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Physiol.</ref-sourcetitle>
<ref-publicationyear first="2021" />
<volisspag>
<volume-issue-number>
<vol-first>236</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5399</first-page>
<last-page>5410</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Di, W.J., et al.: Colorectal cancer prompted adipose tissue browning and cancer cachexia through transferring exosomal miR-146b-5p. J. Cell. Physiol. 236, 5399–5410 (2021)</ref-fulltext>
<ce:source-text>Di, W.J., et al.: Colorectal cancer prompted adipose tissue browning and cancer cachexia through transferring exosomal miR-146b-5p. J. Cell. Physiol. 236, 5399–5410 (2021)</ce:source-text>
</reference>
<reference seq="208">
<ref-info>
<ref-title>
<ref-titletext-english>Paraneoplastic syndromes in rheumatology</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Manger</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Schett</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Rheumatol. </ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>662</first-page>
<last-page>670</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Manger, B., Schett, G.: Paraneoplastic syndromes in rheumatology. Nat. Rev. Rheumatol. 10, 662–670 (2014)</ref-fulltext>
<ce:source-text>Manger, B., Schett, G.: Paraneoplastic syndromes in rheumatology. Nat. Rev. Rheumatol. 10, 662–670 (2014)</ce:source-text>
</reference>
<reference seq="209">
<ref-info>
<ref-title>
<ref-titletext-english>Pancreatic cancer-derived exosomes cause paraneoplastic beta-cell dysfunction</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Javeed</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1722</first-page>
<last-page>1733</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Javeed, N., et al.: Pancreatic cancer-derived exosomes cause paraneoplastic beta-cell dysfunction. Clin. Cancer Res. 21, 1722–1733 (2015)</ref-fulltext>
<ce:source-text>Javeed, N., et al.: Pancreatic cancer-derived exosomes cause paraneoplastic beta-cell dysfunction. Clin. Cancer Res. 21, 1722–1733 (2015)</ce:source-text>
</reference>
<reference seq="210">
<ref-info>
<ref-title>
<ref-titletext-english> Intercellular transfer of tissue factor via the uptake of tumor-derived microvesicles</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.G.</ce:initials>
<ce:surname>Lima</ce:surname>
<ce:given-name>L.G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.C.</ce:initials>
<ce:surname>Leal</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>G.</ce:initials>
<ce:surname>Vargas</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="4">
<ce:initials>I.</ce:initials>
<ce:surname>Porto-Carreiro</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="5">
<ce:initials>R.Q.</ce:initials>
<ce:surname>Monteiro</ce:surname>
<ce:given-name>R.Q.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Thromb. Res.</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>132</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>450</first-page>
<last-page>456</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lima, L.G., Leal, A.C., Vargas, G., Porto-Carreiro, I., Monteiro, R.Q.: Intercellular transfer of tissue factor via the uptake of tumor-derived microvesicles. Thromb. Res. 132, 450–456 (2013)</ref-fulltext>
<ce:source-text>Lima, L.G., Leal, A.C., Vargas, G., Porto-Carreiro, I., Monteiro, R.Q.: Intercellular transfer of tissue factor via the uptake of tumor-derived microvesicles. Thromb. Res. 132, 450–456 (2013)</ce:source-text>
</reference>
<reference seq="211">
<ref-info>
<ref-title>
<ref-titletext-english>Breast-cancer extracellular vesicles induce platelet activation and aggregation by tissue factor-independent and -dependent mechanisms</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.G.</ce:initials>
<ce:surname>Gomes</ce:surname>
<ce:given-name>F.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Thromb. Res.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>159</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>24</first-page>
<last-page>32</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gomes, F.G., et al.: Breast-cancer extracellular vesicles induce platelet activation and aggregation by tissue factor-independent and -dependent mechanisms. Thromb. Res. 159, 24–32 (2017)</ref-fulltext>
<ce:source-text>Gomes, F.G., et al.: Breast-cancer extracellular vesicles induce platelet activation and aggregation by tissue factor-independent and -dependent mechanisms. Thromb. Res. 159, 24–32 (2017)</ce:source-text>
</reference>
<reference seq="212">
<ref-info>
<ref-title>
<ref-titletext-english>International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S.</ce:initials>
<ce:surname>Wefel</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Vardy</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Ahles</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.B.</ce:initials>
<ce:surname>Schagen</ce:surname>
<ce:given-name>S.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Lancet Oncol. </ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>703</first-page>
<last-page>708</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wefel, J.S., Vardy, J., Ahles, T., Schagen, S.B.: International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 12, 703–708 (2011)</ref-fulltext>
<ce:source-text>Wefel, J.S., Vardy, J., Ahles, T., Schagen, S.B.: International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 12, 703–708 (2011)</ce:source-text>
</reference>
<reference seq="213">
<ref-info>
<ref-title>
<ref-titletext-english> Role of exosomes in cancer-related cognitive impairment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.Q.</ce:initials>
<ce:surname>Koh</ce:surname>
<ce:given-name>Y.Q.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Mol. Sci.</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Koh, Y.Q., et al.: Role of exosomes in cancer-related cognitive impairment. Int. J. Mol. Sci. 21 (2020)</ref-fulltext>
<ce:source-text>Koh, Y.Q., et al.: Role of exosomes in cancer-related cognitive impairment. Int. J. Mol. Sci. 21 (2020)</ce:source-text>
</reference>
<reference seq="214">
<ref-info>
<ref-title>
<ref-titletext-english>Ionizing radiation increases the activity of exosomal secretory pathway in MCF-7 human breast cancer cells: a possible way to communicate resistance against radiotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Jabbari</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Nawaz</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Rezaie</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Mol. Sci.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Jabbari, N., Nawaz, M., Rezaie, J.: Ionizing radiation increases the activity of exosomal secretory pathway in MCF-7 human breast cancer cells: a possible way to communicate resistance against radiotherapy. Int. J. Mol. Sci. 20 (2019)</ref-fulltext>
<ce:source-text>Jabbari, N., Nawaz, M., Rezaie, J.: Ionizing radiation increases the activity of exosomal secretory pathway in MCF-7 human breast cancer cells: a possible way to communicate resistance against radiotherapy. Int. J. Mol. Sci. 20 (2019)</ce:source-text>
</reference>
<reference seq="215">
<ref-info>
<ref-title>
<ref-titletext-english>Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.K.</ce:initials>
<ce:surname>Bandari</ce:surname>
<ce:given-name>S.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Matrix Biol.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>65</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>104</first-page>
<last-page>118</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bandari, S.K., et al.: Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior. Matrix Biol. 65, 104–118 (2018)</ref-fulltext>
<ce:source-text>Bandari, S.K., et al.: Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior. Matrix Biol. 65, 104–118 (2018)</ce:source-text>
</reference>
<reference seq="216">
<ref-info>
<ref-title>
<ref-titletext-english> Identifying predictors of taxaneinduced peripheral neuropathy using mass spectrometry-based proteomics technology</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.I.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>E.I.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>PLoS One.</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Chen, E.I., et al.: Identifying predictors of taxaneinduced peripheral neuropathy using mass spectrometry-based proteomics technology. PLoS One. 10 (2015)</ref-fulltext>
<ce:source-text>Chen, E.I., et al.: Identifying predictors of taxaneinduced peripheral neuropathy using mass spectrometry-based proteomics technology. PLoS One. 10 (2015)</ce:source-text>
</reference>
<reference seq="217">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomes as a multicomponent biomarker platform in cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.S.</ce:initials>
<ce:surname>LeBleu</ce:surname>
<ce:given-name>V.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Kalluri</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Trends Cancer.</ref-sourcetitle>
<ref-publicationyear first="2020" />
</ref-info>
<ref-fulltext>LeBleu, V.S., Kalluri, R.: Exosomes as a multicomponent biomarker platform in cancer. Trends Cancer. (2020)</ref-fulltext>
<ce:source-text>LeBleu, V.S., Kalluri, R.: Exosomes as a multicomponent biomarker platform in cancer. Trends Cancer. (2020)</ce:source-text>
</reference>
<reference seq="218">
<ref-info>
<ref-title>
<ref-titletext-english>MicroRNAs in serum exosomes as potential biomarkers in clear-cell renal cell carcinoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. Urol. Focus.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>412</first-page>
<last-page>419</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, W., et al.: MicroRNAs in serum exosomes as potential biomarkers in clear-cell renal cell carcinoma. Eur. Urol. Focus. 4, 412–419 (2018)</ref-fulltext>
<ce:source-text>Zhang, W., et al.: MicroRNAs in serum exosomes as potential biomarkers in clear-cell renal cell carcinoma. Eur. Urol. Focus. 4, 412–419 (2018)</ce:source-text>
</reference>
<reference seq="219">
<ref-info>
<ref-title>
<ref-titletext-english>Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.S.</ce:initials>
<ce:surname>Yang</ce:surname>
<ce:given-name>K.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Transl. Med. </ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Yang, K.S., et al.: Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy. Sci. Transl. Med. 9 (2017)</ref-fulltext>
<ce:source-text>Yang, K.S., et al.: Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy. Sci. Transl. Med. 9 (2017)</ce:source-text>
</reference>
<reference seq="220">
<ref-info>
<ref-title>
<ref-titletext-english>Progress in exosome isolation techniques</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Kaslan</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.H.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>S.H.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Yao</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="5">
<ce:initials>Z.</ce:initials>
<ce:surname>Gao</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Theranostics. </ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>789</first-page>
<last-page>804</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Li, P., Kaslan, M., Lee, S.H., Yao, J., Gao, Z.: Progress in exosome isolation techniques. Theranostics. 7, 789–804 (2017)</ref-fulltext>
<ce:source-text>Li, P., Kaslan, M., Lee, S.H., Yao, J., Gao, Z.: Progress in exosome isolation techniques. Theranostics. 7, 789–804 (2017)</ce:source-text>
</reference>
<reference seq="221">
<ref-info>
<ref-title>
<ref-titletext-english>Cardiovascular effects of systemic cancer treatment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Senkus</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Jassem</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Treat. Rev.</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>37</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>300</first-page>
<last-page>311</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Senkus, E., Jassem, J.: Cardiovascular effects of systemic cancer treatment. Cancer Treat. Rev. 37, 300–311 (2011)</ref-fulltext>
<ce:source-text>Senkus, E., Jassem, J.: Cardiovascular effects of systemic cancer treatment. Cancer Treat. Rev. 37, 300–311 (2011)</ce:source-text>
</reference>
<reference seq="222">
<ref-info>
<ref-title>
<ref-titletext-english>A paradigm shift in cancer immunotherapy: from enhancement to normalization</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.F.</ce:initials>
<ce:surname>Sanmamed</ce:surname>
<ce:given-name>M.F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname> Chen</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>175</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>313</first-page>
<last-page>326</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sanmamed, M.F., Chen, L.: A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. 175, 313–326 (2018)</ref-fulltext>
<ce:source-text>Sanmamed, M.F., Chen, L.: A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. 175, 313–326 (2018)</ce:source-text>
</reference>
<reference seq="223">
<ref-info>
<ref-title>
<ref-titletext-english>Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>X.</ce:initials>
<ce:surname>Han</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest.</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>125</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3384</first-page>
<last-page>3391</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, L., Han, X.: Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J. Clin. Invest. 125, 3384–3391 (2015)</ref-fulltext>
<ce:source-text>Chen, L., Han, X.: Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J. Clin. Invest. 125, 3384–3391 (2015)</ce:source-text>
</reference>
<reference seq="224">
<ref-info>
<ref-title>
<ref-titletext-english>Immune modulation in cancer with antibodies</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.B.</ce:initials>
<ce:surname>Page</ce:surname>
<ce:given-name>D.B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.A.</ce:initials>
<ce:surname>Postow</ce:surname>
<ce:given-name>M.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.K.</ce:initials>
<ce:surname>Callahan</ce:surname>
<ce:given-name>M.K.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.P.</ce:initials>
<ce:surname>Allison</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.D.</ce:initials>
<ce:surname>Wolchok</ce:surname>
<ce:given-name>J.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Annu. Rev. Med.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>65</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>185</first-page>
<last-page>202</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Page, D.B., Postow, M.A., Callahan, M.K., Allison, J.P., Wolchok, J.D.: Immune modulation in cancer with antibodies. Annu. Rev. Med. 65, 185–202 (2014)</ref-fulltext>
<ce:source-text>Page, D.B., Postow, M.A., Callahan, M.K., Allison, J.P., Wolchok, J.D.: Immune modulation in cancer with antibodies. Annu. Rev. Med. 65, 185–202 (2014)</ce:source-text>
</reference>
<reference seq="225">
<ref-info>
<ref-title>
<ref-titletext-english>Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Poggio</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>177</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>414</first-page>
<last-page>427</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Poggio, M., et al.: Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell. 177, 414–427 e413 (2019)</ref-fulltext>
<ce:source-text>Poggio, M., et al.: Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell. 177, 414–427 e413 (2019)</ce:source-text>
</reference>
<reference seq="226">
<ref-info>
<ref-title>
<ref-titletext-english>Engineering exosomes as refined biological nanoplatforms for drug delivery</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Luan</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Acta Pharmacol. Sin.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>754</first-page>
<last-page>763</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Luan, X., et al.: Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacol. Sin. 38, 754–763 (2017)</ref-fulltext>
<ce:source-text>Luan, X., et al.: Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacol. Sin. 38, 754–763 (2017)</ce:source-text>
</reference>
<reference seq="227">
<ref-info>
<ref-title>
<ref-titletext-english>Treatment of brain metastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Lin</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.M.</ce:initials>
<ce:surname>DeAngelis</ce:surname>
<ce:given-name>L.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol.</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3475</first-page>
<last-page>3484</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lin, X., DeAngelis, L.M.: Treatment of brain metastases. J. Clin. Oncol. 33, 3475–3484 (2015)</ref-fulltext>
<ce:source-text>Lin, X., DeAngelis, L.M.: Treatment of brain metastases. J. Clin. Oncol. 33, 3475–3484 (2015)</ce:source-text>
</reference>
<reference seq="228">
<ref-info>
<ref-title>
<ref-titletext-english>A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Tian</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biomaterials.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2383</first-page>
<last-page>2390</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tian, Y., et al.: A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials. 35, 2383–2390 (2014)</ref-fulltext>
<ce:source-text>Tian, Y., et al.: A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials. 35, 2383–2390 (2014)</ce:source-text>
</reference>
<reference seq="229">
<ref-info>
<ref-title>
<ref-titletext-english> Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Kamerkar</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>546</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>498</first-page>
<last-page>503</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kamerkar, S., et al.: Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature. 546, 498–503 (2017)</ref-fulltext>
<ce:source-text>Kamerkar, S., et al.: Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature. 546, 498–503 (2017)</ce:source-text>
</reference>
<reference seq="230">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomal formulation of anthocyanidins against multiple cancer types</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Munagala</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Lett.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>393</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>94</first-page>
<last-page>102</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Munagala, R., et al.: Exosomal formulation of anthocyanidins against multiple cancer types. Cancer Lett. 393, 94–102 (2017)</ref-fulltext>
<ce:source-text>Munagala, R., et al.: Exosomal formulation of anthocyanidins against multiple cancer types. Cancer Lett. 393, 94–102 (2017)</ce:source-text>
</reference>
</bibliography>
</tail>
</bibrecord>
<bibrecord>
<item-info>
<status state="new" stage="S300" />
<itemidlist>
<ce:doi>10.1007/978-3-031-09518-4_3</ce:doi>
<itemid idtype="TPB-ID">20232000349315</itemid>
</itemidlist>
</item-info>
<head>
<citation-info>
<citation-type code="ch" />
<citation-language xml:lang="ENG" />
<abstract-language xml:lang="ENG" />
</citation-info>
<citation-title>
<titletext xml:lang="ENG" original="y">Bone Metastases: Systemic Regulation and Impact on Host</titletext>
</citation-title>
<author-group seq="1">
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Suresh</ce:surname>
<ce:given-name>Sukanya</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.A.</ce:initials>
<ce:surname>Guise</ce:surname>
<ce:given-name>Theresa A.</ce:given-name>
<ce:e-address>TAGuise@mdanderson.org</ce:e-address>
</author>
<affiliation>
<organization>Department of Endocrine Neoplasia and Hormonal Disorders</organization>
<organization>The University of Texas MD Anderson Cancer Center</organization>
<city>Houston</city>
<state>Texas</state>
<country iso-code="USA" />
<ce:source-text>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA</ce:source-text>
</affiliation>
</author-group>
<correspondence>
<person>
<ce:initials>T.A.</ce:initials>
<ce:surname>Guise</ce:surname>
<ce:given-name>Theresa A.</ce:given-name>
<ce:e-address>TAGuise@mdanderson.org</ce:e-address>
</person>
<affiliation>
<organization>Department of Endocrine Neoplasia and Hormonal Disorders</organization>
<organization>The University of Texas MD Anderson Cancer Center</organization>
<city>Houston</city>
<state>Texas</state>
<country iso-code="USA" />
<ce:source-text>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA</ce:source-text>
</affiliation>
</correspondence>
<abstracts>
<abstract xml:lang="ENG" original="y">
<publishercopyright>© Springer Nature Switzerland AG 2022</publishercopyright>
<ce:para>Advanced cancers frequently metastasize to bone and disrupt normal bone remodeling to cause bone destruction. Bone metastases are incurable and result in significant morbidity: pain, fracture, hypercalcemia, spinal cord compression, and muscle weakness. The associated muscle weakness may occur prior to or in the absence of cachexia. Tumorinduced bone destruction causes the release of growth factors that can fuel tumor progression in bone. These factors can also act systemically to cause muscle weakness. The resulting muscle dysfunction adds to cancerassociated morbidity and can increase the risk of falls and fractures in patients with bone metastases. In this review, we discuss the mechanisms by which bone metastases can induce muscle weakness and potential ways to identify and treat cancer-induced systemic dysfunction.</ce:para>
</abstract>
</abstracts>
<source type="book" country="USA">
<sourcetitle>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle>
<sourcetitle-abbrev>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle-abbrev>
<isbn type="print" length="13">9783031072727</isbn>
<isbn type="electronic" length="13">9783031095184</isbn>
<volisspag>
<page-information>
<pages>
<first-page>41</first-page>
<last-page>49</last-page>
</pages>
</page-information>
</volisspag>
<publicationyear first="2022" />
<publicationdate>
<year>2022</year>
<month>09</month>
<day>21</day>
</publicationdate>
<website type="item">
<ce:e-address type="url">https://link.springer.com/</ce:e-address>
</website>
<publisher>
<publishername>Springer International Publishing</publishername>
</publisher>
</source>
<enhancement>
<classificationgroup>
<classifications type="ASJC">
<classification>
<classification-code>2700</classification-code>
<classification-code>2400</classification-code>
<classification-code>1300</classification-code>
</classification>
</classifications>
</classificationgroup>
</enhancement>
</head>
<tail>
<bibliography refcount="72">
<reference seq="1">
<ref-info>
<ref-title>
<ref-titletext-english> Cancer statistics, 2020</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.L.</ce:initials>
<ce:surname>Siegel</ce:surname>
<ce:given-name>R.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.D.</ce:initials>
<ce:surname>Miller</ce:surname>
<ce:given-name>K.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Jemal</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>CA Cancer J. Clin.</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>70</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7</first-page>
<last-page>30</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Siegel, R.L., Miller, K.D., Jemal, A.: Cancer statistics, 2020. CA Cancer J. Clin. 70(1), 7–30 (2020)</ref-fulltext>
<ce:source-text>Siegel, R.L., Miller, K.D., Jemal, A.: Cancer statistics, 2020. CA Cancer J. Clin. 70(1), 7–30 (2020)</ce:source-text>
</reference>
<reference seq="2">
<ref-info>
<ref-title>
<ref-titletext-english> Cytokines and advanced cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.J.</ce:initials>
<ce:surname>Dunlop</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.W.</ce:initials>
<ce:surname>Campbell</ce:surname>
<ce:given-name>C.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Pain Symptom Manag. </ref-sourcetitle>
<ref-publicationyear first="2000" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>214</first-page>
<last-page>232</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dunlop, R.J., Campbell, C.W.: Cytokines and advanced cancer. J. Pain Symptom Manag. 20(3), 214–232 (2000)</ref-fulltext>
<ce:source-text>Dunlop, R.J., Campbell, C.W.: Cytokines and advanced cancer. J. Pain Symptom Manag. 20(3), 214–232 (2000)</ce:source-text>
</reference>
<reference seq="3">
<ref-info>
<ref-title>
<ref-titletext-english>Bone metastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.E.</ce:initials>
<ce:surname>Coleman</ce:surname>
<ce:given-name>R.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Dis. Primers.</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>83</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Coleman, R.E., et al.: Bone metastases. Nat. Rev. Dis. Primers. 6(1), 83 (2020)</ref-fulltext>
<ce:source-text>Coleman, R.E., et al.: Bone metastases. Nat. Rev. Dis. Primers. 6(1), 83 (2020)</ce:source-text>
</reference>
<reference seq="4">
<ref-info>
<ref-title>
<ref-titletext-english> Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.K.</ce:initials>
<ce:surname>Hernandez</ce:surname>
<ce:given-name>R.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>BMC Cancer.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>44</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hernandez, R.K., et al.: Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States. BMC Cancer. 18(1), 44 (2018)</ref-fulltext>
<ce:source-text>Hernandez, R.K., et al.: Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States. BMC Cancer. 18(1), 44 (2018)</ce:source-text>
</reference>
<reference seq="5">
<ref-info>
<ref-title>
<ref-titletext-english>Clinical features of metastatic bone disease and risk of skeletal morbidity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.E.</ce:initials>
<ce:surname>Coleman</ce:surname>
<ce:given-name>R.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>20</iss-first>
<part>Part 2</part>
</volume-issue-number>
<page-information>
<pages>
<first-page>6243s</first-page>
<last-page>6249s</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Coleman, R.E.: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. 12(20 Pt 2), 6243s–6249s (2006)</ref-fulltext>
<ce:source-text>Coleman, R.E.: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. 12(20 Pt 2), 6243s–6249s (2006)</ce:source-text>
</reference>
<reference seq="6">
<ref-info>
<ref-title>
<ref-titletext-english>Pathogenesis of myeloma bone disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.D.</ce:initials>
<ce:surname>Roodman</ce:surname>
<ce:given-name>G.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Biochem. </ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>109</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>283</first-page>
<last-page>291</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Roodman, G.D.: Pathogenesis of myeloma bone disease. J. Cell. Biochem. 109(2), 283–291 (2010)</ref-fulltext>
<ce:source-text>Roodman, G.D.: Pathogenesis of myeloma bone disease. J. Cell. Biochem. 109(2), 283–291 (2010)</ce:source-text>
</reference>
<reference seq="7">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal complications of malignancy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.E.</ce:initials>
<ce:surname>Coleman</ce:surname>
<ce:given-name>R.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer.</ref-sourcetitle>
<ref-publicationyear first="1997" />
<volisspag>
<volume-issue-number>
<vol-first>80</vol-first>
<iss-first>8</iss-first>
<suppl>Supplement</suppl>
</volume-issue-number>
<page-information>
<pages>
<first-page>1588</first-page>
<last-page>1594</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Coleman, R.E.: Skeletal complications of malignancy. Cancer. 80(8 Suppl), 1588–1594 (1997)</ref-fulltext>
<ce:source-text>Coleman, R.E.: Skeletal complications of malignancy. Cancer. 80(8 Suppl), 1588–1594 (1997)</ce:source-text>
</reference>
<reference seq="8">
<ref-info>
<ref-title>
<ref-titletext-english>The distribution of secondary growths in
cancer of the breast. 1889</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Paget</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Metastasis Rev.</ref-sourcetitle>
<ref-publicationyear first="1989" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>98</first-page>
<last-page>101</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Paget, S.: The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 8(2), 98–101 (1989)</ref-fulltext>
<ce:source-text>Paget, S.: The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 8(2), 98–101 (1989)</ce:source-text>
</reference>
<reference seq="9">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer to bone: a fatal attraction</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.N.</ce:initials>
<ce:surname>Weilbaecher</ce:surname>
<ce:given-name>K.N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.A.</ce:initials>
<ce:surname>Guise</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.K.</ce:initials>
<ce:surname>McCauley</ce:surname>
<ce:given-name>L.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>411</first-page>
<last-page>425</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Weilbaecher, K.N., Guise, T.A., McCauley, L.K.: Cancer to bone: a fatal attraction. Nat. Rev. Cancer. 11(6), 411–425 (2011)</ref-fulltext>
<ce:source-text>Weilbaecher, K.N., Guise, T.A., McCauley, L.K.: Cancer to bone: a fatal attraction. Nat. Rev. Cancer. 11(6), 411–425 (2011)</ce:source-text>
</reference>
<reference seq="10">
<ref-info>
<ref-title>
<ref-titletext-english>Understanding the bone in cancer metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Fornetti</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.L.</ce:initials>
<ce:surname>Welm</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.A.</ce:initials>
<ce:surname>Stewart</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Bone Miner. Res.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2099</first-page>
<last-page>2113</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fornetti, J., Welm, A.L., Stewart, S.A.: Understanding the bone in cancer metastasis. J. Bone Miner. Res. 33(12), 2099–2113 (2018)</ref-fulltext>
<ce:source-text>Fornetti, J., Welm, A.L., Stewart, S.A.: Understanding the bone in cancer metastasis. J. Bone Miner. Res. 33(12), 2099–2113 (2018)</ce:source-text>
</reference>
<reference seq="11">
<ref-info>
<ref-title>
<ref-titletext-english>Cellular and molecular mechanisms of bone remodeling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.J.</ce:initials>
<ce:surname>Raggatt</ce:surname>
<ce:given-name>L.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>N.C.</ce:initials>
<ce:surname>Partridge</ce:surname>
<ce:given-name>N.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem.</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>285</vol-first>
<iss-first>33</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>25103</first-page>
<last-page>25108</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Raggatt, L.J., Partridge, N.C.: Cellular and molecular mechanisms of bone remodeling. J. Biol. Chem. 285(33), 25103–25108 (2010)</ref-fulltext>
<ce:source-text>Raggatt, L.J., Partridge, N.C.: Cellular and molecular mechanisms of bone remodeling. J. Biol. Chem. 285(33), 25103–25108 (2010)</ce:source-text>
</reference>
<reference seq="12">
<ref-info>
<ref-title>
<ref-titletext-english>Breast cancer cells interact with osteoblasts to support osteoclast formation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.J.</ce:initials>
<ce:surname>Thomas</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> Endocrinology.</ref-sourcetitle>
<ref-publicationyear first="1999" />
<volisspag>
<volume-issue-number>
<vol-first>140</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4451</first-page>
<last-page>4458</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Thomas, R.J., et al.: Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology. 140(10), 4451–4458 (1999)</ref-fulltext>
<ce:source-text>Thomas, R.J., et al.: Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology. 140(10), 4451–4458 (1999)</ce:source-text>
</reference>
<reference seq="13">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Sethi</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell.
</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>192</first-page>
<last-page>205</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sethi, N., et al.: Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell. 19(2), 192–205 (2011)</ref-fulltext>
<ce:source-text>Sethi, N., et al.: Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell. 19(2), 192–205 (2011)</ce:source-text>
</reference>
<reference seq="14">
<ref-info>
<ref-title>
<ref-titletext-english>TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.J.</ce:initials>
<ce:surname>Yin</ce:surname>
<ce:given-name>J.J.
</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest.</ref-sourcetitle>
<ref-publicationyear first="1999" />
<volisspag>
<volume-issue-number>
<vol-first>103</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>197</first-page>
<last-page>206</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yin, J.J., et al.: TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103(2), 197–206 (1999)</ref-fulltext>
<ce:source-text>Yin, J.J., et al.: TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103(2), 197–206 (1999)</ce:source-text>
</reference>
<reference seq="15">
<ref-info>
<ref-title>
<ref-titletext-english>Metastasis to bone: causes, consequences and therapeutic opportunities</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.R.</ce:initials>
<ce:surname>Mundy</ce:surname>
<ce:given-name>G.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2002" />
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>584</first-page>
<last-page>593</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mundy, G.R.: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer. 2(8), 584–593 (2002)</ref-fulltext>
<ce:source-text>Mundy, G.R.: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer. 2(8), 584–593 (2002)</ce:source-text>
</reference>
<reference seq="16">
<ref-info>
<ref-title>
<ref-titletext-english>Therapeutic strategies to target TGF-beta in the treatment of bone metastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.T.</ce:initials>
<ce:surname>Buijs</ce:surname>
<ce:given-name>J.T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Juarez</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.A.</ce:initials>
<ce:surname>Guise</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Pharm. Biotechnol.</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2121</first-page>
<last-page>2137</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Buijs, J.T., Juarez, P., Guise, T.A.: Therapeutic strategies to target TGF-beta in the treatment of bone metastases. Curr. Pharm. Biotechnol. 12(12), 2121–2137 (2011)</ref-fulltext>
<ce:source-text>Buijs, J.T., Juarez, P., Guise, T.A.: Therapeutic strategies to target TGF-beta in the treatment of bone metastases. Curr. Pharm. Biotechnol. 12(12), 2121–2137 (2011)</ce:source-text>
</reference>
<reference seq="17">
<ref-info>
<ref-title>
<ref-titletext-english>Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.T.</ce:initials>
<ce:surname>Stopeck</ce:surname>
<ce:given-name>A.T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol.</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
<iss-first>35</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5132</first-page>
<last-page>5139</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stopeck, A.T., et al.: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol. 28(35), 5132–5139 (2010)</ref-fulltext>
<ce:source-text>Stopeck, A.T., et al.: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol. 28(35), 5132–5139 (2010)</ce:source-text>
</reference>
<reference seq="18">
<ref-info>
<ref-title>
<ref-titletext-english>Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.N.</ce:initials>
<ce:surname>Hortobagyi</ce:surname>
<ce:given-name>G.N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>N. Engl. J. Med.</ref-sourcetitle>
<ref-publicationyear first="1996" />
<volisspag>
<volume-issue-number>
<vol-first>335</vol-first>
<iss-first>24</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1785</first-page>
<last-page>1791</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hortobagyi, G.N., et al.: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N. Engl. J. Med. 335(24), 1785–1791 (1996)</ref-fulltext>
<ce:source-text>Hortobagyi, G.N., et al.: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N. Engl. J. Med. 335(24), 1785–1791 (1996)</ce:source-text>
</reference>
<reference seq="19">
<ref-info>
<ref-title>
<ref-titletext-english>Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.R.</ce:initials>
<ce:surname>Berenson</ce:surname>
<ce:given-name>J.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>N. Engl. J. Med. </ref-sourcetitle>
<ref-publicationyear first="1996" />
<volisspag>
<volume-issue-number>
<vol-first>334</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>488</first-page>
<last-page>493</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Berenson, J.R., et al.: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N. Engl. J. Med. 334(8), 488–493 (1996)</ref-fulltext>
<ce:source-text>Berenson, J.R., et al.: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N. Engl. J. Med. 334(8), 488–493 (1996)</ce:source-text>
</reference>
<reference seq="20">
<ref-info>
<ref-title>
<ref-titletext-english>Imaging characteristic analysis of metastatic spine lesions from breast, prostate, lung, and renal cell carcinomas for surgical planning: osteolytic versus osteoblastic</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Reddington</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Surg. Neurol. Int.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<suppl>Supplement 13</suppl>
</volume-issue-number>
<page-information>
<pages>
<first-page>S361</first-page>
<last-page>S365</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Reddington, J.A., et al.: Imaging characteristic analysis of metastatic spine lesions from breast, prostate, lung, and renal cell carcinomas for surgical planning: osteolytic versus osteoblastic. Surg. Neurol. Int. 7(Suppl 13), S361–S365 (2016)</ref-fulltext>
<ce:source-text>Reddington, J.A., et al.: Imaging characteristic analysis of metastatic spine lesions from breast, prostate, lung, and renal cell carcinomas for surgical planning: osteolytic versus osteoblastic. Surg. Neurol. Int. 7(Suppl 13), S361–S365 (2016)</ce:source-text>
</reference>
<reference seq="21">
<ref-info>
<ref-title>
<ref-titletext-english>Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.E.</ce:initials>
<ce:surname>Brown</ce:surname>
<ce:given-name>J.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Natl. Cancer Inst.</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>97</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>59</first-page>
<last-page>69</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Brown, J.E., et al.: Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J. Natl. Cancer Inst. 97(1), 59–69 (2005)</ref-fulltext>
<ce:source-text>Brown, J.E., et al.: Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J. Natl. Cancer Inst. 97(1), 59–69 (2005)</ce:source-text>
</reference>
<reference seq="22">
<ref-info>
<ref-title>
<ref-titletext-english> Usefulness of radium-223 in patients with bone metastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Gupta</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. (Bayl. Univ. Med. Cent.).</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>424</first-page>
<last-page>426</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gupta, N., et al.: Usefulness of radium-223 in patients with bone metastases. Proc. (Bayl. Univ. Med. Cent.). 30(4), 424–426 (2017)</ref-fulltext>
<ce:source-text>Gupta, N., et al.: Usefulness of radium-223 in patients with bone metastases. Proc. (Bayl. Univ. Med. Cent.). 30(4), 424–426 (2017)</ce:source-text>
</reference>
<reference seq="23">
<ref-info>
<ref-title>
<ref-titletext-english>Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Autzen</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Cancer.</ref-sourcetitle>
<ref-publicationyear first="1998" />
<volisspag>
<volume-issue-number>
<vol-first>78</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1219</first-page>
<last-page>1223</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Autzen, P., et al.: Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br. J. Cancer. 78(9), 1219–1223 (1998)</ref-fulltext>
<ce:source-text>Autzen, P., et al.: Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br. J. Cancer. 78(9), 1219–1223 (1998)</ce:source-text>
</reference>
<reference seq="24">
<ref-info>
<ref-title>
<ref-titletext-english>A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.J.</ce:initials>
<ce:surname>Yin</ce:surname>
<ce:given-name>J.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA.</ref-sourcetitle>
<ref-publicationyear first="2003" />
<volisspag>
<volume-issue-number>
<vol-first>100</vol-first>
<iss-first>19</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>10954</first-page>
<last-page>10959</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yin, J.J., et al.: A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc. Natl. Acad. Sci. USA. 100(19), 10954–10959 (2003)</ref-fulltext>
<ce:source-text>Yin, J.J., et al.: A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc. Natl. Acad. Sci. USA. 100(19), 10954–10959 (2003)</ce:source-text>
</reference>
<reference seq="25">
<ref-info>
<ref-title>
<ref-titletext-english> Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.B.</ce:initials>
<ce:surname>Nelson</ce:surname>
<ce:given-name>J.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Med.</ref-sourcetitle>
<ref-publicationyear first="1995" />
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>944</first-page>
<last-page>949</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nelson, J.B., et al.: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med. 1(9), 944–949 (1995)</ref-fulltext>
<ce:source-text>Nelson, J.B., et al.: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med. 1(9), 944–949 (1995)</ce:source-text>
</reference>
<reference seq="26">
<ref-info>
<ref-title>
<ref-titletext-english>Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.F.</ce:initials>
<ce:surname>Shariat</ce:surname>
<ce:given-name>S.F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol. </ref-sourcetitle>
<ref-publicationyear first="2001" />
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2856</first-page>
<last-page>2864</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shariat, S.F., et al.: Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J. Clin. Oncol. 19(11), 2856–2864 (2001)</ref-fulltext>
<ce:source-text>Shariat, S.F., et al.: Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J. Clin. Oncol. 19(11), 2856–2864 (2001)</ce:source-text>
</reference>
<reference seq="27">
<ref-info>
<ref-title>
<ref-titletext-english> Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Jiao</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>179</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1177</first-page>
<last-page>1190</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Jiao, S., et al.: Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy. Cell. 179(5), 1177–1190 e13 (2019)</ref-fulltext>
<ce:source-text>Jiao, S., et al.: Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy. Cell. 179(5), 1177–1190 e13 (2019)</ce:source-text>
</reference>
<reference seq="28">
<ref-info>
<ref-title>
<ref-titletext-english>Osteoblasts in prostate cancer metastasis to bone</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.J.</ce:initials>
<ce:surname>Logothetis</ce:surname>
<ce:given-name>C.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.H.</ce:initials>
<ce:surname>Lin</ce:surname>
<ce:given-name>S.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>21</first-page>
<last-page>28</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Logothetis, C.J., Lin, S.H.: Osteoblasts in prostate cancer metastasis to bone. Nat. Rev. Cancer. 5(1), 21–28 (2005)</ref-fulltext>
<ce:source-text>Logothetis, C.J., Lin, S.H.: Osteoblasts in prostate cancer metastasis to bone. Nat. Rev. Cancer. 5(1), 21–28 (2005)</ce:source-text>
</reference>
<reference seq="29">
<ref-info>
<ref-title>
<ref-titletext-english>Enhanced expression of parathyroid hormone-related protein in prostate cancer as compared with benign prostatic hyperplasia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Asadi</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Hum. Pathol.</ref-sourcetitle>
<ref-publicationyear first="1996" />
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1319</first-page>
<last-page>1323</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Asadi, F., et al.: Enhanced expression of parathyroid hormone-related protein in prostate cancer as compared with benign prostatic hyperplasia. Hum. Pathol. 27(12), 1319–1323 (1996)</ref-fulltext>
<ce:source-text>Asadi, F., et al.: Enhanced expression of parathyroid hormone-related protein in prostate cancer as compared with benign prostatic hyperplasia. Hum. Pathol. 27(12), 1319–1323 (1996)</ce:source-text>
</reference>
<reference seq="30">
<ref-info>
<ref-title>
<ref-titletext-english>A N-terminal PTHrP peptide fragment void of a PTH/PTHrPreceptor binding domain activates cardiac ET (A) receptors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.D.</ce:initials>
<ce:surname>Schluter</ce:surname>
<ce:given-name>K.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Katzer</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.M.</ce:initials>
<ce:surname>Piper</ce:surname>
<ce:given-name>H.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Pharmacol.</ref-sourcetitle>
<ref-publicationyear first="2001" />
<volisspag>
<volume-issue-number>
<vol-first>132</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>427</first-page>
<last-page>432</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Schluter, K.D., Katzer, C., Piper, H.M.: A N-terminal PTHrP peptide fragment void of a PTH/PTHrPreceptor binding domain activates cardiac ET (A) receptors. Br. J. Pharmacol. 132(2), 427–432 (2001)</ref-fulltext>
<ce:source-text>Schluter, K.D., Katzer, C., Piper, H.M.: A N-terminal PTHrP peptide fragment void of a PTH/PTHrPreceptor binding domain activates cardiac ET (A) receptors. Br. J. Pharmacol. 132(2), 427–432 (2001)</ce:source-text>
</reference>
<reference seq="31">
<ref-info>
<ref-title>
<ref-titletext-english>Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.D.</ce:initials>
<ce:surname>Ottewell</ce:surname>
<ce:given-name>P.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2922</first-page>
<last-page>2932</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ottewell, P.D., et al.: Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo. Clin. Cancer Res. 20(11), 2922–2932 (2014)</ref-fulltext>
<ce:source-text>Ottewell, P.D., et al.: Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo. Clin. Cancer Res. 20(11), 2922–2932 (2014)</ce:source-text>
</reference>
<reference seq="32">
<ref-info>
<ref-title>
<ref-titletext-english>Aromatase inhibitor-induced bone loss increases the progression of estrogen receptornegative breast cancer in bone and exacerbates muscle weakness in vivo</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.E.</ce:initials>
<ce:surname>Wright</ce:surname>
<ce:given-name>L.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>8406</first-page>
<last-page>8419</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wright, L.E., et al.: Aromatase inhibitor-induced bone loss increases the progression of estrogen receptornegative breast cancer in bone and exacerbates muscle weakness in vivo. Oncotarget. 8(5), 8406–8419 (2017)</ref-fulltext>
<ce:source-text>Wright, L.E., et al.: Aromatase inhibitor-induced bone loss increases the progression of estrogen receptornegative breast cancer in bone and exacerbates muscle weakness in vivo. Oncotarget. 8(5), 8406–8419 (2017)</ce:source-text>
</reference>
<reference seq="33">
<ref-info>
<ref-title>
<ref-titletext-english>Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.D.</ce:initials>
<ce:surname>Ottewell</ce:surname>
<ce:given-name>P.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Endocr. Relat. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>769</first-page>
<last-page>781</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ottewell, P.D., et al.: Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. Endocr. Relat. Cancer. 21(5), 769–781 (2014)</ref-fulltext>
<ce:source-text>Ottewell, P.D., et al.: Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. Endocr. Relat. Cancer. 21(5), 769–781 (2014)</ce:source-text>
</reference>
<reference seq="34">
<ref-info>
<ref-title>
<ref-titletext-english>Understanding cachexia in the context of metastatic progression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.K.</ce:initials>
<ce:surname>Biswas</ce:surname>
<ce:given-name>A.K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Acharyya</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev.
Cancer.</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>274</first-page>
<last-page>284</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Biswas, A.K., Acharyya, S.: Understanding cachexia in the context of metastatic progression. Nat. Rev. Cancer. 20(5), 274–284 (2020)</ref-fulltext>
<ce:source-text>Biswas, A.K., Acharyya, S.: Understanding cachexia in the context of metastatic progression. Nat. Rev. Cancer. 20(5), 274–284 (2020)</ce:source-text>
</reference>
<reference seq="35">
<ref-info>
<ref-title>
<ref-titletext-english>Definition and classification of cancer cachexia: an international consensus</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Lancet Oncol.</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>489</first-page>
<last-page>495</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fearon, K., et al.: Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 12(5), 489–495 (2011)</ref-fulltext>
<ce:source-text>Fearon, K., et al.: Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 12(5), 489–495 (2011)</ce:source-text>
</reference>
<reference seq="36">
<ref-info>
<ref-title>
<ref-titletext-english>Prevalence, incidence and clinical impact of cachexia: facts and numbersupdate 2014</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>von Haehling</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.D.</ce:initials>
<ce:surname>Anker</ce:surname>
<ce:given-name>S.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>261</first-page>
<last-page>263</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>von Haehling, S., Anker, S.D.: Prevalence, incidence and clinical impact of cachexia: facts and numbersupdate 2014. J. Cachexia. Sarcopenia Muscle. 5(4), 261–263 (2014)</ref-fulltext>
<ce:source-text>von Haehling, S., Anker, S.D.: Prevalence, incidence and clinical impact of cachexia: facts and numbersupdate 2014. J. Cachexia. Sarcopenia Muscle. 5(4), 261–263 (2014)</ce:source-text>
</reference>
<reference seq="37">
<ref-info>
<ref-title>
<ref-titletext-english>An epidemiological survey of cachexia in advanced cancer patients and analysis on its diagnostic and treatment status</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Sun</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>X.Q.</ce:initials>
<ce:surname>Quan</ce:surname>
<ce:given-name>X.Q.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Yu</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nutr. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>67</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1056</first-page>
<last-page>1062</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sun, L., Quan, X.Q., Yu, S.: An epidemiological survey of cachexia in advanced cancer patients and analysis on its diagnostic and treatment status. Nutr. Cancer. 67(7), 1056–1062 (2015)</ref-fulltext>
<ce:source-text>Sun, L., Quan, X.Q., Yu, S.: An epidemiological survey of cachexia in advanced cancer patients and analysis on its diagnostic and treatment status. Nutr. Cancer. 67(7), 1056–1062 (2015)</ce:source-text>
</reference>
<reference seq="38">
<ref-info>
<ref-title>
<ref-titletext-english> Cancer-associated cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Dis. Primers.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>17105</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baracos, V.E., et al.: Cancer-associated cachexia. Nat. Rev. Dis. Primers. 4, 17105 (2018)</ref-fulltext>
<ce:source-text>Baracos, V.E., et al.: Cancer-associated cachexia. Nat. Rev. Dis. Primers. 4, 17105 (2018)</ce:source-text>
</reference>
<reference seq="39">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle mass and muscle strength in relation to lower-extremity performance in older men and women</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Visser</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Am. Geriatr. Soc.</ref-sourcetitle>
<ref-publicationyear first="2000" />
<volisspag>
<volume-issue-number>
<vol-first>48</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>381</first-page>
<last-page>386</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Visser, M., et al.: Skeletal muscle mass and muscle strength in relation to lower-extremity performance in older men and women. J. Am. Geriatr. Soc. 48(4), 381–386 (2000)</ref-fulltext>
<ce:source-text>Visser, M., et al.: Skeletal muscle mass and muscle strength in relation to lower-extremity performance in older men and women. J. Am. Geriatr. Soc. 48(4), 381–386 (2000)</ce:source-text>
</reference>
<reference seq="40">
<ref-info>
<ref-title>
<ref-titletext-english>Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.B.</ce:initials>
<ce:surname>Newman</ce:surname>
<ce:given-name>A.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Gerontol. A Biol. Sci. Med. Sci.</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>61</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>72</first-page>
<last-page>77</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Newman, A.B., et al.: Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. J. Gerontol. A Biol. Sci. Med. Sci. 61(1), 72–77 (2006)</ref-fulltext>
<ce:source-text>Newman, A.B., et al.: Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. J. Gerontol. A Biol. Sci. Med. Sci. 61(1), 72–77 (2006)</ce:source-text>
</reference>
<reference seq="41">
<ref-info>
<ref-title>
<ref-titletext-english>The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.H.</ce:initials>
<ce:surname>Goodpaster</ce:surname>
<ce:given-name>B.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Gerontol. A Biol. Sci. Med. Sci.</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>61</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1059</first-page>
<last-page>1064</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Goodpaster, B.H., et al.: The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J. Gerontol. A Biol. Sci. Med. Sci. 61(10), 1059–1064 (2006)</ref-fulltext>
<ce:source-text>Goodpaster, B.H., et al.: The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J. Gerontol. A Biol. Sci. Med. Sci. 61(10), 1059–1064 (2006)</ce:source-text>
</reference>
<reference seq="42">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle strength in breast cancer patients receiving different treatment regimes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>O.</ce:initials>
<ce:surname>Klassen</ce:surname>
<ce:given-name>O.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>305</first-page>
<last-page>316</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Klassen, O., et al.: Muscle strength in breast cancer patients receiving different treatment regimes. J. Cachexia. Sarcopenia Muscle. 8(2), 305–316 (2017)</ref-fulltext>
<ce:source-text>Klassen, O., et al.: Muscle strength in breast cancer patients receiving different treatment regimes. J. Cachexia. Sarcopenia Muscle. 8(2), 305–316 (2017)</ce:source-text>
</reference>
<reference seq="43">
<ref-info>
<ref-title>
<ref-titletext-english>Physical activity and fitness in women with metastatic breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Yee</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cancer Surviv.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>647</first-page>
<last-page>656</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yee, J., et al.: Physical activity and fitness in women with metastatic breast cancer. J. Cancer Surviv. 8(4), 647–656 (2014)</ref-fulltext>
<ce:source-text>Yee, J., et al.: Physical activity and fitness in women with metastatic breast cancer. J. Cancer Surviv. 8(4), 647–656 (2014)</ce:source-text>
</reference>
<reference seq="44">
<ref-info>
<ref-title>
<ref-titletext-english>Impact of primary breast cancer therapy on energetic capacity and body composition</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.J.</ce:initials>
<ce:surname>Ballinger</ce:surname>
<ce:given-name>T.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Breast Cancer Res. Treat.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>172</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>445</first-page>
<last-page>452</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ballinger, T.J., et al.: Impact of primary breast cancer therapy on energetic capacity and body composition. Breast Cancer Res. Treat. 172(2), 445–452 (2018)</ref-fulltext>
<ce:source-text>Ballinger, T.J., et al.: Impact of primary breast cancer therapy on energetic capacity and body composition. Breast Cancer Res. Treat. 172(2), 445–452 (2018)</ce:source-text>
</reference>
<reference seq="45">
<ref-info>
<ref-title>
<ref-titletext-english>Correlation between muscle mass and handgrip strength in digestive cancer patients undergoing chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Moreau</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Med. </ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3677</first-page>
<last-page>3684</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Moreau, J., et al.: Correlation between muscle mass and handgrip strength in digestive cancer patients undergoing chemotherapy. Cancer Med. 8(8), 3677–3684 (2019)</ref-fulltext>
<ce:source-text>Moreau, J., et al.: Correlation between muscle mass and handgrip strength in digestive cancer patients undergoing chemotherapy. Cancer Med. 8(8), 3677–3684 (2019)</ce:source-text>
</reference>
<reference seq="46">
<ref-info>
<ref-title>
<ref-titletext-english>Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.A.</ce:initials>
<ce:surname>Galvao</ce:surname>
<ce:given-name>D.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Prostate Cancer Prostatic Dis.</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>198</first-page>
<last-page>203</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Galvao, D.A., et al.: Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis. 12(2), 198–203 (2009)</ref-fulltext>
<ce:source-text>Galvao, D.A., et al.: Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis. 12(2), 198–203 (2009)</ce:source-text>
</reference>
<reference seq="47">
<ref-info>
<ref-title>
<ref-titletext-english>Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.E.</ce:initials>
<ce:surname>Daly</ce:surname>
<ce:given-name>L.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle. </ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>315</first-page>
<last-page>325</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Daly, L.E., et al.: Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer. J. Cachexia. Sarcopenia Muscle. 9(2), 315–325 (2018)</ref-fulltext>
<ce:source-text>Daly, L.E., et al.: Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer. J. Cachexia. Sarcopenia Muscle. 9(2), 315–325 (2018)</ce:source-text>
</reference>
<reference seq="48">
<ref-info>
<ref-title>
<ref-titletext-english>Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebocontrolled study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Antoun</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol.</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1054</first-page>
<last-page>1060</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Antoun, S., et al.: Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebocontrolled study. J. Clin. Oncol. 28(6), 1054–1060 (2010)</ref-fulltext>
<ce:source-text>Antoun, S., et al.: Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebocontrolled study. J. Clin. Oncol. 28(6), 1054–1060 (2010)</ce:source-text>
</reference>
<reference seq="49">
<ref-info>
<ref-title>
<ref-titletext-english>Chronic treatment with multi-kinase inhibitors causes differential toxicities on skeletal and cardiac muscles</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.R.</ce:initials>
<ce:surname>Huot</ce:surname>
<ce:given-name>J.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancers (Basel)</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Huot, J.R., et al., Chronic treatment with multi-kinase inhibitors causes differential toxicities on skeletal and cardiac muscles. Cancers (Basel), 2019. 11(4)</ref-fulltext>
<ce:source-text>Huot, J.R., et al., Chronic treatment with multi-kinase inhibitors causes differential toxicities on skeletal and cardiac muscles. Cancers (Basel), 2019. 11(4)</ce:source-text>
</reference>
<reference seq="50">
<ref-info>
<ref-title>
<ref-titletext-english> Zoledronic acid improves muscle function in healthy mice treated with chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.A.</ce:initials>
<ce:surname>Hain</ce:surname>
<ce:given-name>B.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Bone Miner. Res.</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>368</first-page>
<last-page>381</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hain, B.A., et al.: Zoledronic acid improves muscle function in healthy mice treated with chemotherapy. J. Bone Miner. Res. 35(2), 368–381 (2020)</ref-fulltext>
<ce:source-text>Hain, B.A., et al.: Zoledronic acid improves muscle function in healthy mice treated with chemotherapy. J. Bone Miner. Res. 35(2), 368–381 (2020)</ce:source-text>
</reference>
<reference seq="51">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle Ca(2+) mishandling: another effect of bone-tomuscle signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.N.</ce:initials>
<ce:surname>Regan</ce:surname>
<ce:given-name>J.N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.L.</ce:initials>
<ce:surname>Waning</ce:surname>
<ce:given-name>D.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.A.</ce:initials>
<ce:surname>Guise</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Semin. Cell Dev. Biol.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>49</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>24</first-page>
<last-page>29</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Regan, J.N., Waning, D.L., Guise, T.A.: Skeletal muscle Ca(2+) mishandling: another effect of bone-tomuscle signaling. Semin. Cell Dev. Biol. 49, 24–29 (2016)</ref-fulltext>
<ce:source-text>Regan, J.N., Waning, D.L., Guise, T.A.: Skeletal muscle Ca(2+) mishandling: another effect of bone-tomuscle signaling. Semin. Cell Dev. Biol. 49, 24–29 (2016)</ce:source-text>
</reference>
<reference seq="52">
<ref-info>
<ref-title>
<ref-titletext-english> Endocrine regulation of energy metabolism by the skeleton</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.K.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>N.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> Cell.</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>130</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>456</first-page>
<last-page>469</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lee, N.K., et al.: Endocrine regulation of energy metabolism by the skeleton. Cell. 130(3), 456–469 (2007)</ref-fulltext>
<ce:source-text>Lee, N.K., et al.: Endocrine regulation of energy metabolism by the skeleton. Cell. 130(3), 456–469 (2007)</ce:source-text>
</reference>
<reference seq="53">
<ref-info>
<ref-title>
<ref-titletext-english>Circulating undercarboxylated osteocalcin as estimator of cardiovascular and type 2 diabetes risk in metabolic syndrome patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Riquelme-Gallego</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep.</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1840</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Riquelme-Gallego, B., et al.: Circulating undercarboxylated osteocalcin as estimator of cardiovascular and type 2 diabetes risk in metabolic syndrome patients. Sci. Rep. 10(1), 1840 (2020)</ref-fulltext>
<ce:source-text>Riquelme-Gallego, B., et al.: Circulating undercarboxylated osteocalcin as estimator of cardiovascular and type 2 diabetes risk in metabolic syndrome patients. Sci. Rep. 10(1), 1840 (2020)</ce:source-text>
</reference>
<reference seq="54">
<ref-info>
<ref-title>
<ref-titletext-english>Undercarboxylated osteocalcin, muscle strength and indices of bone health in older women</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Levinger</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Bone.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>64</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>8</first-page>
<last-page>12</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Levinger, I., et al.: Undercarboxylated osteocalcin, muscle strength and indices of bone health in older women. Bone. 64, 8–12 (2014)</ref-fulltext>
<ce:source-text>Levinger, I., et al.: Undercarboxylated osteocalcin, muscle strength and indices of bone health in older women. Bone. 64, 8–12 (2014)</ce:source-text>
</reference>
<reference seq="55">
<ref-info>
<ref-title>
<ref-titletext-english>Mechanisms of IGF-1- mediated regulation of skeletal muscle hypertrophy and atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Yoshida</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Delafontaine</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell.</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Yoshida, T., Delafontaine, P.: Mechanisms of IGF-1- mediated regulation of skeletal muscle hypertrophy and atrophy. Cell. 9(9) (2020)</ref-fulltext>
<ce:source-text>Yoshida, T., Delafontaine, P.: Mechanisms of IGF-1- mediated regulation of skeletal muscle hypertrophy and atrophy. Cell. 9(9) (2020)</ce:source-text>
</reference>
<reference seq="56">
<ref-info>
<ref-title>
<ref-titletext-english>BMP signaling controls muscle mass</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Sartori</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Genet.</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>45</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1309</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sartori, R., et al.: BMP signaling controls muscle mass. Nat. Genet. 45(11), 1309 (2013)</ref-fulltext>
<ce:source-text>Sartori, R., et al.: BMP signaling controls muscle mass. Nat. Genet. 45(11), 1309 (2013)</ce:source-text>
</reference>
<reference seq="57">
<ref-info>
<ref-title>
<ref-titletext-english>TGF-beta inhibits muscle differentiation through functional repression of myogenic transcription factors by Smad3</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.L.</ce:initials>
<ce:surname>Black</ce:surname>
<ce:given-name>B.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Derynck</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Genes Dev.</ref-sourcetitle>
<ref-publicationyear first="2001" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>22</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2950</first-page>
<last-page>2966</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Liu, D., Black, B.L., Derynck, R.: TGF-beta inhibits muscle differentiation through functional repression of myogenic transcription factors by Smad3. Genes Dev. 15(22), 2950–2966 (2001)</ref-fulltext>
<ce:source-text>Liu, D., Black, B.L., Derynck, R.: TGF-beta inhibits muscle differentiation through functional repression of myogenic transcription factors by Smad3. Genes Dev. 15(22), 2950–2966 (2001)</ce:source-text>
</reference>
<reference seq="58">
<ref-info>
<ref-title>
<ref-titletext-english>Conditional expression of TGF-beta1 in skeletal muscles causes endomysial fibrosis and myofibers atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Narola</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>PLoS One. </ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Narola, J., et al.: Conditional expression of TGF-beta1 in skeletal muscles causes endomysial fibrosis and myofibers atrophy. PLoS One. 8(11), e79356 (2013)</ref-fulltext>
<ce:source-text>Narola, J., et al.: Conditional expression of TGF-beta1 in skeletal muscles causes endomysial fibrosis and myofibers atrophy. PLoS One. 8(11), e79356 (2013)</ce:source-text>
</reference>
<reference seq="59">
<ref-info>
<ref-title>
<ref-titletext-english>Transforming growth factor-beta induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.L.</ce:initials>
<ce:surname>Mendias</ce:surname>
<ce:given-name>C.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Muscle Nerve.</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>45</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>55</first-page>
<last-page>59</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mendias, C.L., et al.: Transforming growth factor-beta induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis. Muscle Nerve. 45(1), 55–59 (2012)</ref-fulltext>
<ce:source-text>Mendias, C.L., et al.: Transforming growth factor-beta induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis. Muscle Nerve. 45(1), 55–59 (2012)</ce:source-text>
</reference>
<reference seq="60">
<ref-info>
<ref-title>
<ref-titletext-english>Aberrant repair and fibrosis development in skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.J.</ce:initials>
<ce:surname>Mann</ce:surname>
<ce:given-name>C.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Skelet. Muscle.</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>21</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mann, C.J., et al.: Aberrant repair and fibrosis development in skeletal muscle. Skelet. Muscle. 1(1), 21 (2011)</ref-fulltext>
<ce:source-text>Mann, C.J., et al.: Aberrant repair and fibrosis development in skeletal muscle. Skelet. Muscle. 1(1), 21 (2011)</ce:source-text>
</reference>
<reference seq="61">
<ref-info>
<ref-title>
<ref-titletext-english>Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.E.</ce:initials>
<ce:surname>Benny Klimek</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochem. Biophys. Res. Commun. </ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>391</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1548</first-page>
<last-page>1554</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Benny Klimek, M.E., et al.: Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem. Biophys. Res. Commun. 391(3), 1548–1554 (2010)</ref-fulltext>
<ce:source-text>Benny Klimek, M.E., et al.: Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem. Biophys. Res. Commun. 391(3), 1548–1554 (2010)</ce:source-text>
</reference>
<reference seq="62">
<ref-info>
<ref-title>
<ref-titletext-english>Specific targeting of TGF-beta family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.L.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>J.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA. </ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>114</vol-first>
<iss-first>26</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>E5266</first-page>
<last-page>E5275</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, J.L., et al.: Specific targeting of TGF-beta family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease. Proc. Natl. Acad. Sci. USA. 114(26), E5266–E5275 (2017)</ref-fulltext>
<ce:source-text>Chen, J.L., et al.: Specific targeting of TGF-beta family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease. Proc. Natl. Acad. Sci. USA. 114(26), E5266–E5275 (2017)</ce:source-text>
</reference>
<reference seq="63">
<ref-info>
<ref-title>
<ref-titletext-english>Proteolysis of latent transforming growth factor-beta (TGF-beta )-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials> S.L.</ce:initials>
<ce:surname>Dallas</ce:surname>
<ce:given-name> S.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem.</ref-sourcetitle>
<ref-publicationyear first="2002" />
<volisspag>
<volume-issue-number>
<vol-first>277</vol-first>
<iss-first>24</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>21352</first-page>
<last-page>21360</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dallas, S.L., et al.: Proteolysis of latent transforming growth factor-beta (TGF-beta )-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J. Biol. Chem. 277(24), 21352–21360 (2002)</ref-fulltext>
<ce:source-text>Dallas, S.L., et al.: Proteolysis of latent transforming growth factor-beta (TGF-beta )-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J. Biol. Chem. 277(24), 21352–21360 (2002)</ce:source-text>
</reference>
<reference seq="64">
<ref-info>
<ref-title>
<ref-titletext-english>TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Tang</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Med.</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>757</first-page>
<last-page>765</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tang, Y., et al.: TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat. Med. 15(7), 757–765 (2009)</ref-fulltext>
<ce:source-text>Tang, Y., et al.: TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat. Med. 15(7), 757–765 (2009)</ce:source-text>
</reference>
<reference seq="65">
<ref-info>
<ref-title>
<ref-titletext-english> Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosislike phenotype</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Erlebacher</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell Biol.</ref-sourcetitle>
<ref-publicationyear first="1996" />
<volisspag>
<volume-issue-number>
<vol-first>132</vol-first>
<iss-first>1</iss-first>
<iss-last>2</iss-last>
</volume-issue-number>
<page-information>
<pages>
<first-page>195</first-page>
<last-page>210</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Erlebacher, A., Derynck, R.: Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosislike phenotype. J. Cell Biol. 132(1–2), 195–210 (1996)</ref-fulltext>
<ce:source-text>Erlebacher, A., Derynck, R.: Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosislike phenotype. J. Cell Biol. 132(1–2), 195–210 (1996)</ce:source-text>
</reference>
<reference seq="66">
<ref-info>
<ref-title>
<ref-titletext-english>Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.S.</ce:initials>
<ce:surname>Mohammad</ce:surname>
<ce:given-name>K.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>PLoS One.</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Mohammad, K.S., et al.: Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS One. 4(4), e5275 (2009)</ref-fulltext>
<ce:source-text>Mohammad, K.S., et al.: Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS One. 4(4), e5275 (2009)</ce:source-text>
</reference>
<reference seq="67">
<ref-info>
<ref-title>
<ref-titletext-english>Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Kang</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA.</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>102</vol-first>
<iss-first>39</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>13909</first-page>
<last-page>13914</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kang, Y., et al.: Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc. Natl. Acad. Sci. USA. 102(39), 13909–13914 (2005)</ref-fulltext>
<ce:source-text>Kang, Y., et al.: Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc. Natl. Acad. Sci. USA. 102(39), 13909–13914 (2005)</ce:source-text>
</reference>
<reference seq="68">
<ref-info>
<ref-title>
<ref-titletext-english>A multigenic program mediating breast cancer metastasis to bone</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Kang</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell. </ref-sourcetitle>
<ref-publicationyear first="2003" />
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>537</first-page>
<last-page>549</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kang, Y., et al.: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 3(6), 537–549 (2003)</ref-fulltext>
<ce:source-text>Kang, Y., et al.: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 3(6), 537–549 (2003)</ce:source-text>
</reference>
<reference seq="69">
<ref-info>
<ref-title>
<ref-titletext-english>Imaging transforming growth factorbeta signaling dynamics and therapeutic response in breast cancer bone metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Korpal</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Med.</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>960</first-page>
<last-page>966</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Korpal, M., et al.: Imaging transforming growth factorbeta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat. Med. 15(8), 960–966 (2009)</ref-fulltext>
<ce:source-text>Korpal, M., et al.: Imaging transforming growth factorbeta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat. Med. 15(8), 960–966 (2009)</ce:source-text>
</reference>
<reference seq="70">
<ref-info>
<ref-title>
<ref-titletext-english>Excess TGF-beta mediates muscle weakness associated with bone metastases in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.L.</ce:initials>
<ce:surname>Waning</ce:surname>
<ce:given-name>D.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Med.</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1262</first-page>
<last-page>1271</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Waning, D.L., et al.: Excess TGF-beta mediates muscle weakness associated with bone metastases in mice. Nat. Med. 21(11), 1262–1271 (2015)</ref-fulltext>
<ce:source-text>Waning, D.L., et al.: Excess TGF-beta mediates muscle weakness associated with bone metastases in mice. Nat. Med. 21(11), 1262–1271 (2015)</ce:source-text>
</reference>
<reference seq="71">
<ref-info>
<ref-title>
<ref-titletext-english>Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.C.</ce:initials>
<ce:surname>Andersson</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab.</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>196</first-page>
<last-page>207</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Andersson, D.C., et al.: Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging. Cell Metab. 14(2), 196–207 (2011)</ref-fulltext>
<ce:source-text>Andersson, D.C., et al.: Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging. Cell Metab. 14(2), 196–207 (2011)</ce:source-text>
</reference>
<reference seq="72">
<ref-info>
<ref-title>
<ref-titletext-english>Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Med.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>770</first-page>
<last-page>781</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, G., et al.: Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle. Nat. Med. 24(6), 770–781 (2018)</ref-fulltext>
<ce:source-text>Wang, G., et al.: Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle. Nat. Med. 24(6), 770–781 (2018)</ce:source-text>
</reference>
</bibliography>
</tail>
</bibrecord>
<bibrecord>
<item-info>
<status state="new" stage="S300" />
<itemidlist>
<ce:doi>10.1007/978-3-031-09518-4_4</ce:doi>
<itemid idtype="TPB-ID">20232000349315</itemid>
</itemidlist>
</item-info>
<head>
<citation-info>
<citation-type code="ch" />
<citation-language xml:lang="ENG" />
<abstract-language xml:lang="ENG" />
</citation-info>
<citation-title>
<titletext xml:lang="ENG" original="y">Targeting Metastatic Disease: Challenges and New Opportunities</titletext>
</citation-title>
<author-group seq="1">
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Hu</ce:surname>
<ce:given-name>Haitian</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Zheng</ce:surname>
<ce:given-name>Hanqiu</ce:given-name>
<ce:e-address>hanzheng@tsinghua.edu.cn</ce:e-address>
</author>
<affiliation>
<organization>Department of Basic Medical Sciences</organization>
<organization>School of Medicine</organization>
<organization>Tsinghua University</organization>
<city>Beijing</city>
<country iso-code="CHN" />
<ce:source-text>Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, China</ce:source-text>
</affiliation>
</author-group>
<author-group seq="2">
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Hu</ce:surname>
<ce:given-name>Zeping</ce:given-name>
</author>
<affiliation>
<organization>School of Pharmaceutical Sciences</organization>
<organization>Tsinghua University</organization>
<city>Beijing</city>
<country iso-code="CHN" />
<ce:source-text>School of Pharmaceutical Sciences, Tsinghua University, Beijing, China</ce:source-text>
</affiliation>
</author-group>
<correspondence>
<person>
<ce:initials>H.</ce:initials>
<ce:surname>Zheng</ce:surname>
<ce:given-name>Hanqiu</ce:given-name>
<ce:e-address>hanzheng@tsinghua.edu.cn</ce:e-address>
</person>
<affiliation>
<organization>School of Pharmaceutical Sciences</organization>
<organization>Tsinghua University</organization>
<city>Beijing</city>
<country iso-code="CHN" />
<ce:source-text>School of Pharmaceutical Sciences, Tsinghua University, Beijing, China</ce:source-text>
</affiliation>
</correspondence>
<abstracts>
<abstract xml:lang="ENG" original="y">
<publishercopyright>© Springer Nature Switzerland AG 2022</publishercopyright>
<ce:para>Metastasis is the major cause of cancerassociated deaths in most cancers. Research in the past two decades revealed the complexity of metastasis process. Metastasis involved not only tumor-intrinsic signaling, but often their interactions with tumor microenvironment composed of extracellular matrix and stromal cells including fibroblast, endothelial cells, macrophages etc. Tumor immune environment and cancer metabolism shunting also contribute to metastasis cascade. Lagging this mechanistic understanding of metastatic cascade is the scarce of effective therapeutic options specifically designed for metastatic patients. A few successful treatment examples include bisphosphonate and denosumab against bone metastasis, immune checkpoint inhibitors for certain metastatic cancer patients. In this chapter, we will discuss the approved therapeutic agents and procedures for metastatic patients and discuss the current progress on metastasis research that could shed light upon future drug development.</ce:para>
</abstract>
</abstracts>
<source type="book" country="USA">
<sourcetitle>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle>
<sourcetitle-abbrev>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle-abbrev>
<isbn type="print" length="13">9783031072727</isbn>
<isbn type="electronic" length="13">9783031095184</isbn>
<volisspag>
<page-information>
<pages>
<first-page>51</first-page>
<last-page>68</last-page>
</pages>
</page-information>
</volisspag>
<publicationyear first="2022" />
<publicationdate>
<year>2022</year>
<month>09</month>
<day>21</day>
</publicationdate>
<website type="item">
<ce:e-address type="url">https://link.springer.com/</ce:e-address>
</website>
<publisher>
<publishername>Springer International Publishing</publishername>
</publisher>
</source>
<enhancement>
<classificationgroup>
<classifications type="ASJC">
<classification>
<classification-code>2700</classification-code>
<classification-code>2400</classification-code>
<classification-code>1300</classification-code>
</classification>
</classifications>
</classificationgroup>
</enhancement>
</head>
<tail>
<bibliography refcount="159">
<reference seq="1">
<ref-info>
<ref-title>
<ref-titletext-english>World Cancer Report: Cancer Research for Cancer Prevention</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.P.</ce:initials>
<ce:surname>Wild</ce:surname>
<ce:given-name>C.P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Weiderpass</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>B.W.</ce:initials>
<ce:surname>Stewart</ce:surname>
<ce:given-name>B.W.</ce:given-name>
</author>
</ref-authors>
<ref-publicationyear first="2020" />
</ref-info>
<ref-fulltext>Wild CP, Weiderpass E, Stewart BW (2020). World Cancer Report: Cancer Research for Cancer Prevention. </ref-fulltext>
<ce:source-text>Wild CP, Weiderpass E, Stewart BW (2020). World Cancer Report: Cancer Research for Cancer Prevention. </ce:source-text>
</reference>
<reference seq="2">
<ref-info>
<ref-title>
<ref-titletext-english>Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2'-deoxyuridine</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.J.</ce:initials>
<ce:surname>Fidler</ce:surname>
<ce:given-name>I.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J Natl Cancer Inst.</ref-sourcetitle>
<ref-publicationyear first="1970" />
<volisspag>
<volume-issue-number>
<vol-first>45</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>773</first-page>
<last-page>782</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fidler, I.J.: Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5- iodo-2'-deoxyuridine. J Natl Cancer Inst. 45, 773–782 (1970)</ref-fulltext>
<ce:source-text>Fidler, I.J.: Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5- iodo-2'-deoxyuridine. J Natl Cancer Inst. 45, 773–782 (1970)</ce:source-text>
</reference>
<reference seq="3">
<ref-info>
<ref-title>
<ref-titletext-english>Dissemination and growth of cancer cells in metastatic sites</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.F.</ce:initials>
<ce:surname>Chambers</ce:surname>
<ce:given-name>A.F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.C.</ce:initials>
<ce:surname>Groom</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>I.C.</ce:initials>
<ce:surname>MacDonald</ce:surname>
<ce:given-name>I.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat Rev Cancer</ref-sourcetitle>
<ref-publicationyear first="2002" />
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>563</first-page>
<last-page>572</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chambers, A.F., Groom, A.C., MacDonald, I.C.: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2, 563–572 (2002)</ref-fulltext>
<ce:source-text>Chambers, A.F., Groom, A.C., MacDonald, I.C.: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2, 563–572 (2002)</ce:source-text>
</reference>
<reference seq="4">
<ref-info>
<ref-title>
<ref-titletext-english>Targeting metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.S.</ce:initials>
<ce:surname>Steeg</ce:surname>
<ce:given-name>P.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature Reviews Cancer</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>201</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Steeg, P.S.: Targeting metastasis. Nature Reviews Cancer. 16, 201 (2016)</ref-fulltext>
<ce:source-text>Steeg, P.S.: Targeting metastasis. Nature Reviews Cancer. 16, 201 (2016)</ce:source-text>
</reference>
<reference seq="5">
<ref-info>
<ref-title>
<ref-titletext-english>Metastasis to bone: causes, consequences and therapeutic opportunities</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.R.</ce:initials>
<ce:surname>Mundy</ce:surname>
<ce:given-name>G.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature reviews Cancer</ref-sourcetitle>
<ref-publicationyear first="2002" />
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>584</first-page>
<last-page>593</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mundy, G.R.: Metastasis to bone: causes, consequences and therapeutic opportunities. Nature reviews Cancer. 2, 584–593 (2002)</ref-fulltext>
<ce:source-text>Mundy, G.R.: Metastasis to bone: causes, consequences and therapeutic opportunities. Nature reviews Cancer. 2, 584–593 (2002)</ce:source-text>
</reference>
<reference seq="6">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer to bone: a fatal attraction</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.N.</ce:initials>
<ce:surname>Weilbaecher</ce:surname>
<ce:given-name>K.N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.A.</ce:initials>
<ce:surname>Guise</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.K.</ce:initials>
<ce:surname>McCauley</ce:surname>
<ce:given-name>L.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature reviews Cancer</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>411</first-page>
<last-page>425</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Weilbaecher, K.N., Guise, T.A., McCauley, L.K.: Cancer to bone: a fatal attraction. Nature reviews Cancer. 11, 411–425 (2011)</ref-fulltext>
<ce:source-text>Weilbaecher, K.N., Guise, T.A., McCauley, L.K.: Cancer to bone: a fatal attraction. Nature reviews Cancer. 11, 411–425 (2011)</ce:source-text>
</reference>
<reference seq="7">
<ref-info>
<ref-title>
<ref-titletext-english>Bone metastasis and the metastatic niche</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Ren</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Esposito</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Kang</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Journal of molecular medicine</ref-sourcetitle>
<ref-publicationyear first="2015" />
<ref-text>Bone metastasis and the metastatic niche</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>93</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1203</first-page>
<last-page>1212</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ren, G., Esposito, M., Kang, Y.: Bone metastasis and the metastatic niche. Journal of molecular medicine. 93, 1203–1212 (2015)</ref-fulltext>
<ce:source-text>Ren, G., Esposito, M., Kang, Y.: Bone metastasis and the metastatic niche. Journal of molecular medicine. 93, 1203–1212 (2015)</ce:source-text>
</reference>
<reference seq="8">
<ref-info>
<ref-title>
<ref-titletext-english>The distribution of secondary growths in cancer of the breast</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Paget</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Lancet</ref-sourcetitle>
<ref-publicationyear first="1889" />
<volisspag>
<volume-issue-number>
<vol-first>133</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Paget, S.: The distribution of secondary growths in cancer of the breast. Lancet. 133, 3 (1889)</ref-fulltext>
<ce:source-text>Paget, S.: The distribution of secondary growths in cancer of the breast. Lancet. 133, 3 (1889)</ce:source-text>
</reference>
<reference seq="9">
<ref-info>
<ref-title>
<ref-titletext-english>SnapShot: Bone Metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Ell</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Kang</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2012" />
<ref-text>SnapShot: Bone Metastasis</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>151</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>690</first-page>
<last-page>690</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ell, B., Kang, Y.: SnapShot: Bone Metastasis. Cell. 151(690-690), e691 (2012)</ref-fulltext>
<ce:source-text>Ell, B., Kang, Y.: SnapShot: Bone Metastasis. Cell. 151(690-690), e691 (2012)</ce:source-text>
</reference>
<reference seq="10">
<ref-info>
<ref-title>
<ref-titletext-english>Dissecting Tumor-Stromal Interactions in Breast Cancer Bone Metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Kang</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Endocrinol Metab (Seoul)</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>31</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>206</first-page>
<last-page>212</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kang, Y.: Dissecting Tumor-Stromal Interactions in Breast Cancer Bone Metastasis. Endocrinol Metab (Seoul). 31, 206–212 (2016)</ref-fulltext>
<ce:source-text>Kang, Y.: Dissecting Tumor-Stromal Interactions in Breast Cancer Bone Metastasis. Endocrinol Metab (Seoul). 31, 206–212 (2016)</ce:source-text>
</reference>
<reference seq="11">
<ref-info>
<ref-title>
<ref-titletext-english>Molecular mechanisms of bone metastasis and associated muscle weakness</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.L.</ce:initials>
<ce:surname>Waning</ce:surname>
<ce:given-name>D.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.A.</ce:initials>
<ce:surname>Guise</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3071</first-page>
<last-page>3077</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Waning, D.L., Guise, T.A.: Molecular mechanisms of bone metastasis and associated muscle weakness. Clin Cancer Res. 20, 3071–3077 (2014)</ref-fulltext>
<ce:source-text>Waning, D.L., Guise, T.A.: Molecular mechanisms of bone metastasis and associated muscle weakness. Clin Cancer Res. 20, 3071–3077 (2014)</ce:source-text>
</reference>
<reference seq="12">
<ref-info>
<ref-title>
<ref-titletext-english>A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Juppner</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.B.</ce:initials>
<ce:surname>Abou-Samra</ce:surname>
<ce:given-name>A.B.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Freeman</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>X.F.</ce:initials>
<ce:surname>Kong</ce:surname>
<ce:given-name>X.F.</ce:given-name>
</author>
<author seq="5">
<ce:initials>E.</ce:initials>
<ce:surname>Schipani</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:surname>Richards</ce:surname>
<ce:given-name />
</author>
<author seq="7">
<ce:initials>L.F.</ce:initials>
<ce:surname>Kolakowski Jr.</ce:surname>
<ce:given-name>L.F.</ce:given-name>
</author>
<author seq="8">
<ce:initials>J.</ce:initials>
<ce:surname>Hock</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="9">
<ce:initials>J.T.</ce:initials>
<ce:surname>Potts Jr.</ce:surname>
<ce:given-name>J.T.</ce:given-name>
</author>
<author seq="10">
<ce:initials>H.M.</ce:initials>
<ce:surname>Kronenberg</ce:surname>
<ce:given-name>H.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="1991" />
<volisspag>
<volume-issue-number>
<vol-first>254</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1024</first-page>
<last-page>1026</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Juppner, H., Abou-Samra, A.B., Freeman, M., Kong, X.F., Schipani, E., Richards, J., Kolakowski Jr., L.F., Hock, J., Potts Jr., J.T., Kronenberg, H.M., et al.: A G protein- linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science. 254, 1024–1026 (1991)</ref-fulltext>
 
</reference>
<reference seq="13">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Sethi</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>X.</ce:initials>
<ce:surname>Dai</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.G.</ce:initials>
<ce:surname>Winter</ce:surname>
<ce:given-name>C.G.</ce:given-name>
</author>
<author seq="4">
<ce:initials>Y.</ce:initials>
<ce:surname>Kang</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>192</first-page>
<last-page>205</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sethi, N., Dai, X., Winter, C.G., Kang, Y.: Tumorderived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell. 19, 192–205 (2011)</ref-fulltext>
<ce:source-text>Sethi, N., Dai, X., Winter, C.G., Kang, Y.: Tumorderived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell. 19, 192–205 (2011)</ce:source-text>
</reference>
<reference seq="14">
<ref-info>
<ref-title>
<ref-titletext-english>Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Kohno</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Aogi</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Minami</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Nakamura</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="5">
<ce:initials>T.</ce:initials>
<ce:surname>Asaga</ce:surname>
<ce:given-name />
</author>
<author seq="6">
<ce:initials>Y.</ce:initials>
<ce:surname>Iino</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="7">
<ce:initials>T.</ce:initials>
<ce:surname>Watanabe</ce:surname>
<ce:given-name />
</author>
<author seq="8">
<ce:initials>C.</ce:initials>
<ce:surname>Goessl</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="9">
<ce:initials>Y.</ce:initials>
<ce:surname>Ohashi</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="10">
<ce:initials>S.</ce:initials>
<ce:surname>Takashima</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J Clin Oncol.</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>23</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3314</first-page>
<last-page>3321</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kohno, N., Aogi, K., Minami, H., Nakamura, S., Asaga, T., Iino, Y., Watanabe, T., Goessl, C., Ohashi, Y., Takashima, S.: Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 23, 3314–3321 (2005)</ref-fulltext>
<ce:source-text>Kohno, N., Aogi, K., Minami, H., Nakamura, S., Asaga, T., Iino, Y., Watanabe, T., Goessl, C., Ohashi, Y., Takashima, S.: Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 23, 3314–3321 (2005)</ce:source-text>
</reference>
<reference seq="15">
<ref-info>
<ref-title>
<ref-titletext-english>Denosumab and bisphosphonates: different mechanisms of action and effects</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Baron</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Ferrari</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.G.</ce:initials>
<ce:surname>Russell</ce:surname>
<ce:given-name>R.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Bone</ref-sourcetitle>
<ref-publicationyear first="2011" />
<ref-text>Denosumab and bisphosphonates: different mechanisms of action and effects</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>48</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>677</first-page>
<last-page>692</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baron, R., Ferrari, S., Russell, R.G.: Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 48, 677–692 (2011) </ref-fulltext>
<ce:source-text>Baron, R., Ferrari, S., Russell, R.G.: Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 48, 677–692 (2011)</ce:source-text>
</reference>
<reference seq="16">
<ref-info>
<ref-title>
<ref-titletext-english>Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Fizazi</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Carducci</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Smith</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Damiao</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Brown</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>L.</ce:initials>
<ce:surname>Karsh</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="7">
<ce:initials>P.</ce:initials>
<ce:surname>Milecki</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="8">
<ce:initials>N.</ce:initials>
<ce:surname>Shore</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="9">
<ce:initials>M.</ce:initials>
<ce:surname>Rader</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="10">
<ce:initials>H.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Lancet</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>377</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>813</first-page>
<last-page>822</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fizazi, K., Carducci, M., Smith, M., Damiao, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., et al.: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 377, 813–822 (2011)</ref-fulltext>
<ce:source-text>Fizazi, K., Carducci, M., Smith, M., Damiao, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., et al.: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 377, 813–822 (2011)</ce:source-text>
</reference>
<reference seq="17">
<ref-info>
<ref-title>
<ref-titletext-english>Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.T.</ce:initials>
<ce:surname>Stopeck</ce:surname>
<ce:given-name>A.T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Lipton</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.J.</ce:initials>
<ce:surname>Body</ce:surname>
<ce:given-name>J.J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>G.G.</ce:initials>
<ce:surname>Steger</ce:surname>
<ce:given-name>G.G.</ce:given-name>
</author>
<author seq="5">
<ce:initials>K.</ce:initials>
<ce:surname>Tonkin</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="6">
<ce:initials>R.H.</ce:initials>
<ce:surname>de Boer</ce:surname>
<ce:given-name>R.H.</ce:given-name>
</author>
<author seq="7">
<ce:initials>M.</ce:initials>
<ce:surname>Lichinitser</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="8">
<ce:initials>Y.</ce:initials>
<ce:surname>Fujiwara</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="9">
<ce:initials>D.A.</ce:initials>
<ce:surname>Yardley</ce:surname>
<ce:given-name>D.A.</ce:given-name>
</author>
<author seq="10">
<ce:initials>M.</ce:initials>
<ce:surname>Viniegra</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J Clin Oncol.</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5132</first-page>
<last-page>5139</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stopeck, A.T., Lipton, A., Body, J.J., Steger, G.G., Tonkin, K., de Boer, R.H., Lichinitser, M., Fujiwara, Y., Yardley, D.A., Viniegra, M., et al.: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 28, 5132–5139 (2010)</ref-fulltext>
<ce:source-text>Stopeck, A.T., Lipton, A., Body, J.J., Steger, G.G., Tonkin, K., de Boer, R.H., Lichinitser, M., Fujiwara, Y., Yardley, D.A., Viniegra, M., et al.: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 28, 5132–5139 (2010)</ce:source-text>
</reference>
<reference seq="18">
<ref-info>
<ref-title>
<ref-titletext-english>Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Durgeau</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Virk</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Corgnac</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>F.</ce:initials>
<ce:surname>Mami-Chouaib</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front Immunol.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>14</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Durgeau, A., Virk, Y., Corgnac, S., Mami-Chouaib, F.: Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy. Front Immunol. 9, 14 (2018)</ref-fulltext>
<ce:source-text>Durgeau, A., Virk, Y., Corgnac, S., Mami-Chouaib, F.: Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy. Front Immunol. 9, 14 (2018)</ce:source-text>
</reference>
<reference seq="19">
<ref-info>
<ref-title>
<ref-titletext-english>CD8(+) T cell states in human cancer: insights from single-cell analysis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.M.</ce:initials>
<ce:surname>van der Leun</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.S.</ce:initials>
<ce:surname>Thommen</ce:surname>
<ce:given-name>D.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.N.</ce:initials>
<ce:surname>Schumacher</ce:surname>
<ce:given-name>T.N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat Rev Cancer</ref-sourcetitle>
<ref-publicationyear first="2020" />
<ref-text>CD8(+) T cell states in human cancer: insights from single-cell analysis</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>218</first-page>
<last-page>232</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>van der Leun, A.M., Thommen, D.S., Schumacher, T.N.: CD8(+) T cell states in human cancer: insights from single-cell analysis. Nat Rev Cancer. 20, 218–232 (2020)</ref-fulltext>
<ce:source-text>van der Leun, A.M., Thommen, D.S., Schumacher, T.N.:CD8(+) T cell states in human cancer: insights from single-cell analysis. Nat Rev Cancer. 20, 218–232 (2020)</ce:source-text>
</reference>
<reference seq="20">
<ref-info>
<ref-title>
<ref-titletext-english>Immune evasion in cancer: Mechanistic basis and therapeutic strategies</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.S.</ce:initials>
<ce:surname>Vinay</ce:surname>
<ce:given-name>D.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.P.</ce:initials>
<ce:surname>Ryan</ce:surname>
<ce:given-name>E.P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>G.</ce:initials>
<ce:surname>Pawelec</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="4">
<ce:initials>W.H.</ce:initials>
<ce:surname>Talib</ce:surname>
<ce:given-name>W.H.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Stagg</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>E.</ce:initials>
<ce:surname>Elkord</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="7">
<ce:initials>T.</ce:initials>
<ce:surname>Lichtor</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="8">
<ce:initials>W.K.</ce:initials>
<ce:surname>Decker</ce:surname>
<ce:given-name>W.K.</ce:given-name>
</author>
<author seq="9">
<ce:initials>R.L.</ce:initials>
<ce:surname>Whelan</ce:surname>
<ce:given-name>R.L.</ce:given-name>
</author>
<author seq="10">
<ce:initials>H.</ce:initials>
<ce:surname>Kumara</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Semin Cancer Biol.</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Vinay, D.S., Ryan, E.P., Pawelec, G., Talib, W.H., Stagg, J., Elkord, E., Lichtor, T., Decker, W.K., Whelan, R.L., Kumara, H., et al.: Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol. 35(Suppl), S185– S198 (2015)</ref-fulltext>
<ce:source-text>Vinay, D.S., Ryan, E.P., Pawelec, G., Talib, W.H., Stagg, J., Elkord, E., Lichtor, T., Decker, W.K., Whelan, R.L., Kumara, H., et al.: Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol. 35(Suppl), S185– S198 (2015)</ce:source-text>
</reference>
<reference seq="21">
<ref-info>
<ref-title>
<ref-titletext-english>Current issues and perspectives in PD-1 blockade cancer immunotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Chamoto</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Hatae</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Honjo</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int J Clin Oncol.</ref-sourcetitle>
<ref-publicationyear first="2020" />
</ref-info>
<ref-fulltext>Chamoto, K., Hatae, R., Honjo, T.: Current issues and perspectives in PD-1 blockade cancer immunotherapy. Int J Clin Oncol. (2020)</ref-fulltext>
<ce:source-text>Chamoto, K., Hatae, R., Honjo, T.: Current issues and perspectives in PD-1 blockade cancer immunotherapy. Int J Clin Oncol. (2020)</ce:source-text>
</reference>
<reference seq="22">
<ref-info>
<ref-title>
<ref-titletext-english>Molecular mechanisms of T cell co-stimulation and co- inhibition</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.B.</ce:initials>
<ce:surname>Flies</ce:surname>
<ce:given-name>D.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat Rev Immunol</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>13</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>227</first-page>
<last-page>242</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, L., Flies, D.B.: Molecular mechanisms of T cell co-stimulation and co- inhibition. Nat Rev Immunol. 13, 227–242 (2013)</ref-fulltext>
<ce:source-text>Chen, L., Flies, D.B.: Molecular mechanisms of T cell co-stimulation and co- inhibition. Nat Rev Immunol. 13, 227–242 (2013)</ce:source-text>
</reference>
<reference seq="23">
<ref-info>
<ref-title>
<ref-titletext-english>Dissecting the mechanisms of immune checkpoint therapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Sharma</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.P.</ce:initials>
<ce:surname>Allison</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat Rev Immunol</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>75</first-page>
<last-page>76</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sharma, P., Allison, J.P.: Dissecting the mechanisms of immune checkpoint therapy. Nat Rev Immunol. 20, 75–76 (2020)</ref-fulltext>
<ce:source-text>Sharma, P., Allison, J.P.: Dissecting the mechanisms of immune checkpoint therapy. Nat Rev Immunol. 20, 75–76 (2020)</ce:source-text>
</reference>
<reference seq="24">
<ref-info>
<ref-title>
<ref-titletext-english>Immune checkpoint inhibitors of PD-L1 as cancer therapeutics</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Akinleye</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Z.</ce:initials>
<ce:surname>Rasool</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J Hematol Oncol</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>92</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Akinleye, A., Rasool, Z.: Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. 12, 92 (2019)</ref-fulltext>
<ce:source-text>Akinleye, A., Rasool, Z.: Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. 12, 92 (2019)</ce:source-text>
</reference>
<reference seq="25">
<ref-info>
<ref-title>
<ref-titletext-english>Improved survival with ipilimumab in patients with metastatic melanoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.S.</ce:initials>
<ce:surname>Hodi</ce:surname>
<ce:given-name>F.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.J.</ce:initials>
<ce:surname>O'day</ce:surname>
<ce:given-name>S.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.F.</ce:initials>
<ce:surname>McDermott</ce:surname>
<ce:given-name>D.F.</ce:given-name>
</author>
<author seq="4">
<ce:initials>R.W.</ce:initials>
<ce:surname>Weber</ce:surname>
<ce:given-name>R.W.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.A.</ce:initials>
<ce:surname>Sosman</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.B.</ce:initials>
<ce:surname>Haanen</ce:surname>
<ce:given-name>J.B.</ce:given-name>
</author>
<author seq="7">
<ce:initials>R.</ce:initials>
<ce:surname>Gonzalez</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="8">
<ce:initials>C.</ce:initials>
<ce:surname>Robert</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="9">
<ce:initials>D.</ce:initials>
<ce:surname>Schadendorf</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="10">
<ce:initials>J.C.</ce:initials>
<ce:surname>Hassel</ce:surname>
<ce:given-name>J.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>N Engl J Med</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>363</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>711</first-page>
<last-page>723</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J.C., et al.: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 363, 711–723 (2010)</ref-fulltext>
<ce:source-text>Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J.C., et al.: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 363, 711–723 (2010)</ce:source-text>
</reference>
<reference seq="26">
<ref-info>
<ref-title>
<ref-titletext-english>Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>McDermott</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Lebbe</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>F.S.</ce:initials>
<ce:surname>Hodi</ce:surname>
<ce:given-name>F.S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Maio</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.S.</ce:initials>
<ce:surname>Weber</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.D.</ce:initials>
<ce:surname>Wolchok</ce:surname>
<ce:given-name>J.D.</ce:given-name>
</author>
<author seq="7">
<ce:initials>J.A.</ce:initials>
<ce:surname>Thompson</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="8">
<ce:initials>C.M.</ce:initials>
<ce:surname>Balch</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Treat Rev</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>40</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1056</first-page>
<last-page>1064</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>McDermott, D., Lebbe, C., Hodi, F.S., Maio, M., Weber, J.S., Wolchok, J.D., Thompson, J.A., Balch, C.M.: Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev. 40, 1056–1064 (2014)</ref-fulltext>
<ce:source-text>McDermott, D., Lebbe, C., Hodi, F.S., Maio, M., Weber, J.S., Wolchok, J.D., Thompson, J.A., Balch, C.M.: Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev. 40, 1056–1064 (2014)</ce:source-text>
</reference>
<reference seq="27">
<ref-info>
<ref-title>
<ref-titletext-english>Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.D.</ce:initials>
<ce:surname>Wolchok</ce:surname>
<ce:given-name>J.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>V.</ce:initials>
<ce:surname>Chiarion-Sileni</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Gonzalez</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="4">
<ce:initials>P.</ce:initials>
<ce:surname>Rutkowski</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.J.</ce:initials>
<ce:surname>Grob</ce:surname>
<ce:given-name>J.J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>C.L.</ce:initials>
<ce:surname>Cowey</ce:surname>
<ce:given-name>C.L.</ce:given-name>
</author>
<author seq="7">
<ce:initials>C.D.</ce:initials>
<ce:surname>Lao</ce:surname>
<ce:given-name>C.D.</ce:given-name>
</author>
<author seq="8">
<ce:initials>J.</ce:initials>
<ce:surname>Wagstaff</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="9">
<ce:initials>D.</ce:initials>
<ce:surname>Schadendorf</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="10">
<ce:initials>P.F.</ce:initials>
<ce:surname>Ferrucci</ce:surname>
<ce:given-name>P.F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>N Engl J Med</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>377</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1345</first-page>
<last-page>1356</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wolchok, J.D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.J., Cowey, C.L., Lao, C.D., Wagstaff, J., Schadendorf, D., Ferrucci, P.F., et al.: Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 377, 1345–1356 (2017)</ref-fulltext>
<ce:source-text>Wolchok, J.D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.J., Cowey, C.L., Lao, C.D., Wagstaff, J., Schadendorf, D., Ferrucci, P.F., et al.: Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 377, 1345–1356 (2017)</ce:source-text>
</reference>
<reference seq="28">
<ref-info>
<ref-title>
<ref-titletext-english>Regorafenib plus nivolumab in patients with advanced colorectal or gastric cancer: An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603)</ref-titletext-english>
</ref-title>
<itemidlist>
<itemid idtype="ARTNUM">iv124</itemid>
</itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Hara</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Fukuoka</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Takahashi</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Kojima</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Kawazoe</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Asayama</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="7">
<ce:initials>T.</ce:initials>
<ce:surname>Yoshii</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="8">
<ce:initials>D.</ce:initials>
<ce:surname>Kotani</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="9">
<ce:initials>H.</ce:initials>
<ce:surname>Tamura</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="10">
<ce:initials>Y.</ce:initials>
<ce:surname>Mikamoto</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ann Oncol</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
<suppl>Supplement 4</suppl>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Hara, H., Fukuoka, S., Takahashi, N., Kojima, T., Kawazoe, A., Asayama, M., Yoshii, T., Kotani, D., Tamura, H., Mikamoto, Y., et al.: Regorafenib plus nivolumab in patients with advanced colorectal or gastric cancer: An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603). Ann Oncol. 30 Suppl 4, iv124 (2019)</ref-fulltext>
<ce:source-text>Hara, H., Fukuoka, S., Takahashi, N., Kojima, T., Kawazoe, A., Asayama, M., Yoshii, T., Kotani, D., Tamura, H., Mikamoto, Y., et al.: Regorafenib plus nivolumab in patients with advanced colorectal or gastric cancer: An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603). Ann Oncol. 30 Suppl 4, iv124 (2019)</ce:source-text>
</reference>
<reference seq="29">
<ref-info>
<ref-title>
<ref-titletext-english>CAR T cell therapy: Inroads to response and resistance</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.E.</ce:initials>
<ce:surname>Brown</ce:surname>
<ce:given-name>C.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.L.</ce:initials>
<ce:surname>Mackall</ce:surname>
<ce:given-name>C.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat Rev Immunol</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>73</first-page>
<last-page>74</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Brown, C.E., Mackall, C.L.: CAR T cell therapy: inroads to response and resistance. Nat Rev Immunol. 19, 73–74 (2019)</ref-fulltext>
<ce:source-text>Brown, C.E., Mackall, C.L.: CAR T cell therapy: inroads to response and resistance. Nat Rev Immunol. 19, 73–74 (2019)</ce:source-text>
</reference>
<reference seq="30">
<ref-info>
<ref-title>
<ref-titletext-english>Engineered T cells: The promise and challenges of cancer immunotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.D.</ce:initials>
<ce:surname>Fesnak</ce:surname>
<ce:given-name>A.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.H.</ce:initials>
<ce:surname>June</ce:surname>
<ce:given-name>C.H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>B.L.</ce:initials>
<ce:surname>Levine</ce:surname>
<ce:given-name>B.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat Rev Cancer</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>566</first-page>
<last-page>581</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fesnak, A.D., June, C.H., Levine, B.L.: Engineered T cells: The promise and challenges of cancer immunotherapy. Nat Rev Cancer. 16, 566–581 (2016)</ref-fulltext>
<ce:source-text>Fesnak, A.D., June, C.H., Levine, B.L.: Engineered T cells: The promise and challenges of cancer immunotherapy. Nat Rev Cancer. 16, 566–581 (2016)</ce:source-text>
</reference>
<reference seq="31">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer vaccines: Between the idea and the reality</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>O.J.</ce:initials>
<ce:surname>Finn</ce:surname>
<ce:given-name>O.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat Rev Immunol</ref-sourcetitle>
<ref-publicationyear first="2003" />
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>630</first-page>
<last-page>641</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Finn, O.J.: Cancer vaccines: between the idea and the reality. Nat Rev Immunol. 3, 630–641 (2003)</ref-fulltext>
<ce:source-text>Finn, O.J.: Cancer vaccines: between the idea and the reality. Nat Rev Immunol. 3, 630–641 (2003)</ce:source-text>
</reference>
<reference seq="32">
<ref-info>
<ref-title>
<ref-titletext-english>Personalized vaccines for cancer immunotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>U.</ce:initials>
<ce:surname>Sahin</ce:surname>
<ce:given-name>U.</ce:given-name>
</author>
<author seq="2">
<ce:initials>O.</ce:initials>
<ce:surname>Tureci</ce:surname>
<ce:given-name>O.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>359</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1355</first-page>
<last-page>1360</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sahin, U., Tureci, O.: Personalized vaccines for cancer immunotherapy. Science. 359, 1355–1360 (2018)</ref-fulltext>
<ce:source-text>Sahin, U., Tureci, O.: Personalized vaccines for cancer immunotherapy. Science. 359, 1355–1360 (2018)</ce:source-text>
</reference>
<reference seq="33">
<ref-info>
<ref-title>
<ref-titletext-english>An immunogenic personal neoantigen vaccine for patients with melanoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.A.</ce:initials>
<ce:surname>Ott</ce:surname>
<ce:given-name>P.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Z.</ce:initials>
<ce:surname>Hu</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.B.</ce:initials>
<ce:surname>Keskin</ce:surname>
<ce:given-name>D.B.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.A.</ce:initials>
<ce:surname>Shukla</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Sun</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>D.J.</ce:initials>
<ce:surname>Bozym</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
<author seq="7">
<ce:initials>W.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="8">
<ce:initials>A.</ce:initials>
<ce:surname>Luoma</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="9">
<ce:initials>A.</ce:initials>
<ce:surname>Giobbie-Hurder</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="10">
<ce:initials>L.</ce:initials>
<ce:surname>Peter</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>547</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>217</first-page>
<last-page>221</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ott, P.A., Hu, Z., Keskin, D.B., Shukla, S.A., Sun, J., Bozym, D.J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al.: An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 547, 217–221 (2017)</ref-fulltext>
<ce:source-text>Ott, P.A., Hu, Z., Keskin, D.B., Shukla, S.A., Sun, J., Bozym, D.J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al.: An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 547, 217–221 (2017)</ce:source-text>
</reference>
<reference seq="34">
<ref-info>
<ref-title>
<ref-titletext-english>Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>U.</ce:initials>
<ce:surname>Sahin</ce:surname>
<ce:given-name>U.</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Derhovanessian</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Miller</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>B.P.</ce:initials>
<ce:surname>Kloke</ce:surname>
<ce:given-name>B.P.</ce:given-name>
</author>
<author seq="5">
<ce:initials>P.</ce:initials>
<ce:surname>Simon</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Lower</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="7">
<ce:initials>V.</ce:initials>
<ce:surname>Bukur</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
<author seq="8">
<ce:initials>A.D.</ce:initials>
<ce:surname>Tadmor</ce:surname>
<ce:given-name>A.D.</ce:given-name>
</author>
<author seq="9">
<ce:initials>U.</ce:initials>
<ce:surname>Luxemburger</ce:surname>
<ce:given-name>U.</ce:given-name>
</author>
<author seq="10">
<ce:initials>B.</ce:initials>
<ce:surname>Schrors</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>547</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>222</first-page>
<last-page>226</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.P., Simon, P., Lower, M., Bukur, V., Tadmor, A.D., Luxemburger, U., Schrors, B., et al.: Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 547, 222–226 (2017)</ref-fulltext>
<ce:source-text>Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.P., Simon, P., Lower, M., Bukur, V., Tadmor, A.D., Luxemburger, U., Schrors, B., et al.: Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 547, 222–226 (2017)</ce:source-text>
</reference>
<reference seq="35">
<ref-info>
<ref-authors>
<author seq="1">
<ce:initials>T.N.</ce:initials>
<ce:surname>Schumacher</ce:surname>
<ce:given-name>T.N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.D.</ce:initials>
<ce:surname>Schreiber</ce:surname>
<ce:given-name>R.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Neoantigens in Cancer Immunotherapy</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>348</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>69</first-page>
<last-page>74</last-page>
</pages>
</page-information>
</volisspag>
<ref-text>Science</ref-text>
</ref-info>
<ref-fulltext>Schumacher, T.N., Schreiber, R.D.: Neoantigens in cancer immunotherapy, vol. 348, pp. 69–74. Science (2015)</ref-fulltext>
<ce:source-text>Schumacher, T.N., Schreiber, R.D.: Neoantigens in cancer immunotherapy, vol. 348, pp. 69–74. Science (2015)</ce:source-text>
</reference>
<reference seq="36">
<ref-info>
<ref-title>
<ref-titletext-english>Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.K.</ce:initials>
<ce:surname>Hong</ce:surname>
<ce:given-name>M.K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Macintyre</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.C.</ce:initials>
<ce:surname>Wedge</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>P.</ce:initials>
<ce:surname>van Loo</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="5">
<ce:initials>K.</ce:initials>
<ce:surname>Patel</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>Lunke</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="7">
<ce:initials>L.B.</ce:initials>
<ce:surname>Alexandrov</ce:surname>
<ce:given-name>L.B.</ce:given-name>
</author>
<author seq="8">
<ce:initials>C.</ce:initials>
<ce:surname>Sloggett</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="9">
<ce:initials>M.</ce:initials>
<ce:surname>Cmero</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="10">
<ce:initials>F.</ce:initials>
<ce:surname>Marass</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat Commun</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>6605</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hong, M.K., Macintyre, G., Wedge, D.C., Van Loo, P., Patel, K., Lunke, S., Alexandrov, L.B., Sloggett, C., Cmero, M., Marass, F., et al.: Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat Commun. 6, 6605 (2015)</ref-fulltext>
<ce:source-text>Hong, M.K., Macintyre, G., Wedge, D.C., Van Loo, P., Patel, K., Lunke, S., Alexandrov, L.B., Sloggett, C., Cmero, M., Marass, F., et al.: Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat Commun. 6, 6605 (2015)</ce:source-text>
</reference>
<reference seq="37">
<ref-info>
<ref-title>
<ref-titletext-english>Primary colorectal cancers and their subsequent hepatic metastases are genetically different: Implications for selection of patients for targeted treatment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S.</ce:initials>
<ce:surname>Vermaat</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>I.J.</ce:initials>
<ce:surname>Nijman</ce:surname>
<ce:given-name>I.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.J.</ce:initials>
<ce:surname>Koudijs</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>F.L.</ce:initials>
<ce:surname>Gerritse</ce:surname>
<ce:given-name>F.L.</ce:given-name>
</author>
<author seq="5">
<ce:initials>S.J.</ce:initials>
<ce:surname>Scherer</ce:surname>
<ce:given-name>S.J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Mokry</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="7">
<ce:initials>W.M.</ce:initials>
<ce:surname>Roessingh</ce:surname>
<ce:given-name>W.M.</ce:given-name>
</author>
<author seq="8">
<ce:initials>N.</ce:initials>
<ce:surname>Lansu</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="9">
<ce:initials>E.</ce:initials>
<ce:surname>de Bruijn</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="10">
<ce:initials>R.</ce:initials>
<ce:surname>van Hillegersberg</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>688</first-page>
<last-page>699</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vermaat, J.S., Nijman, I.J., Koudijs, M.J., Gerritse, F.L., Scherer, S.J., Mokry, M., Roessingh, W.M., Lansu, N., de Bruijn, E., van Hillegersberg, R., et al.: Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment. Clin Cancer Res. 18, 688–699 (2012)</ref-fulltext>
<ce:source-text>Vermaat, J.S., Nijman, I.J., Koudijs, M.J., Gerritse, F.L., Scherer, S.J., Mokry, M., Roessingh, W.M., Lansu, N., de Bruijn, E., van Hillegersberg, R., et al.: Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment. Clin Cancer Res. 18, 688–699 (2012)</ce:source-text>
</reference>
<reference seq="38">
<ref-info>
<ref-title>
<ref-titletext-english>Activating ESR1 mutations in hormone-resistant metastatic breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.R.</ce:initials>
<ce:surname>Robinson</ce:surname>
<ce:given-name>D.R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.M.</ce:initials>
<ce:surname>Wu</ce:surname>
<ce:given-name>Y.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Vats</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="4">
<ce:initials>F.</ce:initials>
<ce:surname>Su</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="5">
<ce:initials>R.J.</ce:initials>
<ce:surname>Lonigro</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>X.</ce:initials>
<ce:surname>Cao</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="7">
<ce:initials>S.</ce:initials>
<ce:surname>Kalyana-Sundaram</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="8">
<ce:initials>R.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="9">
<ce:initials>Y.</ce:initials>
<ce:surname>Ning</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="10">
<ce:initials>L.</ce:initials>
<ce:surname>Hodges</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat Genet</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>45</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1446</first-page>
<last-page>1451</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Robinson, D.R., Wu, Y.M., Vats, P., Su, F., Lonigro, R.J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al.: Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 45, 1446–1451 (2013)</ref-fulltext>
<ce:source-text>Robinson, D.R., Wu, Y.M., Vats, P., Su, F., Lonigro, R.J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al.: Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 45, 1446–1451 (2013)</ce:source-text>
</reference>
<reference seq="39">
<ref-info>
<ref-title>
<ref-titletext-english>ESR1 ligand-binding domain mutations in hormone-resistant breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.</ce:initials>
<ce:surname>Toy</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Shen</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Won</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="4">
<ce:initials>B.</ce:initials>
<ce:surname>Green</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="5">
<ce:initials>R.A.</ce:initials>
<ce:surname>Sakr</ce:surname>
<ce:given-name>R.A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Will</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="7">
<ce:initials>Z.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
<author seq="8">
<ce:initials>K.</ce:initials>
<ce:surname>Gala</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="9">
<ce:initials>S.</ce:initials>
<ce:surname>Fanning</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="10">
<ce:initials>T.A.</ce:initials>
<ce:surname>King</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat Genet</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>45</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1439</first-page>
<last-page>1445</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Toy, W., Shen, Y., Won, H., Green, B., Sakr, R.A., Will, M., Li, Z., Gala, K., Fanning, S., King, T.A., et al.: ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 45, 1439–1445 (2013)</ref-fulltext>
<ce:source-text>Toy, W., Shen, Y., Won, H., Green, B., Sakr, R.A., Will, M., Li, Z., Gala, K., Fanning, S., King, T.A., et al.: ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 45, 1439–1445 (2013)</ce:source-text>
</reference>
<reference seq="40">
<ref-info>
<ref-title>
<ref-titletext-english>Targeted degradation of activating estrogen receptor alpha ligand-binding domain mutations in human breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.L.</ce:initials>
<ce:surname>Gonzalez</ce:surname>
<ce:given-name>T.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Hancock</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Sun</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>C.L.</ce:initials>
<ce:surname>Gersch</ce:surname>
<ce:given-name>C.L.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.M.</ce:initials>
<ce:surname>Larios</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>W.</ce:initials>
<ce:surname>David</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="7">
<ce:initials>J.</ce:initials>
<ce:surname>Hu</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="8">
<ce:initials>D.F.</ce:initials>
<ce:surname>Hayes</ce:surname>
<ce:given-name>D.F.</ce:given-name>
</author>
<author seq="9">
<ce:initials>S.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="10">
<ce:initials>J.M.</ce:initials>
<ce:surname>Rae</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Breast Cancer Res Treat</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>180</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>611</first-page>
<last-page>622</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gonzalez, T.L., Hancock, M., Sun, S., Gersch, C.L., Larios, J.M., David, W., Hu, J., Hayes, D.F., Wang, S., Rae, J.M.: Targeted degradation of activating estrogen receptor alpha ligand-binding domain mutations in human breast cancer. Breast Cancer Res Treat. 180, 611–622 (2020)</ref-fulltext>
<ce:source-text>Gonzalez, T.L., Hancock, M., Sun, S., Gersch, C.L., Larios, J.M., David, W., Hu, J., Hayes, D.F., Wang, S., Rae, J.M.: Targeted degradation of activating estrogen receptor alpha ligand-binding domain mutations in human breast cancer. Breast Cancer Res Treat. 180, 611–622 (2020)</ce:source-text>
</reference>
<reference seq="41">
<ref-info>
<ref-title>
<ref-titletext-english>Pan-cancer whole-genome analyses of metastatic solid tumours</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Priestley</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Baber</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.P.</ce:initials>
<ce:surname>Lolkema</ce:surname>
<ce:given-name>M.P.</ce:given-name>
</author>
<author seq="4">
<ce:initials>N.</ce:initials>
<ce:surname>Steeghs</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="5">
<ce:initials>E.</ce:initials>
<ce:surname>de Bruijn</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:surname>Shale</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="7">
<ce:initials>K.</ce:initials>
<ce:surname>Duyvesteyn</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="8">
<ce:initials>S.</ce:initials>
<ce:surname>Haidari</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="9">
<ce:initials>A.</ce:initials>
<ce:surname>van Hoeck</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="10">
<ce:initials>W.</ce:initials>
<ce:surname>Onstenk</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>575</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>210</first-page>
<last-page>216</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Priestley, P., Baber, J., Lolkema, M.P., Steeghs, N., de Bruijn, E., Shale, C., Duyvesteyn, K., Haidari, S., van Hoeck, A., Onstenk, W., et al.: Pan-cancer whole-genome analyses of metastatic solid tumours. Nature. 575, 210–216 (2019)</ref-fulltext>
<ce:source-text>Priestley, P., Baber, J., Lolkema, M.P., Steeghs, N., de Bruijn, E., Shale, C., Duyvesteyn, K., Haidari, S., van Hoeck, A., Onstenk, W., et al.: Pan-cancer whole-genome analyses of metastatic solid tumours. Nature. 575, 210–216 (2019)</ce:source-text>
</reference>
<reference seq="42">
<ref-info>
<ref-title>
<ref-titletext-english>Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Ferrara</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.J.</ce:initials>
<ce:surname>Hillan</ce:surname>
<ce:given-name>K.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.P.</ce:initials>
<ce:surname>Gerber</ce:surname>
<ce:given-name>H.P.</ce:given-name>
</author>
<author seq="4">
<ce:initials>W.</ce:initials>
<ce:surname>Novotny</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat Rev Drug Discov</ref-sourcetitle>
<ref-publicationyear first="2004" />
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>391</first-page>
<last-page>400</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ferrara, N., Hillan, K.J., Gerber, H.P., Novotny, W.: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 3, 391–400 (2004)</ref-fulltext>
<ce:source-text>Ferrara, N., Hillan, K.J., Gerber, H.P., Novotny, W.: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 3, 391–400 (2004)</ce:source-text>
</reference>
<reference seq="43">
<ref-info>
<ref-title>
<ref-titletext-english>Bevacizumab: A review of its use in metastatic colorectal cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.L.</ce:initials>
<ce:surname>McCormack</ce:surname>
<ce:given-name>P.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.J.</ce:initials>
<ce:surname>Keam</ce:surname>
<ce:given-name>S.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Drugs</ref-sourcetitle>
<ref-publicationyear first="2008" />
<volisspag>
<volume-issue-number>
<vol-first>68</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>487</first-page>
<last-page>506</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>McCormack, P.L., Keam, S.J.: Bevacizumab: A review of its use in metastatic colorectal cancer. Drugs. 68, 487–506 (2008)</ref-fulltext>
<ce:source-text>McCormack, P.L., Keam, S.J.: Bevacizumab: A review of its use in metastatic colorectal cancer. Drugs. 68, 487–506 (2008)</ce:source-text>
</reference>
<reference seq="44">
<ref-info>
<ref-title>
<ref-titletext-english>Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Ebos</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.R.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>C.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>W.</ce:initials>
<ce:surname>Cruz-Munoz</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="4">
<ce:initials>G.A.</ce:initials>
<ce:surname>Bjarnason</ce:surname>
<ce:given-name />
</author>
<author seq="5">
<ce:initials>J.G.</ce:initials>
<ce:surname>Christensen</ce:surname>
<ce:given-name>J.G.</ce:given-name>
</author>
<author seq="6">
<ce:initials>R.S.</ce:initials>
<ce:surname>Kerbel</ce:surname>
<ce:given-name>R.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>232</first-page>
<last-page>239</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ebos, J.M., Lee, C.R., Cruz-Munoz, W., Bjarnason, G.A., Christensen, J.G., Kerbel, R.S.: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 15, 232–239 (2009)</ref-fulltext>
<ce:source-text>Ebos, J.M., Lee, C.R., Cruz-Munoz, W., Bjarnason, G.A., Christensen, J.G., Kerbel, R.S.: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 15, 232–239 (2009)</ce:source-text>
</reference>
<reference seq="45">
<ref-info>
<ref-title>
<ref-titletext-english>Silencing or fueling metastasis with VEGF inhibitors: Antiangiogenesis revisited</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Loges</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Mazzone</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Hohensinner</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="4">
<ce:initials>P.</ce:initials>
<ce:surname>Carmeliet</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>167</first-page>
<last-page>170</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Loges, S., Mazzone, M., Hohensinner, P., Carmeliet, P.: Silencing or fueling metastasis with VEGF inhibitors: Antiangiogenesis revisited. Cancer Cell. 15, 167–170 (2009)</ref-fulltext>
<ce:source-text>Loges, S., Mazzone, M., Hohensinner, P., Carmeliet, P.: Silencing or fueling metastasis with VEGF inhibitors: Antiangiogenesis revisited. Cancer Cell. 15, 167–170 (2009)</ce:source-text>
</reference>
<reference seq="46">
<ref-info>
<ref-title>
<ref-titletext-english>Metastasis: From dissemination to organ- specific colonization</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.X.</ce:initials>
<ce:surname>Nguyen</ce:surname>
<ce:given-name>D.X.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.D.</ce:initials>
<ce:surname>Bos</ce:surname>
<ce:given-name>P.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Massague</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat Rev Cancer</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>274</first-page>
<last-page>284</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nguyen, D.X., Bos, P.D., Massague, J.: Metastasis: from dissemination to organ- specific colonization. Nat Rev Cancer. 9, 274–284 (2009)</ref-fulltext>
<ce:source-text>Nguyen, D.X., Bos, P.D., Massague, J.: Metastasis: from dissemination to organ- specific colonization. Nat Rev Cancer. 9, 274–284 (2009)</ce:source-text>
</reference>
<reference seq="47">
<ref-info>
<ref-title>
<ref-titletext-english>Surviving at a Distance: Organ-Specific Metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.C.</ce:initials>
<ce:surname>Obenauf</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Massague</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Trends Cancer</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>76</first-page>
<last-page>91</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Obenauf, A.C., Massague, J.: Surviving at a Distance: Organ-Specific Metastasis. Trends Cancer. 1, 76–91 (2015)</ref-fulltext>
<ce:source-text>Obenauf, A.C., Massague, J.: Surviving at a Distance: Organ-Specific Metastasis. Trends Cancer. 1, 76–91 (2015)</ce:source-text>
</reference>
<reference seq="48">
<ref-info>
<ref-title>
<ref-titletext-english>Emerging Biological Principles of Metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.W.</ce:initials>
<ce:surname>Lambert</ce:surname>
<ce:given-name>A.W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.R.</ce:initials>
<ce:surname>Pattabiraman</ce:surname>
<ce:given-name>D.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.A.</ce:initials>
<ce:surname>Weinberg</ce:surname>
<ce:given-name>R.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>168</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>670</first-page>
<last-page>691</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lambert, A.W., Pattabiraman, D.R., Weinberg, R.A.: Emerging Biological Principles of Metastasis. Cell. 168, 670–691 (2017)</ref-fulltext>
<ce:source-text>Lambert, A.W., Pattabiraman, D.R., Weinberg, R.A.: Emerging Biological Principles of Metastasis. Cell. 168, 670–691 (2017)</ce:source-text>
</reference>
<reference seq="49">
<ref-info>
<ref-title>
<ref-titletext-english>Metastatic colonization by circulating tumour cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Massague</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.C.</ce:initials>
<ce:surname>Obenauf</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>529</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>298</first-page>
<last-page>306</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Massague, J., Obenauf, A.C.: Metastatic colonization by circulating tumour cells. Nature. 529, 298–306 (2016)</ref-fulltext>
<ce:source-text>Massague, J., Obenauf, A.C.: Metastatic colonization by circulating tumour cells. Nature. 529, 298–306 (2016)</ce:source-text>
</reference>
<reference seq="50">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer treatment and survivorship statistics, 2019</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.D.</ce:initials>
<ce:surname>Miller</ce:surname>
<ce:given-name>K.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Nogueira</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.B.</ce:initials>
<ce:surname>Mariotto</ce:surname>
<ce:given-name>A.B.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.H.</ce:initials>
<ce:surname>Rowland</ce:surname>
<ce:given-name>J.H.</ce:given-name>
</author>
<author seq="5">
<ce:initials>K.R.</ce:initials>
<ce:surname>Yabroff</ce:surname>
<ce:given-name>K.R.</ce:given-name>
</author>
<author seq="6">
<ce:initials>C.M.</ce:initials>
<ce:surname>Alfano</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
<author seq="7">
<ce:initials>A.</ce:initials>
<ce:surname>Jemal</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="8">
<ce:initials>J.L.</ce:initials>
<ce:surname>Kramer</ce:surname>
<ce:given-name>J.L.</ce:given-name>
</author>
<author seq="9">
<ce:initials>R.L.</ce:initials>
<ce:surname>Siegel</ce:surname>
<ce:given-name>R.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>CA Cancer J Clin</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>69</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>363</first-page>
<last-page>385</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Miller, K.D., Nogueira, L., Mariotto, A.B., Rowland, J.H., Yabroff, K.R., Alfano, C.M., Jemal, A., Kramer, J.L., Siegel, R.L.: Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 69, 363–385 (2019)</ref-fulltext>
<ce:source-text>Miller, K.D., Nogueira, L., Mariotto, A.B., Rowland, J.H., Yabroff, K.R., Alfano, C.M., Jemal, A., Kramer, J.L., Siegel, R.L.: Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 69, 363–385 (2019)</ce:source-text>
</reference>
<reference seq="51">
<ref-info>
<ref-title>
<ref-titletext-english>Early dissemination seeds metastasis in breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Hosseini</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.M.S.</ce:initials>
<ce:surname>Obradovic</ce:surname>
<ce:given-name>M.M.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Hoffmann</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>K.L.</ce:initials>
<ce:surname>Harper</ce:surname>
<ce:given-name>K.L.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.S.</ce:initials>
<ce:surname>Sosa</ce:surname>
<ce:given-name>M.S.</ce:given-name>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Werner-Klein</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="7">
<ce:initials>L.K.</ce:initials>
<ce:surname>Nanduri</ce:surname>
<ce:given-name>L.K.</ce:given-name>
</author>
<author seq="8">
<ce:initials>C.</ce:initials>
<ce:surname>Werno</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="9">
<ce:initials>C.</ce:initials>
<ce:surname>Ehrl</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="10">
<ce:initials>M.</ce:initials>
<ce:surname>Maneck</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>540</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>552</first-page>
<last-page>558</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hosseini, H., Obradovic, M.M.S., Hoffmann, M., Harper, K.L., Sosa, M.S., Werner-Klein, M., Nanduri, L.K., Werno, C., Ehrl, C., Maneck, M., et al.: Early dissemination seeds metastasis in breast cancer. Nature. 540, 552–558 (2016)</ref-fulltext>
<ce:source-text>Hosseini, H., Obradovic, M.M.S., Hoffmann, M., Harper, K.L., Sosa, M.S., Werner-Klein, M., Nanduri, L.K., Werno, C., Ehrl, C., Maneck, M., et al.: Early dissemination seeds metastasis in breast cancer. Nature. 540, 552–558 (2016)</ce:source-text>
</reference>
<reference seq="52">
<ref-info>
<ref-title>
<ref-titletext-english>Quantitative evidence for early metastatic seeding in colorectal cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Hu</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Ding</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Z.</ce:initials>
<ce:surname>Ma</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Sun</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.A.</ce:initials>
<ce:surname>Seoane</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:surname>Scott Shaffer</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="7">
<ce:initials>C.J.</ce:initials>
<ce:surname>Suarez</ce:surname>
<ce:given-name>C.J.</ce:given-name>
</author>
<author seq="8">
<ce:initials>A.S.</ce:initials>
<ce:surname>Berghoff</ce:surname>
<ce:given-name>A.S.</ce:given-name>
</author>
<author seq="9">
<ce:initials>C.</ce:initials>
<ce:surname>Cremolini</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="10">
<ce:initials>A.</ce:initials>
<ce:surname>Falcone</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat Genet</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>51</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1113</first-page>
<last-page>1122</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hu, Z., Ding, J., Ma, Z., Sun, R., Seoane, J.A., Scott Shaffer, J., Suarez, C.J., Berghoff, A.S., Cremolini, C., Falcone, A., et al.: Quantitative evidence for early metastatic seeding in colorectal cancer. Nat Genet. 51, 1113–1122 (2019)</ref-fulltext>
<ce:source-text>Hu, Z., Ding, J., Ma, Z., Sun, R., Seoane, J.A., Scott Shaffer, J., Suarez, C.J., Berghoff, A.S., Cremolini, C., Falcone, A., et al.: Quantitative evidence for early metastatic seeding in colorectal cancer. Nat Genet. 51, 1113–1122 (2019)</ce:source-text>
</reference>
<reference seq="53">
<ref-info>
<ref-title>
<ref-titletext-english>The potential of circulating tumor cells as a liquid biopsy to guide therapy in prostate cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Pantel</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Alix-Panabieres</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Discov</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>974</first-page>
<last-page>975</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pantel, K., Alix-Panabieres, C.: The potential of circulating tumor cells as a liquid biopsy to guide therapy in prostate cancer. Cancer Discov. 2, 974–975 (2012)</ref-fulltext>
<ce:source-text>Pantel, K., Alix-Panabieres, C.: The potential of circulating tumor cells as a liquid biopsy to guide therapy in prostate cancer. Cancer Discov. 2, 974–975 (2012)</ce:source-text>
</reference>
<reference seq="54">
<ref-info>
<ref-title>
<ref-titletext-english>Circulating epithelial cells in patients with benign colon diseases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Pantel</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Deneve</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Nocca</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Coffy</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.P.</ce:initials>
<ce:surname>Vendrell</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
<author seq="6">
<ce:initials>T.</ce:initials>
<ce:surname>Maudelonde</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="7">
<ce:initials>S.</ce:initials>
<ce:surname>Riethdorf</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="8">
<ce:initials>C.</ce:initials>
<ce:surname>Alix-Panabieres</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin Chem</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>58</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>936</first-page>
<last-page>940</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pantel, K., Deneve, E., Nocca, D., Coffy, A., Vendrell, J.P., Maudelonde, T., Riethdorf, S., Alix-Panabieres, C.: Circulating epithelial cells in patients with benign colon diseases. Clin Chem. 58, 936–940 (2012)</ref-fulltext>
<ce:source-text>Pantel, K., Deneve, E., Nocca, D., Coffy, A., Vendrell, J.P., Maudelonde, T., Riethdorf, S., Alix-Panabieres, C.: Circulating epithelial cells in patients with benign colon diseases. Clin Chem. 58, 936–940 (2012)</ce:source-text>
</reference>
<reference seq="55">
<ref-info>
<ref-title>
<ref-titletext-english>EMT and dissemination precede pancreatic tumor formation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.D.</ce:initials>
<ce:surname>Rhim</ce:surname>
<ce:given-name>A.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.T.</ce:initials>
<ce:surname>Mirek</ce:surname>
<ce:given-name>E.T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.M.</ce:initials>
<ce:surname>Aiello</ce:surname>
<ce:given-name>N.M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Maitra</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.M.</ce:initials>
<ce:surname>Bailey</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>F.</ce:initials>
<ce:surname>McAllister</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="7">
<ce:initials>M.</ce:initials>
<ce:surname>Reichert</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="8">
<ce:initials>G.L.</ce:initials>
<ce:surname>Beatty</ce:surname>
<ce:given-name>G.L.</ce:given-name>
</author>
<author seq="9">
<ce:initials>A.K.</ce:initials>
<ce:surname>Rustgi</ce:surname>
<ce:given-name>A.K.</ce:given-name>
</author>
<author seq="10">
<ce:initials>R.H.</ce:initials>
<ce:surname>Vonderheide</ce:surname>
<ce:given-name>R.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>148</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>349</first-page>
<last-page>361</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rhim, A.D., Mirek, E.T., Aiello, N.M., Maitra, A., Bailey, J.M., McAllister, F., Reichert, M., Beatty, G.L., Rustgi, A.K., Vonderheide, R.H., et al.: EMT and dissemination precede pancreatic tumor formation. Cell. 148, 349–361 (2012)</ref-fulltext>
<ce:source-text>Rhim, A.D., Mirek, E.T., Aiello, N.M., Maitra, A., Bailey, J.M., McAllister, F., Reichert, M., Beatty, G.L., Rustgi, A.K., Vonderheide, R.H., et al.: EMT and dissemination precede pancreatic tumor formation. Cell. 148, 349–361 (2012)</ce:source-text>
</reference>
<reference seq="56">
<ref-info>
<ref-title>
<ref-titletext-english>New insights into the mechanisms of epithelial- mesenchymal transition and implications for cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Dongre</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.A.</ce:initials>
<ce:surname>Weinberg</ce:surname>
<ce:given-name>R.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat Rev Mol Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>69</first-page>
<last-page>84</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dongre, A., Weinberg, R.A.: New insights into the mechanisms of epithelial- mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 20, 69–84 (2019)</ref-fulltext>
<ce:source-text>Dongre, A., Weinberg, R.A.: New insights into the mechanisms of epithelial- mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 20, 69–84 (2019)</ce:source-text>
</reference>
<reference seq="57">
<ref-info>
<ref-title>
<ref-titletext-english>Classifying collective cancer cell invasion</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Friedl</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Locker</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>E.</ce:initials>
<ce:surname>Sahai</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.E.</ce:initials>
<ce:surname>Segall</ce:surname>
<ce:given-name>J.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>777</first-page>
<last-page>783</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Friedl, P., Locker, J., Sahai, E., Segall, J.E.: Classifying collective cancer cell invasion. Nat Cell Biol. 14, 777–783 (2012)</ref-fulltext>
<ce:source-text>Friedl, P., Locker, J., Sahai, E., Segall, J.E.: Classifying collective cancer cell invasion. Nat Cell Biol. 14, 777–783 (2012)</ce:source-text>
</reference>
<reference seq="58">
<ref-info>
<ref-title>
<ref-titletext-english>Adjuvant CMF chemotherapy in operable breast cancer: Ten years later</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Bonadonna</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Rossi</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Valagussa</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Lancet</ref-sourcetitle>
<ref-publicationyear first="1985" />
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>976</first-page>
<last-page>977</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bonadonna, G., Rossi, A., Valagussa, P.: Adjuvant CMF chemotherapy in operable breast cancer: Ten years later. Lancet. 1, 976–977 (1985)</ref-fulltext>
<ce:source-text>Bonadonna, G., Rossi, A., Valagussa, P.: Adjuvant CMF chemotherapy in operable breast cancer: Ten years later. Lancet. 1, 976–977 (1985)</ce:source-text>
</reference>
<reference seq="59">
<ref-info>
<ref-title>
<ref-titletext-english>The contribution of platelets to intravascular arrest, extravasation, and outgrowth of disseminated tumor cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Foss</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Munoz-Sagredo</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Sleeman</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>W.</ce:initials>
<ce:surname>Thiele</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin Exp Metastasis</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>37</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>47</first-page>
<last-page>67</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Foss, A., Munoz-Sagredo, L., Sleeman, J., Thiele, W.: The contribution of platelets to intravascular arrest, extravasation, and outgrowth of disseminated tumor cells. Clin Exp Metastasis. 37, 47–67 (2020)</ref-fulltext>
<ce:source-text>Foss, A., Munoz-Sagredo, L., Sleeman, J., Thiele, W.: The contribution of platelets to intravascular arrest, extravasation, and outgrowth of disseminated tumor cells. Clin Exp Metastasis. 37, 47–67 (2020)</ce:source-text>
</reference>
<reference seq="60">
<ref-info>
<ref-title>
<ref-titletext-english>TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Padua</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>X.H.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>X.H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Q.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>Q.</ce:given-name>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Nadal</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="5">
<ce:initials>W.L.</ce:initials>
<ce:surname>Gerald</ce:surname>
<ce:given-name>W.L.</ce:given-name>
</author>
<author seq="6">
<ce:initials>R.R.</ce:initials>
<ce:surname>Gomis</ce:surname>
<ce:given-name>R.R.</ce:given-name>
</author>
<author seq="7">
<ce:initials>J.</ce:initials>
<ce:surname>Massague</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2008" />
<volisspag>
<volume-issue-number>
<vol-first>133</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>66</first-page>
<last-page>77</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Padua, D., Zhang, X.H., Wang, Q., Nadal, C., Gerald, W.L., Gomis, R.R., Massague, J.: TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell. 133, 66–77 (2008)</ref-fulltext>
<ce:source-text>Padua, D., Zhang, X.H., Wang, Q., Nadal, C., Gerald, W.L., Gomis, R.R., Massague, J.: TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell. 133, 66–77 (2008)</ce:source-text>
</reference>
<reference seq="61">
<ref-info>
<ref-title>
<ref-titletext-english>Dormant tumour cells, their niches and the influence of immunity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.T.</ce:initials>
<ce:surname>Goddard</ce:surname>
<ce:given-name>E.T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>I.</ce:initials>
<ce:surname>Bozic</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.R.</ce:initials>
<ce:surname>Riddell</ce:surname>
<ce:given-name>S.R.</ce:given-name>
</author>
<author seq="4">
<ce:initials>C.M.</ce:initials>
<ce:surname>Ghajar</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1240</first-page>
<last-page>1249</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Goddard, E.T., Bozic, I., Riddell, S.R., Ghajar, C.M.: Dormant tumour cells, their niches and the influence of immunity. Nat Cell Biol. 20, 1240–1249 (2018)</ref-fulltext>
<ce:source-text>Goddard, E.T., Bozic, I., Riddell, S.R., Ghajar, C.M.: Dormant tumour cells, their niches and the influence of immunity. Nat Cell Biol. 20, 1240–1249 (2018)</ce:source-text>
</reference>
<reference seq="62">
<ref-info>
<ref-title>
<ref-titletext-english>Tumour exosome integrins determine organotropic metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Hoshino</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Costa-Silva</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.L.</ce:initials>
<ce:surname>Shen</ce:surname>
<ce:given-name>T.L.</ce:given-name>
</author>
<author seq="4">
<ce:initials>G.</ce:initials>
<ce:surname>Rodrigues</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Hashimoto</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Tesic Mark</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="7">
<ce:initials>H.</ce:initials>
<ce:surname>Molina</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="8">
<ce:initials>S.</ce:initials>
<ce:surname>Kohsaka</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="9">
<ce:initials>A.</ce:initials>
<ce:surname>Di Giannatale</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="10">
<ce:initials>S.</ce:initials>
<ce:surname>Ceder</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>527</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>329</first-page>
<last-page>335</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hoshino, A., Costa-Silva, B., Shen, T.L., Rodrigues, G., Hashimoto, A., Tesic Mark, M., Molina, H., Kohsaka, S., Di Giannatale, A., Ceder, S., et al.: Tumour exosome integrins determine organotropic metastasis. Nature. 527, 329–335 (2015)</ref-fulltext>
<ce:source-text>Hoshino, A., Costa-Silva, B., Shen, T.L., Rodrigues, G., Hashimoto, A., Tesic Mark, M., Molina, H., Kohsaka, S., Di Giannatale, A., Ceder, S., et al.: Tumour exosome integrins determine organotropic metastasis. Nature. 527, 329–335 (2015)</ce:source-text>
</reference>
<reference seq="63">
<ref-info>
<ref-title>
<ref-titletext-english>KLF4-dependent perivascular cell plasticity mediates pre-metastatic niche formation and metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Murgai</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>W.</ce:initials>
<ce:surname>Ju</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Eason</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Kline</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="5">
<ce:initials>D.W.</ce:initials>
<ce:surname>Beury</ce:surname>
<ce:given-name>D.W.</ce:given-name>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>Kaczanowska</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="7">
<ce:initials>M.M.</ce:initials>
<ce:surname>Miettinen</ce:surname>
<ce:given-name>M.M.</ce:given-name>
</author>
<author seq="8">
<ce:initials>M.</ce:initials>
<ce:surname>Kruhlak</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="9">
<ce:initials>H.</ce:initials>
<ce:surname>Lei</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="10">
<ce:initials>J.F.</ce:initials>
<ce:surname>Shern</ce:surname>
<ce:given-name>J.F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat Med</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>23</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1176</first-page>
<last-page>1190</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Murgai, M., Ju, W., Eason, M., Kline, J., Beury, D.W., Kaczanowska, S., Miettinen, M.M., Kruhlak, M., Lei, H., Shern, J.F., et al.: KLF4-dependent perivascular cell plasticity mediates pre-metastatic niche formation and metastasis. Nat Med. 23, 1176–1190 (2017)</ref-fulltext>
<ce:source-text>Murgai, M., Ju, W., Eason, M., Kline, J., Beury, D.W., Kaczanowska, S., Miettinen, M.M., Kruhlak, M., Lei, H., Shern, J.F., et al.: KLF4-dependent perivascular cell plasticity mediates pre-metastatic niche formation and metastasis. Nat Med. 23, 1176–1190 (2017)</ce:source-text>
</reference>
<reference seq="64">
<ref-info>
<ref-title>
<ref-titletext-english>Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Peinado</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Aleckovic</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Lavotshkin</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>I.</ce:initials>
<ce:surname>Matei</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="5">
<ce:initials>B.</ce:initials>
<ce:surname>Costa-Silva</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="6">
<ce:initials>G.</ce:initials>
<ce:surname>Moreno-Bueno</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="7">
<ce:initials>M.</ce:initials>
<ce:surname>Hergueta-Redondo</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="8">
<ce:initials>C.</ce:initials>
<ce:surname>Williams</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="9">
<ce:initials>G.</ce:initials>
<ce:surname>Garcia-Santos</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="10">
<ce:initials>C.</ce:initials>
<ce:surname>Ghajar</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat Med</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>883</first-page>
<last-page>891</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Peinado, H., Aleckovic, M., Lavotshkin, S., Matei, I., Costa-Silva, B., Moreno-Bueno, G., Hergueta-Redondo, M., Williams, C., Garcia-Santos, G., Ghajar, C., et al.: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 18, 883–891 (2012)</ref-fulltext>
<ce:source-text>Peinado, H., Aleckovic, M., Lavotshkin, S., Matei, I., Costa-Silva, B., Moreno-Bueno, G., Hergueta-Redondo, M., Williams, C., Garcia-Santos, G., Ghajar, C., et al.: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 18, 883–891 (2012)</ce:source-text>
</reference>
<reference seq="65">
<ref-info>
<ref-title>
<ref-titletext-english>Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Rodrigues</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Hoshino</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.M.</ce:initials>
<ce:surname>Kenific</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>I.R.</ce:initials>
<ce:surname>Matei</ce:surname>
<ce:given-name>I.R.</ce:given-name>
</author>
<author seq="5">
<ce:initials>L.</ce:initials>
<ce:surname>Steiner</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="6">
<ce:initials>D.</ce:initials>
<ce:surname>Freitas</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="7">
<ce:initials>H.S.</ce:initials>
<ce:surname>Kim</ce:surname>
<ce:given-name>H.S.</ce:given-name>
</author>
<author seq="8">
<ce:initials>P.R.</ce:initials>
<ce:surname>Oxley</ce:surname>
<ce:given-name>P.R.</ce:given-name>
</author>
<author seq="9">
<ce:initials>I.</ce:initials>
<ce:surname>Scandariato</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="10">
<ce:initials>I.</ce:initials>
<ce:surname>Casanova-Salas</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1403</first-page>
<last-page>1412</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rodrigues, G., Hoshino, A., Kenific, C.M., Matei, I.R., Steiner, L., Freitas, D., Kim, H.S., Oxley, P.R., Scandariato, I., Casanova-Salas, I., et al.: Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. Nat Cell Biol. 21, 1403–1412 (2019)</ref-fulltext>
<ce:source-text>Rodrigues, G., Hoshino, A., Kenific, C.M., Matei, I.R., Steiner, L., Freitas, D., Kim, H.S., Oxley, P.R., Scandariato, I., Casanova-Salas, I., et al.: Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. Nat Cell Biol. 21, 1403–1412 (2019)</ce:source-text>
</reference>
<reference seq="66">
<ref-info>
<ref-title>
<ref-titletext-english>Dormancy in solid tumors: Implications for prostate cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.S.</ce:initials>
<ce:surname>Ruppender</ce:surname>
<ce:given-name>N.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Morrissey</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>P.H.</ce:initials>
<ce:surname>Lange</ce:surname>
<ce:given-name>P.H.</ce:given-name>
</author>
<author seq="4">
<ce:initials>R.L.</ce:initials>
<ce:surname>Vessella</ce:surname>
<ce:given-name>R.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Metastasis Rev</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>501</first-page>
<last-page>509</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ruppender, N.S., Morrissey, C., Lange, P.H., Vessella, R.L.: Dormancy in solid tumors: implications for prostate cancer. Cancer Metastasis Rev. 32, 501–509 (2013)</ref-fulltext>
<ce:source-text>Ruppender, N.S., Morrissey, C., Lange, P.H., Vessella, R.L.: Dormancy in solid tumors: implications for prostate cancer. Cancer Metastasis Rev. 32, 501–509 (2013)</ce:source-text>
</reference>
<reference seq="67">
<ref-info>
<ref-title>
<ref-titletext-english>Metastasis dormancy in estrogen receptor-positive breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.H.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>X.H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Giuliano</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.V.</ce:initials>
<ce:surname>Trivedi</ce:surname>
<ce:given-name>M.V.</ce:given-name>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Schiff</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="5">
<ce:initials>C.K.</ce:initials>
<ce:surname>Osborne</ce:surname>
<ce:given-name>C.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>6389</first-page>
<last-page>6397</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, X.H., Giuliano, M., Trivedi, M.V., Schiff, R., Osborne, C.K.: Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res. 19, 6389–6397 (2013)</ref-fulltext>
<ce:source-text>Zhang, X.H., Giuliano, M., Trivedi, M.V., Schiff, R., Osborne, C.K.: Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res. 19, 6389–6397 (2013)</ce:source-text>
</reference>
<reference seq="68">
<ref-info>
<ref-title>
<ref-titletext-english>Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.J.</ce:initials>
<ce:surname>Aslakson</ce:surname>
<ce:given-name>C.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>F.R.</ce:initials>
<ce:surname>Miller</ce:surname>
<ce:given-name>F.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="1992" />
<volisspag>
<volume-issue-number>
<vol-first>52</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1399</first-page>
<last-page>1405</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Aslakson, C.J., Miller, F.R.: Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52, 1399–1405 (1992)</ref-fulltext>
<ce:source-text>Aslakson, C.J., Miller, F.R.: Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52, 1399–1405 (1992)</ce:source-text>
</reference>
<reference seq="69">
<ref-info>
<ref-title>
<ref-titletext-english>A multigenic program mediating breast cancer metastasis to bone</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Kang</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.M.</ce:initials>
<ce:surname>Siegel</ce:surname>
<ce:given-name>P.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>W.</ce:initials>
<ce:surname>Shu</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Drobnjak</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>S.M.</ce:initials>
<ce:surname>Kakonen</ce:surname>
<ce:given-name>S.M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:surname>Cordon-Cardo</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="7">
<ce:initials>T.A.</ce:initials>
<ce:surname>Guise</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
<author seq="8">
<ce:initials>J.</ce:initials>
<ce:surname>Massague</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2003" />
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>537</first-page>
<last-page>549</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kang, Y., Siegel, P.M., Shu, W., Drobnjak, M., Kakonen, S.M., Cordon-Cardo, C., Guise, T.A., Massague, J.: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 3, 537–549 (2003)</ref-fulltext>
<ce:source-text>Kang, Y., Siegel, P.M., Shu, W., Drobnjak, M., Kakonen, S.M., Cordon-Cardo, C., Guise, T.A., Massague, J.: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 3, 537–549 (2003)</ce:source-text>
</reference>
<reference seq="70">
<ref-info>
<ref-title>
<ref-titletext-english>VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Lu</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Mu</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Wei</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Riethdorf</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="5">
<ce:initials>Q.</ce:initials>
<ce:surname>Yang</ce:surname>
<ce:given-name>Q.</ce:given-name>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Yuan</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="7">
<ce:initials>J.</ce:initials>
<ce:surname>Yan</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="8">
<ce:initials>Y.</ce:initials>
<ce:surname>Hua</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="9">
<ce:initials>B.J.</ce:initials>
<ce:surname>Tiede</ce:surname>
<ce:given-name>B.J.</ce:given-name>
</author>
<author seq="10">
<ce:initials>X.</ce:initials>
<ce:surname>Lu</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>701</first-page>
<last-page>714</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lu, X., Mu, E., Wei, Y., Riethdorf, S., Yang, Q., Yuan, M., Yan, J., Hua, Y., Tiede, B.J., Lu, X., et al.: VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell. 20, 701–714 (2011)</ref-fulltext>
<ce:source-text>Lu, X., Mu, E., Wei, Y., Riethdorf, S., Yang, Q., Yuan, M., Yan, J., Hua, Y., Tiede, B.J., Lu, X., et al.: VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell. 20, 701–714 (2011)</ce:source-text>
</reference>
<reference seq="71">
<ref-info>
<ref-title>
<ref-titletext-english>The Relationship Between Dormant Cancer Cells and Their Microenvironment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Linde</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Fluegen</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.A.</ce:initials>
<ce:surname>Aguirre-Ghiso</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Adv Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>132</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>45</first-page>
<last-page>71</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Linde, N., Fluegen, G., Aguirre-Ghiso, J.A.: The Relationship Between Dormant Cancer Cells and Their Microenvironment. Adv Cancer Res. 132, 45–71 (2016)</ref-fulltext>
<ce:source-text>Linde, N., Fluegen, G., Aguirre-Ghiso, J.A.: The Relationship Between Dormant Cancer Cells and Their Microenvironment. Adv Cancer Res. 132, 45–71 (2016)</ce:source-text>
</reference>
<reference seq="72">
<ref-info>
<ref-title>
<ref-titletext-english>Models, mechanisms and clinical evidence for cancer dormancy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Aguirre-Ghiso</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat Rev Cancer</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>834</first-page>
<last-page>846</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Aguirre-Ghiso, J.A.: Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 7, 834–846 (2007)</ref-fulltext>
<ce:source-text>Aguirre-Ghiso, J.A.: Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 7, 834–846 (2007)</ce:source-text>
</reference>
<reference seq="73">
<ref-info>
<ref-title>
<ref-titletext-english>Mechanism of early dissemination and metastasis in Her2(+) mammary cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.L.</ce:initials>
<ce:surname>Harper</ce:surname>
<ce:given-name>K.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.S.</ce:initials>
<ce:surname>Sosa</ce:surname>
<ce:given-name>M.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Entenberg</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="4">
<ce:initials>H.</ce:initials>
<ce:surname>Hosseini</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.F.</ce:initials>
<ce:surname>Cheung</ce:surname>
<ce:given-name>J.F.</ce:given-name>
</author>
<author seq="6">
<ce:initials>R.</ce:initials>
<ce:surname>Nobre</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="7">
<ce:initials>A.</ce:initials>
<ce:surname>Avivar-Valderas</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="8">
<ce:initials>C.</ce:initials>
<ce:surname>Nagi</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="9">
<ce:initials>N.</ce:initials>
<ce:surname>Girnius</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="10">
<ce:initials>R.J.</ce:initials>
<ce:surname>Davis</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>540</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>588</first-page>
<last-page>592</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Harper, K.L., Sosa, M.S., Entenberg, D., Hosseini, H., Cheung, J.F., Nobre, R., Avivar-Valderas, A., Nagi, C., Girnius, N., Davis, R.J., et al.: Mechanism of early dissemination and metastasis in Her2(+) mammary cancer. Nature. 540, 588–592 (2016)</ref-fulltext>
<ce:source-text>Harper, K.L., Sosa, M.S., Entenberg, D., Hosseini, H., Cheung, J.F., Nobre, R., Avivar-Valderas, A., Nagi, C., Girnius, N., Davis, R.J., et al.: Mechanism of early dissemination and metastasis in Her2(+) mammary cancer. Nature. 540, 588–592 (2016)</ce:source-text>
</reference>
<reference seq="74">
<ref-info>
<ref-title>
<ref-titletext-english>Micrometastatic cancer cells in bone marrow: In vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Schlimok</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>I.</ce:initials>
<ce:surname>Funke</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="3">
<ce:initials>B.</ce:initials>
<ce:surname>Holzmann</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="4">
<ce:initials>G.</ce:initials>
<ce:surname>Gottlinger</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="5">
<ce:initials>G.</ce:initials>
<ce:surname>Schmidt</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="6">
<ce:initials>H.</ce:initials>
<ce:surname>Hauser</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="7">
<ce:initials>S.</ce:initials>
<ce:surname>Swierkot</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="8">
<ce:initials>H.H.</ce:initials>
<ce:surname>Warnecke</ce:surname>
<ce:given-name>H.H.</ce:given-name>
</author>
<author seq="9">
<ce:initials>B.</ce:initials>
<ce:surname>Schneider</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="10">
<ce:initials>H.</ce:initials>
<ce:surname>Koprowski</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc Natl Acad Sci U S A</ref-sourcetitle>
<ref-publicationyear first="1987" />
<volisspag>
<volume-issue-number>
<vol-first>84</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>8672</first-page>
<last-page>8676</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Schlimok, G., Funke, I., Holzmann, B., Gottlinger, G., Schmidt, G., Hauser, H., Swierkot, S., Warnecke, H.H., Schneider, B., Koprowski, H., et al.: Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci U S A. 84, 8672–8676 (1987)</ref-fulltext>
<ce:source-text>Schlimok, G., Funke, I., Holzmann, B., Gottlinger, G., Schmidt, G., Hauser, H., Swierkot, S., Warnecke, H.H., Schneider, B., Koprowski, H., et al.: Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci U S A. 84, 8672–8676 (1987)</ce:source-text>
</reference>
<reference seq="75">
<ref-info>
<ref-title>
<ref-titletext-english>Metastatic niche functions and therapeutic opportunities</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Celia-Terrassa</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Kang</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>868</first-page>
<last-page>877</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Celia-Terrassa, T., Kang, Y.: Metastatic niche functions and therapeutic opportunities. Nat Cell Biol. 20, 868–877 (2018)</ref-fulltext>
<ce:source-text>Celia-Terrassa, T., Kang, Y.: Metastatic niche functions and therapeutic opportunities. Nat Cell Biol. 20, 868–877 (2018)</ce:source-text>
</reference>
<reference seq="76">
<ref-info>
<ref-title>
<ref-titletext-english>Metastasis prevention by targeting the dormant niche</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.M.</ce:initials>
<ce:surname>Ghajar</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat Rev Cancer</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>238</first-page>
<last-page>247</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ghajar, C.M.: Metastasis prevention by targeting the dormant niche. Nat Rev Cancer. 15, 238–247 (2015)</ref-fulltext>
<ce:source-text>Ghajar, C.M.: Metastasis prevention by targeting the dormant niche. Nat Rev Cancer. 15, 238–247 (2015)</ce:source-text>
</reference>
<reference seq="77">
<ref-info>
<ref-title>
<ref-titletext-english>Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Shiozawa</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.A.</ce:initials>
<ce:surname>Pedersen</ce:surname>
<ce:given-name>E.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.M.</ce:initials>
<ce:surname>Havens</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>Y.</ce:initials>
<ce:surname>Jung</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Mishra</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:surname>Joseph</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="7">
<ce:initials>J.K.</ce:initials>
<ce:surname>Kim</ce:surname>
<ce:given-name>J.K.</ce:given-name>
</author>
<author seq="8">
<ce:initials>L.R.</ce:initials>
<ce:surname>Patel</ce:surname>
<ce:given-name>L.R.</ce:given-name>
</author>
<author seq="9">
<ce:initials>C.</ce:initials>
<ce:surname>Ying</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="10">
<ce:initials>A.M.</ce:initials>
<ce:surname>Ziegler</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J Clin Invest</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>121</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1298</first-page>
<last-page>1312</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shiozawa, Y., Pedersen, E.A., Havens, A.M., Jung, Y., Mishra, A., Joseph, J., Kim, J.K., Patel, L.R., Ying, C., Ziegler, A.M., et al.: Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest. 121, 1298–1312 (2011)</ref-fulltext>
<ce:source-text>Shiozawa, Y., Pedersen, E.A., Havens, A.M., Jung, Y., Mishra, A., Joseph, J., Kim, J.K., Patel, L.R., Ying, C., Ziegler, A.M., et al.: Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest. 121, 1298–1312 (2011)</ce:source-text>
</reference>
<reference seq="78">
<ref-info>
<ref-title>
<ref-titletext-english>Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.A.</ce:initials>
<ce:surname>Lawson</ce:surname>
<ce:given-name>M.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.M.</ce:initials>
<ce:surname>McDonald</ce:surname>
<ce:given-name>M.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Kovacic</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="4">
<ce:initials>W.</ce:initials>
<ce:surname>Hua Khoo</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="5">
<ce:initials>R.L.</ce:initials>
<ce:surname>Terry</ce:surname>
<ce:given-name>R.L.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:surname>Down</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="7">
<ce:initials>W.</ce:initials>
<ce:surname>Kaplan</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="8">
<ce:initials>J.</ce:initials>
<ce:surname>Paton-Hough</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="9">
<ce:initials>C.</ce:initials>
<ce:surname>Fellows</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="10">
<ce:initials>J.A.</ce:initials>
<ce:surname>Pettitt</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat Commun</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>8983</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lawson, M.A., McDonald, M.M., Kovacic, N., Hua Khoo, W., Terry, R.L., Down, J., Kaplan, W., Paton-Hough, J., Fellows, C., Pettitt, J.A., et al.: Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nat Commun. 6, 8983 (2015)</ref-fulltext>
<ce:source-text>Lawson, M.A., McDonald, M.M., Kovacic, N., Hua Khoo, W., Terry, R.L., Down, J., Kaplan, W., Paton-Hough, J., Fellows, C., Pettitt, J.A., et al.: Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nat Commun. 6, 8983 (2015)</ce:source-text>
</reference>
<reference seq="79">
<ref-info>
<ref-title>
<ref-titletext-english>The Osteogenic Niche Is a Calcium Reservoir of Bone Micrometastases and Confers Unexpected Therapeutic Vulnerability</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Tian</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Goldstein</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="5">
<ce:initials>I.</ce:initials>
<ce:surname>Bado</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="6">
<ce:initials>W.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="7">
<ce:initials>B.R.</ce:initials>
<ce:surname>Arenkiel</ce:surname>
<ce:given-name>B.R.</ce:given-name>
</author>
<author seq="8">
<ce:initials>Z.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
<author seq="9">
<ce:initials>M.</ce:initials>
<ce:surname>Yang</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="10">
<ce:initials>S.</ce:initials>
<ce:surname>Du</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>34</vol-first>
<iss-first>823</iss-first>
<iss-last>839</iss-last>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Wang, H., Tian, L., Liu, J., Goldstein, A., Bado, I., Zhang, W., Arenkiel, B.R., Li, Z., Yang, M., Du, S., et al.: The Osteogenic Niche Is a Calcium Reservoir of Bone Micrometastases and Confers Unexpected Therapeutic Vulnerability. Cancer Cell. 34(823-839), e827 (2018)</ref-fulltext>
<ce:source-text>Wang, H., Tian, L., Liu, J., Goldstein, A., Bado, I., Zhang, W., Arenkiel, B.R., Li, Z., Yang, M., Du, S., et al.: The Osteogenic Niche Is a Calcium Reservoir of Bone Micrometastases and Confers Unexpected Therapeutic Vulnerability. Cancer Cell. 34(823-839), e827 (2018)</ce:source-text>
</reference>
<reference seq="80">
<ref-info>
<ref-title>
<ref-titletext-english>The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Yu</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>X.</ce:initials>
<ce:surname>Gao</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Welte</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="5">
<ce:initials>A.M.</ce:initials>
<ce:surname>Muscarella</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>L.</ce:initials>
<ce:surname>Tian</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="7">
<ce:initials>H.</ce:initials>
<ce:surname>Zhao</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="8">
<ce:initials>Z.</ce:initials>
<ce:surname>Zhao</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
<author seq="9">
<ce:initials>S.</ce:initials>
<ce:surname>Du</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="10">
<ce:initials>J.</ce:initials>
<ce:surname>Tao</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>193</first-page>
<last-page>210</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, H., Yu, C., Gao, X., Welte, T., Muscarella, A.M., Tian, L., Zhao, H., Zhao, Z., Du, S., Tao, J., et al.: The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell. 27, 193–210 (2015)</ref-fulltext>
<ce:source-text>Wang, H., Yu, C., Gao, X., Welte, T., Muscarella, A.M., Tian, L., Zhao, H., Zhao, Z., Du, S., Tao, J., et al.: The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell. 27, 193–210 (2015)</ce:source-text>
</reference>
<reference seq="81">
<ref-info>
<ref-title>
<ref-titletext-english>Therapeutic Antibody Targeting Tumor- and Osteoblastic Niche-Derived Jagged1 Sensitizes Bone Metastasis to Chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Zheng</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Bae</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Kasimir-Bauer</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Tang</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>G.</ce:initials>
<ce:surname>Ren</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="7">
<ce:initials>M.</ce:initials>
<ce:surname>Yuan</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="8">
<ce:initials>M.</ce:initials>
<ce:surname>Esposito</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="9">
<ce:initials>W.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="10">
<ce:initials>Y.</ce:initials>
<ce:surname>Wei</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
<iss-first>731</iss-first>
<iss-last>747</iss-last>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Zheng, H., Bae, Y., Kasimir-Bauer, S., Tang, R., Chen, J., Ren, G., Yuan, M., Esposito, M., Li, W., Wei, Y., et al.: Therapeutic Antibody Targeting Tumor- and Osteoblastic Niche-Derived Jagged1 Sensitizes Bone Metastasis to Chemotherapy. Cancer Cell. 32(731-747), e736 (2017)</ref-fulltext>
<ce:source-text>Zheng, H., Bae, Y., Kasimir-Bauer, S., Tang, R., Chen, J., Ren, G., Yuan, M., Esposito, M., Li, W., Wei, Y., et al.: Therapeutic Antibody Targeting Tumor- and Osteoblastic Niche-Derived Jagged1 Sensitizes Bone Metastasis to Chemotherapy. Cancer Cell. 32(731-747), e736 (2017)</ce:source-text>
</reference>
<reference seq="82">
<ref-info>
<ref-title>
<ref-titletext-english>Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Ding</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.J.</ce:initials>
<ce:surname>Morrison</ce:surname>
<ce:given-name>S.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>495</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>231</first-page>
<last-page>235</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ding, L., Morrison, S.J.: Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches. Nature. 495, 231–235 (2013)</ref-fulltext>
<ce:source-text>Ding, L., Morrison, S.J.: Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches. Nature. 495, 231–235 (2013)</ce:source-text>
</reference>
<reference seq="83">
<ref-info>
<ref-title>
<ref-titletext-english>The bone marrow niche for haematopoietic stem cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.J.</ce:initials>
<ce:surname>Morrison</ce:surname>
<ce:given-name>S.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.T.</ce:initials>
<ce:surname>Scadden</ce:surname>
<ce:given-name>D.T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>505</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>327</first-page>
<last-page>334</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Morrison, S.J., Scadden, D.T.: The bone marrow niche for haematopoietic stem cells. Nature. 505, 327–334 (2014)</ref-fulltext>
<ce:source-text>Morrison, S.J., Scadden, D.T.: The bone marrow niche for haematopoietic stem cells. Nature. 505, 327–334 (2014)</ce:source-text>
</reference>
<reference seq="84">
<ref-info>
<ref-title>
<ref-titletext-english>Involvement of chemokine receptors in breast cancer metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Muller</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Homey</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Soto</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="4">
<ce:initials>N.</ce:initials>
<ce:surname>Ge</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="5">
<ce:initials>D.</ce:initials>
<ce:surname>Catron</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="6">
<ce:initials>M.E.</ce:initials>
<ce:surname>Buchanan</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
<author seq="7">
<ce:initials>T.</ce:initials>
<ce:surname>McClanahan</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="8">
<ce:initials>E.</ce:initials>
<ce:surname>Murphy</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="9">
<ce:initials>W.</ce:initials>
<ce:surname>Yuan</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="10">
<ce:initials>S.N.</ce:initials>
<ce:surname>Wagner</ce:surname>
<ce:given-name>S.N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2001" />
<volisspag>
<volume-issue-number>
<vol-first>410</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>50</first-page>
<last-page>56</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M.E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S.N., et al.: Involvement of chemokine receptors in breast cancer metastasis. Nature. 410, 50–56 (2001)</ref-fulltext>
<ce:source-text>Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M.E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S.N., et al.: Involvement of chemokine receptors in breast cancer metastasis. Nature. 410, 50–56 (2001)</ce:source-text>
</reference>
<reference seq="85">
<ref-info>
<ref-title>
<ref-titletext-english>Homeostatic chemokine receptors and organ-specific metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Zlotnik</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.M.</ce:initials>
<ce:surname>Burkhardt</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>B.</ce:initials>
<ce:surname>Homey</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat Rev Immunol</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>597</first-page>
<last-page>606</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zlotnik, A., Burkhardt, A.M., Homey, B.: Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol. 11, 597–606 (2011)</ref-fulltext>
<ce:source-text>Zlotnik, A., Burkhardt, A.M., Homey, B.: Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol. 11, 597–606 (2011)</ce:source-text>
</reference>
<reference seq="86">
<ref-info>
<ref-title>
<ref-titletext-english>The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Gao</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Chakraborty</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.P.</ce:initials>
<ce:surname>Lee-Lim</ce:surname>
<ce:given-name>A.P.</ce:given-name>
</author>
<author seq="4">
<ce:initials>Q.</ce:initials>
<ce:surname>Mo</ce:surname>
<ce:given-name>Q.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Decker</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Vonica</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="7">
<ce:initials>R.</ce:initials>
<ce:surname>Shen</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="8">
<ce:initials>E.</ce:initials>
<ce:surname>Brogi</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="9">
<ce:initials>A.H.</ce:initials>
<ce:surname>Brivanlou</ce:surname>
<ce:given-name>A.H.</ce:given-name>
</author>
<author seq="10">
<ce:initials>F.G.</ce:initials>
<ce:surname>Giancotti</ce:surname>
<ce:given-name>F.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>150</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>764</first-page>
<last-page>779</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gao, H., Chakraborty, G., Lee-Lim, A.P., Mo, Q., Decker, M., Vonica, A., Shen, R., Brogi, E., Brivanlou, A.H., Giancotti, F.G.: The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell. 150, 764–779 (2012)</ref-fulltext>
<ce:source-text>Gao, H., Chakraborty, G., Lee-Lim, A.P., Mo, Q., Decker, M., Vonica, A., Shen, R., Brogi, E., Brivanlou, A.H., Giancotti, F.G.: The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell. 150, 764–779 (2012)</ce:source-text>
</reference>
<reference seq="87">
<ref-info>
<ref-title>
<ref-titletext-english>Niches for Hematopoietic Stem Cells and Their Progeny</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Q.</ce:initials>
<ce:surname>Wei</ce:surname>
<ce:given-name>Q.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.S.</ce:initials>
<ce:surname>Frenette</ce:surname>
<ce:given-name>P.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Immunity</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>48</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>632</first-page>
<last-page>648</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wei, Q., Frenette, P.S.: Niches for Hematopoietic Stem Cells and Their Progeny. Immunity. 48, 632–648 (2018)</ref-fulltext>
<ce:source-text>Wei, Q., Frenette, P.S.: Niches for Hematopoietic Stem Cells and Their Progeny. Immunity. 48, 632–648 (2018)</ce:source-text>
</reference>
<reference seq="88">
<ref-info>
<ref-title>
<ref-titletext-english>Urokinase receptor and fibronectin regulate the ERK (MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Aguirre-Ghiso</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Mignatti</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>K.</ce:initials>
<ce:surname>Kovalski</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="5">
<ce:initials>L.</ce:initials>
<ce:surname>Ossowski</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol Biol Cell</ref-sourcetitle>
<ref-publicationyear first="2001" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>863</first-page>
<last-page>879</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Aguirre-Ghiso, J.A., Liu, D., Mignatti, A., Kovalski, K., Ossowski, L.: Urokinase receptor and fibronectin regulate the ERK (MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell. 12, 863–879 (2001)</ref-fulltext>
<ce:source-text>Aguirre-Ghiso, J.A., Liu, D., Mignatti, A., Kovalski, K., Ossowski, L.: Urokinase receptor and fibronectin regulate the ERK (MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell. 12, 863–879 (2001)</ce:source-text>
</reference>
<reference seq="89">
<ref-info>
<ref-title>
<ref-titletext-english>Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Kobayashi</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Okuda</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:surname>Xing</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="4">
<ce:initials>P.R.</ce:initials>
<ce:surname>Pandey</ce:surname>
<ce:given-name>P.R.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Watabe</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>Hirota</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="7">
<ce:initials>S.K.</ce:initials>
<ce:surname>Pai</ce:surname>
<ce:given-name>S.K.</ce:given-name>
</author>
<author seq="8">
<ce:initials>W.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="9">
<ce:initials>K.</ce:initials>
<ce:surname>Fukuda</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="10">
<ce:initials>C.</ce:initials>
<ce:surname>Chambers</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J Exp Med</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>208</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2641</first-page>
<last-page>2655</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kobayashi, A., Okuda, H., Xing, F., Pandey, P.R., Watabe, M., Hirota, S., Pai, S.K., Liu, W., Fukuda, K., Chambers, C., et al.: Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J Exp Med. 208, 2641–2655 (2011)</ref-fulltext>
<ce:source-text>Kobayashi, A., Okuda, H., Xing, F., Pandey, P.R., Watabe, M., Hirota, S., Pai, S.K., Liu, W., Fukuda, K., Chambers, C., et al.: Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J Exp Med. 208, 2641–2655 (2011)</ce:source-text>
</reference>
<reference seq="90">
<ref-info>
<ref-title>
<ref-titletext-english>TGF-beta2 dictates disseminated tumour cell fate in target organs through TGF-beta-RIII and p38alpha/beta signalling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Bragado</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Estrada</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:surname>Parikh</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Krause</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="5">
<ce:initials>C.</ce:initials>
<ce:surname>Capobianco</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="6">
<ce:initials>H.G.</ce:initials>
<ce:surname>Farina</ce:surname>
<ce:given-name>H.G.</ce:given-name>
</author>
<author seq="7">
<ce:initials>D.M.</ce:initials>
<ce:surname>Schewe</ce:surname>
<ce:given-name />
</author>
<author seq="8">
<ce:initials>J.A.</ce:initials>
<ce:surname>Aguirre-Ghiso</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1351</first-page>
<last-page>1361</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bragado, P., Estrada, Y., Parikh, F., Krause, S., Capobianco, C., Farina, H.G., Schewe, D.M., Aguirre-Ghiso, J.A.: TGF-beta2 dictates disseminated tumour cell fate in target organs through TGF-beta-RIII and p38alpha/beta signalling. Nat Cell Biol. 15, 1351–1361 (2013)</ref-fulltext>
<ce:source-text>Bragado, P., Estrada, Y., Parikh, F., Krause, S., Capobianco, C., Farina, H.G., Schewe, D.M., Aguirre-Ghiso, J.A.: TGF-beta2 dictates disseminated tumour cell fate in target organs through TGF-beta-RIII and p38alpha/beta signalling. Nat Cell Biol. 15, 1351–1361 (2013)</ce:source-text>
</reference>
<reference seq="91">
<ref-info>
<ref-title>
<ref-titletext-english>Bone marrow-derived Gr1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Catena</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:surname>Bhattacharya</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>El Rayes</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="5">
<ce:initials>H.</ce:initials>
<ce:surname>Choi</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="6">
<ce:initials>D.</ce:initials>
<ce:surname>Gao</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="7">
<ce:initials>S.</ce:initials>
<ce:surname>Ryu</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="8">
<ce:initials>N.</ce:initials>
<ce:surname>Joshi</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="9">
<ce:initials>D.</ce:initials>
<ce:surname>Bielenberg</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="10">
<ce:initials>S.B.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>S.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Discov</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>578</first-page>
<last-page>589</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Catena, R., Bhattacharya, N., El Rayes, T., Wang, S., Choi, H., Gao, D., Ryu, S., Joshi, N., Bielenberg, D., Lee, S.B., et al.: Bone marrow-derived Gr1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1. Cancer Discov. 3, 578–589 (2013)</ref-fulltext>
<ce:source-text>Catena, R., Bhattacharya, N., El Rayes, T., Wang, S., Choi, H., Gao, D., Ryu, S., Joshi, N., Bielenberg, D., Lee, S.B., et al.: Bone marrow-derived Gr1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1. Cancer Discov. 3, 578–589 (2013)</ce:source-text>
</reference>
<reference seq="92">
<ref-info>
<ref-title>
<ref-titletext-english>Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.W.</ce:initials>
<ce:surname>Johnson</ce:surname>
<ce:given-name>R.W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.C.</ce:initials>
<ce:surname>Finger</ce:surname>
<ce:given-name>E.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.M.</ce:initials>
<ce:surname>Olcina</ce:surname>
<ce:given-name>M.M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Vilalta</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>T.</ce:initials>
<ce:surname>Aguilera</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="6">
<ce:initials>Y.</ce:initials>
<ce:surname>Miao</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="7">
<ce:initials>A.R.</ce:initials>
<ce:surname>Merkel</ce:surname>
<ce:given-name>A.R.</ce:given-name>
</author>
<author seq="8">
<ce:initials>J.R.</ce:initials>
<ce:surname>Johnson</ce:surname>
<ce:given-name>J.R.</ce:given-name>
</author>
<author seq="9">
<ce:initials>J.A.</ce:initials>
<ce:surname>Sterling</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="10">
<ce:initials>J.Y.</ce:initials>
<ce:surname>Wu</ce:surname>
<ce:given-name>J.Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1078</first-page>
<last-page>1089</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Johnson, R.W., Finger, E.C., Olcina, M.M., Vilalta, M., Aguilera, T., Miao, Y., Merkel, A.R., Johnson, J.R., Sterling, J.A., Wu, J.Y., et al.: Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow. Nat Cell Biol. 18, 1078–1089 (2016)</ref-fulltext>
<ce:source-text>Johnson, R.W., Finger, E.C., Olcina, M.M., Vilalta, M., Aguilera, T., Miao, Y., Merkel, A.R., Johnson, J.R., Sterling, J.A., Wu, J.Y., et al.: Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow. Nat Cell Biol. 18, 1078–1089 (2016)</ce:source-text>
</reference>
<reference seq="93">
<ref-info>
<ref-title>
<ref-titletext-english>Metastases in immune-mediated dormancy: A new opportunity for targeting cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Romero</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Garrido</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.M.</ce:initials>
<ce:surname>Garcia-Lora</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>74</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>6750</first-page>
<last-page>6757</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Romero, I., Garrido, F., Garcia-Lora, A.M.: Metastases in immune-mediated dormancy: A new opportunity for targeting cancer. Cancer Res. 74, 6750–6757 (2014)</ref-fulltext>
<ce:source-text>Romero, I., Garrido, F., Garcia-Lora, A.M.: Metastases in immune-mediated dormancy: A new opportunity for targeting cancer. Cancer Res. 74, 6750–6757 (2014)</ce:source-text>
</reference>
<reference seq="94">
<ref-info>
<ref-title>
<ref-titletext-english>Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Malladi</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.G.</ce:initials>
<ce:surname>Macalinao</ce:surname>
<ce:given-name>D.G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>X.</ce:initials>
<ce:surname>Jin</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="4">
<ce:initials>L.</ce:initials>
<ce:surname>He</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="5">
<ce:initials>H.</ce:initials>
<ce:surname>Basnet</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="6">
<ce:initials>Y.</ce:initials>
<ce:surname>Zou</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="7">
<ce:initials>E.</ce:initials>
<ce:surname>de Stanchina</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="8">
<ce:initials>J.</ce:initials>
<ce:surname>Massague</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>165</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>45</first-page>
<last-page>60</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Malladi, S., Macalinao, D.G., Jin, X., He, L., Basnet, H., Zou, Y., de Stanchina, E., Massague, J.: Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT. Cell. 165, 45–60 (2016)</ref-fulltext>
<ce:source-text>Malladi, S., Macalinao, D.G., Jin, X., He, L., Basnet, H., Zou, Y., de Stanchina, E., Massague, J.: Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT. Cell. 165, 45–60 (2016)</ce:source-text>
</reference>
<reference seq="95">
<ref-info>
<ref-title>
<ref-titletext-english>Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Pantel</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Schlimok</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Kutter</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="4">
<ce:initials>G.</ce:initials>
<ce:surname>Schaller</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="5">
<ce:initials>T.</ce:initials>
<ce:surname>Genz</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="6">
<ce:initials>B.</ce:initials>
<ce:surname>Wiebecke</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="7">
<ce:initials>R.</ce:initials>
<ce:surname>Backmann</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="8">
<ce:initials>I.</ce:initials>
<ce:surname>Funke</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="9">
<ce:initials>G.</ce:initials>
<ce:surname>Riethmuller</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="1991" />
<volisspag>
<volume-issue-number>
<vol-first>51</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4712</first-page>
<last-page>4715</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pantel, K., Schlimok, G., Kutter, D., Schaller, G., Genz, T., Wiebecke, B., Backmann, R., Funke, I., Riethmuller, G.: Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res. 51, 4712–4715 (1991)</ref-fulltext>
<ce:source-text>Pantel, K., Schlimok, G., Kutter, D., Schaller, G., Genz, T., Wiebecke, B., Backmann, R., Funke, I., Riethmuller, G.: Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res. 51, 4712–4715 (1991)</ce:source-text>
</reference>
<reference seq="96">
<ref-info>
<ref-title>
<ref-titletext-english>Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Pommier</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:surname>Anaparthy</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Memos</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="4">
<ce:initials>Z.L.</ce:initials>
<ce:surname>Kelley</ce:surname>
<ce:given-name>Z.L.</ce:given-name>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Gouronnec</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>R.</ce:initials>
<ce:surname>Yan</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="7">
<ce:initials>C.</ce:initials>
<ce:surname>Auffray</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="8">
<ce:initials>J.</ce:initials>
<ce:surname>Albrengues</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="9">
<ce:initials>M.</ce:initials>
<ce:surname>Egeblad</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="10">
<ce:initials>C.A.</ce:initials>
<ce:surname>Iacobuzio-Donahue</ce:surname>
<ce:given-name>C.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<page-information>
<pages>
<first-page>360</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pommier, A., Anaparthy, N., Memos, N., Kelley, Z.L., Gouronnec, A., Yan, R., Auffray, C., Albrengues, J., Egeblad, M., Iacobuzio-Donahue, C.A., et al.: Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases. Science. 360 (2018)</ref-fulltext>
<ce:source-text>Pommier, A., Anaparthy, N., Memos, N., Kelley, Z.L., Gouronnec, A., Yan, R., Auffray, C., Albrengues, J., Egeblad, M., Iacobuzio-Donahue, C.A., et al.: Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases. Science. 360 (2018)</ce:source-text>
</reference>
<reference seq="97">
<ref-info>
<ref-title>
<ref-titletext-english>A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.F.</ce:initials>
<ce:surname>Sanmamed</ce:surname>
<ce:given-name>M.F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>175</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>313</first-page>
<last-page>326</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sanmamed, M.F., Chen, L.: A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell. 175, 313–326 (2018)</ref-fulltext>
<ce:source-text>Sanmamed, M.F., Chen, L.: A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell. 175, 313–326 (2018)</ce:source-text>
</reference>
<reference seq="98">
<ref-info>
<ref-title>
<ref-titletext-english>Adaptive immunity maintains occult cancer in an equilibrium state</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.M.</ce:initials>
<ce:surname>Koebel</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>W.</ce:initials>
<ce:surname>Vermi</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.B.</ce:initials>
<ce:surname>Swann</ce:surname>
<ce:given-name>J.B.</ce:given-name>
</author>
<author seq="4">
<ce:initials>N.</ce:initials>
<ce:surname>Zerafa</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="5">
<ce:initials>S.J.</ce:initials>
<ce:surname>Rodig</ce:surname>
<ce:given-name>S.J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>L.J.</ce:initials>
<ce:surname>Old</ce:surname>
<ce:given-name>L.J.</ce:given-name>
</author>
<author seq="7">
<ce:initials>M.J.</ce:initials>
<ce:surname>Smyth</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
<author seq="8">
<ce:initials>R.D.</ce:initials>
<ce:surname>Schreiber</ce:surname>
<ce:given-name>R.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>450</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>903</first-page>
<last-page>907</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Koebel, C.M., Vermi, W., Swann, J.B., Zerafa, N., Rodig, S.J., Old, L.J., Smyth, M.J., Schreiber, R.D.: Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 450, 903–907 (2007)</ref-fulltext>
<ce:source-text>Koebel, C.M., Vermi, W., Swann, J.B., Zerafa, N., Rodig, S.J., Old, L.J., Smyth, M.J., Schreiber, R.D.: Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 450, 903–907 (2007)</ce:source-text>
</reference>
<reference seq="99">
<ref-info>
<ref-title>
<ref-titletext-english>Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.E.</ce:initials>
<ce:surname>Buroni</ce:surname>
<ce:given-name>F.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.G.</ce:initials>
<ce:surname>Persico</ce:surname>
<ce:given-name>M.G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:surname>Pasi</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="4">
<ce:initials>L.</ce:initials>
<ce:surname>Lodola</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="5">
<ce:initials>R.</ce:initials>
<ce:surname>Nano</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:surname>Aprile</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Anticancer Res</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5719</first-page>
<last-page>5730</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Buroni, F.E., Persico, M.G., Pasi, F., Lodola, L., Nano, R., Aprile, C.: Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer. Anticancer Res. 36, 5719–5730 (2016)</ref-fulltext>
<ce:source-text>Buroni, F.E., Persico, M.G., Pasi, F., Lodola, L., Nano, R., Aprile, C.: Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer. Anticancer Res. 36, 5719–5730 (2016)</ce:source-text>
</reference>
<reference seq="100">
<ref-info>
<ref-title>
<ref-titletext-english>Alpha emitter radium-223 and survival in metastatic prostate cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Parker</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Nilsson</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Heinrich</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.I.</ce:initials>
<ce:surname>Helle</ce:surname>
<ce:given-name>S.I.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.M.</ce:initials>
<ce:surname>O'sullivan</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>S.D.</ce:initials>
<ce:surname>Fossa</ce:surname>
<ce:given-name>S.D.</ce:given-name>
</author>
<author seq="7">
<ce:initials>A.</ce:initials>
<ce:surname>Chodacki</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="8">
<ce:initials>P.</ce:initials>
<ce:surname>Wiechno</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="9">
<ce:initials>J.</ce:initials>
<ce:surname>Logue</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="10">
<ce:initials>M.</ce:initials>
<ce:surname>Seke</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>N Engl J Med</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>369</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>213</first-page>
<last-page>223</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Parker, C., Nilsson, S., Heinrich, D., Helle, S.I., O'Sullivan, J.M., Fossa, S.D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al.: Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 369, 213–223 (2013)</ref-fulltext>
<ce:source-text>Parker, C., Nilsson, S., Heinrich, D., Helle, S.I., O'Sullivan, J.M., Fossa, S.D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al.: Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 369, 213–223 (2013)</ce:source-text>
</reference>
<reference seq="101">
<ref-info>
<ref-title>
<ref-titletext-english>The Mode-of-Action of Targeted Alpha Therapy Radium-223 as an Enabler for Novel Combinations to Treat Patients with Bone Metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.I.</ce:initials>
<ce:surname>Suominen</ce:surname>
<ce:given-name>M.I.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Wilson</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.M.</ce:initials>
<ce:surname>Kakonen</ce:surname>
<ce:given-name>S.M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Scholz</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int J Mol Sci</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<page-information>
<pages>
<first-page>20</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Suominen, M.I., Wilson, T., Kakonen, S.M., Scholz, A.: The Mode-of-Action of Targeted Alpha Therapy Radium-223 as an Enabler for Novel Combinations to Treat Patients with Bone Metastasis. Int J Mol Sci. 20 (2019)</ref-fulltext>
<ce:source-text>Suominen, M.I., Wilson, T., Kakonen, S.M., Scholz, A.: The Mode-of-Action of Targeted Alpha Therapy Radium-223 as an Enabler for Novel Combinations to Treat Patients with Bone Metastasis. Int J Mol Sci. 20 (2019)</ce:source-text>
</reference>
<reference seq="102">
<ref-info>
<ref-title>
<ref-titletext-english>Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>von Minckwitz</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.S.</ce:initials>
<ce:surname>Huang</ce:surname>
<ce:given-name>C.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.S.</ce:initials>
<ce:surname>Mano</ce:surname>
<ce:given-name>M.S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Loibl</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="5">
<ce:initials>E.P.</ce:initials>
<ce:surname>Mamounas</ce:surname>
<ce:given-name />
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Untch</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="7">
<ce:initials>N.</ce:initials>
<ce:surname>Wolmark</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="8">
<ce:initials>P.</ce:initials>
<ce:surname>Rastogi</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="9">
<ce:initials>A.</ce:initials>
<ce:surname>Schneeweiss</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="10">
<ce:initials>A.</ce:initials>
<ce:surname>Redondo</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>N Engl J Med</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>380</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>617</first-page>
<last-page>628</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>von Minckwitz, G., Huang, C.S., Mano, M.S., Loibl, S., Mamounas, E.P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., et al.: Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 380, 617–628 (2019)</ref-fulltext>
<ce:source-text>von Minckwitz, G., Huang, C.S., Mano, M.S., Loibl, S., Mamounas, E.P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., et al.: Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 380, 617–628 (2019)</ce:source-text>
</reference>
<reference seq="103">
<ref-info>
<ref-title>
<ref-titletext-english>Trastuzumab emtansine: Mechanisms of action and drug resistance</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Barok</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Joensuu</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Isola</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Breast Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>209</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Barok, M., Joensuu, H., Isola, J.: Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 16, 209 (2014)</ref-fulltext>
<ce:source-text>Barok, M., Joensuu, H., Isola, J.: Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 16, 209 (2014)</ce:source-text>
</reference>
<reference seq="104">
<ref-info>
<ref-title>
<ref-titletext-english>Local Control by Radiofrequency Thermal Ablation Increased Overall Survival in Patients With Refractory Liver Metastases of Colorectal Cancer</ref-titletext-english>
</ref-title>
<itemidlist>
<itemid idtype="ARTNUM">e3338</itemid>
</itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>P.C.</ce:initials>
<ce:surname>Yang</ce:surname>
<ce:given-name>P.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.R.</ce:initials>
<ce:surname>Lin</ce:surname>
<ce:given-name>B.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Y.C.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>Y.C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>Y.L.</ce:initials>
<ce:surname>Lin</ce:surname>
<ce:given-name>Y.L.</ce:given-name>
</author>
<author seq="5">
<ce:initials>H.S.</ce:initials>
<ce:surname>Lai</ce:surname>
<ce:given-name>H.S.</ce:given-name>
</author>
<author seq="6">
<ce:initials>K.W.</ce:initials>
<ce:surname>Huang</ce:surname>
<ce:given-name>K.W.</ce:given-name>
</author>
<author seq="7">
<ce:initials>J.T.</ce:initials>
<ce:surname>Liang</ce:surname>
<ce:given-name>J.T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Medicine (Baltimore)</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>95</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Yang, P.C., Lin, B.R., Chen, Y.C., Lin, Y.L., Lai, H.S., Huang, K.W., Liang, J.T.: Local Control by Radiofrequency Thermal Ablation Increased Overall Survival in Patients With Refractory Liver Metastases of Colorectal Cancer. Medicine (Baltimore). 95, e3338 (2016)</ref-fulltext>
<ce:source-text>Yang, P.C., Lin, B.R., Chen, Y.C., Lin, Y.L., Lai, H.S., Huang, K.W., Liang, J.T.: Local Control by Radiofrequency Thermal Ablation Increased Overall Survival in Patients With Refractory Liver Metastases of Colorectal Cancer. Medicine (Baltimore). 95, e3338 (2016)</ce:source-text>
</reference>
<reference seq="105">
<ref-info>
<ref-title>
<ref-titletext-english>Thermal Ablation of Metastatic Colon Cancer to the Liver</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.C.</ce:initials>
<ce:surname>Camacho</ce:surname>
<ce:given-name>J.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.N.</ce:initials>
<ce:surname>Petre</ce:surname>
<ce:given-name>E.N.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.T.</ce:initials>
<ce:surname>Sofocleous</ce:surname>
<ce:given-name>C.T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Semin Intervent Radiol</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>310</first-page>
<last-page>318</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Camacho, J.C., Petre, E.N., Sofocleous, C.T.: Thermal Ablation of Metastatic Colon Cancer to the Liver. Semin Intervent Radiol. 36, 310–318 (2019)</ref-fulltext>
<ce:source-text>Camacho, J.C., Petre, E.N., Sofocleous, C.T.: Thermal Ablation of Metastatic Colon Cancer to the Liver. Semin Intervent Radiol. 36, 310–318 (2019)</ce:source-text>
</reference>
<reference seq="106">
<ref-info>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Faubert</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Solmonson</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.J.</ce:initials>
<ce:surname>Deberardinis</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Metabolic Reprogramming and Cancer Progression</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<page-information>
<pages>
<first-page>368</first-page>
</pages>
</page-information>
</volisspag>
<ref-text>Science (New York, NY</ref-text>
</ref-info>
<ref-fulltext>Faubert, B., Solmonson, A., DeBerardinis, R.J.: Metabolic reprogramming and cancer progression, p. 368. Science New York, NY (2020)</ref-fulltext>
<ce:source-text>Faubert, B., Solmonson, A., DeBerardinis, R.J.: Metabolic reprogramming and cancer progression, p. 368. Science New York, NY (2020)</ce:source-text>
</reference>
<reference seq="107">
<ref-info>
<ref-title>
<ref-titletext-english>Hallmarks of cancer: The next generation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Hanahan</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.A.</ce:initials>
<ce:surname>Weinberg</ce:surname>
<ce:given-name>R.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>144</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>646</first-page>
<last-page>674</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hanahan, D., Weinberg, R.A.: Hallmarks of cancer: The next generation. Cell. 144, 646–674 (2011)</ref-fulltext>
<ce:source-text>Hanahan, D., Weinberg, R.A.: Hallmarks of cancer: The next generation. Cell. 144, 646–674 (2011)</ce:source-text>
</reference>
<reference seq="108">
<ref-info>
<ref-title>
<ref-titletext-english>Understanding the Warburg effect: The metabolic requirements of cell proliferation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.G.</ce:initials>
<ce:surname>Vander Heiden</ce:surname>
<ce:given-name>M.G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.C.</ce:initials>
<ce:surname>Cantley</ce:surname>
<ce:given-name>L.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.B.</ce:initials>
<ce:surname>Thompson</ce:surname>
<ce:given-name>C.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science (New York, NY)</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>324</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1029</first-page>
<last-page>1033</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vander Heiden, M.G., Cantley, L.C., Thompson, C.B.: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science (New York, NY). 324, 1029–1033 (2009)</ref-fulltext>
<ce:source-text>Vander Heiden, M.G., Cantley, L.C., Thompson, C.B.: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science (New York, NY). 324, 1029–1033 (2009)</ce:source-text>
</reference>
<reference seq="109">
<ref-info>
<ref-title>
<ref-titletext-english>The Metabolism of Tumors in the Body</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>O.</ce:initials>
<ce:surname>Warburg</ce:surname>
<ce:given-name>O.</ce:given-name>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Wind</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="3">
<ce:initials>E.</ce:initials>
<ce:surname>Negelein</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J Gen Physiol</ref-sourcetitle>
<ref-publicationyear first="1927" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>519</first-page>
<last-page>530</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Warburg, O., Wind, F., Negelein, E.: The Metabolism of Tumors in the Body. J Gen Physiol. 8, 519–530 (1927)</ref-fulltext>
<ce:source-text>Warburg, O., Wind, F., Negelein, E.: The Metabolism of Tumors in the Body. J Gen Physiol. 8, 519–530 (1927)</ce:source-text>
</reference>
<reference seq="110">
<ref-info>
<ref-title>
<ref-titletext-english>Metabolomics and Isotope Tracing</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Jang</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.D.</ce:initials>
<ce:surname>Rabinowitz</ce:surname>
<ce:given-name>J.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>173</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>822</first-page>
<last-page>837</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Jang, C., Chen, L., Rabinowitz, J.D.: Metabolomics and Isotope Tracing. Cell. 173, 822–837 (2018)</ref-fulltext>
<ce:source-text>Jang, C., Chen, L., Rabinowitz, J.D.: Metabolomics and Isotope Tracing. Cell. 173, 822–837 (2018)</ce:source-text>
</reference>
<reference seq="111">
<ref-info>
<ref-title>
<ref-titletext-english>Applications of metabolomics to study cancer metabolism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.K.</ce:initials>
<ce:surname>Kaushik</ce:surname>
<ce:given-name>A.K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.J.</ce:initials>
<ce:surname>Deberardinis</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochim Biophys Acta Rev Cancer</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>1870</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2</first-page>
<last-page>14</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kaushik, A.K., DeBerardinis, R.J.: Applications of metabolomics to study cancer metabolism. Biochim Biophys Acta Rev Cancer. 1870, 2–14 (2018)</ref-fulltext>
<ce:source-text>Kaushik, A.K., DeBerardinis, R.J.: Applications of metabolomics to study cancer metabolism. Biochim Biophys Acta Rev Cancer. 1870, 2–14 (2018)</ce:source-text>
</reference>
<reference seq="112">
<ref-info>
<ref-title>
<ref-titletext-english>Regulation of cancer cell metabolism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.A.</ce:initials>
<ce:surname>Cairns</ce:surname>
<ce:given-name>R.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>I.S.</ce:initials>
<ce:surname>Harris</ce:surname>
<ce:given-name>I.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.W.</ce:initials>
<ce:surname>Mak</ce:surname>
<ce:given-name>T.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat Rev Cancer</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>85</first-page>
<last-page>95</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cairns, R.A., Harris, I.S., Mak, T.W.: Regulation of cancer cell metabolism. Nat Rev Cancer. 11, 85–95 (2011)</ref-fulltext>
<ce:source-text>Cairns, R.A., Harris, I.S., Mak, T.W.: Regulation of cancer cell metabolism. Nat Rev Cancer. 11, 85–95 (2011)</ce:source-text>
</reference>
<reference seq="113">
<ref-info>
<ref-title>
<ref-titletext-english>The abundance of metabolites related to protein methylation correlates with the metastatic capacity of human melanoma xenografts</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Shi</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Tasdogan</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:surname>Huang</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="4">
<ce:initials>Z.</ce:initials>
<ce:surname>Hu</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
<author seq="5">
<ce:initials>S.J.</ce:initials>
<ce:surname>Morrison</ce:surname>
<ce:given-name>S.J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>R.J.</ce:initials>
<ce:surname>Deberardinis</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci Adv</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Shi, X., Tasdogan, A., Huang, F., Hu, Z., Morrison, S.J., DeBerardinis, R.J.: The abundance of metabolites related to protein methylation correlates with the metastatic capacity of human melanoma xenografts. Sci Adv. 3, eaao5268 (2017)</ref-fulltext>
<ce:source-text>Shi, X., Tasdogan, A., Huang, F., Hu, Z., Morrison, S.J., DeBerardinis, R.J.: The abundance of metabolites related to protein methylation correlates with the metastatic capacity of human melanoma xenografts. Sci Adv. 3, eaao5268 (2017)</ce:source-text>
</reference>
<reference seq="114">
<ref-info>
<ref-title>
<ref-titletext-english>Understanding the Intersections between Metabolism and Cancer Biology</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.G.</ce:initials>
<ce:surname>Vander Heiden</ce:surname>
<ce:given-name>M.G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.J.</ce:initials>
<ce:surname>Deberardinis</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>168</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>657</first-page>
<last-page>669</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vander Heiden, M.G., DeBerardinis, R.J.: Understanding the Intersections between Metabolism and Cancer Biology. Cell. 168, 657–669 (2017)</ref-fulltext>
<ce:source-text>Vander Heiden, M.G., DeBerardinis, R.J.: Understanding the Intersections between Metabolism and Cancer Biology. Cell. 168, 657–669 (2017)</ce:source-text>
</reference>
<reference seq="115">
<ref-info>
<ref-title>
<ref-titletext-english>Modelling glandular epithelial cancers in three-dimensional cultures</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Debnath</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.S.</ce:initials>
<ce:surname>Brugge</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat Rev Cancer</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>675</first-page>
<last-page>688</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Debnath, J., Brugge, J.S.: Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer. 5, 675–688 (2005)</ref-fulltext>
<ce:source-text>Debnath, J., Brugge, J.S.: Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer. 5, 675–688 (2005)</ce:source-text>
</reference>
<reference seq="116">
<ref-info>
<ref-title>
<ref-titletext-english>Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.J.</ce:initials>
<ce:surname>Kishton</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Sukumar</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.P.</ce:initials>
<ce:surname>Restifo</ce:surname>
<ce:given-name>N.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>94</first-page>
<last-page>109</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kishton, R.J., Sukumar, M., Restifo, N.P.: Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy. Cell Metab. 26, 94–109 (2017)</ref-fulltext>
<ce:source-text>Kishton, R.J., Sukumar, M., Restifo, N.P.: Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy. Cell Metab. 26, 94–109 (2017)</ce:source-text>
</reference>
<reference seq="117">
<ref-info>
<ref-title>
<ref-titletext-english>Metabolic Hallmarks of Metastasis Formation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Elia</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Doglioni</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.M.</ce:initials>
<ce:surname>Fendt</ce:surname>
<ce:given-name>S.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Trends in Cell Biology</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>673</first-page>
<last-page>684</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Elia, I., Doglioni, G., Fendt, S.M.: Metabolic Hallmarks of Metastasis Formation. Trends in cell biology. 28, 673–684 (2018a)</ref-fulltext>
<ce:source-text>Elia, I., Doglioni, G., Fendt, S.M.: Metabolic Hallmarks of Metastasis Formation. Trends in cell biology. 28, 673–684 (2018a)</ce:source-text>
</reference>
<reference seq="118">
<ref-info>
<ref-title>
<ref-titletext-english>Metabolic Adaptation Fuels Lymph Node Metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Ubellacker</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.J.</ce:initials>
<ce:surname>Morrison</ce:surname>
<ce:given-name>S.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>29</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>785</first-page>
<last-page>786</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ubellacker, J.M., Morrison, S.J.: Metabolic Adaptation Fuels Lymph Node Metastasis. Cell Metab. 29, 785–786 (2019)</ref-fulltext>
<ce:source-text>Ubellacker, J.M., Morrison, S.J.: Metabolic Adaptation Fuels Lymph Node Metastasis. Cell Metab. 29, 785–786 (2019)</ce:source-text>
</reference>
<reference seq="119">
<ref-info>
<ref-title>
<ref-titletext-english>Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.D.</ce:initials>
<ce:surname>Dinardo</ce:surname>
<ce:given-name>C.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.M.</ce:initials>
<ce:surname>Stein</ce:surname>
<ce:given-name>E.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>de Botton</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>G.J.</ce:initials>
<ce:surname>Roboz</ce:surname>
<ce:given-name>G.J.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.K.</ce:initials>
<ce:surname>Altman</ce:surname>
<ce:given-name>J.K.</ce:given-name>
</author>
<author seq="6">
<ce:initials>A.S.</ce:initials>
<ce:surname>Mims</ce:surname>
<ce:given-name>A.S.</ce:given-name>
</author>
<author seq="7">
<ce:initials>R.</ce:initials>
<ce:surname>Swords</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="8">
<ce:initials>R.H.</ce:initials>
<ce:surname>Collins</ce:surname>
<ce:given-name>R.H.</ce:given-name>
</author>
<author seq="9">
<ce:initials>G.N.</ce:initials>
<ce:surname>Mannis</ce:surname>
<ce:given-name>G.N.</ce:given-name>
</author>
<author seq="10">
<ce:initials>D.A.</ce:initials>
<ce:surname>Pollyea</ce:surname>
<ce:given-name>D.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>The New England Journal of Medicine</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>378</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2386</first-page>
<last-page>2398</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>DiNardo, C.D., Stein, E.M., de Botton, S., Roboz, G.J., Altman, J.K., Mims, A.S., Swords, R., Collins, R.H., Mannis, G.N., Pollyea, D.A., et al.: Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. The New England journal of medicine. 378, 2386–2398 (2018)</ref-fulltext>
<ce:source-text>DiNardo, C.D., Stein, E.M., de Botton, S., Roboz, G.J., Altman, J.K., Mims, A.S., Swords, R., Collins, R.H., Mannis, G.N., Pollyea, D.A., et al.: Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. The New England journal of medicine. 378, 2386–2398 (2018)</ce:source-text>
</reference>
<reference seq="120">
<ref-info>
<ref-title>
<ref-titletext-english>Acetate is a bioenergetic substrate for human glioblastoma and brain metastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Mashimo</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Pichumani</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="3">
<ce:initials>V.</ce:initials>
<ce:surname>Vemireddy</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
<author seq="4">
<ce:initials>K.J.</ce:initials>
<ce:surname>Hatanpaa</ce:surname>
<ce:given-name>K.J.</ce:given-name>
</author>
<author seq="5">
<ce:initials>D.K.</ce:initials>
<ce:surname>Singh</ce:surname>
<ce:given-name>D.K.</ce:given-name>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>Sirasanagandla</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="7">
<ce:initials>S.</ce:initials>
<ce:surname>Nannepaga</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="8">
<ce:initials>S.G.</ce:initials>
<ce:surname>Piccirillo</ce:surname>
<ce:given-name>S.G.</ce:given-name>
</author>
<author seq="9">
<ce:initials>Z.</ce:initials>
<ce:surname>Kovacs</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
<author seq="10">
<ce:initials>C.</ce:initials>
<ce:surname>Foong</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>159</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1603</first-page>
<last-page>1614</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mashimo, T., Pichumani, K., Vemireddy, V., Hatanpaa, K.J., Singh, D.K., Sirasanagandla, S., Nannepaga, S., Piccirillo, S.G., Kovacs, Z., Foong, C., et al.: Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell. 159, 1603–1614 (2014)</ref-fulltext>
<ce:source-text>Mashimo, T., Pichumani, K., Vemireddy, V., Hatanpaa, K.J., Singh, D.K., Sirasanagandla, S., Nannepaga, S., Piccirillo, S.G., Kovacs, Z., Foong, C., et al.: Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell. 159, 1603–1614 (2014)</ce:source-text>
</reference>
<reference seq="121">
<ref-info>
<ref-title>
<ref-titletext-english>Pharmacologic or Genetic Targeting of Glutamine Synthetase Skews Macrophages toward an M1-like Phenotype and Inhibits Tumor Metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.M.</ce:initials>
<ce:surname>Palmieri</ce:surname>
<ce:given-name>E.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Menga</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Martin-Perez</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Quinto</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="5">
<ce:initials>C.</ce:initials>
<ce:surname>Riera-Domingo</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="6">
<ce:initials>G.</ce:initials>
<ce:surname>de Tullio</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="7">
<ce:initials>D.C.</ce:initials>
<ce:surname>Hooper</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
<author seq="8">
<ce:initials>W.H.</ce:initials>
<ce:surname>Lamers</ce:surname>
<ce:given-name>W.H.</ce:given-name>
</author>
<author seq="9">
<ce:initials>B.</ce:initials>
<ce:surname>Ghesquiere</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="10">
<ce:initials>D.W.</ce:initials>
<ce:surname>McVicar</ce:surname>
<ce:given-name>D.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Rep</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1654</first-page>
<last-page>1666</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Palmieri, E.M., Menga, A., Martin-Perez, R., Quinto, A., Riera-Domingo, C., De Tullio, G., Hooper, D.C., Lamers, W.H., Ghesquiere, B., McVicar, D.W., et al.: Pharmacologic or Genetic Targeting of Glutamine Synthetase Skews Macrophages toward an M1-like Phenotype and Inhibits Tumor Metastasis. Cell Rep. 20, 1654–1666 (2017)</ref-fulltext>
<ce:source-text>Palmieri, E.M., Menga, A., Martin-Perez, R., Quinto, A., Riera-Domingo, C., De Tullio, G., Hooper, D.C., Lamers, W.H., Ghesquiere, B., McVicar, D.W., et al.: Pharmacologic or Genetic Targeting of Glutamine Synthetase Skews Macrophages toward an M1-like Phenotype and Inhibits Tumor Metastasis. Cell Rep. 20, 1654–1666 (2017)</ce:source-text>
</reference>
<reference seq="122">
<ref-info>
<ref-title>
<ref-titletext-english>HMGCS2 Mediates Ketone Production and Regulates the Proliferation and Metastasis of Hepatocellular Carcinoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.H.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>Y.H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.L.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>C.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>W.C.</ce:initials>
<ce:surname>Chiu</ce:surname>
<ce:given-name>W.C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>Y.C.</ce:initials>
<ce:surname>Twu</ce:surname>
<ce:given-name>Y.C.</ce:given-name>
</author>
<author seq="5">
<ce:initials>Y.J.</ce:initials>
<ce:surname>Liao</ce:surname>
<ce:given-name>Y.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancers</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<page-information>
<pages>
<first-page>11</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, Y.H., Liu, C.L., Chiu, W.C., Twu, Y.C., Liao, Y.J.: HMGCS2 Mediates Ketone Production and Regulates the Proliferation and Metastasis of Hepatocellular Carcinoma. Cancers, 11 (2019b)</ref-fulltext>
<ce:source-text>Wang, Y.H., Liu, C.L., Chiu, W.C., Twu, Y.C., Liao, Y.J.: HMGCS2 Mediates Ketone Production and Regulates the Proliferation and Metastasis of Hepatocellular Carcinoma. Cancers, 11 (2019b)</ce:source-text>
</reference>
<reference seq="123">
<ref-info>
<ref-title>
<ref-titletext-english>Gain of glucose-independent growth upon metastasis of breast cancer cells to the brain</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.J.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>H.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>X.</ce:initials>
<ce:surname>Wu</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="4">
<ce:initials>L.</ce:initials>
<ce:surname>Huo</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="5">
<ce:initials>S.J.</ce:initials>
<ce:surname>Kim</ce:surname>
<ce:given-name>S.J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>L.</ce:initials>
<ce:surname>Xu</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="7">
<ce:initials>Y.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="8">
<ce:initials>J.</ce:initials>
<ce:surname>He</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="9">
<ce:initials>L.R.</ce:initials>
<ce:surname>Bollu</ce:surname>
<ce:given-name>L.R.</ce:given-name>
</author>
<author seq="10">
<ce:initials>G.</ce:initials>
<ce:surname>Gao</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>75</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>554</first-page>
<last-page>565</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, J., Lee, H.J., Wu, X., Huo, L., Kim, S.J., Xu, L., Wang, Y., He, J., Bollu, L.R., Gao, G., et al.: Gain of glucose-independent growth upon metastasis of breast cancer cells to the brain. Cancer Res. 75, 554–565 (2015)</ref-fulltext>
<ce:source-text>Chen, J., Lee, H.J., Wu, X., Huo, L., Kim, S.J., Xu, L., Wang, Y., He, J., Bollu, L.R., Gao, G., et al.: Gain of glucose-independent growth upon metastasis of breast cancer cells to the brain. Cancer Res. 75, 554–565 (2015)</ce:source-text>
</reference>
<reference seq="124">
<ref-info>
<ref-title>
<ref-titletext-english>Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Elia</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Broekaert</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Christen</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Boon</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="5">
<ce:initials>E.</ce:initials>
<ce:surname>Radaelli</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="6">
<ce:initials>M.F.</ce:initials>
<ce:surname>Orth</ce:surname>
<ce:given-name>M.F.</ce:given-name>
</author>
<author seq="7">
<ce:initials>C.</ce:initials>
<ce:surname>Verfaillie</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="8">
<ce:initials>T.G.P.</ce:initials>
<ce:surname>Grunewald</ce:surname>
<ce:given-name>T.G.P.</ce:given-name>
</author>
<author seq="9">
<ce:initials>S.M.</ce:initials>
<ce:surname>Fendt</ce:surname>
<ce:given-name>S.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat Commun</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>15267</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Elia, I., Broekaert, D., Christen, S., Boon, R., Radaelli, E., Orth, M.F., Verfaillie, C., Grunewald, T.G.P., Fendt, S.M.: Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells. Nat Commun. 8, 15267 (2017a)</ref-fulltext>
<ce:source-text>Elia, I., Broekaert, D., Christen, S., Boon, R., Radaelli, E., Orth, M.F., Verfaillie, C., Grunewald, T.G.P., Fendt, S.M.: Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells. Nat Commun. 8, 15267 (2017a)</ce:source-text>
</reference>
<reference seq="125">
<ref-info>
<ref-title>
<ref-titletext-english>PGC-1alpha Promotes Breast Cancer Metastasis and Confers Bioenergetic Flexibility against Metabolic Drugs</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Andrzejewski</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Klimcakova</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.M.</ce:initials>
<ce:surname>Johnson</ce:surname>
<ce:given-name>R.M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Tabaries</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.G.</ce:initials>
<ce:surname>Annis</ce:surname>
<ce:given-name>M.G.</ce:given-name>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>McGuirk</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="7">
<ce:initials>J.J.</ce:initials>
<ce:surname>Northey</ce:surname>
<ce:given-name>J.J.</ce:given-name>
</author>
<author seq="8">
<ce:initials>V.</ce:initials>
<ce:surname>Chenard</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
<author seq="9">
<ce:initials>U.</ce:initials>
<ce:surname>Sriram</ce:surname>
<ce:given-name>U.</ce:given-name>
</author>
<author seq="10">
<ce:initials>D.J.</ce:initials>
<ce:surname>Papadopoli</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
<iss-first>778</iss-first>
<iss-last>787</iss-last>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Andrzejewski, S., Klimcakova, E., Johnson, R.M., Tabaries, S., Annis, M.G., McGuirk, S., Northey, J.J., Chenard, V., Sriram, U., Papadopoli, D.J., et al.: PGC-1alpha Promotes Breast Cancer Metastasis and Confers Bioenergetic Flexibility against Metabolic Drugs. Cell Metab. 26(778-787), e775 (2017)</ref-fulltext>
<ce:source-text>Andrzejewski, S., Klimcakova, E., Johnson, R.M., Tabaries, S., Annis, M.G., McGuirk, S., Northey, J.J., Chenard, V., Sriram, U., Papadopoli, D.J., et al.: PGC-1alpha Promotes Breast Cancer Metastasis and Confers Bioenergetic Flexibility against Metabolic Drugs. Cell Metab. 26(778-787), e775 (2017)</ce:source-text>
</reference>
<reference seq="126">
<ref-info>
<ref-title>
<ref-titletext-english>Extracellular Metabolic Energetics Can Promote Cancer Progression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Loo</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Scherl</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Nguyen</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>F.Y.</ce:initials>
<ce:surname>Man</ce:surname>
<ce:given-name>F.Y.</ce:given-name>
</author>
<author seq="5">
<ce:initials>E.</ce:initials>
<ce:surname>Weinberg</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="6">
<ce:initials>Z.S.</ce:initials>
<ce:surname>Zeng</ce:surname>
<ce:given-name>Z.S.</ce:given-name>
</author>
<author seq="7">
<ce:initials>L.</ce:initials>
<ce:surname>Saltz</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="8">
<ce:initials>P.B.</ce:initials>
<ce:surname>Paty</ce:surname>
<ce:given-name>P.B.</ce:given-name>
</author>
<author seq="9">
<ce:initials>S.F.</ce:initials>
<ce:surname>Tavazoie</ce:surname>
<ce:given-name>S.F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>160</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>393</first-page>
<last-page>406</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Loo, J.M., Scherl, A., Nguyen, A., Man, F.Y., Weinberg, E., Zeng, Z.S., Saltz, L., Paty, P.B., Tavazoie, S.F.: Extracellular Metabolic Energetics Can Promote Cancer Progression. Cell. 160, 393–406 (2015)</ref-fulltext>
<ce:source-text>Loo, J.M., Scherl, A., Nguyen, A., Man, F.Y., Weinberg, E., Zeng, Z.S., Saltz, L., Paty, P.B., Tavazoie, S.F.: Extracellular Metabolic Energetics Can Promote Cancer Progression. Cell. 160, 393–406 (2015)</ce:source-text>
</reference>
<reference seq="127">
<ref-info>
<ref-title>
<ref-titletext-english>Metabolic reprogramming during TGFbeta1-induced epithelial-to- mesenchymal transition</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Jiang</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Xiao</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Sugiura</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="4">
<ce:initials>X.</ce:initials>
<ce:surname>Huang</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Ali</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Kuro-O</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="7">
<ce:initials>R.J.</ce:initials>
<ce:surname>Deberardinis</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
<author seq="8">
<ce:initials>D.A.</ce:initials>
<ce:surname>Boothman</ce:surname>
<ce:given-name>D.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>34</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3908</first-page>
<last-page>3916</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Jiang, L., Xiao, L., Sugiura, H., Huang, X., Ali, A., Kuro-o, M., Deberardinis, R.J., Boothman, D.A.: Metabolic reprogramming during TGFbeta1-induced epithelial-to- mesenchymal transition. Oncogene. 34, 3908–3916 (2015)</ref-fulltext>
<ce:source-text>Jiang, L., Xiao, L., Sugiura, H., Huang, X., Ali, A., Kuro-o, M., Deberardinis, R.J., Boothman, D.A.: Metabolic reprogramming during TGFbeta1-induced epithelial-to- mesenchymal transition. Oncogene. 34, 3908–3916 (2015)</ce:source-text>
</reference>
<reference seq="128">
<ref-info>
<ref-title>
<ref-titletext-english>Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Curtis</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.A.</ce:initials>
<ce:surname>Kenny</ce:surname>
<ce:given-name />
</author>
<author seq="3">
<ce:initials>B.</ce:initials>
<ce:surname>Ashcroft</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Mukherjee</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Johnson</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>Y.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="7">
<ce:initials>Y.</ce:initials>
<ce:surname>Helou</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="8">
<ce:initials>R.</ce:initials>
<ce:surname>Batlle</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="9">
<ce:initials>X.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="10">
<ce:initials>N.</ce:initials>
<ce:surname>Gutierrez</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2018" />
</ref-info>
<ref-fulltext>Curtis, M., Kenny, H.A., Ashcroft, B., Mukherjee, A., Johnson, A., Zhang, Y., Helou, Y., Batlle, R., Liu, X., Gutierrez, N., et al.: Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis. Cell Metab. (2018)</ref-fulltext>
<ce:source-text>Curtis, M., Kenny, H.A., Ashcroft, B., Mukherjee, A., Johnson, A., Zhang, Y., Helou, Y., Batlle, R., Liu, X., Gutierrez, N., et al.: Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis. Cell Metab. (2018)</ce:source-text>
</reference>
<reference seq="129">
<ref-info>
<ref-title>
<ref-titletext-english>Asparagine bioavailability governs metastasis in a model of breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.R.V.</ce:initials>
<ce:surname>Knott</ce:surname>
<ce:given-name>S.R.V.</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Wagenblast</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Khan</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.Y.</ce:initials>
<ce:surname>Kim</ce:surname>
<ce:given-name>S.Y.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Soto</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Wagner</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="7">
<ce:initials>M.O.</ce:initials>
<ce:surname>Turgeon</ce:surname>
<ce:given-name>M.O.</ce:given-name>
</author>
<author seq="8">
<ce:initials>L.</ce:initials>
<ce:surname>Fish</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="9">
<ce:initials>N.</ce:initials>
<ce:surname>Erard</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="10">
<ce:initials>A.L.</ce:initials>
<ce:surname>Gable</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>554</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>378</first-page>
<last-page>381</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Knott, S.R.V., Wagenblast, E., Khan, S., Kim, S.Y., Soto, M., Wagner, M., Turgeon, M.O., Fish, L., Erard, N., Gable, A.L., et al.: Asparagine bioavailability governs metastasis in a model of breast cancer. Nature. 554, 378–381 (2018a)</ref-fulltext>
<ce:source-text>Knott, S.R.V., Wagenblast, E., Khan, S., Kim, S.Y., Soto, M., Wagner, M., Turgeon, M.O., Fish, L., Erard, N., Gable, A.L., et al.: Asparagine bioavailability governs metastasis in a model of breast cancer. Nature. 554, 378–381 (2018a)</ce:source-text>
</reference>
<reference seq="130">
<ref-info>
<ref-title>
<ref-titletext-english>UDP-glucose accelerates SNAI1 mRNA decay and impairs lung cancer metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>W.</ce:initials>
<ce:surname>Zhu</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="4">
<ce:initials>H.</ce:initials>
<ce:surname>Chu</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="5">
<ce:initials>H.</ce:initials>
<ce:surname>Yu</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="6">
<ce:initials>P.</ce:initials>
<ce:surname>Wei</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="7">
<ce:initials>X.</ce:initials>
<ce:surname>Wu</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="8">
<ce:initials>H.</ce:initials>
<ce:surname>Zhu</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="9">
<ce:initials>H.</ce:initials>
<ce:surname>Gao</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="10">
<ce:initials>J.</ce:initials>
<ce:surname>Liang</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>571</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>127</first-page>
<last-page>131</last-page>
</pages>
</page-information>
</volisspag>
<ref-text>(a)</ref-text>
</ref-info>
<ref-fulltext>Wang, X., Liu, R., Zhu, W., Chu, H., Yu, H., Wei, P., Wu, X., Zhu, H., Gao, H., Liang, J., et al.: UDP-glucose accelerates SNAI1 mRNA decay and impairs lung cancer metastasis. Nature. 571, 127–131 (2019a)</ref-fulltext>
<ce:source-text>Wang, X., Liu, R., Zhu, W., Chu, H., Yu, H., Wei, P., Wu, X., Zhu, H., Gao, H., Liang, J., et al.: UDP-glucose accelerates SNAI1 mRNA decay and impairs lung cancer metastasis. Nature. 571, 127–131 (2019a)</ce:source-text>
</reference>
<reference seq="131">
<ref-info>
<ref-title>
<ref-titletext-english>A Novel Allosteric Inhibitor of Phosphoglycerate Mutase 1 Suppresses Growth and Metastasis of Non-Small-Cell Lung Cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Huang</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Q.</ce:initials>
<ce:surname>Liang</ce:surname>
<ce:given-name>Q.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Zhou</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="4">
<ce:initials>L.L.</ce:initials>
<ce:surname>Jiang</ce:surname>
<ce:given-name>L.L.</ce:given-name>
</author>
<author seq="5">
<ce:initials>W.M.</ce:initials>
<ce:surname>Gu</ce:surname>
<ce:given-name>W.M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>M.Y.</ce:initials>
<ce:surname>Luo</ce:surname>
<ce:given-name>M.Y.</ce:given-name>
</author>
<author seq="7">
<ce:initials>Y.B.</ce:initials>
<ce:surname>Tang</ce:surname>
<ce:given-name>Y.B.</ce:given-name>
</author>
<author seq="8">
<ce:initials>Y.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="9">
<ce:initials>W.</ce:initials>
<ce:surname>Lu</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="10">
<ce:initials>M.</ce:initials>
<ce:surname>Huang</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
<iss-first>1107</iss-first>
<iss-last>1119</iss-last>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Huang, K., Liang, Q., Zhou, Y., Jiang, L.L., Gu, W.M., Luo, M.Y., Tang, Y.B., Wang, Y., Lu, W., Huang, M., et al.: A Novel Allosteric Inhibitor of Phosphoglycerate Mutase 1 Suppresses Growth and Metastasis of Non-Small-Cell Lung Cancer. Cell Metab. 30(1107-1119), e1108 (2019)</ref-fulltext>
<ce:source-text>Huang, K., Liang, Q., Zhou, Y., Jiang, L.L., Gu, W.M., Luo, M.Y., Tang, Y.B., Wang, Y., Lu, W., Huang, M., et al.: A Novel Allosteric Inhibitor of Phosphoglycerate Mutase 1 Suppresses Growth and Metastasis of Non-Small-Cell Lung Cancer. Cell Metab. 30(1107-1119), e1108 (2019)</ce:source-text>
</reference>
<reference seq="132">
<ref-info>
<ref-title>
<ref-titletext-english>Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>van Weverwijk</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:surname>Koundouros</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Iravani</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Ashenden</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>Q.</ce:initials>
<ce:surname>Gao</ce:surname>
<ce:given-name>Q.</ce:given-name>
</author>
<author seq="6">
<ce:initials>G.</ce:initials>
<ce:surname>Poulogiannis</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="7">
<ce:initials>U.</ce:initials>
<ce:surname>Jungwirth</ce:surname>
<ce:given-name>U.</ce:given-name>
</author>
<author seq="8">
<ce:initials>C.M.</ce:initials>
<ce:surname>Isacke</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat Commun</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2698</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>van Weverwijk, A., Koundouros, N., Iravani, M., Ashenden, M., Gao, Q., Poulogiannis, G., Jungwirth, U., Isacke, C.M.: Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation. Nat Commun. 10, 2698 (2019)</ref-fulltext>
<ce:source-text>van Weverwijk, A., Koundouros, N., Iravani, M., Ashenden, M., Gao, Q., Poulogiannis, G., Jungwirth, U., Isacke, C.M.: Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation. Nat Commun. 10, 2698 (2019)</ce:source-text>
</reference>
<reference seq="133">
<ref-info>
<ref-title>
<ref-titletext-english>Aldolase B-Mediated Fructose Metabolism Drives Metabolic Reprogramming of Colon Cancer Liver Metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Bu</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.Y.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>K.Y.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.</ce:initials>
<ce:surname>Xiang</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Johnson</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="5">
<ce:initials>S.B.</ce:initials>
<ce:surname>Crown</ce:surname>
<ce:given-name>S.B.</ce:given-name>
</author>
<author seq="6">
<ce:initials>N.</ce:initials>
<ce:surname>Rakhilin</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="7">
<ce:initials>Y.</ce:initials>
<ce:surname>Ai</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="8">
<ce:initials>L.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="9">
<ce:initials>R.</ce:initials>
<ce:surname>Xi</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="10">
<ce:initials>I.</ce:initials>
<ce:surname>Astapova</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
<iss-first>1249</iss-first>
<iss-last>1262</iss-last>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Bu, P., Chen, K.Y., Xiang, K., Johnson, C., Crown, S.B., Rakhilin, N., Ai, Y., Wang, L., Xi, R., Astapova, I., et al.: Aldolase B-Mediated Fructose Metabolism Drives Metabolic Reprogramming of Colon Cancer Liver Metastasis. Cell Metab. 27(1249-1262), e1244 (2018)</ref-fulltext>
<ce:source-text>Bu, P., Chen, K.Y., Xiang, K., Johnson, C., Crown, S.B., Rakhilin, N., Ai, Y., Wang, L., Xi, R., Astapova, I., et al.: Aldolase B-Mediated Fructose Metabolism Drives Metabolic Reprogramming of Colon Cancer Liver Metastasis. Cell Metab. 27(1249-1262), e1244 (2018)</ce:source-text>
</reference>
<reference seq="134">
<ref-info>
<ref-title>
<ref-titletext-english>TGFbeta2-induced formation of lipid droplets supports acidosis-driven EMT and the metastatic spreading of cancer cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Corbet</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Bastien</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.P.</ce:initials>
<ce:surname>Santiago de Jesus</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
<author seq="4">
<ce:initials>E.</ce:initials>
<ce:surname>Dierge</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="5">
<ce:initials>R.</ce:initials>
<ce:surname>Martherus</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:surname>Vander Linden</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="7">
<ce:initials>B.</ce:initials>
<ce:surname>Doix</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="8">
<ce:initials>C.</ce:initials>
<ce:surname>Degavre</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="9">
<ce:initials>C.</ce:initials>
<ce:surname>Guilbaud</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="10">
<ce:initials>L.</ce:initials>
<ce:surname>Petit</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat Commun</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>454</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Corbet, C., Bastien, E., Santiago de Jesus, J.P., Dierge, E., Martherus, R., Vander Linden, C., Doix, B., Degavre, C., Guilbaud, C., Petit, L., et al.: TGFbeta2-induced formation of lipid droplets supports acidosis-driven EMT and the metastatic spreading of cancer cells. Nat Commun. 11, 454 (2020)</ref-fulltext>
<ce:source-text>Corbet, C., Bastien, E., Santiago de Jesus, J.P., Dierge, E., Martherus, R., Vander Linden, C., Doix, B., Degavre, C., Guilbaud, C., Petit, L., et al.: TGFbeta2-induced formation of lipid droplets supports acidosis-driven EMT and the metastatic spreading of cancer cells. Nat Commun. 11, 454 (2020)</ce:source-text>
</reference>
<reference seq="135">
<ref-info>
<ref-title>
<ref-titletext-english>Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.H.</ce:initials>
<ce:surname>Park</ce:surname>
<ce:given-name>J.H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Vithayathil</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Kumar</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>P.L.</ce:initials>
<ce:surname>Sung</ce:surname>
<ce:given-name>P.L.</ce:given-name>
</author>
<author seq="5">
<ce:initials>L.E.</ce:initials>
<ce:surname>Dobrolecki</ce:surname>
<ce:given-name>L.E.</ce:given-name>
</author>
<author seq="6">
<ce:initials>V.</ce:initials>
<ce:surname>Putluri</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
<author seq="7">
<ce:initials>V.B.</ce:initials>
<ce:surname>Bhat</ce:surname>
<ce:given-name>V.B.</ce:given-name>
</author>
<author seq="8">
<ce:initials>S.K.</ce:initials>
<ce:surname>Bhowmik</ce:surname>
<ce:given-name>S.K.</ce:given-name>
</author>
<author seq="9">
<ce:initials>V.</ce:initials>
<ce:surname>Gupta</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
<author seq="10">
<ce:initials>K.</ce:initials>
<ce:surname>Arora</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Rep</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2154</first-page>
<last-page>2165</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Park, J.H., Vithayathil, S., Kumar, S., Sung, P.L., Dobrolecki, L.E., Putluri, V., Bhat, V.B., Bhowmik, S.K., Gupta, V., Arora, K., et al.: Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer. Cell Rep. 14, 2154–2165 (2016)</ref-fulltext>
<ce:source-text>Park, J.H., Vithayathil, S., Kumar, S., Sung, P.L., Dobrolecki, L.E., Putluri, V., Bhat, V.B., Bhowmik, S.K., Gupta, V., Arora, K., et al.: Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer. Cell Rep. 14, 2154–2165 (2016)</ce:source-text>
</reference>
<reference seq="136">
<ref-info>
<ref-title>
<ref-titletext-english>Targeting metastasis-initiating cells through the fatty acid receptor CD36</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Pascual</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Avgustinova</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Mejetta</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Martin</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Castellanos</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>C.S.</ce:initials>
<ce:surname>Attolini</ce:surname>
<ce:given-name>C.S.</ce:given-name>
</author>
<author seq="7">
<ce:initials>A.</ce:initials>
<ce:surname>Berenguer</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="8">
<ce:initials>N.</ce:initials>
<ce:surname>Prats</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="9">
<ce:initials>A.</ce:initials>
<ce:surname>Toll</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="10">
<ce:initials>J.A.</ce:initials>
<ce:surname>Hueto</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>541</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>41</first-page>
<last-page>45</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pascual, G., Avgustinova, A., Mejetta, S., Martin, M., Castellanos, A., Attolini, C.S., Berenguer, A., Prats, N., Toll, A., Hueto, J.A., et al.: Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature. 541, 41–45 (2017)</ref-fulltext>
<ce:source-text>Pascual, G., Avgustinova, A., Mejetta, S., Martin, M., Castellanos, A., Attolini, C.S., Berenguer, A., Prats, N., Toll, A., Hueto, J.A., et al.: Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature. 541, 41–45 (2017)</ce:source-text>
</reference>
<reference seq="137">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor metastasis to lymph nodes requires YAP-dependent metabolic adaptation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.K.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>C.K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.H.</ce:initials>
<ce:surname>Jeong</ce:surname>
<ce:given-name>S.H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Jang</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>H.</ce:initials>
<ce:surname>Bae</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="5">
<ce:initials>Y.H.</ce:initials>
<ce:surname>Kim</ce:surname>
<ce:given-name>Y.H.</ce:given-name>
</author>
<author seq="6">
<ce:initials>I.</ce:initials>
<ce:surname>Park</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="7">
<ce:initials>S.K.</ce:initials>
<ce:surname>Kim</ce:surname>
<ce:given-name>S.K.</ce:given-name>
</author>
<author seq="8">
<ce:initials>G.Y.</ce:initials>
<ce:surname>Koh</ce:surname>
<ce:given-name>G.Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science (New York, NY)</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>363</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>644</first-page>
<last-page>649</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lee, C.K., Jeong, S.H., Jang, C., Bae, H., Kim, Y.H., Park, I., Kim, S.K., Koh, G.Y.: Tumor metastasis to lymph nodes requires YAP-dependent metabolic adaptation. Science (New York, NY). 363, 644–649 (2019)</ref-fulltext>
<ce:source-text>Lee, C.K., Jeong, S.H., Jang, C., Bae, H., Kim, Y.H., Park, I., Kim, S.K., Koh, G.Y.: Tumor metastasis to lymph nodes requires YAP-dependent metabolic adaptation. Science (New York, NY). 363, 644–649 (2019)</ce:source-text>
</reference>
<reference seq="138">
<ref-info>
<ref-title>
<ref-titletext-english>Mechanisms of redox metabolism and cancer cell survival during extracellular matrix detachment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.A.</ce:initials>
<ce:surname>Hawk</ce:surname>
<ce:given-name>M.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Z.T.</ce:initials>
<ce:surname>Schafer</ce:surname>
<ce:given-name>Z.T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J Biol Chem</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>293</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7531</first-page>
<last-page>7537</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hawk, M.A., Schafer, Z.T.: Mechanisms of redox metabolism and cancer cell survival during extracellular matrix detachment. J Biol Chem. 293, 7531–7537 (2018)</ref-fulltext>
<ce:source-text>Hawk, M.A., Schafer, Z.T.: Mechanisms of redox metabolism and cancer cell survival during extracellular matrix detachment. J Biol Chem. 293, 7531–7537 (2018)</ce:source-text>
</reference>
<reference seq="139">
<ref-info>
<ref-title>
<ref-titletext-english>Reductive carboxylation supports redox homeostasis during anchorage-independent growth</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Jiang</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.A.</ce:initials>
<ce:surname>Shestov</ce:surname>
<ce:given-name>A.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Swain</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Yang</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="5">
<ce:initials>S.J.</ce:initials>
<ce:surname>Parker</ce:surname>
<ce:given-name>S.J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>Q.A.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>Q.A.</ce:given-name>
</author>
<author seq="7">
<ce:initials>L.S.</ce:initials>
<ce:surname>Terada</ce:surname>
<ce:given-name>L.S.</ce:given-name>
</author>
<author seq="8">
<ce:initials>N.D.</ce:initials>
<ce:surname>Adams</ce:surname>
<ce:given-name>N.D.</ce:given-name>
</author>
<author seq="9">
<ce:initials>M.T.</ce:initials>
<ce:surname>McCabe</ce:surname>
<ce:given-name>M.T.</ce:given-name>
</author>
<author seq="10">
<ce:initials>B.</ce:initials>
<ce:surname>Pietrak</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>532</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>255</first-page>
<last-page>258</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Jiang, L., Shestov, A.A., Swain, P., Yang, C., Parker, S.J., Wang, Q.A., Terada, L.S., Adams, N.D., McCabe, M.T., Pietrak, B., et al.: Reductive carboxylation supports redox homeostasis during anchorage-independent growth. Nature. 532, 255–258 (2016)</ref-fulltext>
<ce:source-text>Jiang, L., Shestov, A.A., Swain, P., Yang, C., Parker, S.J., Wang, Q.A., Terada, L.S., Adams, N.D., McCabe, M.T., Pietrak, B., et al.: Reductive carboxylation supports redox homeostasis during anchorage-independent growth. Nature. 532, 255–258 (2016)</ce:source-text>
</reference>
<reference seq="140">
<ref-info>
<ref-title>
<ref-titletext-english>Oxidative stress inhibits distant metastasis by human melanoma cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Piskounova</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Agathocleous</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.M.</ce:initials>
<ce:surname>Murphy</ce:surname>
<ce:given-name>M.M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>Z.</ce:initials>
<ce:surname>Hu</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
<author seq="5">
<ce:initials>S.E.</ce:initials>
<ce:surname>Huddlestun</ce:surname>
<ce:given-name>S.E.</ce:given-name>
</author>
<author seq="6">
<ce:initials>Z.</ce:initials>
<ce:surname>Zhao</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
<author seq="7">
<ce:initials>A.M.</ce:initials>
<ce:surname>Leitch</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
<author seq="8">
<ce:initials>T.M.</ce:initials>
<ce:surname>Johnson</ce:surname>
<ce:given-name>T.M.</ce:given-name>
</author>
<author seq="9">
<ce:initials>R.J.</ce:initials>
<ce:surname>Deberardinis</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
<author seq="10">
<ce:initials>S.J.</ce:initials>
<ce:surname>Morrison</ce:surname>
<ce:given-name>S.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>527</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>186</first-page>
<last-page>191</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Piskounova, E., Agathocleous, M., Murphy, M.M., Hu, Z., Huddlestun, S.E., Zhao, Z., Leitch, A.M., Johnson, T.M., DeBerardinis, R.J., Morrison, S.J.: Oxidative stress inhibits distant metastasis by human melanoma cells. Nature. 527, 186–191 (2015)</ref-fulltext>
<ce:source-text>Piskounova, E., Agathocleous, M., Murphy, M.M., Hu, Z., Huddlestun, S.E., Zhao, Z., Leitch, A.M., Johnson, T.M., DeBerardinis, R.J., Morrison, S.J.: Oxidative stress inhibits distant metastasis by human melanoma cells. Nature. 527, 186–191 (2015)</ce:source-text>
</reference>
<reference seq="141">
<ref-info>
<ref-title>
<ref-titletext-english>Antioxidants can increase melanoma metastasis in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Le Gal</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.X.</ce:initials>
<ce:surname>Ibrahim</ce:surname>
<ce:given-name>M.X.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Wiel</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>V.I.</ce:initials>
<ce:surname>Sayin</ce:surname>
<ce:given-name>V.I.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.K.</ce:initials>
<ce:surname>Akula</ce:surname>
<ce:given-name>M.K.</ce:given-name>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:surname>Karlsson</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="7">
<ce:initials>M.G.</ce:initials>
<ce:surname>Dalin</ce:surname>
<ce:given-name>M.G.</ce:given-name>
</author>
<author seq="8">
<ce:initials>L.M.</ce:initials>
<ce:surname>Akyurek</ce:surname>
<ce:given-name>L.M.</ce:given-name>
</author>
<author seq="9">
<ce:initials>P.</ce:initials>
<ce:surname>Lindahl</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="10">
<ce:initials>J.</ce:initials>
<ce:surname>Nilsson</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science Translational Medicine</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Le Gal, K., Ibrahim, M.X., Wiel, C., Sayin, V.I., Akula, M.K., Karlsson, C., Dalin, M.G., Akyurek, L.M., Lindahl, P., Nilsson, J., et al.: Antioxidants can increase melanoma metastasis in mice. Science translational medicine. 7, 308re308 (2015)</ref-fulltext>
<ce:source-text>Le Gal, K., Ibrahim, M.X., Wiel, C., Sayin, V.I., Akula, M.K., Karlsson, C., Dalin, M.G., Akyurek, L.M., Lindahl, P., Nilsson, J., et al.: Antioxidants can increase melanoma metastasis in mice. Science translational medicine. 7, 308re308 (2015)</ce:source-text>
</reference>
<reference seq="142">
<ref-info>
<ref-title>
<ref-titletext-english>PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.S.</ce:initials>
<ce:surname>Lebleu</ce:surname>
<ce:given-name>V.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.T.</ce:initials>
<ce:surname>O'connell</ce:surname>
<ce:given-name>J.T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.N.</ce:initials>
<ce:surname>Gonzalez Herrera</ce:surname>
<ce:given-name>K.N.</ce:given-name>
</author>
<author seq="4">
<ce:initials>H.</ce:initials>
<ce:surname>Wikman</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="5">
<ce:initials>K.</ce:initials>
<ce:surname>Pantel</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="6">
<ce:initials>M.C.</ce:initials>
<ce:surname>Haigis</ce:surname>
<ce:given-name>M.C.</ce:given-name>
</author>
<author seq="7">
<ce:initials>F.M.</ce:initials>
<ce:surname>de Carvalho</ce:surname>
<ce:given-name>F.M.</ce:given-name>
</author>
<author seq="8">
<ce:initials>A.</ce:initials>
<ce:surname>Damascena</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="9">
<ce:initials>L.T.</ce:initials>
<ce:surname>Domingos Chinen</ce:surname>
<ce:given-name>L.T.</ce:given-name>
</author>
<author seq="10">
<ce:initials>R.M.</ce:initials>
<ce:surname>Rocha</ce:surname>
<ce:given-name>R.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
<iss-first>992</iss-first>
<iss-text>1003</iss-text>
</volume-issue-number>
<page-information>
<pages>
<first-page>1001</first-page>
<last-page>1015</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>LeBleu, V.S., O'Connell, J.T., Gonzalez Herrera, K.N., Wikman, H., Pantel, K., Haigis, M.C., de Carvalho, F.M., Damascena, A., Domingos Chinen, L.T., Rocha, R.M., et al.: PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol. 16(992-1003), 1001–1015 (2014)</ref-fulltext>
<ce:source-text>LeBleu, V.S., O'Connell, J.T., Gonzalez Herrera, K.N., Wikman, H., Pantel, K., Haigis, M.C., de Carvalho, F.M., Damascena, A., Domingos Chinen, L.T., Rocha, R.M., et al.: PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol. 16(992-1003), 1001–1015 (2014)</ce:source-text>
</reference>
<reference seq="143">
<ref-info>
<ref-title>
<ref-titletext-english>NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>X.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Long</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>Y.</ce:initials>
<ce:surname>Huang</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="5">
<ce:initials>L.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="6">
<ce:initials>R.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="7">
<ce:initials>Y.</ce:initials>
<ce:surname>Zheng</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="8">
<ce:initials>X.</ce:initials>
<ce:surname>Liao</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="9">
<ce:initials>Y.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="10">
<ce:initials>Q.</ce:initials>
<ce:surname>Liao</ce:surname>
<ce:given-name>Q.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science Translational Medicine</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Wang, H., Liu, X., Long, M., Huang, Y., Zhang, L., Zhang, R., Zheng, Y., Liao, X., Wang, Y., Liao, Q., et al.: NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis. Science translational medicine. 8, 334ra351 (2016)</ref-fulltext>
<ce:source-text>Wang, H., Liu, X., Long, M., Huang, Y., Zhang, L., Zhang, R., Zheng, Y., Liao, X., Wang, Y., Liao, Q., et al.: NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis. Science translational medicine. 8, 334ra351 (2016)</ce:source-text>
</reference>
<reference seq="144">
<ref-info>
<ref-title>
<ref-titletext-english>BACH1 Stabilization by Antioxidants Stimulates Lung Cancer Metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Wiel</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Le Gal</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.X.</ce:initials>
<ce:surname>Ibrahim</ce:surname>
<ce:given-name>M.X.</ce:given-name>
</author>
<author seq="4">
<ce:initials>C.A.</ce:initials>
<ce:surname>Jahangir</ce:surname>
<ce:given-name>C.A.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Kashif</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>H.</ce:initials>
<ce:surname>Yao</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="7">
<ce:initials>D.V.</ce:initials>
<ce:surname>Ziegler</ce:surname>
<ce:given-name>D.V.</ce:given-name>
</author>
<author seq="8">
<ce:initials>X.</ce:initials>
<ce:surname>Xu</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="9">
<ce:initials>T.</ce:initials>
<ce:surname>Ghosh</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="10">
<ce:initials>T.</ce:initials>
<ce:surname>Mondal</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>178</vol-first>
<iss-first>330</iss-first>
<iss-last>345</iss-last>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Wiel, C., Le Gal, K., Ibrahim, M.X., Jahangir, C.A., Kashif, M., Yao, H., Ziegler, D.V., Xu, X., Ghosh, T., Mondal, T., et al.: BACH1 Stabilization by Antioxidants Stimulates Lung Cancer Metastasis. Cell. 178(330-345), e322 (2019)</ref-fulltext>
<ce:source-text>Wiel, C., Le Gal, K., Ibrahim, M.X., Jahangir, C.A., Kashif, M., Yao, H., Ziegler, D.V., Xu, X., Ghosh, T., Mondal, T., et al.: BACH1 Stabilization by Antioxidants Stimulates Lung Cancer Metastasis. Cell. 178(330-345), e322 (2019)</ce:source-text>
</reference>
<reference seq="145">
<ref-info>
<ref-title>
<ref-titletext-english>Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.M.</ce:initials>
<ce:surname>Fischer</ce:surname>
<ce:given-name>G.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Jalali</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.A.</ce:initials>
<ce:surname>Kircher</ce:surname>
<ce:given-name>D.A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>W.C.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>W.C.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.L.</ce:initials>
<ce:surname>McQuade</ce:surname>
<ce:given-name>J.L.</ce:given-name>
</author>
<author seq="6">
<ce:initials>L.E.</ce:initials>
<ce:surname>Haydu</ce:surname>
<ce:given-name>L.E.</ce:given-name>
</author>
<author seq="7">
<ce:initials>A.Y.</ce:initials>
<ce:surname>Joon</ce:surname>
<ce:given-name>A.Y.</ce:given-name>
</author>
<author seq="8">
<ce:initials>A.</ce:initials>
<ce:surname>Reuben</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="9">
<ce:initials>M.P.</ce:initials>
<ce:surname>de Macedo</ce:surname>
<ce:given-name>M.P.</ce:given-name>
</author>
<author seq="10">
<ce:initials>F.C.L.</ce:initials>
<ce:surname>Carapeto</ce:surname>
<ce:given-name>F.C.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Discovery</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>628</first-page>
<last-page>645</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fischer, G.M., Jalali, A., Kircher, D.A., Lee, W.C., McQuade, J.L., Haydu, L.E., Joon, A.Y., Reuben, A., de Macedo, M.P., Carapeto, F.C.L., et al.: Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer discovery. 9, 628–645 (2019)</ref-fulltext>
<ce:source-text>Fischer, G.M., Jalali, A., Kircher, D.A., Lee, W.C., McQuade, J.L., Haydu, L.E., Joon, A.Y., Reuben, A., de Macedo, M.P., Carapeto, F.C.L., et al.: Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer discovery. 9, 628–645 (2019)</ce:source-text>
</reference>
<reference seq="146">
<ref-info>
<ref-title>
<ref-titletext-english>Metabolic heterogeneity confers differences in melanoma metastatic potential</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Tasdogan</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Faubert</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="3">
<ce:initials>V.</ce:initials>
<ce:surname>Ramesh</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.M.</ce:initials>
<ce:surname>Ubellacker</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>B.</ce:initials>
<ce:surname>Shen</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Solmonson</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="7">
<ce:initials>M.M.</ce:initials>
<ce:surname>Murphy</ce:surname>
<ce:given-name>M.M.</ce:given-name>
</author>
<author seq="8">
<ce:initials>Z.</ce:initials>
<ce:surname>Gu</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
<author seq="9">
<ce:initials>W.</ce:initials>
<ce:surname>Gu</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="10">
<ce:initials>M.</ce:initials>
<ce:surname>Martin</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>577</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>115</first-page>
<last-page>120</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tasdogan, A., Faubert, B., Ramesh, V., Ubellacker, J.M., Shen, B., Solmonson, A., Murphy, M.M., Gu, Z., Gu, W., Martin, M., et al.: Metabolic heterogeneity confers differences in melanoma metastatic potential. Nature. 577, 115–120 (2020)</ref-fulltext>
<ce:source-text>Tasdogan, A., Faubert, B., Ramesh, V., Ubellacker, J.M., Shen, B., Solmonson, A., Murphy, M.M., Gu, Z., Gu, W., Martin, M., et al.: Metabolic heterogeneity confers differences in melanoma metastatic potential. Nature. 577, 115–120 (2020)</ce:source-text>
</reference>
<reference seq="147">
<ref-info>
<ref-title>
<ref-titletext-english>Breast Cancer-Derived Lung Metastases Show Increased Pyruvate Carboxylase-Dependent Anaplerosis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Christen</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Lorendeau</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Schmieder</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="4">
<ce:initials>D.</ce:initials>
<ce:surname>Broekaert</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="5">
<ce:initials>K.</ce:initials>
<ce:surname>Metzger</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="6">
<ce:initials>K.</ce:initials>
<ce:surname>Veys</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="7">
<ce:initials>I.</ce:initials>
<ce:surname>Elia</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="8">
<ce:initials>J.M.</ce:initials>
<ce:surname>Buescher</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="9">
<ce:initials>M.F.</ce:initials>
<ce:surname>Orth</ce:surname>
<ce:given-name>M.F.</ce:given-name>
</author>
<author seq="10">
<ce:initials>S.M.</ce:initials>
<ce:surname>Davidson</ce:surname>
<ce:given-name>S.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Reports</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>837</first-page>
<last-page>848</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Christen, S., Lorendeau, D., Schmieder, R., Broekaert, D., Metzger, K., Veys, K., Elia, I., Buescher, J.M., Orth, M.F., Davidson, S.M., et al.: Breast Cancer-Derived Lung Metastases Show Increased Pyruvate Carboxylase-Dependent Anaplerosis. Cell Reports. 17, 837–848 (2016)</ref-fulltext>
<ce:source-text>Christen, S., Lorendeau, D., Schmieder, R., Broekaert, D., Metzger, K., Veys, K., Elia, I., Buescher, J.M., Orth, M.F., Davidson, S.M., et al.: Breast Cancer-Derived Lung Metastases Show Increased Pyruvate Carboxylase-Dependent Anaplerosis. Cell Reports. 17, 837–848 (2016)</ce:source-text>
</reference>
<reference seq="148">
<ref-info>
<ref-title>
<ref-titletext-english>Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Ngo</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Kim</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>V.</ce:initials>
<ce:surname>Osorio-Vasquez</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Doll</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Bustraan</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="6">
<ce:initials>R.J.</ce:initials>
<ce:surname>Liang</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
<author seq="7">
<ce:initials>A.</ce:initials>
<ce:surname>Luengo</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="8">
<ce:initials>S.M.</ce:initials>
<ce:surname>Davidson</ce:surname>
<ce:given-name>S.M.</ce:given-name>
</author>
<author seq="9">
<ce:initials>A.</ce:initials>
<ce:surname>Ali</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="10">
<ce:initials>G.B.</ce:initials>
<ce:surname>Ferraro</ce:surname>
<ce:given-name>G.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Discov</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1352</first-page>
<last-page>1373</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ngo, B., Kim, E., Osorio-Vasquez, V., Doll, S., Bustraan, S., Liang, R.J., Luengo, A., Davidson, S.M., Ali, A., Ferraro, G.B., et al.: Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition. Cancer Discov. 10, 1352–1373 (2020)</ref-fulltext>
<ce:source-text>Ngo, B., Kim, E., Osorio-Vasquez, V., Doll, S., Bustraan, S., Liang, R.J., Luengo, A., Davidson, S.M., Ali, A., Ferraro, G.B., et al.: Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition. Cancer Discov. 10, 1352–1373 (2020)</ce:source-text>
</reference>
<reference seq="149">
<ref-info>
<ref-title>
<ref-titletext-english>Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.Y.</ce:initials>
<ce:surname>Fong</ce:surname>
<ce:given-name>M.Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>W.Y.</ce:initials>
<ce:surname>Zhou</ce:surname>
<ce:given-name>W.Y.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.Y.</ce:initials>
<ce:surname>Alontaga</ce:surname>
<ce:given-name>A.Y.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Chandra</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:surname>Ashby</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="7">
<ce:initials>A.</ce:initials>
<ce:surname>Chow</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="8">
<ce:initials>S.T.F.</ce:initials>
<ce:surname>O'connor</ce:surname>
<ce:given-name>S.T.F.</ce:given-name>
</author>
<author seq="9">
<ce:initials>S.S.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>S.S.</ce:given-name>
</author>
<author seq="10">
<ce:initials>A.R.</ce:initials>
<ce:surname>Chin</ce:surname>
<ce:given-name>A.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature Cell Biology</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>183</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fong, M.Y., Zhou, W.Y., Liu, L., Alontaga, A.Y., Chandra, M., Ashby, J., Chow, A., O'Connor, S.T.F., Li, S.S., Chin, A.R., et al.: Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nature Cell Biology. 17, 183-+ (2015)</ref-fulltext>
<ce:source-text>Fong, M.Y., Zhou, W.Y., Liu, L., Alontaga, A.Y., Chandra, M., Ashby, J., Chow, A., O'Connor, S.T.F., Li, S.S., Chin, A.R., et al.: Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nature Cell Biology. 17, 183-+ (2015)</ce:source-text>
</reference>
<reference seq="150">
<ref-info>
<ref-title>
<ref-titletext-english>Metabolites and the tumour microenvironment: From cellular mechanisms to systemic metabolism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Elia</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.C.</ce:initials>
<ce:surname>Haigis</ce:surname>
<ce:given-name>M.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat Metab</ref-sourcetitle>
<ref-publicationyear first="2021" />
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>21</first-page>
<last-page>32</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Elia, I., Haigis, M.C.: Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism. Nat Metab. 3, 21–32 (2021)</ref-fulltext>
<ce:source-text>Elia, I., Haigis, M.C.: Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism. Nat Metab. 3, 21–32 (2021)</ce:source-text>
</reference>
<reference seq="151">
<ref-info>
<ref-title>
<ref-titletext-english>Modulating the therapeutic response of tumours to dietary serine and glycine starvation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>O.D.K.</ce:initials>
<ce:surname>Maddocks</ce:surname>
<ce:given-name>O.D.K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Athineos</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>E.C.</ce:initials>
<ce:surname>Cheung</ce:surname>
<ce:given-name>E.C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>P.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="5">
<ce:initials>T.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="6">
<ce:initials>N.J.F.</ce:initials>
<ce:surname>Van den Broek</ce:surname>
<ce:given-name>N.J.F.</ce:given-name>
</author>
<author seq="7">
<ce:initials>G.M.</ce:initials>
<ce:surname>Mackay</ce:surname>
<ce:given-name>G.M.</ce:given-name>
</author>
<author seq="8">
<ce:initials>C.F.</ce:initials>
<ce:surname>Labuschagne</ce:surname>
<ce:given-name>C.F.</ce:given-name>
</author>
<author seq="9">
<ce:initials>D.</ce:initials>
<ce:surname>Gay</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="10">
<ce:initials>F.</ce:initials>
<ce:surname>Kruiswijk</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>544</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>372</first-page>
<last-page>376</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Maddocks, O.D.K., Athineos, D., Cheung, E.C., Lee, P., Zhang, T., van den Broek, N.J.F., Mackay, G.M., Labuschagne, C.F., Gay, D., Kruiswijk, F., et al.: Modulating the therapeutic response of tumours to dietary serine and glycine starvation. Nature. 544, 372–376 (2017)</ref-fulltext>
<ce:source-text>Maddocks, O.D.K., Athineos, D., Cheung, E.C., Lee, P., Zhang, T., van den Broek, N.J.F., Mackay, G.M., Labuschagne, C.F., Gay, D., Kruiswijk, F., et al.: Modulating the therapeutic response of tumours to dietary serine and glycine starvation. Nature. 544, 372–376 (2017)</ce:source-text>
</reference>
<reference seq="152">
<ref-info>
<ref-title>
<ref-titletext-english>Serine Is an Essential Metabolite for Effector T Cell Expansion</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.H.</ce:initials>
<ce:surname>Ma</ce:surname>
<ce:given-name>E.H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Bantug</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Griss</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Condotta</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="5">
<ce:initials>R.M.</ce:initials>
<ce:surname>Johnson</ce:surname>
<ce:given-name>R.M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>B.</ce:initials>
<ce:surname>Samborska</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="7">
<ce:initials>N.</ce:initials>
<ce:surname>Mainolfi</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="8">
<ce:initials>V.</ce:initials>
<ce:surname>Suri</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
<author seq="9">
<ce:initials>H.</ce:initials>
<ce:surname>Guak</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="10">
<ce:initials>M.L.</ce:initials>
<ce:surname>Balmer</ce:surname>
<ce:given-name>M.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>25</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>482</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ma, E.H., Bantug, G., Griss, T., Condotta, S., Johnson, R.M., Samborska, B., Mainolfi, N., Suri, V., Guak, H., Balmer, M.L., et al.: Serine Is an Essential Metabolite for Effector T Cell Expansion. Cell Metab. 25, 482 (2017)</ref-fulltext>
<ce:source-text>Ma, E.H., Bantug, G., Griss, T., Condotta, S., Johnson, R.M., Samborska, B., Mainolfi, N., Suri, V., Guak, H., Balmer, M.L., et al.: Serine Is an Essential Metabolite for Effector T Cell Expansion. Cell Metab. 25, 482 (2017)</ce:source-text>
</reference>
<reference seq="153">
<ref-info>
<ref-title>
<ref-titletext-english>Methionine Metabolism Shapes T Helper Cell Responses through Regulation of Epigenetic Reprogramming</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.G.</ce:initials>
<ce:surname>Roy</ce:surname>
<ce:given-name>D.G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>V.</ce:initials>
<ce:surname>Mamane</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
<author seq="4">
<ce:initials>E.H.</ce:initials>
<ce:surname>Ma</ce:surname>
<ce:given-name>E.H.</ce:given-name>
</author>
<author seq="5">
<ce:initials>B.M.</ce:initials>
<ce:surname>Muhire</ce:surname>
<ce:given-name>B.M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>R.D.</ce:initials>
<ce:surname>Sheldon</ce:surname>
<ce:given-name>R.D.</ce:given-name>
</author>
<author seq="7">
<ce:initials>T.</ce:initials>
<ce:surname>Shorstova</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="8">
<ce:initials>R.</ce:initials>
<ce:surname>Koning</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="9">
<ce:initials>R.M.</ce:initials>
<ce:surname>Johnson</ce:surname>
<ce:given-name>R.M.</ce:given-name>
</author>
<author seq="10">
<ce:initials>E.</ce:initials>
<ce:surname>Esaulova</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>31</vol-first>
<iss-first>250</iss-first>
<iss-last>266</iss-last>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Roy, D.G., Chen, J., Mamane, V., Ma, E.H., Muhire, B.M., Sheldon, R.D., Shorstova, T., Koning, R., Johnson, R.M., Esaulova, E., et al.: Methionine Metabolism Shapes T Helper Cell Responses through Regulation of Epigenetic Reprogramming. Cell Metab. 31(250-266), e259 (2020)</ref-fulltext>
<ce:source-text>Roy, D.G., Chen, J., Mamane, V., Ma, E.H., Muhire, B.M., Sheldon, R.D., Shorstova, T., Koning, R., Johnson, R.M., Esaulova, E., et al.: Methionine Metabolism Shapes T Helper Cell Responses through Regulation of Epigenetic Reprogramming. Cell Metab. 31(250-266), e259 (2020)</ce:source-text>
</reference>
<reference seq="154">
<ref-info>
<ref-title>
<ref-titletext-english>Dietary methionine influences therapy in mouse cancer models and alters human metabolism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Gao</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.M.</ce:initials>
<ce:surname>Sanderson</ce:surname>
<ce:given-name>S.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Z.</ce:initials>
<ce:surname>Dai</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.A.</ce:initials>
<ce:surname>Reid</ce:surname>
<ce:given-name>M.A.</ce:given-name>
</author>
<author seq="5">
<ce:initials>D.E.</ce:initials>
<ce:surname>Cooper</ce:surname>
<ce:given-name>D.E.</ce:given-name>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Lu</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="7">
<ce:initials>J.P.</ce:initials>
<ce:surname>Richie</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
<author seq="8">
<ce:initials>A.</ce:initials>
<ce:surname>Ciccarella</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="9">
<ce:initials>A.</ce:initials>
<ce:surname>Calcagnotto</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="10">
<ce:initials>P.G.</ce:initials>
<ce:surname>Mikhael</ce:surname>
<ce:given-name>P.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>572</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>397</first-page>
<last-page>401</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gao, X., Sanderson, S.M., Dai, Z., Reid, M.A., Cooper, D.E., Lu, M., Richie Jr., J.P., Ciccarella, A., Calcagnotto, A., Mikhael, P.G., et al.: Dietary methionine influences therapy in mouse cancer models and alters human metabolism. Nature. 572, 397–401 (2019)</ref-fulltext>
<ce:source-text>Gao, X., Sanderson, S.M., Dai, Z., Reid, M.A., Cooper, D.E., Lu, M., Richie Jr., J.P., Ciccarella, A., Calcagnotto, A., Mikhael, P.G., et al.: Dietary methionine influences therapy in mouse cancer models and alters human metabolism. Nature. 572, 397–401 (2019)</ce:source-text>
</reference>
<reference seq="155">
<ref-info>
<ref-title>
<ref-titletext-english>Creatine promotes cancer metastasis through activation of Smad2/3</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Z.</ce:initials>
<ce:surname>Zhu</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Yan</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="4">
<ce:initials>W.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="5">
<ce:initials>Z.</ce:initials>
<ce:surname>Wu</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
<author seq="6">
<ce:initials>F.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="7">
<ce:initials>Q.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>Q.</ce:given-name>
</author>
<author seq="8">
<ce:initials>G.</ce:initials>
<ce:surname>Shi</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="9">
<ce:initials>J.</ce:initials>
<ce:surname>Du</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="10">
<ce:initials>H.</ce:initials>
<ce:surname>Cai</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2021" />
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
<iss-first>1111</iss-first>
<iss-last>1123</iss-last>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, L., Zhu, Z., Yan, H., Wang, W., Wu, Z., Zhang, F., Zhang, Q., Shi, G., Du, J., Cai, H., et al.: Creatine promotes cancer metastasis through activation of Smad2/3. Cell Metab. 33(1111-1123), e1114 (2021)</ref-fulltext>
<ce:source-text>Zhang, L., Zhu, Z., Yan, H., Wang, W., Wu, Z., Zhang, F., Zhang, Q., Shi, G., Du, J., Cai, H., et al.: Creatine promotes cancer metastasis through activation of Smad2/3. Cell Metab. 33(1111-1123), e1114 (2021)</ce:source-text>
</reference>
<reference seq="156">
<ref-info>
<ref-title>
<ref-titletext-english>Low glycaemic diets alter lipid metabolism to influence tumour growth</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.C.</ce:initials>
<ce:surname>Lien</ce:surname>
<ce:given-name>E.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.M.</ce:initials>
<ce:surname>Westermark</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Yuan</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="5">
<ce:initials>Z.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
<author seq="6">
<ce:initials>A.N.</ce:initials>
<ce:surname>Lau</ce:surname>
<ce:given-name>A.N.</ce:given-name>
</author>
<author seq="7">
<ce:initials>K.M.</ce:initials>
<ce:surname>Sapp</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
<author seq="8">
<ce:initials>B.M.</ce:initials>
<ce:surname>Wolpin</ce:surname>
<ce:given-name>B.M.</ce:given-name>
</author>
<author seq="9">
<ce:initials>M.G.</ce:initials>
<ce:surname>Vander Heiden</ce:surname>
<ce:given-name>M.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2021" />
<volisspag>
<volume-issue-number>
<vol-first>599</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>302</first-page>
<last-page>307</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lien, E.C., Westermark, A.M., Zhang, Y., Yuan, C., Li, Z., Lau, A.N., Sapp, K.M., Wolpin, B.M., Vander Heiden, M.G.: Low glycaemic diets alter lipid metabolism to influence tumour growth. Nature. 599, 302–307 (2021)</ref-fulltext>
<ce:source-text>Lien, E.C., Westermark, A.M., Zhang, Y., Yuan, C., Li, Z., Lau, A.N., Sapp, K.M., Wolpin, B.M., Vander Heiden, M.G.: Low glycaemic diets alter lipid metabolism to influence tumour growth. Nature. 599, 302–307 (2021)</ce:source-text>
</reference>
<reference seq="157">
<ref-info>
<ref-title>
<ref-titletext-english>Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Elia</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Broekaert</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Christen</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Boon</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="5">
<ce:initials>E.</ce:initials>
<ce:surname>Radaelli</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="6">
<ce:initials>M.F.</ce:initials>
<ce:surname>Orth</ce:surname>
<ce:given-name>M.F.</ce:given-name>
</author>
<author seq="7">
<ce:initials>C.</ce:initials>
<ce:surname>Verfaillie</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="8">
<ce:initials>T.G.P.</ce:initials>
<ce:surname>Grunewald</ce:surname>
<ce:given-name>T.G.P.</ce:given-name>
</author>
<author seq="9">
<ce:initials>S.M.</ce:initials>
<ce:surname>Fendt</ce:surname>
<ce:given-name>S.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat Commun</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>15267</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Elia, I., Broekaert, D., Christen, S., Boon, R., Radaelli, E., Orth, M.F., Verfaillie, C., Grunewald, T.G.P., Fendt, S.M.: Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells. Nat Commun. 8, 15267 (2017b)</ref-fulltext>
<ce:source-text>Elia, I., Broekaert, D., Christen, S., Boon, R., Radaelli, E., Orth, M.F., Verfaillie, C., Grunewald, T.G.P., Fendt, S.M.: Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells. Nat Commun. 8, 15267 (2017b)</ce:source-text>
</reference>
<reference seq="158">
<ref-info>
<ref-title>
<ref-titletext-english>Metabolic Hallmarks of Metastasis Formation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Elia</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Doglioni</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.M.</ce:initials>
<ce:surname>Fendt</ce:surname>
<ce:given-name>S.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Trends Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>673</first-page>
<last-page>684</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Elia, I., Doglioni, G., Fendt, S.M.: Metabolic Hallmarks of Metastasis Formation. Trends Cell Biol. 28, 673–684 (2018b)</ref-fulltext>
<ce:source-text>Elia, I., Doglioni, G., Fendt, S.M.: Metabolic Hallmarks of Metastasis Formation. Trends Cell Biol. 28, 673–684 (2018b)</ce:source-text>
</reference>
<reference seq="159">
<ref-info>
<ref-title>
<ref-titletext-english>Asparagine bioavailability governs metastasis in a model of breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.R.V.</ce:initials>
<ce:surname>Knott</ce:surname>
<ce:given-name>S.R.V.</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Wagenblast</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Khan</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.Y.</ce:initials>
<ce:surname>Kim</ce:surname>
<ce:given-name>S.Y.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Soto</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Wagner</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="7">
<ce:initials>M.O.</ce:initials>
<ce:surname>Turgeon</ce:surname>
<ce:given-name>M.O.</ce:given-name>
</author>
<author seq="8">
<ce:initials>L.</ce:initials>
<ce:surname>Fish</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="9">
<ce:initials>N.</ce:initials>
<ce:surname>Erard</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="10">
<ce:initials>A.L.</ce:initials>
<ce:surname>Gable</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>554</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>378</first-page>
<last-page>381</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Knott, S.R.V., Wagenblast, E., Khan, S., Kim, S.Y., Soto, M., Wagner, M., Turgeon, M.O., Fish, L., Erard, N., Gable, A.L., et al.: Asparagine bioavailability governs metastasis in a model of breast cancer. Nature. 554, 378–381 (2018b)</ref-fulltext>
<ce:source-text>Knott, S.R.V., Wagenblast, E., Khan, S., Kim, S.Y., Soto, M., Wagner, M., Turgeon, M.O., Fish, L., Erard, N., Gable, A.L., et al.: Asparagine bioavailability governs metastasis in a model of breast cancer. Nature. 554, 378–381 (2018b)</ce:source-text>
</reference>
</bibliography>
</tail>
</bibrecord>
<bibrecord>
<item-info>
<status state="new" stage="S300" />
<itemidlist>
<ce:doi>10.1007/978-3-031-09518-4_5</ce:doi>
<itemid idtype="TPB-ID">20232000349315</itemid>
</itemidlist>
</item-info>
<head>
<citation-info>
<citation-type code="ch" />
<citation-language xml:lang="ENG" />
<abstract-language xml:lang="ENG" />
</citation-info>
<citation-title>
<titletext xml:lang="ENG" original="y">Signaling Pathways That Promote Muscle Catabolism in Cachexia</titletext>
</citation-title>
<author-group seq="1">
<author seq="1">
<ce:initials>J.E.</ce:initials> 
<ce:surname>Gilda</ce:surname>
<ce:given-name>J.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials> 
<ce:surname>Cohen</ce:surname>
<ce:given-name>S.</ce:given-name>
<ce:e-address>shenhavc@technion.ac.il</ce:e-address>
</author>
<affiliation>
<organization>Technion-Israel Institute of Technology</organization>
<state>Haifa</state>
<country iso-code="ISR" />
<ce:source-text>Technion-Israel Institute of Technology, Haifa, Israel.</ce:source-text>
</affiliation>
</author-group>
<correspondence>
<person>
<ce:initials>S.</ce:initials> 
<ce:surname>Cohen</ce:surname>
<ce:given-name>S.</ce:given-name>
<ce:e-address>shenhavc@technion.ac.il</ce:e-address>
</person>
<affiliation>
<organization>Technion-Israel Institute of Technology</organization>
<state>Haifa</state>
<country iso-code="ISR" />
<ce:source-text>Technion-Israel Institute of Technology, Haifa, Israel.</ce:source-text>
</affiliation>
</correspondence>
<abstracts>
<abstract xml:lang="ENG" original="y">
<publishercopyright>© Springer Nature Switzerland AG 2022</publishercopyright>
<ce:para>Cachexia is a severe loss of muscle mass in chronic disease, often accompanied by meta- bolic dysfunction, fatigue, loss of appetite, general weight loss, and poor patient outcomes. This debilitating condition is highly prevalent in cancer patients, lowering their quality of life and likelihood of survival. Pre- vention of muscle loss is expected to prolong survival, however, currently there are no accepted effective treatments, and cachexia is usually only diagnosed in advanced stages when therapeutic intervention is particularly challenging. Development and administration of effective therapies require foundational understanding of the underlying mechanisms that promote protein breakdown and cause wasting. Recently, the sequence of key molecular and cellular events driving catabolism, and the regulatory signals stimulating overall proteolysis, have become clearer from studies on animal models for muscle atrophy. Different types of atrophy share common transcriptional changes and proteolytic pathways that activate degradation of soluble and contractile myofibrillar proteins; consequently, identified key regulators of these common mechanisms should be attractive drug targets for treatment of numerous wasting conditions. In this chapter, we discuss our current knowledge on these catabolic events and key regulators, which orchestrate the continuous progression of the atrophy process from its initial cues. We also highlight promising avenues of research for better understanding and treating cancer cachexia.</ce:para>
</abstract>
</abstracts>
<source type="book" country="USA">
<sourcetitle>The Systemic Effects of Advanced Cancer A Textbook on Cancer-Associated Cachexia</sourcetitle>
<sourcetitle-abbrev>The Systemic Effects of Advanced Cancer A Textbook on Cancer-Associated Cachexia</sourcetitle-abbrev>
<isbn type="print" length="13">9783031072727</isbn>
<isbn type="electronic" length="13">9783031095184</isbn>
<volisspag>
<page-information>
<pages>
<first-page>72</first-page>
<last-page>95</last-page>
</pages>
</page-information>
</volisspag>
<publicationyear first="2022" />
<publicationdate>
<year>2022</year>
<month>01</month>
<day>01</day>
</publicationdate>
<website type="item">
<ce:e-address type="url">https://link.springer.com</ce:e-address>
</website>
<publisher>
<publishername>Springer International Publishing</publishername>
</publisher>
</source>
<enhancement>
<classificationgroup>
<classifications type="ASJC">
<classification>
<classification-code>2700</classification-code>
<classification-code>2400</classification-code>
<classification-code>1300</classification-code>
</classification>
</classifications>
</classificationgroup>
</enhancement>
</head>
<tail>
<bibliography refcount="261">
<reference seq="1">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle regulates metabolism via interorgan crosstalk: Roles in health and disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Argilés</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:surname>Campos</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.M.</ce:initials>
<ce:surname>Lopez-Pedrosa</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Am. Med. Dir. Assoc</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>789</first-page>
<last-page>796</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Argilés, J.M., Campos, N., Lopez-Pedrosa, J.M., et al.: Skeletal muscle regulates metabolism via interorgan crosstalk: roles in health and disease. J. Am. Med. Dir. Assoc. 17(9), 789–796 (2016)</ref-fulltext>
<ce:source-text>Argilés, J.M., Campos, N., Lopez-Pedrosa, J.M., et al.: Skeletal muscle regulates metabolism via interorgan crosstalk: roles in health and disease. J. Am. Med. Dir. Assoc. 17(9), 789–796 (2016)</ce:source-text>
</reference>
<reference seq="2">
<ref-info>
<ref-title>
<ref-titletext-english>Cellular and molecular mechanisms of muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Bonaldo</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Sandri</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>DMM Disease Models and Mechanisms</ref-sourcetitle>
<ref-publicationyear first="2013" />
</ref-info>
<ref-fulltext>Bonaldo, P., Sandri, M.: Cellular and molecular mechanisms of muscle atrophy. DMM Disease Models and Mechanisms. (2013)</ref-fulltext>
<ce:source-text>Bonaldo, P., Sandri, M.: Cellular and molecular mechanisms of muscle atrophy. DMM Disease Models and Mechanisms. (2013)</ce:source-text>
</reference>
<reference seq="3">
<ref-info>
<ref-title>
<ref-titletext-english>The Lethal Phenotype of Cancer: The Molecular Basis of Death Due to Malignancy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.D.</ce:initials>
<ce:surname>Loberg</ce:surname>
<ce:given-name>R.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.A.</ce:initials>
<ce:surname>Bradley</ce:surname>
<ce:given-name>D.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.A.</ce:initials>
<ce:surname>Tomlins</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>CA Cancer J. Clin</ref-sourcetitle>
<ref-publicationyear first="2007" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.3322/canjclin.57.4.225</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Loberg, R.D., Bradley, D.A., Tomlins, S.A., et al.: The Lethal Phenotype of Cancer: The Molecular Basis of Death Due to Malignancy. CA Cancer J. Clin. (2007). https://doi.org/10.3322/canjclin.57.4.225</ref-fulltext>
<ce:source-text>Loberg, R.D., Bradley, D.A., Tomlins, S.A., et al.: The Lethal Phenotype of Cancer: The Molecular Basis of Death Due to Malignancy. CA Cancer J. Clin. (2007). https://doi.org/10.3322/canjclin.57.4.225</ce:source-text>
</reference>
<reference seq="4">
<ref-info>
<ref-title>
<ref-titletext-english>Metastasis and cachexia: Alongside in clinics, but not so in animal models</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Tomasin</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.C.B.M.</ce:initials>
<ce:surname>Martin</ce:surname>
<ce:given-name>A.C.B.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.R.</ce:initials>
<ce:surname>Cominetti</ce:surname>
<ce:given-name>M.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2019" />
</ref-info>
<ref-fulltext>Tomasin, R., Martin, A.C.B.M., Cominetti, M.R.: Metastasis and cachexia: Alongside in clinics, but not so in animal models. J. Cachexia Sarcopenia Muscle (2019)</ref-fulltext>
<ce:source-text>Tomasin, R., Martin, A.C.B.M., Cominetti, M.R.: Metastasis and cachexia: Alongside in clinics, but not so in animal models. J. Cachexia Sarcopenia Muscle (2019)</ce:source-text>
</reference>
<reference seq="5">
<ref-info>
<ref-title>
<ref-titletext-english>Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.A.</ce:initials>
<ce:surname>Parsons</ce:surname>
<ce:given-name>H.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Dhillon</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2012" />
</ref-info>
<ref-fulltext>Parsons, H.A., Baracos, V.E., Dhillon, N., et al.: Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service. PLoS One. (2012)</ref-fulltext>
<ce:source-text>Parsons, H.A., Baracos, V.E., Dhillon, N., et al.: Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service. PLoS One. (2012)</ce:source-text>
</reference>
<reference seq="6">
<ref-info>
<ref-title>
<ref-titletext-english>Mechanisms of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.J.</ce:initials>
<ce:surname>Tisdale</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Physiol. Rev</ref-sourcetitle>
<ref-publicationyear first="2009" />
</ref-info>
<ref-fulltext>Tisdale, M.J.: Mechanisms of cancer cachexia. Physiol. Rev. (2009)</ref-fulltext>
<ce:source-text>Tisdale, M.J.: Mechanisms of cancer cachexia. Physiol. Rev. (2009)</ce:source-text>
</reference>
<reference seq="7">
<ref-info>
<ref-title>
<ref-titletext-english>Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Zhou</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.L.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>J.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Lu</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>142</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>531</first-page>
<last-page>543</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.cell.2010.07.011</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Zhou, X., Wang, J.L., Lu, J., et al.: Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 142, 531–543 (2010). https://doi.org/10.1016/j.cell.2010.07.011</ref-fulltext>
<ce:source-text>Zhou, X., Wang, J.L., Lu, J., et al.: Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 142, 531–543 (2010). https://doi.org/10.1016/j.cell.2010.07.011</ce:source-text>
</reference>
<reference seq="8">
<ref-info>
<ref-title>
<ref-titletext-english>Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Busquets</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Toledo</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Orpí</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2012" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1007/s13539-011-0049-z</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Busquets, S., Toledo, M., Orpí, M., et al.: Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. J. Cachexia. Sarcopenia Muscle. (2012). https://doi.org/10.1007/s13539-011-0049-z</ref-fulltext>
<ce:source-text>Busquets, S., Toledo, M., Orpí, M., et al.: Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. J. Cachexia. Sarcopenia Muscle. (2012). https://doi.org/10.1007/s13539-011-0049-z</ce:source-text>
</reference>
<reference seq="9">
<ref-info>
<ref-title>
<ref-titletext-english>Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and β-2 agonist</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Toledo</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Busquets</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:surname>Penna</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2016" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/ijc.29930</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Toledo, M., Busquets, S., Penna, F., et al.: Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and β-2 agonist. Int. J. Cancer. (2016). https://doi.org/10.1002/ijc.29930</ref-fulltext>
<ce:source-text>Toledo, M., Busquets, S., Penna, F., et al.: Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and β-2 agonist. Int. J. Cancer. (2016). https://doi.org/10.1002/ijc.29930</ce:source-text>
</reference>
<reference seq="10">
<ref-info>
<ref-title>
<ref-titletext-english>The metabolic basis of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Argilés</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Alvarez</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="3">
<ce:initials>F.J.</ce:initials>
<ce:surname>López-Soriano</ce:surname>
<ce:given-name>F.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Med. Res. Rev</ref-sourcetitle>
<ref-publicationyear first="1997" />
</ref-info>
<ref-fulltext>Argilés, J.M., Alvarez, B., López-Soriano, F.J.: The metabolic basis of cancer cachexia. Med. Res. Rev. (1997)</ref-fulltext>
<ce:source-text>Argilés, J.M., Alvarez, B., López-Soriano, F.J.: The metabolic basis of cancer cachexia. Med. Res. Rev. (1997)</ce:source-text>
</reference>
<reference seq="11">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia: Mediators, signaling, and metabolic pathways</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.C.H.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.C.H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.J.</ce:initials>
<ce:surname>Glass</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.C.</ce:initials>
<ce:surname>Guttridge</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2012" />
</ref-info>
<ref-fulltext>Fearon, K.C.H., Glass, D.J., Guttridge, D.C.: Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. (2012)</ref-fulltext>
<ce:source-text>Fearon, K.C.H., Glass, D.J., Guttridge, D.C.: Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. (2012)</ce:source-text>
</reference>
<reference seq="12">
<ref-info>
<ref-title>
<ref-titletext-english>Chemotherapy-induced muscle wasting: Association with NF-κB and cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S.</ce:initials>
<ce:surname>Damrauer</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.E.</ce:initials>
<ce:surname>Stadler</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Acharyya</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Transl. Myol</ref-sourcetitle>
<ref-publicationyear first="2018" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.4081/ejtm.2018.7590</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Damrauer, J.S., Stadler, M.E., Acharyya, S., et al.: Chemotherapy-induced muscle wasting: Association with NF-κB and cancer cachexia. Eur. J. Transl. Myol. (2018). https://doi.org/10.4081/ejtm.2018.7590</ref-fulltext>
<ce:source-text>Damrauer, J.S., Stadler, M.E., Acharyya, S., et al.: Chemotherapy-induced muscle wasting: Association with NF-κB and cancer cachexia. Eur. J. Transl. Myol. (2018). https://doi.org/10.4081/ejtm.2018.7590</ce:source-text>
</reference>
<reference seq="13">
<ref-info>
<ref-title>
<ref-titletext-english>Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Barreto</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.E.</ce:initials>
<ce:surname>Couch</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2019" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/jcsm.12360</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Pin, F., Barreto, R., Couch, M.E., et al.: Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism. J. Cachexia. Sarcopenia Muscle. (2019). https://doi.org/10.1002/jcsm.12360</ref-fulltext>
<ce:source-text>Pin, F., Barreto, R., Couch, M.E., et al.: Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism. J. Cachexia. Sarcopenia Muscle. (2019). https://doi.org/10.1002/jcsm.12360</ce:source-text>
</reference>
<reference seq="14">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Colotta</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Allavena</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Sica</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Carcinogenesis</ref-sourcetitle>
<ref-publicationyear first="2009" />
</ref-info>
<ref-fulltext>Colotta, F., Allavena, P., Sica, A., et al.: Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. (2009)</ref-fulltext>
<ce:source-text>Colotta, F., Allavena, P., Sica, A., et al.: Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. (2009)</ce:source-text>
</reference>
<reference seq="15">
<ref-info>
<ref-title>
<ref-titletext-english>Hallmarks of cancer: The next generation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Hanahan</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.A.</ce:initials>
<ce:surname>Weinberg</ce:surname>
<ce:given-name>R.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2011" />
</ref-info>
<ref-fulltext>Hanahan, D., Weinberg, R.A.: Hallmarks of cancer: The next generation. Cell. (2011)</ref-fulltext>
<ce:source-text>Hanahan, D., Weinberg, R.A.: Hallmarks of cancer: The next generation. Cell. (2011)</ce:source-text>
</reference>
<reference seq="16">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-related inflammation and treatment effectiveness</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.I.</ce:initials>
<ce:surname>Diakos</ce:surname>
<ce:given-name>C.I.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.A.</ce:initials>
<ce:surname>Charles</ce:surname>
<ce:given-name>K.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.C.</ce:initials>
<ce:surname>McMillan</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.J.</ce:initials>
<ce:surname>Clarke</ce:surname>
<ce:given-name>S.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Lancet Oncol</ref-sourcetitle>
<ref-publicationyear first="2014" />
</ref-info>
<ref-fulltext>Diakos, C.I., Charles, K.A., McMillan, D.C., Clarke, S.J.: Cancer-related inflammation and treatment effectiveness. Lancet Oncol. (2014)</ref-fulltext>
<ce:source-text>Diakos, C.I., Charles, K.A., McMillan, D.C., Clarke, S.J.: Cancer-related inflammation and treatment effectiveness. Lancet Oncol. (2014)</ce:source-text>
</reference>
<reference seq="17">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer and systemic inflammation: Treat the tumour and treat the host</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.S.D.</ce:initials>
<ce:surname>Roxburgh</ce:surname>
<ce:given-name>C.S.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.C.</ce:initials>
<ce:surname>McMillan</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2014" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/bjc.2014.90</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Roxburgh, C.S.D., McMillan, D.C.: Cancer and systemic inflammation: Treat the tumour and treat the host. Br. J. Cancer. (2014). https://doi.org/10.1038/bjc.2014.90</ref-fulltext>
<ce:source-text>Roxburgh, C.S.D., McMillan, D.C.: Cancer and systemic inflammation: Treat the tumour and treat the host. Br. J. Cancer. (2014). https://doi.org/10.1038/bjc.2014.90</ce:source-text>
</reference>
<reference seq="18">
<ref-info>
<ref-title>
<ref-titletext-english>The influence of systemic inflammation, dietary intake and stage of disease on rate of weight loss in patients with gastro-oesophageal cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.A.C.</ce:initials>
<ce:surname>Deans</ce:surname>
<ce:given-name>D.A.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.H.</ce:initials>
<ce:surname>Tan</ce:surname>
<ce:given-name>B.H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.J.</ce:initials>
<ce:surname>Wigmore</ce:surname>
<ce:given-name>S.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2009" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/sj.bjc.6604828</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Deans, D.A.C., Tan, B.H., Wigmore, S.J., et al.: The influence of systemic inflammation, dietary intake and stage of disease on rate of weight loss in patients with gastro-oesophageal cancer. Br. J. Cancer. (2009). https://doi.org/10.1038/sj.bjc.6604828</ref-fulltext>
<ce:source-text>Deans, D.A.C., Tan, B.H., Wigmore, S.J., et al.: The influence of systemic inflammation, dietary intake and stage of disease on rate of weight loss in patients with gastro-oesophageal cancer. Br. J. Cancer. (2009). https://doi.org/10.1038/sj.bjc.6604828</ce:source-text>
</reference>
<reference seq="19">
<ref-info>
<ref-title>
<ref-titletext-english>Serum levels of leptin and proinflammatory cytokines in patients with gastrointestinal cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Dülger</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Alici</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.R.</ce:initials>
<ce:surname>Şekeroǧlu</ce:surname>
<ce:given-name>M.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Clin. Pract</ref-sourcetitle>
<ref-publicationyear first="2004" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1111/j.1368-5031.2004.00149.x</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Dülger, H., Alici, S., Şekeroǧlu, M.R., et al.: Serum levels of leptin and proinflammatory cytokines in patients with gastrointestinal cancer. Int. J. Clin. Pract. (2004). https://doi.org/10.1111/j.1368-5031.2004.00149.x</ref-fulltext>
<ce:source-text>Dülger, H., Alici, S., Şekeroǧlu, M.R., et al.: Serum levels of leptin and proinflammatory cytokines in patients with gastrointestinal cancer. Int. J. Clin. Pract. (2004). https://doi.org/10.1111/j.1368-5031.2004.00149.x</ce:source-text>
</reference>
<reference seq="20">
<ref-info>
<ref-title>
<ref-titletext-english>Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Mantovani</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Macciò</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Madeddu</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Mol. Med</ref-sourcetitle>
<ref-publicationyear first="2001" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1007/s001090100234</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Mantovani, G., Macciò, A., Madeddu, C., et al.: Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites. J. Mol. Med. (2001). https://doi.org/10.1007/s001090100234</ref-fulltext>
<ce:source-text>Mantovani, G., Macciò, A., Madeddu, C., et al.: Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites. J. Mol. Med. (2001). https://doi.org/10.1007/s001090100234</ce:source-text>
</reference>
<reference seq="21">
<ref-info>
<ref-title>
<ref-titletext-english>Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.J.</ce:initials>
<ce:surname>Staal-Van Cen Brekel</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.A.</ce:initials>
<ce:surname>Dentener</ce:surname>
<ce:given-name>M.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.M.W.J.</ce:initials>
<ce:surname>Schols</ce:surname>
<ce:given-name>A.M.W.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="1995" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1200/JCO.1995.13.10.2600</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Staal-van Cen Brekel, A.J., Dentener, M.A., Schols, A.M.W.J., et al.: Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J. Clin. Oncol. (1995). https://doi.org/10.1200/JCO.1995.13.10.2600</ref-fulltext>
<ce:source-text>Staal-van Cen Brekel, A.J., Dentener, M.A., Schols, A.M.W.J., et al.: Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J. Clin. Oncol. (1995). https://doi.org/10.1200/JCO.1995.13.10.2600</ce:source-text>
</reference>
<reference seq="22">
<ref-info>
<ref-title>
<ref-titletext-english>Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Tas</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Duranyildiz</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Argon</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Med. Oncol</ref-sourcetitle>
<ref-publicationyear first="2005" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1385/MO:22:4:353</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Tas, F., Duranyildiz, D., Argon, A., et al.: Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer. Med. Oncol. (2005). https://doi.org/10.1385/MO:22:4:353</ref-fulltext>
<ce:source-text>Tas, F., Duranyildiz, D., Argon, A., et al.: Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer. Med. Oncol. (2005). https://doi.org/10.1385/MO:22:4:353</ce:source-text>
</reference>
<reference seq="23">
<ref-info>
<ref-title>
<ref-titletext-english>Roles of the immune system in cancer: From tumor initiation to metastatic progression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Gonzalez</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Hagerling</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Z.</ce:initials>
<ce:surname>Werb</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Genes Dev</ref-sourcetitle>
<ref-publicationyear first="2018" />
</ref-info>
<ref-fulltext>Gonzalez, H., Hagerling, C., Werb, Z.: Roles of the immune system in cancer: From tumor initiation to metastatic progression. Genes Dev. (2018)</ref-fulltext>
<ce:source-text>Gonzalez, H., Hagerling, C., Werb, Z.: Roles of the immune system in cancer: From tumor initiation to metastatic progression. Genes Dev. (2018)</ce:source-text>
</reference>
<reference seq="24">
<ref-info>
<ref-title>
<ref-titletext-english>The immune contexture in human tumours: Impact on clinical outcome</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.H.</ce:initials>
<ce:surname>Fridman</ce:surname>
<ce:given-name>W.H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Pagès</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Sauts-Fridman</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Galon</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2012" />
</ref-info>
<ref-fulltext>Fridman, W.H., Pagès, F., Sauts-Fridman, C., Galon, J.: The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer. (2012)</ref-fulltext>
<ce:source-text>Fridman, W.H., Pagès, F., Sauts-Fridman, C., Galon, J.: The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer. (2012)</ce:source-text>
</reference>
<reference seq="25">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Casneuf</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.E.</ce:initials>
<ce:surname>Axel</ce:surname>
<ce:given-name>A.E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>King</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Breast Cancer Targets Therapy</ref-sourcetitle>
<ref-publicationyear first="2016" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.2147/BCTT.S92414</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Casneuf, T., Axel, A.E., King, P., et al.: Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer. Breast Cancer Targets Therapy. (2016). https://doi.org/10.2147/BCTT.S92414</ref-fulltext>
<ce:source-text>Casneuf, T., Axel, A.E., King, P., et al.: Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer. Breast Cancer Targets Therapy. (2016). https://doi.org/10.2147/BCTT.S92414</ce:source-text>
</reference>
<reference seq="26">
<ref-info>
<ref-title>
<ref-titletext-english>Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.W.</ce:initials>
<ce:surname>Edwardson</ce:surname>
<ce:given-name>D.W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Boudreau</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Mapletoft</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2017" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1371/journal.pone.0183662</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Edwardson, D.W., Boudreau, J., Mapletoft, J., et al.: Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance. PLoS One. (2017). https://doi.org/10.1371/journal.pone.0183662</ref-fulltext>
<ce:source-text>Edwardson, D.W., Boudreau, J., Mapletoft, J., et al.: Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance. PLoS One. (2017). https://doi.org/10.1371/journal.pone.0183662</ce:source-text>
</reference>
<reference seq="27">
<ref-info>
<ref-title>
<ref-titletext-english>Alterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: A study in isogenic resistant tumor cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Sprowl</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Reed</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.R.</ce:initials>
<ce:surname>Armstrong</ce:surname>
<ce:given-name>S.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Breast Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2012" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1186/bcr3083</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Sprowl, J.A., Reed, K., Armstrong, S.R., et al.: Alterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: A study in isogenic resistant tumor cells. Breast Cancer Res. (2012). https://doi.org/10.1186/bcr3083</ref-fulltext>
<ce:source-text>Sprowl, J.A., Reed, K., Armstrong, S.R., et al.: Alterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: A study in isogenic resistant tumor cells. Breast Cancer Res. (2012). https://doi.org/10.1186/bcr3083</ce:source-text>
</reference>
<reference seq="28">
<ref-info>
<ref-title>
<ref-titletext-english>Hormone, cytokine, and nutritional regulation of sepsis-induced increases in atrogin-1 and MuRF1 in skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.A.</ce:initials>
<ce:surname>Frost</ce:surname>
<ce:given-name>R.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.J.</ce:initials>
<ce:surname>Nystrom</ce:surname>
<ce:given-name>G.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.S.</ce:initials>
<ce:surname>Jefferson</ce:surname>
<ce:given-name>L.S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>C.H.</ce:initials>
<ce:surname>Lang</ce:surname>
<ce:given-name>C.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Endocrinol. Metab</ref-sourcetitle>
<ref-publicationyear first="2007" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpendo.00359.2006</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Frost, R.A., Nystrom, G.J., Jefferson, L.S., Lang, C.H.: Hormone, cytokine, and nutritional regulation of sepsis-induced increases in atrogin-1 and MuRF1 in skeletal muscle. Am. J. Physiol. Endocrinol. Metab. (2007). https://doi.org/10.1152/ajpendo.00359.2006</ref-fulltext>
<ce:source-text>Frost, R.A., Nystrom, G.J., Jefferson, L.S., Lang, C.H.: Hormone, cytokine, and nutritional regulation of sepsis-induced increases in atrogin-1 and MuRF1 in skeletal muscle. Am. J. Physiol. Endocrinol. Metab. (2007). https://doi.org/10.1152/ajpendo.00359.2006</ce:source-text>
</reference>
<reference seq="29">
<ref-info>
<ref-title>
<ref-titletext-english>TNF-α acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.P.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>Y.P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>John</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>FASEB J</ref-sourcetitle>
<ref-publicationyear first="2005" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1096/fj.04-2364com</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Li, Y.P., Chen, Y., John, J., et al.: TNF-α acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J. (2005). https://doi.org/10.1096/fj.04-2364com</ref-fulltext>
<ce:source-text>Li, Y.P., Chen, Y., John, J., et al.: TNF-α acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J. (2005). https://doi.org/10.1096/fj.04-2364com</ce:source-text>
</reference>
<reference seq="30">
<ref-info>
<ref-title>
<ref-titletext-english>TNF induction of atrogin-1/MAFbx mRNA depends on Foxo4 expression but not AKT-Foxo1/3 signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S.</ce:initials>
<ce:surname>Moylan</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.D.</ce:initials>
<ce:surname>Smith</ce:surname>
<ce:given-name>J.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.A.</ce:initials>
<ce:surname>Chambers</ce:surname>
<ce:given-name>M.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Cell Physiol</ref-sourcetitle>
<ref-publicationyear first="2008" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpcell.00041.2008</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Moylan, J.S., Smith, J.D., Chambers, M.A., et al.: TNF induction of atrogin-1/MAFbx mRNA depends on Foxo4 expression but not AKT-Foxo1/3 signaling. Am. J. Physiol. Cell Physiol. (2008). https://doi.org/10.1152/ajpcell.00041.2008</ref-fulltext>
<ce:source-text>Moylan, J.S., Smith, J.D., Chambers, M.A., et al.: TNF induction of atrogin-1/MAFbx mRNA depends on Foxo4 expression but not AKT-Foxo1/3 signaling. Am. J. Physiol. Cell Physiol. (2008). https://doi.org/10.1152/ajpcell.00041.2008</ce:source-text>
</reference>
<reference seq="31">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor necrosis factor alpha (TNF-α) inactivates the PI3-kinase/PKB pathway and induces atrophy and apoptosis in L6 myotubes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.J.N.</ce:initials>
<ce:surname>Sishi</ce:surname>
<ce:given-name>B.J.N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.M.</ce:initials>
<ce:surname>Engelbrecht</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine</ref-sourcetitle>
<ref-publicationyear first="2011" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.cyto.2011.01.009</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Sishi, B.J.N., Engelbrecht, A.M.: Tumor necrosis factor alpha (TNF-α) inactivates the PI3-kinase/PKB pathway and induces atrophy and apoptosis in L6 myotubes. Cytokine. (2011). https://doi.org/10.1016/j.cyto.2011.01.009</ref-fulltext>
<ce:source-text>Sishi, B.J.N., Engelbrecht, A.M.: Tumor necrosis factor alpha (TNF-α) inactivates the PI3-kinase/PKB pathway and induces atrophy and apoptosis in L6 myotubes. Cytokine. (2011). https://doi.org/10.1016/j.cyto.2011.01.009</ce:source-text>
</reference>
<reference seq="32">
<ref-info>
<ref-title>
<ref-titletext-english>Tumors secreting human TNF/cachectin induce cachexia in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Oliff</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Defeo-Jones</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Boyer</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="1987" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/0092-8674(87)90028-6</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Oliff, A., Defeo-Jones, D., Boyer, M., et al.: Tumors secreting human TNF/cachectin induce cachexia in mice. Cell. (1987). https://doi.org/10.1016/0092-8674(87)90028-6</ref-fulltext>
<ce:source-text>Oliff, A., Defeo-Jones, D., Boyer, M., et al.: Tumors secreting human TNF/cachectin induce cachexia in mice. Cell. (1987). https://doi.org/10.1016/0092-8674(87)90028-6</ce:source-text>
</reference>
<reference seq="33">
<ref-info>
<ref-title>
<ref-titletext-english>A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9)</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Jatoi</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.L.</ce:initials>
<ce:surname>Ritter</ce:surname>
<ce:given-name>H.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Dueck</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Lung Cancer</ref-sourcetitle>
<ref-publicationyear first="2010" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.lungcan.2009.06.020</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Jatoi, A., Ritter, H.L., Dueck, A., et al.: A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). Lung Cancer. (2010). https://doi.org/10.1016/j.lungcan.2009.06.020</ref-fulltext>
<ce:source-text>Jatoi, A., Ritter, H.L., Dueck, A., et al.: A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). Lung Cancer. (2010). https://doi.org/10.1016/j.lungcan.2009.06.020</ce:source-text>
</reference>
<reference seq="34">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin-6 and cachexia in ApcMin/+ mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.A.</ce:initials>
<ce:surname>Baltgalvis</ce:surname>
<ce:given-name>K.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>F.G.</ce:initials>
<ce:surname>Berger</ce:surname>
<ce:given-name>F.G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.M.O.</ce:initials>
<ce:surname>Pena</ce:surname>
<ce:given-name>M.M.O.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Regul. Integr. Comp. Physiol</ref-sourcetitle>
<ref-publicationyear first="2008" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpregu.00716.2007</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Baltgalvis, K.A., Berger, F.G., Pena, M.M.O., et al.: Interleukin-6 and cachexia in ApcMin/+ mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2008). https://doi.org/10.1152/ajpregu.00716.2007</ref-fulltext>
<ce:source-text>Baltgalvis, K.A., Berger, F.G., Pena, M.M.O., et al.: Interleukin-6 and cachexia in ApcMin/+ mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2008). https://doi.org/10.1152/ajpregu.00716.2007</ce:source-text>
</reference>
<reference seq="35">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin 6 as a key regulator of muscle mass during cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Carson</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.A.</ce:initials>
<ce:surname>Baltgalvis</ce:surname>
<ce:given-name>K.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Exerc. Sport Sci. Rev</ref-sourcetitle>
<ref-publicationyear first="2010" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1097/JES.0b013e3181f44f11</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Carson, J.A., Baltgalvis, K.A.: Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc. Sport Sci. Rev. (2010). https://doi.org/10.1097/JES.0b013e3181f44f11</ref-fulltext>
<ce:source-text>Carson, J.A., Baltgalvis, K.A.: Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc. Sport Sci. Rev. (2010). https://doi.org/10.1097/JES.0b013e3181f44f11</ce:source-text>
</reference>
<reference seq="36">
<ref-info>
<ref-title>
<ref-titletext-english>Pro-inflammatory cytokine release by peripheral blood mononuclear cells from patients with advanced pancreatic cancer: Relationship to acute phase response and survival</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.G.W.</ce:initials>
<ce:surname>Moses</ce:surname>
<ce:given-name>A.G.W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Maingay</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.</ce:initials>
<ce:surname>Sangster</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncol. Rep</ref-sourcetitle>
<ref-publicationyear first="2009" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.3892/or_00000328</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Moses, A.G.W., Maingay, J., Sangster, K., et al.: Pro-inflammatory cytokine release by peripheral blood mononuclear cells from patients with advanced pancreatic cancer: relationship to acute phase response and survival. Oncol. Rep. (2009). https://doi.org/10.3892/or_00000328</ref-fulltext>
<ce:source-text>Moses, A.G.W., Maingay, J., Sangster, K., et al.: Pro-inflammatory cytokine release by peripheral blood mononuclear cells from patients with advanced pancreatic cancer: relationship to acute phase response and survival. Oncol. Rep. (2009). https://doi.org/10.3892/or_00000328</ce:source-text>
</reference>
<reference seq="37">
<ref-info>
<ref-title>
<ref-titletext-english>The relationship between weight loss and interleukin 6 in non-small-cell lung cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.R.</ce:initials>
<ce:surname>Scott</ce:surname>
<ce:given-name>H.R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.C.</ce:initials>
<ce:surname>McMillan</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Crilly</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="1996" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/bjc.1996.294</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Scott, H.R., McMillan, D.C., Crilly, A., et al.: The relationship between weight loss and interleukin 6 in non-small-cell lung cancer. Br. J. Cancer. (1996). https://doi.org/10.1038/bjc.1996.294</ref-fulltext>
<ce:source-text>Scott, H.R., McMillan, D.C., Crilly, A., et al.: The relationship between weight loss and interleukin 6 in non-small-cell lung cancer. Br. J. Cancer. (1996). https://doi.org/10.1038/bjc.1996.294</ce:source-text>
</reference>
<reference seq="38">
<ref-info>
<ref-title>
<ref-titletext-english>Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Fujlta</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Tsujinaka</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Yano</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="1996" />
</ref-info>
<ref-fulltext>Fujlta, J., Tsujinaka, T., Yano, M., et al.: Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways. Int. J. Cancer. (1996). 10.1002/(SICI)1097-0215(19961127)68:5&lt;637::AID-IJC14&gt;3.0.CO;2-Z</ref-fulltext>
<ce:source-text>Fujlta, J., Tsujinaka, T., Yano, M., et al.: Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways. Int. J. Cancer. (1996). 10.1002/(SICI)1097-0215(19961127)68:5&lt;637::AID-IJC14&gt;3.0.CO;2-Z</ce:source-text>
</reference>
<reference seq="39">
<ref-info>
<ref-title>
<ref-titletext-english>The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc Min/+ mouse</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.P.</ce:initials>
<ce:surname>White</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.W.</ce:initials>
<ce:surname>Baynes</ce:surname>
<ce:given-name>J.W.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.L.</ce:initials>
<ce:surname>Welle</ce:surname>
<ce:given-name>S.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2011" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1371/journal.pone.0024650</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>White, J.P., Baynes, J.W., Welle, S.L., et al.: The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc Min/+ mouse. PLoS One. (2011). https://doi.org/10.1371/journal.pone.0024650</ref-fulltext>
<ce:source-text>White, J.P., Baynes, J.W., Welle, S.L., et al.: The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc Min/+ mouse. PLoS One. (2011). https://doi.org/10.1371/journal.pone.0024650</ce:source-text>
</reference>
<reference seq="40">
<ref-info>
<ref-title>
<ref-titletext-english>A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.J.</ce:initials>
<ce:surname>Bayliss</ce:surname>
<ce:given-name>T.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.T.</ce:initials>
<ce:surname>Smith</ce:surname>
<ce:given-name>J.T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Schuster</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Expert. Opin. Biol. Ther</ref-sourcetitle>
<ref-publicationyear first="2011" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1517/14712598.2011.627850</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Bayliss, T.J., Smith, J.T., Schuster, M., et al.: A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert. Opin. Biol. Ther. (2011). https://doi.org/10.1517/14712598.2011.627850</ref-fulltext>
<ce:source-text>Bayliss, T.J., Smith, J.T., Schuster, M., et al.: A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert. Opin. Biol. Ther. (2011). https://doi.org/10.1517/14712598.2011.627850</ce:source-text>
</reference>
<reference seq="41">
<ref-info>
<ref-title>
<ref-titletext-english>TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Dogra</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Changotra</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Wedhas</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>FASEB J</ref-sourcetitle>
<ref-publicationyear first="2007" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1096/fj.06-7537com</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Dogra, C., Changotra, H., Wedhas, N., et al.: TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. FASEB J. (2007). https://doi.org/10.1096/fj.06-7537com</ref-fulltext>
<ce:source-text>Dogra, C., Changotra, H., Wedhas, N., et al.: TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. FASEB J. (2007). https://doi.org/10.1096/fj.06-7537com</ce:source-text>
</reference>
<reference seq="42">
<ref-info>
<ref-title>
<ref-titletext-english>The TWEAK-Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Mittal</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Bhatnagar</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Kumar</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2010" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1083/jcb.200909117</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Mittal, A., Bhatnagar, S., Kumar, A., et al.: The TWEAK-Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice. J. Cell Biol. (2010). https://doi.org/10.1083/jcb.200909117</ref-fulltext>
<ce:source-text>Mittal, A., Bhatnagar, S., Kumar, A., et al.: The TWEAK-Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice. J. Cell Biol. (2010). https://doi.org/10.1083/jcb.200909117</ce:source-text>
</reference>
<reference seq="43">
<ref-info>
<ref-title>
<ref-titletext-english>STAT3 in skeletal muscle function and disorders</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Guadagnin</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Mázala</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Y.W.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>Y.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Mol. Sci</ref-sourcetitle>
<ref-publicationyear first="2018" />
</ref-info>
<ref-fulltext>Guadagnin, E., Mázala, D., Chen, Y.W.: STAT3 in skeletal muscle function and disorders. Int. J. Mol. Sci. (2018)</ref-fulltext>
<ce:source-text>Guadagnin, E., Mázala, D., Chen, Y.W.: STAT3 in skeletal muscle function and disorders. Int. J. Mol. Sci. (2018)</ce:source-text>
</reference>
<reference seq="44">
<ref-info>
<ref-title>
<ref-titletext-english>Signal transducer and activator of transcription 3 signaling as a potential target to treat muscle wasting diseases.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Sala</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Sacco</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Opin. Clin. Nutr. Metab. Care.</ref-sourcetitle>
<ref-publicationyear first="2016" />
</ref-info>
<ref-fulltext>Sala, D., Sacco, A.: Signal transducer and activator of transcription 3 signaling as a potential target to treat muscle wasting diseases. Curr. Opin. Clin. Nutr. Metab. Care. (2016)</ref-fulltext>
<ce:source-text>Sala, D., Sacco, A.: Signal transducer and activator of transcription 3 signaling as a potential target to treat muscle wasting diseases. Curr. Opin. Clin. Nutr. Metab. Care. (2016)</ce:source-text>
</reference>
<reference seq="45">
<ref-info>
<ref-title>
<ref-titletext-english>STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Aydogdu</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Kunzevitzky</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2011" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1371/journal.pone.0022538</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Bonetto, A., Aydogdu, T., Kunzevitzky, N., et al.: STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS One. (2011). https://doi.org/10.1371/journal.pone.0022538</ref-fulltext>
<ce:source-text>Bonetto, A., Aydogdu, T., Kunzevitzky, N., et al.: STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS One. (2011). https://doi.org/10.1371/journal.pone.0022538</ce:source-text>
</reference>
<reference seq="46">
<ref-info>
<ref-title>
<ref-titletext-english>Stat3 activation links a C/EBPδ to myostatin pathway to stimulate loss of muscle mass</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Pan</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Dong</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2013" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.cmet.2013.07.012</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Zhang, L., Pan, J., Dong, Y., et al.: Stat3 activation links a C/EBPδ to myostatin pathway to stimulate loss of muscle mass. Cell Metab. (2013a). https://doi.org/10.1016/j.cmet.2013.07.012</ref-fulltext>
<ce:source-text>Zhang, L., Pan, J., Dong, Y., et al.: Stat3 activation links a C/EBPδ to myostatin pathway to stimulate loss of muscle mass. Cell Metab. (2013a). https://doi.org/10.1016/j.cmet.2013.07.012</ce:source-text>
</reference>
<reference seq="47">
<ref-info>
<ref-title>
<ref-titletext-english>CCAAT/enhancer binding protein-δ expression is increased in fast skeletal muscle by food deprivation and regulates myostatin transcription in vitro</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.L.</ce:initials>
<ce:surname>Allen</ce:surname>
<ce:given-name>D.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.S.</ce:initials>
<ce:surname>Cleary</ce:surname>
<ce:given-name>A.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.M.</ce:initials>
<ce:surname>Hanson</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Regul. Integr. Comp. Physiol.</ref-sourcetitle>
<ref-publicationyear first="2010" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpregu.00247.2010</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Allen, D.L., Cleary, A.S., Hanson, A.M., et al.: CCAAT/enhancer binding protein-δ expression is increased in fast skeletal muscle by food deprivation and regulates myostatin transcription in vitro. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2010). https://doi.org/10.1152/ajpregu.00247.2010</ref-fulltext>
<ce:source-text>Allen, D.L., Cleary, A.S., Hanson, A.M., et al.: CCAAT/enhancer binding protein-δ expression is increased in fast skeletal muscle by food deprivation and regulates myostatin transcription in vitro. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2010). https://doi.org/10.1152/ajpregu.00247.2010</ce:source-text>
</reference>
<reference seq="48">
<ref-info>
<ref-title>
<ref-titletext-english>Pancreatic cancer-induced cachexia is Jak2-dependent in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Gilabert</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Calvo</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Airoldi</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Physiol</ref-sourcetitle>
<ref-publicationyear first="2014" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/jcp.24580</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Gilabert, M., Calvo, E., Airoldi, A., et al.: Pancreatic cancer-induced cachexia is Jak2-dependent in mice. J. Cell. Physiol. (2014). https://doi.org/10.1002/jcp.24580</ref-fulltext>
<ce:source-text>Gilabert, M., Calvo, E., Airoldi, A., et al.: Pancreatic cancer-induced cachexia is Jak2-dependent in mice. J. Cell. Physiol. (2014). https://doi.org/10.1002/jcp.24580</ce:source-text>
</reference>
<reference seq="49">
<ref-info>
<ref-title>
<ref-titletext-english>Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.A.S.</ce:initials>
<ce:surname>Silva</ce:surname>
<ce:given-name>K.A.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Dong</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Dong</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2015" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1074/jbc.M115.641514</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Silva, K.A.S., Dong, J., Dong, Y., et al.: Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia. J. Biol. Chem. (2015). https://doi.org/10.1074/jbc.M115.641514</ref-fulltext>
<ce:source-text>Silva, K.A.S., Dong, J., Dong, Y., et al.: Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia. J. Biol. Chem. (2015). https://doi.org/10.1074/jbc.M115.641514</ce:source-text>
</reference>
<reference seq="50">
<ref-info>
<ref-title>
<ref-titletext-english>Imperatorin alleviates cancer cachexia and prevents muscle wasting via directly inhibiting STAT3</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>W.</ce:initials>
<ce:surname>Xu</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Q.</ce:initials>
<ce:surname>Yang</ce:surname>
<ce:given-name>Q.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Pharmacol. Res</ref-sourcetitle>
<ref-publicationyear first="2020" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.phrs.2020.104871</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Chen, L., Xu, W., Yang, Q., et al.: Imperatorin alleviates cancer cachexia and prevents muscle wasting via directly inhibiting STAT3. Pharmacol. Res. (2020). https://doi.org/10.1016/j.phrs.2020.104871</ref-fulltext>
<ce:source-text>Chen, L., Xu, W., Yang, Q., et al.: Imperatorin alleviates cancer cachexia and prevents muscle wasting via directly inhibiting STAT3. Pharmacol. Res. (2020). https://doi.org/10.1016/j.phrs.2020.104871</ce:source-text>
</reference>
<reference seq="51">
<ref-info>
<ref-title>
<ref-titletext-english>IKK [beta]/NF-[kappa] B activation causes severe muscle wasting in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Cai</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Frantz</ce:surname>
<ce:given-name>J.</ce:given-name><degree>Jr</degree>
</author>
<author seq="3">
<ce:initials>E.T.</ce:initials>
<ce:surname>Nicholas</ce:surname>
<ce:given-name>E.T.</ce:given-name>
<degree>Jr</degree>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2004" />
</ref-info>
<ref-fulltext>Cai, D., Frantz Jr., J., Nicholas Jr., E.T., et al.: IKK [beta]/NF-[kappa] B activation causes severe muscle wasting in mice. Cell. (2004)</ref-fulltext>
<ce:source-text>Cai, D., Frantz Jr., J., Nicholas Jr., E.T., et al.: IKK [beta]/NF-[kappa] B activation causes severe muscle wasting in mice. Cell. (2004)</ce:source-text>
</reference>
<reference seq="52">
<ref-info>
<ref-title>
<ref-titletext-english>Nf-kb and inflammatory cytokine signalling: Role in skeletal muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Thoma</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.P.</ce:initials>
<ce:surname>Lightfoot</ce:surname>
<ce:given-name>A.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Advances in Experimental Medicine and Biology</ref-sourcetitle>
<ref-publicationyear first="2018" />
</ref-info>
<ref-fulltext>Thoma, A., Lightfoot, A.P.: Nf-kb and inflammatory cytokine signalling: role in skeletal muscle atrophy. In: Advances in experimental medicine and biology (2018)</ref-fulltext>
<ce:source-text>Thoma, A., Lightfoot, A.P.: Nf-kb and inflammatory cytokine signalling: role in skeletal muscle atrophy. In: Advances in experimental medicine and biology (2018)</ce:source-text>
</reference>
<reference seq="53">
<ref-info>
<ref-title>
<ref-titletext-english>Pulsatile stimulation determines timing and specificity of NF-κB-dependent transcription</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Ashall</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.A.</ce:initials>
<ce:surname>Horton</ce:surname>
<ce:given-name>C.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.E.</ce:initials>
<ce:surname>Nelson</ce:surname>
<ce:given-name>D.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="2009" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1126/science.1164860</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Ashall, L., Horton, C.A., Nelson, D.E., et al.: Pulsatile stimulation determines timing and specificity of NF-κB-dependent transcription. Science. (2009). https://doi.org/10.1126/science.1164860</ref-fulltext>
<ce:source-text>Ashall, L., Horton, C.A., Nelson, D.E., et al.: Pulsatile stimulation determines timing and specificity of NF-κB-dependent transcription. Science. (2009). https://doi.org/10.1126/science.1164860</ce:source-text>
</reference>
<reference seq="54">
<ref-info>
<ref-title>
<ref-titletext-english>Dystrophin glycoprotein complex dysfunction: A regulatory link between muscular dystrophy and cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Acharyya</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.E.R.</ce:initials>
<ce:surname>Butchbach</ce:surname>
<ce:given-name>M.E.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Z.</ce:initials>
<ce:surname>Sahenk</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2005" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.ccr.2005.10.004</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Acharyya, S., Butchbach, M.E.R., Sahenk, Z., et al.: Dystrophin glycoprotein complex dysfunction: A regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell. (2005). https://doi.org/10.1016/j.ccr.2005.10.004</ref-fulltext>
<ce:source-text>Acharyya, S., Butchbach, M.E.R., Sahenk, Z., et al.: Dystrophin glycoprotein complex dysfunction: A regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell. (2005). https://doi.org/10.1016/j.ccr.2005.10.004</ce:source-text>
</reference>
<reference seq="55">
<ref-info>
<ref-title>
<ref-titletext-english>Expression of NF-κB and IκB proteins in skeletal muscle of gastric cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.G.</ce:initials>
<ce:surname>Rhoads</ce:surname>
<ce:given-name>M.G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.C.</ce:initials>
<ce:surname>Kandarian</ce:surname>
<ce:given-name>S.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:surname>Pacelli</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2010" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.ejca.2009.10.008</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Rhoads, M.G., Kandarian, S.C., Pacelli, F., et al.: Expression of NF-κB and IκB proteins in skeletal muscle of gastric cancer patients. Eur. J. Cancer. (2010). https://doi.org/10.1016/j.ejca.2009.10.008</ref-fulltext>
<ce:source-text>Rhoads, M.G., Kandarian, S.C., Pacelli, F., et al.: Expression of NF-κB and IκB proteins in skeletal muscle of gastric cancer patients. Eur. J. Cancer. (2010). https://doi.org/10.1016/j.ejca.2009.10.008</ce:source-text>
</reference>
<reference seq="56">
<ref-info>
<ref-title>
<ref-titletext-english>Intratumoral injection of oligonucleotides to the NFκB binding site inhibits cachexia in a mouse tumor model</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Kawamura</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Morishita</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Tomita</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Gene Ther</ref-sourcetitle>
<ref-publicationyear first="1999" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/sj.gt.3300819</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Kawamura, I., Morishita, R., Tomita, N., et al.: Intratumoral injection of oligonucleotides to the NFκB binding site inhibits cachexia in a mouse tumor model. Gene Ther. (1999). https://doi.org/10.1038/sj.gt.3300819</ref-fulltext>
<ce:source-text>Kawamura, I., Morishita, R., Tomita, N., et al.: Intratumoral injection of oligonucleotides to the NFκB binding site inhibits cachexia in a mouse tumor model. Gene Ther. (1999). https://doi.org/10.1038/sj.gt.3300819</ce:source-text>
</reference>
<reference seq="57">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer- and endotoxin-induced cachexia require intact glucocorticoid signaling in skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.P.</ce:initials>
<ce:surname>Braun</ce:surname>
<ce:given-name>T.P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.J.</ce:initials>
<ce:surname>Grossberg</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.M.</ce:initials>
<ce:surname>Krasnow</ce:surname>
<ce:given-name>S.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>FASEB J</ref-sourcetitle>
<ref-publicationyear first="2013" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1096/fj.13-230375</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Braun, T.P., Grossberg, A.J., Krasnow, S.M., et al.: Cancer- and endotoxin-induced cachexia require intact glucocorticoid signaling in skeletal muscle. FASEB J. (2013). https://doi.org/10.1096/fj.13-230375</ref-fulltext>
<ce:source-text>Braun, T.P., Grossberg, A.J., Krasnow, S.M., et al.: Cancer- and endotoxin-induced cachexia require intact glucocorticoid signaling in skeletal muscle. FASEB J. (2013). https://doi.org/10.1096/fj.13-230375</ce:source-text>
</reference>
<reference seq="58">
<ref-info>
<ref-title>
<ref-titletext-english>Neurobiology of inflammation-associated anorexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Gautron</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Neurosci</ref-sourcetitle>
<ref-publicationyear first="2009" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.3389/neuro.23.003.2009</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Gautron, L.: Neurobiology of inflammation-associated anorexia. Front. Neurosci. (2009). https://doi.org/10.3389/neuro.23.003.2009</ref-fulltext>
<ce:source-text>Gautron, L.: Neurobiology of inflammation-associated anorexia. Front. Neurosci. (2009). https://doi.org/10.3389/neuro.23.003.2009</ce:source-text>
</reference>
<reference seq="59">
<ref-info>
<ref-title>
<ref-titletext-english>The role of systemic inflammation in cancer-associated muscle wasting and rationale for exercise as a therapeutic intervention</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.L.</ce:initials>
<ce:surname>Cole</ce:surname>
<ce:given-name>C.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>I.R.</ce:initials>
<ce:surname>Kleckner</ce:surname>
<ce:given-name>I.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Jatoi</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>JCSM Clin. Reports</ref-sourcetitle>
<ref-publicationyear first="2018" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.17987/jcsm-cr.v3i2.65</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Cole, C.L., Kleckner, I.R., Jatoi, A., et al.: The role of systemic inflammation in cancer-associated muscle wasting and rationale for exercise as a therapeutic intervention. JCSM Clin. Reports. (2018). https://doi.org/10.17987/jcsm-cr.v3i2.65</ref-fulltext>
<ce:source-text>Cole, C.L., Kleckner, I.R., Jatoi, A., et al.: The role of systemic inflammation in cancer-associated muscle wasting and rationale for exercise as a therapeutic intervention. JCSM Clin. Reports. (2018). https://doi.org/10.17987/jcsm-cr.v3i2.65</ce:source-text>
</reference>
<reference seq="60">
<ref-info>
<ref-title>
<ref-titletext-english>Therapeutic effects of aerobic and resistance exercises for cancer survivors: A systematic review of meta-analyses of clinical trials</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.T.</ce:initials>
<ce:surname>Fuller</ce:surname>
<ce:given-name>J.T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.C.</ce:initials>
<ce:surname>Hartland</ce:surname>
<ce:given-name>M.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.T.</ce:initials>
<ce:surname>Maloney</ce:surname>
<ce:given-name>L.T.</ce:given-name>
</author>
<author seq="4">
<ce:initials>K.</ce:initials>
<ce:surname>Davison</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Sports Med</ref-sourcetitle>
<ref-publicationyear first="2018" />
</ref-info>
<ref-fulltext>Fuller, J.T., Hartland, M.C., Maloney, L.T., Davison, K.: Therapeutic effects of aerobic and resistance exercises for cancer survivors: A systematic review of meta-analyses of clinical trials. Br. J. Sports Med. (2018)</ref-fulltext>
<ce:source-text>Fuller, J.T., Hartland, M.C., Maloney, L.T., Davison, K.: Therapeutic effects of aerobic and resistance exercises for cancer survivors: A systematic review of meta-analyses of clinical trials. Br. J. Sports Med. (2018)</ce:source-text>
</reference>
<reference seq="61">
<ref-info>
<ref-title>
<ref-titletext-english>Progressive resistance training rebuilds lean body mass in head and neck cancer patients after radiotherapy – results from the randomized DAHANCA 25B trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Lønbro</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>U.</ce:initials>
<ce:surname>Dalgas</ce:surname>
<ce:given-name>U.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Primdahl</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Radiother. Oncol</ref-sourcetitle>
<ref-publicationyear first="2013" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.radonc.2013.07.002</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Lønbro, S., Dalgas, U., Primdahl, H., et al.: Progressive resistance training rebuilds lean body mass in head and neck cancer patients after radiotherapy – results from the randomized DAHANCA 25B trial. Radiother. Oncol. (2013). https://doi.org/10.1016/j.radonc.2013.07.002</ref-fulltext>
<ce:source-text>Lønbro, S., Dalgas, U., Primdahl, H., et al.: Progressive resistance training rebuilds lean body mass in head and neck cancer patients after radiotherapy – results from the randomized DAHANCA 25B trial. Radiother. Oncol. (2013). https://doi.org/10.1016/j.radonc.2013.07.002</ce:source-text>
</reference>
<reference seq="62">
<ref-info>
<ref-title>
<ref-titletext-english>Exercise interventions on health-related quality of life for cancer survivors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.I.</ce:initials>
<ce:surname>Mishra</ce:surname>
<ce:given-name>S.I.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.W.</ce:initials>
<ce:surname>Scherer</ce:surname>
<ce:given-name>R.W.</ce:given-name>
</author>
<author seq="3">
<ce:initials>P.M.</ce:initials>
<ce:surname>Geigle</ce:surname>
<ce:given-name>P.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cochrane Database Syst. Rev</ref-sourcetitle>
<ref-publicationyear first="2012" />
</ref-info>
<ref-fulltext>Mishra, S.I., Scherer, R.W., Geigle, P.M., et al.: Exercise interventions on health-related quality of life for cancer survivors. Cochrane Database Syst. Rev. (2012)</ref-fulltext>
<ce:source-text>Mishra, S.I., Scherer, R.W., Geigle, P.M., et al.: Exercise interventions on health-related quality of life for cancer survivors. Cochrane Database Syst. Rev. (2012)</ce:source-text>
</reference>
<reference seq="63">
<ref-info>
<ref-title>
<ref-titletext-english>The effect of exercise on quality of life, fatigue, physical function, and safety in advanced solid tumor cancers: A meta-analysis of randomized control trials</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.B.</ce:initials>
<ce:surname>Nadler</ce:surname>
<ce:given-name>M.B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Desnoyers</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.M.</ce:initials>
<ce:surname>Langelier</ce:surname>
<ce:given-name>D.M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>E.</ce:initials>
<ce:surname>Amir</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Pain Sympt. Manag</ref-sourcetitle>
<ref-publicationyear first="2019" />
</ref-info>
<ref-fulltext>Nadler, M.B., Desnoyers, A., Langelier, D.M., Amir, E.: The effect of exercise on quality of life, fatigue, physical function, and safety in advanced solid tumor cancers: A meta-analysis of randomized control trials. J. Pain Sympt. Manag. (2019)</ref-fulltext>
<ce:source-text>Nadler, M.B., Desnoyers, A., Langelier, D.M., Amir, E.: The effect of exercise on quality of life, fatigue, physical function, and safety in advanced solid tumor cancers: A meta-analysis of randomized control trials. J. Pain Sympt. Manag. (2019)</ce:source-text>
</reference>
<reference seq="64">
<ref-info>
<ref-title>
<ref-titletext-english>Physical exercise for cancer patients with advanced disease: A randomized controlled trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.M.</ce:initials>
<ce:surname>Oldervoll</ce:surname>
<ce:given-name>L.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.H.</ce:initials>
<ce:surname>Loge</ce:surname>
<ce:given-name>J.H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Lydersen</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncologist</ref-sourcetitle>
<ref-publicationyear first="2011" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1634/theoncologist.2011-0133</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Oldervoll, L.M., Loge, J.H., Lydersen, S., et al.: Physical exercise for cancer patients with advanced disease: A randomized controlled trial. Oncologist. (2011). https://doi.org/10.1634/theoncologist.2011-0133</ref-fulltext>
<ce:source-text>Oldervoll, L.M., Loge, J.H., Lydersen, S., et al.: Physical exercise for cancer patients with advanced disease: A randomized controlled trial. Oncologist. (2011). https://doi.org/10.1634/theoncologist.2011-0133</ce:source-text>
</reference>
<reference seq="65">
<ref-info>
<ref-title>
<ref-titletext-english>Aerobic exercise training as therapy for cardiac and cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.R.R.</ce:initials>
<ce:surname>Alves</ce:surname>
<ce:given-name>C.R.R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.F.</ce:initials>
<ce:surname>da Cunha</ce:surname>
<ce:given-name>T.F.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.A.</ce:initials>
<ce:surname>da Paixão</ce:surname>
<ce:given-name>N.A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>P.C.</ce:initials>
<ce:surname>Brum</ce:surname>
<ce:given-name>P.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Life Sci</ref-sourcetitle>
<ref-publicationyear first="2015" />
</ref-info>
<ref-fulltext>Alves, C.R.R., Da Cunha, T.F., Da Paixão, N.A., Brum, P.C.: Aerobic exercise training as therapy for cardiac and cancer cachexia. Life Sci. (2015)</ref-fulltext>
<ce:source-text>Alves, C.R.R., Da Cunha, T.F., Da Paixão, N.A., Brum, P.C.: Aerobic exercise training as therapy for cardiac and cancer cachexia. Life Sci. (2015)</ce:source-text>
</reference>
<reference seq="66">
<ref-info>
<ref-title>
<ref-titletext-english>Preventive effects of low-intensity exercise on cancer cachexia-induced muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Tanaka</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Sugimoto</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Fujimoto</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>FASEB J</ref-sourcetitle>
<ref-publicationyear first="2019" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1096/fj.201802430R</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Tanaka, M., Sugimoto, K., Fujimoto, T., et al.: Preventive effects of low-intensity exercise on cancer cachexia-induced muscle atrophy. FASEB J. (2019). https://doi.org/10.1096/fj.201802430R</ref-fulltext>
<ce:source-text>Tanaka, M., Sugimoto, K., Fujimoto, T., et al.: Preventive effects of low-intensity exercise on cancer cachexia-induced muscle atrophy. FASEB J. (2019). https://doi.org/10.1096/fj.201802430R</ce:source-text>
</reference>
<reference seq="67">
<ref-info>
<ref-title>
<ref-titletext-english>The anti-inflammatory effects of exercise: Mechanisms and implications for the prevention and treatment of disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Gleeson</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>N.C.</ce:initials>
<ce:surname>Bishop</ce:surname>
<ce:given-name>N.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.J.</ce:initials>
<ce:surname>Stensel</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Immunol</ref-sourcetitle>
<ref-publicationyear first="2011" />
</ref-info>
<ref-fulltext>Gleeson, M., Bishop, N.C., Stensel, D.J., et al.: The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat. Rev. Immunol. (2011)</ref-fulltext>
<ce:source-text>Gleeson, M., Bishop, N.C., Stensel, D.J., et al.: The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat. Rev. Immunol. (2011)</ce:source-text>
</reference>
<reference seq="68">
<ref-info>
<ref-title>
<ref-titletext-english>The effects of physical activity on serum C-reactive protein and inflammatory markers: A systematic review</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Kasapis</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.D.</ce:initials>
<ce:surname>Thompson</ce:surname>
<ce:given-name>P.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Am. Coll. Cardiol</ref-sourcetitle>
<ref-publicationyear first="2005" />
</ref-info>
<ref-fulltext>Kasapis, C., Thompson, P.D.: The effects of physical activity on serum C-reactive protein and inflammatory markers: A systematic review. J. Am. Coll. Cardiol. (2005)</ref-fulltext>
<ce:source-text>Kasapis, C., Thompson, P.D.: The effects of physical activity on serum C-reactive protein and inflammatory markers: A systematic review. J. Am. Coll. Cardiol. (2005)</ce:source-text>
</reference>
<reference seq="69">
<ref-info>
<ref-title>
<ref-titletext-english>The anti-inflammatory effect of exercise</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.M.W.</ce:initials>
<ce:surname>Petersen</ce:surname>
<ce:given-name>A.M.W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.K.</ce:initials>
<ce:surname>Pedersen</ce:surname>
<ce:given-name>B.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Appl. Physiol</ref-sourcetitle>
<ref-publicationyear first="2005" />
</ref-info>
<ref-fulltext>Petersen, A.M.W., Pedersen, B.K.: The anti-inflammatory effect of exercise. J. Appl. Physiol. (2005)</ref-fulltext>
<ce:source-text>Petersen, A.M.W., Pedersen, B.K.: The anti-inflammatory effect of exercise. J. Appl. Physiol. (2005)</ce:source-text>
</reference>
<reference seq="70">
<ref-info>
<ref-title>
<ref-titletext-english>The discovery of TGF-β: A historical perspective</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.L.</ce:initials>
<ce:surname>Moses</ce:surname>
<ce:given-name>H.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>The TGF-β Family</ref-sourcetitle>
<ref-publicationyear first="2008" />
</ref-info>
<ref-fulltext>Moses, H.L.: The discovery of TGF-β: A historical perspective. In: The TGF-β Family (2008)</ref-fulltext>
<ce:source-text>Moses, H.L.: The discovery of TGF-β: A historical perspective. In: The TGF-β Family (2008)</ce:source-text>
</reference>
<reference seq="71">
<ref-info>
<ref-title>
<ref-titletext-english>TGF-β signaling in cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.</ce:initials>
<ce:surname>Syed</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Biochem</ref-sourcetitle>
<ref-publicationyear first="2016" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/jcb.25496</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Syed, V.: TGF-β signaling in cancer. J. Cell. Biochem. (2016). https://doi.org/10.1002/jcb.25496</ref-fulltext>
<ce:source-text>Syed, V.: TGF-β signaling in cancer. J. Cell. Biochem. (2016). https://doi.org/10.1002/jcb.25496</ce:source-text>
</reference>
<reference seq="72">
<ref-info>
<ref-title>
<ref-titletext-english>Targeting the myostatin signaling pathway to treat muscle wasting diseases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.Q.</ce:initials>
<ce:surname>Han</ce:surname>
<ce:given-name>H.Q.</ce:given-name>
</author>
<author seq="2">
<ce:initials>W.E.</ce:initials>
<ce:surname>Mitch</ce:surname>
<ce:given-name>W.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Opin. Support. Palliative Care</ref-sourcetitle>
<ref-publicationyear first="2011" />
</ref-info>
<ref-fulltext>Han, H.Q., Mitch, W.E.: Targeting the myostatin signaling pathway to treat muscle wasting diseases. Curr. Opin. Support. Palliative Care. (2011)</ref-fulltext>
<ce:source-text>Han, H.Q., Mitch, W.E.: Targeting the myostatin signaling pathway to treat muscle wasting diseases. Curr. Opin. Support. Palliative Care. (2011)</ce:source-text>
</reference>
<reference seq="73">
<ref-info>
<ref-title>
<ref-titletext-english>Myostatin/activin pathway antagonism: Molecular basis and therapeutic potential</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.Q.</ce:initials>
<ce:surname>Han</ce:surname>
<ce:given-name>H.Q.</ce:given-name>
</author>
<author seq="2">
<ce:initials>X.</ce:initials>
<ce:surname>Zhou</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="3">
<ce:initials>W.E.</ce:initials>
<ce:surname>Mitch</ce:surname>
<ce:given-name>W.E.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.L.</ce:initials>
<ce:surname>Goldberg</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Biochem. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2013" />
</ref-info>
<ref-fulltext>Han, H.Q., Zhou, X., Mitch, W.E., Goldberg, A.L.: Myostatin/activin pathway antagonism: molecular basis and therapeutic potential. Int. J. Biochem. Cell Biol. (2013)</ref-fulltext>
<ce:source-text>Han, H.Q., Zhou, X., Mitch, W.E., Goldberg, A.L.: Myostatin/activin pathway antagonism: molecular basis and therapeutic potential. Int. J. Biochem. Cell Biol. (2013)</ce:source-text>
</reference>
<reference seq="74">
<ref-info>
<ref-title>
<ref-titletext-english>Target genes of myostatin loss-of-function in muscles of late bovine fetuses</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Cassar-Malek</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Passelaigue</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Bernard</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>BMC Genomics</ref-sourcetitle>
<ref-publicationyear first="2007" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1186/1471-2164-8-63</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Cassar-Malek, I., Passelaigue, F., Bernard, C., et al.: Target genes of myostatin loss-of-function in muscles of late bovine fetuses. BMC Genomics. (2007). https://doi.org/10.1186/1471-2164-8-63</ref-fulltext>
<ce:source-text>Cassar-Malek, I., Passelaigue, F., Bernard, C., et al.: Target genes of myostatin loss-of-function in muscles of late bovine fetuses. BMC Genomics. (2007). https://doi.org/10.1186/1471-2164-8-63</ce:source-text>
</reference>
<reference seq="75">
<ref-info>
<ref-title>
<ref-titletext-english>A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Clop</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Marcq</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Takeda</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Genet</ref-sourcetitle>
<ref-publicationyear first="2006" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/ng1810</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Clop, A., Marcq, F., Takeda, H., et al.: A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. Nat. Genet. (2006). https://doi.org/10.1038/ng1810</ref-fulltext>
<ce:source-text>Clop, A., Marcq, F., Takeda, H., et al.: A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. Nat. Genet. (2006). https://doi.org/10.1038/ng1810</ce:source-text>
</reference>
<reference seq="76">
<ref-info>
<ref-title>
<ref-titletext-english>Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.C.</ce:initials>
<ce:surname>McPherron</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.M.</ce:initials>
<ce:surname>Lawler</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.J.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>S.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="1997" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/387083a0</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>McPherron, A.C., Lawler, A.M., Lee, S.J.: Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member. Nature. (1997). https://doi.org/10.1038/387083a0</ref-fulltext>
<ce:source-text>McPherron, A.C., Lawler, A.M., Lee, S.J.: Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member. Nature. (1997). https://doi.org/10.1038/387083a0</ce:source-text>
</reference>
<reference seq="77">
<ref-info>
<ref-title>
<ref-titletext-english>A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.S.</ce:initials>
<ce:surname>Mosher</ce:surname>
<ce:given-name>D.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Quignon</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.D.</ce:initials>
<ce:surname>Bustamante</ce:surname>
<ce:given-name>C.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Plos Genet</ref-sourcetitle>
<ref-publicationyear first="2007" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1371/journal.pgen.0030079</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Mosher, D.S., Quignon, P., Bustamante, C.D., et al.: A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genet. (2007). https://doi.org/10.1371/journal.pgen.0030079</ref-fulltext>
<ce:source-text>Mosher, D.S., Quignon, P., Bustamante, C.D., et al.: A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genet. (2007). https://doi.org/10.1371/journal.pgen.0030079</ce:source-text>
</reference>
<reference seq="78">
<ref-info>
<ref-title>
<ref-titletext-english>Myostatin mutation associated with gross muscle hypertrophy in a child</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Schuelke</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.R.</ce:initials>
<ce:surname>Wagner</ce:surname>
<ce:given-name>K.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.E.</ce:initials>
<ce:surname>Stolz</ce:surname>
<ce:given-name>L.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>N. Engl. J. Med</ref-sourcetitle>
<ref-publicationyear first="2004" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1056/NEJMoa040933</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Schuelke, M., Wagner, K.R., Stolz, L.E., et al.: Myostatin mutation associated with gross muscle hypertrophy in a child. N. Engl. J. Med. (2004). https://doi.org/10.1056/NEJMoa040933</ref-fulltext>
<ce:source-text>Schuelke, M., Wagner, K.R., Stolz, L.E., et al.: Myostatin mutation associated with gross muscle hypertrophy in a child. N. Engl. J. Med. (2004). https://doi.org/10.1056/NEJMoa040933</ce:source-text>
</reference>
<reference seq="79">
<ref-info>
<ref-title>
<ref-titletext-english>Ectopic expression of myostatin induces atrophy of adult skeletal muscle by decreasing muscle gene expression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.C.</ce:initials>
<ce:surname>Durieux</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Amirouche</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Banzet</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Endocrinology</ref-sourcetitle>
<ref-publicationyear first="2007" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1210/en.2006-1500</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Durieux, A.C., Amirouche, A., Banzet, S., et al.: Ectopic expression of myostatin induces atrophy of adult skeletal muscle by decreasing muscle gene expression. Endocrinology. (2007). https://doi.org/10.1210/en.2006-1500</ref-fulltext>
<ce:source-text>Durieux, A.C., Amirouche, A., Banzet, S., et al.: Ectopic expression of myostatin induces atrophy of adult skeletal muscle by decreasing muscle gene expression. Endocrinology. (2007). https://doi.org/10.1210/en.2006-1500</ce:source-text>
</reference>
<reference seq="80">
<ref-info>
<ref-title>
<ref-titletext-english>Induction of cachexia in mice by systemically administered myostatin</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.A.</ce:initials>
<ce:surname>Zimmers</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.V.</ce:initials>
<ce:surname>Davies</ce:surname>
<ce:given-name>M.V.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.G.</ce:initials>
<ce:surname>Koniaris</ce:surname>
<ce:given-name>L.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="2002" />
<volisspag>
<volume-issue-number>
<vol-first>296</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1486</first-page>
<last-page>1488</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1126/science.1069525</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Zimmers, T.A., Davies, M.V., Koniaris, L.G., et al.: Induction of cachexia in mice by systemically administered myostatin. Science. 296, 1486–1488 (2002). https://doi.org/10.1126/science.1069525</ref-fulltext>
<ce:source-text>Zimmers, T.A., Davies, M.V., Koniaris, L.G., et al.: Induction of cachexia in mice by systemically administered myostatin. Science. 296, 1486–1488 (2002). https://doi.org/10.1126/science.1069525</ce:source-text>
</reference>
<reference seq="81">
<ref-info>
<ref-title>
<ref-titletext-english>Myostatin from the heart: Local and systemic actions in cardiac failure and muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Breitbart</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Auger-Messier</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.D.</ce:initials>
<ce:surname>Molkentin</ce:surname>
<ce:given-name>J.D.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Heineke</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Heart Circ. Physiol</ref-sourcetitle>
<ref-publicationyear first="2011" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpheart.00200.2011</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Breitbart, A., Auger-Messier, M., Molkentin, J.D., Heineke, J.: Myostatin from the heart: local and systemic actions in cardiac failure and muscle wasting. Am. J. Physiol. Heart Circ. Physiol. (2011). https://doi.org/10.1152/ajpheart.00200.2011</ref-fulltext>
<ce:source-text>Breitbart, A., Auger-Messier, M., Molkentin, J.D., Heineke, J.: Myostatin from the heart: local and systemic actions in cardiac failure and muscle wasting. Am. J. Physiol. Heart Circ. Physiol. (2011). https://doi.org/10.1152/ajpheart.00200.2011</ce:source-text>
</reference>
<reference seq="82">
<ref-info>
<ref-title>
<ref-titletext-english>Highly specific detection of myostatin prodomain by an immunoradiometric sandwich assay in serum of healthy individuals and patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Breitbart</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.M.</ce:initials>
<ce:surname>Scharf</ce:surname>
<ce:given-name>G.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Duncker</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2013" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1371/journal.pone.0080454</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Breitbart, A., Scharf, G.M., Duncker, D., et al.: Highly specific detection of myostatin prodomain by an immunoradiometric sandwich assay in serum of healthy individuals and patients. PLoS One. (2013). https://doi.org/10.1371/journal.pone.0080454</ref-fulltext>
<ce:source-text>Breitbart, A., Scharf, G.M., Duncker, D., et al.: Highly specific detection of myostatin prodomain by an immunoradiometric sandwich assay in serum of healthy individuals and patients. PLoS One. (2013). https://doi.org/10.1371/journal.pone.0080454</ce:source-text>
</reference>
<reference seq="83">
<ref-info>
<ref-title>
<ref-titletext-english>Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.F.</ce:initials>
<ce:surname>Gonzalez-Cadavid</ce:surname>
<ce:given-name>N.F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>W.E.</ce:initials>
<ce:surname>Taylor</ce:surname>
<ce:given-name>W.E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.</ce:initials>
<ce:surname>Yarasheski</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="1998" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1073/pnas.95.25.14938</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Gonzalez-Cadavid, N.F., Taylor, W.E., Yarasheski, K., et al.: Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proc. Natl. Acad. Sci. USA. (1998). https://doi.org/10.1073/pnas.95.25.14938</ref-fulltext>
<ce:source-text>Gonzalez-Cadavid, N.F., Taylor, W.E., Yarasheski, K., et al.: Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proc. Natl. Acad. Sci. USA. (1998). https://doi.org/10.1073/pnas.95.25.14938</ce:source-text>
</reference>
<reference seq="84">
<ref-info>
<ref-title>
<ref-titletext-english>Role of activin A and myostatin in human cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Loumaye</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>de Barsy</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Nachit</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Endocrinol. Metab</ref-sourcetitle>
<ref-publicationyear first="2015" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1210/jc.2014-4318</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Loumaye, A., De Barsy, M., Nachit, M., et al.: Role of activin A and myostatin in human cancer cachexia. J. Clin. Endocrinol. Metab. (2015). https://doi.org/10.1210/jc.2014-4318</ref-fulltext>
<ce:source-text>Loumaye, A., De Barsy, M., Nachit, M., et al.: Role of activin A and myostatin in human cancer cachexia. J. Clin. Endocrinol. Metab. (2015). https://doi.org/10.1210/jc.2014-4318</ce:source-text>
</reference>
<reference seq="85">
<ref-info>
<ref-title>
<ref-titletext-english>Serum myostatin-immunoreactive protein is increased in 60–92 year old women and men with muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.E.</ce:initials>
<ce:surname>Yarasheski</ce:surname>
<ce:given-name>K.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Bhasin</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>I.</ce:initials>
<ce:surname>Sinha-Hikim</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Nutr. Health Aging</ref-sourcetitle>
<ref-publicationyear first="2002" />
</ref-info>
<ref-fulltext>Yarasheski, K.E., Bhasin, S., Sinha-Hikim, I., et al.: Serum myostatin-immunoreactive protein is increased in 60–92 year old women and men with muscle wasting. J. Nutr. Health Aging. (2002)</ref-fulltext>
<ce:source-text>Yarasheski, K.E., Bhasin, S., Sinha-Hikim, I., et al.: Serum myostatin-immunoreactive protein is increased in 60–92 year old women and men with muscle wasting. J. Nutr. Health Aging. (2002)</ce:source-text>
</reference>
<reference seq="86">
<ref-info>
<ref-title>
<ref-titletext-english>The roles of activin A and its binding protein, follistatin, in inflammation and tissue repair</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.M.</ce:initials>
<ce:surname>de Kretser</ce:surname>
<ce:given-name>D.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.E.</ce:initials>
<ce:surname>O’Hehir</ce:surname>
<ce:given-name>R.E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.L.</ce:initials>
<ce:surname>Hardy</ce:surname>
<ce:given-name>C.L.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.P.</ce:initials>
<ce:surname>Hedger</ce:surname>
<ce:given-name>M.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cell. Endocrinol</ref-sourcetitle>
<ref-publicationyear first="2012" />
</ref-info>
<ref-fulltext>de Kretser, D.M., O’Hehir, R.E., Hardy, C.L., Hedger, M.P.: The roles of activin A and its binding protein, follistatin, in inflammation and tissue repair. Mol. Cell. Endocrinol. (2012)</ref-fulltext>
<ce:source-text>de Kretser, D.M., O’Hehir, R.E., Hardy, C.L., Hedger, M.P.: The roles of activin A and its binding protein, follistatin, in inflammation and tissue repair. Mol. Cell. Endocrinol. (2012)</ce:source-text>
</reference>
<reference seq="87">
<ref-info>
<ref-title>
<ref-titletext-english>The immunoregulatory and fibrotic roles of activin A in allergic asthma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.L.</ce:initials>
<ce:surname>Hardy</ce:surname>
<ce:given-name>C.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.M.</ce:initials>
<ce:surname>Rolland</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.E.</ce:initials>
<ce:surname>O’Hehir</ce:surname>
<ce:given-name>R.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Exp. Allergy</ref-sourcetitle>
<ref-publicationyear first="2015" />
</ref-info>
<ref-fulltext>Hardy, C.L., Rolland, J.M., O’Hehir, R.E.: The immunoregulatory and fibrotic roles of activin A in allergic asthma. Clin. Exp. Allergy. (2015)</ref-fulltext>
<ce:source-text>Hardy, C.L., Rolland, J.M., O’Hehir, R.E.: The immunoregulatory and fibrotic roles of activin A in allergic asthma. Clin. Exp. Allergy. (2015)</ce:source-text>
</reference>
<reference seq="88">
<ref-info>
<ref-title>
<ref-titletext-english>Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.L.</ce:initials>
<ce:surname>Jones</ce:surname>
<ce:given-name>K.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Mansell</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Patella</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2007" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1073/pnas.0705971104</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Jones, K.L., Mansell, A., Patella, S., et al.: Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia. Proc. Natl. Acad. Sci. USA. (2007). https://doi.org/10.1073/pnas.0705971104</ref-fulltext>
<ce:source-text>Jones, K.L., Mansell, A., Patella, S., et al.: Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia. Proc. Natl. Acad. Sci. USA. (2007). https://doi.org/10.1073/pnas.0705971104</ce:source-text>
</reference>
<reference seq="89">
<ref-info>
<ref-title>
<ref-titletext-english>Myostatin is a direct regulator of osteoclast differentiation and its inhibition reduces inflammatory joint destruction in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Dankbar</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Fennen</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Brunert</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Med</ref-sourcetitle>
<ref-publicationyear first="2015" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/nm.3917</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Dankbar, B., Fennen, M., Brunert, D., et al.: Myostatin is a direct regulator of osteoclast differentiation and its inhibition reduces inflammatory joint destruction in mice. Nat. Med. (2015). https://doi.org/10.1038/nm.3917</ref-fulltext>
<ce:source-text>Dankbar, B., Fennen, M., Brunert, D., et al.: Myostatin is a direct regulator of osteoclast differentiation and its inhibition reduces inflammatory joint destruction in mice. Nat. Med. (2015). https://doi.org/10.1038/nm.3917</ce:source-text>
</reference>
<reference seq="90">
<ref-info>
<ref-title>
<ref-titletext-english>Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>V.</ce:initials>
<ce:surname>Rajan</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
<author seq="3">
<ce:initials>E.</ce:initials>
<ce:surname>Lin</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>FASEB J</ref-sourcetitle>
<ref-publicationyear first="2011" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1096/fj.10-176917</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Zhang, L., Rajan, V., Lin, E., et al.: Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J. (2011). https://doi.org/10.1096/fj.10-176917</ref-fulltext>
<ce:source-text>Zhang, L., Rajan, V., Lin, E., et al.: Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J. (2011). https://doi.org/10.1096/fj.10-176917</ce:source-text>
</reference>
<reference seq="91">
<ref-info>
<ref-title>
<ref-titletext-english>Changes in myostatin signaling in non-weight-losing cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Aversa</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:surname>Penna</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Surg. Oncol</ref-sourcetitle>
<ref-publicationyear first="2012" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1245/s10434-011-1720-5</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Aversa, Z., Bonetto, A., Penna, F., et al.: Changes in myostatin signaling in non-weight-losing cancer patients. Ann. Surg. Oncol. (2012). https://doi.org/10.1245/s10434-011-1720-5</ref-fulltext>
<ce:source-text>Aversa, Z., Bonetto, A., Penna, F., et al.: Changes in myostatin signaling in non-weight-losing cancer patients. Ann. Surg. Oncol. (2012). https://doi.org/10.1245/s10434-011-1720-5</ce:source-text>
</reference>
<reference seq="92">
<ref-info>
<ref-title>
<ref-titletext-english>Serum immunoreactive activin A levels in normal subjects and patients with various diseases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Harada</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Shintani</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Sakamoto</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Endocrinol. Metab</ref-sourcetitle>
<ref-publicationyear first="1996" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1210/jc.81.6.2125</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Harada, K., Shintani, Y., Sakamoto, Y., et al.: Serum immunoreactive activin A levels in normal subjects and patients with various diseases. J. Clin. Endocrinol. Metab. (1996). https://doi.org/10.1210/jc.81.6.2125</ref-fulltext>
<ce:source-text>Harada, K., Shintani, Y., Sakamoto, Y., et al.: Serum immunoreactive activin A levels in normal subjects and patients with various diseases. J. Clin. Endocrinol. Metab. (1996). https://doi.org/10.1210/jc.81.6.2125</ce:source-text>
</reference>
<reference seq="93">
<ref-info>
<ref-title>
<ref-titletext-english>MMP-2, MMP-9 and activin a blood levels in patients with breast cancer or prostate cancer metastatic to the bone</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Incorvaia</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Badalamenti</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>G.</ce:initials>
<ce:surname>Rini</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Anticancer Res</ref-sourcetitle>
<ref-publicationyear first="2007" />
</ref-info>
<ref-fulltext>Incorvaia, L., Badalamenti, G., Rini, G., et al.: MMP-2, MMP-9 and activin a blood levels in patients with breast cancer or prostate cancer metastatic to the bone. Anticancer Res. (2007)</ref-fulltext>
<ce:source-text>Incorvaia, L., Badalamenti, G., Rini, G., et al.: MMP-2, MMP-9 and activin a blood levels in patients with breast cancer or prostate cancer metastatic to the bone. Anticancer Res. (2007)</ce:source-text>
</reference>
<reference seq="94">
<ref-info>
<ref-title>
<ref-titletext-english>Activin A circulating levels in patients with bone metastasis from breast or prostate cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Leto</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Incorvaia</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>G.</ce:initials>
<ce:surname>Badalamenti</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Exp. Metastasis</ref-sourcetitle>
<ref-publicationyear first="2006" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1007/s10585-006-9010-5</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Leto, G., Incorvaia, L., Badalamenti, G., et al.: Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin. Exp. Metastasis. (2006). https://doi.org/10.1007/s10585-006-9010-5</ref-fulltext>
<ce:source-text>Leto, G., Incorvaia, L., Badalamenti, G., et al.: Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin. Exp. Metastasis. (2006). https://doi.org/10.1007/s10585-006-9010-5</ce:source-text>
</reference>
<reference seq="95">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle myostatin signalling is enhanced in experimental cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Costelli</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Muscaritoli</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Clin. Investig</ref-sourcetitle>
<ref-publicationyear first="2008" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1111/j.1365-2362.2008.01970.x</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Costelli, P., Muscaritoli, M., Bonetto, A., et al.: Muscle myostatin signalling is enhanced in experimental cancer cachexia. Eur. J. Clin. Investig. (2008). https://doi.org/10.1111/j.1365-2362.2008.01970.x</ref-fulltext>
<ce:source-text>Costelli, P., Muscaritoli, M., Bonetto, A., et al.: Muscle myostatin signalling is enhanced in experimental cancer cachexia. Eur. J. Clin. Investig. (2008). https://doi.org/10.1111/j.1365-2362.2008.01970.x</ce:source-text>
</reference>
<reference seq="96">
<ref-info>
<ref-title>
<ref-titletext-english>Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.E.</ce:initials>
<ce:surname>Benny Klimek</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Aydogdu</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.J.</ce:initials>
<ce:surname>Link</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochem. Biophys. Res. Commun</ref-sourcetitle>
<ref-publicationyear first="2010" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.bbrc.2009.12.123</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Benny Klimek, M.E., Aydogdu, T., Link, M.J., et al.: Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem. Biophys. Res. Commun. (2010). https://doi.org/10.1016/j.bbrc.2009.12.123</ref-fulltext>
<ce:source-text>Benny Klimek, M.E., Aydogdu, T., Link, M.J., et al.: Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem. Biophys. Res. Commun. (2010). https://doi.org/10.1016/j.bbrc.2009.12.123</ce:source-text>
</reference>
<reference seq="97">
<ref-info>
<ref-title>
<ref-titletext-english>ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Barreto</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Kitase</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Matsumoto</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep</ref-sourcetitle>
<ref-publicationyear first="2017" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/s41598-017-15040-1</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Barreto, R., Kitase, Y., Matsumoto, T., et al.: ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass. Sci. Rep. (2017). https://doi.org/10.1038/s41598-017-15040-1</ref-fulltext>
<ce:source-text>Barreto, R., Kitase, Y., Matsumoto, T., et al.: ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass. Sci. Rep. (2017). https://doi.org/10.1038/s41598-017-15040-1</ce:source-text>
</reference>
<reference seq="98">
<ref-info>
<ref-title>
<ref-titletext-english>Treatment with soluble activin receptor type IIB alters metabolic response in chemotherapy-induced cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.M.</ce:initials>
<ce:surname>O’Connell</ce:surname>
<ce:given-name>T.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.E.</ce:initials>
<ce:surname>Couch</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancers</ref-sourcetitle>
<ref-publicationyear first="2019" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.3390/cancers11091222</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>O’Connell, T.M., Pin, F., Couch, M.E., Bonetto, A.: Treatment with soluble activin receptor type IIB alters metabolic response in chemotherapy-induced cachexia. Cancers. (2019). https://doi.org/10.3390/cancers11091222</ref-fulltext>
<ce:source-text>O’Connell, T.M., Pin, F., Couch, M.E., Bonetto, A.: Treatment with soluble activin receptor type IIB alters metabolic response in chemotherapy-induced cachexia. Cancers. (2019). https://doi.org/10.3390/cancers11091222</ce:source-text>
</reference>
<reference seq="99">
<ref-info>
<ref-title>
<ref-titletext-english>TGF-β blockade reduces mortality and metabolic changes in a validated murine model of pancreatic cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.H.</ce:initials>
<ce:surname>Greco</ce:surname>
<ce:given-name>S.H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Tomkötter</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.K.</ce:initials>
<ce:surname>Vahle</ce:surname>
<ce:given-name>A.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2015" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1371/journal.pone.0132786</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Greco, S.H., Tomkötter, L., Vahle, A.K., et al.: TGF-β blockade reduces mortality and metabolic changes in a validated murine model of pancreatic cancer cachexia. PLoS One. (2015). https://doi.org/10.1371/journal.pone.0132786</ref-fulltext>
<ce:source-text>Greco, S.H., Tomkötter, L., Vahle, A.K., et al.: TGF-β blockade reduces mortality and metabolic changes in a validated murine model of pancreatic cancer cachexia. PLoS One. (2015). https://doi.org/10.1371/journal.pone.0132786</ce:source-text>
</reference>
<reference seq="100">
<ref-info>
<ref-title>
<ref-titletext-english>Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.C.</ce:initials>
<ce:surname>Smith</ce:surname>
<ce:given-name>R.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.K.</ce:initials>
<ce:surname>Lin</ce:surname>
<ce:given-name>B.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Opin. Support. Palliative Care</ref-sourcetitle>
<ref-publicationyear first="2013" />
</ref-info>
<ref-fulltext>Smith, R.C., Lin, B.K.: Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr. Opin. Support. Palliative Care. (2013)</ref-fulltext>
<ce:source-text>Smith, R.C., Lin, B.K.: Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr. Opin. Support. Palliative Care. (2013)</ce:source-text>
</reference>
<reference seq="101">
<ref-info>
<ref-title>
<ref-titletext-english>Safety of the antimyostatin monoclonal antibody LY2495655 in healthy subjects and patients with advanced cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.S.</ce:initials>
<ce:surname>Jameson</ce:surname>
<ce:given-name>G.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.D.</ce:initials>
<ce:surname>von Hoff</ce:surname>
<ce:given-name>D.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>G.J.</ce:initials>
<ce:surname>Weiss</ce:surname>
<ce:given-name>G.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2012" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1200/jco.2012.30.15_suppl.2516</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Jameson, G.S., Von Hoff, D.D., Weiss, G.J., et al.: Safety of the antimyostatin monoclonal antibody LY2495655 in healthy subjects and patients with advanced cancer. J. Clin. Oncol. (2012). https://doi.org/10.1200/jco.2012.30.15_suppl.2516</ref-fulltext>
<ce:source-text>Jameson, G.S., Von Hoff, D.D., Weiss, G.J., et al.: Safety of the antimyostatin monoclonal antibody LY2495655 in healthy subjects and patients with advanced cancer. J. Clin. Oncol. (2012). https://doi.org/10.1200/jco.2012.30.15_suppl.2516</ce:source-text>
</reference>
<reference seq="102">
<ref-info>
<ref-title>
<ref-titletext-english>Molecular therapeutic strategies targeting pancreatic cancer induced cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Yakovenko</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Cameron</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.G.</ce:initials>
<ce:surname>Trevino</ce:surname>
<ce:given-name>J.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>World J. Gastroint. Surg</ref-sourcetitle>
<ref-publicationyear first="2018" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.4240/wjgs.v10.i9.95</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Yakovenko, A., Cameron, M., Trevino, J.G.: Molecular therapeutic strategies targeting pancreatic cancer induced cachexia. World J. Gastroint. Surg. (2018). https://doi.org/10.4240/wjgs.v10.i9.95</ref-fulltext>
<ce:source-text>Yakovenko, A., Cameron, M., Trevino, J.G.: Molecular therapeutic strategies targeting pancreatic cancer induced cachexia. World J. Gastroint. Surg. (2018). https://doi.org/10.4240/wjgs.v10.i9.95</ce:source-text>
</reference>
<reference seq="103">
<ref-info>
<ref-title>
<ref-titletext-english>Hormone therapy and maximal eccentric exercise alters myostatin-related gene expression in postmenopausal women</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.M.</ce:initials>
<ce:surname>Dieli-Conwright</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.M.</ce:initials>
<ce:surname>Spektor</ce:surname>
<ce:given-name>T.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.C.</ce:initials>
<ce:surname>Rice</ce:surname>
<ce:given-name>J.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Strength Cond. Res</ref-sourcetitle>
<ref-publicationyear first="2012" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1519/JSC.0b013e318251083f</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Dieli-Conwright, C.M., Spektor, T.M., Rice, J.C., et al.: Hormone therapy and maximal eccentric exercise alters myostatin-related gene expression in postmenopausal women. J. Strength Cond. Res. (2012). https://doi.org/10.1519/JSC.0b013e318251083f</ref-fulltext>
<ce:source-text>Dieli-Conwright, C.M., Spektor, T.M., Rice, J.C., et al.: Hormone therapy and maximal eccentric exercise alters myostatin-related gene expression in postmenopausal women. J. Strength Cond. Res. (2012). https://doi.org/10.1519/JSC.0b013e318251083f</ce:source-text>
</reference>
<reference seq="104">
<ref-info>
<ref-title>
<ref-titletext-english>Short-term endurance training results in a muscle-specific decrease of myostatin mRNA content in the rat</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Matsakas</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Friedel</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Hertrampf</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="4">
<ce:initials>P.</ce:initials>
<ce:surname>Diel</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Acta Physiol. Scand</ref-sourcetitle>
<ref-publicationyear first="2005" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1111/j.1365-201X.2005.01406.x</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Matsakas, A., Friedel, A., Hertrampf, T., Diel, P.: Short-term endurance training results in a muscle-specific decrease of myostatin mRNA content in the rat. Acta Physiol. Scand. (2005). https://doi.org/10.1111/j.1365-201X.2005.01406.x</ref-fulltext>
<ce:source-text>Matsakas, A., Friedel, A., Hertrampf, T., Diel, P.: Short-term endurance training results in a muscle-specific decrease of myostatin mRNA content in the rat. Acta Physiol. Scand. (2005). https://doi.org/10.1111/j.1365-201X.2005.01406.x</ce:source-text>
</reference>
<reference seq="105">
<ref-info>
<ref-title>
<ref-titletext-english>Exercise alters myostatin protein expression in sedentary and exercised streptozotocin-diabetic rats</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Bassi</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.D.G.</ce:initials>
<ce:surname>Bueno</ce:surname>
<ce:given-name>P.D.G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.O.</ce:initials>
<ce:surname>Nonaka</ce:surname>
<ce:given-name>K.O.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Arch. Endocrinol. Metab</ref-sourcetitle>
<ref-publicationyear first="2015" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1590/2359-3997000000028</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Bassi, D., Bueno, P.d.G., Nonaka, K.O., et al.: Exercise alters myostatin protein expression in sedentary and exercised streptozotocin-diabetic rats. Arch. Endocrinol. Metab. (2015). https://doi.org/10.1590/2359-3997000000028</ref-fulltext>
<ce:source-text>Bassi, D., Bueno, P.d.G., Nonaka, K.O., et al.: Exercise alters myostatin protein expression in sedentary and exercised streptozotocin-diabetic rats. Arch. Endocrinol. Metab. (2015). https://doi.org/10.1590/2359-3997000000028</ce:source-text>
</reference>
<reference seq="106">
<ref-info>
<ref-title>
<ref-titletext-english>Myostatin decreases with aerobic exercise and associates with insulin resistance</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.S.</ce:initials>
<ce:surname>Hittel</ce:surname>
<ce:given-name>D.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Axelson</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Sarna</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Med. Sci. Sports Exerc</ref-sourcetitle>
<ref-publicationyear first="2010" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1249/MSS.0b013e3181e0b9a8</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Hittel, D.S., Axelson, M., Sarna, N., et al.: Myostatin decreases with aerobic exercise and associates with insulin resistance. Med. Sci. Sports Exerc. (2010). https://doi.org/10.1249/MSS.0b013e3181e0b9a8</ref-fulltext>
<ce:source-text>Hittel, D.S., Axelson, M., Sarna, N., et al.: Myostatin decreases with aerobic exercise and associates with insulin resistance. Med. Sci. Sports Exerc. (2010). https://doi.org/10.1249/MSS.0b013e3181e0b9a8</ce:source-text>
</reference>
<reference seq="107">
<ref-info>
<ref-title>
<ref-titletext-english>Effect of exercise on mRNA levels for growth factors in skeletal muscle of hemodialysis patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.D.</ce:initials>
<ce:surname>Kopple</ce:surname>
<ce:given-name>J.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.H.</ce:initials>
<ce:surname>Cohen</ce:surname>
<ce:given-name>A.H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Ren. Nutr</ref-sourcetitle>
<ref-publicationyear first="2006" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1053/j.jrn.2006.04.028</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Kopple, J.D., Cohen, A.H., Wang, H., et al.: Effect of exercise on mRNA levels for growth factors in skeletal muscle of hemodialysis patients. J. Ren. Nutr. (2006). https://doi.org/10.1053/j.jrn.2006.04.028</ref-fulltext>
<ce:source-text>Kopple, J.D., Cohen, A.H., Wang, H., et al.: Effect of exercise on mRNA levels for growth factors in skeletal muscle of hemodialysis patients. J. Ren. Nutr. (2006). https://doi.org/10.1053/j.jrn.2006.04.028</ce:source-text>
</reference>
<reference seq="108">
<ref-info>
<ref-title>
<ref-titletext-english>Impact of exercise training on myostatin expression in the myocardium and skeletal muscle in a chronic heart failure model</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Lenk</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Schur</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Linke</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Heart Fail</ref-sourcetitle>
<ref-publicationyear first="2009" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1093/eurjhf/hfp020</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Lenk, K., Schur, R., Linke, A., et al.: Impact of exercise training on myostatin expression in the myocardium and skeletal muscle in a chronic heart failure model. Eur. J. Heart Fail. (2009). https://doi.org/10.1093/eurjhf/hfp020</ref-fulltext>
<ce:source-text>Lenk, K., Schur, R., Linke, A., et al.: Impact of exercise training on myostatin expression in the myocardium and skeletal muscle in a chronic heart failure model. Eur. J. Heart Fail. (2009). https://doi.org/10.1093/eurjhf/hfp020</ce:source-text>
</reference>
<reference seq="109">
<ref-info>
<ref-title>
<ref-titletext-english>Molecular adaptations to aerobic exercise training in skeletal muscle of older women</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.R.</ce:initials>
<ce:surname>Konopka</ce:surname>
<ce:given-name>A.R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.D.</ce:initials>
<ce:surname>Douglass</ce:surname>
<ce:given-name>M.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.A.</ce:initials>
<ce:surname>Kaminsky</ce:surname>
<ce:given-name>L.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Gerontol. Ser a Biol. Sci. Med. Sci</ref-sourcetitle>
<ref-publicationyear first="2010" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1093/gerona/glq109</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Konopka, A.R., Douglass, M.D., Kaminsky, L.A., et al.: Molecular adaptations to aerobic exercise training in skeletal muscle of older women. J. Gerontol. Ser A Biol. Sci. Med. Sci. (2010). https://doi.org/10.1093/gerona/glq109</ref-fulltext>
<ce:source-text>Konopka, A.R., Douglass, M.D., Kaminsky, L.A., et al.: Molecular adaptations to aerobic exercise training in skeletal muscle of older women. J. Gerontol. Ser A Biol. Sci. Med. Sci. (2010). https://doi.org/10.1093/gerona/glq109</ce:source-text>
</reference>
<reference seq="110">
<ref-info>
<ref-title>
<ref-titletext-english>Aerobic exercise + weight loss decreases skeletal muscle myostatin expression and improves insulin sensitivity in older adults</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.S.</ce:initials>
<ce:surname>Ryan</ce:surname>
<ce:given-name>A.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.B.</ce:initials>
<ce:surname>Blumenthal</ce:surname>
<ce:given-name>J.B.</ce:given-name>
</author>
<author seq="4">
<ce:initials>H.K.</ce:initials>
<ce:surname>Ortmeyer</ce:surname>
<ce:given-name>H.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Obesity</ref-sourcetitle>
<ref-publicationyear first="2013" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/oby.20216</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Ryan, A.S., Li, G., Blumenthal, J.B., Ortmeyer, H.K.: Aerobic exercise + weight loss decreases skeletal muscle myostatin expression and improves insulin sensitivity in older adults. Obesity. (2013). https://doi.org/10.1002/oby.20216</ref-fulltext>
<ce:source-text>Ryan, A.S., Li, G., Blumenthal, J.B., Ortmeyer, H.K.: Aerobic exercise + weight loss decreases skeletal muscle myostatin expression and improves insulin sensitivity in older adults. Obesity. (2013). https://doi.org/10.1002/oby.20216</ce:source-text>
</reference>
<reference seq="111">
<ref-info>
<ref-title>
<ref-titletext-english>The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.E.</ce:initials>
<ce:surname>Coutinho</ce:surname>
<ce:given-name>A.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.E.</ce:initials>
<ce:surname>Chapman</ce:surname>
<ce:given-name>K.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cell. Endocrinol</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>335</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2</first-page>
<last-page>13</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.mce.2010.04.005</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Coutinho, A.E., Chapman, K.E.: The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol. Cell. Endocrinol. 335, 2–13 (2011). https://doi.org/10.1016/j.mce.2010.04.005</ref-fulltext>
<ce:source-text>Coutinho, A.E., Chapman, K.E.: The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol. Cell. Endocrinol. 335, 2–13 (2011). https://doi.org/10.1016/j.mce.2010.04.005</ce:source-text>
</reference>
<reference seq="112">
<ref-info>
<ref-title>
<ref-titletext-english>Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Tanaka</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Eda</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Tanaka</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="1990" />
</ref-info>
<ref-fulltext>Tanaka, Y., Eda, H., Tanaka, T., et al.: Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. Cancer Res. (1990)</ref-fulltext>
<ce:source-text>Tanaka, Y., Eda, H., Tanaka, T., et al.: Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. Cancer Res. (1990)</ce:source-text>
</reference>
<reference seq="113">
<ref-info>
<ref-title>
<ref-titletext-english>Energy-ubiquitin-dependent muscle proteolysis during sepsis in rats is regulated by glucocorticoids</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Tiao</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Fagan</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>V.</ce:initials>
<ce:surname>Roegner</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Investig</ref-sourcetitle>
<ref-publicationyear first="1996" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1172/JCI118421</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Tiao, G., Fagan, J., Roegner, V., et al.: Energy-ubiquitin-dependent muscle proteolysis during sepsis in rats is regulated by glucocorticoids. J. Clin. Investig. (1996). https://doi.org/10.1172/JCI118421</ref-fulltext>
<ce:source-text>Tiao, G., Fagan, J., Roegner, V., et al.: Energy-ubiquitin-dependent muscle proteolysis during sepsis in rats is regulated by glucocorticoids. J. Clin. Investig. (1996). https://doi.org/10.1172/JCI118421</ce:source-text>
</reference>
<reference seq="114">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle atrophy in response to cytotoxic chemotherapy is dependent on intact glucocorticoid signaling in skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.P.</ce:initials>
<ce:surname>Braun</ce:surname>
<ce:given-name>T.P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Szumowski</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>P.R.</ce:initials>
<ce:surname>Levasseur</ce:surname>
<ce:given-name>P.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2014" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1371/journal.pone.0106489</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Braun, T.P., Szumowski, M., Levasseur, P.R., et al.: Muscle atrophy in response to cytotoxic chemotherapy is dependent on intact glucocorticoid signaling in skeletal muscle. PLoS One. (2014). https://doi.org/10.1371/journal.pone.0106489</ref-fulltext>
<ce:source-text>Braun, T.P., Szumowski, M., Levasseur, P.R., et al.: Muscle atrophy in response to cytotoxic chemotherapy is dependent on intact glucocorticoid signaling in skeletal muscle. PLoS One. (2014). https://doi.org/10.1371/journal.pone.0106489</ce:source-text>
</reference>
<reference seq="115">
<ref-info>
<ref-title>
<ref-titletext-english>Glucocorticoid-induced skeletal muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>O.</ce:initials>
<ce:surname>Schakman</ce:surname>
<ce:given-name>O.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Kalista</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Barbé</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Biochem. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2013" />
</ref-info>
<ref-fulltext>Schakman, O., Kalista, S., Barbé, C., et al.: Glucocorticoid-induced skeletal muscle atrophy. Int. J. Biochem. Cell Biol. (2013)</ref-fulltext>
<ce:source-text>Schakman, O., Kalista, S., Barbé, C., et al.: Glucocorticoid-induced skeletal muscle atrophy. Int. J. Biochem. Cell Biol. (2013)</ce:source-text>
</reference>
<reference seq="116">
<ref-info>
<ref-title>
<ref-titletext-english>Regulation of gluconeogenesis by glucocorticoids</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.H.</ce:initials>
<ce:surname>Exton</ce:surname>
<ce:given-name>J.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Monogr. Endocrinol</ref-sourcetitle>
<ref-publicationyear first="1979" />
</ref-info>
<ref-fulltext>Exton, J.H.: Regulation of gluconeogenesis by glucocorticoids. Monogr. Endocrinol. (1979)</ref-fulltext>
<ce:source-text>Exton, J.H.: Regulation of gluconeogenesis by glucocorticoids. Monogr. Endocrinol. (1979)</ce:source-text>
</reference>
<reference seq="117">
<ref-info>
<ref-title>
<ref-titletext-english>11β-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.A.</ce:initials>
<ce:surname>Morgan</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Sherlock</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.L.</ce:initials>
<ce:surname>Gathercole</ce:surname>
<ce:given-name>L.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Diabetes</ref-sourcetitle>
<ref-publicationyear first="2009" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.2337/db09-0525</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Morgan, S.A., Sherlock, M., Gathercole, L.L., et al.: 11β-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle. Diabetes. (2009). https://doi.org/10.2337/db09-0525</ref-fulltext>
<ce:source-text>Morgan, S.A., Sherlock, M., Gathercole, L.L., et al.: 11β-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle. Diabetes. (2009). https://doi.org/10.2337/db09-0525</ce:source-text>
</reference>
<reference seq="118">
<ref-info>
<ref-title>
<ref-titletext-english>Ubiquitin ligase Cbl-b is a negative regulator for insulin-like growth factor 1 signaling during muscle atrophy caused by unloading</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Nakao</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Hirasaka</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Goto</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cell. Biol</ref-sourcetitle>
<ref-publicationyear first="2009" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1128/mcb.01347-08</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Nakao, R., Hirasaka, K., Goto, J., et al.: Ubiquitin ligase Cbl-b is a negative regulator for insulin-like growth factor 1 signaling during muscle atrophy caused by unloading. Mol. Cell. Biol. (2009). https://doi.org/10.1128/mcb.01347-08</ref-fulltext>
<ce:source-text>Nakao, R., Hirasaka, K., Goto, J., et al.: Ubiquitin ligase Cbl-b is a negative regulator for insulin-like growth factor 1 signaling during muscle atrophy caused by unloading. Mol. Cell. Biol. (2009). https://doi.org/10.1128/mcb.01347-08</ce:source-text>
</reference>
<reference seq="119">
<ref-info>
<ref-title>
<ref-titletext-english>FOXO3a mediates signaling crosstalk that coordinates ubiquitin and atrogin-1/MAFbx expression during glucocorticoid-induced skeletal muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Zheng</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Ohkawa</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>FASEB J</ref-sourcetitle>
<ref-publicationyear first="2010" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1096/fj.09-151480</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Zheng, B., Ohkawa, S., Li, H., et al.: FOXO3a mediates signaling crosstalk that coordinates ubiquitin and atrogin-1/MAFbx expression during glucocorticoid-induced skeletal muscle atrophy. FASEB J. (2010). https://doi.org/10.1096/fj.09-151480</ref-fulltext>
<ce:source-text>Zheng, B., Ohkawa, S., Li, H., et al.: FOXO3a mediates signaling crosstalk that coordinates ubiquitin and atrogin-1/MAFbx expression during glucocorticoid-induced skeletal muscle atrophy. FASEB J. (2010). https://doi.org/10.1096/fj.09-151480</ce:source-text>
</reference>
<reference seq="120">
<ref-info>
<ref-title>
<ref-titletext-english>Specific increase in p85α expression in response to dexamethasone is associated with inhibition of insulin-like growth factor-I stimulated phosphatidylinositol 3-kinase activity in cultured muscle cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Giorgino</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.T.</ce:initials>
<ce:surname>Pedrini</ce:surname>
<ce:given-name>M.T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:surname>Matera</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="4">
<ce:initials>R.J.</ce:initials>
<ce:surname>Smithi</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="1997" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1074/jbc.272.11.7455</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Giorgino, F., Pedrini, M.T., Matera, L., Smithi, R.J.: Specific increase in p85α expression in response to dexamethasone is associated with inhibition of insulin-like growth factor-I stimulated phosphatidylinositol 3-kinase activity in cultured muscle cells. J. Biol. Chem. (1997). https://doi.org/10.1074/jbc.272.11.7455</ref-fulltext>
<ce:source-text>Giorgino, F., Pedrini, M.T., Matera, L., Smithi, R.J.: Specific increase in p85α expression in response to dexamethasone is associated with inhibition of insulin-like growth factor-I stimulated phosphatidylinositol 3-kinase activity in cultured muscle cells. J. Biol. Chem. (1997). https://doi.org/10.1074/jbc.272.11.7455</ce:source-text>
</reference>
<reference seq="121">
<ref-info>
<ref-title>
<ref-titletext-english>Endogenous glucocorticoids and impaired insulin signaling are both required to stimulate muscle wasting under pathophysiological conditions in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Hu</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.L.</ce:initials>
<ce:surname>In</ce:surname>
<ce:given-name>H.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Investig</ref-sourcetitle>
<ref-publicationyear first="2009" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1172/JCI38770</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Hu, Z., Wang, H., In, H.L., et al.: Endogenous glucocorticoids and impaired insulin signaling are both required to stimulate muscle wasting under pathophysiological conditions in mice. J. Clin. Investig. (2009). https://doi.org/10.1172/JCI38770</ref-fulltext>
<ce:source-text>Hu, Z., Wang, H., In, H.L., et al.: Endogenous glucocorticoids and impaired insulin signaling are both required to stimulate muscle wasting under pathophysiological conditions in mice. J. Clin. Investig. (2009). https://doi.org/10.1172/JCI38770</ce:source-text>
</reference>
<reference seq="122">
<ref-info>
<ref-title>
<ref-titletext-english>Genome-wide analysis of glucocorticoid receptor-binding sites in myotubes identifies gene networks modulating insulin signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Kuo</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.J.</ce:initials>
<ce:surname>Lew</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>O.</ce:initials>
<ce:surname>Mayba</ce:surname>
<ce:given-name>O.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2012" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1073/pnas.1111334109</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Kuo, T., Lew, M.J., Mayba, O., et al.: Genome-wide analysis of glucocorticoid receptor-binding sites in myotubes identifies gene networks modulating insulin signaling. Proc. Natl. Acad. Sci. USA. (2012). https://doi.org/10.1073/pnas.1111334109</ref-fulltext>
<ce:source-text>Kuo, T., Lew, M.J., Mayba, O., et al.: Genome-wide analysis of glucocorticoid receptor-binding sites in myotubes identifies gene networks modulating insulin signaling. Proc. Natl. Acad. Sci. USA. (2012). https://doi.org/10.1073/pnas.1111334109</ce:source-text>
</reference>
<reference seq="123">
<ref-info>
<ref-title>
<ref-titletext-english>Endogenous expression and localization of myostatin and its relation to myosin heavy chain distribution in C2C12 skeletal muscle cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.N.</ce:initials>
<ce:surname>Artaza</ce:surname>
<ce:given-name>J.N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Bhasin</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Mallidis</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Physiol</ref-sourcetitle>
<ref-publicationyear first="2002" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/jcp.10044</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Artaza, J.N., Bhasin, S., Mallidis, C., et al.: Endogenous expression and localization of myostatin and its relation to myosin heavy chain distribution in C2C12 skeletal muscle cells. J. Cell. Physiol. (2002). https://doi.org/10.1002/jcp.10044</ref-fulltext>
<ce:source-text>Artaza, J.N., Bhasin, S., Mallidis, C., et al.: Endogenous expression and localization of myostatin and its relation to myosin heavy chain distribution in C2C12 skeletal muscle cells. J. Cell. Physiol. (2002). https://doi.org/10.1002/jcp.10044</ce:source-text>
</reference>
<reference seq="124">
<ref-info>
<ref-title>
<ref-titletext-english>Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Ma</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Mallidis</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Bhasin</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Endocrinol. Metab</ref-sourcetitle>
<ref-publicationyear first="2003" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpendo.00487.2002</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Ma, K., Mallidis, C., Bhasin, S., et al.: Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. Am. J. Physiol. Endocrinol. Metab. (2003). https://doi.org/10.1152/ajpendo.00487.2002</ref-fulltext>
<ce:source-text>Ma, K., Mallidis, C., Bhasin, S., et al.: Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. Am. J. Physiol. Endocrinol. Metab. (2003). https://doi.org/10.1152/ajpendo.00487.2002</ce:source-text>
</reference>
<reference seq="125">
<ref-info>
<ref-title>
<ref-titletext-english>Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-κB-independent, FoxO1-dependent mechanism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>McFarlane</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Plummer</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Thomas</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Physiol</ref-sourcetitle>
<ref-publicationyear first="2006" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/jcp.20757</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>McFarlane, C., Plummer, E., Thomas, M., et al.: Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-κB-independent, FoxO1-dependent mechanism. J. Cell. Physiol. (2006). https://doi.org/10.1002/jcp.20757</ref-fulltext>
<ce:source-text>McFarlane, C., Plummer, E., Thomas, M., et al.: Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-κB-independent, FoxO1-dependent mechanism. J. Cell. Physiol. (2006). https://doi.org/10.1002/jcp.20757</ce:source-text>
</reference>
<reference seq="126">
<ref-info>
<ref-title>
<ref-titletext-english>The effect of graded doses of insulin on peripheral glucose uptake and lactate release in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Cersosimo</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.W.T.</ce:initials>
<ce:surname>Pisters</ce:surname>
<ce:given-name>P.W.T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>G.</ce:initials>
<ce:surname>Pesola</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Surgery</ref-sourcetitle>
<ref-publicationyear first="1991" />
</ref-info>
<ref-fulltext>Cersosimo, E., Pisters, P.W.T., Pesola, G., et al.: The effect of graded doses of insulin on peripheral glucose uptake and lactate release in cancer cachexia. Surgery. (1991)</ref-fulltext>
<ce:source-text>Cersosimo, E., Pisters, P.W.T., Pesola, G., et al.: The effect of graded doses of insulin on peripheral glucose uptake and lactate release in cancer cachexia. Surgery. (1991)</ce:source-text>
</reference>
<reference seq="127">
<ref-info>
<ref-title>
<ref-titletext-english>Protein, glucose and lipid metabolism in the cancer cachexia: A preliminary report [1]</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.R.</ce:initials>
<ce:surname>Dodesini</ce:surname>
<ce:given-name>A.R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Benedini</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>I.</ce:initials>
<ce:surname>Terruzzi</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Acta Oncol</ref-sourcetitle>
<ref-publicationyear first="2007" />
</ref-info>
<ref-fulltext>Dodesini, A.R., Benedini, S., Terruzzi, I., et al.: Protein, glucose and lipid metabolism in the cancer cachexia: A preliminary report [1]. Acta Oncol. (2007)</ref-fulltext>
<ce:source-text>Dodesini, A.R., Benedini, S., Terruzzi, I., et al.: Protein, glucose and lipid metabolism in the cancer cachexia: A preliminary report [1]. Acta Oncol. (2007)</ce:source-text>
</reference>
<reference seq="128">
<ref-info>
<ref-title>
<ref-titletext-english>Diabetes and altered carbohydrate metabolism in patients with cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.S.</ce:initials>
<ce:surname>Glicksman</ce:surname>
<ce:given-name>A.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.W.</ce:initials>
<ce:surname>Rawson</ce:surname>
<ce:given-name>R.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer</ref-sourcetitle>
<ref-publicationyear first="1956" />
<ref-text>10.1002/1097-0142(195611/12)9:6&lt;1127::AID-CNCR2820090610&gt;3.0.CO;2-4</ref-text>
</ref-info>
<ref-fulltext>Glicksman, A.S., Rawson, R.W.: Diabetes and altered carbohydrate metabolism in patients with cancer. Cancer. (1956) 10.1002/1097-0142(195611/12)9:6&lt;1127::AID-CNCR2820090610&gt;3.0.CO;2-4</ref-fulltext>
<ce:source-text>Glicksman, A.S., Rawson, R.W.: Diabetes and altered carbohydrate metabolism in patients with cancer. Cancer. (1956) 10.1002/1097-0142(195611/12)9:6&lt;1127::AID-CNCR2820090610&gt;3.0.CO;2-4</ce:source-text>
</reference>
<reference seq="129">
<ref-info>
<ref-title>
<ref-titletext-english>Sugar tolerance in cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.L.</ce:initials>
<ce:surname>Rohdenburg</ce:surname>
<ce:given-name>G.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Bernhard</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>O.</ce:initials>
<ce:surname>Krehbiel</ce:surname>
<ce:given-name>O.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Am. Med. Assoc</ref-sourcetitle>
<ref-publicationyear first="1919" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1001/jama.1919.02610210024007</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Rohdenburg, G.L., Bernhard, A., Krehbiel, O.: Sugar tolerance in cancer. J. Am. Med. Assoc. (1919). https://doi.org/10.1001/jama.1919.02610210024007</ref-fulltext>
<ce:source-text>Rohdenburg, G.L., Bernhard, A., Krehbiel, O.: Sugar tolerance in cancer. J. Am. Med. Assoc. (1919). https://doi.org/10.1001/jama.1919.02610210024007</ce:source-text>
</reference>
<reference seq="130">
<ref-info>
<ref-title>
<ref-titletext-english>A review of cancer cachexia and abnormal glucose metabolism in humans with cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Tayek</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Am. Coll. Nutr</ref-sourcetitle>
<ref-publicationyear first="1992" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1080/07315724.1992.10718249</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Tayek, J.A.: A review of cancer cachexia and abnormal glucose metabolism in humans with cancer. J. Am. Coll. Nutr. (1992). https://doi.org/10.1080/07315724.1992.10718249</ref-fulltext>
<ce:source-text>Tayek, J.A.: A review of cancer cachexia and abnormal glucose metabolism in humans with cancer. J. Am. Coll. Nutr. (1992). https://doi.org/10.1080/07315724.1992.10718249</ce:source-text>
</reference>
<reference seq="131">
<ref-info>
<ref-title>
<ref-titletext-english>Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.L.</ce:initials>
<ce:surname>Asp</ce:surname>
<ce:given-name>M.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Tian</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.A.</ce:initials>
<ce:surname>Wendel</ce:surname>
<ce:given-name>A.A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.A.</ce:initials>
<ce:surname>Belury</ce:surname>
<ce:given-name>M.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2010" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/ijc.24784</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Asp, M.L., Tian, M., Wendel, A.A., Belury, M.A.: Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice. Int. J. Cancer. (2010). https://doi.org/10.1002/ijc.24784</ref-fulltext>
<ce:source-text>Asp, M.L., Tian, M., Wendel, A.A., Belury, M.A.: Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice. Int. J. Cancer. (2010). https://doi.org/10.1002/ijc.24784</ce:source-text>
</reference>
<reference seq="132">
<ref-info>
<ref-title>
<ref-titletext-english>Cachexia: A problem of energetic inefficiency</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Argilés</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.C.</ce:initials>
<ce:surname>Fontes-Oliveira</ce:surname>
<ce:given-name>C.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Toledo</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2014" />
</ref-info>
<ref-fulltext>Argilés, J.M., Fontes-Oliveira, C.C., Toledo, M., et al.: Cachexia: A problem of energetic inefficiency. J. Cachexia Sarcopenia Muscle. (2014)</ref-fulltext>
<ce:source-text>Argilés, J.M., Fontes-Oliveira, C.C., Toledo, M., et al.: Cachexia: A problem of energetic inefficiency. J. Cachexia Sarcopenia Muscle. (2014)</ce:source-text>
</reference>
<reference seq="133">
<ref-info>
<ref-title>
<ref-titletext-english>Elevated energy expenditure in cancer patients with solid tumours</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Hyltander</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Drott</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>U.</ce:initials>
<ce:surname>Körner</ce:surname>
<ce:given-name>U.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Cancer Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="1991" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/0277-5379(91)90050-N</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Hyltander, A., Drott, C., Körner, U., et al.: Elevated energy expenditure in cancer patients with solid tumours. Eur. J. Cancer Clin. Oncol. (1991). https://doi.org/10.1016/0277-5379(91)90050-N</ref-fulltext>
<ce:source-text>Hyltander, A., Drott, C., Körner, U., et al.: Elevated energy expenditure in cancer patients with solid tumours. Eur. J. Cancer Clin. Oncol. (1991). https://doi.org/10.1016/0277-5379(91)90050-N</ce:source-text>
</reference>
<reference seq="134">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia, mechanism and treatment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Aoyagi</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.P.</ce:initials>
<ce:surname>Terracina</ce:surname>
<ce:given-name>K.P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Raza</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>World J. Gastrointest. Oncol</ref-sourcetitle>
<ref-publicationyear first="2015" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.4251/wjgo.v7.i4.17</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Aoyagi, T., Terracina, K.P., Raza, A., et al.: Cancer cachexia, mechanism and treatment. World J. Gastrointest. Oncol. (2015). https://doi.org/10.4251/wjgo.v7.i4.17</ref-fulltext>
<ce:source-text>Aoyagi, T., Terracina, K.P., Raza, A., et al.: Cancer cachexia, mechanism and treatment. World J. Gastrointest. Oncol. (2015). https://doi.org/10.4251/wjgo.v7.i4.17</ce:source-text>
</reference>
<reference seq="135">
<ref-info>
<ref-title>
<ref-titletext-english>Improved body weight and performance status and reduced serum PGE2 levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro-esophageal junction</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Faber</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.J.</ce:initials>
<ce:surname>Uitdehaag</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Spaander</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2015" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/jcsm.12009</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Faber, J., Uitdehaag, M.J., Spaander, M., et al.: Improved body weight and performance status and reduced serum PGE2 levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro-esophageal junction. J. Cachexia. Sarcopenia Muscle. (2015). https://doi.org/10.1002/jcsm.12009</ref-fulltext>
<ce:source-text>Faber, J., Uitdehaag, M.J., Spaander, M., et al.: Improved body weight and performance status and reduced serum PGE2 levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro-esophageal junction. J. Cachexia. Sarcopenia Muscle. (2015). https://doi.org/10.1002/jcsm.12009</ce:source-text>
</reference>
<reference seq="136">
<ref-info>
<ref-title>
<ref-titletext-english>Effects of megestrol acetate in patients with cancer anorexia-cachexia syndrome – a systematic review and meta-analysis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.</ce:initials>
<ce:surname>Leśniak</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Bała</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Jaeschke</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Krzakowski</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Polskie Archiwum Medycyny Wewnetrznej</ref-sourcetitle>
<ref-publicationyear first="2008" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.20452/pamw.510</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Leśniak, W., Bała, M., Jaeschke, R., Krzakowski, M.: Effects of megestrol acetate in patients with cancer anorexia-cachexia syndrome – a systematic review and meta-analysis. Polskie Archiwum Medycyny Wewnetrznej. (2008). https://doi.org/10.20452/pamw.510</ref-fulltext>
<ce:source-text>Leśniak, W., Bała, M., Jaeschke, R., Krzakowski, M.: Effects of megestrol acetate in patients with cancer anorexia-cachexia syndrome – a systematic review and meta-analysis. Polskie Archiwum Medycyny Wewnetrznej. (2008). https://doi.org/10.20452/pamw.510</ce:source-text>
</reference>
<reference seq="137">
<ref-info>
<ref-title>
<ref-titletext-english>Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.P.</ce:initials>
<ce:surname>López</ce:surname>
<ce:given-name>A.P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Roqué I Figuls</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>G.U.</ce:initials>
<ce:surname>Cuchi</ce:surname>
<ce:given-name>G.U.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Pain Sympt. Manag</ref-sourcetitle>
<ref-publicationyear first="2004" />
</ref-info>
<ref-fulltext>López AP, Roqué I Figuls M, Cuchi GU, et al (2004) Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J. Pain Sympt. Manag.</ref-fulltext>
<ce:source-text>López AP, Roqué I Figuls M, Cuchi GU, et al (2004) Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J. Pain Sympt. Manag.</ce:source-text>
</reference>
<reference seq="138">
<ref-info>
<ref-title>
<ref-titletext-english>Megestrol acetate for treatment of anorexia-cachexia syndrome</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.</ce:initials>
<ce:surname>Ruiz Garcia</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>López-Briz</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Carbonell Sanchis</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cochrane Database Syst. Rev</ref-sourcetitle>
<ref-publicationyear first="2013" />
</ref-info>
<ref-fulltext>Ruiz Garcia, V., López-Briz, E., Carbonell Sanchis, R., et al.: Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst. Rev. (2013)</ref-fulltext>
<ce:source-text>Ruiz Garcia, V., López-Briz, E., Carbonell Sanchis, R., et al.: Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst. Rev. (2013)</ce:source-text>
</reference>
<reference seq="139">
<ref-info>
<ref-title>
<ref-titletext-english>Systematic review of the treatment of cancer-associated anorexia and weight loss</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Tugba</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.P.</ce:initials>
<ce:surname>Davis</ce:surname>
<ce:given-name>M.P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>W.</ce:initials>
<ce:surname>Declan</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>23</vol-first>
<iss-first>33</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>8500</first-page>
<last-page>8511</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tugba, Y., Davis, M.P., Declan, W., et al.: Systematic review of the treatment of cancer-associated anorexia and weight loss. J. Clin. Oncol. 23(33), 8500–8511 (2005)</ref-fulltext>
<ce:source-text>Tugba, Y., Davis, M.P., Declan, W., et al.: Systematic review of the treatment of cancer-associated anorexia and weight loss. J. Clin. Oncol. 23(33), 8500–8511 (2005)</ce:source-text>
</reference>
<reference seq="140">
<ref-info>
<ref-title>
<ref-titletext-english>Progesterone therapy for the treatment of non-cancer cachexia: A systematic review</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.P.</ce:initials>
<ce:surname>Taylor</ce:surname>
<ce:given-name>M.P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:surname>Pendleton</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>BMJ Support. Palliative Care</ref-sourcetitle>
<ref-publicationyear first="2016" />
</ref-info>
<ref-fulltext>Taylor, J.K., Pendleton, N.: Progesterone therapy for the treatment of non-cancer cachexia: A systematic review. BMJ Support. Palliative Care. (2016)</ref-fulltext>
<ce:source-text>Taylor, J.K., Pendleton, N.: Progesterone therapy for the treatment of non-cancer cachexia: A systematic review. BMJ Support. Palliative Care. (2016)</ce:source-text>
</reference>
<reference seq="141">
<ref-info>
<ref-title>
<ref-titletext-english>Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.H.</ce:initials>
<ce:surname>Lecker</ce:surname>
<ce:given-name>S.H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.T.</ce:initials>
<ce:surname>Jagoe</ce:surname>
<ce:given-name>R.T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Gilbert</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>FASEB J</ref-sourcetitle>
<ref-publicationyear first="2004" />
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>39</first-page>
<last-page>51</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1096/fj.03-0610com</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Lecker, S.H., Jagoe, R.T., Gilbert, A., et al.: Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J. 18, 39–51 (2004). https://doi.org/10.1096/fj.03-0610com</ref-fulltext>
<ce:source-text>Lecker, S.H., Jagoe, R.T., Gilbert, A., et al.: Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J. 18, 39–51 (2004). https://doi.org/10.1096/fj.03-0610com</ce:source-text>
</reference>
<reference seq="142">
<ref-info>
<ref-title>
<ref-titletext-english>Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Sacheck</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.P.</ce:initials>
<ce:surname>Hyatt</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Raffaello</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>FASEB J</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>140</first-page>
<last-page>155</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1096/fj.06-6604com</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Sacheck, J.M., Hyatt, J.P., Raffaello, A., et al.: Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases. FASEB J. 21, 140–155 (2007). https://doi.org/10.1096/fj.06-6604com</ref-fulltext>
<ce:source-text>Sacheck, J.M., Hyatt, J.P., Raffaello, A., et al.: Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases. FASEB J. 21, 140–155 (2007). https://doi.org/10.1096/fj.06-6604com</ce:source-text>
</reference>
<reference seq="143">
<ref-info>
<ref-title>
<ref-titletext-english>FoxO3 controls autophagy in skeletal muscle in vivo</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Mammucari</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Milan</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>V.</ce:initials>
<ce:surname>Romanello</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>458</first-page>
<last-page>471</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mammucari, C., Milan, G., Romanello, V., et al.: FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab. 6, 458–471 (2007)</ref-fulltext>
<ce:source-text>Mammucari, C., Milan, G., Romanello, V., et al.: FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab. 6, 458–471 (2007)</ce:source-text>
</reference>
<reference seq="144">
<ref-info>
<ref-title>
<ref-titletext-english>Regulation and involvement of the ubiquitin ligases in muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Sandri</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Free Radic. Biol. Med</ref-sourcetitle>
<ref-publicationyear first="2014" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.freeradbiomed.2014.10.833</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Sandri, M.: Regulation and involvement of the ubiquitin ligases in muscle atrophy. Free Radic. Biol. Med. (2014). https://doi.org/10.1016/j.freeradbiomed.2014.10.833</ref-fulltext>
<ce:source-text>Sandri, M.: Regulation and involvement of the ubiquitin ligases in muscle atrophy. Free Radic. Biol. Med. (2014). https://doi.org/10.1016/j.freeradbiomed.2014.10.833</ce:source-text>
</reference>
<reference seq="145">
<ref-info>
<ref-title>
<ref-titletext-english>FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Zhao</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.J.</ce:initials>
<ce:surname>Brault</ce:surname>
<ce:given-name>J.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Schild</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2007" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.cmet.2007.11.004</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Zhao, J., Brault, J.J., Schild, A., et al.: FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab. (2007). https://doi.org/10.1016/j.cmet.2007.11.004</ref-fulltext>
<ce:source-text>Zhao, J., Brault, J.J., Schild, A., et al.: FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab. (2007). https://doi.org/10.1016/j.cmet.2007.11.004</ce:source-text>
</reference>
<reference seq="146">
<ref-info>
<ref-title>
<ref-titletext-english>Peroxisome proliferator-activated receptor gamma coactivator 1alpha or 1beta overexpression inhibits muscle protein degradation, induction of ubiquitin ligases, and disuse atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.J.</ce:initials>
<ce:surname>Brault</ce:surname>
<ce:given-name>J.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.G.</ce:initials>
<ce:surname>Jespersen</ce:surname>
<ce:given-name>J.G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.L.</ce:initials>
<ce:surname>Goldberg</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>285</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>19460</first-page>
<last-page>19471</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1074/jbc.M110.113092</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Brault, J.J., Jespersen, J.G., Goldberg, A.L.: Peroxisome proliferator-activated receptor gamma coactivator 1alpha or 1beta overexpression inhibits muscle protein degradation, induction of ubiquitin ligases, and disuse atrophy. J. Biol. Chem. 285, 19460–19471 (2010). https://doi.org/10.1074/jbc.M110.113092</ref-fulltext>
<ce:source-text>Brault, J.J., Jespersen, J.G., Goldberg, A.L.: Peroxisome proliferator-activated receptor gamma coactivator 1alpha or 1beta overexpression inhibits muscle protein degradation, induction of ubiquitin ligases, and disuse atrophy. J. Biol. Chem. 285, 19460–19471 (2010). https://doi.org/10.1074/jbc.M110.113092</ce:source-text>
</reference>
<reference seq="147">
<ref-info>
<ref-title>
<ref-titletext-english>PGC-1α protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Sandri</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Lin</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Handschin</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2006" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1073/pnas.0607795103</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Sandri, M., Lin, J., Handschin, C., et al.: PGC-1α protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc. Natl. Acad. Sci. USA. (2006). https://doi.org/10.1073/pnas.0607795103</ref-fulltext>
<ce:source-text>Sandri, M., Lin, J., Handschin, C., et al.: PGC-1α protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc. Natl. Acad. Sci. USA. (2006). https://doi.org/10.1073/pnas.0607795103</ce:source-text>
</reference>
<reference seq="148">
<ref-info>
<ref-title>
<ref-titletext-english>JunB transcription factor maintains skeletal muscle mass and promotes hypertrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Raffaello</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Milan</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>E.</ce:initials>
<ce:surname>Masiero</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>191</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>101</first-page>
<last-page>113</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1083/jcb.201001136</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Raffaello, A., Milan, G., Masiero, E., et al.: JunB transcription factor maintains skeletal muscle mass and promotes hypertrophy. J. Cell Biol. 191, 101–113 (2010). https://doi.org/10.1083/jcb.201001136</ref-fulltext>
<ce:source-text>Raffaello, A., Milan, G., Masiero, E., et al.: JunB transcription factor maintains skeletal muscle mass and promotes hypertrophy. J. Cell Biol. 191, 101–113 (2010). https://doi.org/10.1083/jcb.201001136</ce:source-text>
</reference>
<reference seq="149">
<ref-info>
<ref-title>
<ref-titletext-english>SIRT1 protein, by blocking the activities of transcription factors FoxO1 and FoxO3, inhibits muscle atrophy and promotes muscle growth</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.L.</ce:initials>
<ce:surname>Goldberg</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2013" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1074/jbc.M113.489716</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Lee, D., Goldberg, A.L.: SIRT1 protein, by blocking the activities of transcription factors FoxO1 and FoxO3, inhibits muscle atrophy and promotes muscle growth. J. Biol. Chem. (2013). https://doi.org/10.1074/jbc.M113.489716</ref-fulltext>
<ce:source-text>Lee, D., Goldberg, A.L.: SIRT1 protein, by blocking the activities of transcription factors FoxO1 and FoxO3, inhibits muscle atrophy and promotes muscle growth. J. Biol. Chem. (2013). https://doi.org/10.1074/jbc.M113.489716</ce:source-text>
</reference>
<reference seq="150">
<ref-info>
<ref-title>
<ref-titletext-english>PI3 kinase regulation of skeletal muscle hypertrophy and atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.J.</ce:initials>
<ce:surname>Glass</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Top. Microbiol. Immunol</ref-sourcetitle>
<ref-publicationyear first="2010" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1007/82-2010-78</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Glass, D.J.: PI3 kinase regulation of skeletal muscle hypertrophy and atrophy. Curr. Top. Microbiol. Immunol. (2010). https://doi.org/10.1007/82-2010-78</ref-fulltext>
<ce:source-text>Glass, D.J.: PI3 kinase regulation of skeletal muscle hypertrophy and atrophy. Curr. Top. Microbiol. Immunol. (2010). https://doi.org/10.1007/82-2010-78</ce:source-text>
</reference>
<reference seq="151">
<ref-info>
<ref-title>
<ref-titletext-english>Role and regulation of starvation-induced autophagy in the Drosophila fat body</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.C.</ce:initials>
<ce:surname>Scott</ce:surname>
<ce:given-name>R.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>O.</ce:initials>
<ce:surname>Schuldiner</ce:surname>
<ce:given-name>O.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.P.</ce:initials>
<ce:surname>Neufeld</ce:surname>
<ce:given-name>T.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Dev. Cell</ref-sourcetitle>
<ref-publicationyear first="2004" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.devcel.2004.07.009</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Scott, R.C., Schuldiner, O., Neufeld, T.P.: Role and regulation of starvation-induced autophagy in the Drosophila fat body. Dev. Cell. (2004). https://doi.org/10.1016/j.devcel.2004.07.009</ref-fulltext>
<ce:source-text>Scott, R.C., Schuldiner, O., Neufeld, T.P.: Role and regulation of starvation-induced autophagy in the Drosophila fat body. Dev. Cell. (2004). https://doi.org/10.1016/j.devcel.2004.07.009</ce:source-text>
</reference>
<reference seq="152">
<ref-info>
<ref-title>
<ref-titletext-english>Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Latres</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.R.</ce:initials>
<ce:surname>Amini</ce:surname>
<ce:given-name>A.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.A.</ce:initials>
<ce:surname>Amini</ce:surname>
<ce:given-name>A.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2005" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1074/jbc.M407517200</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Latres, E., Amini, A.R., Amini, A.A., et al.: Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J. Biol. Chem. (2005). https://doi.org/10.1074/jbc.M407517200</ref-fulltext>
<ce:source-text>Latres, E., Amini, A.R., Amini, A.A., et al.: Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J. Biol. Chem. (2005). https://doi.org/10.1074/jbc.M407517200</ce:source-text>
</reference>
<reference seq="153">
<ref-info>
<ref-title>
<ref-titletext-english>Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Shimizu</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:surname>Yoshikawa</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Ito</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2011" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.cmet.2011.01.001</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Shimizu, N., Yoshikawa, N., Ito, N., et al.: Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metab. (2011). https://doi.org/10.1016/j.cmet.2011.01.001</ref-fulltext>
<ce:source-text>Shimizu, N., Yoshikawa, N., Ito, N., et al.: Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metab. (2011). https://doi.org/10.1016/j.cmet.2011.01.001</ce:source-text>
</reference>
<reference seq="154">
<ref-info>
<ref-title>
<ref-titletext-english>Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Z.</ce:initials>
<ce:surname>Hu</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Hu</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Endocrinology</ref-sourcetitle>
<ref-publicationyear first="2006" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1210/en.2006-0251</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Wang, X., Hu, Z., Hu, J., et al.: Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology. (2006). https://doi.org/10.1210/en.2006-0251</ref-fulltext>
<ce:source-text>Wang, X., Hu, Z., Hu, J., et al.: Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology. (2006). https://doi.org/10.1210/en.2006-0251</ce:source-text>
</reference>
<reference seq="155">
<ref-info>
<ref-title>
<ref-titletext-english>Increased Smad signaling and reduced MRF expression in skeletal muscle from obese subjects</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Watts</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.J.</ce:initials>
<ce:surname>McAinch</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.B.</ce:initials>
<ce:surname>Dixon</ce:surname>
<ce:given-name>J.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Obesity</ref-sourcetitle>
<ref-publicationyear first="2013" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/oby.20070</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Watts, R., McAinch, A.J., Dixon, J.B., et al.: Increased Smad signaling and reduced MRF expression in skeletal muscle from obese subjects. Obesity. (2013). https://doi.org/10.1002/oby.20070</ref-fulltext>
<ce:source-text>Watts, R., McAinch, A.J., Dixon, J.B., et al.: Increased Smad signaling and reduced MRF expression in skeletal muscle from obese subjects. Obesity. (2013). https://doi.org/10.1002/oby.20070</ce:source-text>
</reference>
<reference seq="156">
<ref-info>
<ref-title>
<ref-titletext-english>Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Devivo</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.H.R.</ce:initials>
<ce:surname>Hoyle</ce:surname>
<ce:given-name>D.H.R.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.L.</ce:initials>
<ce:surname>Goldberg</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Endocrinol. Metab</ref-sourcetitle>
<ref-publicationyear first="1995" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpendo.1995.268.5.e996</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Baracos, V.E., DeVivo, C., Hoyle, D.H.R., Goldberg, A.L.: Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma. Am. J. Physiol. Endocrinol. Metab. (1995). https://doi.org/10.1152/ajpendo.1995.268.5.e996</ref-fulltext>
<ce:source-text>Baracos, V.E., DeVivo, C., Hoyle, D.H.R., Goldberg, A.L.: Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma. Am. J. Physiol. Endocrinol. Metab. (1995). https://doi.org/10.1152/ajpendo.1995.268.5.e996</ce:source-text>
</reference>
<reference seq="157">
<ref-info>
<ref-title>
<ref-titletext-english>Expression of the ubiquitin-proteasome pathway and muscle loss in experimental cancer cachexi</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Khal</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.M.</ce:initials>
<ce:surname>Wyke</ce:surname>
<ce:given-name>S.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.T.</ce:initials>
<ce:surname>Russell</ce:surname>
<ce:given-name>S.T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2005" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/sj.bjc.6602780</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Khal, J., Wyke, S.M., Russell, S.T., et al.: Expression of the ubiquitin-proteasome pathway and muscle loss in experimental cancer cachexia. Br. J. Cancer. (2005b). https://doi.org/10.1038/sj.bjc.6602780</ref-fulltext>
<ce:source-text>Khal, J., Wyke, S.M., Russell, S.T., et al.: Expression of the ubiquitin-proteasome pathway and muscle loss in experimental cancer cachexia. Br. J. Cancer. (2005b). https://doi.org/10.1038/sj.bjc.6602780</ce:source-text>
</reference>
<reference seq="158">
<ref-info>
<ref-title>
<ref-titletext-english>Autophagy exacerbates muscle wasting in cancer cachexia and impairs mitochondrial function</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Penna</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Ballarò</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Martinez-Cristobal</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Mol. Biol</ref-sourcetitle>
<ref-publicationyear first="2019" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.jmb.2019.05.032</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Penna, F., Ballarò, R., Martinez-Cristobal, P., et al.: Autophagy exacerbates muscle wasting in cancer cachexia and impairs mitochondrial function. J. Mol. Biol. (2019). https://doi.org/10.1016/j.jmb.2019.05.032</ref-fulltext>
<ce:source-text>Penna, F., Ballarò, R., Martinez-Cristobal, P., et al.: Autophagy exacerbates muscle wasting in cancer cachexia and impairs mitochondrial function. J. Mol. Biol. (2019). https://doi.org/10.1016/j.jmb.2019.05.032</ce:source-text>
</reference>
<reference seq="159">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: An in vitro and in vivo study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Yuan</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Han</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Q.</ce:initials>
<ce:surname>Meng</ce:surname>
<ce:given-name>Q.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncol. Rep</ref-sourcetitle>
<ref-publicationyear first="2015" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.3892/or.2015.3845</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Yuan, L., Han, J., Meng, Q., et al.: Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: An in vitro and in vivo study. Oncol. Rep. (2015). https://doi.org/10.3892/or.2015.3845</ref-fulltext>
<ce:source-text>Yuan, L., Han, J., Meng, Q., et al.: Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: An in vitro and in vivo study. Oncol. Rep. (2015). https://doi.org/10.3892/or.2015.3845</ce:source-text>
</reference>
<reference seq="160">
<ref-info>
<ref-title>
<ref-titletext-english>Identification of ubiquitin ligases required for skeletal Muscle Atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.C.</ce:initials>
<ce:surname>Bodine</ce:surname>
<ce:given-name>S.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Latres</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Baumhueter</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="2001" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1126/science.1065874</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Bodine, S.C., Latres, E., Baumhueter, S., et al.: Identification of ubiquitin ligases required for skeletal Muscle Atrophy. Science. (2001). https://doi.org/10.1126/science.1065874</ref-fulltext>
<ce:source-text>Bodine, S.C., Latres, E., Baumhueter, S., et al.: Identification of ubiquitin ligases required for skeletal Muscle Atrophy. Science. (2001). https://doi.org/10.1126/science.1065874</ce:source-text>
</reference>
<reference seq="161">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle wasting in disease: Molecular mechanisms and promising therapies</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Cohen</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.A.</ce:initials>
<ce:surname>Nathan</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.L.</ce:initials>
<ce:surname>Goldberg</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Drug Discov</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>58</first-page>
<last-page>74</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/nrd4467</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Cohen, S., Nathan, J.A., Goldberg, A.L.: Muscle wasting in disease: molecular mechanisms and promising therapies. Nat. Rev. Drug Discov. 14, 58–74 (2015). https://doi.org/10.1038/nrd4467</ref-fulltext>
<ce:source-text>Cohen, S., Nathan, J.A., Goldberg, A.L.: Muscle wasting in disease: molecular mechanisms and promising therapies. Nat. Rev. Drug Discov. 14, 58–74 (2015). https://doi.org/10.1038/nrd4467</ce:source-text>
</reference>
<reference seq="162">
<ref-info>
<ref-title>
<ref-titletext-english>Bortezomib induced reversible left ventricular systolic dysfunction: A case report and review of literature</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Chakraborty</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.K.R.</ce:initials>
<ce:surname>Mukkamalla</ce:surname>
<ce:given-name>S.K.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Calderon</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Med. Pract</ref-sourcetitle>
<ref-publicationyear first="2013" />
</ref-info>
<ref-fulltext>Chakraborty, R., Mukkamalla, S.K.R., Calderon, N.: Bortezomib induced reversible left ventricular systolic dysfunction: A case report and review of literature. Br. J. Med. Pract. (2013)</ref-fulltext>
<ce:source-text>Chakraborty, R., Mukkamalla, S.K.R., Calderon, N.: Bortezomib induced reversible left ventricular systolic dysfunction: A case report and review of literature. Br. J. Med. Pract. (2013)</ce:source-text>
</reference>
<reference seq="163">
<ref-info>
<ref-title>
<ref-titletext-english>Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.W.</ce:initials>
<ce:surname>Grandin</ce:surname>
<ce:given-name>E.W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Ky</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.F.</ce:initials>
<ce:surname>Cornell</ce:surname>
<ce:given-name>R.F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Card. Fail</ref-sourcetitle>
<ref-publicationyear first="2015" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.cardfail.2014.11.008</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Grandin, E.W., Ky, B., Cornell, R.F., et al.: Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma. J. Card. Fail. (2015). https://doi.org/10.1016/j.cardfail.2014.11.008</ref-fulltext>
<ce:source-text>Grandin, E.W., Ky, B., Cornell, R.F., et al.: Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma. J. Card. Fail. (2015). https://doi.org/10.1016/j.cardfail.2014.11.008</ce:source-text>
</reference>
<reference seq="164">
<ref-info>
<ref-title>
<ref-titletext-english>Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Hacihanefioglu</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Tarkun</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>E.</ce:initials>
<ce:surname>Gonullu</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Hematol</ref-sourcetitle>
<ref-publicationyear first="2008" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1007/s12185-008-0139-7</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Hacihanefioglu, A., Tarkun, P., Gonullu, E.: Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. Int. J. Hematol. (2008). https://doi.org/10.1007/s12185-008-0139-7</ref-fulltext>
<ce:source-text>Hacihanefioglu, A., Tarkun, P., Gonullu, E.: Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. Int. J. Hematol. (2008). https://doi.org/10.1007/s12185-008-0139-7</ce:source-text>
</reference>
<reference seq="165">
<ref-info>
<ref-title>
<ref-titletext-english>Primary proteasome inhibition results in cardiac dysfunction. Eur. J</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Herrmann</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Wohlert</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.M.</ce:initials>
<ce:surname>Saguner</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Heart Fail</ref-sourcetitle>
<ref-publicationyear first="2013" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1093/eurjhf/hft034</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Herrmann, J., Wohlert, C., Saguner, A.M., et al.: Primary proteasome inhibition results in cardiac dysfunction. Eur. J. Heart Fail. (2013). https://doi.org/10.1093/eurjhf/hft034</ref-fulltext>
<ce:source-text>Herrmann, J., Wohlert, C., Saguner, A.M., et al.: Primary proteasome inhibition results in cardiac dysfunction. Eur. J. Heart Fail. (2013). https://doi.org/10.1093/eurjhf/hft034</ce:source-text>
</reference>
<reference seq="166">
<ref-info>
<ref-title>
<ref-titletext-english>Left ventricular dysfunction development after bortezomib treatment in patients with oncologic diagnoses</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Jorge</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Patricia</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Asaf</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Circulation</ref-sourcetitle>
<ref-publicationyear first="2013" />
</ref-info>
<ref-fulltext>Jorge, R., Patricia, C., Asaf, R., et al.: Left ventricular dysfunction development after bortezomib treatment in patients with oncologic diagnoses. Circulation. (2013)</ref-fulltext>
<ce:source-text>Jorge, R., Patricia, C., Asaf, R., et al.: Left ventricular dysfunction development after bortezomib treatment in patients with oncologic diagnoses. Circulation. (2013)</ce:source-text>
</reference>
<reference seq="167">
<ref-info>
<ref-title>
<ref-titletext-english>Bortezomib-induced severe congestive heart failure</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Jerkins</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cardiol. Res</ref-sourcetitle>
<ref-publicationyear first="2010" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.4021/cr105e</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Jerkins, J.: Bortezomib-induced severe congestive heart failure. Cardiol. Res. (2010). https://doi.org/10.4021/cr105e</ref-fulltext>
<ce:source-text>Jerkins, J.: Bortezomib-induced severe congestive heart failure. Cardiol. Res. (2010). https://doi.org/10.4021/cr105e</ce:source-text>
</reference>
<reference seq="168">
<ref-info>
<ref-title>
<ref-titletext-english>Unexpected cardiotoxicity in haematological bortezomib treated patients [1]</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Orciuolo</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Gabriele</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Cecconi</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Haematol</ref-sourcetitle>
<ref-publicationyear first="2007" />
</ref-info>
<ref-fulltext>Orciuolo, E., Gabriele, B., Cecconi, N., et al.: Unexpected cardiotoxicity in haematological bortezomib treated patients [1]. Br. J. Haematol. (2007)</ref-fulltext>
<ce:source-text>Orciuolo, E., Gabriele, B., Cecconi, N., et al.: Unexpected cardiotoxicity in haematological bortezomib treated patients [1]. Br. J. Haematol. (2007)</ce:source-text>
</reference>
<reference seq="169">
<ref-info>
<ref-title>
<ref-titletext-english>The first autopsy case of fatal acute cardiac failure after administration of carfilzomib in a patient with multiple myeloma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Takakuwa</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>I.</ce:initials>
<ce:surname>Otomaru</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Araki</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Case Reports Hematol</ref-sourcetitle>
<ref-publicationyear first="2019" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1155/2019/1816287</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Takakuwa, T., Otomaru, I., Araki, T., et al.: The first autopsy case of fatal acute cardiac failure after administration of carfilzomib in a patient with multiple myeloma. Case Reports Hematol. (2019). https://doi.org/10.1155/2019/1816287</ref-fulltext>
<ce:source-text>Takakuwa, T., Otomaru, I., Araki, T., et al.: The first autopsy case of fatal acute cardiac failure after administration of carfilzomib in a patient with multiple myeloma. Case Reports Hematol. (2019). https://doi.org/10.1155/2019/1816287</ce:source-text>
</reference>
<reference seq="170">
<ref-info>
<ref-title>
<ref-titletext-english>Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: A case report</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Voortman</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Giaccone</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>BMC Cancer</ref-sourcetitle>
<ref-publicationyear first="2006" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1186/1471-2407-6-129</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Voortman, J., Giaccone, G.: Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: A case report. BMC Cancer. (2006). https://doi.org/10.1186/1471-2407-6-129</ref-fulltext>
<ce:source-text>Voortman, J., Giaccone, G.: Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: A case report. BMC Cancer. (2006). https://doi.org/10.1186/1471-2407-6-129</ce:source-text>
</reference>
<reference seq="171">
<ref-info>
<ref-title>
<ref-titletext-english>Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Penna</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Z.</ce:initials>
<ce:surname>Aversa</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2016" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/jcsm.12050</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Penna, F., Bonetto, A., Aversa, Z., et al.: Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting. J. Cachexia. Sarcopenia Muscle. (2016). https://doi.org/10.1002/jcsm.12050</ref-fulltext>
<ce:source-text>Penna, F., Bonetto, A., Aversa, Z., et al.: Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting. J. Cachexia. Sarcopenia Muscle. (2016). https://doi.org/10.1002/jcsm.12050</ce:source-text>
</reference>
<reference seq="172">
<ref-info>
<ref-title>
<ref-titletext-english>MG132-mediated inhibition of the ubiquitin-proteasome pathway ameliorates cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Tang</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Kou</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cancer Res. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2013" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1007/s00432-013-1412-6</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Zhang, L., Tang, H., Kou, Y., et al.: MG132-mediated inhibition of the ubiquitin-proteasome pathway ameliorates cancer cachexia. J. Cancer Res. Clin. Oncol. (2013b). https://doi.org/10.1007/s00432-013-1412-6</ref-fulltext>
<ce:source-text>Zhang, L., Tang, H., Kou, Y., et al.: MG132-mediated inhibition of the ubiquitin-proteasome pathway ameliorates cancer cachexia. J. Cancer Res. Clin. Oncol. (2013b). https://doi.org/10.1007/s00432-013-1412-6</ce:source-text>
</reference>
<reference seq="173">
<ref-info>
<ref-title>
<ref-titletext-english>Small-molecule inhibition of MuRF1 attenuates skeletal muscle atrophy and dysfunction in cardiac cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.S.</ce:initials>
<ce:surname>Bowen</ce:surname>
<ce:given-name>T.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>V.</ce:initials>
<ce:surname>Adams</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Werner</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2017" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/jcsm.12233</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Bowen, T.S., Adams, V., Werner, S., et al.: Small-molecule inhibition of MuRF1 attenuates skeletal muscle atrophy and dysfunction in cardiac cachexia. J. Cachexia. Sarcopenia Muscle. (2017). https://doi.org/10.1002/jcsm.12233</ref-fulltext>
<ce:source-text>Bowen, T.S., Adams, V., Werner, S., et al.: Small-molecule inhibition of MuRF1 attenuates skeletal muscle atrophy and dysfunction in cardiac cachexia. J. Cachexia. Sarcopenia Muscle. (2017). https://doi.org/10.1002/jcsm.12233</ce:source-text>
</reference>
<reference seq="174">
<ref-info>
<ref-title>
<ref-titletext-english>Inhibition of atrogin-1/MAFbx expression by adenovirus-delivered small hairpin RNAs attenuates muscle atrophy in fasting mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Cong</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Sun</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>P.</ce:initials>
<ce:surname>Tien</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Hum. Gene Ther</ref-sourcetitle>
<ref-publicationyear first="2011" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1089/hum.2010.057</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Cong, H., Sun, L., Liu, C., Tien, P.: Inhibition of atrogin-1/MAFbx expression by adenovirus-delivered small hairpin RNAs attenuates muscle atrophy in fasting mice. Hum. Gene Ther. (2011). https://doi.org/10.1089/hum.2010.057</ref-fulltext>
<ce:source-text>Cong, H., Sun, L., Liu, C., Tien, P.: Inhibition of atrogin-1/MAFbx expression by adenovirus-delivered small hairpin RNAs attenuates muscle atrophy in fasting mice. Hum. Gene Ther. (2011). https://doi.org/10.1089/hum.2010.057</ce:source-text>
</reference>
<reference seq="175">
<ref-info>
<ref-title>
<ref-titletext-english>Translational suppression of atrophic regulators by Micro RNA-23a integrates resistance to skeletal muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Wada</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Kato</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Okutsu</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2011" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1074/jbc.M111.271270</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Wada, S., Kato, Y., Okutsu, M., et al.: Translational suppression of atrophic regulators by Micro RNA-23a integrates resistance to skeletal muscle atrophy. J. Biol. Chem. (2011). https://doi.org/10.1074/jbc.M111.271270</ref-fulltext>
<ce:source-text>Wada, S., Kato, Y., Okutsu, M., et al.: Translational suppression of atrophic regulators by Micro RNA-23a integrates resistance to skeletal muscle atrophy. J. Biol. Chem. (2011). https://doi.org/10.1074/jbc.M111.271270</ce:source-text>
</reference>
<reference seq="176">
<ref-info>
<ref-title>
<ref-titletext-english>Proteasome proteolytic activity in skeletal muscle is increased in patients with sepsis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Klaude</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Fredriksson</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="3">
<ce:initials>I.</ce:initials>
<ce:surname>Tjäder</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Sci</ref-sourcetitle>
<ref-publicationyear first="2007" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1042/CS20060265</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Klaude, M., Fredriksson, K., Tjäder, I., et al.: Proteasome proteolytic activity in skeletal muscle is increased in patients with sepsis. Clin. Sci. (2007). https://doi.org/10.1042/CS20060265</ref-fulltext>
<ce:source-text>Klaude, M., Fredriksson, K., Tjäder, I., et al.: Proteasome proteolytic activity in skeletal muscle is increased in patients with sepsis. Clin. Sci. (2007). https://doi.org/10.1042/CS20060265</ce:source-text>
</reference>
<reference seq="177">
<ref-info>
<ref-title>
<ref-titletext-english>Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Tiao</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Hobler</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.J.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>J.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Investig</ref-sourcetitle>
<ref-publicationyear first="1997" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1172/JCI119143</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Tiao, G., Hobler, S., Wang, J.J., et al.: Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle. J. Clin. Investig. (1997). https://doi.org/10.1172/JCI119143</ref-fulltext>
<ce:source-text>Tiao, G., Hobler, S., Wang, J.J., et al.: Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle. J. Clin. Investig. (1997). https://doi.org/10.1172/JCI119143</ce:source-text>
</reference>
<reference seq="178">
<ref-info>
<ref-title>
<ref-titletext-english>Ubiquitin and proteasome gene expression is increased in skeletal muscle of slim AIDS patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Llovera</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Garcia-Martinez</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Agell</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Mol. Med</ref-sourcetitle>
<ref-publicationyear first="1998" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.3892/ijmm.2.1.69</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Llovera, M., Garcia-Martinez, C., Agell, N., et al.: Ubiquitin and proteasome gene expression is increased in skeletal muscle of slim AIDS patients. Int. J. Mol. Med. (1998). https://doi.org/10.3892/ijmm.2.1.69</ref-fulltext>
<ce:source-text>Llovera, M., Garcia-Martinez, C., Agell, N., et al.: Ubiquitin and proteasome gene expression is increased in skeletal muscle of slim AIDS patients. Int. J. Mol. Med. (1998). https://doi.org/10.3892/ijmm.2.1.69</ce:source-text>
</reference>
<reference seq="179">
<ref-info>
<ref-title>
<ref-titletext-english>Proteasome inhibition in skeletal muscle cells unmasks metabolic derangements in type 2 diabetes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Al-Khalili</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.T.</ce:initials>
<ce:surname>de Castro</ce:surname>
<ce:given-name>B.T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Östling</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Cell Physiol</ref-sourcetitle>
<ref-publicationyear first="2014" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpcell.00110.2014</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Al-Khalili, L., de Castro, B.T., Östling, J., et al.: Proteasome inhibition in skeletal muscle cells unmasks metabolic derangements in type 2 diabetes. Am. J. Physiol. Cell Physiol. (2014). https://doi.org/10.1152/ajpcell.00110.2014</ref-fulltext>
<ce:source-text>Al-Khalili, L., de Castro, B.T., Östling, J., et al.: Proteasome inhibition in skeletal muscle cells unmasks metabolic derangements in type 2 diabetes. Am. J. Physiol. Cell Physiol. (2014). https://doi.org/10.1152/ajpcell.00110.2014</ce:source-text>
</reference>
<reference seq="180">
<ref-info>
<ref-title>
<ref-titletext-english>Aging affects the transcriptional regulation of human skeletal muscle disuse atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Suetta</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>U.</ce:initials>
<ce:surname>Frandsen</ce:surname>
<ce:given-name>U.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:surname>Jensen</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2012" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1371/journal.pone.0051238</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Suetta, C., Frandsen, U., Jensen, L., et al.: Aging affects the transcriptional regulation of human skeletal muscle disuse atrophy. PLoS One. (2012). https://doi.org/10.1371/journal.pone.0051238</ref-fulltext>
<ce:source-text>Suetta, C., Frandsen, U., Jensen, L., et al.: Aging affects the transcriptional regulation of human skeletal muscle disuse atrophy. PLoS One. (2012). https://doi.org/10.1371/journal.pone.0051238</ce:source-text>
</reference>
<reference seq="181">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle atrophy due to nerve damage is accompanied by elevated myofibrillar protein synthesis rates</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.T.</ce:initials>
<ce:surname>Langer</ce:surname>
<ce:given-name>H.T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.M.G.</ce:initials>
<ce:surname>Senden</ce:surname>
<ce:given-name>J.M.G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.P.</ce:initials>
<ce:surname>Gijsen</ce:surname>
<ce:given-name>A.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Physiol</ref-sourcetitle>
<ref-publicationyear first="2018" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.3389/fphys.2018.01220</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Langer, H.T., Senden, J.M.G., Gijsen, A.P., et al.: Muscle atrophy due to nerve damage is accompanied by elevated myofibrillar protein synthesis rates. Front. Physiol. (2018). https://doi.org/10.3389/fphys.2018.01220</ref-fulltext>
<ce:source-text>Langer, H.T., Senden, J.M.G., Gijsen, A.P., et al.: Muscle atrophy due to nerve damage is accompanied by elevated myofibrillar protein synthesis rates. Front. Physiol. (2018). https://doi.org/10.3389/fphys.2018.01220</ce:source-text>
</reference>
<reference seq="182">
<ref-info>
<ref-title>
<ref-titletext-english>Increased muscle proteasome activity correlates with disease severity in gastric cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Bossola</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Muscaritoli</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Costelli</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Surg</ref-sourcetitle>
<ref-publicationyear first="2003" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1097/01.SLA.0000055225.96357.71</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Bossola, M., Muscaritoli, M., Costelli, P., et al.: Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann. Surg. (2003). https://doi.org/10.1097/01.SLA.0000055225.96357.71</ref-fulltext>
<ce:source-text>Bossola, M., Muscaritoli, M., Costelli, P., et al.: Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann. Surg. (2003). https://doi.org/10.1097/01.SLA.0000055225.96357.71</ce:source-text>
</reference>
<reference seq="183">
<ref-info>
<ref-title>
<ref-titletext-english>Increased muscle ubiquitin mrna levels in gastric cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Bossola</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Muscaritoli</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Costelli</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Regul. Integr. Comp. Physiol</ref-sourcetitle>
<ref-publicationyear first="2001" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpregu.2001.280.5.r1518</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Bossola, M., Muscaritoli, M., Costelli, P., et al.: Increased muscle ubiquitin mrna levels in gastric cancer patients. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2001). https://doi.org/10.1152/ajpregu.2001.280.5.r1518</ref-fulltext>
<ce:source-text>Bossola, M., Muscaritoli, M., Costelli, P., et al.: Increased muscle ubiquitin mrna levels in gastric cancer patients. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2001). https://doi.org/10.1152/ajpregu.2001.280.5.r1518</ce:source-text>
</reference>
<reference seq="184">
<ref-info>
<ref-title>
<ref-titletext-english>Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.H.C.</ce:initials>
<ce:surname>Dejong</ce:surname>
<ce:given-name>C.H.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Busquets</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.G.W.</ce:initials>
<ce:surname>Moses</ce:surname>
<ce:given-name>A.G.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncol. Rep</ref-sourcetitle>
<ref-publicationyear first="2005" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.3892/or.14.1.257</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Dejong, C.H.C., Busquets, S., Moses, A.G.W., et al.: Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia. Oncol. Rep. (2005). https://doi.org/10.3892/or.14.1.257</ref-fulltext>
<ce:source-text>Dejong, C.H.C., Busquets, S., Moses, A.G.W., et al.: Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia. Oncol. Rep. (2005). https://doi.org/10.3892/or.14.1.257</ce:source-text>
</reference>
<reference seq="185">
<ref-info>
<ref-title>
<ref-titletext-english>Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Khal</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.V.</ce:initials>
<ce:surname>Hine</ce:surname>
<ce:given-name>A.V.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.C.H.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.C.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Biochem. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2005" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.biocel.2004.10.017</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Khal, J., Hine, A.V., Fearon, K.C.H., et al.: Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. Int. J. Biochem. Cell Biol. (2005a). https://doi.org/10.1016/j.biocel.2004.10.017</ref-fulltext>
<ce:source-text>Khal, J., Hine, A.V., Fearon, K.C.H., et al.: Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. Int. J. Biochem. Cell Biol. (2005a). https://doi.org/10.1016/j.biocel.2004.10.017</ce:source-text>
</reference>
<reference seq="186">
<ref-info>
<ref-title>
<ref-titletext-english>Expression of TRAF6 and ubiquitin mRNA in skeletal muscle of gastric cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.S.</ce:initials>
<ce:surname>Sun</ce:surname>
<ce:given-name>Y.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Z.Y.</ce:initials>
<ce:surname>Ye</ce:surname>
<ce:given-name>Z.Y.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Z.Y.</ce:initials>
<ce:surname>Qian</ce:surname>
<ce:given-name>Z.Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Exp. Clin. Can</ref-sourcetitle>
<ref-publicationyear first="2012" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1186/1756-9966-31-81</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Sun, Y.S., Ye, Z.Y., Qian, Z.Y., et al.: Expression of TRAF6 and ubiquitin mRNA in skeletal muscle of gastric cancer patients. J. Exp. Clin. Cancer Res. (2012). https://doi.org/10.1186/1756-9966-31-81</ref-fulltext>
<ce:source-text>Sun, Y.S., Ye, Z.Y., Qian, Z.Y., et al.: Expression of TRAF6 and ubiquitin mRNA in skeletal muscle of gastric cancer patients. J. Exp. Clin. Cancer Res. (2012). https://doi.org/10.1186/1756-9966-31-81</ce:source-text>
</reference>
<reference seq="187">
<ref-info>
<ref-title>
<ref-titletext-english>The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Williams</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>X.</ce:initials>
<ce:surname>Sun</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.E.</ce:initials>
<ce:surname>Fischer</ce:surname>
<ce:given-name>J.E.</ce:given-name>
</author>
<author seq="4">
<ce:initials>P.O.</ce:initials>
<ce:surname>Hasselgren</ce:surname>
<ce:given-name>P.O.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Surgery</ref-sourcetitle>
<ref-publicationyear first="1999" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/S0039-6060(99)70131-5</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Williams, A., Sun, X., Fischer, J.E., Hasselgren, P.O.: The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery. (1999). https://doi.org/10.1016/S0039-6060(99)70131-5</ref-fulltext>
<ce:source-text>Williams, A., Sun, X., Fischer, J.E., Hasselgren, P.O.: The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery. (1999). https://doi.org/10.1016/S0039-6060(99)70131-5</ce:source-text>
</reference>
<reference seq="188">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle wasting in patients with end-stage renal disease or early-stage lung cancer: Common mechanisms at work</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Aniort</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Stella</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Philipponnet</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2019" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/jcsm.12376</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Aniort, J., Stella, A., Philipponnet, C., et al.: Muscle wasting in patients with end-stage renal disease or early-stage lung cancer: Common mechanisms at work. J. Cachexia. Sarcopenia Muscle. (2019). https://doi.org/10.1002/jcsm.12376</ref-fulltext>
<ce:source-text>Aniort, J., Stella, A., Philipponnet, C., et al.: Muscle wasting in patients with end-stage renal disease or early-stage lung cancer: Common mechanisms at work. J. Cachexia. Sarcopenia Muscle. (2019). https://doi.org/10.1002/jcsm.12376</ce:source-text>
</reference>
<reference seq="189">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle mRNA levels for cathepsin B, but not components of the ubiquitin-proteasome pathway, are increased in patients with lung cancer referred for thoracotomy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.T.</ce:initials>
<ce:surname>Jagoe</ce:surname>
<ce:given-name>R.T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.P.F.</ce:initials>
<ce:surname>Redfern</ce:surname>
<ce:given-name>C.P.F.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.G.</ce:initials>
<ce:surname>Roberts</ce:surname>
<ce:given-name>R.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Sci</ref-sourcetitle>
<ref-publicationyear first="2002" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1042/CS20010270</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Jagoe, R.T., Redfern, C.P.F., Roberts, R.G., et al.: Skeletal muscle mRNA levels for cathepsin B, but not components of the ubiquitin-proteasome pathway, are increased in patients with lung cancer referred for thoracotomy. Clin. Sci. (2002). https://doi.org/10.1042/CS20010270</ref-fulltext>
<ce:source-text>Jagoe, R.T., Redfern, C.P.F., Roberts, R.G., et al.: Skeletal muscle mRNA levels for cathepsin B, but not components of the ubiquitin-proteasome pathway, are increased in patients with lung cancer referred for thoracotomy. Clin. Sci. (2002). https://doi.org/10.1042/CS20010270</ce:source-text>
</reference>
<reference seq="190">
<ref-info>
<ref-title>
<ref-titletext-english>Pre-cachexia in patients with stages I-III non-small cell lung cancer: Systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.M.</ce:initials>
<ce:surname>Op Den Kamp</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.C.</ce:initials>
<ce:surname>Langen</ce:surname>
<ce:given-name>R.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Minnaard</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Lung Cancer</ref-sourcetitle>
<ref-publicationyear first="2012" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.lungcan.2011.09.012</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Op den Kamp, C.M., Langen, R.C., Minnaard, R., et al.: Pre-cachexia in patients with stages I-III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system. Lung Cancer. (2012). https://doi.org/10.1016/j.lungcan.2011.09.012</ref-fulltext>
<ce:source-text>Op den Kamp, C.M., Langen, R.C., Minnaard, R., et al.: Pre-cachexia in patients with stages I-III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system. Lung Cancer. (2012). https://doi.org/10.1016/j.lungcan.2011.09.012</ce:source-text>
</reference>
<reference seq="191">
<ref-info>
<ref-title>
<ref-titletext-english>Consequences of late-stage non-small-cell lung cancer cachexia on muscle metabolic processes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.J.</ce:initials>
<ce:surname>Murton</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Maddocks</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>F.B.</ce:initials>
<ce:surname>Stephens</ce:surname>
<ce:given-name>F.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Lung Cancer</ref-sourcetitle>
<ref-publicationyear first="2017" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.cllc.2016.06.003</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Murton, A.J., Maddocks, M., Stephens, F.B., et al.: Consequences of late-stage non-small-cell lung cancer cachexia on muscle metabolic processes. Clin. Lung Cancer. (2017). https://doi.org/10.1016/j.cllc.2016.06.003</ref-fulltext>
<ce:source-text>Murton, A.J., Maddocks, M., Stephens, F.B., et al.: Consequences of late-stage non-small-cell lung cancer cachexia on muscle metabolic processes. Clin. Lung Cancer. (2017). https://doi.org/10.1016/j.cllc.2016.06.003</ce:source-text>
</reference>
<reference seq="192">
<ref-info>
<ref-title>
<ref-titletext-english>Differential gene expression of muscle-specific ubiquitin ligase MAFbx/Atrogin-1 and MuRF1 in response to immobilization-induced atrophy of slow-twitch and fast-twitch muscles</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Okamoto</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Torii</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Machida</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Physiol. Sci</ref-sourcetitle>
<ref-publicationyear first="2011" />
</ref-info>
<ref-fulltext>Okamoto, T., Torii, S., Machida, S.: Differential gene expression of muscle-specific ubiquitin ligase MAFbx/Atrogin-1 and MuRF1 in response to immobilization-induced atrophy of slow-twitch and fast-twitch muscles. J. Physiol. Sci. (2011)</ref-fulltext>
<ce:source-text>Okamoto, T., Torii, S., Machida, S.: Differential gene expression of muscle-specific ubiquitin ligase MAFbx/Atrogin-1 and MuRF1 in response to immobilization-induced atrophy of slow-twitch and fast-twitch muscles. J. Physiol. Sci. (2011)</ce:source-text>
</reference>
<reference seq="193">
<ref-info>
<ref-title>
<ref-titletext-english>Breakdown of filamentous myofibrils by the UPS-step by step</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Aweida</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Cohen</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biomol. Ther</ref-sourcetitle>
<ref-publicationyear first="2021" />
<volisspag>
<page-information>
<pages>
<first-page>11</first-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.3390/biom11010110</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Aweida, D., Cohen, S.: Breakdown of filamentous myofibrils by the UPS-step by step. Biomol. Ther. 11 (2021). https://doi.org/10.3390/biom11010110</ref-fulltext>
<ce:source-text>Aweida, D., Cohen, S.: Breakdown of filamentous myofibrils by the UPS-step by step. Biomol. Ther. 11 (2021). https://doi.org/10.3390/biom11010110</ce:source-text>
</reference>
<reference seq="194">
<ref-info>
<ref-title>
<ref-titletext-english>GSK3-β promotes calpain-1-mediated desmin filament depolymerization and myofibril loss in atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Aweida</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>I.</ce:initials>
<ce:surname>Rudesky</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Volodin</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>217</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3698</first-page>
<last-page>3714</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1083/jcb.201802018</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Aweida, D., Rudesky, I., Volodin, A., et al.: GSK3-β promotes calpain-1-mediated desmin filament depolymerization and myofibril loss in atrophy. J. Cell Biol. 217, 3698–3714 (2018). https://doi.org/10.1083/jcb.201802018</ref-fulltext>
<ce:source-text>Aweida, D., Rudesky, I., Volodin, A., et al.: GSK3-β promotes calpain-1-mediated desmin filament depolymerization and myofibril loss in atrophy. J. Cell Biol. 217, 3698–3714 (2018). https://doi.org/10.1083/jcb.201802018</ce:source-text>
</reference>
<reference seq="195">
<ref-info>
<ref-title>
<ref-titletext-english>During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Cohen</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.J.</ce:initials>
<ce:surname>Brault</ce:surname>
<ce:given-name>J.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.P.</ce:initials>
<ce:surname>Gygi</ce:surname>
<ce:given-name>S.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2009" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1083/jcb.200901052</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Cohen, S., Brault, J.J., Gygi, S.P., et al.: During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J. Cell Biol. (2009). https://doi.org/10.1083/jcb.200901052</ref-fulltext>
<ce:source-text>Cohen, S., Brault, J.J., Gygi, S.P., et al.: During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J. Cell Biol. (2009). https://doi.org/10.1083/jcb.200901052</ce:source-text>
</reference>
<reference seq="196">
<ref-info>
<ref-title>
<ref-titletext-english>Ubiquitylation by Trim32 causes coupled loss of desmin, Z-bands, and thin filaments in muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Cohen</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Zhai</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.P.</ce:initials>
<ce:surname>Gygi</ce:surname>
<ce:given-name>S.P.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.L.</ce:initials>
<ce:surname>Goldberg</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>198</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>575</first-page>
<last-page>589</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1083/jcb.201110067</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Cohen, S., Zhai, B., Gygi, S.P., Goldberg, A.L.: Ubiquitylation by Trim32 causes coupled loss of desmin, Z-bands, and thin filaments in muscle atrophy. J. Cell Biol. 198, 575–589 (2012). https://doi.org/10.1083/jcb.201110067</ref-fulltext>
<ce:source-text>Cohen, S., Zhai, B., Gygi, S.P., Goldberg, A.L.: Ubiquitylation by Trim32 causes coupled loss of desmin, Z-bands, and thin filaments in muscle atrophy. J. Cell Biol. 198, 575–589 (2012). https://doi.org/10.1083/jcb.201110067</ce:source-text>
</reference>
<reference seq="197">
<ref-info>
<ref-title>
<ref-titletext-english>Myofibril breakdown during atrophy is a delayed response requiring the transcription factor PAX4 and desmin depolymerization</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Volodin</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>I.</ce:initials>
<ce:surname>Kosti</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.L.</ce:initials>
<ce:surname>Goldberg</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Cohen</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2017" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1073/pnas.1612988114</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Volodin, A., Kosti, I., Goldberg, A.L., Cohen, S.: Myofibril breakdown during atrophy is a delayed response requiring the transcription factor PAX4 and desmin depolymerization. Proc. Natl. Acad. Sci. USA. (2017). https://doi.org/10.1073/pnas.1612988114</ref-fulltext>
<ce:source-text>Volodin, A., Kosti, I., Goldberg, A.L., Cohen, S.: Myofibril breakdown during atrophy is a delayed response requiring the transcription factor PAX4 and desmin depolymerization. Proc. Natl. Acad. Sci. USA. (2017). https://doi.org/10.1073/pnas.1612988114</ce:source-text>
</reference>
<reference seq="198">
<ref-info>
<ref-title>
<ref-titletext-english>Autophagic degradation contributes to muscle wasting in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Penna</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Costamagna</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Pathol.</ref-sourcetitle>
<ref-publicationyear first="2013" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.ajpath.2012.12.023</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Penna, F., Costamagna, D., Pin, F., et al.: Autophagic degradation contributes to muscle wasting in cancer cachexia. Am. J. Pathol. (2013). https://doi.org/10.1016/j.ajpath.2012.12.023</ref-fulltext>
<ce:source-text>Penna, F., Costamagna, D., Pin, F., et al.: Autophagic degradation contributes to muscle wasting in cancer cachexia. Am. J. Pathol. (2013). https://doi.org/10.1016/j.ajpath.2012.12.023</ce:source-text>
</reference>
<reference seq="199">
<ref-info>
<ref-title>
<ref-titletext-english>Autophagy is induced in the skeletal muscle of cachectic cancer patients. Sci</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Aversa</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Lucia</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Rep</ref-sourcetitle>
<ref-publicationyear first="2016" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/srep30340</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Aversa, Z., Pin, F., Lucia, S., et al.: Autophagy is induced in the skeletal muscle of cachectic cancer patients. Sci. Rep. (2016). https://doi.org/10.1038/srep30340</ref-fulltext>
<ce:source-text>Aversa, Z., Pin, F., Lucia, S., et al.: Autophagy is induced in the skeletal muscle of cachectic cancer patients. Sci. Rep. (2016). https://doi.org/10.1038/srep30340</ce:source-text>
</reference>
<reference seq="200">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Pettersen</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Andersen</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Degen</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep</ref-sourcetitle>
<ref-publicationyear first="2017" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/s41598-017-02088-2</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Pettersen, K., Andersen, S., Degen, S., et al.: Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signaling. Sci. Rep. (2017). https://doi.org/10.1038/s41598-017-02088-2</ref-fulltext>
<ce:source-text>Pettersen, K., Andersen, S., Degen, S., et al.: Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signaling. Sci. Rep. (2017). https://doi.org/10.1038/s41598-017-02088-2</ce:source-text>
</reference>
<reference seq="201">
<ref-info>
<ref-title>
<ref-titletext-english>Striated muscle cytoarchitecture: An intricate web of form and function</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.A.</ce:initials>
<ce:surname>Clark</ce:surname>
<ce:given-name>K.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.S.</ce:initials>
<ce:surname>McElhinny</ce:surname>
<ce:given-name>A.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.C.</ce:initials>
<ce:surname>Beckerle</ce:surname>
<ce:given-name>M.C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>C.C.</ce:initials>
<ce:surname>Gregorio</ce:surname>
<ce:given-name>C.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Annu. Rev. Cell Dev. Biol</ref-sourcetitle>
<ref-publicationyear first="2002" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1146/annurev.cellbio.18.012502.105840</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Clark, K.A., McElhinny, A.S., Beckerle, M.C., Gregorio, C.C.: Striated muscle cytoarchitecture: An intricate web of form and function. Annu. Rev. Cell Dev. Biol. (2002). https://doi.org/10.1146/annurev.cellbio.18.012502.105840</ref-fulltext>
<ce:source-text>Clark, K.A., McElhinny, A.S., Beckerle, M.C., Gregorio, C.C.: Striated muscle cytoarchitecture: An intricate web of form and function. Annu. Rev. Cell Dev. Biol. (2002). https://doi.org/10.1146/annurev.cellbio.18.012502.105840</ce:source-text>
</reference>
<reference seq="202">
<ref-info>
<ref-title>
<ref-titletext-english>Depletion of zebrafish essential and regulatory myosin light chains reduces cardiac function through distinct mechanisms</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
<author seq="2">
<ce:initials>W.</ce:initials>
<ce:surname>Huang</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Dahme</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cardiovasc. Res</ref-sourcetitle>
<ref-publicationyear first="2008" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1093/cvr/cvn073</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Chen, Z., Huang, W., Dahme, T., et al.: Depletion of zebrafish essential and regulatory myosin light chains reduces cardiac function through distinct mechanisms. Cardiovasc. Res. (2008). https://doi.org/10.1093/cvr/cvn073</ref-fulltext>
<ce:source-text>Chen, Z., Huang, W., Dahme, T., et al.: Depletion of zebrafish essential and regulatory myosin light chains reduces cardiac function through distinct mechanisms. Cardiovasc. Res. (2008). https://doi.org/10.1093/cvr/cvn073</ce:source-text>
</reference>
<reference seq="203">
<ref-info>
<ref-title>
<ref-titletext-english>Cardiac myosin light chain-2: A novel essential component of thick-myofilament assembly and contractility of the heart</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.</ce:initials>
<ce:surname>Rottbauer</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Wessels</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Dahme</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Circ. Res</ref-sourcetitle>
<ref-publicationyear first="2006" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1161/01.RES.0000234807.16034.fe</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Rottbauer, W., Wessels, G., Dahme, T., et al.: Cardiac myosin light chain-2: A novel essential component of thick-myofilament assembly and contractility of the heart. Circ. Res. (2006). https://doi.org/10.1161/01.RES.0000234807.16034.fe</ref-fulltext>
<ce:source-text>Rottbauer, W., Wessels, G., Dahme, T., et al.: Cardiac myosin light chain-2: A novel essential component of thick-myofilament assembly and contractility of the heart. Circ. Res. (2006). https://doi.org/10.1161/01.RES.0000234807.16034.fe</ce:source-text>
</reference>
<reference seq="204">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle myosin light chains are essential for physiological speeds of shortening</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Lowey</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.S.</ce:initials>
<ce:surname>Waller</ce:surname>
<ce:given-name>G.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.M.</ce:initials>
<ce:surname>Trybus</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="1993" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/365454a0</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Lowey, S., Waller, G.S., Trybus, K.M.: Skeletal muscle myosin light chains are essential for physiological speeds of shortening. Nature. (1993). https://doi.org/10.1038/365454a0</ref-fulltext>
<ce:source-text>Lowey, S., Waller, G.S., Trybus, K.M.: Skeletal muscle myosin light chains are essential for physiological speeds of shortening. Nature. (1993). https://doi.org/10.1038/365454a0</ce:source-text>
</reference>
<reference seq="205">
<ref-info>
<ref-title>
<ref-titletext-english>Interaction of monomeric and polymeric actin with myosin subfragment 1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Offer</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Baker</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:surname>Baker</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Mol. Biol</ref-sourcetitle>
<ref-publicationyear first="1972" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/0022-2836(72)90425-1</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Offer, G., Baker, H., Baker, L.: Interaction of monomeric and polymeric actin with myosin subfragment 1. J. Mol. Biol. (1972). https://doi.org/10.1016/0022-2836(72)90425-1</ref-fulltext>
<ce:source-text>Offer, G., Baker, H., Baker, L.: Interaction of monomeric and polymeric actin with myosin subfragment 1. J. Mol. Biol. (1972). https://doi.org/10.1016/0022-2836(72)90425-1</ce:source-text>
</reference>
<reference seq="206">
<ref-info>
<ref-title>
<ref-titletext-english>A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Q.</ce:initials>
<ce:surname>Yang</ce:surname>
<ce:given-name>Q.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Sanbe</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Osinska</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Investig</ref-sourcetitle>
<ref-publicationyear first="1998" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1172/JCI3880</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Yang, Q., Sanbe, A., Osinska, H., et al.: A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy. J. Clin. Investig. (1998). https://doi.org/10.1172/JCI3880</ref-fulltext>
<ce:source-text>Yang, Q., Sanbe, A., Osinska, H., et al.: A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy. J. Clin. Investig. (1998). https://doi.org/10.1172/JCI3880</ce:source-text>
</reference>
<reference seq="207">
<ref-info>
<ref-title>
<ref-titletext-english>Desmin: A major intermediate filament protein essential for the structural integrity and function of muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Paulin</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Z.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Exp. Cell Res</ref-sourcetitle>
<ref-publicationyear first="2004" />
</ref-info>
<ref-fulltext>Paulin, D., Li, Z.: Desmin: A major intermediate filament protein essential for the structural integrity and function of muscle. Exp. Cell Res. (2004)</ref-fulltext>
<ce:source-text>Paulin, D., Li, Z.: Desmin: A major intermediate filament protein essential for the structural integrity and function of muscle. Exp. Cell Res. (2004)</ce:source-text>
</reference>
<reference seq="208">
<ref-info>
<ref-title>
<ref-titletext-english>The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.A.</ce:initials>
<ce:surname>Clarke</ce:surname>
<ce:given-name>B.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Drujan</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.S.</ce:initials>
<ce:surname>Willis</ce:surname>
<ce:given-name>M.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>376</first-page>
<last-page>385</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.cmet.2007.09.009</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Clarke, B.A., Drujan, D., Willis, M.S., et al.: The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab. 6, 376–385 (2007). https://doi.org/10.1016/j.cmet.2007.09.009</ref-fulltext>
<ce:source-text>Clarke, B.A., Drujan, D., Willis, M.S., et al.: The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab. 6, 376–385 (2007). https://doi.org/10.1016/j.cmet.2007.09.009</ce:source-text>
</reference>
<reference seq="209">
<ref-info>
<ref-title>
<ref-titletext-english>Novel TRIM32 mutation in sarcotubular myopathy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Panicucci</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Traverso</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Baratto</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Acta Myologica</ref-sourcetitle>
<ref-publicationyear first="2019" />
</ref-info>
<ref-fulltext>Panicucci, C., Traverso, M., Baratto, S., et al.: Novel TRIM32 mutation in sarcotubular myopathy. Acta Myologica. (2019)</ref-fulltext>
<ce:source-text>Panicucci, C., Traverso, M., Baratto, S., et al.: Novel TRIM32 mutation in sarcotubular myopathy. Acta Myologica. (2019)</ce:source-text>
</reference>
<reference seq="210">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle actin is polyubiquitinylated in vitro and in vivo and targeted for breakdown by the E3 ligase MuRF1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Cécile</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Anne-Elisabeth</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Marianne</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>FASEB J</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>25</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3790</first-page>
<last-page>3802</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1096/FJ.11-180968</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Cécile, P., Anne-Elisabeth, H., Marianne, J., et al.: Muscle actin is polyubiquitinylated in vitro and in vivo and targeted for breakdown by the E3 ligase MuRF1. FASEB J. 25, 3790–3802 (2011). https://doi.org/10.1096/FJ.11-180968</ref-fulltext>
<ce:source-text>Cécile, P., Anne-Elisabeth, H., Marianne, J., et al.: Muscle actin is polyubiquitinylated in vitro and in vivo and targeted for breakdown by the E3 ligase MuRF1. FASEB J. 25, 3790–3802 (2011). https://doi.org/10.1096/FJ.11-180968</ce:source-text>
</reference>
<reference seq="211">
<ref-info>
<ref-title>
<ref-titletext-english>UBE2L3, a partner of MuRF1/TRIM63, is involved in the degradation of myofibrillar actin and myosin</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.-M.</ce:initials>
<ce:surname>Dulce</ce:surname>
<ce:given-name>P.-M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Mélodie</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Agnès</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2021" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.3390/CELLS10081974</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Dulce, P.-M., Mélodie, M., Agnès, C., et al.: UBE2L3, a partner of MuRF1/TRIM63, is involved in the degradation of myofibrillar actin and myosin. Cell. 10 (2021). https://doi.org/10.3390/CELLS10081974</ref-fulltext>
<ce:source-text>Dulce, P.-M., Mélodie, M., Agnès, C., et al.: UBE2L3, a partner of MuRF1/TRIM63, is involved in the degradation of myofibrillar actin and myosin. Cell. 10 (2021). https://doi.org/10.3390/CELLS10081974</ce:source-text>
</reference>
<reference seq="212">
<ref-info>
<ref-title>
<ref-titletext-english>Autophagy induction in atrophic muscle cells requires ULK1 activation by TRIM32 through unanchored K63-linked polyubiquitin chains</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Di Rienzo</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Antonioli</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Fusco</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Adv</ref-sourcetitle>
<ref-publicationyear first="2019" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1126/sciadv.aau8857</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Di Rienzo, M., Antonioli, M., Fusco, C., et al.: Autophagy induction in atrophic muscle cells requires ULK1 activation by TRIM32 through unanchored K63-linked polyubiquitin chains. Sci. Adv. (2019a). https://doi.org/10.1126/sciadv.aau8857</ref-fulltext>
<ce:source-text>Di Rienzo, M., Antonioli, M., Fusco, C., et al.: Autophagy induction in atrophic muscle cells requires ULK1 activation by TRIM32 through unanchored K63-linked polyubiquitin chains. Sci. Adv. (2019a). https://doi.org/10.1126/sciadv.aau8857</ce:source-text>
</reference>
<reference seq="213">
<ref-info>
<ref-title>
<ref-titletext-english>A TRIM32-AMBRA1-ULK1 complex initiates the autophagy response in atrophic muscle cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Di Rienzo</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Piacentini</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>G.M.</ce:initials>
<ce:surname>Fimia</ce:surname>
<ce:given-name>G.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Autophagy</ref-sourcetitle>
<ref-publicationyear first="2019" />
</ref-info>
<ref-fulltext>Di Rienzo, M., Piacentini, M., Fimia, G.M.: A TRIM32-AMBRA1-ULK1 complex initiates the autophagy response in atrophic muscle cells. Autophagy. (2019b)</ref-fulltext>
<ce:source-text>Di Rienzo, M., Piacentini, M., Fimia, G.M.: A TRIM32-AMBRA1-ULK1 complex initiates the autophagy response in atrophic muscle cells. Autophagy. (2019b)</ce:source-text>
</reference>
<reference seq="214">
<ref-info>
<ref-title>
<ref-titletext-english>Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Sandri</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Sandri</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Gilbert</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2004" />
<volisspag>
<volume-issue-number>
<vol-first>117</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>399</first-page>
<last-page>412</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/S0092867404004003</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Sandri, M., Sandri, C., Gilbert, A., et al.: Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 117, 399–412 (2004) https://doi.org/S0092867404004003</ref-fulltext>
<ce:source-text>Sandri, M., Sandri, C., Gilbert, A., et al.: Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 117, 399–412 (2004) https://doi.org/S0092867404004003</ce:source-text>
</reference>
<reference seq="215">
<ref-info>
<ref-title>
<ref-titletext-english>The p97/VCP ATPase is critical in muscle atrophy and the accelerated degradation of muscle proteins</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Piccirillo</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.L.</ce:initials>
<ce:surname>Goldberg</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>EMBO J</ref-sourcetitle>
<ref-publicationyear first="2012" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/emboj.2012.178</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Piccirillo, R., Goldberg, A.L.: The p97/VCP ATPase is critical in muscle atrophy and the accelerated degradation of muscle proteins. EMBO J. (2012). https://doi.org/10.1038/emboj.2012.178</ref-fulltext>
<ce:source-text>Piccirillo, R., Goldberg, A.L.: The p97/VCP ATPase is critical in muscle atrophy and the accelerated degradation of muscle proteins. EMBO J. (2012). https://doi.org/10.1038/emboj.2012.178</ce:source-text>
</reference>
<reference seq="216">
<ref-info>
<ref-title>
<ref-titletext-english>Remodeling of the cytoskeletal lattice in denervated skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Boudriau</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.H.</ce:initials>
<ce:surname>Côté</ce:surname>
<ce:given-name>C.H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Vincent</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Muscle Nerve</ref-sourcetitle>
<ref-publicationyear first="1996" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/(SICI)1097-4598(199611)19:11&lt;1383::AID-MUS2&gt;3.0.CO;2-8</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Boudriau, S., Côté, C.H., Vincent, M., et al.: Remodeling of the cytoskeletal lattice in denervated skeletal muscle. Muscle Nerve. (1996). https://doi.org/10.1002/(SICI)1097-4598(199611)19:11&lt;1383::AID-MUS2&gt;3.0.CO;2-8</ref-fulltext>
<ce:source-text>Boudriau, S., Côté, C.H., Vincent, M., et al.: Remodeling of the cytoskeletal lattice in denervated skeletal muscle. Muscle Nerve. (1996). https://doi.org/10.1002/(SICI)1097-4598(199611)19:11&lt;1383::AID-MUS2&gt;3.0.CO;2-8</ce:source-text>
</reference>
<reference seq="217">
<ref-info>
<ref-title>
<ref-titletext-english>Role of calpains in promoting desmin filaments depolymerization and muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Cohen</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochim. Biophys. Acta Mol. Cell Res</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>1867</vol-first>
</volume-issue-number>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.bbamcr.2020.118788</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Cohen, S.: Role of calpains in promoting desmin filaments depolymerization and muscle atrophy. Biochim. Biophys. Acta Mol. Cell Res. 1867, 118788 (2020). https://doi.org/10.1016/j.bbamcr.2020.118788</ref-fulltext>
<ce:source-text>Cohen, S.: Role of calpains in promoting desmin filaments depolymerization and muscle atrophy. Biochim. Biophys. Acta Mol. Cell Res. 1867, 118788 (2020). https://doi.org/10.1016/j.bbamcr.2020.118788</ce:source-text>
</reference>
<reference seq="218">
<ref-info>
<ref-title>
<ref-titletext-english>The distribution of desmin (100 Å) filaments in primary cultures of embryonic chick cardiac cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Lazarides</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Exp. Cell Res</ref-sourcetitle>
<ref-publicationyear first="1978" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/0014-4827(78)90209-4</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Lazarides, E.: The distribution of desmin (100 Å) filaments in primary cultures of embryonic chick cardiac cells. Exp. Cell Res. (1978). https://doi.org/10.1016/0014-4827(78)90209-4</ref-fulltext>
<ce:source-text>Lazarides, E.: The distribution of desmin (100 Å) filaments in primary cultures of embryonic chick cardiac cells. Exp. Cell Res. (1978). https://doi.org/10.1016/0014-4827(78)90209-4</ce:source-text>
</reference>
<reference seq="219">
<ref-info>
<ref-title>
<ref-titletext-english>Immunological characterization of the subunit of the 100 Å filaments from muscle cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Lazarides</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.D.</ce:initials>
<ce:surname>Hubbard</ce:surname>
<ce:given-name>B.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="1976" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1073/pnas.73.12.4344</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Lazarides, E., Hubbard, B.D.: Immunological characterization of the subunit of the 100 Å filaments from muscle cells. Proc. Natl. Acad. Sci. USA. (1976). https://doi.org/10.1073/pnas.73.12.4344</ref-fulltext>
<ce:source-text>Lazarides, E., Hubbard, B.D.: Immunological characterization of the subunit of the 100 Å filaments from muscle cells. Proc. Natl. Acad. Sci. USA. (1976). https://doi.org/10.1073/pnas.73.12.4344</ce:source-text>
</reference>
<reference seq="220">
<ref-info>
<ref-title>
<ref-titletext-english>Disruption of muscle architecture and myocardial degeneration in mice lacking desmin</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.J.</ce:initials>
<ce:surname>Milner</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Weitzer</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Tran</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="1996" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1083/jcb.134.5.1255</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Milner, D.J., Weitzer, G., Tran, D., et al.: Disruption of muscle architecture and myocardial degeneration in mice lacking desmin. J. Cell Biol. (1996). https://doi.org/10.1083/jcb.134.5.1255</ref-fulltext>
<ce:source-text>Milner, D.J., Weitzer, G., Tran, D., et al.: Disruption of muscle architecture and myocardial degeneration in mice lacking desmin. J. Cell Biol. (1996). https://doi.org/10.1083/jcb.134.5.1255</ce:source-text>
</reference>
<reference seq="221">
<ref-info>
<ref-title>
<ref-titletext-english>A myopathy-linked desmin mutation perturbs striated muscle actin filament architecture</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.M.</ce:initials>
<ce:surname>Conover</ce:surname>
<ce:given-name>G.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.N.</ce:initials>
<ce:surname>Henderson</ce:surname>
<ce:given-name>S.N.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.C.</ce:initials>
<ce:surname>Gregorio</ce:surname>
<ce:given-name>C.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Biol. Cell</ref-sourcetitle>
<ref-publicationyear first="2009" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1091/mbc.E08-07-0753</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Conover, G.M., Henderson, S.N., Gregorio, C.C.: A myopathy-linked desmin mutation perturbs striated muscle actin filament architecture. Mol. Biol. Cell. (2009). https://doi.org/10.1091/mbc.E08-07-0753</ref-fulltext>
<ce:source-text>Conover, G.M., Henderson, S.N., Gregorio, C.C.: A myopathy-linked desmin mutation perturbs striated muscle actin filament architecture. Mol. Biol. Cell. (2009). https://doi.org/10.1091/mbc.E08-07-0753</ce:source-text>
</reference>
<reference seq="222">
<ref-info>
<ref-title>
<ref-titletext-english>Proteomic profiling of skeletal and cardiac muscle in cancer cachexia: Alterations in sarcomeric and mitochondrial protein expression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.M.Y.</ce:initials>
<ce:surname>Shum</ce:surname>
<ce:given-name>A.M.Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Poljak</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.L.</ce:initials>
<ce:surname>Bentley</ce:surname>
<ce:given-name>N.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2018" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.18632/oncotarget.25146</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Shum, A.M.Y., Poljak, A., Bentley, N.L., et al.: Proteomic profiling of skeletal and cardiac muscle in cancer cachexia: Alterations in sarcomeric and mitochondrial protein expression. Oncotarget. (2018) https://doi.org/10.18632/oncotarget.25146</ref-fulltext>
<ce:source-text>Shum, A.M.Y., Poljak, A., Bentley, N.L., et al.: Proteomic profiling of skeletal and cardiac muscle in cancer cachexia: Alterations in sarcomeric and mitochondrial protein expression. Oncotarget. (2018) https://doi.org/10.18632/oncotarget.25146</ce:source-text>
</reference>
<reference seq="223">
<ref-info>
<ref-title>
<ref-titletext-english>Lectin binding and desmin expression during necrosis, regeneration, and neurogenic atrophy of human skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.R.</ce:initials>
<ce:surname>Helliwell</ce:surname>
<ce:given-name>T.R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>O.</ce:initials>
<ce:surname>Gunhan</ce:surname>
<ce:given-name>O.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.H.T.</ce:initials>
<ce:surname>Edwards</ce:surname>
<ce:given-name>R.H.T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Pathol</ref-sourcetitle>
<ref-publicationyear first="1989" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/path.1711590111</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Helliwell, T.R., Gunhan, O., Edwards, R.H.T.: Lectin binding and desmin expression during necrosis, regeneration, and neurogenic atrophy of human skeletal muscle. J. Pathol. (1989). https://doi.org/10.1002/path.1711590111</ref-fulltext>
<ce:source-text>Helliwell, T.R., Gunhan, O., Edwards, R.H.T.: Lectin binding and desmin expression during necrosis, regeneration, and neurogenic atrophy of human skeletal muscle. J. Pathol. (1989). https://doi.org/10.1002/path.1711590111</ce:source-text>
</reference>
<reference seq="224">
<ref-info>
<ref-title>
<ref-titletext-english>New roles for desmin in maintenance of muscle homeostasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Agnetti</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Herrmann</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Cohen</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>FEBS J</ref-sourcetitle>
<ref-publicationyear first="2021" />
<volisspag>
<volume-issue-number>
<vol-first>15864</vol-first>
</volume-issue-number>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1111/febs.15864</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Agnetti, G., Herrmann, H., Cohen, S.: New roles for desmin in maintenance of muscle homeostasis. FEBS J. 15864 (2021). https://doi.org/10.1111/febs.15864</ref-fulltext>
<ce:source-text>Agnetti, G., Herrmann, H., Cohen, S.: New roles for desmin in maintenance of muscle homeostasis. FEBS J. 15864 (2021). https://doi.org/10.1111/febs.15864</ce:source-text>
</reference>
<reference seq="225">
<ref-info>
<ref-title>
<ref-titletext-english>GSK-3β inhibitors reduce protein degradation in muscles from septic rats and in dexamethasone-treated myotubes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.R.</ce:initials>
<ce:surname>Evenson</ce:surname>
<ce:given-name>A.R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.U.</ce:initials>
<ce:surname>Fareed</ce:surname>
<ce:given-name>M.U.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.J.</ce:initials>
<ce:surname>Menconi</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Biochem. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2005" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.biocel.2005.06.002</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Evenson, A.R., Fareed, M.U., Menconi, M.J., et al.: GSK-3β inhibitors reduce protein degradation in muscles from septic rats and in dexamethasone-treated myotubes. Int. J. Biochem. Cell Biol. (2005). https://doi.org/10.1016/j.biocel.2005.06.002</ref-fulltext>
<ce:source-text>Evenson, A.R., Fareed, M.U., Menconi, M.J., et al.: GSK-3β inhibitors reduce protein degradation in muscles from septic rats and in dexamethasone-treated myotubes. Int. J. Biochem. Cell Biol. (2005). https://doi.org/10.1016/j.biocel.2005.06.002</ce:source-text>
</reference>
<reference seq="226">
<ref-info>
<ref-title>
<ref-titletext-english>Glycogen synthase kinase-3β is required for the induction of skeletal muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.J.P.</ce:initials>
<ce:surname>Verhees</ce:surname>
<ce:given-name>K.J.P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.M.W.J.</ce:initials>
<ce:surname>Schols</ce:surname>
<ce:given-name>A.M.W.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.C.J.M.</ce:initials>
<ce:surname>Kelders</ce:surname>
<ce:given-name>M.C.J.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Cell Physiol</ref-sourcetitle>
<ref-publicationyear first="2011" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpcell.00520.2010</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Verhees, K.J.P., Schols, A.M.W.J., Kelders, M.C.J.M., et al.: Glycogen synthase kinase-3β is required for the induction of skeletal muscle atrophy. Am. J. Physiol. Cell Physiol. (2011). https://doi.org/10.1152/ajpcell.00520.2010</ref-fulltext>
<ce:source-text>Verhees, K.J.P., Schols, A.M.W.J., Kelders, M.C.J.M., et al.: Glycogen synthase kinase-3β is required for the induction of skeletal muscle atrophy. Am. J. Physiol. Cell Physiol. (2011). https://doi.org/10.1152/ajpcell.00520.2010</ce:source-text>
</reference>
<reference seq="227">
<ref-info>
<ref-title>
<ref-titletext-english>Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.A.E.</ce:initials>
<ce:surname>Cross</ce:surname>
<ce:given-name>D.A.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.R.</ce:initials>
<ce:surname>Alessi</ce:surname>
<ce:given-name>D.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Cohen</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="1995" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/378785a0</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Cross, D.A.E., Alessi, D.R., Cohen, P., et al.: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. (1995). https://doi.org/10.1038/378785a0</ref-fulltext>
<ce:source-text>Cross, D.A.E., Alessi, D.R., Cohen, P., et al.: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. (1995). https://doi.org/10.1038/378785a0</ce:source-text>
</reference>
<reference seq="228">
<ref-info>
<ref-title>
<ref-titletext-english>Measuring GSK3 expression and activity in cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.R.</ce:initials>
<ce:surname>Cole</ce:surname>
<ce:given-name>A.R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Sutherland</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Methods Mol. Biol</ref-sourcetitle>
<ref-publicationyear first="2008" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1007/978-1-59745-249-6_4</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Cole, A.R., Sutherland, C.: Measuring GSK3 expression and activity in cells. Methods Mol. Biol. (2008). https://doi.org/10.1007/978-1-59745-249-6_4</ref-fulltext>
<ce:source-text>Cole, A.R., Sutherland, C.: Measuring GSK3 expression and activity in cells. Methods Mol. Biol. (2008). https://doi.org/10.1007/978-1-59745-249-6_4</ce:source-text>
</reference>
<reference seq="229">
<ref-info>
<ref-title>
<ref-titletext-english>What are the bona fide GSK3 substrates?</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Sutherland</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Alzheimer’s Dis</ref-sourcetitle>
<ref-publicationyear first="2011" />
</ref-info>
<ref-fulltext>Sutherland, C.: What are the bona fide GSK3 substrates? Int. J. Alzheimer’s Dis. (2011)</ref-fulltext>
<ce:source-text>Sutherland, C.: What are the bona fide GSK3 substrates? Int. J. Alzheimer’s Dis. (2011)</ce:source-text>
</reference>
<reference seq="230">
<ref-info>
<ref-title>
<ref-titletext-english>Calpain inhibitors ameliorate muscle wasting in a cachectic mouse model bearing CT26 colorectal adenocarcinoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.Y.</ce:initials>
<ce:surname>Lin</ce:surname>
<ce:given-name>X.Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.Z.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>S.Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncol. Rep</ref-sourcetitle>
<ref-publicationyear first="2017" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.3892/or.2017.5396</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Lin, X.Y., Chen, S.Z.: Calpain inhibitors ameliorate muscle wasting in a cachectic mouse model bearing CT26 colorectal adenocarcinoma. Oncol. Rep. (2017). https://doi.org/10.3892/or.2017.5396</ref-fulltext>
<ce:source-text>Lin, X.Y., Chen, S.Z.: Calpain inhibitors ameliorate muscle wasting in a cachectic mouse model bearing CT26 colorectal adenocarcinoma. Oncol. Rep. (2017). https://doi.org/10.3892/or.2017.5396</ce:source-text>
</reference>
<reference seq="231">
<ref-info>
<ref-title>
<ref-titletext-english>Interference with Ca2+-dependent proteolysis does not alter the course of muscle wasting in experimental cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>V.G.</ce:initials>
<ce:surname>Minero</ce:surname>
<ce:given-name>V.G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:surname>Penna</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Physiol</ref-sourcetitle>
<ref-publicationyear first="2017" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.3389/fphys.2017.00213</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Pin, F., Minero, V.G., Penna, F., et al.: Interference with Ca2+-dependent proteolysis does not alter the course of muscle wasting in experimental cancer cachexia. Front. Physiol. (2017). https://doi.org/10.3389/fphys.2017.00213</ref-fulltext>
<ce:source-text>Pin, F., Minero, V.G., Penna, F., et al.: Interference with Ca2+-dependent proteolysis does not alter the course of muscle wasting in experimental cancer cachexia. Front. Physiol. (2017). https://doi.org/10.3389/fphys.2017.00213</ce:source-text>
</reference>
<reference seq="232">
<ref-info>
<ref-title>
<ref-titletext-english>A signaling hub of insulin receptor, dystrophin glycoprotein complex and plakoglobin regulates muscle size</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Eid Mutlak</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Aweida</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Volodin</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1381</first-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/s41467-020-14895-9</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Eid Mutlak, Y., Aweida, D., Volodin, A., et al.: A signaling hub of insulin receptor, dystrophin glycoprotein complex and plakoglobin regulates muscle size. Nat. Commun. 11, 1381 (2020). https://doi.org/10.1038/s41467-020-14895-9</ref-fulltext>
<ce:source-text>Eid Mutlak, Y., Aweida, D., Volodin, A., et al.: A signaling hub of insulin receptor, dystrophin glycoprotein complex and plakoglobin regulates muscle size. Nat. Commun. 11, 1381 (2020). https://doi.org/10.1038/s41467-020-14895-9</ce:source-text>
</reference>
<reference seq="233">
<ref-info>
<ref-title>
<ref-titletext-english>The dystrophin glycoprotein complex</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.A.</ce:initials>
<ce:surname>Lapidos</ce:surname>
<ce:given-name>K.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Kakkar</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>E.M.</ce:initials>
<ce:surname>McNally</ce:surname>
<ce:given-name>E.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Circ. Res</ref-sourcetitle>
<ref-publicationyear first="2004" />
<volisspag>
<volume-issue-number>
<vol-first>94</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1023</first-page>
<last-page>1031</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1161/01.RES.0000126574.61061.25</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Lapidos, K.A., Kakkar, R., McNally, E.M.: The dystrophin glycoprotein complex. Circ. Res. 94, 1023–1031 (2004). https://doi.org/10.1161/01.RES.0000126574.61061.25</ref-fulltext>
<ce:source-text>Lapidos, K.A., Kakkar, R., McNally, E.M.: The dystrophin glycoprotein complex. Circ. Res. 94, 1023–1031 (2004). https://doi.org/10.1161/01.RES.0000126574.61061.25</ce:source-text>
</reference>
<reference seq="234">
<ref-info>
<ref-title>
<ref-titletext-english>The costamere bridges sarcomeres to the sarcolemma in striated muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.K.</ce:initials>
<ce:surname>Peter</ce:surname>
<ce:given-name>A.K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Cheng</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.S.</ce:initials>
<ce:surname>Ross</ce:surname>
<ce:given-name>R.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Prog. Pediatr. Cardiol</ref-sourcetitle>
<ref-publicationyear first="2011" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.ppedcard.2011.02.003</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Peter, A.K., Cheng, H., Ross, R.S., et al.: The costamere bridges sarcomeres to the sarcolemma in striated muscle. Prog. Pediatr. Cardiol. (2011). https://doi.org/10.1016/j.ppedcard.2011.02.003</ref-fulltext>
<ce:source-text>Peter, A.K., Cheng, H., Ross, R.S., et al.: The costamere bridges sarcomeres to the sarcolemma in striated muscle. Prog. Pediatr. Cardiol. (2011). https://doi.org/10.1016/j.ppedcard.2011.02.003</ce:source-text>
</reference>
<reference seq="235">
<ref-info>
<ref-title>
<ref-titletext-english>Membrane organization of the dystrophin-glycoprotein complex</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Ervasti</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.P.</ce:initials>
<ce:surname>Campbell</ce:surname>
<ce:given-name>K.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="1991" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/0092-8674(91)90035-W</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Ervasti, J.M., Campbell, K.P.: Membrane organization of the dystrophin-glycoprotein complex. Cell. (1991). https://doi.org/10.1016/0092-8674(91)90035-W</ref-fulltext>
<ce:source-text>Ervasti, J.M., Campbell, K.P.: Membrane organization of the dystrophin-glycoprotein complex. Cell. (1991). https://doi.org/10.1016/0092-8674(91)90035-W</ce:source-text>
</reference>
<reference seq="236">
<ref-info>
<ref-title>
<ref-titletext-english>Calmodulin specifically binds three proteins of the dystrophin-glycoprotein complex</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Madhavan</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.R.</ce:initials>
<ce:surname>Massom</ce:surname>
<ce:given-name>L.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.W.</ce:initials>
<ce:surname>Jarrett</ce:surname>
<ce:given-name>H.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochem. Biophys. Res. Commun</ref-sourcetitle>
<ref-publicationyear first="1992" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/0006-291X(92)91690-R</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Madhavan, R., Massom, L.R., Jarrett, H.W.: Calmodulin specifically binds three proteins of the dystrophin-glycoprotein complex. Biochem. Biophys. Res. Commun. (1992). https://doi.org/10.1016/0006-291X(92)91690-R</ref-fulltext>
<ce:source-text>Madhavan, R., Massom, L.R., Jarrett, H.W.: Calmodulin specifically binds three proteins of the dystrophin-glycoprotein complex. Biochem. Biophys. Res. Commun. (1992). https://doi.org/10.1016/0006-291X(92)91690-R</ce:source-text>
</reference>
<reference seq="237">
<ref-info>
<ref-title>
<ref-titletext-english>The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.A.</ce:initials>
<ce:surname>Rando</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Muscle Nerve</ref-sourcetitle>
<ref-publicationyear first="2001" />
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1575</first-page>
<last-page>1594</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/mus.1192</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Rando, T.A.: The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies. Muscle Nerve. 24, 1575–1594 (2001). https://doi.org/10.1002/mus.1192</ref-fulltext>
<ce:source-text>Rando, T.A.: The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies. Muscle Nerve. 24, 1575–1594 (2001). https://doi.org/10.1002/mus.1192</ce:source-text>
</reference>
<reference seq="238">
<ref-info>
<ref-title>
<ref-titletext-english>Lateral transmission of force is impaired in skeletal muscles of dystrophic mice and very old rats</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.S.</ce:initials>
<ce:surname>Ramaswamy</ce:surname>
<ce:given-name>K.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.L.</ce:initials>
<ce:surname>Palmer</ce:surname>
<ce:given-name>M.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.H.</ce:initials>
<ce:surname>Van der Meulen</ce:surname>
<ce:given-name>J.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Physiol</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>589</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1195</first-page>
<last-page>1208</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1113/jphysiol.2010.201921</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Ramaswamy, K.S., Palmer, M.L., van der Meulen, J.H., et al.: Lateral transmission of force is impaired in skeletal muscles of dystrophic mice and very old rats. J. Physiol. 589, 1195–1208 (2011). https://doi.org/10.1113/jphysiol.2010.201921</ref-fulltext>
<ce:source-text>Ramaswamy, K.S., Palmer, M.L., van der Meulen, J.H., et al.: Lateral transmission of force is impaired in skeletal muscles of dystrophic mice and very old rats. J. Physiol. 589, 1195–1208 (2011). https://doi.org/10.1113/jphysiol.2010.201921</ce:source-text>
</reference>
<reference seq="239">
<ref-info>
<ref-title>
<ref-titletext-english>The dystrophin-glycoprotein complex in the prevention of muscle damage</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.D.</ce:initials>
<ce:surname>Gumerson</ce:surname>
<ce:given-name>J.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.E.</ce:initials>
<ce:surname>Michele</ce:surname>
<ce:given-name>D.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biomed. Biotechnol</ref-sourcetitle>
<ref-publicationyear first="2011" />
</ref-info>
<ref-fulltext>Gumerson, J.D., Michele, D.E.: The dystrophin-glycoprotein complex in the prevention of muscle damage. J. Biomed. Biotechnol. (2011)</ref-fulltext>
<ce:source-text>Gumerson, J.D., Michele, D.E.: The dystrophin-glycoprotein complex in the prevention of muscle damage. J. Biomed. Biotechnol. (2011)</ce:source-text>
</reference>
<reference seq="240">
<ref-info>
<ref-title>
<ref-titletext-english>Direct observation of failing fibers in muscles of dystrophic mice provides mechanistic insight into muscular dystrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.R.</ce:initials>
<ce:surname>Claflin</ce:surname>
<ce:given-name>D.R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.V.</ce:initials>
<ce:surname>Brooks</ce:surname>
<ce:given-name>S.V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Cell Physiol</ref-sourcetitle>
<ref-publicationyear first="2008" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpcell.00244.2007</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Claflin, D.R., Brooks, S.V.: Direct observation of failing fibers in muscles of dystrophic mice provides mechanistic insight into muscular dystrophy. Am. J. Physiol. Cell Physiol. (2008). https://doi.org/10.1152/ajpcell.00244.2007</ref-fulltext>
<ce:source-text>Claflin, D.R., Brooks, S.V.: Direct observation of failing fibers in muscles of dystrophic mice provides mechanistic insight into muscular dystrophy. Am. J. Physiol. Cell Physiol. (2008). https://doi.org/10.1152/ajpcell.00244.2007</ce:source-text>
</reference>
<reference seq="241">
<ref-info>
<ref-title>
<ref-titletext-english>Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Dellorusso</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.W.</ce:initials>
<ce:surname>Crawford</ce:surname>
<ce:given-name>R.W.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.S.</ce:initials>
<ce:surname>Chamberlain</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.V.</ce:initials>
<ce:surname>Brooks</ce:surname>
<ce:given-name>S.V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Muscle Res. Cell Motil</ref-sourcetitle>
<ref-publicationyear first="2001" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1023/A:1014587918367</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Dellorusso, C., Crawford, R.W., Chamberlain, J.S., Brooks, S.V.: Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury. J. Muscle Res. Cell Motil. (2001). https://doi.org/10.1023/A:1014587918367</ref-fulltext>
<ce:source-text>Dellorusso, C., Crawford, R.W., Chamberlain, J.S., Brooks, S.V.: Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury. J. Muscle Res. Cell Motil. (2001). https://doi.org/10.1023/A:1014587918367</ce:source-text>
</reference>
<reference seq="242">
<ref-info>
<ref-title>
<ref-titletext-english>A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Kimura</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Ng</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Hum. Mol. Genet</ref-sourcetitle>
<ref-publicationyear first="2006" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1093/hmg/ddl082</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Li, S., Kimura, E., Ng, R., et al.: A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy. Hum. Mol. Genet. (2006). https://doi.org/10.1093/hmg/ddl082</ref-fulltext>
<ce:source-text>Li, S., Kimura, E., Ng, R., et al.: A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy. Hum. Mol. Genet. (2006). https://doi.org/10.1093/hmg/ddl082</ce:source-text>
</reference>
<reference seq="243">
<ref-info>
<ref-title>
<ref-titletext-english>The extracellular matrix protein agrin promotes heart regeneration in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Bassat</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.E.</ce:initials>
<ce:surname>Mutlak</ce:surname>
<ce:given-name>Y.E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Genzelinakh</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>547</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>179</first-page>
<last-page>184</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/nature22978</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Bassat, E., Mutlak, Y.E., Genzelinakh, A., et al.: The extracellular matrix protein agrin promotes heart regeneration in mice. Nature. 547, 179–184 (2017). https://doi.org/10.1038/nature22978</ref-fulltext>
<ce:source-text>Bassat, E., Mutlak, Y.E., Genzelinakh, A., et al.: The extracellular matrix protein agrin promotes heart regeneration in mice. Nature. 547, 179–184 (2017). https://doi.org/10.1038/nature22978</ce:source-text>
</reference>
<reference seq="244">
<ref-info>
<ref-title>
<ref-titletext-english>The molecular cross talk of the dystrophin–glycoprotein complex</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Gawor</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.J.</ce:initials>
<ce:surname>Prószyński</ce:surname>
<ce:given-name>T.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ann. NY Acad. Sci</ref-sourcetitle>
<ref-publicationyear first="2018" />
</ref-info>
<ref-fulltext>Gawor, M., Prószyński, T.J.: The molecular cross talk of the dystrophin–glycoprotein complex. Ann. NY Acad. Sci. (2018)</ref-fulltext>
<ce:source-text>Gawor, M., Prószyński, T.J.: The molecular cross talk of the dystrophin–glycoprotein complex. Ann. NY Acad. Sci. (2018)</ce:source-text>
</reference>
<reference seq="245">
<ref-info>
<ref-title>
<ref-titletext-english>Profiling of the muscle-specific dystroglycan interactome reveals the role of Hippo signaling in muscular dystrophy and age-dependent muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.S.</ce:initials>
<ce:surname>Yatsenko</ce:surname>
<ce:given-name>A.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.M.</ce:initials>
<ce:surname>Kucherenko</ce:surname>
<ce:given-name>M.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Xie</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>BMC Med</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>8</first-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1186/s12916-019-1478-3</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Yatsenko, A.S., Kucherenko, M.M., Xie, Y., et al.: Profiling of the muscle-specific dystroglycan interactome reveals the role of Hippo signaling in muscular dystrophy and age-dependent muscle atrophy. BMC Med. 18, 8 (2020). https://doi.org/10.1186/s12916-019-1478-3</ref-fulltext>
<ce:source-text>Yatsenko, A.S., Kucherenko, M.M., Xie, Y., et al.: Profiling of the muscle-specific dystroglycan interactome reveals the role of Hippo signaling in muscular dystrophy and age-dependent muscle atrophy. BMC Med. 18, 8 (2020). https://doi.org/10.1186/s12916-019-1478-3</ce:source-text>
</reference>
<reference seq="246">
<ref-info>
<ref-title>
<ref-titletext-english>Ca2+−calmodulin binds to the carboxyl-terminal domain of dystrophin</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.T.</ce:initials>
<ce:surname>Anderson</ce:surname>
<ce:given-name>J.T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.P.</ce:initials>
<ce:surname>Rogers</ce:surname>
<ce:given-name>R.P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.W.</ce:initials>
<ce:surname>Jarrett</ce:surname>
<ce:given-name>H.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="1996" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1074/jbc.271.12.6605</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Anderson, J.T., Rogers, R.P., Jarrett, H.W.: Ca2+−calmodulin binds to the carboxyl-terminal domain of dystrophin. J. Biol. Chem. (1996). https://doi.org/10.1074/jbc.271.12.6605</ref-fulltext>
<ce:source-text>Anderson, J.T., Rogers, R.P., Jarrett, H.W.: Ca2+−calmodulin binds to the carboxyl-terminal domain of dystrophin. J. Biol. Chem. (1996). https://doi.org/10.1074/jbc.271.12.6605</ce:source-text>
</reference>
<reference seq="247">
<ref-info>
<ref-title>
<ref-titletext-english>Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Lai</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.D.</ce:initials>
<ce:surname>Thomas</ce:surname>
<ce:given-name>G.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Yue</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Investig</ref-sourcetitle>
<ref-publicationyear first="2009" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1172/JCI36612</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Lai, Y., Thomas, G.D., Yue, Y., et al.: Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J. Clin. Investig. (2009). https://doi.org/10.1172/JCI36612</ref-fulltext>
<ce:source-text>Lai, Y., Thomas, G.D., Yue, Y., et al.: Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J. Clin. Investig. (2009). https://doi.org/10.1172/JCI36612</ce:source-text>
</reference>
<reference seq="248">
<ref-info>
<ref-title>
<ref-titletext-english>Mouse α1-syntrophin binding to Grb2: Further evidence of a role for syntrophin in cell signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.A.</ce:initials>
<ce:surname>Oak</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Russo</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.C.</ce:initials>
<ce:surname>Petrucci</ce:surname>
<ce:given-name>T.C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>H.W.</ce:initials>
<ce:surname>Jarrett</ce:surname>
<ce:given-name>H.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochemistry</ref-sourcetitle>
<ref-publicationyear first="2001" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1021/bi010490n</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Oak, S.A., Russo, K., Petrucci, T.C., Jarrett, H.W.: Mouse α1-syntrophin binding to Grb2: further evidence of a role for syntrophin in cell signaling. Biochemistry. (2001). https://doi.org/10.1021/bi010490n</ref-fulltext>
<ce:source-text>Oak, S.A., Russo, K., Petrucci, T.C., Jarrett, H.W.: Mouse α1-syntrophin binding to Grb2: further evidence of a role for syntrophin in cell signaling. Biochemistry. (2001). https://doi.org/10.1021/bi010490n</ce:source-text>
</reference>
<reference seq="249">
<ref-info>
<ref-title>
<ref-titletext-english>SH3 domain-mediated interaction of dystroglycan and Grb2</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Yang</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Jung</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Motto</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="1995" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1074/jbc.270.20.11711</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Yang, B., Jung, D., Motto, D., et al.: SH3 domain-mediated interaction of dystroglycan and Grb2. J. Biol. Chem. (1995). https://doi.org/10.1074/jbc.270.20.11711</ref-fulltext>
<ce:source-text>Yang, B., Jung, D., Motto, D., et al.: SH3 domain-mediated interaction of dystroglycan and Grb2. J. Biol. Chem. (1995). https://doi.org/10.1074/jbc.270.20.11711</ce:source-text>
</reference>
<reference seq="250">
<ref-info>
<ref-title>
<ref-titletext-english>Inhibition of dystroglycan binding to laminin disrupts the PI3K/AKT pathway and survival signaling in muscle cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.J.</ce:initials>
<ce:surname>Langenbach</ce:surname>
<ce:given-name>K.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.A.</ce:initials>
<ce:surname>Rando</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Muscle Nerve</ref-sourcetitle>
<ref-publicationyear first="2002" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/mus.10258</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Langenbach, K.J., Rando, T.A.: Inhibition of dystroglycan binding to laminin disrupts the PI3K/AKT pathway and survival signaling in muscle cells. Muscle Nerve. (2002). https://doi.org/10.1002/mus.10258</ref-fulltext>
<ce:source-text>Langenbach, K.J., Rando, T.A.: Inhibition of dystroglycan binding to laminin disrupts the PI3K/AKT pathway and survival signaling in muscle cells. Muscle Nerve. (2002). https://doi.org/10.1002/mus.10258</ce:source-text>
</reference>
<reference seq="251">
<ref-info>
<ref-title>
<ref-titletext-english>Trim32 reduces PI3K-Akt-FoxO signaling in muscle atrophy by promoting plakoglobin-PI3K dissociation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Cohen</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>B.</ce:initials>
<ce:surname>Zhai</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>204</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>747</first-page>
<last-page>758</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1083/jcb.201304167</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Cohen, S., Lee, D., Zhai, B., et al.: Trim32 reduces PI3K-Akt-FoxO signaling in muscle atrophy by promoting plakoglobin-PI3K dissociation. J. Cell Biol. 204, 747–758 (2014). https://doi.org/10.1083/jcb.201304167</ref-fulltext>
<ce:source-text>Cohen, S., Lee, D., Zhai, B., et al.: Trim32 reduces PI3K-Akt-FoxO signaling in muscle atrophy by promoting plakoglobin-PI3K dissociation. J. Cell Biol. 204, 747–758 (2014). https://doi.org/10.1083/jcb.201304167</ce:source-text>
</reference>
<reference seq="252">
<ref-info>
<ref-title>
<ref-titletext-english>Muscular dystrophies at different ages: Metabolic and endocrine alterations</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>O.D.R.</ce:initials>
<ce:surname>Cruz Guzmán</ce:surname>
<ce:given-name>O.D.R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.L.</ce:initials>
<ce:surname>Chávez García</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Rodríguez-Cruz</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Endocrinol</ref-sourcetitle>
<ref-publicationyear first="2012" />
</ref-info>
<ref-fulltext>Cruz Guzmán, O.D.R., Chávez García, A.L., Rodríguez-Cruz, M.: Muscular dystrophies at different ages: metabolic and endocrine alterations. Int. J. Endocrinol. (2012)</ref-fulltext>
<ce:source-text>Cruz Guzmán, O.D.R., Chávez García, A.L., Rodríguez-Cruz, M.: Muscular dystrophies at different ages: metabolic and endocrine alterations. Int. J. Endocrinol. (2012)</ce:source-text>
</reference>
<reference seq="253">
<ref-info>
<ref-title>
<ref-titletext-english>Dissociation of insulin resistance and decreased insulin receptor binding in duchenne muscular dystrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.R.</ce:initials>
<ce:surname>Freidenberg</ce:surname>
<ce:given-name>G.R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.M.</ce:initials>
<ce:surname>Olefsky</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Endocrinol. Metab</ref-sourcetitle>
<ref-publicationyear first="1985" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1210/jcem-60-2-320</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Freidenberg, G.R., Olefsky, J.M.: Dissociation of insulin resistance and decreased insulin receptor binding in duchenne muscular dystrophy. J. Clin. Endocrinol. Metab. (1985). https://doi.org/10.1210/jcem-60-2-320</ref-fulltext>
<ce:source-text>Freidenberg, G.R., Olefsky, J.M.: Dissociation of insulin resistance and decreased insulin receptor binding in duchenne muscular dystrophy. J. Clin. Endocrinol. Metab. (1985). https://doi.org/10.1210/jcem-60-2-320</ce:source-text>
</reference>
<reference seq="254">
<ref-info>
<ref-title>
<ref-titletext-english>Evidence of insulin resistance and other metabolic alterations in boys with Duchenne or becker muscular dystrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Rodriguez-Cruz</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Sanchez</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.E.</ce:initials>
<ce:surname>Escobar</ce:surname>
<ce:given-name>R.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Endocrinol</ref-sourcetitle>
<ref-publicationyear first="2015" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1155/2015/867273</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Rodriguez-Cruz, M., Sanchez, R., Escobar, R.E., et al.: Evidence of insulin resistance and other metabolic alterations in boys with Duchenne or becker muscular dystrophy. Int. J. Endocrinol. 2015, 867273 (2015). https://doi.org/10.1155/2015/867273</ref-fulltext>
<ce:source-text>Rodriguez-Cruz, M., Sanchez, R., Escobar, R.E., et al.: Evidence of insulin resistance and other metabolic alterations in boys with Duchenne or becker muscular dystrophy. Int. J. Endocrinol. 2015, 867273 (2015). https://doi.org/10.1155/2015/867273</ce:source-text>
</reference>
<reference seq="255">
<ref-info>
<ref-title>
<ref-titletext-english>iLIR database: A web resource for LIR motif-containing proteins in eukaryotes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.C.</ce:initials>
<ce:surname>Jacomin</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Samavedam</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>V.</ce:initials>
<ce:surname>Promponas</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
<author seq="4">
<ce:initials>I.P.</ce:initials>
<ce:surname>Nezis</ce:surname>
<ce:given-name>I.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Autophagy</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1945</first-page>
<last-page>1953</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1080/15548627.2016.1207016</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Jacomin, A.C., Samavedam, S., Promponas, V., Nezis, I.P.: iLIR database: A web resource for LIR motif-containing proteins in eukaryotes. Autophagy. 12, 1945–1953 (2016). https://doi.org/10.1080/15548627.2016.1207016</ref-fulltext>
<ce:source-text>Jacomin, A.C., Samavedam, S., Promponas, V., Nezis, I.P.: iLIR database: A web resource for LIR motif-containing proteins in eukaryotes. Autophagy. 12, 1945–1953 (2016). https://doi.org/10.1080/15548627.2016.1207016</ce:source-text>
</reference>
<reference seq="256">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle hypertrophy and atrophy signaling pathways</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.J.</ce:initials>
<ce:surname>Glass</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Biochem. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>37</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1974</first-page>
<last-page>1984</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.biocel.2005.04.018</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Glass, D.J.: Skeletal muscle hypertrophy and atrophy signaling pathways. Int. J. Biochem. Cell Biol. 37, 1974–1984 (2005). https://doi.org/10.1016/j.biocel.2005.04.018</ref-fulltext>
<ce:source-text>Glass, D.J.: Skeletal muscle hypertrophy and atrophy signaling pathways. Int. J. Biochem. Cell Biol. 37, 1974–1984 (2005). https://doi.org/10.1016/j.biocel.2005.04.018</ce:source-text>
</reference>
<reference seq="257">
<ref-info>
<ref-title>
<ref-titletext-english>IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Sacheck</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Ohtsuka</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.C.</ce:initials>
<ce:surname>McLary</ce:surname>
<ce:given-name>S.C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.L.</ce:initials>
<ce:surname>Goldberg</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Phys. Endocrinol. Metab</ref-sourcetitle>
<ref-publicationyear first="2004" />
<volisspag>
<volume-issue-number>
<vol-first>287</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>E591</first-page>
<last-page>E601</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpendo.00073.2004</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Sacheck, J.M., Ohtsuka, A., McLary, S.C., Goldberg, A.L.: IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am. J. Phys. Endocrinol. Metab. 287, E591–E601 (2004). https://doi.org/10.1152/ajpendo.00073.2004</ref-fulltext>
<ce:source-text>Sacheck, J.M., Ohtsuka, A., McLary, S.C., Goldberg, A.L.: IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am. J. Phys. Endocrinol. Metab. 287, E591–E601 (2004). https://doi.org/10.1152/ajpendo.00073.2004</ce:source-text>
</reference>
<reference seq="258">
<ref-info>
<ref-title>
<ref-titletext-english>The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.N.</ce:initials>
<ce:surname>Stitt</ce:surname>
<ce:given-name>T.N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Drujan</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>B.A.</ce:initials>
<ce:surname>Clarke</ce:surname>
<ce:given-name>B.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cell</ref-sourcetitle>
<ref-publicationyear first="2004" />
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>395</first-page>
<last-page>403</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stitt, T.N., Drujan, D., Clarke, B.A., et al.: The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol. Cell. 14, 395–403 (2004)</ref-fulltext>
<ce:source-text>Stitt, T.N., Drujan, D., Clarke, B.A., et al.: The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol. Cell. 14, 395–403 (2004)</ce:source-text>
</reference>
<reference seq="259">
<ref-info>
<ref-title>
<ref-titletext-english>The LIR motif – crucial for selective autophagy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Å.B.</ce:initials>
<ce:surname>Birgisdottir</ce:surname>
<ce:given-name>Å.B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Lamark</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Johansen</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell Sci</ref-sourcetitle>
<ref-publicationyear first="2013" />
<ref-website>
<ce:e-address type="url">https://doi.org/10.1242/jcs.126128</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Birgisdottir, Å.B., Lamark, T., Johansen, T., et al.: The LIR motif – crucial for selective autophagy. J. Cell Sci. (2013). https://doi.org/10.1242/jcs.126128</ref-fulltext>
<ce:source-text>Birgisdottir, Å.B., Lamark, T., Johansen, T., et al.: The LIR motif – crucial for selective autophagy. J. Cell Sci. (2013). https://doi.org/10.1242/jcs.126128</ce:source-text>
</reference>
<reference seq="260">
<ref-info>
<ref-title>
<ref-titletext-english>Clinical trials of cancer cachexia therapy, now and hereafter</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2013" />
</ref-info>
<ref-fulltext>Baracos, V.E.: Clinical trials of cancer cachexia therapy, now and hereafter. J. Clin. Oncol. (2013)</ref-fulltext>
<ce:source-text>Baracos, V.E.: Clinical trials of cancer cachexia therapy, now and hereafter. J. Clin. Oncol. (2013)</ce:source-text>
</reference>
<reference seq="261">
<ref-info>
<ref-title>
<ref-titletext-english>Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia – can findings from animal models be translated to humans?</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.C.</ce:initials>
<ce:surname>Mueller</ce:surname>
<ce:given-name>T.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Bachmann</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>O.</ce:initials>
<ce:surname>Prokopchuk</ce:surname>
<ce:given-name>O.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>BMC Cancer</ref-sourcetitle>
<ref-publicationyear first="2016" />
</ref-info>
<ref-fulltext>Mueller, T.C., Bachmann, J., Prokopchuk, O., et al.: Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia – can findings from animal models be translated to humans? BMC Cancer. (2016)</ref-fulltext>
<ce:source-text>Mueller, T.C., Bachmann, J., Prokopchuk, O., et al.: Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia – can findings from animal models be translated to humans? BMC Cancer. (2016)</ce:source-text>
</reference>
</bibliography>
</tail>
</bibrecord>
<bibrecord>
<item-info>
<status state="new" stage="S300" />
<itemidlist>
<ce:doi>10.1007/978-3-031-09518-4_6</ce:doi>
<itemid idtype="TPB-ID">20232000349315</itemid>
</itemidlist>
</item-info>
<head>
<citation-info>
<citation-type code="ch" />
<citation-language xml:lang="ENG" />
<abstract-language xml:lang="ENG" />
</citation-info>
<citation-title>
<titletext xml:lang="ENG" original="y">The Role of Interleukin-6/GP130 Cytokines in Cancer Cachexia</titletext>
</citation-title>
<author-group seq="1">
<author seq="1">
<ce:initials>D.H.A.</ce:initials> 
<ce:surname>Jengelley</ce:surname>
<ce:given-name>Daenique H. A</ce:given-name>
</author>
<affiliation>
<organization>Department of Biochemistry and Molecular Biology</organization>
<state>Indianapolis</state>
<country iso-code="USA" />
<ce:source-text>Department of Biochemistry and Molecular Biology, Indianapolis, IN, USA</ce:source-text>
</affiliation>
</author-group>
<author-group seq="2">
<author seq="1">
<ce:initials>T.A.</ce:initials> 
<ce:surname>Zimmers</ce:surname>
<ce:given-name>Teresa A.</ce:given-name>
<ce:e-address>zimmerst@iu.edu</ce:e-address>
</author>
<affiliation>
<organization>Department of Biochemistry and Molecular Biology</organization>
<organization>Department of Surgery</organization>
<organization>Department of Otolaryngology—Head &amp; Neck Surgery</organization>
<state>Indianapolis</state>
<country iso-code="USA" />
<ce:source-text>Department of Biochemistry and Molecular Biology, Indianapolis, IN, USA Department of Surgery, Indianapolis, IN, USA Department of Anatomy, Cell Biology, &amp; Physiology, Indianapolis, IN, USA Department of Otolaryngology—Head &amp; Neck Surgery, Indiana University School of Medicine, Indianapolis, IN, USA Research Service, Richard L. Roudebush Veterans Administration Medical Center, Indianapolis, IN, USA Indiana Center for Musculoskeletal Health, Indianapolis, IN, USA Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, USA</ce:source-text>
</affiliation>
</author-group>
<correspondence>
<person>
<ce:initials>T.A.</ce:initials> 
<ce:surname>Zimmers</ce:surname>
<ce:given-name>Teresa A.</ce:given-name>
<ce:e-address>zimmerst@iu.edu</ce:e-address>
</person>
<affiliation>
<organization>Department of Biochemistry and Molecular Biology</organization>
<organization>Department of Surgery</organization>
<organization>Department of Otolaryngology—Head &amp; Neck Surgery</organization>
<state>Indianapolis</state>
<country iso-code="USA" />
<ce:source-text>Department of Biochemistry and Molecular Biology, Indianapolis, IN, USA Department of Surgery, Indianapolis, IN, USA Department of Anatomy, Cell Biology, &amp; Physiology, Indianapolis, IN, USA Department of Otolaryngology—Head &amp; Neck Surgery, Indiana University School of Medicine, Indianapolis, IN, USA Research Service, Richard L. Roudebush Veterans Administration Medical Center, Indianapolis, IN, USA Indiana Center for Musculoskeletal Health, Indianapolis, IN, USA Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, USA</ce:source-text>
</affiliation>
</correspondence>
<abstracts>
<abstract xml:lang="ENG" original="y">
<publishercopyright>© Springer Nature Switzerland AG 2022</publishercopyright>
<ce:para>Cancer cachexia is characterized by the invol- untary loss of skeletal muscle with or without adipose tissue loss in the presence of tumor burden. It is a prevalent yet clinically unmet need that results in devastating systemic wasting effects. Chronic inflammation triggers cancer progression and is observed in cachexia. This review will highlight the Interleukin-6 (IL-6) family of cytokines, including IL-6 itself, Leukemia Inhibitory Fac- tor (LIF), Ciliary Neurotrophic Factor (CNTF), Cardiotrophin-1 (CT-1), Oncostatin M (OSM), Interleukin-11 (IL-11), Interleukin-27 (IL-27), and Cardiotrophin- like cytokine (CLC), which all share signaling through IL-6 Signal Transducer (IL6ST), also known as Glycoprotein 130 (GP130) to acti- vate common downstream pathways including the JAK/STAT, MAPK, and AKT pathways. IL-6 has been long linked to cancer cachexia through both associative and functional stud- ies; furthermore, anti-IL-6 therapies have been trialed in patients. Recently, LIF has emerged as a novel cachexia mediator in experimental systems. Far less is known about the other cytokines in cachexia, although they have sug- gestive properties on adipose and muscle tissues in other contexts. Future studies are required to determine the roles of these other factors in cancer cachexia and their potential for designing therapies.</ce:para>
</abstract>
</abstracts>
<source type="book" country="USA">
<sourcetitle>The Systemic Effects of Advanced Cancer A Textbook on Cancer-Associated Cachexia</sourcetitle>
<sourcetitle-abbrev>The Systemic Effects of Advanced Cancer A Textbook on Cancer-Associated Cachexia</sourcetitle-abbrev>
<isbn type="print" length="13">9783031072727</isbn>
<isbn type="electronic" length="13">9783031095184</isbn>
<volisspag>
<page-information>
<pages>
<first-page>97</first-page>
<last-page>117</last-page>
</pages>
</page-information>
</volisspag>
<publicationyear first="2022" />
<publicationdate>
<year>2022</year>
<month>01</month>
<day>01</day>
</publicationdate>
<website type="item">
<ce:e-address type="url">https://link.springer.com</ce:e-address>
</website>
<publisher>
<publishername>Springer International Publishing</publishername>
</publisher>
</source>
<enhancement>
<classificationgroup>
<classifications type="ASJC">
<classification>
<classification-code>2700</classification-code>
<classification-code>2400</classification-code>
<classification-code>1300</classification-code>
</classification>
</classifications>
</classificationgroup>
</enhancement>
</head>
<tail>
<bibliography refcount="240">
<reference seq="1">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia is defined by an ongoing loss of skeletal muscle mass</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>V.C.</ce:initials>
<ce:surname>Mazurak</ce:surname>
<ce:given-name>V.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.S.</ce:initials>
<ce:surname>Bhullar</ce:surname>
<ce:given-name>A.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ann Palliat Med</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3</first-page>
<last-page>12</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baracos, V.E., Mazurak, V.C., Bhullar, A.S.: Cancer cachexia is defined by an ongoing loss of skeletal muscle mass. Ann Palliat Med. 8(1), 3–12 (2019)</ref-fulltext>
<ce:source-text>Baracos, V.E., Mazurak, V.C., Bhullar, A.S.: Cancer cachexia is defined by an ongoing loss of skeletal muscle mass. Ann Palliat Med. 8(1), 3–12 (2019)</ce:source-text>
</reference>
<reference seq="2">
<ref-info>
<ref-title>
<ref-titletext-english>Definition and classification of cancer cachexia: An international consensus</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Lancet Oncol</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>489</first-page>
<last-page>495</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fearon, K., et al.: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 12(5), 489–495 (2011)</ref-fulltext>
<ce:source-text>Fearon, K., et al.: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 12(5), 489–495 (2011)</ce:source-text>
</reference>
<reference seq="3">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-associated cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Dis. Primers</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>17105</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baracos, V.E., et al.: Cancer-associated cachexia. Nat. Rev. Dis. Primers. 4, 17105 (2018)</ref-fulltext>
<ce:source-text>Baracos, V.E., et al.: Cancer-associated cachexia. Nat. Rev. Dis. Primers. 4, 17105 (2018)</ce:source-text>
</reference>
<reference seq="4">
<ref-info>
<ref-title>
<ref-titletext-english>tenet of cancer cachexia therapy: Do patients with advanced cancer have exploitable anabolic potential</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.M.</ce:initials>
<ce:surname>Prado</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>98</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1012</first-page>
<last-page>1019</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Prado, C.M., et al.: Tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential? Am. J. Clin. Nutr. 98(4), 1012–1019 (2013)</ref-fulltext>
<ce:source-text>Prado, C.M., et al.: Tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential? Am. J. Clin. Nutr. 98(4), 1012–1019 (2013)</ce:source-text>
</reference>
<reference seq="5">
<ref-info>
<ref-title>
<ref-titletext-english>Sarcopenic obesity: Hidden muscle wasting and its impact for survival and complications of cancer therapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Arribas</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Oncol</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>29</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>ii1</first-page>
<last-page>ii9</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baracos, V.E., Arribas, L.: Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy. Ann. Oncol. 29, ii1–ii9 (2018)</ref-fulltext>
<ce:source-text>Baracos, V.E., Arribas, L.: Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy. Ann. Oncol. 29, ii1–ii9 (2018)</ce:source-text>
</reference>
<reference seq="6">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia, mechanism and treatment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Aoyagi</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>World J Gastrointest Oncol</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>17</first-page>
<last-page>29</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Aoyagi, T., et al.: Cancer cachexia, mechanism and treatment. World J Gastrointest Oncol. 7(4), 17–29 (2015)</ref-fulltext>
<ce:source-text>Aoyagi, T., et al.: Cancer cachexia, mechanism and treatment. World J Gastrointest Oncol. 7(4), 17–29 (2015)</ce:source-text>
</reference>
<reference seq="7">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia: Understanding the molecular basis. Nat</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Argiles</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>754</first-page>
<last-page>762</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Argiles, J.M., et al.: Cancer cachexia: understanding the molecular basis. Nat. Rev. Cancer. 14(11), 754–762 (2014)</ref-fulltext>
<ce:source-text>Argiles, J.M., et al.: Cancer cachexia: understanding the molecular basis. Nat. Rev. Cancer. 14(11), 754–762 (2014)</ce:source-text>
</reference>
<reference seq="8">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia and related metabolic dysfunction</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Fonseca</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Mol. Sci</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Fonseca, G., et al.: Cancer cachexia and related metabolic dysfunction. Int. J. Mol. Sci. 21(7) (2020)</ref-fulltext>
<ce:source-text>Fonseca, G., et al.: Cancer cachexia and related metabolic dysfunction. Int. J. Mol. Sci. 21(7) (2020)</ce:source-text>
</reference>
<reference seq="9">
<ref-info>
<ref-title>
<ref-titletext-english>Understanding the mechanisms and treatment options in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Arends</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>V.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>90</first-page>
<last-page>99</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fearon, K., Arends, J., Baracos, V.: Understanding the mechanisms and treatment options in cancer cachexia. Nat. Rev. Clin. Oncol. 10(2), 90–99 (2013)</ref-fulltext>
<ce:source-text>Fearon, K., Arends, J., Baracos, V.: Understanding the mechanisms and treatment options in cancer cachexia. Nat. Rev. Clin. Oncol. 10(2), 90–99 (2013)</ce:source-text>
</reference>
<reference seq="10">
<ref-info>
<ref-title>
<ref-titletext-english>Understanding cachexia as a cancer metabolism syndrome</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.E.</ce:initials>
<ce:surname>Porporato</ce:surname>
<ce:given-name>P.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogenesis</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Porporato, P.E.: Understanding cachexia as a cancer metabolism syndrome. Oncogenesis. 5, e200 (2016)</ref-fulltext>
<ce:source-text>Porporato, P.E.: Understanding cachexia as a cancer metabolism syndrome. Oncogenesis. 5, e200 (2016)</ce:source-text>
</reference>
<reference seq="11">
<ref-info>
<ref-title>
<ref-titletext-english>Mechanisms of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.J.</ce:initials>
<ce:surname>Tisdale</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Physiol. Rev</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>89</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>381</first-page>
<last-page>410</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tisdale, M.J.: Mechanisms of cancer cachexia. Physiol. Rev. 89(2), 381–410 (2009)</ref-fulltext>
<ce:source-text>Tisdale, M.J.: Mechanisms of cancer cachexia. Physiol. Rev. 89(2), 381–410 (2009)</ce:source-text>
</reference>
<reference seq="12">
<ref-info>
<ref-title>
<ref-titletext-english>Principles of interleukin (IL)-6-type cytokine signalling and its regulation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.C.</ce:initials>
<ce:surname>Heinrich</ce:surname>
<ce:given-name>P.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochem. J</ref-sourcetitle>
<ref-publicationyear first="2003" />
<volisspag>
<volume-issue-number>
<vol-first>374</vol-first>
<part>Part 1</part>
</volume-issue-number>
<page-information>
<pages>
<first-page>1</first-page>
<last-page>20</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Heinrich, P.C., et al.: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374(Pt 1), 1–20 (2003)</ref-fulltext>
<ce:source-text>Heinrich, P.C., et al.: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374(Pt 1), 1–20 (2003)</ce:source-text>
</reference>
<reference seq="13">
<ref-info>
<ref-title>
<ref-titletext-english>ER stress and unfolded protein response in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Roy</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Kumar</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancers (Basel)</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Roy, A., Kumar, A.: ER stress and unfolded protein response in cancer cachexia. Cancers (Basel). 11(12) (2019)</ref-fulltext>
<ce:source-text>Roy, A., Kumar, A.: ER stress and unfolded protein response in cancer cachexia. Cancers (Basel). 11(12) (2019)</ce:source-text>
</reference>
<reference seq="14">
<ref-info>
<ref-title>
<ref-titletext-english>Mechanisms of cancer cachexia. Hematol. Oncol. Clin</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.N.</ce:initials>
<ce:surname>Langstein</ce:surname>
<ce:given-name>H.N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.A.</ce:initials>
<ce:surname>Norton</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>North Am</ref-sourcetitle>
<ref-publicationyear first="1991" />
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>103</first-page>
<last-page>123</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Langstein, H.N., Norton, J.A.: Mechanisms of cancer cachexia. Hematol. Oncol. Clin. North Am. 5(1), 103–123 (1991)</ref-fulltext>
<ce:source-text>Langstein, H.N., Norton, J.A.: Mechanisms of cancer cachexia. Hematol. Oncol. Clin. North Am. 5(1), 103–123 (1991)</ce:source-text>
</reference>
<reference seq="15">
<ref-info>
<ref-title>
<ref-titletext-english>Catabolic mediators of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.J.</ce:initials>
<ce:surname>Tisdale</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Opin. Support. Palliat. Care</ref-sourcetitle>
<ref-publicationyear first="2008" />
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>256</first-page>
<last-page>261</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tisdale, M.J.: Catabolic mediators of cancer cachexia. Curr. Opin. Support. Palliat. Care. 2(4), 256–261 (2008)</ref-fulltext>
<ce:source-text>Tisdale, M.J.: Catabolic mediators of cancer cachexia. Curr. Opin. Support. Palliat. Care. 2(4), 256–261 (2008)</ce:source-text>
</reference>
<reference seq="16">
<ref-info>
<ref-title>
<ref-titletext-english>STAT3 in the systemic inflammation of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.A.</ce:initials>
<ce:surname>Zimmers</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.L.</ce:initials>
<ce:surname>Fishel</ce:surname>
<ce:given-name>M.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Semin. Cell Dev. Biol</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>54</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>28</first-page>
<last-page>41</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zimmers, T.A., Fishel, M.L., Bonetto, A.: STAT3 in the systemic inflammation of cancer cachexia. Semin. Cell Dev. Biol. 54, 28–41 (2016)</ref-fulltext>
<ce:source-text>Zimmers, T.A., Fishel, M.L., Bonetto, A.: STAT3 in the systemic inflammation of cancer cachexia. Semin. Cell Dev. Biol. 54, 28–41 (2016)</ce:source-text>
</reference>
<reference seq="17">
<ref-info>
<ref-title>
<ref-titletext-english>Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.E.</ce:initials>
<ce:surname>Benny Klimek</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochem. Biophys. Res. Commun</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>391</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1548</first-page>
<last-page>1554</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Benny Klimek, M.E., et al.: Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem. Biophys. Res. Commun. 391(3), 1548–1554 (2010)</ref-fulltext>
<ce:source-text>Benny Klimek, M.E., et al.: Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem. Biophys. Res. Commun. 391(3), 1548–1554 (2010)</ce:source-text>
</reference>
<reference seq="18">
<ref-info>
<ref-title>
<ref-titletext-english>MicroRNA in cancer and cachexia – a mini-review</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Acunzo</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.M.</ce:initials>
<ce:surname>Croce</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Infect. Dis</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>212</vol-first>
<suppl>Supplement 1</suppl>
</volume-issue-number>
<page-information>
<pages>
<first-page>S74</first-page>
<last-page>S77</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Acunzo, M., Croce, C.M.: MicroRNA in cancer and cachexia – a mini-review. J. Infect. Dis. 212(Suppl 1), S74–S77 (2015)</ref-fulltext>
<ce:source-text>Acunzo, M., Croce, C.M.: MicroRNA in cancer and cachexia – a mini-review. J. Infect. Dis. 212(Suppl 1), S74–S77 (2015)</ce:source-text>
</reference>
<reference seq="19">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>589</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, G., et al.: Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90. Nat. Commun. 8(1), 589 (2017)</ref-fulltext>
<ce:source-text>Zhang, G., et al.: Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90. Nat. Commun. 8(1), 589 (2017)</ce:source-text>
</reference>
<reference seq="20">
<ref-info>
<ref-title>
<ref-titletext-english>The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.A.</ce:initials>
<ce:surname>Michaelis</ce:surname>
<ce:given-name>K.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4682</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Michaelis, K.A., et al.: The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer. Nat. Commun. 10(1), 4682 (2019)</ref-fulltext>
<ce:source-text>Michaelis, K.A., et al.: The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer. Nat. Commun. 10(1), 4682 (2019)</ce:source-text>
</reference>
<reference seq="21">
<ref-info>
<ref-title>
<ref-titletext-english>Cachexia: A problem of energetic inefficiency</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Argilés</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>279</first-page>
<last-page>286</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Argilés, J.M., et al.: Cachexia: A problem of energetic inefficiency. J. Cachexia. Sarcopenia Muscle. 5(4), 279–286 (2014)</ref-fulltext>
<ce:source-text>Argilés, J.M., et al.: Cachexia: A problem of energetic inefficiency. J. Cachexia. Sarcopenia Muscle. 5(4), 279–286 (2014)</ce:source-text>
</reference>
<reference seq="22">
<ref-info>
<ref-title>
<ref-titletext-english>Inflammation and cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.M.</ce:initials>
<ce:surname>Coussens</ce:surname>
<ce:given-name>L.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Z.</ce:initials>
<ce:surname>Werb</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2002" />
<volisspag>
<volume-issue-number>
<vol-first>420</vol-first>
<iss-first>6917</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>860</first-page>
<last-page>867</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Coussens, L.M., Werb, Z.: Inflammation and cancer. Nature. 420(6917), 860–867 (2002)</ref-fulltext>
<ce:source-text>Coussens, L.M., Werb, Z.: Inflammation and cancer. Nature. 420(6917), 860–867 (2002)</ce:source-text>
</reference>
<reference seq="23">
<ref-info>
<ref-title>
<ref-titletext-english>Inflammation and cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Singh</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Afr. Med</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>121</first-page>
<last-page>126</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Singh, N., et al.: Inflammation and cancer. Ann. Afr. Med. 18(3), 121–126 (2019)</ref-fulltext>
<ce:source-text>Singh, N., et al.: Inflammation and cancer. Ann. Afr. Med. 18(3), 121–126 (2019)</ce:source-text>
</reference>
<reference seq="24">
<ref-info>
<ref-title>
<ref-titletext-english>Coordination of immune-stroma crosstalk by IL-6 family cytokines</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.R.</ce:initials>
<ce:surname>West</ce:surname>
<ce:given-name>N.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Immunol</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1093</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>West, N.R.: Coordination of immune-stroma crosstalk by IL-6 family cytokines. Front. Immunol. 10, 1093 (2019)</ref-fulltext>
<ce:source-text>West, N.R.: Coordination of immune-stroma crosstalk by IL-6 family cytokines. Front. Immunol. 10, 1093 (2019)</ce:source-text>
</reference>
<reference seq="25">
<ref-info>
<ref-title>
<ref-titletext-english>The gp130 receptor cytokine family: Regulators of adipocyte development and function</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>U.A.</ce:initials>
<ce:surname>White</ce:surname>
<ce:given-name>U.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.M.</ce:initials>
<ce:surname>Stephens</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Pharm. Des</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>340</first-page>
<last-page>346</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>White, U.A., Stephens, J.M.: The gp130 receptor cytokine family: regulators of adipocyte development and function. Curr. Pharm. Des. 17(4), 340–346 (2011)</ref-fulltext>
<ce:source-text>White, U.A., Stephens, J.M.: The gp130 receptor cytokine family: regulators of adipocyte development and function. Curr. Pharm. Des. 17(4), 340–346 (2011)</ce:source-text>
</reference>
<reference seq="26">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin-6 family cytokines</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Rose-John</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cold Spring Harb. Perspect. Biol</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Rose-John, S.: Interleukin-6 family cytokines. Cold Spring Harb. Perspect. Biol. 10(2) (2018)</ref-fulltext>
<ce:source-text>Rose-John, S.: Interleukin-6 family cytokines. Cold Spring Harb. Perspect. Biol. 10(2) (2018)</ce:source-text>
</reference>
<reference seq="27">
<ref-info>
<ref-title>
<ref-titletext-english>Leukemia inhibitory factor receptor is structurally related to the IL-6 signal transducer, gp130</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.P.</ce:initials>
<ce:surname>Gearing</ce:surname>
<ce:given-name>D.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>EMBO J</ref-sourcetitle>
<ref-publicationyear first="1991" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2839</first-page>
<last-page>2848</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gearing, D.P., et al.: Leukemia inhibitory factor receptor is structurally related to the IL-6 signal transducer, gp130. EMBO J. 10(10), 2839–2848 (1991)</ref-fulltext>
<ce:source-text>Gearing, D.P., et al.: Leukemia inhibitory factor receptor is structurally related to the IL-6 signal transducer, gp130. EMBO J. 10(10), 2839–2848 (1991)</ce:source-text>
</reference>
<reference seq="28">
<ref-info>
<ref-title>
<ref-titletext-english>Cardiotrophin-1. Biological activities and binding to the leukemia inhibitory factor receptor/gp130 signaling complex</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Pennica</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="1995" />
<volisspag>
<volume-issue-number>
<vol-first>270</vol-first>
<iss-first>18</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>10915</first-page>
<last-page>10922</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pennica, D., et al.: Cardiotrophin-1. Biological activities and binding to the leukemia inhibitory factor receptor/gp130 signaling complex. J. Biol. Chem. 270(18), 10915–10922 (1995)</ref-fulltext>
<ce:source-text>Pennica, D., et al.: Cardiotrophin-1. Biological activities and binding to the leukemia inhibitory factor receptor/gp130 signaling complex. J. Biol. Chem. 270(18), 10915–10922 (1995)</ce:source-text>
</reference>
<reference seq="29">
<ref-info>
<ref-title>
<ref-titletext-english>The IL-6 signal transducer, gp130: An oncostatin M receptor and affinity converter for the LIF receptor</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.P.</ce:initials>
<ce:surname>Gearing</ce:surname>
<ce:given-name>D.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="1992" />
<volisspag>
<volume-issue-number>
<vol-first>255</vol-first>
<iss-first>5050</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1434</first-page>
<last-page>1437</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gearing, D.P., et al.: The IL-6 signal transducer, gp130: An oncostatin M receptor and affinity converter for the LIF receptor. Science. 255(5050), 1434–1437 (1992)</ref-fulltext>
<ce:source-text>Gearing, D.P., et al.: The IL-6 signal transducer, gp130: An oncostatin M receptor and affinity converter for the LIF receptor. Science. 255(5050), 1434–1437 (1992)</ce:source-text>
</reference>
<reference seq="30">
<ref-info>
<ref-title>
<ref-titletext-english>Oncostatin M and leukemia inhibitory factor do not use the same functional receptor in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Ichihara</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Blood</ref-sourcetitle>
<ref-publicationyear first="1997" />
<volisspag>
<volume-issue-number>
<vol-first>90</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>165</first-page>
<last-page>173</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ichihara, M., et al.: Oncostatin M and leukemia inhibitory factor do not use the same functional receptor in mice. Blood. 90(1), 165–173 (1997)</ref-fulltext>
<ce:source-text>Ichihara, M., et al.: Oncostatin M and leukemia inhibitory factor do not use the same functional receptor in mice. Blood. 90(1), 165–173 (1997)</ce:source-text>
</reference>
<reference seq="31">
<ref-info>
<ref-title>
<ref-titletext-english>Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.M.</ce:initials>
<ce:surname>Hermanns</ce:surname>
<ce:given-name>H.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine Growth Factor Rev</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>545</first-page>
<last-page>558</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hermanns, H.M.: Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology. Cytokine Growth Factor Rev. 26(5), 545–558 (2015)</ref-fulltext>
<ce:source-text>Hermanns, H.M.: Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology. Cytokine Growth Factor Rev. 26(5), 545–558 (2015)</ce:source-text>
</reference>
<reference seq="32">
<ref-info>
<ref-title>
<ref-titletext-english>Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Mosley</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="1996" />
<volisspag>
<volume-issue-number>
<vol-first>271</vol-first>
<iss-first>51</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>32635</first-page>
<last-page>32643</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mosley, B., et al.: Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation. J. Biol. Chem. 271(51), 32635–32643 (1996)</ref-fulltext>
<ce:source-text>Mosley, B., et al.: Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation. J. Biol. Chem. 271(51), 32635–32643 (1996)</ce:source-text>
</reference>
<reference seq="33">
<ref-info>
<ref-title>
<ref-titletext-english>LIFR beta and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Davis</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="1993" />
<volisspag>
<volume-issue-number>
<vol-first>260</vol-first>
<iss-first>5115</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1805</first-page>
<last-page>1808</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Davis, S., et al.: LIFR beta and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor. Science. 260(5115), 1805–1808 (1993)</ref-fulltext>
<ce:source-text>Davis, S., et al.: LIFR beta and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor. Science. 260(5115), 1805–1808 (1993)</ce:source-text>
</reference>
<reference seq="34">
<ref-info>
<ref-title>
<ref-titletext-english>CLF associates with CLC to form a functional heteromeric ligand for the CNTF receptor complex</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.C.</ce:initials>
<ce:surname>Elson</ce:surname>
<ce:given-name>G.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Neurosci</ref-sourcetitle>
<ref-publicationyear first="2000" />
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>867</first-page>
<last-page>872</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Elson, G.C., et al.: CLF associates with CLC to form a functional heteromeric ligand for the CNTF receptor complex. Nat. Neurosci. 3(9), 867–872 (2000)</ref-fulltext>
<ce:source-text>Elson, G.C., et al.: CLF associates with CLC to form a functional heteromeric ligand for the CNTF receptor complex. Nat. Neurosci. 3(9), 867–872 (2000)</ce:source-text>
</reference>
<reference seq="35">
<ref-info>
<ref-title>
<ref-titletext-english>Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.A.</ce:initials>
<ce:surname>Jones</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.J.</ce:initials>
<ce:surname>Jenkins</ce:surname>
<ce:given-name>B.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Immunol</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>773</first-page>
<last-page>789</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Jones, S.A., Jenkins, B.J.: Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat. Rev. Immunol. 18(12), 773–789 (2018)</ref-fulltext>
<ce:source-text>Jones, S.A., Jenkins, B.J.: Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat. Rev. Immunol. 18(12), 773–789 (2018)</ce:source-text>
</reference>
<reference seq="36">
<ref-info>
<ref-title>
<ref-titletext-english>IL-6 in inflammation, immunity, and disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Tanaka</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Narazaki</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Kishimoto</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cold Spring Harb. Perspect. Biol</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Tanaka, T., Narazaki, M., Kishimoto, T.: IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect. Biol. 6(10), a016295 (2014)</ref-fulltext>
<ce:source-text>Tanaka, T., Narazaki, M., Kishimoto, T.: IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect. Biol. 6(10), a016295 (2014)</ce:source-text>
</reference>
<reference seq="37">
<ref-info>
<ref-title>
<ref-titletext-english>Factors affecting B-cell growth and differentiation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Kishimoto</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Annu. Rev. Immunol</ref-sourcetitle>
<ref-publicationyear first="1985" />
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>133</first-page>
<last-page>157</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kishimoto, T.: Factors affecting B-cell growth and differentiation. Annu. Rev. Immunol. 3, 133–157 (1985)</ref-fulltext>
<ce:source-text>Kishimoto, T.: Factors affecting B-cell growth and differentiation. Annu. Rev. Immunol. 3, 133–157 (1985)</ce:source-text>
</reference>
<reference seq="38">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin-6 and the acute phase response</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.C.</ce:initials>
<ce:surname>Heinrich</ce:surname>
<ce:given-name>P.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.V.</ce:initials>
<ce:surname>Castell</ce:surname>
<ce:given-name>J.V.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Andus</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochem. J</ref-sourcetitle>
<ref-publicationyear first="1990" />
<volisspag>
<volume-issue-number>
<vol-first>265</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>621</first-page>
<last-page>636</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Heinrich, P.C., Castell, J.V., Andus, T.: Interleukin-6 and the acute phase response. Biochem. J. 265(3), 621–636 (1990)</ref-fulltext>
<ce:source-text>Heinrich, P.C., Castell, J.V., Andus, T.: Interleukin-6 and the acute phase response. Biochem. J. 265(3), 621–636 (1990)</ce:source-text>
</reference>
<reference seq="39">
<ref-info>
<ref-title>
<ref-titletext-english>Targeting the IL-6/JAK/STAT3 signalling axis in cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.E.</ce:initials>
<ce:surname>Johnson</ce:surname>
<ce:given-name>D.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.A.</ce:initials>
<ce:surname>O’Keefe</ce:surname>
<ce:given-name>R.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.R.</ce:initials>
<ce:surname>Grandis</ce:surname>
<ce:given-name>J.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>234</first-page>
<last-page>248</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Johnson, D.E., O’Keefe, R.A., Grandis, J.R.: Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol. 15(4), 234–248 (2018)</ref-fulltext>
<ce:source-text>Johnson, D.E., O’Keefe, R.A., Grandis, J.R.: Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol. 15(4), 234–248 (2018)</ce:source-text>
</reference>
<reference seq="40">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin-6 is a potent thrombopoietic factor in vivo in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Ishibashi</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Blood</ref-sourcetitle>
<ref-publicationyear first="1989" />
<volisspag>
<volume-issue-number>
<vol-first>74</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1241</first-page>
<last-page>1244</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ishibashi, T., et al.: Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood. 74(4), 1241–1244 (1989)</ref-fulltext>
<ce:source-text>Ishibashi, T., et al.: Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood. 74(4), 1241–1244 (1989)</ce:source-text>
</reference>
<reference seq="41">
<ref-info>
<ref-title>
<ref-titletext-english>Molecular pathways: Cachexia signaling-A targeted approach to cancer treatment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Miyamoto</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>22</vol-first>
<iss-first>16</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3999</first-page>
<last-page>4004</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Miyamoto, Y., et al.: Molecular pathways: Cachexia signaling-A targeted approach to cancer treatment. Clin. Cancer Res. 22(16), 3999–4004 (2016)</ref-fulltext>
<ce:source-text>Miyamoto, Y., et al.: Molecular pathways: Cachexia signaling-A targeted approach to cancer treatment. Clin. Cancer Res. 22(16), 3999–4004 (2016)</ce:source-text>
</reference>
<reference seq="42">
<ref-info>
<ref-title>
<ref-titletext-english>Clodronate alleviates cachexia and prolongs survival in nude mice xenografted with an anaplastic thyroid carcinoma cell line</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.H.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>C.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Endocrinol</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>190</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>415</first-page>
<last-page>423</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, C.H., et al.: Clodronate alleviates cachexia and prolongs survival in nude mice xenografted with an anaplastic thyroid carcinoma cell line. J. Endocrinol. 190(2), 415–423 (2006)</ref-fulltext>
<ce:source-text>Wang, C.H., et al.: Clodronate alleviates cachexia and prolongs survival in nude mice xenografted with an anaplastic thyroid carcinoma cell line. J. Endocrinol. 190(2), 415–423 (2006)</ce:source-text>
</reference>
<reference seq="43">
<ref-info>
<ref-title>
<ref-titletext-english>IL-6 trans-signaling via the soluble IL-6 receptor: Importance for the pro-inflammatory activities of IL-6</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Rose-John</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Biol. Sci</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1237</first-page>
<last-page>1247</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rose-John, S.: IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int. J. Biol. Sci. 8(9), 1237–1247 (2012)</ref-fulltext>
<ce:source-text>Rose-John, S.: IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int. J. Biol. Sci. 8(9), 1237–1247 (2012)</ce:source-text>
</reference>
<reference seq="44">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia is mediated in part by the induction of IL-6-like cytokines from the spleen</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.E.</ce:initials>
<ce:surname>Barton</ce:surname>
<ce:given-name>B.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.F.</ce:initials>
<ce:surname>Murphy</ce:surname>
<ce:given-name>T.F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine</ref-sourcetitle>
<ref-publicationyear first="2001" />
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>251</first-page>
<last-page>257</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Barton, B.E., Murphy, T.F.: Cancer cachexia is mediated in part by the induction of IL-6-like cytokines from the spleen. Cytokine. 16(6), 251–257 (2001)</ref-fulltext>
<ce:source-text>Barton, B.E., Murphy, T.F.: Cancer cachexia is mediated in part by the induction of IL-6-like cytokines from the spleen. Cytokine. 16(6), 251–257 (2001)</ce:source-text>
</reference>
<reference seq="45">
<ref-info>
<ref-title>
<ref-titletext-english>Involvement of human interleukin 6 in experimental cachexia induced by a human uterine cervical carcinoma xenograft</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Tamura</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Cancer Res</ref-sourcetitle>
<ref-publicationyear first="1995" />
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1353</first-page>
<last-page>1358</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tamura, S., et al.: Involvement of human interleukin 6 in experimental cachexia induced by a human uterine cervical carcinoma xenograft. Clin. Cancer Res. 1(11), 1353–1358 (1995)</ref-fulltext>
<ce:source-text>Tamura, S., et al.: Involvement of human interleukin 6 in experimental cachexia induced by a human uterine cervical carcinoma xenograft. Clin. Cancer Res. 1(11), 1353–1358 (1995)</ce:source-text>
</reference>
<reference seq="46">
<ref-info>
<ref-title>
<ref-titletext-english>The colon-26 carcinoma tumor-bearing mouse as a model for the study of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Vis. Exp</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>117</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Bonetto, A., et al.: The colon-26 carcinoma tumor-bearing mouse as a model for the study of cancer cachexia. J. Vis. Exp. 117 (2016)</ref-fulltext>
<ce:source-text>Bonetto, A., et al.: The colon-26 carcinoma tumor-bearing mouse as a model for the study of cancer cachexia. J. Vis. Exp. 117 (2016)</ce:source-text>
</reference>
<reference seq="47">
<ref-info>
<ref-title>
<ref-titletext-english>Growth of ovarian cancer xenografts causes loss of muscle and bone mass: A new model for the study of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>685</first-page>
<last-page>700</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pin, F., et al.: Growth of ovarian cancer xenografts causes loss of muscle and bone mass: A new model for the study of cancer cachexia. J. Cachexia. Sarcopenia Muscle. 9(4), 685–700 (2018)</ref-fulltext>
<ce:source-text>Pin, F., et al.: Growth of ovarian cancer xenografts causes loss of muscle and bone mass: A new model for the study of cancer cachexia. J. Cachexia. Sarcopenia Muscle. 9(4), 685–700 (2018)</ce:source-text>
</reference>
<reference seq="48">
<ref-info>
<ref-title>
<ref-titletext-english>Evidence for the involvement of interleukin 6 in experimental cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Strassmann</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="1992" />
<volisspag>
<volume-issue-number>
<vol-first>89</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1681</first-page>
<last-page>1684</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Strassmann, G., et al.: Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J. Clin. Invest. 89(5), 1681–1684 (1992)</ref-fulltext>
<ce:source-text>Strassmann, G., et al.: Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J. Clin. Invest. 89(5), 1681–1684 (1992)</ce:source-text>
</reference>
<reference seq="49">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin 6 as a key regulator of muscle mass during cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Carson</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.A.</ce:initials>
<ce:surname>Baltgalvis</ce:surname>
<ce:given-name>K.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Exerc. Sport Sci. Rev</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>168</first-page>
<last-page>176</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Carson, J.A., Baltgalvis, K.A.: Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc. Sport Sci. Rev. 38(4), 168–176 (2010)</ref-fulltext>
<ce:source-text>Carson, J.A., Baltgalvis, K.A.: Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc. Sport Sci. Rev. 38(4), 168–176 (2010)</ce:source-text>
</reference>
<reference seq="50">
<ref-info>
<ref-title>
<ref-titletext-english>Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Fujimoto-Ouchi</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Chemother. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>59</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>807</first-page>
<last-page>815</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fujimoto-Ouchi, K., et al.: Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models. Cancer Chemother. Pharmacol. 59(6), 807–815 (2007)</ref-fulltext>
<ce:source-text>Fujimoto-Ouchi, K., et al.: Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models. Cancer Chemother. Pharmacol. 59(6), 807–815 (2007)</ce:source-text>
</reference>
<reference seq="51">
<ref-info>
<ref-title>
<ref-titletext-english>JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Endocrinol. Metab</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>303</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>E410</first-page>
<last-page>E421</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bonetto, A., et al.: JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am. J. Physiol. Endocrinol. Metab. 303(3), E410–E421 (2012)</ref-fulltext>
<ce:source-text>Bonetto, A., et al.: JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am. J. Physiol. Endocrinol. Metab. 303(3), E410–E421 (2012)</ce:source-text>
</reference>
<reference seq="52">
<ref-info>
<ref-title>
<ref-titletext-english>Establishment and characterization of cachexia-inducing and -non-inducing clones of murine colon 26 carcinoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Fujimoto-Ouchi</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="1995" />
<volisspag>
<volume-issue-number>
<vol-first>61</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>522</first-page>
<last-page>528</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fujimoto-Ouchi, K., et al.: Establishment and characterization of cachexia-inducing and -non-inducing clones of murine colon 26 carcinoma. Int. J. Cancer. 61(4), 522–528 (1995)</ref-fulltext>
<ce:source-text>Fujimoto-Ouchi, K., et al.: Establishment and characterization of cachexia-inducing and -non-inducing clones of murine colon 26 carcinoma. Int. J. Cancer. 61(4), 522–528 (1995)</ce:source-text>
</reference>
<reference seq="53">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor inoculation site affects the development of cancer cachexia and muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Matsuyama</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>137</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2558</first-page>
<last-page>2565</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Matsuyama, T., et al.: Tumor inoculation site affects the development of cancer cachexia and muscle wasting. Int. J. Cancer. 137(11), 2558–2565 (2015)</ref-fulltext>
<ce:source-text>Matsuyama, T., et al.: Tumor inoculation site affects the development of cancer cachexia and muscle wasting. Int. J. Cancer. 137(11), 2558–2565 (2015)</ce:source-text>
</reference>
<reference seq="54">
<ref-info>
<ref-title>
<ref-titletext-english>Myofiber degeneration/regeneration is induced in the cachectic ApcMin/+ mouse</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.A.</ce:initials>
<ce:surname>Mehl</ce:surname>
<ce:given-name>K.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Appl. Physiol. (1985)</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>99</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2379</first-page>
<last-page>2387</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mehl, K.A., et al.: Myofiber degeneration/regeneration is induced in the cachectic ApcMin/+ mouse. J. Appl. Physiol. (1985), 2005. 99(6): 2379–2387</ref-fulltext>
<ce:source-text>Mehl, K.A., et al.: Myofiber degeneration/regeneration is induced in the cachectic ApcMin/+ mouse. J. Appl. Physiol. (1985), 2005. 99(6): 2379–2387</ce:source-text>
</reference>
<reference seq="55">
<ref-info>
<ref-title>
<ref-titletext-english>A switch from white to brown fat increases energy expenditure in cancer-associated cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Petruzzelli</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>433</first-page>
<last-page>447</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Petruzzelli, M., et al.: A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab. 20(3), 433–447 (2014)</ref-fulltext>
<ce:source-text>Petruzzelli, M., et al.: A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab. 20(3), 433–447 (2014)</ce:source-text>
</reference>
<reference seq="56">
<ref-info>
<ref-title>
<ref-titletext-english>Parathyroid hormone-related protein (PTHrP) as a causative factor of cancer-associated wasting: Possible involvement of PTHrP in the repression of locomotor activity in rats bearing human tumor xenografts</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Onuma</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>116</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>471</first-page>
<last-page>478</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Onuma, E., et al.: Parathyroid hormone-related protein (PTHrP) as a causative factor of cancer-associated wasting: Possible involvement of PTHrP in the repression of locomotor activity in rats bearing human tumor xenografts. Int. J. Cancer. 116(3), 471–478 (2005)</ref-fulltext>
<ce:source-text>Onuma, E., et al.: Parathyroid hormone-related protein (PTHrP) as a causative factor of cancer-associated wasting: Possible involvement of PTHrP in the repression of locomotor activity in rats bearing human tumor xenografts. Int. J. Cancer. 116(3), 471–478 (2005)</ce:source-text>
</reference>
<reference seq="57">
<ref-info>
<ref-title>
<ref-titletext-english>Involvement of parathyroid hormone-related protein in experimental cachexia induced by a human lung cancer-derived cell line established from a bone metastasis specimen</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Iguchi</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2001" />
<volisspag>
<volume-issue-number>
<vol-first>94</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>24</first-page>
<last-page>27</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Iguchi, H., et al.: Involvement of parathyroid hormone-related protein in experimental cachexia induced by a human lung cancer-derived cell line established from a bone metastasis specimen. Int. J. Cancer. 94(1), 24–27 (2001)</ref-fulltext>
<ce:source-text>Iguchi, H., et al.: Involvement of parathyroid hormone-related protein in experimental cachexia induced by a human lung cancer-derived cell line established from a bone metastasis specimen. Int. J. Cancer. 94(1), 24–27 (2001)</ce:source-text>
</reference>
<reference seq="58">
<ref-info>
<ref-title>
<ref-titletext-english>CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.H.</ce:initials>
<ce:surname>Zaki</ce:surname>
<ce:given-name>M.H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.A.</ce:initials>
<ce:surname>Nemeth</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Trikha</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2004" />
<volisspag>
<volume-issue-number>
<vol-first>111</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>592</first-page>
<last-page>595</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zaki, M.H., Nemeth, J.A., Trikha, M.: CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int. J. Cancer. 111(4), 592–595 (2004)</ref-fulltext>
<ce:source-text>Zaki, M.H., Nemeth, J.A., Trikha, M.: CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int. J. Cancer. 111(4), 592–595 (2004)</ce:source-text>
</reference>
<reference seq="59">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.R.</ce:initials>
<ce:surname>Flint</ce:surname>
<ce:given-name>T.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>672</first-page>
<last-page>684</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Flint, T.R., et al.: Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity. Cell Metab. 24(5), 672–684 (2016)</ref-fulltext>
<ce:source-text>Flint, T.R., et al.: Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity. Cell Metab. 24(5), 672–684 (2016)</ce:source-text>
</reference>
<reference seq="60">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.E.</ce:initials>
<ce:surname>Rupert</ce:surname>
<ce:given-name>J.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Exp. Med</ref-sourcetitle>
<ref-publicationyear first="2021" />
<volisspag>
<volume-issue-number>
<vol-first>218</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Rupert, J.E., et al.: Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia. J. Exp. Med. 218(6), e20190450 (2021)</ref-fulltext>
<ce:source-text>Rupert, J.E., et al.: Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia. J. Exp. Med. 218(6), e20190450 (2021)</ce:source-text>
</reference>
<reference seq="61">
<ref-info>
<ref-title>
<ref-titletext-english>Role of cytokines in cancer cachexia in a murine model of intracerebral injection of human tumours</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.R.</ce:initials>
<ce:surname>Negri</ce:surname>
<ce:given-name>D.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine</ref-sourcetitle>
<ref-publicationyear first="2001" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>27</first-page>
<last-page>38</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Negri, D.R., et al.: Role of cytokines in cancer cachexia in a murine model of intracerebral injection of human tumours. Cytokine. 15(1), 27–38 (2001)</ref-fulltext>
<ce:source-text>Negri, D.R., et al.: Role of cytokines in cancer cachexia in a murine model of intracerebral injection of human tumours. Cytokine. 15(1), 27–38 (2001)</ce:source-text>
</reference>
<reference seq="62">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin-6 and cachexia in ApcMin/+ mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.A.</ce:initials>
<ce:surname>Baltgalvis</ce:surname>
<ce:given-name>K.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Regul. Integr. Comp. Physiol</ref-sourcetitle>
<ref-publicationyear first="2008" />
<volisspag>
<volume-issue-number>
<vol-first>294</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>R393</first-page>
<last-page>R401</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baltgalvis, K.A., et al.: Interleukin-6 and cachexia in ApcMin/+ mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294(2), R393–R401 (2008)</ref-fulltext>
<ce:source-text>Baltgalvis, K.A., et al.: Interleukin-6 and cachexia in ApcMin/+ mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294(2), R393–R401 (2008)</ce:source-text>
</reference>
<reference seq="63">
<ref-info>
<ref-title>
<ref-titletext-english>Ginsenoside Rb1 can ameliorate the key inflammatory cytokines TNF-alpha and IL-6 in a cancer cachexia mouse model</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Lu</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>BMC Complement Med Ther</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>11</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lu, S., et al.: Ginsenoside Rb1 can ameliorate the key inflammatory cytokines TNF-alpha and IL-6 in a cancer cachexia mouse model. BMC Complement Med Ther. 20(1), 11 (2020)</ref-fulltext>
<ce:source-text>Lu, S., et al.: Ginsenoside Rb1 can ameliorate the key inflammatory cytokines TNF-alpha and IL-6 in a cancer cachexia mouse model. BMC Complement Med Ther. 20(1), 11 (2020)</ce:source-text>
</reference>
<reference seq="64">
<ref-info>
<ref-title>
<ref-titletext-english>Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.G.</ce:initials>
<ce:surname>Liva</ce:surname>
<ce:given-name>S.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>EMBO Mol. Med</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Liva, S.G., et al.: Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor. EMBO Mol. Med. 12(2), e9910 (2020)</ref-fulltext>
<ce:source-text>Liva, S.G., et al.: Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor. EMBO Mol. Med. 12(2), e9910 (2020)</ce:source-text>
</reference>
<reference seq="65">
<ref-info>
<ref-title>
<ref-titletext-english>Coix seed oil ameliorates cancer cachexia by counteracting muscle loss and fat lipolysis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>BMC Complement. Altern. Med</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>267</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Liu, H., et al.: Coix seed oil ameliorates cancer cachexia by counteracting muscle loss and fat lipolysis. BMC Complement. Altern. Med. 19(1), 267 (2019)</ref-fulltext>
<ce:source-text>Liu, H., et al.: Coix seed oil ameliorates cancer cachexia by counteracting muscle loss and fat lipolysis. BMC Complement. Altern. Med. 19(1), 267 (2019)</ce:source-text>
</reference>
<reference seq="66">
<ref-info>
<ref-title>
<ref-titletext-english>A ketogenic formula prevents tumor progression and cancer cachexia by attenuating systemic inflammation in colon 26 tumor-bearing mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Nakamura</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nutrients</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Nakamura, K., et al.: A ketogenic formula prevents tumor progression and cancer cachexia by attenuating systemic inflammation in colon 26 tumor-bearing mice. Nutrients. 10(2) (2018)</ref-fulltext>
<ce:source-text>Nakamura, K., et al.: A ketogenic formula prevents tumor progression and cancer cachexia by attenuating systemic inflammation in colon 26 tumor-bearing mice. Nutrients. 10(2) (2018)</ce:source-text>
</reference>
<reference seq="67">
<ref-info>
<ref-title>
<ref-titletext-english>Dietary intake of probiotic kimchi ameliorated IL-6-driven cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>An</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Biochem. Nutr</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>65</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>109</first-page>
<last-page>117</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>An, J.M., et al.: Dietary intake of probiotic kimchi ameliorated IL-6-driven cancer cachexia. J. Clin. Biochem. Nutr. 65(2), 109–117 (2019)</ref-fulltext>
<ce:source-text>An, J.M., et al.: Dietary intake of probiotic kimchi ameliorated IL-6-driven cancer cachexia. J. Clin. Biochem. Nutr. 65(2), 109–117 (2019)</ce:source-text>
</reference>
<reference seq="68">
<ref-info>
<ref-title>
<ref-titletext-english>Suppression of cancer cachexia by 20S,21-epoxy-resibufogenin-3-acetate-a novel nonpeptide IL-6 receptor antagonist. Biochem. Biophys. Res</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Enomoto</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Commun</ref-sourcetitle>
<ref-publicationyear first="2004" />
<volisspag>
<volume-issue-number>
<vol-first>323</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1096</first-page>
<last-page>1102</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Enomoto, A., et al.: Suppression of cancer cachexia by 20S,21-epoxy-resibufogenin-3-acetate-a novel nonpeptide IL-6 receptor antagonist. Biochem. Biophys. Res. Commun. 323(3), 1096–1102 (2004)</ref-fulltext>
<ce:source-text>Enomoto, A., et al.: Suppression of cancer cachexia by 20S,21-epoxy-resibufogenin-3-acetate-a novel nonpeptide IL-6 receptor antagonist. Biochem. Biophys. Res. Commun. 323(3), 1096–1102 (2004)</ce:source-text>
</reference>
<reference seq="69">
<ref-info>
<ref-title>
<ref-titletext-english>The MEK-inhibitor selumetinib attenuates tumor growth and reduces IL-6 expression but does not protect against muscle wasting in lewis lung cancer cachexia. Front</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.D.</ce:initials>
<ce:surname>Au</ce:surname>
<ce:given-name>E.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Physiol</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>682</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Au, E.D., et al.: The MEK-inhibitor selumetinib attenuates tumor growth and reduces IL-6 expression but does not protect against muscle wasting in lewis lung cancer cachexia. Front. Physiol. 7, 682 (2016)</ref-fulltext>
<ce:source-text>Au, E.D., et al.: The MEK-inhibitor selumetinib attenuates tumor growth and reduces IL-6 expression but does not protect against muscle wasting in lewis lung cancer cachexia. Front. Physiol. 7, 682 (2016)</ce:source-text>
</reference>
<reference seq="70">
<ref-info>
<ref-title>
<ref-titletext-english>Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Miller</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
<iss-first>21</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3059</first-page>
<last-page>3066</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Miller, A., et al.: Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma. Oncogene. 36(21), 3059–3066 (2017)</ref-fulltext>
<ce:source-text>Miller, A., et al.: Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma. Oncogene. 36(21), 3059–3066 (2017)</ce:source-text>
</reference>
<reference seq="71">
<ref-info>
<ref-title>
<ref-titletext-english>STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Bonetto, A., et al.: STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS One. 6(7), e22538 (2011)</ref-fulltext>
<ce:source-text>Bonetto, A., et al.: STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS One. 6(7), e22538 (2011)</ce:source-text>
</reference>
<reference seq="72">
<ref-info>
<ref-title>
<ref-titletext-english>Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Mantovani</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Mol. Med. (Berl).</ref-sourcetitle>
<ref-publicationyear first="2000" />
<volisspag>
<volume-issue-number>
<vol-first>78</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>554</first-page>
<last-page>561</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mantovani, G., et al.: Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J. Mol. Med. (Berl). 78(10), 554–561 (2000)</ref-fulltext>
<ce:source-text>Mantovani, G., et al.: Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J. Mol. Med. (Berl). 78(10), 554–561 (2000)</ce:source-text>
</reference>
<reference seq="73">
<ref-info>
<ref-title>
<ref-titletext-english>The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc(Min/+) mouse</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.P.</ce:initials>
<ce:surname>White</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>White, J.P., et al.: The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc(Min/+) mouse. PLoS One. 6(9), e24650 (2011)</ref-fulltext>
<ce:source-text>White, J.P., et al.: The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc(Min/+) mouse. PLoS One. 6(9), e24650 (2011)</ce:source-text>
</reference>
<reference seq="74">
<ref-info>
<ref-title>
<ref-titletext-english>Differential effects of IL6 and activin A in the development of cancer-associated cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.L.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>J.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>76</vol-first>
<iss-first>18</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5372</first-page>
<last-page>5382</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, J.L., et al.: Differential effects of IL6 and activin A in the development of cancer-associated cachexia. Cancer Res. 76(18), 5372–5382 (2016)</ref-fulltext>
<ce:source-text>Chen, J.L., et al.: Differential effects of IL6 and activin A in the development of cancer-associated cachexia. Cancer Res. 76(18), 5372–5382 (2016)</ce:source-text>
</reference>
<reference seq="75">
<ref-info>
<ref-title>
<ref-titletext-english>The regulation of skeletal muscle fatigability and mitochondrial function by chronically elevated interleukin-6</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.N.</ce:initials>
<ce:surname>Vanderveen</ce:surname>
<ce:given-name>B.N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Exp. Physiol</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>104</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>385</first-page>
<last-page>397</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>VanderVeen, B.N., et al.: The regulation of skeletal muscle fatigability and mitochondrial function by chronically elevated interleukin-6. Exp. Physiol. 104(3), 385–397 (2019)</ref-fulltext>
<ce:source-text>VanderVeen, B.N., et al.: The regulation of skeletal muscle fatigability and mitochondrial function by chronically elevated interleukin-6. Exp. Physiol. 104(3), 385–397 (2019)</ce:source-text>
</reference>
<reference seq="76">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin 6 is associated with cachexia in patients with prostate cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Kuroda</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Urology</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>69</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>113</first-page>
<last-page>117</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kuroda, K., et al.: Interleukin 6 is associated with cachexia in patients with prostate cancer. Urology. 69(1), 113–117 (2007)</ref-fulltext>
<ce:source-text>Kuroda, K., et al.: Interleukin 6 is associated with cachexia in patients with prostate cancer. Urology. 69(1), 113–117 (2007)</ce:source-text>
</reference>
<reference seq="77">
<ref-info>
<ref-title>
<ref-titletext-english>Relationships between oxycodone pharmacokinetics, symptoms, and serum interleukin-6 in cachectic cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Sato</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Clin. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>72</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1463</first-page>
<last-page>1470</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sato, H., et al.: Relationships between oxycodone pharmacokinetics, symptoms, and serum interleukin-6 in cachectic cancer patients. Eur. J. Clin. Pharmacol. 72(12), 1463–1470 (2016)</ref-fulltext>
<ce:source-text>Sato, H., et al.: Relationships between oxycodone pharmacokinetics, symptoms, and serum interleukin-6 in cachectic cancer patients. Eur. J. Clin. Pharmacol. 72(12), 1463–1470 (2016)</ce:source-text>
</reference>
<reference seq="78">
<ref-info>
<ref-title>
<ref-titletext-english>IL-6 mediated JAK/STAT3 signaling pathway in cancer patients with cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.G.</ce:initials>
<ce:surname>Eskiler</ce:surname>
<ce:given-name>G.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Bratisl. Lek. Listy</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>66</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>819</first-page>
<last-page>826</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Eskiler, G.G., et al.: IL-6 mediated JAK/STAT3 signaling pathway in cancer patients with cachexia. Bratisl. Lek. Listy. 66(11), 819–826 (2019)</ref-fulltext>
<ce:source-text>Eskiler, G.G., et al.: IL-6 mediated JAK/STAT3 signaling pathway in cancer patients with cachexia. Bratisl. Lek. Listy. 66(11), 819–826 (2019)</ce:source-text>
</reference>
<reference seq="79">
<ref-info>
<ref-title>
<ref-titletext-english>Steep elevation of blood interleukin-6 (IL-6) associated only with late stages of cachexia in cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Iwase</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. Cytokine Netw</ref-sourcetitle>
<ref-publicationyear first="2004" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>312</first-page>
<last-page>316</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Iwase, S., et al.: Steep elevation of blood interleukin-6 (IL-6) associated only with late stages of cachexia in cancer patients. Eur. Cytokine Netw. 15(4), 312–316 (2004)</ref-fulltext>
<ce:source-text>Iwase, S., et al.: Steep elevation of blood interleukin-6 (IL-6) associated only with late stages of cachexia in cancer patients. Eur. Cytokine Netw. 15(4), 312–316 (2004)</ce:source-text>
</reference>
<reference seq="80">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin-6 induces fat loss in cancer cachexia by promoting white adipose tissue lipolysis and browning</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Han</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Lipids Health Dis</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>14</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Han, J., et al.: Interleukin-6 induces fat loss in cancer cachexia by promoting white adipose tissue lipolysis and browning. Lipids Health Dis. 17(1), 14 (2018)</ref-fulltext>
<ce:source-text>Han, J., et al.: Interleukin-6 induces fat loss in cancer cachexia by promoting white adipose tissue lipolysis and browning. Lipids Health Dis. 17(1), 14 (2018)</ce:source-text>
</reference>
<reference seq="81">
<ref-info>
<ref-title>
<ref-titletext-english>Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naive pancreatic cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.E.</ce:initials>
<ce:surname>Talbert</ce:surname>
<ce:given-name>E.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>358</first-page>
<last-page>368</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Talbert, E.E., et al.: Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naive pancreatic cancer patients. J. Cachexia. Sarcopenia Muscle. 9(2), 358–368 (2018)</ref-fulltext>
<ce:source-text>Talbert, E.E., et al.: Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naive pancreatic cancer patients. J. Cachexia. Sarcopenia Muscle. 9(2), 358–368 (2018)</ce:source-text>
</reference>
<reference seq="82">
<ref-info>
<ref-title>
<ref-titletext-english>Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Garcia</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Endocrinol. Metab</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>90</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2920</first-page>
<last-page>2926</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Garcia, J.M., et al.: Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J. Clin. Endocrinol. Metab. 90(5), 2920–2926 (2005)</ref-fulltext>
<ce:source-text>Garcia, J.M., et al.: Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J. Clin. Endocrinol. Metab. 90(5), 2920–2926 (2005)</ce:source-text>
</reference>
<reference seq="83">
<ref-info>
<ref-title>
<ref-titletext-english>Predicting survival in cancer patients: The role of cachexia and hormonal, nutritional and inflammatory markers</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.E.</ce:initials>
<ce:surname>Utech</ce:surname>
<ce:given-name>A.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>245</first-page>
<last-page>251</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Utech, A.E., et al.: Predicting survival in cancer patients: The role of cachexia and hormonal, nutritional and inflammatory markers. J. Cachexia. Sarcopenia Muscle. 3(4), 245–251 (2012)</ref-fulltext>
<ce:source-text>Utech, A.E., et al.: Predicting survival in cancer patients: The role of cachexia and hormonal, nutritional and inflammatory markers. J. Cachexia. Sarcopenia Muscle. 3(4), 245–251 (2012)</ce:source-text>
</reference>
<reference seq="84">
<ref-info>
<ref-title>
<ref-titletext-english>Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Ando</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>31</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>e69</first-page>
<last-page>e72</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ando, K., et al.: Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia. J. Clin. Oncol. 31(6), e69–e72 (2013)</ref-fulltext>
<ce:source-text>Ando, K., et al.: Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia. J. Clin. Oncol. 31(6), e69–e72 (2013)</ce:source-text>
</reference>
<reference seq="85">
<ref-info>
<ref-title>
<ref-titletext-english>Molecular cloning and expression of cDNA encoding a murine myeloid leukaemia inhibitory factor (LIF)</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.P.</ce:initials>
<ce:surname>Gearing</ce:surname>
<ce:given-name>D.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>EMBO J</ref-sourcetitle>
<ref-publicationyear first="1987" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>13</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3995</first-page>
<last-page>4002</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gearing, D.P., et al.: Molecular cloning and expression of cDNA encoding a murine myeloid leukaemia inhibitory factor (LIF). EMBO J. 6(13), 3995–4002 (1987)</ref-fulltext>
<ce:source-text>Gearing, D.P., et al.: Molecular cloning and expression of cDNA encoding a murine myeloid leukaemia inhibitory factor (LIF). EMBO J. 6(13), 3995–4002 (1987)</ce:source-text>
</reference>
<reference seq="86">
<ref-info>
<ref-title>
<ref-titletext-english>Inhibition of pluripotential embryonic stem cell differentiation by purified polypeptides</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.G.</ce:initials>
<ce:surname>Smith</ce:surname>
<ce:given-name>A.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="1988" />
<volisspag>
<volume-issue-number>
<vol-first>336</vol-first>
<iss-first>6200</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>688</first-page>
<last-page>690</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Smith, A.G., et al.: Inhibition of pluripotential embryonic stem cell differentiation by purified polypeptides. Nature. 336(6200), 688–690 (1988)</ref-fulltext>
<ce:source-text>Smith, A.G., et al.: Inhibition of pluripotential embryonic stem cell differentiation by purified polypeptides. Nature. 336(6200), 688–690 (1988)</ce:source-text>
</reference>
<reference seq="87">
<ref-info>
<ref-title>
<ref-titletext-english>Distinct sets of acute phase plasma proteins are stimulated by separate human hepatocyte-stimulating factors and monokines in rat hepatoma cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Baumann</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="1987" />
<volisspag>
<volume-issue-number>
<vol-first>262</vol-first>
<iss-first>20</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>9756</first-page>
<last-page>9768</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baumann, H., et al.: Distinct sets of acute phase plasma proteins are stimulated by separate human hepatocyte-stimulating factors and monokines in rat hepatoma cells. J. Biol. Chem. 262(20), 9756–9768 (1987)</ref-fulltext>
<ce:source-text>Baumann, H., et al.: Distinct sets of acute phase plasma proteins are stimulated by separate human hepatocyte-stimulating factors and monokines in rat hepatoma cells. J. Biol. Chem. 262(20), 9756–9768 (1987)</ce:source-text>
</reference>
<reference seq="88">
<ref-info>
<ref-title>
<ref-titletext-english>The induction of acetylcholine synthesis in primary cultures of dissociated rat sympathetic neurons. II. Developmental aspects</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.H.</ce:initials>
<ce:surname>Patterson</ce:surname>
<ce:given-name>P.H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.L.</ce:initials>
<ce:surname>Chun</ce:surname>
<ce:given-name>L.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Dev Biol</ref-sourcetitle>
<ref-publicationyear first="1977" />
<volisspag>
<volume-issue-number>
<vol-first>60</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>473</first-page>
<last-page>481</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Patterson, P.H., Chun, L.L.: The induction of acetylcholine synthesis in primary cultures of dissociated rat sympathetic neurons. II. Developmental aspects. Dev Biol. 60(2), 473–481 (1977)</ref-fulltext>
<ce:source-text>Patterson, P.H., Chun, L.L.: The induction of acetylcholine synthesis in primary cultures of dissociated rat sympathetic neurons. II. Developmental aspects. Dev Biol. 60(2), 473–481 (1977)</ce:source-text>
</reference>
<reference seq="89">
<ref-info>
<ref-title>
<ref-titletext-english>Purification of a lipoprotein lipase-inhibiting protein produced by a melanoma cell line associated with cancer cachexia. Biochem. Biophys. Res</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Mori</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Yamaguchi</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.</ce:initials>
<ce:surname>Abe</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Commun</ref-sourcetitle>
<ref-publicationyear first="1989" />
<volisspag>
<volume-issue-number>
<vol-first>160</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1085</first-page>
<last-page>1092</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mori, M., Yamaguchi, K., Abe, K.: Purification of a lipoprotein lipase-inhibiting protein produced by a melanoma cell line associated with cancer cachexia. Biochem. Biophys. Res. Commun. 160(3), 1085–1092 (1989)</ref-fulltext>
<ce:source-text>Mori, M., Yamaguchi, K., Abe, K.: Purification of a lipoprotein lipase-inhibiting protein produced by a melanoma cell line associated with cancer cachexia. Biochem. Biophys. Res. Commun. 160(3), 1085–1092 (1989)</ce:source-text>
</reference>
<reference seq="90">
<ref-info>
<ref-title>
<ref-titletext-english>Leukemia inhibitory factor (LIF)</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.A.</ce:initials>
<ce:surname>Nicola</ce:surname>
<ce:given-name>N.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.J.</ce:initials>
<ce:surname>Babon</ce:surname>
<ce:given-name>J.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine Growth Factor Rev</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>533</first-page>
<last-page>544</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nicola, N.A., Babon, J.J.: Leukemia inhibitory factor (LIF). Cytokine Growth Factor Rev. 26(5), 533–544 (2015)</ref-fulltext>
<ce:source-text>Nicola, N.A., Babon, J.J.: Leukemia inhibitory factor (LIF). Cytokine Growth Factor Rev. 26(5), 533–544 (2015)</ce:source-text>
</reference>
<reference seq="91">
<ref-info>
<ref-title>
<ref-titletext-english>The crystal structure and biological function of leukemia inhibitory factor: Implications for receptor binding</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.C.</ce:initials>
<ce:surname>Robinson</ce:surname>
<ce:given-name>R.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="1994" />
<volisspag>
<volume-issue-number>
<vol-first>77</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1101</first-page>
<last-page>1116</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Robinson, R.C., et al.: The crystal structure and biological function of leukemia inhibitory factor: implications for receptor binding. Cell. 77(7), 1101–1116 (1994)</ref-fulltext>
<ce:source-text>Robinson, R.C., et al.: The crystal structure and biological function of leukemia inhibitory factor: implications for receptor binding. Cell. 77(7), 1101–1116 (1994)</ce:source-text>
</reference>
<reference seq="92">
<ref-info>
<ref-title>
<ref-titletext-english>Kinetic analyses of the binding of leukemia inhibitory factor to receptor on cells and membranes and in detergent solution</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.J.</ce:initials>
<ce:surname>Hilton</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>N.A.</ce:initials>
<ce:surname>Nicola</ce:surname>
<ce:given-name>N.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="1992" />
<volisspag>
<volume-issue-number>
<vol-first>267</vol-first>
<iss-first>15</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>10238</first-page>
<last-page>10247</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hilton, D.J., Nicola, N.A.: Kinetic analyses of the binding of leukemia inhibitory factor to receptor on cells and membranes and in detergent solution. J. Biol. Chem. 267(15), 10238–10247 (1992)</ref-fulltext>
<ce:source-text>Hilton, D.J., Nicola, N.A.: Kinetic analyses of the binding of leukemia inhibitory factor to receptor on cells and membranes and in detergent solution. J. Biol. Chem. 267(15), 10238–10247 (1992)</ce:source-text>
</reference>
<reference seq="93">
<ref-info>
<ref-title>
<ref-titletext-english>Myeloid leukaemia inhibitory factor maintains the developmental potential of embryonic stem cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.L.</ce:initials>
<ce:surname>Williams</ce:surname>
<ce:given-name>R.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="1988" />
<volisspag>
<volume-issue-number>
<vol-first>336</vol-first>
<iss-first>6200</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>684</first-page>
<last-page>687</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Williams, R.L., et al.: Myeloid leukaemia inhibitory factor maintains the developmental potential of embryonic stem cells. Nature. 336(6200), 684–687 (1988)</ref-fulltext>
<ce:source-text>Williams, R.L., et al.: Myeloid leukaemia inhibitory factor maintains the developmental potential of embryonic stem cells. Nature. 336(6200), 684–687 (1988)</ce:source-text>
</reference>
<reference seq="94">
<ref-info>
<ref-title>
<ref-titletext-english>Distribution and comparison of receptors for leukemia inhibitory factor on murine hemopoietic and hepatic cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.J.</ce:initials>
<ce:surname>Hilton</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>N.A.</ce:initials>
<ce:surname>Nicola</ce:surname>
<ce:given-name>N.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Metcalf</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Physiol</ref-sourcetitle>
<ref-publicationyear first="1991" />
<volisspag>
<volume-issue-number>
<vol-first>146</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>207</first-page>
<last-page>215</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hilton, D.J., Nicola, N.A., Metcalf, D.: Distribution and comparison of receptors for leukemia inhibitory factor on murine hemopoietic and hepatic cells. J. Cell. Physiol. 146(2), 207–215 (1991)</ref-fulltext>
<ce:source-text>Hilton, D.J., Nicola, N.A., Metcalf, D.: Distribution and comparison of receptors for leukemia inhibitory factor on murine hemopoietic and hepatic cells. J. Cell. Physiol. 146(2), 207–215 (1991)</ce:source-text>
</reference>
<reference seq="95">
<ref-info>
<ref-title>
<ref-titletext-english>Expression of leukemia inhibitory factor receptor and gp130 in mouse uterus during early pregnancy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Ni</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Reprod. Dev</ref-sourcetitle>
<ref-publicationyear first="2002" />
<volisspag>
<volume-issue-number>
<vol-first>63</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>143</first-page>
<last-page>150</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ni, H., et al.: Expression of leukemia inhibitory factor receptor and gp130 in mouse uterus during early pregnancy. Mol. Reprod. Dev. 63(2), 143–150 (2002)</ref-fulltext>
<ce:source-text>Ni, H., et al.: Expression of leukemia inhibitory factor receptor and gp130 in mouse uterus during early pregnancy. Mol. Reprod. Dev. 63(2), 143–150 (2002)</ce:source-text>
</reference>
<reference seq="96">
<ref-info>
<ref-title>
<ref-titletext-english>Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.C.</ce:initials>
<ce:surname>Walker</ce:surname>
<ce:given-name>E.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>120</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>582</first-page>
<last-page>592</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Walker, E.C., et al.: Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. J. Clin. Invest. 120(2), 582–592 (2010)</ref-fulltext>
<ce:source-text>Walker, E.C., et al.: Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. J. Clin. Invest. 120(2), 582–592 (2010)</ce:source-text>
</reference>
<reference seq="97">
<ref-info>
<ref-title>
<ref-titletext-english>Murine leukemia inhibitory factor gene disruption attenuates the hypothalamo-pituitary-adrenal axis stress response</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.</ce:initials>
<ce:surname>Chesnokova</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.J.</ce:initials>
<ce:surname>Auernhammer</ce:surname>
<ce:given-name>C.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Melmed</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Endocrinology</ref-sourcetitle>
<ref-publicationyear first="1998" />
<volisspag>
<volume-issue-number>
<vol-first>139</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2209</first-page>
<last-page>2216</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chesnokova, V., Auernhammer, C.J., Melmed, S.: Murine leukemia inhibitory factor gene disruption attenuates the hypothalamo-pituitary-adrenal axis stress response. Endocrinology. 139(5), 2209–2216 (1998)</ref-fulltext>
<ce:source-text>Chesnokova, V., Auernhammer, C.J., Melmed, S.: Murine leukemia inhibitory factor gene disruption attenuates the hypothalamo-pituitary-adrenal axis stress response. Endocrinology. 139(5), 2209–2216 (1998)</ce:source-text>
</reference>
<reference seq="98">
<ref-info>
<ref-title>
<ref-titletext-english>Leukemia inhibitory factor blocks early differentiation of skeletal muscle cells by activating ERK</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Jo</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochim. Biophys. Acta</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>1743</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>187</first-page>
<last-page>197</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Jo, C., et al.: Leukemia inhibitory factor blocks early differentiation of skeletal muscle cells by activating ERK. Biochim. Biophys. Acta. 1743(3), 187–197 (2005)</ref-fulltext>
<ce:source-text>Jo, C., et al.: Leukemia inhibitory factor blocks early differentiation of skeletal muscle cells by activating ERK. Biochim. Biophys. Acta. 1743(3), 187–197 (2005)</ce:source-text>
</reference>
<reference seq="99">
<ref-info>
<ref-title>
<ref-titletext-english>LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>788</first-page>
<last-page>801</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Li, X., et al.: LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway. Oncotarget. 5(3), 788–801 (2014)</ref-fulltext>
<ce:source-text>Li, X., et al.: LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway. Oncotarget. 5(3), 788–801 (2014)</ce:source-text>
</reference>
<reference seq="100">
<ref-info>
<ref-title>
<ref-titletext-english>Leukemia inhibitory factor promotes EMT through STAT3-dependent miR-21 induction</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Yue</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3777</first-page>
<last-page>3790</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yue, X., et al.: Leukemia inhibitory factor promotes EMT through STAT3-dependent miR-21 induction. Oncotarget. 7(4), 3777–3790 (2016)</ref-fulltext>
<ce:source-text>Yue, X., et al.: Leukemia inhibitory factor promotes EMT through STAT3-dependent miR-21 induction. Oncotarget. 7(4), 3777–3790 (2016)</ce:source-text>
</reference>
<reference seq="101">
<ref-info>
<ref-title>
<ref-titletext-english>Fatal syndrome in mice engrafted with cells producing high levels of the leukemia inhibitory factor</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Metcalf</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.P.</ce:initials>
<ce:surname>Gearing</ce:surname>
<ce:given-name>D.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="1989" />
<volisspag>
<volume-issue-number>
<vol-first>86</vol-first>
<iss-first>15</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5948</first-page>
<last-page>5952</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Metcalf, D., Gearing, D.P.: Fatal syndrome in mice engrafted with cells producing high levels of the leukemia inhibitory factor. Proc. Natl. Acad. Sci. USA. 86(15), 5948–5952 (1989)</ref-fulltext>
<ce:source-text>Metcalf, D., Gearing, D.P.: Fatal syndrome in mice engrafted with cells producing high levels of the leukemia inhibitory factor. Proc. Natl. Acad. Sci. USA. 86(15), 5948–5952 (1989)</ce:source-text>
</reference>
<reference seq="102">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia syndrome developed in nude mice bearing melanoma cells producing leukemia-inhibitory factor</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Mori</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="1991" />
<volisspag>
<volume-issue-number>
<vol-first>51</vol-first>
<iss-first>24</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>6656</first-page>
<last-page>6659</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mori, M., et al.: Cancer cachexia syndrome developed in nude mice bearing melanoma cells producing leukemia-inhibitory factor. Cancer Res. 51(24), 6656–6659 (1991)</ref-fulltext>
<ce:source-text>Mori, M., et al.: Cancer cachexia syndrome developed in nude mice bearing melanoma cells producing leukemia-inhibitory factor. Cancer Res. 51(24), 6656–6659 (1991)</ce:source-text>
</reference>
<reference seq="103">
<ref-info>
<ref-title>
<ref-titletext-english>Leukemia inhibitory factor functions as a growth factor in pancreas carcinoma cells: Involvement of regulation of LIF and its receptor expression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Kamohara</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Oncol</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>977</first-page>
<last-page>983</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kamohara, H., et al.: Leukemia inhibitory factor functions as a growth factor in pancreas carcinoma cells: involvement of regulation of LIF and its receptor expression. Int. J. Oncol. 30(4), 977–983 (2007)</ref-fulltext>
<ce:source-text>Kamohara, H., et al.: Leukemia inhibitory factor functions as a growth factor in pancreas carcinoma cells: involvement of regulation of LIF and its receptor expression. Int. J. Oncol. 30(4), 977–983 (2007)</ce:source-text>
</reference>
<reference seq="104">
<ref-info>
<ref-title>
<ref-titletext-english>Production of multiple cytokines and induction of cachexia in athymic nude mice by a new anaplastic thyroid carcinoma cell line</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.W.</ce:initials>
<ce:surname>Chang</ce:surname>
<ce:given-name>J.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Endocrinol</ref-sourcetitle>
<ref-publicationyear first="2003" />
<volisspag>
<volume-issue-number>
<vol-first>179</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>387</first-page>
<last-page>394</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chang, J.W., et al.: Production of multiple cytokines and induction of cachexia in athymic nude mice by a new anaplastic thyroid carcinoma cell line. J. Endocrinol. 179(3), 387–394 (2003)</ref-fulltext>
<ce:source-text>Chang, J.W., et al.: Production of multiple cytokines and induction of cachexia in athymic nude mice by a new anaplastic thyroid carcinoma cell line. J. Endocrinol. 179(3), 387–394 (2003)</ce:source-text>
</reference>
<reference seq="105">
<ref-info>
<ref-title>
<ref-titletext-english>Expression of cancer cachexia-related factors in human cancer xenografts: An immunohistochemical analysis. Biomed</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Kamoshida</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Res</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>275</first-page>
<last-page>281</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kamoshida, S., et al.: Expression of cancer cachexia-related factors in human cancer xenografts: An immunohistochemical analysis. Biomed. Res. 27(6), 275–281 (2006)</ref-fulltext>
<ce:source-text>Kamoshida, S., et al.: Expression of cancer cachexia-related factors in human cancer xenografts: An immunohistochemical analysis. Biomed. Res. 27(6), 275–281 (2006)</ce:source-text>
</reference>
<reference seq="106">
<ref-info>
<ref-title>
<ref-titletext-english>Cytokine production in five tumor cell lines with activity to induce cancer cachexia syndrome in nude mice. Jpn</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Iseki</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cancer Res</ref-sourcetitle>
<ref-publicationyear first="1995" />
<volisspag>
<volume-issue-number>
<vol-first>86</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>562</first-page>
<last-page>567</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Iseki, H., et al.: Cytokine production in five tumor cell lines with activity to induce cancer cachexia syndrome in nude mice. Jpn. J. Cancer Res. 86(6), 562–567 (1995)</ref-fulltext>
<ce:source-text>Iseki, H., et al.: Cytokine production in five tumor cell lines with activity to induce cancer cachexia syndrome in nude mice. Jpn. J. Cancer Res. 86(6), 562–567 (1995)</ce:source-text>
</reference>
<reference seq="107">
<ref-info>
<ref-title>
<ref-titletext-english>Triple paraneoplastic syndrome of hypercalcemia, leukocytosis and cachexia in two human tumor xenografts in nude mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Tanaka</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Jpn. J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="1996" />
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>88</first-page>
<last-page>94</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tanaka, R., et al.: Triple paraneoplastic syndrome of hypercalcemia, leukocytosis and cachexia in two human tumor xenografts in nude mice. Jpn. J. Clin. Oncol. 26(2), 88–94 (1996)</ref-fulltext>
<ce:source-text>Tanaka, R., et al.: Triple paraneoplastic syndrome of hypercalcemia, leukocytosis and cachexia in two human tumor xenografts in nude mice. Jpn. J. Clin. Oncol. 26(2), 88–94 (1996)</ce:source-text>
</reference>
<reference seq="108">
<ref-info>
<ref-title>
<ref-titletext-english>Leukemia inhibitory factor via the Toll-like receptor 5 signaling pathway involves aggravation of cachexia induced by human gastric cancer-derived 85As2 cells in rats</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Terawaki</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>78</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>34748</first-page>
<last-page>34764</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Terawaki, K., et al.: Leukemia inhibitory factor via the Toll-like receptor 5 signaling pathway involves aggravation of cachexia induced by human gastric cancer-derived 85As2 cells in rats. Oncotarget. 9(78), 34748–34764 (2018)</ref-fulltext>
<ce:source-text>Terawaki, K., et al.: Leukemia inhibitory factor via the Toll-like receptor 5 signaling pathway involves aggravation of cachexia induced by human gastric cancer-derived 85As2 cells in rats. Oncotarget. 9(78), 34748–34764 (2018)</ce:source-text>
</reference>
<reference seq="109">
<ref-info>
<ref-title>
<ref-titletext-english>A key role for leukemia inhibitory factor in c26 cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.N.</ce:initials>
<ce:surname>Seto</ce:surname>
<ce:given-name>D.N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.C.</ce:initials>
<ce:surname>Kandarian</ce:surname>
<ce:given-name>S.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.W.</ce:initials>
<ce:surname>Jackman</ce:surname>
<ce:given-name>R.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>290</vol-first>
<iss-first>32</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>19976</first-page>
<last-page>19986</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Seto, D.N., Kandarian, S.C., Jackman, R.W.: A key role for leukemia inhibitory factor in c26 cancer cachexia. J. Biol. Chem. 290(32), 19976–19986 (2015)</ref-fulltext>
<ce:source-text>Seto, D.N., Kandarian, S.C., Jackman, R.W.: A key role for leukemia inhibitory factor in c26 cancer cachexia. J. Biol. Chem. 290(32), 19976–19986 (2015)</ce:source-text>
</reference>
<reference seq="110">
<ref-info>
<ref-title>
<ref-titletext-english>Cachexia-associated adipose loss induced by tumor-secreted leukemia inhibitory factor is counterbalanced by decreased leptin</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.K.</ce:initials>
<ce:surname>Arora</ce:surname>
<ce:given-name>G.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Jci Insight</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>14</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>26</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Arora, G.K., et al.: Cachexia-associated adipose loss induced by tumor-secreted leukemia inhibitory factor is counterbalanced by decreased leptin. Jci Insight. 3(14), 26 (2018)</ref-fulltext>
<ce:source-text>Arora, G.K., et al.: Cachexia-associated adipose loss induced by tumor-secreted leukemia inhibitory factor is counterbalanced by decreased leptin. Jci Insight. 3(14), 26 (2018)</ce:source-text>
</reference>
<reference seq="111">
<ref-info>
<ref-title>
<ref-titletext-english>In vivo effect of recombinant human leukemia inhibitory factor in primates. Jpn</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Akiyama</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cancer Res</ref-sourcetitle>
<ref-publicationyear first="1997" />
<volisspag>
<volume-issue-number>
<vol-first>88</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>578</first-page>
<last-page>583</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Akiyama, Y., et al.: In vivo effect of recombinant human leukemia inhibitory factor in primates. Jpn. J. Cancer Res. 88(6), 578–583 (1997)</ref-fulltext>
<ce:source-text>Akiyama, Y., et al.: In vivo effect of recombinant human leukemia inhibitory factor in primates. Jpn. J. Cancer Res. 88(6), 578–583 (1997)</ce:source-text>
</reference>
<reference seq="112">
<ref-info>
<ref-title>
<ref-titletext-english>Tumour-derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour-bearing mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.C.</ce:initials>
<ce:surname>Kandarian</ce:surname>
<ce:given-name>S.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1109</first-page>
<last-page>1120</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kandarian, S.C., et al.: Tumour-derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour-bearing mice. J. Cachexia. Sarcopenia Muscle. 9(6), 1109–1120 (2018)</ref-fulltext>
<ce:source-text>Kandarian, S.C., et al.: Tumour-derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour-bearing mice. J. Cachexia. Sarcopenia Muscle. 9(6), 1109–1120 (2018)</ce:source-text>
</reference>
<reference seq="113">
<ref-info>
<ref-title>
<ref-titletext-english>New cancer cachexia rat model generated by implantation of a peritoneal dissemination-derived human stomach cancer cell line</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Terawaki</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Endocrinol. Metab</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>306</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>E373</first-page>
<last-page>E387</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Terawaki, K., et al.: New cancer cachexia rat model generated by implantation of a peritoneal dissemination-derived human stomach cancer cell line. Am. J. Physiol. Endocrinol. Metab. 306(4), E373–E387 (2014)</ref-fulltext>
<ce:source-text>Terawaki, K., et al.: New cancer cachexia rat model generated by implantation of a peritoneal dissemination-derived human stomach cancer cell line. Am. J. Physiol. Endocrinol. Metab. 306(4), E373–E387 (2014)</ce:source-text>
</reference>
<reference seq="114">
<ref-info>
<ref-title>
<ref-titletext-english>Macrophage-derived tumor necrosis factor and tumor-derived of leukemia inhibitory factor and interleukin-6: Possible cellular mechanisms of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.G.</ce:initials>
<ce:surname>Billingsley</ce:surname>
<ce:given-name>K.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Surg. Oncol</ref-sourcetitle>
<ref-publicationyear first="1996" />
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>29</first-page>
<last-page>35</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Billingsley, K.G., et al.: Macrophage-derived tumor necrosis factor and tumor-derived of leukemia inhibitory factor and interleukin-6: Possible cellular mechanisms of cancer cachexia. Ann. Surg. Oncol. 3(1), 29–35 (1996)</ref-fulltext>
<ce:source-text>Billingsley, K.G., et al.: Macrophage-derived tumor necrosis factor and tumor-derived of leukemia inhibitory factor and interleukin-6: Possible cellular mechanisms of cancer cachexia. Ann. Surg. Oncol. 3(1), 29–35 (1996)</ce:source-text>
</reference>
<reference seq="115">
<ref-info>
<ref-title>
<ref-titletext-english>Toxohormones responsible for cancer cachexia syndrome in nude mice bearing human cancer cell lines</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Kajimura</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Chemother. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="1996" />
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
<suppl>Supplement</suppl>
</volume-issue-number>
<page-information>
<pages>
<first-page>S48</first-page>
<last-page>S52</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kajimura, N., et al.: Toxohormones responsible for cancer cachexia syndrome in nude mice bearing human cancer cell lines. Cancer Chemother. Pharmacol. 38(Suppl), S48–S52 (1996)</ref-fulltext>
<ce:source-text>Kajimura, N., et al.: Toxohormones responsible for cancer cachexia syndrome in nude mice bearing human cancer cell lines. Cancer Chemother. Pharmacol. 38(Suppl), S48–S52 (1996)</ce:source-text>
</reference>
<reference seq="116">
<ref-info>
<ref-title>
<ref-titletext-english>Leukaemia inhibitory factor increases myoblast replication and survival and affects extracellular matrix production: Combined in vivo and in vitro studies in post-natal skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.D.</ce:initials>
<ce:surname>White</ce:surname>
<ce:given-name>J.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Davies</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.D.</ce:initials>
<ce:surname>Grounds</ce:surname>
<ce:given-name>M.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Tissue Res</ref-sourcetitle>
<ref-publicationyear first="2001" />
<volisspag>
<volume-issue-number>
<vol-first>306</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>129</first-page>
<last-page>141</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>White, J.D., Davies, M., Grounds, M.D.: Leukaemia inhibitory factor increases myoblast replication and survival and affects extracellular matrix production: Combined in vivo and in vitro studies in post-natal skeletal muscle. Cell Tissue Res. 306(1), 129–141 (2001)</ref-fulltext>
<ce:source-text>White, J.D., Davies, M., Grounds, M.D.: Leukaemia inhibitory factor increases myoblast replication and survival and affects extracellular matrix production: Combined in vivo and in vitro studies in post-natal skeletal muscle. Cell Tissue Res. 306(1), 129–141 (2001)</ce:source-text>
</reference>
<reference seq="117">
<ref-info>
<ref-title>
<ref-titletext-english>Leukemia inhibitory factor restores the hypertrophic response to increased loading in the LIF(−/−) mouse</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.E.</ce:initials>
<ce:surname>Spangenburg</ce:surname>
<ce:given-name>E.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>F.W.</ce:initials>
<ce:surname>Booth</ce:surname>
<ce:given-name>F.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>34</vol-first>
<iss-first>3</iss-first>
<iss-last>4</iss-last>
</volume-issue-number>
<page-information>
<pages>
<first-page>125</first-page>
<last-page>130</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Spangenburg, E.E., Booth, F.W.: Leukemia inhibitory factor restores the hypertrophic response to increased loading in the LIF(−/−) mouse. Cytokine. 34(3–4), 125–130 (2006)</ref-fulltext>
<ce:source-text>Spangenburg, E.E., Booth, F.W.: Leukemia inhibitory factor restores the hypertrophic response to increased loading in the LIF(−/−) mouse. Cytokine. 34(3–4), 125–130 (2006)</ce:source-text>
</reference>
<reference seq="118">
<ref-info>
<ref-title>
<ref-titletext-english>Therapeutic approaches for muscle wasting disorders</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.S.</ce:initials>
<ce:surname>Lynch</ce:surname>
<ce:given-name>G.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.D.</ce:initials>
<ce:surname>Schertzer</ce:surname>
<ce:given-name>J.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.G.</ce:initials>
<ce:surname>Ryall</ce:surname>
<ce:given-name>J.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Pharmacol. Ther</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>113</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>461</first-page>
<last-page>487</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lynch, G.S., Schertzer, J.D., Ryall, J.G.: Therapeutic approaches for muscle wasting disorders. Pharmacol. Ther. 113(3), 461–487 (2007)</ref-fulltext>
<ce:source-text>Lynch, G.S., Schertzer, J.D., Ryall, J.G.: Therapeutic approaches for muscle wasting disorders. Pharmacol. Ther. 113(3), 461–487 (2007)</ce:source-text>
</reference>
<reference seq="119">
<ref-info>
<ref-title>
<ref-titletext-english>Lewis lung carcinoma regulation of mechanical stretch-induced protein synthesis in cultured myotubes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Gao</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.A.</ce:initials>
<ce:surname>Carson</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Cell Physiol</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>310</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>C66</first-page>
<last-page>C79</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gao, S., Carson, J.A.: Lewis lung carcinoma regulation of mechanical stretch-induced protein synthesis in cultured myotubes. Am. J. Physiol. Cell Physiol. 310(1), C66–C79 (2016)</ref-fulltext>
<ce:source-text>Gao, S., Carson, J.A.: Lewis lung carcinoma regulation of mechanical stretch-induced protein synthesis in cultured myotubes. Am. J. Physiol. Cell Physiol. 310(1), C66–C79 (2016)</ce:source-text>
</reference>
<reference seq="120">
<ref-info>
<ref-title>
<ref-titletext-english>Leukemia inhibitory factor induces changes in lipid metabolism in cultured adipocytes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.K.</ce:initials>
<ce:surname>Marshall</ce:surname>
<ce:given-name>M.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Endocrinology</ref-sourcetitle>
<ref-publicationyear first="1994" />
<volisspag>
<volume-issue-number>
<vol-first>135</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>141</first-page>
<last-page>147</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Marshall, M.K., et al.: Leukemia inhibitory factor induces changes in lipid metabolism in cultured adipocytes. Endocrinology. 135(1), 141–147 (1994)</ref-fulltext>
<ce:source-text>Marshall, M.K., et al.: Leukemia inhibitory factor induces changes in lipid metabolism in cultured adipocytes. Endocrinology. 135(1), 141–147 (1994)</ce:source-text>
</reference>
<reference seq="121">
<ref-info>
<ref-title>
<ref-titletext-english>The N-terminal cytokine binding domain of LIFR is required for CNTF binding and signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.</ce:initials>
<ce:surname>He</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>FEBS Lett</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>579</vol-first>
<iss-first>20</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4317</first-page>
<last-page>4323</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>He, W., et al.: The N-terminal cytokine binding domain of LIFR is required for CNTF binding and signaling. FEBS Lett. 579(20), 4317–4323 (2005)</ref-fulltext>
<ce:source-text>He, W., et al.: The N-terminal cytokine binding domain of LIFR is required for CNTF binding and signaling. FEBS Lett. 579(20), 4317–4323 (2005)</ce:source-text>
</reference>
<reference seq="122">
<ref-info>
<ref-title>
<ref-titletext-english>Ciliary neurotrophic factor</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Sendtner</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Neurobiol</ref-sourcetitle>
<ref-publicationyear first="1994" />
<volisspag>
<volume-issue-number>
<vol-first>25</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1436</first-page>
<last-page>1453</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sendtner, M., et al.: Ciliary neurotrophic factor. J. Neurobiol. 25(11), 1436–1453 (1994)</ref-fulltext>
<ce:source-text>Sendtner, M., et al.: Ciliary neurotrophic factor. J. Neurobiol. 25(11), 1436–1453 (1994)</ce:source-text>
</reference>
<reference seq="123">
<ref-info>
<ref-title>
<ref-titletext-english>Sequence and structural organization of the human gene encoding ciliary neurotrophic factor</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Lam</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Gene</ref-sourcetitle>
<ref-publicationyear first="1991" />
<volisspag>
<volume-issue-number>
<vol-first>102</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>271</first-page>
<last-page>276</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lam, A., et al.: Sequence and structural organization of the human gene encoding ciliary neurotrophic factor. Gene. 102(2), 271–276 (1991)</ref-fulltext>
<ce:source-text>Lam, A., et al.: Sequence and structural organization of the human gene encoding ciliary neurotrophic factor. Gene. 102(2), 271–276 (1991)</ce:source-text>
</reference>
<reference seq="124">
<ref-info>
<ref-title>
<ref-titletext-english>Purification of the chick eye ciliary neuronotrophic factor</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Barbin</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Manthorpe</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Varon</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Neurochem</ref-sourcetitle>
<ref-publicationyear first="1984" />
<volisspag>
<volume-issue-number>
<vol-first>43</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1468</first-page>
<last-page>1478</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Barbin, G., Manthorpe, M., Varon, S.: Purification of the chick eye ciliary neuronotrophic factor. J. Neurochem. 43(5), 1468–1478 (1984)</ref-fulltext>
<ce:source-text>Barbin, G., Manthorpe, M., Varon, S.: Purification of the chick eye ciliary neuronotrophic factor. J. Neurochem. 43(5), 1468–1478 (1984)</ce:source-text>
</reference>
<reference seq="125">
<ref-info>
<ref-title>
<ref-titletext-english>Ciliary neurotrophic factor induces type-2 astrocyte differentiation in culture</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.M.</ce:initials>
<ce:surname>Hughes</ce:surname>
<ce:given-name>S.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="1988" />
<volisspag>
<volume-issue-number>
<vol-first>335</vol-first>
<iss-first>6185</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>70</first-page>
<last-page>73</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hughes, S.M., et al.: Ciliary neurotrophic factor induces type-2 astrocyte differentiation in culture. Nature. 335(6185), 70–73 (1988)</ref-fulltext>
<ce:source-text>Hughes, S.M., et al.: Ciliary neurotrophic factor induces type-2 astrocyte differentiation in culture. Nature. 335(6185), 70–73 (1988)</ce:source-text>
</reference>
<reference seq="126">
<ref-info>
<ref-title>
<ref-titletext-english>The receptor for ciliary neurotrophic factor</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Davis</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="1991" />
<volisspag>
<volume-issue-number>
<vol-first>253</vol-first>
<iss-first>5015</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>59</first-page>
<last-page>63</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Davis, S., et al.: The receptor for ciliary neurotrophic factor. Science. 253(5015), 59–63 (1991)</ref-fulltext>
<ce:source-text>Davis, S., et al.: The receptor for ciliary neurotrophic factor. Science. 253(5015), 59–63 (1991)</ce:source-text>
</reference>
<reference seq="127">
<ref-info>
<ref-title>
<ref-titletext-english>The alpha component of the CNTF receptor is required for signaling and defines potential CNTF targets in the adult and during development</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.Y.</ce:initials>
<ce:surname>Ip</ce:surname>
<ce:given-name>N.Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Neuron</ref-sourcetitle>
<ref-publicationyear first="1993" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>89</first-page>
<last-page>102</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ip, N.Y., et al.: The alpha component of the CNTF receptor is required for signaling and defines potential CNTF targets in the adult and during development. Neuron. 10(1), 89–102 (1993)</ref-fulltext>
<ce:source-text>Ip, N.Y., et al.: The alpha component of the CNTF receptor is required for signaling and defines potential CNTF targets in the adult and during development. Neuron. 10(1), 89–102 (1993)</ce:source-text>
</reference>
<reference seq="128">
<ref-info>
<ref-title>
<ref-titletext-english>Regional distribution, developmental changes, and cellular localization of CNTF-mRNA and protein in the rat brain</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.A.</ce:initials>
<ce:surname>Stockli</ce:surname>
<ce:given-name>K.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="1991" />
<volisspag>
<volume-issue-number>
<vol-first>115</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>447</first-page>
<last-page>459</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stockli, K.A., et al.: Regional distribution, developmental changes, and cellular localization of CNTF-mRNA and protein in the rat brain. J. Cell Biol. 115(2), 447–459 (1991)</ref-fulltext>
<ce:source-text>Stockli, K.A., et al.: Regional distribution, developmental changes, and cellular localization of CNTF-mRNA and protein in the rat brain. J. Cell Biol. 115(2), 447–459 (1991)</ce:source-text>
</reference>
<reference seq="129">
<ref-info>
<ref-title>
<ref-titletext-english>Immunolocalization of ciliary neuronotrophic factor in adult rat sciatic nerve</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Rende</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Glia</ref-sourcetitle>
<ref-publicationyear first="1992" />
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>25</first-page>
<last-page>32</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rende, M., et al.: Immunolocalization of ciliary neuronotrophic factor in adult rat sciatic nerve. Glia. 5(1), 25–32 (1992)</ref-fulltext>
<ce:source-text>Rende, M., et al.: Immunolocalization of ciliary neuronotrophic factor in adult rat sciatic nerve. Glia. 5(1), 25–32 (1992)</ce:source-text>
</reference>
<reference seq="130">
<ref-info>
<ref-title>
<ref-titletext-english>Regulation of ciliary neurotrophic factor expression in myelin-related Schwann cells in vivo</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Friedman</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Neuron</ref-sourcetitle>
<ref-publicationyear first="1992" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>295</first-page>
<last-page>305</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Friedman, B., et al.: Regulation of ciliary neurotrophic factor expression in myelin-related Schwann cells in vivo. Neuron. 9(2), 295–305 (1992)</ref-fulltext>
<ce:source-text>Friedman, B., et al.: Regulation of ciliary neurotrophic factor expression in myelin-related Schwann cells in vivo. Neuron. 9(2), 295–305 (1992)</ce:source-text>
</reference>
<reference seq="131">
<ref-info>
<ref-title>
<ref-titletext-english>Synthesis and localization of ciliary neurotrophic factor in the sciatic nerve of the adult rat after lesion and during regeneration</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Sendtner</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.A.</ce:initials>
<ce:surname>Stockli</ce:surname>
<ce:given-name>K.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Thoenen</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="1992" />
<volisspag>
<volume-issue-number>
<vol-first>118</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>139</first-page>
<last-page>148</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sendtner, M., Stockli, K.A., Thoenen, H.: Synthesis and localization of ciliary neurotrophic factor in the sciatic nerve of the adult rat after lesion and during regeneration. J. Cell Biol. 118(1), 139–148 (1992)</ref-fulltext>
<ce:source-text>Sendtner, M., Stockli, K.A., Thoenen, H.: Synthesis and localization of ciliary neurotrophic factor in the sciatic nerve of the adult rat after lesion and during regeneration. J. Cell Biol. 118(1), 139–148 (1992)</ce:source-text>
</reference>
<reference seq="132">
<ref-info>
<ref-title>
<ref-titletext-english>Cytokines of the LIF/CNTF family and metabolism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Pasquin</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Sharma</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.F.</ce:initials>
<ce:surname>Gauchat</ce:surname>
<ce:given-name>J.F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>82</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>122</first-page>
<last-page>124</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pasquin, S., Sharma, M., Gauchat, J.F.: Cytokines of the LIF/CNTF family and metabolism. Cytokine. 82, 122–124 (2016)</ref-fulltext>
<ce:source-text>Pasquin, S., Sharma, M., Gauchat, J.F.: Cytokines of the LIF/CNTF family and metabolism. Cytokine. 82, 122–124 (2016)</ce:source-text>
</reference>
<reference seq="133">
<ref-info>
<ref-title>
<ref-titletext-english>Cachectic effect of ciliary neurotrophic factor on innervated skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Martin</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Phys</ref-sourcetitle>
<ref-publicationyear first="1996" />
<volisspag>
<volume-issue-number>
<vol-first>271</vol-first>
<iss-first>5</iss-first>
<suppl>Supplement Pt 2</suppl>
</volume-issue-number>
<page-information>
<pages>
<first-page>R1422</first-page>
<last-page>R1428</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Martin, D., et al.: Cachectic effect of ciliary neurotrophic factor on innervated skeletal muscle. Am. J. Phys. 271(5 Pt 2), R1422–R1428 (1996)</ref-fulltext>
<ce:source-text>Martin, D., et al.: Cachectic effect of ciliary neurotrophic factor on innervated skeletal muscle. Am. J. Phys. 271(5 Pt 2), R1422–R1428 (1996)</ce:source-text>
</reference>
<reference seq="134">
<ref-info>
<ref-title>
<ref-titletext-english>Physiological effects of CNTF-induced wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.T.</ce:initials>
<ce:surname>Henderson</ce:surname>
<ce:given-name>J.T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.J.</ce:initials>
<ce:surname>Mullen</ce:surname>
<ce:given-name>B.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.C.</ce:initials>
<ce:surname>Roder</ce:surname>
<ce:given-name>J.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine</ref-sourcetitle>
<ref-publicationyear first="1996" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>784</first-page>
<last-page>793</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Henderson, J.T., Mullen, B.J., Roder, J.C.: Physiological effects of CNTF-induced wasting. Cytokine. 8(10), 784–793 (1996)</ref-fulltext>
<ce:source-text>Henderson, J.T., Mullen, B.J., Roder, J.C.: Physiological effects of CNTF-induced wasting. Cytokine. 8(10), 784–793 (1996)</ce:source-text>
</reference>
<reference seq="135">
<ref-info>
<ref-title>
<ref-titletext-english>Systemic administration of ciliary neurotrophic factor induces cachexia in rodents</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.T.</ce:initials>
<ce:surname>Henderson</ce:surname>
<ce:given-name>J.T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Investig</ref-sourcetitle>
<ref-publicationyear first="1994" />
<volisspag>
<volume-issue-number>
<vol-first>93</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2632</first-page>
<last-page>2638</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Henderson, J.T., et al.: Systemic administration of ciliary neurotrophic factor induces cachexia in rodents. J. Clin. Investig. 93(6), 2632–2638 (1994)</ref-fulltext>
<ce:source-text>Henderson, J.T., et al.: Systemic administration of ciliary neurotrophic factor induces cachexia in rodents. J. Clin. Investig. 93(6), 2632–2638 (1994)</ce:source-text>
</reference>
<reference seq="136">
<ref-info>
<ref-title>
<ref-titletext-english>Ciliary neurotrophic factor is catabolic and shares with IL-6 the capacity to induce an acute phase response</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.J.</ce:initials>
<ce:surname>Espat</ce:surname>
<ce:given-name>N.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Phys</ref-sourcetitle>
<ref-publicationyear first="1996" />
<volisspag>
<volume-issue-number>
<vol-first>271</vol-first>
<iss-first>1</iss-first>
<part>Part 2</part>
</volume-issue-number>
<page-information>
<pages>
<first-page>R185</first-page>
<last-page>R190</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Espat, N.J., et al.: Ciliary neurotrophic factor is catabolic and shares with IL-6 the capacity to induce an acute phase response. Am. J. Phys. 271(1 Pt 2), R185–R190 (1996)</ref-fulltext>
<ce:source-text>Espat, N.J., et al.: Ciliary neurotrophic factor is catabolic and shares with IL-6 the capacity to induce an acute phase response. Am. J. Phys. 271(1 Pt 2), R185–R190 (1996)</ce:source-text>
</reference>
<reference seq="137">
<ref-info>
<ref-title>
<ref-titletext-english>Cytokines and cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Matthys</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Billiau</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nutrition</ref-sourcetitle>
<ref-publicationyear first="1997" />
<volisspag>
<volume-issue-number>
<vol-first>13</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>763</first-page>
<last-page>770</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Matthys, P., Billiau, A.: Cytokines and cachexia. Nutrition. 13(9), 763–770 (1997)</ref-fulltext>
<ce:source-text>Matthys, P., Billiau, A.: Cytokines and cachexia. Nutrition. 13(9), 763–770 (1997)</ce:source-text>
</reference>
<reference seq="138">
<ref-info>
<ref-title>
<ref-titletext-english>Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Pennica</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="1995" />
<volisspag>
<volume-issue-number>
<vol-first>92</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1142</first-page>
<last-page>1146</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pennica, D., et al.: Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Proc. Natl. Acad. Sci. USA. 92(4), 1142–1146 (1995)</ref-fulltext>
<ce:source-text>Pennica, D., et al.: Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Proc. Natl. Acad. Sci. USA. 92(4), 1142–1146 (1995)</ce:source-text>
</reference>
<reference seq="139">
<ref-info>
<ref-title>
<ref-titletext-english>Cardiotrophin-1 induces heat shock protein accumulation in cultured cardiac cells and protects them from stressful stimuli</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Stephanou</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Mol. Cell. Cardiol</ref-sourcetitle>
<ref-publicationyear first="1998" />
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>849</first-page>
<last-page>855</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stephanou, A., et al.: Cardiotrophin-1 induces heat shock protein accumulation in cultured cardiac cells and protects them from stressful stimuli. J. Mol. Cell. Cardiol. 30(4), 849–855 (1998)</ref-fulltext>
<ce:source-text>Stephanou, A., et al.: Cardiotrophin-1 induces heat shock protein accumulation in cultured cardiac cells and protects them from stressful stimuli. J. Mol. Cell. Cardiol. 30(4), 849–855 (1998)</ce:source-text>
</reference>
<reference seq="140">
<ref-info>
<ref-title>
<ref-titletext-english>Cardiotrophin-1 phosphorylates akt and BAD, and prolongs cell survival via a PI3K-dependent pathway in cardiac myocytes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Kuwahara</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Mol. Cell. Cardiol</ref-sourcetitle>
<ref-publicationyear first="2000" />
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1385</first-page>
<last-page>1394</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kuwahara, K., et al.: Cardiotrophin-1 phosphorylates akt and BAD, and prolongs cell survival via a PI3K-dependent pathway in cardiac myocytes. J. Mol. Cell. Cardiol. 32(8), 1385–1394 (2000)</ref-fulltext>
<ce:source-text>Kuwahara, K., et al.: Cardiotrophin-1 phosphorylates akt and BAD, and prolongs cell survival via a PI3K-dependent pathway in cardiac myocytes. J. Mol. Cell. Cardiol. 32(8), 1385–1394 (2000)</ce:source-text>
</reference>
<reference seq="141">
<ref-info>
<ref-title>
<ref-titletext-english>Liver damage using suicide genes. A model for oval cell activation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Bustos</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Pathol</ref-sourcetitle>
<ref-publicationyear first="2000" />
<volisspag>
<volume-issue-number>
<vol-first>157</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>549</first-page>
<last-page>559</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bustos, M., et al.: Liver damage using suicide genes. A model for oval cell activation. Am. J. Pathol. 157(2), 549–559 (2000)</ref-fulltext>
<ce:source-text>Bustos, M., et al.: Liver damage using suicide genes. A model for oval cell activation. Am. J. Pathol. 157(2), 549–559 (2000)</ce:source-text>
</reference>
<reference seq="142">
<ref-info>
<ref-title>
<ref-titletext-english>Therapeutic potential of cardiotrophin 1 in fulminant hepatic failure: Dual roles in antiapoptosis and cell repair</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.W.</ce:initials>
<ce:surname>Ho</ce:surname>
<ce:given-name>D.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Arch. Surg</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>141</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1077</first-page>
<last-page>1084</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ho, D.W., et al.: Therapeutic potential of cardiotrophin 1 in fulminant hepatic failure: dual roles in antiapoptosis and cell repair. Arch. Surg. 141(11), 1077–1084 (2006) discussion 1084</ref-fulltext>
<ce:source-text>Ho, D.W., et al.: Therapeutic potential of cardiotrophin 1 in fulminant hepatic failure: dual roles in antiapoptosis and cell repair. Arch. Surg. 141(11), 1077–1084 (2006) discussion 1084</ce:source-text>
</reference>
<reference seq="143">
<ref-info>
<ref-title>
<ref-titletext-english>Cardiotrophin-1 induces interleukin-6 synthesis in human umbilical vein endothelial cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Fritzenwanger</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
<iss-first>3</iss-first>
<iss-last>4</iss-last>
</volume-issue-number>
<page-information>
<pages>
<first-page>101</first-page>
<last-page>106</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fritzenwanger, M., et al.: Cardiotrophin-1 induces interleukin-6 synthesis in human umbilical vein endothelial cells. Cytokine. 36(3–4), 101–106 (2006)</ref-fulltext>
<ce:source-text>Fritzenwanger, M., et al.: Cardiotrophin-1 induces interleukin-6 synthesis in human umbilical vein endothelial cells. Cytokine. 36(3–4), 101–106 (2006)</ce:source-text>
</reference>
<reference seq="144">
<ref-info>
<ref-title>
<ref-titletext-english>The resolution of inflammation: Anti-inflammatory roles for NF-kappaB</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Lawrence</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Fong</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Biochem. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>42</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>519</first-page>
<last-page>523</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lawrence, T., Fong, C.: The resolution of inflammation: Anti-inflammatory roles for NF-kappaB. Int. J. Biochem. Cell Biol. 42(4), 519–523 (2010)</ref-fulltext>
<ce:source-text>Lawrence, T., Fong, C.: The resolution of inflammation: Anti-inflammatory roles for NF-kappaB. Int. J. Biochem. Cell Biol. 42(4), 519–523 (2010)</ce:source-text>
</reference>
<reference seq="145">
<ref-info>
<ref-title>
<ref-titletext-english>Cardiotrophin-1 induces tumor necrosis factor alpha synthesis in human peripheral blood mononuclear cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Fritzenwanger</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mediat. Inflamm</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>2009</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Fritzenwanger, M., et al.: Cardiotrophin-1 induces tumor necrosis factor alpha synthesis in human peripheral blood mononuclear cells. Mediat. Inflamm. 2009, 489802 (2009)</ref-fulltext>
<ce:source-text>Fritzenwanger, M., et al.: Cardiotrophin-1 induces tumor necrosis factor alpha synthesis in human peripheral blood mononuclear cells. Mediat. Inflamm. 2009, 489802 (2009)</ce:source-text>
</reference>
<reference seq="146">
<ref-info>
<ref-title>
<ref-titletext-english>Cardiotrophin-1 stimulates intercellular adhesion molecule-1 and monocyte chemoattractant protein-1 in human aortic endothelial cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Ichiki</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Heart Circ. Physiol</ref-sourcetitle>
<ref-publicationyear first="2008" />
<volisspag>
<volume-issue-number>
<vol-first>294</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>H750</first-page>
<last-page>H763</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ichiki, T., et al.: Cardiotrophin-1 stimulates intercellular adhesion molecule-1 and monocyte chemoattractant protein-1 in human aortic endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 294(2), H750–H763 (2008)</ref-fulltext>
<ce:source-text>Ichiki, T., et al.: Cardiotrophin-1 stimulates intercellular adhesion molecule-1 and monocyte chemoattractant protein-1 in human aortic endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 294(2), H750–H763 (2008)</ce:source-text>
</reference>
<reference seq="147">
<ref-info>
<ref-title>
<ref-titletext-english>Cardiotrophin-1 induces intercellular adhesion molecule-1 expression by nuclear factor kappaB activation in human umbilical vein endothelial cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Fritzenwanger</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Chin. Med. J</ref-sourcetitle>
<ref-publicationyear first="2008" />
<volisspag>
<volume-issue-number>
<vol-first>121</vol-first>
<iss-first>24</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2592</first-page>
<last-page>2598</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fritzenwanger, M., et al.: Cardiotrophin-1 induces intercellular adhesion molecule-1 expression by nuclear factor kappaB activation in human umbilical vein endothelial cells. Chin. Med. J. 121(24), 2592–2598 (2008)</ref-fulltext>
<ce:source-text>Fritzenwanger, M., et al.: Cardiotrophin-1 induces intercellular adhesion molecule-1 expression by nuclear factor kappaB activation in human umbilical vein endothelial cells. Chin. Med. J. 121(24), 2592–2598 (2008)</ce:source-text>
</reference>
<reference seq="148">
<ref-info>
<ref-title>
<ref-titletext-english>Versatile functions for IL-6 in metabolism and cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Mauer</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.L.</ce:initials>
<ce:surname>Denson</ce:surname>
<ce:given-name>J.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.C.</ce:initials>
<ce:surname>Bruning</ce:surname>
<ce:given-name>J.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Trends Immunol</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>92</first-page>
<last-page>101</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mauer, J., Denson, J.L., Bruning, J.C.: Versatile functions for IL-6 in metabolism and cancer. Trends Immunol. 36(2), 92–101 (2015)</ref-fulltext>
<ce:source-text>Mauer, J., Denson, J.L., Bruning, J.C.: Versatile functions for IL-6 in metabolism and cancer. Trends Immunol. 36(2), 92–101 (2015)</ce:source-text>
</reference>
<reference seq="149">
<ref-info>
<ref-title>
<ref-titletext-english>Absence of cardiotrophin 1 is associated with decreased age-dependent arterial stiffness and increased longevity in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Lopez-Andres</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Hypertension</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>61</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>120</first-page>
<last-page>129</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lopez-Andres, N., et al.: Absence of cardiotrophin 1 is associated with decreased age-dependent arterial stiffness and increased longevity in mice. Hypertension. 61(1), 120–129 (2013)</ref-fulltext>
<ce:source-text>Lopez-Andres, N., et al.: Absence of cardiotrophin 1 is associated with decreased age-dependent arterial stiffness and increased longevity in mice. Hypertension. 61(1), 120–129 (2013)</ce:source-text>
</reference>
<reference seq="150">
<ref-info>
<ref-title>
<ref-titletext-english>Cardiotrophin-1 is a key regulator of glucose and lipid metabolism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.J.</ce:initials>
<ce:surname>Moreno-Aliaga</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>242</first-page>
<last-page>253</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Moreno-Aliaga, M.J., et al.: Cardiotrophin-1 is a key regulator of glucose and lipid metabolism. Cell Metab. 14(2), 242–253 (2011)</ref-fulltext>
<ce:source-text>Moreno-Aliaga, M.J., et al.: Cardiotrophin-1 is a key regulator of glucose and lipid metabolism. Cell Metab. 14(2), 242–253 (2011)</ce:source-text>
</reference>
<reference seq="151">
<ref-info>
<ref-title>
<ref-titletext-english>Cardiotrophin-1 and TNF-alpha circulating levels at rest and during cardiopulmonary exercise test in athletes and healthy individuals</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Limongelli</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>50</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>245</first-page>
<last-page>247</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Limongelli, G., et al.: Cardiotrophin-1 and TNF-alpha circulating levels at rest and during cardiopulmonary exercise test in athletes and healthy individuals. Cytokine. 50(3), 245–247 (2010)</ref-fulltext>
<ce:source-text>Limongelli, G., et al.: Cardiotrophin-1 and TNF-alpha circulating levels at rest and during cardiopulmonary exercise test in athletes and healthy individuals. Cytokine. 50(3), 245–247 (2010)</ce:source-text>
</reference>
<reference seq="152">
<ref-info>
<ref-title>
<ref-titletext-english>Cardiotrophin-1 enhances regeneration of cirrhotic liver remnant after hepatectomy through promotion of angiogenesis and cell proliferation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.F.</ce:initials>
<ce:surname>Yang</ce:surname>
<ce:given-name>Z.F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Liver Int</ref-sourcetitle>
<ref-publicationyear first="2008" />
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>622</first-page>
<last-page>631</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yang, Z.F., et al.: Cardiotrophin-1 enhances regeneration of cirrhotic liver remnant after hepatectomy through promotion of angiogenesis and cell proliferation. Liver Int. 28(5), 622–631 (2008)</ref-fulltext>
<ce:source-text>Yang, Z.F., et al.: Cardiotrophin-1 enhances regeneration of cirrhotic liver remnant after hepatectomy through promotion of angiogenesis and cell proliferation. Liver Int. 28(5), 622–631 (2008)</ce:source-text>
</reference>
<reference seq="153">
<ref-info>
<ref-title>
<ref-titletext-english>Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Castano</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Hepatol</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>60</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1017</first-page>
<last-page>1025</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Castano, D., et al.: Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation. J. Hepatol. 60(5), 1017–1025 (2014)</ref-fulltext>
<ce:source-text>Castano, D., et al.: Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation. J. Hepatol. 60(5), 1017–1025 (2014)</ce:source-text>
</reference>
<reference seq="154">
<ref-info>
<ref-title>
<ref-titletext-english>Association of increased plasma cardiotrophin-1 with left ventricular mass indexes in normotensive morbid obesity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.E.</ce:initials>
<ce:surname>Malavazos</ce:surname>
<ce:given-name>A.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Hypertension</ref-sourcetitle>
<ref-publicationyear first="2008" />
<volisspag>
<volume-issue-number>
<vol-first>51</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>e8</first-page>
<last-page>e9</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Malavazos, A.E., et al.: Association of increased plasma cardiotrophin-1 with left ventricular mass indexes in normotensive morbid obesity. Hypertension. 51(2), e8–e9 (2008) author reply e10</ref-fulltext>
<ce:source-text>Malavazos, A.E., et al.: Association of increased plasma cardiotrophin-1 with left ventricular mass indexes in normotensive morbid obesity. Hypertension. 51(2), e8–e9 (2008) author reply e10</ce:source-text>
</reference>
<reference seq="155">
<ref-info>
<ref-title>
<ref-titletext-english>Decreased cardiotrophin-1 levels are associated with a lower risk of developing the metabolic syndrome in overweight/obese children after a weight loss program</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Rendo-Urteaga</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Metabolism</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>62</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1429</first-page>
<last-page>1436</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rendo-Urteaga, T., et al.: Decreased cardiotrophin-1 levels are associated with a lower risk of developing the metabolic syndrome in overweight/obese children after a weight loss program. Metabolism. 62(10), 1429–1436 (2013)</ref-fulltext>
<ce:source-text>Rendo-Urteaga, T., et al.: Decreased cardiotrophin-1 levels are associated with a lower risk of developing the metabolic syndrome in overweight/obese children after a weight loss program. Metabolism. 62(10), 1429–1436 (2013)</ce:source-text>
</reference>
<reference seq="156">
<ref-info>
<ref-title>
<ref-titletext-english>Evidence that embryonic neurons regulate the onset of cortical gliogenesis via cardiotrophin-1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Barnabe-Heider</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Neuron</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>48</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>253</first-page>
<last-page>265</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Barnabe-Heider, F., et al.: Evidence that embryonic neurons regulate the onset of cortical gliogenesis via cardiotrophin-1. Neuron. 48(2), 253–265 (2005)</ref-fulltext>
<ce:source-text>Barnabe-Heider, F., et al.: Evidence that embryonic neurons regulate the onset of cortical gliogenesis via cardiotrophin-1. Neuron. 48(2), 253–265 (2005)</ce:source-text>
</reference>
<reference seq="157">
<ref-info>
<ref-title>
<ref-titletext-english>Emerging evidence for the role of cardiotrophin-1 in cardiac repair in the infarcted heart</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.H.</ce:initials>
<ce:surname>Freed</ce:surname>
<ce:given-name>D.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cardiovasc. Res</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>65</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>782</first-page>
<last-page>792</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Freed, D.H., et al.: Emerging evidence for the role of cardiotrophin-1 in cardiac repair in the infarcted heart. Cardiovasc. Res. 65(4), 782–792 (2005)</ref-fulltext>
<ce:source-text>Freed, D.H., et al.: Emerging evidence for the role of cardiotrophin-1 in cardiac repair in the infarcted heart. Cardiovasc. Res. 65(4), 782–792 (2005)</ce:source-text>
</reference>
<reference seq="158">
<ref-info>
<ref-title>
<ref-titletext-english>A heart-specific increase in cardiotrophin-1 gene expression precedes the establishment of ventricular hypertrophy in genetically hypertensive rats</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Ishikawa</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Hypertens</ref-sourcetitle>
<ref-publicationyear first="1999" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>807</first-page>
<last-page>816</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ishikawa, M., et al.: A heart-specific increase in cardiotrophin-1 gene expression precedes the establishment of ventricular hypertrophy in genetically hypertensive rats. J. Hypertens. 17(6), 807–816 (1999)</ref-fulltext>
<ce:source-text>Ishikawa, M., et al.: A heart-specific increase in cardiotrophin-1 gene expression precedes the establishment of ventricular hypertrophy in genetically hypertensive rats. J. Hypertens. 17(6), 807–816 (1999)</ce:source-text>
</reference>
<reference seq="159">
<ref-info>
<ref-title>
<ref-titletext-english>Involvement of gp130-mediated signaling in pressure overload-induced activation of the JAK/STAT pathway in rodent heart</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Pan</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Heart Vessel</ref-sourcetitle>
<ref-publicationyear first="1998" />
<volisspag>
<volume-issue-number>
<vol-first>13</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>199</first-page>
<last-page>208</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pan, J., et al.: Involvement of gp130-mediated signaling in pressure overload-induced activation of the JAK/STAT pathway in rodent heart. Heart Vessel. 13(4), 199–208 (1998)</ref-fulltext>
<ce:source-text>Pan, J., et al.: Involvement of gp130-mediated signaling in pressure overload-induced activation of the JAK/STAT pathway in rodent heart. Heart Vessel. 13(4), 199–208 (1998)</ce:source-text>
</reference>
<reference seq="160">
<ref-info>
<ref-title>
<ref-titletext-english>Tuberculous aneurysms of the aorta</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Talwar</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.K.</ce:initials>
<ce:surname>Choudhary</ce:surname>
<ce:given-name>S.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Thorac. Cardiovasc. Surg</ref-sourcetitle>
<ref-publicationyear first="2003" />
<volisspag>
<volume-issue-number>
<vol-first>125</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1184</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Talwar, S., Choudhary, S.K.: Tuberculous aneurysms of the aorta. J. Thorac. Cardiovasc. Surg. 125(5), 1184 (2003)</ref-fulltext>
<ce:source-text>Talwar, S., Choudhary, S.K.: Tuberculous aneurysms of the aorta. J. Thorac. Cardiovasc. Surg. 125(5), 1184 (2003)</ce:source-text>
</reference>
<reference seq="161">
<ref-info>
<ref-title>
<ref-titletext-english>Is plasma cardiotrophin-1 a marker of hypertensive heart disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Lopez</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Hypertens</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>23</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>625</first-page>
<last-page>632</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lopez, B., et al.: Is plasma cardiotrophin-1 a marker of hypertensive heart disease? J. Hypertens. 23(3), 625–632 (2005)</ref-fulltext>
<ce:source-text>Lopez, B., et al.: Is plasma cardiotrophin-1 a marker of hypertensive heart disease? J. Hypertens. 23(3), 625–632 (2005)</ce:source-text>
</reference>
<reference seq="162">
<ref-info>
<ref-title>
<ref-titletext-english>The enigmatic cytokine oncostatin m and roles in disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.D.</ce:initials>
<ce:surname>Richards</ce:surname>
<ce:given-name>C.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>ISRN Inflamm</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>2013</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Richards, C.D.: The enigmatic cytokine oncostatin m and roles in disease. ISRN Inflamm. 2013, 512103 (2013)</ref-fulltext>
<ce:source-text>Richards, C.D.: The enigmatic cytokine oncostatin m and roles in disease. ISRN Inflamm. 2013, 512103 (2013)</ce:source-text>
</reference>
<reference seq="163">
<ref-info>
<ref-title>
<ref-titletext-english>Cooperative signaling between oncostatin M, hepatocyte growth factor and transforming growth factor-beta enhances epithelial to mesenchymal transition in lung and pancreatic tumor models</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.M.</ce:initials>
<ce:surname>Argast</ce:surname>
<ce:given-name>G.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cells Tissues Organs</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>193</vol-first>
<iss-first>1</iss-first>
<iss-last>2</iss-last>
</volume-issue-number>
<page-information>
<pages>
<first-page>114</first-page>
<last-page>132</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Argast, G.M., et al.: Cooperative signaling between oncostatin M, hepatocyte growth factor and transforming growth factor-beta enhances epithelial to mesenchymal transition in lung and pancreatic tumor models. Cells Tissues Organs. 193(1–2), 114–132 (2011)</ref-fulltext>
<ce:source-text>Argast, G.M., et al.: Cooperative signaling between oncostatin M, hepatocyte growth factor and transforming growth factor-beta enhances epithelial to mesenchymal transition in lung and pancreatic tumor models. Cells Tissues Organs. 193(1–2), 114–132 (2011)</ce:source-text>
</reference>
<reference seq="164">
<ref-info>
<ref-title>
<ref-titletext-english>Unique methylation pattern of oncostatin m receptor gene in cancers of colorectum and other digestive organs</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Deng</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1519</first-page>
<last-page>1526</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Deng, G., et al.: Unique methylation pattern of oncostatin m receptor gene in cancers of colorectum and other digestive organs. Clin. Cancer Res. 15(5), 1519–1526 (2009)</ref-fulltext>
<ce:source-text>Deng, G., et al.: Unique methylation pattern of oncostatin m receptor gene in cancers of colorectum and other digestive organs. Clin. Cancer Res. 15(5), 1519–1526 (2009)</ce:source-text>
</reference>
<reference seq="165">
<ref-info>
<ref-title>
<ref-titletext-english>A unique loop structure in oncostatin M determines binding affinity toward oncostatin M receptor and leukemia inhibitory factor receptor</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Chollangi</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>287</vol-first>
<iss-first>39</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>32848</first-page>
<last-page>32859</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chollangi, S., et al.: A unique loop structure in oncostatin M determines binding affinity toward oncostatin M receptor and leukemia inhibitory factor receptor. J. Biol. Chem. 287(39), 32848–32859 (2012)</ref-fulltext>
<ce:source-text>Chollangi, S., et al.: A unique loop structure in oncostatin M determines binding affinity toward oncostatin M receptor and leukemia inhibitory factor receptor. J. Biol. Chem. 287(39), 32848–32859 (2012)</ce:source-text>
</reference>
<reference seq="166">
<ref-info>
<ref-title>
<ref-titletext-english>Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.J.</ce:initials>
<ce:surname>Junk</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
<iss-first>28</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4001</first-page>
<last-page>4013</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Junk, D.J., et al.: Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling. Oncogene. 36(28), 4001–4013 (2017)</ref-fulltext>
<ce:source-text>Junk, D.J., et al.: Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling. Oncogene. 36(28), 4001–4013 (2017)</ce:source-text>
</reference>
<reference seq="167">
<ref-info>
<ref-title>
<ref-titletext-english>Serum levels of oncostatin M (a gp 130 cytokine): An inflammatory biomarker in periodontal disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.R.</ce:initials>
<ce:surname>Pradeep</ce:surname>
<ce:given-name>A.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biomarkers</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>277</first-page>
<last-page>282</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pradeep, A.R., et al.: Serum levels of oncostatin M (a gp 130 cytokine): An inflammatory biomarker in periodontal disease. Biomarkers. 15(3), 277–282 (2010)</ref-fulltext>
<ce:source-text>Pradeep, A.R., et al.: Serum levels of oncostatin M (a gp 130 cytokine): An inflammatory biomarker in periodontal disease. Biomarkers. 15(3), 277–282 (2010)</ce:source-text>
</reference>
<reference seq="168">
<ref-info>
<ref-title>
<ref-titletext-english>Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Hasegawa</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Rheumatol</ref-sourcetitle>
<ref-publicationyear first="1998" />
<volisspag>
<volume-issue-number>
<vol-first>25</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>308</first-page>
<last-page>313</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hasegawa, M., et al.: Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J. Rheumatol. 25(2), 308–313 (1998)</ref-fulltext>
<ce:source-text>Hasegawa, M., et al.: Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J. Rheumatol. 25(2), 308–313 (1998)</ce:source-text>
</reference>
<reference seq="169">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Liang</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Biomark</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>161</first-page>
<last-page>171</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Liang, H., et al.: Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73. Cancer Biomark. 11(4), 161–171 (2012)</ref-fulltext>
<ce:source-text>Liang, H., et al.: Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73. Cancer Biomark. 11(4), 161–171 (2012)</ce:source-text>
</reference>
<reference seq="170">
<ref-info>
<ref-title>
<ref-titletext-english>Circulating interleukin-6 type cytokines in patients with systemic lupus erythematosus</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Robak</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. Cytokine Netw</ref-sourcetitle>
<ref-publicationyear first="1997" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>281</first-page>
<last-page>286</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Robak, E., et al.: Circulating interleukin-6 type cytokines in patients with systemic lupus erythematosus. Eur. Cytokine Netw. 8(3), 281–286 (1997)</ref-fulltext>
<ce:source-text>Robak, E., et al.: Circulating interleukin-6 type cytokines in patients with systemic lupus erythematosus. Eur. Cytokine Netw. 8(3), 281–286 (1997)</ce:source-text>
</reference>
<reference seq="171">
<ref-info>
<ref-title>
<ref-titletext-english>Oncostatin M: Potential implications for malignancy and metabolism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Stephens</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.M.</ce:initials>
<ce:surname>Elks</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Pharm. Des</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>23</vol-first>
<iss-first>25</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3645</first-page>
<last-page>3657</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stephens, J.M., Elks, C.M.: Oncostatin M: Potential implications for malignancy and metabolism. Curr. Pharm. Des. 23(25), 3645–3657 (2017)</ref-fulltext>
<ce:source-text>Stephens, J.M., Elks, C.M.: Oncostatin M: Potential implications for malignancy and metabolism. Curr. Pharm. Des. 23(25), 3645–3657 (2017)</ce:source-text>
</reference>
<reference seq="172">
<ref-info>
<ref-title>
<ref-titletext-english>Oncostatin M induces C2C12 myotube atrophy by modulating muscle differentiation and degradation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Miki</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochem. Biophys. Res. Commun</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>516</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>951</first-page>
<last-page>956</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Miki, Y., et al.: Oncostatin M induces C2C12 myotube atrophy by modulating muscle differentiation and degradation. Biochem. Biophys. Res. Commun. 516(3), 951–956 (2019)</ref-fulltext>
<ce:source-text>Miki, Y., et al.: Oncostatin M induces C2C12 myotube atrophy by modulating muscle differentiation and degradation. Biochem. Biophys. Res. Commun. 516(3), 951–956 (2019)</ce:source-text>
</reference>
<reference seq="173">
<ref-info>
<ref-title>
<ref-titletext-english>Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn’s disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.E.</ce:initials>
<ce:surname>Sands</ce:surname>
<ce:given-name>B.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Aliment. Pharmacol. Ther</ref-sourcetitle>
<ref-publicationyear first="2002" />
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>399</first-page>
<last-page>406</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sands, B.E., et al.: Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn’s disease. Aliment. Pharmacol. Ther. 16(3), 399–406 (2002)</ref-fulltext>
<ce:source-text>Sands, B.E., et al.: Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn’s disease. Aliment. Pharmacol. Ther. 16(3), 399–406 (2002)</ce:source-text>
</reference>
<reference seq="174">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin-11: A multifunctional cytokine with intrinsically disordered regions</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.A.</ce:initials>
<ce:surname>Permyakov</ce:surname>
<ce:given-name>E.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>V.N.</ce:initials>
<ce:surname>Uversky</ce:surname>
<ce:given-name>V.N.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.E.</ce:initials>
<ce:surname>Permyakov</ce:surname>
<ce:given-name>S.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Biochem. Biophys</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>74</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>285</first-page>
<last-page>296</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Permyakov, E.A., Uversky, V.N., Permyakov, S.E.: Interleukin-11: A multifunctional cytokine with intrinsically disordered regions. Cell Biochem. Biophys. 74(3), 285–296 (2016)</ref-fulltext>
<ce:source-text>Permyakov, E.A., Uversky, V.N., Permyakov, S.E.: Interleukin-11: A multifunctional cytokine with intrinsically disordered regions. Cell Biochem. Biophys. 74(3), 285–296 (2016)</ce:source-text>
</reference>
<reference seq="175">
<ref-info>
<ref-title>
<ref-titletext-english>The dynamics of signal triggering in a gp130-receptor complex</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Matadeen</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Structure</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>441</first-page>
<last-page>448</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Matadeen, R., et al.: The dynamics of signal triggering in a gp130-receptor complex. Structure. 15(4), 441–448 (2007)</ref-fulltext>
<ce:source-text>Matadeen, R., et al.: The dynamics of signal triggering in a gp130-receptor complex. Structure. 15(4), 441–448 (2007)</ce:source-text>
</reference>
<reference seq="176">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin-11 signals through the formation of a hexameric receptor complex</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.A.</ce:initials>
<ce:surname>Barton</ce:surname>
<ce:given-name>V.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2000" />
<volisspag>
<volume-issue-number>
<vol-first>275</vol-first>
<iss-first>46</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>36197</first-page>
<last-page>36203</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Barton, V.A., et al.: Interleukin-11 signals through the formation of a hexameric receptor complex. J. Biol. Chem. 275(46), 36197–36203 (2000)</ref-fulltext>
<ce:source-text>Barton, V.A., et al.: Interleukin-11 signals through the formation of a hexameric receptor complex. J. Biol. Chem. 275(46), 36197–36203 (2000)</ce:source-text>
</reference>
<reference seq="177">
<ref-info>
<ref-title>
<ref-titletext-english>STAT3-activating cytokines: A therapeutic opportunity for inflammatory bowel disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.M.</ce:initials>
<ce:surname>Nguyen</ce:surname>
<ce:given-name>P.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.L.</ce:initials>
<ce:surname>Putoczki</ce:surname>
<ce:given-name>T.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Ernst</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Interf. Cytokine Res</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>340</first-page>
<last-page>350</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nguyen, P.M., Putoczki, T.L., Ernst, M.: STAT3-activating cytokines: A therapeutic opportunity for inflammatory bowel disease? J. Interf. Cytokine Res. 35(5), 340–350 (2015)</ref-fulltext>
<ce:source-text>Nguyen, P.M., Putoczki, T.L., Ernst, M.: STAT3-activating cytokines: A therapeutic opportunity for inflammatory bowel disease? J. Interf. Cytokine Res. 35(5), 340–350 (2015)</ce:source-text>
</reference>
<reference seq="178">
<ref-info>
<ref-title>
<ref-titletext-english>Hematopoietic, immunomodulatory and epithelial effects of interleukin-11</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>U.S.</ce:initials>
<ce:surname>Schwertschlag</ce:surname>
<ce:given-name>U.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Leukemia</ref-sourcetitle>
<ref-publicationyear first="1999" />
<volisspag>
<volume-issue-number>
<vol-first>13</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1307</first-page>
<last-page>1315</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Schwertschlag, U.S., et al.: Hematopoietic, immunomodulatory and epithelial effects of interleukin-11. Leukemia. 13(9), 1307–1315 (1999)</ref-fulltext>
<ce:source-text>Schwertschlag, U.S., et al.: Hematopoietic, immunomodulatory and epithelial effects of interleukin-11. Leukemia. 13(9), 1307–1315 (1999)</ce:source-text>
</reference>
<reference seq="179">
<ref-info>
<ref-title>
<ref-titletext-english>More than a sidekick: The IL-6 family cytokine IL-11 links inflammation to cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Putoczki</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Ernst</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Leukoc. Biol</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>88</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1109</first-page>
<last-page>1117</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Putoczki, T., Ernst, M.: More than a sidekick: The IL-6 family cytokine IL-11 links inflammation to cancer. J. Leukoc. Biol. 88(6), 1109–1117 (2010)</ref-fulltext>
<ce:source-text>Putoczki, T., Ernst, M.: More than a sidekick: The IL-6 family cytokine IL-11 links inflammation to cancer. J. Leukoc. Biol. 88(6), 1109–1117 (2010)</ce:source-text>
</reference>
<reference seq="180">
<ref-info>
<ref-title>
<ref-titletext-english>Recombinant human interleukin-11 (IL-11) is a protective factor in severe sepsis with thrombocytopenia: A case-control study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Wan</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>76</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>138</first-page>
<last-page>143</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wan, B., et al.: Recombinant human interleukin-11 (IL-11) is a protective factor in severe sepsis with thrombocytopenia: A case-control study. Cytokine. 76(2), 138–143 (2015)</ref-fulltext>
<ce:source-text>Wan, B., et al.: Recombinant human interleukin-11 (IL-11) is a protective factor in severe sepsis with thrombocytopenia: A case-control study. Cytokine. 76(2), 138–143 (2015)</ce:source-text>
</reference>
<reference seq="181">
<ref-info>
<ref-title>
<ref-titletext-english>Therapeutic administration of IL-11 exhibits the postconditioning effects against ischemia-reperfusion injury via STAT3 in the heart</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Obana</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Heart Circ. Physiol</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>303</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>H569</first-page>
<last-page>H577</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Obana, M., et al.: Therapeutic administration of IL-11 exhibits the postconditioning effects against ischemia-reperfusion injury via STAT3 in the heart. Am. J. Physiol. Heart Circ. Physiol. 303(5), H569–H577 (2012)</ref-fulltext>
<ce:source-text>Obana, M., et al.: Therapeutic administration of IL-11 exhibits the postconditioning effects against ischemia-reperfusion injury via STAT3 in the heart. Am. J. Physiol. Heart Circ. Physiol. 303(5), H569–H577 (2012)</ce:source-text>
</reference>
<reference seq="182">
<ref-info>
<ref-title>
<ref-titletext-english>Identification of cardiac myocytes as the target of interleukin 11, a cardioprotective cytokine</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Kimura</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>107</first-page>
<last-page>115</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kimura, R., et al.: Identification of cardiac myocytes as the target of interleukin 11, a cardioprotective cytokine. Cytokine. 38(2), 107–115 (2007)</ref-fulltext>
<ce:source-text>Kimura, R., et al.: Identification of cardiac myocytes as the target of interleukin 11, a cardioprotective cytokine. Cytokine. 38(2), 107–115 (2007)</ce:source-text>
</reference>
<reference seq="183">
<ref-info>
<ref-title>
<ref-titletext-english>Therapeutic activation of signal transducer and activator of transcription 3 by interleukin-11 ameliorates cardiac fibrosis after myocardial infarction</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Obana</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Circulation</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>121</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>684</first-page>
<last-page>691</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Obana, M., et al.: Therapeutic activation of signal transducer and activator of transcription 3 by interleukin-11 ameliorates cardiac fibrosis after myocardial infarction. Circulation. 121(5), 684–691 (2010)</ref-fulltext>
<ce:source-text>Obana, M., et al.: Therapeutic activation of signal transducer and activator of transcription 3 by interleukin-11 ameliorates cardiac fibrosis after myocardial infarction. Circulation. 121(5), 684–691 (2010)</ce:source-text>
</reference>
<reference seq="184">
<ref-info>
<ref-title>
<ref-titletext-english>Targeting IL-11 signaling in colon cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Ernst</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.L.</ce:initials>
<ce:surname>Putoczki</ce:surname>
<ce:given-name>T.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1860</first-page>
<last-page>1861</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ernst, M., Putoczki, T.L.: Targeting IL-11 signaling in colon cancer. Oncotarget. 4(11), 1860–1861 (2013)</ref-fulltext>
<ce:source-text>Ernst, M., Putoczki, T.L.: Targeting IL-11 signaling in colon cancer. Oncotarget. 4(11), 1860–1861 (2013)</ce:source-text>
</reference>
<reference seq="185">
<ref-info>
<ref-title>
<ref-titletext-english>Emerging roles for IL-11 signaling in cancer development and progression: Focus on breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.N.</ce:initials>
<ce:surname>Johnstone</ce:surname>
<ce:given-name>C.N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine Growth Factor Rev</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>489</first-page>
<last-page>498</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Johnstone, C.N., et al.: Emerging roles for IL-11 signaling in cancer development and progression: focus on breast cancer. Cytokine Growth Factor Rev. 26(5), 489–498 (2015)</ref-fulltext>
<ce:source-text>Johnstone, C.N., et al.: Emerging roles for IL-11 signaling in cancer development and progression: focus on breast cancer. Cytokine Growth Factor Rev. 26(5), 489–498 (2015)</ce:source-text>
</reference>
<reference seq="186">
<ref-info>
<ref-title>
<ref-titletext-english>Targeting interleukin-11 receptor-alpha impairs human endometrial cancer cell proliferation and invasion in vitro and reduces tumor growth and metastasis in vivo</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.L.</ce:initials>
<ce:surname>Winship</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cancer Ther</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>720</first-page>
<last-page>730</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Winship, A.L., et al.: Targeting interleukin-11 receptor-alpha impairs human endometrial cancer cell proliferation and invasion in vitro and reduces tumor growth and metastasis in vivo. Mol. Cancer Ther. 15(4), 720–730 (2016)</ref-fulltext>
<ce:source-text>Winship, A.L., et al.: Targeting interleukin-11 receptor-alpha impairs human endometrial cancer cell proliferation and invasion in vitro and reduces tumor growth and metastasis in vivo. Mol. Cancer Ther. 15(4), 720–730 (2016)</ce:source-text>
</reference>
<reference seq="187">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.L.</ce:initials>
<ce:surname>Putoczki</ce:surname>
<ce:given-name>T.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>257</first-page>
<last-page>271</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Putoczki, T.L., et al.: Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell. 24(2), 257–271 (2013)</ref-fulltext>
<ce:source-text>Putoczki, T.L., et al.: Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell. 24(2), 257–271 (2013)</ce:source-text>
</reference>
<reference seq="188">
<ref-info>
<ref-title>
<ref-titletext-english>Lipolytic and lipoprotein lipase (LPL)-inhibiting activities produced by a human lung cancer cell line responsible for cachexia induction</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Nara-Ashizawa</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Anticancer Res</ref-sourcetitle>
<ref-publicationyear first="2001" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3381</first-page>
<last-page>3387</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nara-Ashizawa, N., et al.: Lipolytic and lipoprotein lipase (LPL)-inhibiting activities produced by a human lung cancer cell line responsible for cachexia induction. Anticancer Res. 21(5), 3381–3387 (2001)</ref-fulltext>
<ce:source-text>Nara-Ashizawa, N., et al.: Lipolytic and lipoprotein lipase (LPL)-inhibiting activities produced by a human lung cancer cell line responsible for cachexia induction. Anticancer Res. 21(5), 3381–3387 (2001)</ce:source-text>
</reference>
<reference seq="189">
<ref-info>
<ref-title>
<ref-titletext-english>Recombinant human interleukin-11 improved carboplatin-induced thrombocytopenia without affecting antitumor activities in mice bearing Lewis lung carcinoma cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Saitoh</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Chemother. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2002" />
<volisspag>
<volume-issue-number>
<vol-first>49</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>161</first-page>
<last-page>166</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Saitoh, M., et al.: Recombinant human interleukin-11 improved carboplatin-induced thrombocytopenia without affecting antitumor activities in mice bearing Lewis lung carcinoma cells. Cancer Chemother. Pharmacol. 49(2), 161–166 (2002)</ref-fulltext>
<ce:source-text>Saitoh, M., et al.: Recombinant human interleukin-11 improved carboplatin-induced thrombocytopenia without affecting antitumor activities in mice bearing Lewis lung carcinoma cells. Cancer Chemother. Pharmacol. 49(2), 161–166 (2002)</ce:source-text>
</reference>
<reference seq="190">
<ref-info>
<ref-title>
<ref-titletext-english>Binding of madindoline A to the extracellular domain of gp130</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.Z.</ce:initials>
<ce:surname>Saleh</ce:surname>
<ce:given-name>A.Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochemistry</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>44</vol-first>
<iss-first>32</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>10822</first-page>
<last-page>10827</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Saleh, A.Z., et al.: Binding of madindoline A to the extracellular domain of gp130. Biochemistry. 44(32), 10822–10827 (2005)</ref-fulltext>
<ce:source-text>Saleh, A.Z., et al.: Binding of madindoline A to the extracellular domain of gp130. Biochemistry. 44(32), 10822–10827 (2005)</ce:source-text>
</reference>
<reference seq="191">
<ref-info>
<ref-title>
<ref-titletext-english>Inhibition of protein kinase II (CK2) prevents induced signal transducer and activator of transcription (STAT) 1/3 and constitutive STAT3 activation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Aparicio-Siegmund</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2131</first-page>
<last-page>2148</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Aparicio-Siegmund, S., et al.: Inhibition of protein kinase II (CK2) prevents induced signal transducer and activator of transcription (STAT) 1/3 and constitutive STAT3 activation. Oncotarget. 5(8), 2131–2148 (2014)</ref-fulltext>
<ce:source-text>Aparicio-Siegmund, S., et al.: Inhibition of protein kinase II (CK2) prevents induced signal transducer and activator of transcription (STAT) 1/3 and constitutive STAT3 activation. Oncotarget. 5(8), 2131–2148 (2014)</ce:source-text>
</reference>
<reference seq="192">
<ref-info>
<ref-title>
<ref-titletext-english>A novel role for interleukin-27 (IL-27) as mediator of intestinal epithelial barrier protection mediated via differential signal transducer and activator of transcription (STAT) protein signaling and induction of antibacterial and anti-inflammatory proteins</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Diegelmann</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>287</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>286</first-page>
<last-page>298</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Diegelmann, J., et al.: A novel role for interleukin-27 (IL-27) as mediator of intestinal epithelial barrier protection mediated via differential signal transducer and activator of transcription (STAT) protein signaling and induction of antibacterial and anti-inflammatory proteins. J. Biol. Chem. 287(1), 286–298 (2012)</ref-fulltext>
<ce:source-text>Diegelmann, J., et al.: A novel role for interleukin-27 (IL-27) as mediator of intestinal epithelial barrier protection mediated via differential signal transducer and activator of transcription (STAT) protein signaling and induction of antibacterial and anti-inflammatory proteins. J. Biol. Chem. 287(1), 286–298 (2012)</ce:source-text>
</reference>
<reference seq="193">
<ref-info>
<ref-title>
<ref-titletext-english>The biology of interleukin-27 reveals unique pro- and anti-inflammatory functions in immunity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Aparicio-Siegmund</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Garbers</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine Growth Factor Rev</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>579</first-page>
<last-page>586</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Aparicio-Siegmund, S., Garbers, C.: The biology of interleukin-27 reveals unique pro- and anti-inflammatory functions in immunity. Cytokine Growth Factor Rev. 26(5), 579–586 (2015)</ref-fulltext>
<ce:source-text>Aparicio-Siegmund, S., Garbers, C.: The biology of interleukin-27 reveals unique pro- and anti-inflammatory functions in immunity. Cytokine Growth Factor Rev. 26(5), 579–586 (2015)</ce:source-text>
</reference>
<reference seq="194">
<ref-info>
<ref-title>
<ref-titletext-english>The immunobiology of IL-27. Adv</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.O.</ce:initials>
<ce:surname>Hall</ce:surname>
<ce:given-name>A.O.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.S.</ce:initials>
<ce:surname>Silver</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.A.</ce:initials>
<ce:surname>Hunter</ce:surname>
<ce:given-name>C.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Immunol</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>115</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1</first-page>
<last-page>44</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hall, A.O., Silver, J.S., Hunter, C.A.: The immunobiology of IL-27. Adv. Immunol. 115, 1–44 (2012)</ref-fulltext>
<ce:source-text>Hall, A.O., Silver, J.S., Hunter, C.A.: The immunobiology of IL-27. Adv. Immunol. 115, 1–44 (2012)</ce:source-text>
</reference>
<reference seq="195">
<ref-info>
<ref-title>
<ref-titletext-english>IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Pflanz</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Immunity</ref-sourcetitle>
<ref-publicationyear first="2002" />
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>779</first-page>
<last-page>790</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pflanz, S., et al.: IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity. 16(6), 779–790 (2002)</ref-fulltext>
<ce:source-text>Pflanz, S., et al.: IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity. 16(6), 779–790 (2002)</ce:source-text>
</reference>
<reference seq="196">
<ref-info>
<ref-title>
<ref-titletext-english>Clinical implications of the interleukin 27 serum level in breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Lu</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Investig. Med</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>62</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>627</first-page>
<last-page>631</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lu, D., et al.: Clinical implications of the interleukin 27 serum level in breast cancer. J. Investig. Med. 62(3), 627–631 (2014)</ref-fulltext>
<ce:source-text>Lu, D., et al.: Clinical implications of the interleukin 27 serum level in breast cancer. J. Investig. Med. 62(3), 627–631 (2014)</ce:source-text>
</reference>
<reference seq="197">
<ref-info>
<ref-title>
<ref-titletext-english>Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Chiyo</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>115</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>437</first-page>
<last-page>442</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chiyo, M., et al.: Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals. Int. J. Cancer. 115(3), 437–442 (2005)</ref-fulltext>
<ce:source-text>Chiyo, M., et al.: Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals. Int. J. Cancer. 115(3), 437–442 (2005)</ce:source-text>
</reference>
<reference seq="198">
<ref-info>
<ref-title>
<ref-titletext-english>Potent antitumor activity of interleukin-27</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Hisada</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2004" />
<volisspag>
<volume-issue-number>
<vol-first>64</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1152</first-page>
<last-page>1156</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hisada, M., et al.: Potent antitumor activity of interleukin-27. Cancer Res. 64(3), 1152–1156 (2004)</ref-fulltext>
<ce:source-text>Hisada, M., et al.: Potent antitumor activity of interleukin-27. Cancer Res. 64(3), 1152–1156 (2004)</ce:source-text>
</reference>
<reference seq="199">
<ref-info>
<ref-title>
<ref-titletext-english>Immunologic and therapeutic synergy of IL-27 and IL-2: Enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Salcedo</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Immunol</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>182</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4328</first-page>
<last-page>4338</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Salcedo, R., et al.: Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow. J. Immunol. 182(7), 4328–4338 (2009)</ref-fulltext>
<ce:source-text>Salcedo, R., et al.: Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow. J. Immunol. 182(7), 4328–4338 (2009)</ce:source-text>
</reference>
<reference seq="200">
<ref-info>
<ref-title>
<ref-titletext-english>IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: Role for CD8+ T cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Salcedo</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Immunol</ref-sourcetitle>
<ref-publicationyear first="2004" />
<volisspag>
<volume-issue-number>
<vol-first>173</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7170</first-page>
<last-page>7182</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Salcedo, R., et al.: IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells. J. Immunol. 173(12), 7170–7182 (2004)</ref-fulltext>
<ce:source-text>Salcedo, R., et al.: IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells. J. Immunol. 173(12), 7170–7182 (2004)</ce:source-text>
</reference>
<reference seq="201">
<ref-info>
<ref-title>
<ref-titletext-english>Increased interleukin-27 promotes Th1 differentiation in patients with chronic immune thrombocytopenia. Scand</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Q.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>Q.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Immunol</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>80</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>276</first-page>
<last-page>282</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Li, Q., et al.: Increased interleukin-27 promotes Th1 differentiation in patients with chronic immune thrombocytopenia. Scand. J. Immunol. 80(4), 276–282 (2014)</ref-fulltext>
<ce:source-text>Li, Q., et al.: Increased interleukin-27 promotes Th1 differentiation in patients with chronic immune thrombocytopenia. Scand. J. Immunol. 80(4), 276–282 (2014)</ce:source-text>
</reference>
<reference seq="202">
<ref-info>
<ref-title>
<ref-titletext-english>Suppression of autoimmune inflammation of the nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.C.</ce:initials>
<ce:surname>Fitzgerald</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Immunol</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1372</first-page>
<last-page>1379</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fitzgerald, D.C., et al.: Suppression of autoimmune inflammation of the nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat. Immunol. 8(12), 1372–1379 (2007)</ref-fulltext>
<ce:source-text>Fitzgerald, D.C., et al.: Suppression of autoimmune inflammation of the nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat. Immunol. 8(12), 1372–1379 (2007)</ce:source-text>
</reference>
<reference seq="203">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S.</ce:initials>
<ce:surname>Stumhofer</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Immunol</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1363</first-page>
<last-page>1371</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stumhofer, J.S., et al.: Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat. Immunol. 8(12), 1363–1371 (2007)</ref-fulltext>
<ce:source-text>Stumhofer, J.S., et al.: Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat. Immunol. 8(12), 1363–1371 (2007)</ce:source-text>
</reference>
<reference seq="204">
<ref-info>
<ref-title>
<ref-titletext-english>Cutting edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Pot</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Immunol</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>183</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>797</first-page>
<last-page>801</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pot, C., et al.: Cutting edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cells. J. Immunol. 183(2), 797–801 (2009)</ref-fulltext>
<ce:source-text>Pot, C., et al.: Cutting edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cells. J. Immunol. 183(2), 797–801 (2009)</ce:source-text>
</reference>
<reference seq="205">
<ref-info>
<ref-title>
<ref-titletext-english>IL-27 induces Th1 differentiation via p38 MAPK/T-bet- and intercellular adhesion molecule-1/LFA-1/ERK1/2-dependent pathways</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Owaki</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Immunol</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>177</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7579</first-page>
<last-page>7587</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Owaki, T., et al.: IL-27 induces Th1 differentiation via p38 MAPK/T-bet- and intercellular adhesion molecule-1/LFA-1/ERK1/2-dependent pathways. J. Immunol. 177(11), 7579–7587 (2006)</ref-fulltext>
<ce:source-text>Owaki, T., et al.: IL-27 induces Th1 differentiation via p38 MAPK/T-bet- and intercellular adhesion molecule-1/LFA-1/ERK1/2-dependent pathways. J. Immunol. 177(11), 7579–7587 (2006)</ce:source-text>
</reference>
<reference seq="206">
<ref-info>
<ref-title>
<ref-titletext-english>IL-27 receptor signaling regulates CD4+ T cell chemotactic responses during infection</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Gwyer Findlay</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Immunol</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>190</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4553</first-page>
<last-page>4561</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gwyer Findlay, E., et al.: IL-27 receptor signaling regulates CD4+ T cell chemotactic responses during infection. J. Immunol. 190(9), 4553–4561 (2013)</ref-fulltext>
<ce:source-text>Gwyer Findlay, E., et al.: IL-27 receptor signaling regulates CD4+ T cell chemotactic responses during infection. J. Immunol. 190(9), 4553–4561 (2013)</ce:source-text>
</reference>
<reference seq="207">
<ref-info>
<ref-title>
<ref-titletext-english>IL-27 induces the production of IgG1 by human B cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Boumendjel</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. Cytokine Netw</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>281</first-page>
<last-page>289</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Boumendjel, A., et al.: IL-27 induces the production of IgG1 by human B cells. Eur. Cytokine Netw. 17(4), 281–289 (2006)</ref-fulltext>
<ce:source-text>Boumendjel, A., et al.: IL-27 induces the production of IgG1 by human B cells. Eur. Cytokine Netw. 17(4), 281–289 (2006)</ce:source-text>
</reference>
<reference seq="208">
<ref-info>
<ref-title>
<ref-titletext-english>Differential effects of IL-27 on human B cell subsets</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Larousserie</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Immunol</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>176</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5890</first-page>
<last-page>5897</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Larousserie, F., et al.: Differential effects of IL-27 on human B cell subsets. J. Immunol. 176(10), 5890–5897 (2006)</ref-fulltext>
<ce:source-text>Larousserie, F., et al.: Differential effects of IL-27 on human B cell subsets. J. Immunol. 176(10), 5890–5897 (2006)</ce:source-text>
</reference>
<reference seq="209">
<ref-info>
<ref-title>
<ref-titletext-english>New IL-6 (gp130) family cytokine members, CLC/NNT1/BSF3 and IL-27</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Murakami</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Kamimura</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Hirano</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Growth Factors</ref-sourcetitle>
<ref-publicationyear first="2004" />
<volisspag>
<volume-issue-number>
<vol-first>22</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>75</first-page>
<last-page>77</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Murakami, M., Kamimura, D., Hirano, T.: New IL-6 (gp130) family cytokine members, CLC/NNT1/BSF3 and IL-27. Growth Factors. 22(2), 75–77 (2004)</ref-fulltext>
<ce:source-text>Murakami, M., Kamimura, D., Hirano, T.: New IL-6 (gp130) family cytokine members, CLC/NNT1/BSF3 and IL-27. Growth Factors. 22(2), 75–77 (2004)</ce:source-text>
</reference>
<reference seq="210">
<ref-info>
<ref-title>
<ref-titletext-english>Novel neurotrophin-1/B cell-stimulating factor-3: A cytokine of the IL-6 family</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Senaldi</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="1999" />
<volisspag>
<volume-issue-number>
<vol-first>96</vol-first>
<iss-first>20</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>11458</first-page>
<last-page>11463</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Senaldi, G., et al.: Novel neurotrophin-1/B cell-stimulating factor-3: A cytokine of the IL-6 family. Proc. Natl. Acad. Sci. USA. 96(20), 11458–11463 (1999)</ref-fulltext>
<ce:source-text>Senaldi, G., et al.: Novel neurotrophin-1/B cell-stimulating factor-3: A cytokine of the IL-6 family. Proc. Natl. Acad. Sci. USA. 96(20), 11458–11463 (1999)</ce:source-text>
</reference>
<reference seq="211">
<ref-info>
<ref-title>
<ref-titletext-english>Computational EST database analysis identifies a novel member of the neuropoietic cytokine family</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Shi</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochem. Biophys. Res. Commun</ref-sourcetitle>
<ref-publicationyear first="1999" />
<volisspag>
<volume-issue-number>
<vol-first>262</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>132</first-page>
<last-page>138</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shi, Y., et al.: Computational EST database analysis identifies a novel member of the neuropoietic cytokine family. Biochem. Biophys. Res. Commun. 262(1), 132–138 (1999)</ref-fulltext>
<ce:source-text>Shi, Y., et al.: Computational EST database analysis identifies a novel member of the neuropoietic cytokine family. Biochem. Biophys. Res. Commun. 262(1), 132–138 (1999)</ce:source-text>
</reference>
<reference seq="212">
<ref-info>
<ref-title>
<ref-titletext-english>Six different cytokines that share GP130 as a receptor subunit, induce serum amyloid A and potentiate the induction of interleukin-6 and the activation of the hypothalamus-pituitary-adrenal axis by interleukin-1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Benigni</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Blood</ref-sourcetitle>
<ref-publicationyear first="1996" />
<volisspag>
<volume-issue-number>
<vol-first>87</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1851</first-page>
<last-page>1854</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Benigni, F., et al.: Six different cytokines that share GP130 as a receptor subunit, induce serum amyloid A and potentiate the induction of interleukin-6 and the activation of the hypothalamus-pituitary-adrenal axis by interleukin-1. Blood. 87(5), 1851–1854 (1996)</ref-fulltext>
<ce:source-text>Benigni, F., et al.: Six different cytokines that share GP130 as a receptor subunit, induce serum amyloid A and potentiate the induction of interleukin-6 and the activation of the hypothalamus-pituitary-adrenal axis by interleukin-1. Blood. 87(5), 1851–1854 (1996)</ce:source-text>
</reference>
<reference seq="213">
<ref-info>
<ref-title>
<ref-titletext-english>Novel neurotrophin-1/B cell-stimulating factor-3 (NNT-1/BSF-3)/cardiotrophin-like cytokine (CLC) – a novel gp130 cytokine with pleiotropic functions</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Vlotides</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine Growth Factor Rev</ref-sourcetitle>
<ref-publicationyear first="2004" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>325</first-page>
<last-page>336</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vlotides, G., et al.: Novel neurotrophin-1/B cell-stimulating factor-3 (NNT-1/BSF-3)/cardiotrophin-like cytokine (CLC) – a novel gp130 cytokine with pleiotropic functions. Cytokine Growth Factor Rev. 15(5), 325–336 (2004)</ref-fulltext>
<ce:source-text>Vlotides, G., et al.: Novel neurotrophin-1/B cell-stimulating factor-3 (NNT-1/BSF-3)/cardiotrophin-like cytokine (CLC) – a novel gp130 cytokine with pleiotropic functions. Cytokine Growth Factor Rev. 15(5), 325–336 (2004)</ce:source-text>
</reference>
<reference seq="214">
<ref-info>
<ref-title>
<ref-titletext-english>The ciliary neurotrophic factor receptor alpha component induces the secretion of and is required for functional responses to cardiotrophin-like cytokine</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Plun-Favreau</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>EMBO J</ref-sourcetitle>
<ref-publicationyear first="2001" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1692</first-page>
<last-page>1703</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Plun-Favreau, H., et al.: The ciliary neurotrophic factor receptor alpha component induces the secretion of and is required for functional responses to cardiotrophin-like cytokine. EMBO J. 20(7), 1692–1703 (2001)</ref-fulltext>
<ce:source-text>Plun-Favreau, H., et al.: The ciliary neurotrophic factor receptor alpha component induces the secretion of and is required for functional responses to cardiotrophin-like cytokine. EMBO J. 20(7), 1692–1703 (2001)</ce:source-text>
</reference>
<reference seq="215">
<ref-info>
<ref-title>
<ref-titletext-english>Cardiotrophin-like cytokine/cytokine-like factor 1 is an essential trophic factor for lumbar and facial motoneurons in vivo</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.G.</ce:initials>
<ce:surname>Forger</ce:surname>
<ce:given-name>N.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Neurosci</ref-sourcetitle>
<ref-publicationyear first="2003" />
<volisspag>
<volume-issue-number>
<vol-first>23</vol-first>
<iss-first>26</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>8854</first-page>
<last-page>8858</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Forger, N.G., et al.: Cardiotrophin-like cytokine/cytokine-like factor 1 is an essential trophic factor for lumbar and facial motoneurons in vivo. J. Neurosci. 23(26), 8854–8858 (2003)</ref-fulltext>
<ce:source-text>Forger, N.G., et al.: Cardiotrophin-like cytokine/cytokine-like factor 1 is an essential trophic factor for lumbar and facial motoneurons in vivo. J. Neurosci. 23(26), 8854–8858 (2003)</ce:source-text>
</reference>
<reference seq="216">
<ref-info>
<ref-title>
<ref-titletext-english>Cardiotrophin-like cytokine induces astrocyte differentiation of fetal neuroepithelial cells via activation of STAT3</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Uemura</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine</ref-sourcetitle>
<ref-publicationyear first="2002" />
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1</first-page>
<last-page>7</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Uemura, A., et al.: Cardiotrophin-like cytokine induces astrocyte differentiation of fetal neuroepithelial cells via activation of STAT3. Cytokine. 18(1), 1–7 (2002)</ref-fulltext>
<ce:source-text>Uemura, A., et al.: Cardiotrophin-like cytokine induces astrocyte differentiation of fetal neuroepithelial cells via activation of STAT3. Cytokine. 18(1), 1–7 (2002)</ce:source-text>
</reference>
<reference seq="217">
<ref-info>
<ref-title>
<ref-titletext-english>Novel regulators of kidney development from the tips of the ureteric bud</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.M.</ce:initials>
<ce:surname>Schmidt-Ott</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Am. Soc. Nephrol</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1993</first-page>
<last-page>2002</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Schmidt-Ott, K.M., et al.: Novel regulators of kidney development from the tips of the ureteric bud. J. Am. Soc. Nephrol. 16(7), 1993–2002 (2005)</ref-fulltext>
<ce:source-text>Schmidt-Ott, K.M., et al.: Novel regulators of kidney development from the tips of the ureteric bud. J. Am. Soc. Nephrol. 16(7), 1993–2002 (2005)</ce:source-text>
</reference>
<reference seq="218">
<ref-info>
<ref-title>
<ref-titletext-english>Suckling defect in mice lacking the soluble haemopoietin receptor NR6</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.S.</ce:initials>
<ce:surname>Alexander</ce:surname>
<ce:given-name>W.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Biol</ref-sourcetitle>
<ref-publicationyear first="1999" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>605</first-page>
<last-page>608</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Alexander, W.S., et al.: Suckling defect in mice lacking the soluble haemopoietin receptor NR6. Curr. Biol. 9(11), 605–608 (1999)</ref-fulltext>
<ce:source-text>Alexander, W.S., et al.: Suckling defect in mice lacking the soluble haemopoietin receptor NR6. Curr. Biol. 9(11), 605–608 (1999)</ce:source-text>
</reference>
<reference seq="219">
<ref-info>
<ref-title>
<ref-titletext-english>Cytokine-like factor-1, a novel soluble protein, shares homology with members of the cytokine type I receptor family</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.C.</ce:initials>
<ce:surname>Elson</ce:surname>
<ce:given-name>G.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Immunol</ref-sourcetitle>
<ref-publicationyear first="1998" />
<volisspag>
<volume-issue-number>
<vol-first>161</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1371</first-page>
<last-page>1379</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Elson, G.C., et al.: Cytokine-like factor-1, a novel soluble protein, shares homology with members of the cytokine type I receptor family. J. Immunol. 161(3), 1371–1379 (1998)</ref-fulltext>
<ce:source-text>Elson, G.C., et al.: Cytokine-like factor-1, a novel soluble protein, shares homology with members of the cytokine type I receptor family. J. Immunol. 161(3), 1371–1379 (1998)</ce:source-text>
</reference>
<reference seq="220">
<ref-info>
<ref-title>
<ref-titletext-english>Cross-species functional analysis of cancer-associated fibroblasts identifies a critical role for CLCF1 and IL-6 in non-small cell lung cancer in vivo</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Vicent</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>72</vol-first>
<iss-first>22</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5744</first-page>
<last-page>5756</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vicent, S., et al.: Cross-species functional analysis of cancer-associated fibroblasts identifies a critical role for CLCF1 and IL-6 in non-small cell lung cancer in vivo. Cancer Res. 72(22), 5744–5756 (2012)</ref-fulltext>
<ce:source-text>Vicent, S., et al.: Cross-species functional analysis of cancer-associated fibroblasts identifies a critical role for CLCF1 and IL-6 in non-small cell lung cancer in vivo. Cancer Res. 72(22), 5744–5756 (2012)</ce:source-text>
</reference>
<reference seq="221">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle glycoprotein 130’s role in Lewis lung carcinoma-induced cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.J.</ce:initials>
<ce:surname>Puppa</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>FASEB J</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>998</first-page>
<last-page>1009</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Puppa, M.J., et al.: Skeletal muscle glycoprotein 130’s role in Lewis lung carcinoma-induced cachexia. FASEB J. 28(2), 998–1009 (2014)</ref-fulltext>
<ce:source-text>Puppa, M.J., et al.: Skeletal muscle glycoprotein 130’s role in Lewis lung carcinoma-induced cachexia. FASEB J. 28(2), 998–1009 (2014)</ce:source-text>
</reference>
<reference seq="222">
<ref-info>
<ref-website>
<ce:e-address type="url">Clinicaltrials.gov</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Clinicaltrials.gov.</ref-fulltext>
<ce:source-text>Clinicaltrials.gov.</ce:source-text>
</reference>
<reference seq="223">
<ref-info>
<ref-title>
<ref-titletext-english>Emerging treatment options for cancer-associated cachexia: A literature review</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Naito</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ther. Clin. Risk Manag</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1253</first-page>
<last-page>1266</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Naito, T.: Emerging treatment options for cancer-associated cachexia: A literature review. Ther. Clin. Risk Manag. 15, 1253–1266 (2019)</ref-fulltext>
<ce:source-text>Naito, T.: Emerging treatment options for cancer-associated cachexia: A literature review. Ther. Clin. Risk Manag. 15, 1253–1266 (2019)</ce:source-text>
</reference>
<reference seq="224">
<ref-info>
<ref-title>
<ref-titletext-english>Therapeutic strategies against cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Argilés</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur J Transl Myol</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>29</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7960</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Argilés, J.M., et al.: Therapeutic strategies against cancer cachexia. Eur J Transl Myol. 29(1), 7960 (2019)</ref-fulltext>
<ce:source-text>Argilés, J.M., et al.: Therapeutic strategies against cancer cachexia. Eur J Transl Myol. 29(1), 7960 (2019)</ce:source-text>
</reference>
<reference seq="225">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-induced cardiac cachexia: Pathogenesis and impact of physical activity (Review)</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Belloum</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Rannou-Bekono</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="3">
<ce:initials>F.B.</ce:initials>
<ce:surname>Favier</ce:surname>
<ce:given-name>F.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncol. Rep</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>37</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2543</first-page>
<last-page>2552</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Belloum, Y., Rannou-Bekono, F., Favier, F.B.: Cancer-induced cardiac cachexia: Pathogenesis and impact of physical activity (Review). Oncol. Rep. 37(5), 2543–2552 (2017)</ref-fulltext>
<ce:source-text>Belloum, Y., Rannou-Bekono, F., Favier, F.B.: Cancer-induced cardiac cachexia: Pathogenesis and impact of physical activity (Review). Oncol. Rep. 37(5), 2543–2552 (2017)</ce:source-text>
</reference>
<reference seq="226">
<ref-info>
<ref-title>
<ref-titletext-english>Chemotherapy-induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.A.</ce:initials>
<ce:surname>Hain</ce:surname>
<ce:given-name>B.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>JCSM Rapid Commun</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Hain, B.A., et al.: Chemotherapy-induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia. JCSM Rapid Commun. 2(1) (2019)</ref-fulltext>
<ce:source-text>Hain, B.A., et al.: Chemotherapy-induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia. JCSM Rapid Commun. 2(1) (2019)</ce:source-text>
</reference>
<reference seq="227">
<ref-info>
<ref-title>
<ref-titletext-english>Differential bone loss in mouse models of colon cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Physiol</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>679</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bonetto, A., et al.: Differential bone loss in mouse models of colon cancer cachexia. Front. Physiol. 7, 679 (2016)</ref-fulltext>
<ce:source-text>Bonetto, A., et al.: Differential bone loss in mouse models of colon cancer cachexia. Front. Physiol. 7, 679 (2016)</ce:source-text>
</reference>
<reference seq="228">
<ref-info>
<ref-title>
<ref-titletext-english>Anti-cytokines in the treatment of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.L.</ce:initials>
<ce:surname>Prado</ce:surname>
<ce:given-name>B.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Qian</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ann Palliat Med</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>67</first-page>
<last-page>79</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Prado, B.L., Qian, Y.: Anti-cytokines in the treatment of cancer cachexia. Ann Palliat Med. 8(1), 67–79 (2019)</ref-fulltext>
<ce:source-text>Prado, B.L., Qian, Y.: Anti-cytokines in the treatment of cancer cachexia. Ann Palliat Med. 8(1), 67–79 (2019)</ce:source-text>
</reference>
<reference seq="229">
<ref-info>
<ref-title>
<ref-titletext-english>Endpoints in clinical trials in cancer cachexia: Where to start</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.J.A.</ce:initials>
<ce:surname>Laird</ce:surname>
<ce:given-name>B.J.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.R.</ce:initials>
<ce:surname>Balstad</ce:surname>
<ce:given-name>T.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.S.</ce:initials>
<ce:surname>Solheim</ce:surname>
<ce:given-name>T.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Opin. Support. Palliat. Care</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>445</first-page>
<last-page>452</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Laird, B.J.A., Balstad, T.R., Solheim, T.S.: Endpoints in clinical trials in cancer cachexia: where to start? Curr. Opin. Support. Palliat. Care. 12(4), 445–452 (2018)</ref-fulltext>
<ce:source-text>Laird, B.J.A., Balstad, T.R., Solheim, T.S.: Endpoints in clinical trials in cancer cachexia: where to start? Curr. Opin. Support. Palliat. Care. 12(4), 445–452 (2018)</ce:source-text>
</reference>
<reference seq="230">
<ref-info>
<ref-title>
<ref-titletext-english>A critical review of multimodal interventions for cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>McKeaveney</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Adv. Nutr</ref-sourcetitle>
<ref-publicationyear first="2020" />
</ref-info>
<ref-fulltext>McKeaveney, C., et al.: A critical review of multimodal interventions for cachexia. Adv. Nutr. (2020)</ref-fulltext>
<ce:source-text>McKeaveney, C., et al.: A critical review of multimodal interventions for cachexia. Adv. Nutr. (2020)</ce:source-text>
</reference>
<reference seq="231">
<ref-info>
<ref-title>
<ref-titletext-english>Management of cancer cachexia: ASCO guideline</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.J.</ce:initials>
<ce:surname>Roeland</ce:surname>
<ce:given-name>E.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
<iss-first>21</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2438</first-page>
<last-page>2453</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Roeland, E.J., et al.: Management of cancer cachexia: ASCO guideline. J. Clin. Oncol. 38(21), 2438–2453 (2020)</ref-fulltext>
<ce:source-text>Roeland, E.J., et al.: Management of cancer cachexia: ASCO guideline. J. Clin. Oncol. 38(21), 2438–2453 (2020)</ce:source-text>
</reference>
<reference seq="232">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia: Impact, mechanisms and emerging treatments</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.C.</ce:initials>
<ce:surname>Vaughan</ce:surname>
<ce:given-name>V.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Martin</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>P.A.</ce:initials>
<ce:surname>Lewandowski</ce:surname>
<ce:given-name>P.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>95</first-page>
<last-page>109</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vaughan, V.C., Martin, P., Lewandowski, P.A.: Cancer cachexia: impact, mechanisms and emerging treatments. J. Cachexia. Sarcopenia Muscle. 4(2), 95–109 (2013)</ref-fulltext>
<ce:source-text>Vaughan, V.C., Martin, P., Lewandowski, P.A.: Cancer cachexia: impact, mechanisms and emerging treatments. J. Cachexia. Sarcopenia Muscle. 4(2), 95–109 (2013)</ce:source-text>
</reference>
<reference seq="233">
<ref-info>
<ref-title>
<ref-titletext-english>Efect of ALD518, a humanized anti-IL-6 antibody, on lean body mass loss and symptoms in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II randomized, double-blind safety and efficacy trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.R.</ce:initials>
<ce:surname>Rigas</ce:surname>
<ce:given-name>J.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
<iss-first>15</iss-first>
<suppl>Supplement</suppl>
</volume-issue-number>
<page-information>
<pages>
<first-page>7622</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rigas, J.R., et al.: Efect of ALD518, a humanized anti-IL-6 antibody, on lean body mass loss and symptoms in patients with advanced non-small cell lung cancer (NSCLC): results of a phase II randomized, double-blind safety and efficacy trial. J. Clin. Oncol. 28(15_suppl), 7622–7622 (2010)</ref-fulltext>
<ce:source-text>Rigas, J.R., et al.: Efect of ALD518, a humanized anti-IL-6 antibody, on lean body mass loss and symptoms in patients with advanced non-small cell lung cancer (NSCLC): results of a phase II randomized, double-blind safety and efficacy trial. J. Clin. Oncol. 28(15_suppl), 7622–7622 (2010)</ce:source-text>
</reference>
<reference seq="234">
<ref-info>
<ref-title>
<ref-titletext-english>Favorable responses to tocilizumab in two patients with cancer-related cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Hirata</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Pain Symptom Manag</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>46</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>e9</first-page>
<last-page>e13</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hirata, H., et al.: Favorable responses to tocilizumab in two patients with cancer-related cachexia. J. Pain Symptom Manag. 46(2), e9–e13 (2013)</ref-fulltext>
<ce:source-text>Hirata, H., et al.: Favorable responses to tocilizumab in two patients with cancer-related cachexia. J. Pain Symptom Manag. 46(2), e9–e13 (2013)</ce:source-text>
</reference>
<reference seq="235">
<ref-info>
<ref-title>
<ref-titletext-english>Assessment of tocilizumab in the treatment of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Berti</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>31</vol-first>
<iss-first>23</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2970</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Berti, A., et al.: Assessment of tocilizumab in the treatment of cancer cachexia. J. Clin. Oncol. 31(23), 2970 (2013)</ref-fulltext>
<ce:source-text>Berti, A., et al.: Assessment of tocilizumab in the treatment of cancer cachexia. J. Clin. Oncol. 31(23), 2970 (2013)</ce:source-text>
</reference>
<reference seq="236">
<ref-info>
<ref-title>
<ref-titletext-english>PACTO: A single center, randomized, phase II study of the combination of nab-paclitaxel and gemcitabine with or without tocilizumab, an IL-6R inhibitor, as first-line treatment in patients with locally advanced or metastatic pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Oncol</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Chen, I., et al.: PACTO: A single center, randomized, phase II study of the combination of nab-paclitaxel and gemcitabine with or without tocilizumab, an IL-6R inhibitor, as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Ann. Oncol. 28, v266 (2017)</ref-fulltext>
<ce:source-text>Chen, I., et al.: PACTO: A single center, randomized, phase II study of the combination of nab-paclitaxel and gemcitabine with or without tocilizumab, an IL-6R inhibitor, as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Ann. Oncol. 28, v266 (2017)</ce:source-text>
</reference>
<reference seq="237">
<ref-info>
<ref-title>
<ref-titletext-english>Understanding the role of interleukin-6 (IL-6) in the joint and beyond: A comprehensive review of IL-6 inhibition for the management of rheumatoid arthritis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.G.</ce:initials>
<ce:surname>Favalli</ce:surname>
<ce:given-name>E.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Rheumatol Ther</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>473</first-page>
<last-page>516</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Favalli, E.G.: Understanding the role of interleukin-6 (IL-6) in the joint and beyond: A comprehensive review of IL-6 inhibition for the management of rheumatoid arthritis. Rheumatol Ther. 7(3), 473–516 (2020)</ref-fulltext>
<ce:source-text>Favalli, E.G.: Understanding the role of interleukin-6 (IL-6) in the joint and beyond: A comprehensive review of IL-6 inhibition for the management of rheumatoid arthritis. Rheumatol Ther. 7(3), 473–516 (2020)</ce:source-text>
</reference>
<reference seq="238">
<ref-info>
<ref-title>
<ref-titletext-english>Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.H.</ce:initials>
<ce:surname>Heo</ce:surname>
<ce:given-name>T.H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Wahler</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Suh</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>13</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>15460</first-page>
<last-page>15473</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Heo, T.H., Wahler, J., Suh, N.: Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer. Oncotarget. 7(13), 15460–15473 (2016)</ref-fulltext>
<ce:source-text>Heo, T.H., Wahler, J., Suh, N.: Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer. Oncotarget. 7(13), 15460–15473 (2016)</ce:source-text>
</reference>
<reference seq="239">
<ref-info>
<ref-title>
<ref-titletext-english>Pantoprazole blocks the JAK2/STAT3 pathway to alleviate skeletal muscle wasting in cancer cachexia by inhibiting inflammatory response</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Guo</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>24</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>39640</first-page>
<last-page>39648</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Guo, D., et al.: Pantoprazole blocks the JAK2/STAT3 pathway to alleviate skeletal muscle wasting in cancer cachexia by inhibiting inflammatory response. Oncotarget. 8(24), 39640–39648 (2017)</ref-fulltext>
<ce:source-text>Guo, D., et al.: Pantoprazole blocks the JAK2/STAT3 pathway to alleviate skeletal muscle wasting in cancer cachexia by inhibiting inflammatory response. Oncotarget. 8(24), 39640–39648 (2017)</ce:source-text>
</reference>
<reference seq="240">
<ref-info>
<ref-title>
<ref-titletext-english>Increased thrombin generation in a mouse model of cancer cachexia is partially interleukin-6 dependent</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.J.</ce:initials>
<ce:surname>Reddel</ce:surname>
<ce:given-name>C.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Thromb. Haemost</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>477</first-page>
<last-page>486</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Reddel, C.J., et al.: Increased thrombin generation in a mouse model of cancer cachexia is partially interleukin-6 dependent. J. Thromb. Haemost. 15(3), 477–486 (2017)</ref-fulltext>
<ce:source-text>Reddel, C.J., et al.: Increased thrombin generation in a mouse model of cancer cachexia is partially interleukin-6 dependent. J. Thromb. Haemost. 15(3), 477–486 (2017)</ce:source-text>
</reference>
</bibliography>
</tail>
</bibrecord>
<bibrecord>
<item-info>
<status state="new" stage="S300" />
<itemidlist>
<ce:doi>10.1007/978-3-031-09518-4_7</ce:doi>
<itemid idtype="TPB-ID">20232000349315</itemid>
</itemidlist>
</item-info>
<head>
<citation-info>
<citation-type code="Ch" />
<citation-language xml:lang="ENG" />
<abstract-language xml:lang="ENG" />
</citation-info>
<citation-title>
<titletext xml:lang="ENG" original="y">NF-kB Signaling in the Macro environment of Cancer Cachexia</titletext>
</citation-title>
<author-group seq="1">
<author seq="1">
<ce:initials>B.R.</ce:initials>
<ce:surname>Benjamin</ce:surname>
<ce:given-name>Pryce</ce:given-name>
</author>
<affiliation>
<organization>Hollings Cancer Center</organization>
<organization>Medical University of South Carolina</organization>
<organization>Department of Pediatrics</organization>
<city>Charleston</city>
<state>South Carolina</state>
<country iso-code="USA" />
<ce:source-text>Department of Pediatrics, and the Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA</ce:source-text>
</affiliation>
</author-group>
<author-group seq="2">
<author seq="1">
<ce:initials>D.C.</ce:initials>
<ce:surname>Denis</ce:surname>
<ce:given-name>Guttridge</ce:given-name>
<ce:e-address>guttridg@musc.edu</ce:e-address>
</author>
<affiliation>
<organization>Hollings Cancer Center</organization>
<organization>Medical University of South Carolina</organization>
<organization>Department of Pediatrics</organization>
<city>Charleston</city>
<state>SouthCarolina</state>
<country iso-code="USA" />
<ce:source-text>Department of Pediatrics, and the Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA</ce:source-text>
</affiliation>
</author-group>
<correspondence>
<person>
<ce:initials>D.C.</ce:initials>
<ce:surname>Denis</ce:surname>
<ce:given-name>Guttridge</ce:given-name>
<ce:e-address>guttridg@musc.edu</ce:e-address>
</person>
<affiliation>
<organization>Hollings Cancer Center</organization>
<organization>Medical University of South Carolina</organization>
<organization>Department of Pediatrics</organization>
<city>Charleston</city>
<state>SouthCarolina</state>
<country iso-code="USA" />
<ce:source-text>Department of Pediatrics, and the Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA</ce:source-text>
</affiliation>
</correspondence>
<abstracts>
<abstract xml:lang="ENG" original="y">
<publishercopyright>@SpringerNatureSwitzerlandAG2022</publishercopyright>
<ce:para>The Nuclear Factor Kappa B(NF-κB) tran-scription factor is ubiquitously expressed and has been shown to control various cellular processes such as survival, proliferation, differentiation, and inflammation. While critical for cellular survival, dysregulation of NF-κB signaling has been linked to the progression of cancer. Although NF-κB has been shown to play a role in various cancers, this chapter will focus on pancreatic cancer and how canonical NF-κB signaling perturbs the macroenvironment of tumor–tissue interactions. This will include exploring how NF-κB canmediate various stages of disease development, beginning with tumor initiation and progression through interactions with the immune systems as well as promoting epithelial–mesenchymal transition(EMT), metastasis, and chemoresistance. All these aspects underscore NF-κB as being involved in various stages of pancreatic cancer develop-ment. We will also describe the role of NF-κB in normal skeletal muscle and how this is changed drastically in pancreatic cancer patients, leading to a muscle wasting disease known as cancer cachexia. These effects can be observed by NF-κB activity in both the myofiber and muscle
stem cells, ultimately leading to muscle decline. Overall, this chapter will illustrate the central role that NF-κB sig-naling plays in the macroenvironment between pancreatic tumor cells and peripheral skeletal muscle</ce:para>
</abstract>
</abstracts>
<source type="book" country="USA">
<sourcetitle>NF-kB Signaling in the Macroenvironment of Cancer Cachexia</sourcetitle>
<sourcetitle-abbrev>NF-kB Signaling in the Macroenvironment of Cancer Cachexia</sourcetitle-abbrev>
<isbn type="print" length="13">9783031072727</isbn>
<isbn type="electronic" length="13">9783031095184</isbn>
<volisspag>
<page-information>
<pages>
<first-page>119</first-page>
<last-page>135</last-page>
</pages>
</page-information>
</volisspag>
<publicationyear first="2022">
<publicationdate>
<year>2022</year>
<month>09</month>
<day>21</day>
</publicationdate>
</publicationyear>
<website type="item">
<ce:e-address type="url">https://doi.org/10.1007/9783031095184_7</ce:e-address>
</website>
<publisher>
<publishername>Springer International Publishing</publishername>
</publisher>
</source>
<enhancement>
<classificationgroup>
<classifications type="ASJC">
<classification>
<classification-code>2700</classification-code>
<classification-code>2400</classification-code>
<classification-code>1300</classification-code>
</classification>
</classifications>
</classificationgroup>
</enhancement>
</head>
<tail>
<bibliography refcount="132">
<reference seq="1">
<ref-info>
<ref-title>
<ref-titletext-english>Inducibility of kappa immu-noglobulin enhancer-binding protein Nf-kappaB by a posttranslational mechanism.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Sen</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Baltimore</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="1986" />
<volisspag>
<volume-issue-number>
<vol-first>47</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>921</first-page>
<last-page>928</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sen,R., Baltimore, D. :Inducibility of kappa immu-noglobulin enhancer-binding protein Nf-kappaB by a post translational mechanism. Cell. 47(6), 921–928 (1986)</ref-fulltext>
<ce:source-text>Sen,R., Baltimore, D. :Inducibility of kappa immu-noglobulin enhancer-binding protein Nf-kappaB by a post translational mechanism. Cell. 47(6), 921–928 (1986)</ce:source-text>
</reference>
<reference seq="2">
<ref-info>
<ref-title>
<ref-titletext-english>NF-kappaB signaling: a
tale of two pathways in skeletal myogenesis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Bakkar</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.C.</ce:initials>
<ce:surname>Guttridge</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> Physiol. Rev</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>90</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>495</first-page>
<last-page>511</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bakkar, N., Guttridge, D.C.: NF-kappaB signaling: a
tale of two pathways in skeletal myogenesis. Physiol.
Rev. 90(2), 495–511 (2010)</ref-fulltext>
<ce:source-text>Bakkar, N., Guttridge, D.C.: NF-kappaB signaling: a tale of two pathways in skeletal myogenesis. Physiol. Rev. 90(2), 495–511 (2010)</ce:source-text>
</reference>
<reference seq="3">
<ref-info>
<ref-title>
<ref-titletext-english>Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-publicationyear first="2004" />
<volisspag>
<volume-issue-number>
<vol-first>101</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2351</first-page>
<last-page>2362</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Li, L., et al.: Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer. 101(10), 2351–2362 (2004)</ref-fulltext>
<ce:source-text>Li, L., et al.: Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer. 101(10), 2351–2362 (2004)</ce:source-text>
</reference>
<reference seq="4">
<ref-info>
<ref-title>
<ref-titletext-english> Cancer-associated cachexia.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Dis. Primers.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Baracos, V.E., et al.: Cancer-associated cachexia. Nat. Rev. Dis. Primers. 4, 17105 (2018)</ref-fulltext>
<ce:source-text>Baracos, V.E., et al.: Cancer-associated cachexia. Nat. Rev. Dis. Primers. 4, 17105 (2018)</ce:source-text>
</reference>
<reference seq="5">
<ref-info>
<ref-title>
<ref-titletext-english>: An epidemiological survey of cachexia in advanced cancer patients and analysis on its diagnostic and treatment status</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Sun</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>X.Q.</ce:initials>
<ce:surname>Quan</ce:surname>
<ce:given-name>X.Q.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Yu</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nutr. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>67</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1056</first-page>
<last-page>1062</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sun, L., Quan, X.Q., Yu, S.: An epidemiological survey of cachexia in advanced cancer patients and analysis on its diagnostic and treatment status. Nutr. Cancer. 67(7), 1056–1062 (2015)</ref-fulltext>
<ce:source-text>Sun, L., Quan, X.Q., Yu, S.: An epidemiological survey of cachexia in advanced cancer patients and analysis on its diagnostic and treatment status. Nutr. Cancer. 67(7), 1056–1062 (2015)</ce:source-text>
</reference>
<reference seq="6">
<ref-info>
<ref-title>
<ref-titletext-english>: Nuclear factor-kappaB in cancer development and progression.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Karin</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>441</vol-first>
<iss-first>7092</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>431</first-page>
<last-page>436</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Karin, M.: Nuclear factor-kappaB in cancer development and progression. Nature. 441(7092), 431–436 (2006)</ref-fulltext>
<ce:source-text>Karin, M.: Nuclear factor-kappaB in cancer development and progression. Nature. 441(7092), 431–436 (2006)</ce:source-text>
</reference>
<reference seq="7">
<ref-info>
<ref-title>
<ref-titletext-english>NF-kappaB functions in tumor initiation by suppressing the surveillance of both innate and adaptive immune cells.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.J.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Rep.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>90</first-page>
<last-page>103</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, D.J., et al.: NF-kappaB functions in tumor initiation by suppressing the surveillance of both innate and adaptive immune cells. Cell Rep. 9(1), 90–103 (2014)</ref-fulltext>
<ce:source-text>Wang, D.J., et al.: NF-kappaB functions in tumor initiation by suppressing the surveillance of both innate and adaptive immune cells. Cell Rep. 9(1), 90–103 (2014)</ce:source-text>
</reference>
<reference seq="8">
<ref-info>
<ref-title>
<ref-titletext-english> The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="1999" />
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>119</first-page>
<last-page>127</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, W., et al.: The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin. Cancer Res. 5(1), 119–127 (1999)</ref-fulltext>
<ce:source-text>Wang, W., et al.: The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin. Cancer Res. 5(1), 119–127 (1999)</ce:source-text>
</reference>
<reference seq="9">
<ref-info>
<ref-title>
<ref-titletext-english>Signaling to NF-kappaB.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.S.</ce:initials>
<ce:surname>Hayden</ce:surname>
<ce:given-name>M.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Ghosh</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Genes Dev</ref-sourcetitle>
<ref-publicationyear first="2004" />
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
<iss-first>18</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2195</first-page>
<last-page>2224</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>. Hayden, M.S., Ghosh, S.: Signaling to NF-kappaB. Genes Dev. 18(18), 2195–2224 (2004)</ref-fulltext>
<ce:source-text>. Hayden, M.S., Ghosh, S.: Signaling to NF-kappaB. Genes Dev. 18(18), 2195–2224 (2004)</ce:source-text>
</reference>
<reference seq="10">
<ref-info>
<ref-title>
<ref-titletext-english>The NF-kappa B and I kappa B proteins: new discoveries and insights.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.S.</ce:initials>
<ce:surname>Baldwin</ce:surname>
<ce:given-name>A.S.</ce:given-name>
<ce:suffix>Jr.</ce:suffix>
</author>
</ref-authors>
<ref-sourcetitle>Annu. Rev. Immunol.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>649</first-page>
<last-page>683</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baldwin Jr., A.S.: The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 14, 649–683 (1996)</ref-fulltext>
<ce:source-text>Baldwin Jr., A.S.: The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 14, 649–683 (1996)</ce:source-text>
</reference>
<reference seq="11">
<ref-info>
<ref-title>
<ref-titletext-english>Shared principles in NF-kappaB signaling.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.S.</ce:initials>
<ce:surname>Hayden</ce:surname>
<ce:given-name>M.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Ghosh</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2008" />
<volisspag>
<volume-issue-number>
<vol-first>132</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>344</first-page>
<last-page>362</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hayden, M.S., Ghosh, S.: Shared principles in NF-kappaB signaling. Cell. 132(3), 344–362 (2008)</ref-fulltext>
<ce:source-text>Hayden, M.S., Ghosh, S.: Shared principles in NF-kappaB signaling. Cell. 132(3), 344–362 (2008)</ce:source-text>
</reference>
<reference seq="12">
<ref-info>
<ref-title>
<ref-titletext-english>NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Ghosh</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.J.</ce:initials>
<ce:surname>May</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>E.B.</ce:initials>
<ce:surname>Kopp</ce:surname>
<ce:given-name>E.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Annu. Rev. Immunol</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>225</first-page>
<last-page>260</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ghosh, S., May, M.J., Kopp, E.B.: NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16, 225–260 (1998)</ref-fulltext>
<ce:source-text>Ghosh, S., May, M.J., Kopp, E.B.: NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16, 225–260 (1998)</ce:source-text>
</reference>
<reference seq="13">
<ref-info>
<ref-title>
<ref-titletext-english>30 Years of NF-kappaB: a blossoming of relevance to human pathobiology</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Q.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>Q.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.J.</ce:initials>
<ce:surname>Lenardo</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Baltimore</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>168</vol-first>
<iss-first>1</iss-first>
<iss-last>2</iss-last>
</volume-issue-number>
<page-information>
<pages>
<first-page>37</first-page>
<last-page>57</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, Q., Lenardo, M.J., Baltimore, D.: 30 Years of NF-kappaB: a blossoming of relevance to human pathobiology. Cell. 168(1–2), 37–57 (2017)</ref-fulltext>
<ce:source-text>Zhang, Q., Lenardo, M.J., Baltimore, D.: 30 Years of NF-kappaB: a blossoming of relevance to human pathobiology. Cell. 168(1–2), 37–57 (2017)</ce:source-text>
</reference>
<reference seq="14">
<ref-info>
<ref-title>
<ref-titletext-english>Role for IkappaBalpha, but not c-Rel, in skeletal muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.R.</ce:initials>
<ce:surname>Judge</ce:surname>
<ce:given-name>A.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Cell Physiol</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>292</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>372</first-page>
<last-page>382</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Judge, A.R., et al.: Role for IkappaBalpha, but not c-Rel, in skeletal muscle atrophy. Am. J. Physiol. Cell Physiol. 292(1), C372–C382 (2007) </ref-fulltext>
<ce:source-text>Judge, A.R., et al.: Role for IkappaBalpha, but not c-Rel, in skeletal muscle atrophy. Am. J. Physiol. Cell Physiol. 292(1), C372–C382 (2007) </ce:source-text>
</reference>
<reference seq="15">
<ref-info>
<ref-title>
<ref-titletext-english>Dimer-specific regulatory mechanisms within the NF-kappaB family of transcription factors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.T.</ce:initials>
<ce:surname>Smale</ce:surname>
<ce:given-name>S.T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Immunol. Rev.</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>246</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>193</first-page>
<last-page>204</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Smale, S.T.: Dimer-specific regulatory mechanisms within the NF-kappaB family of transcription factors. Immunol. Rev. 246(1), 193–204 (2012)</ref-fulltext>
<ce:source-text>Smale, S.T.: Dimer-specific regulatory mechanisms within the NF-kappaB family of transcription factors. Immunol. Rev. 246(1), 193–204 (2012)</ce:source-text>
</reference>
<reference seq="16">
<ref-info>
<ref-title>
<ref-titletext-english>Genetic approaches to study Rel/ NF-kappa B/I kappa B function in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.M.</ce:initials>
<ce:surname>Attar</ce:surname>
<ce:given-name>R.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Semin. Cancer Biol</ref-sourcetitle>
<ref-publicationyear first="1997" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>93</first-page>
<last-page>101</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Attar, R.M., et al.: Genetic approaches to study Rel/ NF-kappa B/I kappa B function in mice. Semin. Cancer Biol. 8(2), 93–101 (1997)</ref-fulltext>
<ce:source-text>Attar, R.M., et al.: Genetic approaches to study Rel/ NF-kappa B/I kappa B function in mice. Semin. Cancer Biol. 8(2), 93–101 (1997)</ce:source-text>
</reference>
<reference seq="17">
<ref-info>
<ref-title>
<ref-titletext-english>Induction of p100 processing by NF-kappaB-inducing kinase involves docking IkappaB kinase alpha (IKKalpha) to p100 and IKKalpha-mediated phosphorylation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Xiao</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Fong</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.C.</ce:initials>
<ce:surname>Sun</ce:surname>
<ce:given-name>S.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem.</ref-sourcetitle>
<ref-publicationyear first="2004" />
<volisspag>
<volume-issue-number>
<vol-first>279</vol-first>
<iss-first>29</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>30099</first-page>
<last-page>30105</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xiao, G., Fong, A., Sun, S.C.: Induction of p100 processing by NF-kappaB-inducing kinase involves docking IkappaB kinase alpha (IKKalpha) to p100 and IKKalpha-mediated phosphorylation. J. Biol. Chem. 279(29), 30099–30105 (2004)</ref-fulltext>
<ce:source-text>Xiao, G., Fong, A., Sun, S.C.: Induction of p100 processing by NF-kappaB-inducing kinase involves docking IkappaB kinase alpha (IKKalpha) to p100 and IKKalpha-mediated phosphorylation. J. Biol. Chem. 279(29), 30099–30105 (2004)</ce:source-text>
</reference>
<reference seq="18">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.A.</ce:initials>
<ce:surname>Beg</ce:surname>
<ce:given-name>A.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cell. Biol.</ref-sourcetitle>
<ref-publicationyear first="1993" />
<volisspag>
<volume-issue-number>
<vol-first>13</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3301</first-page>
<last-page>3310</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Beg, A.A., et al.: Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation. Mol. Cell. Biol. 13(6), 3301–3310 (1993)</ref-fulltext>
<ce:source-text>Beg, A.A., et al.: Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation. Mol. Cell. Biol. 13(6), 3301–3310 (1993)</ce:source-text>
</reference>
<reference seq="19">
<ref-info>
<ref-title>
<ref-titletext-english>IL-6 induces NF-kappa B activation in the intestinal epithelia.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Immunol</ref-sourcetitle>
<ref-publicationyear first="2003" />
<volisspag>
<volume-issue-number>
<vol-first>171</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3194</first-page>
<last-page>3201</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, L., et al.: IL-6 induces NF-kappa B activation in the intestinal epithelia. J. Immunol. 171(6), 3194–3201 (2003)</ref-fulltext>
<ce:source-text>Wang, L., et al.: IL-6 induces NF-kappa B activation in the intestinal epithelia. J. Immunol. 171(6), 3194–3201 (2003)</ce:source-text>
</reference>
<reference seq="20">
<ref-info>
<ref-title>
<ref-titletext-english>Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Schreck</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Rieber</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>P.A.</ce:initials>
<ce:surname>Baeuerle</ce:surname>
<ce:given-name>P.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>EMBO J.</ref-sourcetitle>
<ref-publicationyear first="1991" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2247</first-page>
<last-page>2258</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Schreck, R., Rieber, P., Baeuerle, P.A.: Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J. 10(8), 2247–2258 (1991)</ref-fulltext>
<ce:source-text>Schreck, R., Rieber, P., Baeuerle, P.A.: Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J. 10(8), 2247–2258 (1991)</ce:source-text>
</reference>
<reference seq="21">
<ref-info>
<ref-title>
<ref-titletext-english>BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Claudio</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Immunol</ref-sourcetitle>
<ref-publicationyear first="2002" />
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>958</first-page>
<last-page>965</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Claudio, E., et al.: BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat. Immunol. 3(10), 958–965 (2002) </ref-fulltext>
<ce:source-text>Claudio, E., et al.: BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat. Immunol. 3(10), 958–965 (2002) </ce:source-text>
</reference>
<reference seq="22">
<ref-info>
<ref-title>
<ref-titletext-english>The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.V.</ce:initials>
<ce:surname>Novack</ce:surname>
<ce:given-name>D.V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Exp. Med</ref-sourcetitle>
<ref-publicationyear first="2003" />
<volisspag>
<volume-issue-number>
<vol-first>198</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>771</first-page>
<last-page>781</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Novack, D.V., et al.: The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis. J. Exp. Med. 198(5), 771–781 (2003) </ref-fulltext>
<ce:source-text>Novack, D.V., et al.: The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis. J. Exp. Med. 198(5), 771–781 (2003) </ce:source-text>
</reference>
<reference seq="23">
<ref-info>
<ref-title>
<ref-titletext-english>NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.C.</ce:initials>
<ce:surname>Guttridge</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cell. Biol</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5785</first-page>
<last-page>5799</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Guttridge, D.C., et al.: NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell. Biol. 19(8), 5785–5799 (1999)</ref-fulltext>
<ce:source-text>Guttridge, D.C., et al.: NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell. Biol. 19(8), 5785–5799 (1999)</ce:source-text>
</reference>
<reference seq="24">
<ref-info>
<ref-title>
<ref-titletext-english>Canonical NF-kappaB signaling regulates satellite stem cell homeostasis and function during regenerative myogenesis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.R.</ce:initials>
<ce:surname>Straughn</ce:surname>
<ce:given-name>A.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Mol. Cell Biol.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>53</first-page>
<last-page>66</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Straughn, A.R., et al.: Canonical NF-kappaB signaling regulates satellite stem cell homeostasis and function during regenerative myogenesis. J. Mol. Cell Biol. 11(1), 53–66 (2019)</ref-fulltext>
<ce:source-text>Straughn, A.R., et al.: Canonical NF-kappaB signaling regulates satellite stem cell homeostasis and function during regenerative myogenesis. J. Mol. Cell Biol. 11(1), 53–66 (2019)</ce:source-text>
</reference>
<reference seq="25">
<ref-info>
<ref-title>
<ref-titletext-english>TWEAK and cIAP1 regulate
myoblast fusion through the noncanonical
NF-kappaB signaling pathway.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.K.</ce:initials>
<ce:surname>Enwere</ce:surname>
<ce:given-name>E.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Signal</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>246</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Enwere, E.K., et al., TWEAK and cIAP1 regulate myoblast fusion through the noncanonical NF-kappaB signaling pathway. Sci. Signal., 2012. 5(246): p. ra75</ref-fulltext>
<ce:source-text>Enwere, E.K., et al., TWEAK and cIAP1 regulate myoblast fusion through the noncanonical NF-kappaB signaling pathway. Sci. Signal., 2012. 5(246): p. ra75</ce:source-text>
</reference>
<reference seq="26">
<ref-info>
<ref-title>
<ref-titletext-english>IKK/NF-kappaB regulates skeletal
myogenesis via a signaling switch to inhibit differentiation and promote mitochondrial biogenesis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Bakkar</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell Biol.</ref-sourcetitle>
<ref-publicationyear first="2008" />
<volisspag>
<volume-issue-number>
<vol-first>180</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>787</first-page>
<last-page>802</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bakkar, N., et al.: IKK/NF-kappaB regulates skeletal myogenesis via a signaling switch to inhibit differentiation and promote mitochondrial biogenesis. J. Cell Biol. 180(4), 787–802 (2008)</ref-fulltext>
<ce:source-text>Bakkar, N., et al.: IKK/NF-kappaB regulates skeletal myogenesis via a signaling switch to inhibit differentiation and promote mitochondrial biogenesis. J. Cell Biol. 180(4), 787–802 (2008)</ce:source-text>
</reference>
<reference seq="27">
<ref-info>
<ref-title>
<ref-titletext-english> IKKalpha and alternative NF-kappaB regulate PGC-1beta to promote oxidative muscle metabolism.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Bakkar</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell Biol.</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>196</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>497</first-page>
<last-page>511</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bakkar, N., et al.: IKKalpha and alternative NF-kappaB regulate PGC-1beta to promote oxidative muscle metabolism. J. Cell Biol. 196(4), 497–511 (2012)</ref-fulltext>
<ce:source-text>Bakkar, N., et al.: IKKalpha and alternative NF-kappaB regulate PGC-1beta to promote oxidative muscle metabolism. J. Cell Biol. 196(4), 497–511 (2012)</ce:source-text>
</reference>
<reference seq="28">
<ref-info>
<ref-title>
<ref-titletext-english>MyoD regulates skeletal muscle oxidative metabolism cooperatively with alternative NF-kappaB.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Shintaku</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Rep.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>514</first-page>
<last-page>526</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shintaku, J., et al.: MyoD regulates skeletal muscle oxidative metabolism cooperatively with alternative NF-kappaB. Cell Rep. 17(2), 514–526 (2016)</ref-fulltext>
<ce:source-text>Shintaku, J., et al.: MyoD regulates skeletal muscle oxidative metabolism cooperatively with alternative NF-kappaB. Cell Rep. 17(2), 514–526 (2016)</ce:source-text>
</reference>
<reference seq="29">
<ref-info>
<ref-title>
<ref-titletext-english>Epidemiology of pancreatic cancer: global trends, etiology and risk factors.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>p.</ce:initials>
<ce:surname>Rawla</ce:surname>
<ce:given-name>p.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Sunkara</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>V.</ce:initials>
<ce:surname>Gaduput</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>World J. Oncol</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>10</first-page>
<last-page>27</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rawla, P., Sunkara, T., Gaduputi, V.: Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J. Oncol. 10(1), 10–27 (2019)</ref-fulltext>
<ce:source-text>Rawla, P., Sunkara, T., Gaduputi, V.: Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J. Oncol. 10(1), 10–27 (2019)</ce:source-text>
</reference>
<reference seq="30">
<ref-info>
<ref-title>
<ref-titletext-english>Advancement of NF-kappaB signaling pathway: a novel target in pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.C.</ce:initials>
<ce:surname>Pramanik</ce:surname>
<ce:given-name>K.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Mol. Sci.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Pramanik, K.C., et al.: Advancement of NF-kappaB signaling pathway: a novel target in pancreatic cancer. Int. J. Mol. Sci. 19(12) (2018)</ref-fulltext>
<ce:source-text>Pramanik, K.C., et al.: Advancement of NF-kappaB signaling pathway: a novel target in pancreatic cancer. Int. J. Mol. Sci. 19(12) (2018)</ce:source-text>
</reference>
<reference seq="31">
<ref-info>
<ref-title>
<ref-titletext-english>Targeting apoptosis pathways in pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Arlt</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.S.</ce:initials>
<ce:surname>Muerkoster</ce:surname>
<ce:given-name>S.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Schafer</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Lett</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>332</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>346</first-page>
<last-page>358</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Arlt, A., Muerkoster, S.S., Schafer, H.: Targeting
apoptosis pathways in pancreatic cancer. Cancer
Lett. 332(2), 346–358 (2013)</ref-fulltext>
<ce:source-text>Arlt, A., Muerkoster, S.S., Schafer, H.: Targeting
apoptosis pathways in pancreatic cancer. Cancer
Lett. 332(2), 346–358 (2013)</ce:source-text>
</reference>
<reference seq="32">
<ref-info>
<ref-title>
<ref-titletext-english>KrasG12D-induced IKK2/beta/NFkappaB activation by IL-1alpha and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Ling</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell.</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>105</first-page>
<last-page>120</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ling, J., et al.: KrasG12D-induced IKK2/beta/NFkappaB activation by IL-1alpha and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell. 21(1), 105–120 (2012)</ref-fulltext>
<ce:source-text>Ling, J., et al.: KrasG12D-induced IKK2/beta/NFkappaB activation by IL-1alpha and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell. 21(1), 105–120 (2012)</ce:source-text>
</reference>
<reference seq="33">
<ref-info>
<ref-title>
<ref-titletext-english>IL1 receptor antagonist inhibits pancreatic cancer growth by abrogating NF-kappaB activation.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Zhuang</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>22</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1432</first-page>
<last-page>1444</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>. Zhuang, Z., et al.: IL1 receptor antagonist inhibits pancreatic cancer growth by abrogating NF-kappaB activation. Clin. Cancer Res. 22(6), 1432–1444 (2016)</ref-fulltext>
<ce:source-text>. Zhuang, Z., et al.: IL1 receptor antagonist inhibits pancreatic cancer growth by abrogating NF-kappaB activation. Clin. Cancer Res. 22(6), 1432–1444 (2016)</ce:source-text>
</reference>
<reference seq="34">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor suppressive functions of p53. Cold Spring Harb. Perspect.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.T.</ce:initials>
<ce:surname>Zilfou</ce:surname>
<ce:given-name>J.T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.W.</ce:initials>
<ce:surname>Lowe</ce:surname>
<ce:given-name>S.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biol.</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Zilfou, J.T., Lowe, S.W.: Tumor suppressive functions of p53. Cold Spring Harb. Perspect. Biol. 1(5), a001883 (2009)</ref-fulltext>
<ce:source-text>Zilfou, J.T., Lowe, S.W.: Tumor suppressive functions of p53. Cold Spring Harb. Perspect. Biol. 1(5), a001883 (2009)</ce:source-text>
</reference>
<reference seq="35">
<ref-info>
<ref-title>
<ref-titletext-english>Phosphorylation of p53 by IkappaB kinase 2 promotes its degradation by beta-TrCP</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Xia</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA.</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>106</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2629</first-page>
<last-page>2634</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xia, Y., et al.: Phosphorylation of p53 by IkappaB kinase 2 promotes its degradation by beta-TrCP. Proc. Natl. Acad. Sci. USA. 106(8), 2629–2634 (2009)</ref-fulltext>
<ce:source-text>Xia, Y., et al.: Phosphorylation of p53 by IkappaB kinase 2 promotes its degradation by beta-TrCP. Proc. Natl. Acad. Sci. USA. 106(8), 2629–2634 (2009)</ce:source-text>
</reference>
<reference seq="36">
<ref-info>
<ref-title>
<ref-titletext-english>Transcriptional cross talk between NF-kappaB and p53. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.A.</ce:initials>
<ce:surname>Webster</ce:surname>
<ce:given-name>G.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>N.D.</ce:initials>
<ce:surname>Perkins</ce:surname>
<ce:given-name>N.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cell. Biol.</ref-sourcetitle>
<ref-publicationyear first="1999" />
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3485</first-page>
<last-page>3495</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Webster, G.A., Perkins, N.D.: Transcriptional cross talk between NF-kappaB and p53. Mol. Cell. Biol. 19(5), 3485–3495 (1999)</ref-fulltext>
<ce:source-text>Webster, G.A., Perkins, N.D.: Transcriptional cross talk between NF-kappaB and p53. Mol. Cell. Biol. 19(5), 3485–3495 (1999)</ce:source-text>
</reference>
<reference seq="37">
<ref-info>
<ref-title>
<ref-titletext-english>Suppression of PTEN expression by NF-kappa B prevents apoptosis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.M.</ce:initials>
<ce:surname>Vasudevan</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Vasudevan</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>V.M.</ce:initials>
<ce:surname>Rangnekar</ce:surname>
<ce:given-name>V.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cell. Biol.</ref-sourcetitle>
<ref-publicationyear first="2004" />
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1007</first-page>
<last-page>1021</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vasudevan, K.M., Gurumurthy, S., Rangnekar, V. M.: Suppression of PTEN expression by NF-kappa B prevents apoptosis. Mol. Cell. Biol. 24(3), 1007–1021 (2004)</ref-fulltext>
<ce:source-text>Vasudevan, K.M., Gurumurthy, S., Rangnekar, V. M.: Suppression of PTEN expression by NF-kappa B prevents apoptosis. Mol. Cell. Biol. 24(3), 1007–1021 (2004)</ce:source-text>
</reference>
<reference seq="38">
<ref-info>
<ref-title>
<ref-titletext-english>Inflammation and development of pancreatic ductal adenocarcinoma.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Shi</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Xue</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Chin. Clin. Oncol.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>19</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shi, J., Xue, J.: Inflammation and development of pancreatic ductal adenocarcinoma. Chin. Clin. Oncol. 8(2), 19 (2019)</ref-fulltext>
<ce:source-text>Shi, J., Xue, J.: Inflammation and development of pancreatic ductal adenocarcinoma. Chin. Clin. Oncol. 8(2), 19 (2019)</ce:source-text>
</reference>
<reference seq="39">
<ref-info>
<ref-title>
<ref-titletext-english>: NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Hinz</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cell. Biol</ref-sourcetitle>
<ref-publicationyear first="1999" />
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2690</first-page>
<last-page>2698</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hinz, M., et al.: NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol. Cell. Biol. 19(4), 2690–2698 (1999)</ref-fulltext>
<ce:source-text>Hinz, M., et al.: NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol. Cell. Biol. 19(4), 2690–2698 (1999)</ce:source-text>
</reference>
<reference seq="40">
<ref-info>
<ref-title>
<ref-titletext-english>NF-kappaB regulates GDF-15 to suppress macrophage surveillance during early tumor development.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.M.</ce:initials>
<ce:surname>Ratnam</ce:surname>
<ce:given-name>N.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>127</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3796</first-page>
<last-page>3809</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ratnam, N.M., et al.: NF-kappaB regulates GDF-15 to suppress macrophage surveillance during early tumor development. J. Clin. Invest. 127(10), 3796–3809 (2017)</ref-fulltext>
<ce:source-text>Ratnam, N.M., et al.: NF-kappaB regulates GDF-15 to suppress macrophage surveillance during early tumor development. J. Clin. Invest. 127(10), 3796–3809 (2017)</ce:source-text>
</reference>
<reference seq="41">
<ref-info>
<ref-title>
<ref-titletext-english>Inhibition of survival pathways MAPK and NF-kB triggers apoptosis in pancreatic ductal adenocarcinoma cells via suppression of autophagy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.L.</ce:initials>
<ce:surname>Papademetrio</ce:surname>
<ce:given-name>D.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Target. Oncol.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>183</first-page>
<last-page>195</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Papademetrio, D.L., et al.: Inhibition of survival pathways MAPK and NF-kB triggers apoptosis in pancreatic ductal adenocarcinoma cells via suppression of autophagy. Target. Oncol. 11(2), 183–195 (2016)</ref-fulltext>
<ce:source-text>Papademetrio, D.L., et al.: Inhibition of survival pathways MAPK and NF-kB triggers apoptosis in pancreatic ductal adenocarcinoma cells via suppression of autophagy. Target. Oncol. 11(2), 183–195 (2016)</ce:source-text>
</reference>
<reference seq="42">
<ref-info>
<ref-title>
<ref-titletext-english>NF-kappaB, an active player in human cancers.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Xia</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Shen</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>I.M.</ce:initials>
<ce:surname>Verma</ce:surname>
<ce:given-name>I.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Immunol. Res.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>823</first-page>
<last-page>830</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xia, Y., Shen, S., Verma, I.M.: NF-kappaB, an active player in human cancers. Cancer Immunol. Res. 2(9), 823–830 (2014)</ref-fulltext>
<ce:source-text>Xia, Y., Shen, S., Verma, I.M.: NF-kappaB, an active player in human cancers. Cancer Immunol. Res. 2(9), 823–830 (2014)</ce:source-text>
</reference>
<reference seq="43">
<ref-info>
<ref-title>
<ref-titletext-english>TGF-betainduced epithelial to mesenchymal transition.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Xu</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Lamouille</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Derynck</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Res.</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>156</first-page>
<last-page>172</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xu, J., Lamouille, S., Derynck, R.: TGF-betainduced epithelial to mesenchymal transition. Cell Res. 19(2), 156–172 (2009)</ref-fulltext>
<ce:source-text>Xu, J., Lamouille, S., Derynck, R.: TGF-betainduced epithelial to mesenchymal transition. Cell Res. 19(2), 156–172 (2009)</ce:source-text>
</reference>
<reference seq="44">
<ref-info>
<ref-title>
<ref-titletext-english>NF-kappaB promotes epithelialmesenchymal transition, migration and invasion of pancreatic carcinoma cells.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.J.</ce:initials>
<ce:surname>Maier</ce:surname>
<ce:given-name>H.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Lett</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>295</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>214</first-page>
<last-page>228</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Maier, H.J., et al.: NF-kappaB promotes epithelialmesenchymal transition, migration and invasion of pancreatic carcinoma cells. Cancer Lett. 295(2), 214–228 (2010)</ref-fulltext>
<ce:source-text>Maier, H.J., et al.: NF-kappaB promotes epithelialmesenchymal transition, migration and invasion of pancreatic carcinoma cells. Cancer Lett. 295(2), 214–228 (2010)</ce:source-text>
</reference>
<reference seq="45">
<ref-info>
<ref-title>
<ref-titletext-english> Proteasome inhibitor MG132 inhibits angiogenesis in pancreatic cancer by blocking NF-kappaB activity.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Matsuo</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Dig. Dis. Sci.</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>55</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1167</first-page>
<last-page>1176</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Matsuo, Y., et al.: Proteasome inhibitor MG132 inhibits angiogenesis in pancreatic cancer by blocking NF-kappaB activity. Dig. Dis. Sci. 55(4), 1167–1176 (2010)</ref-fulltext>
<ce:source-text>Matsuo, Y., et al.: Proteasome inhibitor MG132 inhibits angiogenesis in pancreatic cancer by blocking NF-kappaB activity. Dig. Dis. Sci. 55(4), 1167–1176 (2010)</ce:source-text>
</reference>
<reference seq="46">
<ref-info>
<ref-title>
<ref-titletext-english>Nuclear factor-kappa B is essential for up-regulation of interleukin-8 expression in human amnion and cervical epithelial cells.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.L.</ce:initials>
<ce:surname>Elliott</ce:surname>
<ce:given-name>C.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Hum. Reprod.</ref-sourcetitle>
<ref-publicationyear first="2001" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>787</first-page>
<last-page>790</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Elliott, C.L., et al.: Nuclear factor-kappa B is essential for up-regulation of interleukin-8 expression in human amnion and cervical epithelial cells. Mol. Hum. Reprod. 7(8), 787–790 (2001)</ref-fulltext>
<ce:source-text>Elliott, C.L., et al.: Nuclear factor-kappa B is essential for up-regulation of interleukin-8 expression in human amnion and cervical epithelial cells. Mol. Hum. Reprod. 7(8), 787–790 (2001)</ce:source-text>
</reference>
<reference seq="47">
<ref-info>
<ref-title>
<ref-titletext-english>Constitutive NF-kappaB activity regulates the expression of VEGF and IL-8 and tumor angiogenesis of human glioblastoma.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.X.</ce:initials>
<ce:surname>Xie</ce:surname>
<ce:given-name>T.X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncol. Rep.</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>23</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>725</first-page>
<last-page>732</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xie, T.X., et al.: Constitutive NF-kappaB activity regulates the expression of VEGF and IL-8 and tumor angiogenesis of human glioblastoma. Oncol. Rep. 23(3), 725–732 (2010)</ref-fulltext>
<ce:source-text>Xie, T.X., et al.: Constitutive NF-kappaB activity regulates the expression of VEGF and IL-8 and tumor angiogenesis of human glioblastoma. Oncol. Rep. 23(3), 725–732 (2010)</ce:source-text>
</reference>
<reference seq="48">
<ref-info>
<ref-title>
<ref-titletext-english>NF-kappaB-dependent regulation of matrix metalloproteinase-9 gene expression by lipopolysaccharide in a macrophage cell line RAW 264.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Rhee</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biochem. Mol. Biol.</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>40</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>88</first-page>
<last-page>94</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rhee, J.W., et al.: NF-kappaB-dependent regulation of matrix metalloproteinase-9 gene expression by lipopolysaccharide in a macrophage cell line RAW 264.7. J. Biochem. Mol. Biol. 40(1), 88–94 (2007)</ref-fulltext>
<ce:source-text>Rhee, J.W., et al.: NF-kappaB-dependent regulation of matrix metalloproteinase-9 gene expression by lipopolysaccharide in a macrophage cell line RAW 264.7. J. Biochem. Mol. Biol. 40(1), 88–94 (2007)</ce:source-text>
</reference>
<reference seq="49">
<ref-info>
<ref-title>
<ref-titletext-english>Role of angiogenesis in tumor growth
and metastasis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Folkman</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Semin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2002" />
<volisspag>
<volume-issue-number>
<vol-first>29</vol-first>
<iss-first>6</iss-first>
<suppl>Supplement 16</suppl>
</volume-issue-number>
<page-information>
<pages>
<first-page>15</first-page>
<last-page>18</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Folkman, J.: Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29(6 Suppl 16), 15–18 (2002</ref-fulltext>
<ce:source-text>Folkman, J.: Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29(6 Suppl 16), 15–18 (2002</ce:source-text>
</reference>
<reference seq="50">
<ref-info>
<ref-title>
<ref-titletext-english>Epigenetic regulation of SOX9 by the NF-kappaB signaling pathway in pancreatic cancer stem cells.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Sun</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Stem Cells.</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>31</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1454</first-page>
<last-page>1466</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sun, L., et al.: Epigenetic regulation of SOX9 by the NF-kappaB signaling pathway in pancreatic cancer stem cells. Stem Cells. 31(8), 1454–1466 (2013)</ref-fulltext>
<ce:source-text>Sun, L., et al.: Epigenetic regulation of SOX9 by the NF-kappaB signaling pathway in pancreatic cancer stem cells. Stem Cells. 31(8), 1454–1466 (2013)</ce:source-text>
</reference>
<reference seq="51">
<ref-info>
<ref-title>
<ref-titletext-english>Hypoxia-inducible factor-1 promotes pancreatic ductal adenocarcinoma invasion and metastasis by activating transcription of the actinbundling protein fascin.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Zhao</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>74</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2455</first-page>
<last-page>2464</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhao, X., et al.: Hypoxia-inducible factor-1 promotes pancreatic ductal adenocarcinoma invasion and metastasis by activating transcription of the actinbundling protein fascin. Cancer Res. 74(9), 2455–2464 (2014)</ref-fulltext>
<ce:source-text>Zhao, X., et al.: Hypoxia-inducible factor-1 promotes pancreatic ductal adenocarcinoma invasion and metastasis by activating transcription of the actinbundling protein fascin. Cancer Res. 74(9), 2455–2464 (2014)</ce:source-text>
</reference>
<reference seq="52">
<ref-info>
<ref-title>
<ref-titletext-english>Variable NF-kappaB pathway responses in colon cancer cells treated with chemotherapeutic drugs.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Samuel</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>BMC Cancer.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>599</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Samuel, T., et al.: Variable NF-kappaB pathway responses in colon cancer cells treated with chemotherapeutic drugs. BMC Cancer. 14, 599 (2014)</ref-fulltext>
<ce:source-text>Samuel, T., et al.: Variable NF-kappaB pathway responses in colon cancer cells treated with chemotherapeutic drugs. BMC Cancer. 14, 599 (2014)</ce:source-text>
</reference>
<reference seq="53">
<ref-info>
<ref-title>
<ref-titletext-english> An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen speciesdependent, nuclear factor kappaB- and hypoxiainducible factor 1alpha-mediated up-regulation of CXCR4.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Arora</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem.</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>288</vol-first>
<iss-first>29</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>21197</first-page>
<last-page>21207</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Arora, S., et al.: An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen speciesdependent, nuclear factor kappaB- and hypoxiainducible factor 1alpha-mediated up-regulation of CXCR4. J. Biol. Chem. 288(29), 21197–21207 (2013</ref-fulltext>
<ce:source-text>Arora, S., et al.: An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen speciesdependent, nuclear factor kappaB- and hypoxiainducible factor 1alpha-mediated up-regulation of CXCR4. J. Biol. Chem. 288(29), 21197–21207 (2013</ce:source-text>
</reference>
<reference seq="54">
<ref-info>
<ref-title>
<ref-titletext-english>Molecular linkage between the kinase ATM and NF-kappaB signaling in response to genotoxic stimuli. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.H.</ce:initials>
<ce:surname>Wu</ce:surname>
<ce:given-name>Z.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science.</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>311</vol-first>
<iss-first>23</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1141</first-page>
<last-page>1146</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wu, Z.H., et al.: Molecular linkage between the kinase ATM and NF-kappaB signaling in response to genotoxic stimuli. Science. 311(5764), 1141–1146 (2006)</ref-fulltext>
<ce:source-text>Wu, Z.H., et al.: Molecular linkage between the kinase ATM and NF-kappaB signaling in response to genotoxic stimuli. Science. 311(5764), 1141–1146 (2006)</ce:source-text>
</reference>
<reference seq="55">
<ref-info>
<ref-title>
<ref-titletext-english>Activation of NF-kappaB by antineoplastic agents.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.C.</ce:initials>
<ce:surname>Das</ce:surname>
<ce:given-name>K.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.W.</ce:initials>
<ce:surname>White</ce:surname>
<ce:given-name>C.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem.</ref-sourcetitle>
<ref-publicationyear first="1997" />
<volisspag>
<volume-issue-number>
<vol-first>272</vol-first>
<iss-first>23</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>14914</first-page>
<last-page>14920</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Das, K.C., White, C.W.: Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C. J. Biol. Chem. 272(23), 14914–14920 (1997)</ref-fulltext>
<ce:source-text>Das, K.C., White, C.W.: Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C. J. Biol. Chem. 272(23), 14914–14920 (1997)</ce:source-text>
</reference>
<reference seq="56">
<ref-info>
<ref-title>
<ref-titletext-english>Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Arlt</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene.</ref-sourcetitle>
<ref-publicationyear first="2003" />
<volisspag>
<volume-issue-number>
<vol-first>22</vol-first>
<iss-first>21</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3243</first-page>
<last-page>3251</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Arlt, A., et al.: Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene. 22(21), 3243–3251 (2003)</ref-fulltext>
<ce:source-text>Arlt, A., et al.: Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene. 22(21), 3243–3251 (2003)</ce:source-text>
</reference>
<reference seq="57">
<ref-info>
<ref-title>
<ref-titletext-english>Evodiamine inactivates NF-kappaB
and potentiates the antitumor effects of gemcitabine
on tongue cancer both in vitro and in vivo.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Q.</ce:initials>
<ce:surname>Guo</ce:surname>
<ce:given-name>Q.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Onco. Targets. Ther.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>257</first-page>
<last-page>267</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Guo, Q., et al.: Evodiamine inactivates NF-kappaB and potentiates the antitumor effects of gemcitabine on tongue cancer both in vitro and in vivo. Onco. Targets. Ther. 12, 257–267 (2019)</ref-fulltext>
<ce:source-text>Guo, Q., et al.: Evodiamine inactivates NF-kappaB and potentiates the antitumor effects of gemcitabine on tongue cancer both in vitro and in vivo. Onco. Targets. Ther. 12, 257–267 (2019)</ce:source-text>
</reference>
<reference seq="58">
<ref-info>
<ref-title>
<ref-titletext-english>Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Waters</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Surgery.</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>158</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>881</first-page>
<last-page>888</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Waters, J.A., et al.: Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts. Surgery. 158(4), 881–8 (2015); discussion 888–9</ref-fulltext>
<ce:source-text>Waters, J.A., et al.: Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts. Surgery. 158(4), 881–8 (2015); discussion 888–9</ce:source-text>
</reference>
<reference seq="59">
<ref-info>
<ref-title>
<ref-titletext-english>Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Uwagawa</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Anticancer Res.</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>29</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3173</first-page>
<last-page>3178</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Uwagawa, T., et al.: Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation. Anticancer Res. 29(8), 3173–3178 (2009)</ref-fulltext>
<ce:source-text>Uwagawa, T., et al.: Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation. Anticancer Res. 29(8), 3173–3178 (2009)</ce:source-text>
</reference>
<reference seq="60">
<ref-info>
<ref-title>
<ref-titletext-english>Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.R.</ce:initials>
<ce:surname>Mackey</ce:surname>
<ce:given-name>J.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="1998" />
<volisspag>
<volume-issue-number>
<vol-first>58</vol-first>
<iss-first>19</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4349</first-page>
<last-page>4357</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mackey, J.R., et al.: Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res. 58(19), 4349–4357 (1998)</ref-fulltext>
<ce:source-text>Mackey, J.R., et al.: Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res. 58(19), 4349–4357 (1998)</ce:source-text>
</reference>
<reference seq="61">
<ref-info>
<ref-title>
<ref-titletext-english>Pancreatic cancer chemoresistance to gemcitabine</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Amrutkar</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>I.P.</ce:initials>
<ce:surname>Gladhaug</ce:surname>
<ce:given-name>I.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancers (Basel).</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>11</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Amrutkar, M., Gladhaug, I.P.: Pancreatic cancer chemoresistance to gemcitabine. Cancers (Basel). 9, 11 (2017</ref-fulltext>
<ce:source-text>Amrutkar, M., Gladhaug, I.P.: Pancreatic cancer chemoresistance to gemcitabine. Cancers (Basel). 9, 11 (2017</ce:source-text>
</reference>
<reference seq="62">
<ref-info>
<ref-title>
<ref-titletext-english>The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Spratlin</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2004" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>20</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>6956</first-page>
<last-page>6961</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Spratlin, J., et al.: The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin. Cancer Res. 10(20), 6956–6961 (2004)</ref-fulltext>
<ce:source-text>Spratlin, J., et al.: The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin. Cancer Res. 10(20), 6956–6961 (2004)</ce:source-text>
</reference>
<reference seq="63">
<ref-info>
<ref-title>
<ref-titletext-english>CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.D.</ce:initials>
<ce:surname>Bhutia</ce:surname>
<ce:given-name>Y.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>71</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1825</first-page>
<last-page>1835</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bhutia, Y.D., et al.: CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells. Cancer Res. 71(5), 1825–1835 (2011)</ref-fulltext>
<ce:source-text>Bhutia, Y.D., et al.: CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells. Cancer Res. 71(5), 1825–1835 (2011)</ce:source-text>
</reference>
<reference seq="64">
<ref-info>
<ref-title>
<ref-titletext-english>The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Skrypek</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
<iss-first>13</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1714</first-page>
<last-page>1723</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Skrypek, N., et al.: The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family. Oncogene. 32(13), 1714–1723 (2013)</ref-fulltext>
<ce:source-text>Skrypek, N., et al.: The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family. Oncogene. 32(13), 1714–1723 (2013)</ce:source-text>
</reference>
<reference seq="65">
<ref-info>
<ref-title>
<ref-titletext-english>Blockade of nuclear factorkappaB (NF-kappaB) pathway inhibits growth and induces apoptosis in chemoresistant ovarian carcinoma cells.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Momeny</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Biochem. Cell Biol.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>99</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1</first-page>
<last-page>9</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Momeny, M., et al.: Blockade of nuclear factorkappaB (NF-kappaB) pathway inhibits growth and induces apoptosis in chemoresistant ovarian carcinoma cells. Int. J. Biochem. Cell Biol. 99, 1–9 (2018)</ref-fulltext>
<ce:source-text>Momeny, M., et al.: Blockade of nuclear factorkappaB (NF-kappaB) pathway inhibits growth and induces apoptosis in chemoresistant ovarian carcinoma cells. Int. J. Biochem. Cell Biol. 99, 1–9 (2018)</ce:source-text>
</reference>
<reference seq="66">
<ref-info>
<ref-title>
<ref-titletext-english> Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: overcoming transport defects using a nanoparticle approach</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.W.</ce:initials>
<ce:surname>Hung</ce:surname>
<ce:given-name>S.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Lett.</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>359</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>233</first-page>
<last-page>240</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hung, S.W., et al.: Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: overcoming transport defects using a nanoparticle approach. Cancer Lett. 359(2), 233–240 (2015)</ref-fulltext>
<ce:source-text>Hung, S.W., et al.: Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: overcoming transport defects using a nanoparticle approach. Cancer Lett. 359(2), 233–240 (2015)</ce:source-text>
</reference>
<reference seq="67">
<ref-info>
<ref-title>
<ref-titletext-english>Gemcitabine treatment promotes pancreatic cancer stemness through the Nox/ROS/ NF-kappaB/STAT3 signaling cascade.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Lett.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>382</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>53</first-page>
<last-page>63</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, Z., et al.: Gemcitabine treatment promotes pancreatic cancer stemness through the Nox/ROS/ NF-kappaB/STAT3 signaling cascade. Cancer Lett. 382(1), 53–63 (2016)</ref-fulltext>
<ce:source-text>Zhang, Z., et al.: Gemcitabine treatment promotes pancreatic cancer stemness through the Nox/ROS/ NF-kappaB/STAT3 signaling cascade. Cancer Lett. 382(1), 53–63 (2016)</ce:source-text>
</reference>
<reference seq="68">
<ref-info>
<ref-title>
<ref-titletext-english>Curcumin and gemcitabine in patients with advanced pancreatic cancer.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Epelbaum</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nutr. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>62</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1137</first-page>
<last-page>1141</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Epelbaum, R., et al.: Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr. Cancer. 62(8), 1137–1141 (2010</ref-fulltext>
<ce:source-text>Epelbaum, R., et al.: Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr. Cancer. 62(8), 1137–1141 (2010</ce:source-text>
</reference>
<reference seq="69">
<ref-info>
<ref-title>
<ref-titletext-english>Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Q.</ce:initials>
<ce:surname>Cao</ce:surname>
<ce:given-name>Q.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.Z.</ce:initials>
<ce:surname>Dudek</ce:surname>
<ce:given-name>A.Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Anticancer Res</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1027</first-page>
<last-page>1031</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, H., Cao, Q., Dudek, A.Z.: Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy. Anticancer Res. 32(3), 1027–1031 (2012)</ref-fulltext>
<ce:source-text>Wang, H., Cao, Q., Dudek, A.Z.: Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy. Anticancer Res. 32(3), 1027–1031 (2012)</ce:source-text>
</reference>
<reference seq="70">
<ref-info>
<ref-title>
<ref-titletext-english>Stimuli and sensors that initiate skeletal muscle hypertrophy following resistance exercise</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Wackerhage</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Appl. Physiol.</ref-sourcetitle>
<ref-publicationyear first="1985" />
<volisspag>
<volume-issue-number>
<vol-first>126</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>30</first-page>
<last-page>43</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wackerhage, H., et al.: Stimuli and sensors that initiate skeletal muscle hypertrophy following resistance exercise. J. Appl. Physiol. 2019. 126(1), 30–43 (1985)</ref-fulltext>
<ce:source-text>Wackerhage, H., et al.: Stimuli and sensors that initiate skeletal muscle hypertrophy following resistance exercise. J. Appl. Physiol. 2019. 126(1), 30–43 (1985)</ce:source-text>
</reference>
<reference seq="71">
<ref-info>
<ref-title>
<ref-titletext-english>Nuclear factor-kappa B signaling in skeletal muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Malhotra</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Kumar</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Mol. Med. (Berl).</ref-sourcetitle>
<ref-publicationyear first="2008" />
<volisspag>
<volume-issue-number>
<vol-first>86</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1113</first-page>
<last-page>1126</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Li, H., Malhotra, S., Kumar, A.: Nuclear factor-kappa B signaling in skeletal muscle atrophy. J. Mol. Med. (Berl). 86(10), 1113–1126 (2008) </ref-fulltext>
<ce:source-text>Li, H., Malhotra, S., Kumar, A.: Nuclear factor-kappa B signaling in skeletal muscle atrophy. J. Mol. Med. (Berl). 86(10), 1113–1126 (2008) </ce:source-text>
</reference>
<reference seq="72">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle atrophy induced by mechanical unloading: mechanisms and potential countermeasures.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Gao</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Physiol.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>235</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gao, Y., et al.: Muscle atrophy induced by mechanical unloading: mechanisms and potential countermeasures. Front. Physiol. 9, 235 (2018)</ref-fulltext>
<ce:source-text>Gao, Y., et al.: Muscle atrophy induced by mechanical unloading: mechanisms and potential countermeasures. Front. Physiol. 9, 235 (2018)</ce:source-text>
</reference>
<reference seq="73">
<ref-info>
<ref-title>
<ref-titletext-english>Signaling pathways perturbing muscle mass</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.J.</ce:initials>
<ce:surname>Glass</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Opin. Clin. Nutr. Metab. Care</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>13</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>225</first-page>
<last-page>229</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Glass, D.J.: Signaling pathways perturbing muscle mass. Curr. Opin. Clin. Nutr. Metab. Care. 13(3), 225–229 (2010)</ref-fulltext>
<ce:source-text>Glass, D.J.: Signaling pathways perturbing muscle mass. Curr. Opin. Clin. Nutr. Metab. Care. 13(3), 225–229 (2010)</ce:source-text>
</reference>
<reference seq="74">
<ref-info>
<ref-title>
<ref-titletext-english>Structural insights into the catalysis and regulation of E3 ubiquitin ligases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Buetow</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.T.</ce:initials>
<ce:surname>Huang</ce:surname>
<ce:given-name>D.T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Mol. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>626</first-page>
<last-page>642</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Buetow, L., Huang, D.T.: Structural insights into the catalysis and regulation of E3 ubiquitin ligases. Nat. Rev. Mol. Cell Biol. 17(10), 626–642 (2016)</ref-fulltext>
<ce:source-text>Buetow, L., Huang, D.T.: Structural insights into the catalysis and regulation of E3 ubiquitin ligases. Nat. Rev. Mol. Cell Biol. 17(10), 626–642 (2016)</ce:source-text>
</reference>
<reference seq="75">
<ref-info>
<ref-title>
<ref-titletext-english>Identification of ubiquitin ligases
required for skeletal muscle atrophy.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.C.</ce:initials>
<ce:surname>Bodine</ce:surname>
<ce:given-name>S.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science.</ref-sourcetitle>
<ref-publicationyear first="2001" />
<volisspag>
<volume-issue-number>
<vol-first>294</vol-first>
<iss-first>5547</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1704</first-page>
<last-page>1708</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bodine, S.C., et al.: Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 294(5547), 1704–1708 (2001)</ref-fulltext>
<ce:source-text>Bodine, S.C., et al.: Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 294(5547), 1704–1708 (2001)</ce:source-text>
</reference>
<reference seq="76">
<ref-info>
<ref-title>
<ref-titletext-english> Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.D.</ce:initials>
<ce:surname>Gomes</ce:surname>
<ce:given-name>M.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2001" />
<volisspag>
<volume-issue-number>
<vol-first>98</vol-first>
<iss-first>25</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>14440</first-page>
<last-page>14445</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gomes, M.D., et al.: Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc. Natl. Acad. Sci. USA. 98(25), 14440–14445 (2001)</ref-fulltext>
<ce:source-text>Gomes, M.D., et al.: Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc. Natl. Acad. Sci. USA. 98(25), 14440–14445 (2001)</ce:source-text>
</reference>
<reference seq="77">
<ref-info>
<ref-title>
<ref-titletext-english>Ubiquitin-protein ligases in muscle wasting. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.R.</ce:initials>
<ce:surname>Cao</ce:surname>
<ce:given-name>P.R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.J.</ce:initials>
<ce:surname>Kim</ce:surname>
<ce:given-name>H.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.H.</ce:initials>
<ce:surname>Lecker</ce:surname>
<ce:given-name>S.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Biochem. Cell Biol.</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>37</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2088</first-page>
<last-page>2097</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cao, P.R., Kim, H.J., Lecker, S.H.: Ubiquitin-protein ligases in muscle wasting. Int. J. Biochem. Cell Biol. 37(10), 2088–2097 (2005)</ref-fulltext>
<ce:source-text>Cao, P.R., Kim, H.J., Lecker, S.H.: Ubiquitin-protein ligases in muscle wasting. Int. J. Biochem. Cell Biol. 37(10), 2088–2097 (2005)</ce:source-text>
</reference>
<reference seq="78">
<ref-info>
<ref-title>
<ref-titletext-english>The SCF-Fbxo40 complex induces IRS1 ubiquitination in skeletal muscle, limiting IGF1 signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Shi</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Dev. Cell.</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>835</first-page>
<last-page>847</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shi, J., et al.: The SCF-Fbxo40 complex induces IRS1 ubiquitination in skeletal muscle, limiting IGF1 signaling. Dev. Cell. 21(5), 835–847 (2011)</ref-fulltext>
<ce:source-text>Shi, J., et al.: The SCF-Fbxo40 complex induces IRS1 ubiquitination in skeletal muscle, limiting IGF1 signaling. Dev. Cell. 21(5), 835–847 (2011)</ce:source-text>
</reference>
<reference seq="79">
<ref-info>
<ref-title>
<ref-titletext-english>FBXO40, a gene encoding a novel muscle-specific F-box protein, is upregulated in denervation-related muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Ye</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Gene</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>404</vol-first>
<iss-first>1</iss-first>
<iss-last>2</iss-last>
</volume-issue-number>
<page-information>
<pages>
<first-page>53</first-page>
<last-page>60</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ye, J., et al.: FBXO40, a gene encoding a novel muscle-specific F-box protein, is upregulated in denervation-related muscle atrophy. Gene. 404(1–2), 53–60 (2007)</ref-fulltext>
<ce:source-text>Ye, J., et al.: FBXO40, a gene encoding a novel muscle-specific F-box protein, is upregulated in denervation-related muscle atrophy. Gene. 404(1–2), 53–60 (2007)</ce:source-text>
</reference>
<reference seq="80">
<ref-info>
<ref-title>
<ref-titletext-english>Expression of NF-kappaB and IkappaB proteins in skeletal muscle of gastric cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.G.</ce:initials>
<ce:surname>Rhoads</ce:surname>
<ce:given-name>M.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>46</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>191</first-page>
<last-page>197</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rhoads, M.G., et al.: Expression of NF-kappaB and IkappaB proteins in skeletal muscle of gastric cancer patients. Eur. J. Cancer. 46(1), 191–197 (2010)</ref-fulltext>
<ce:source-text>Rhoads, M.G., et al.: Expression of NF-kappaB and IkappaB proteins in skeletal muscle of gastric cancer patients. Eur. J. Cancer. 46(1), 191–197 (2010)</ce:source-text>
</reference>
<reference seq="81">
<ref-info>
<ref-title>
<ref-titletext-english>IKKbeta/NF-kappaB activation causes
severe muscle wasting in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Cai</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell.</ref-sourcetitle>
<ref-publicationyear first="2004" />
<volisspag>
<volume-issue-number>
<vol-first>119</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>285</first-page>
<last-page>298</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cai, D., et al.: IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell. 119(2), 285–298 (2004)</ref-fulltext>
<ce:source-text>Cai, D., et al.: IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell. 119(2), 285–298 (2004)</ce:source-text>
</reference>
<reference seq="82">
<ref-info>
<ref-title>
<ref-titletext-english>Targeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regeneration</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Mourkioti</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>116</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2945</first-page>
<last-page>2954</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mourkioti, F., et al.: Targeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regeneration. J. Clin. Invest. 116(11), 2945–2954 (2006)</ref-fulltext>
<ce:source-text>Mourkioti, F., et al.: Targeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regeneration. J. Clin. Invest. 116(11), 2945–2954 (2006)</ce:source-text>
</reference>
<reference seq="83">
<ref-info>
<ref-title>
<ref-titletext-english>NF-kappaB but not FoxO sites in the MuRF1 promoter are required for transcriptional activation in disuse muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.L.</ce:initials>
<ce:surname>Wu</ce:surname>
<ce:given-name>C.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Cell Physiol</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>306</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Wu, C.L., et al.: NF-kappaB but not FoxO sites in the MuRF1 promoter are required for transcriptional activation in disuse muscle atrophy. Am. J. Physiol. Cell Physiol. 306(8), C762–C767 (2014)</ref-fulltext>
<ce:source-text>Wu, C.L., et al.: NF-kappaB but not FoxO sites in the MuRF1 promoter are required for transcriptional activation in disuse muscle atrophy. Am. J. Physiol. Cell Physiol. 306(8), C762–C767 (2014)</ce:source-text>
</reference>
<reference seq="84">
<ref-info>
<ref-title>
<ref-titletext-english>Goldberg, A.L.: Muscle wasting in fasting requires activation of NF-kappaB and inhibition of AKT/Mechanistic Target of Rapamycin (mTOR) by the protein acetylase, GCN5</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>290</vol-first>
<iss-first>51</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>30269</first-page>
<last-page>30279</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lee, D., Goldberg, A.L.: Muscle wasting in fasting requires activation of NF-kappaB and inhibition of AKT/Mechanistic Target of Rapamycin (mTOR) by the protein acetylase, GCN5. J. Biol. Chem. 290(51), 30269–30279 (2015)</ref-fulltext>
<ce:source-text>Lee, D., Goldberg, A.L.: Muscle wasting in fasting requires activation of NF-kappaB and inhibition of AKT/Mechanistic Target of Rapamycin (mTOR) by the protein acetylase, GCN5. J. Biol. Chem. 290(51), 30269–30279 (2015)</ce:source-text>
</reference>
<reference seq="85">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia is regulated by selective targeting of skeletal muscle gene products</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Acharyya</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest.</ref-sourcetitle>
<ref-publicationyear first="2004" />
<volisspag>
<volume-issue-number>
<vol-first>114</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>370</first-page>
<last-page>378</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Acharyya, S., et al.: Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J. Clin. Invest. 114(3), 370–378 (2004)</ref-fulltext>
<ce:source-text>Acharyya, S., et al.: Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J. Clin. Invest. 114(3), 370–378 (2004)</ce:source-text>
</reference>
<reference seq="86">
<ref-info>
<ref-title>
<ref-titletext-english> Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: an in vitro and in vivo study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Yuan</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncol. Rep</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2261</first-page>
<last-page>2268</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yuan, L., et al.: Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: an in vitro and in vivo study. Oncol. Rep. 33(5), 2261–2268 (2015) </ref-fulltext>
<ce:source-text>Yuan, L., et al.: Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: an in vitro and in vivo study. Oncol. Rep. 33(5), 2261–2268 (2015) </ce:source-text>
</reference>
<reference seq="87">
<ref-info>
<ref-title>
<ref-titletext-english>Gastric cancer does not affect the expression of atrophy-related genes in human skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>D'Orlando</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Muscle Nerve</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>49</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>528</first-page>
<last-page>533</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>D'Orlando, C., et al.: Gastric cancer does not affect the expression of atrophy-related genes in human skeletal muscle. Muscle Nerve. 49(4), 528–533 (2014)</ref-fulltext>
<ce:source-text>D'Orlando, C., et al.: Gastric cancer does not affect the expression of atrophy-related genes in human skeletal muscle. Muscle Nerve. 49(4), 528–533 (2014)</ce:source-text>
</reference>
<reference seq="88">
<ref-info>
<ref-title>
<ref-titletext-english>The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Williams</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Surgery</ref-sourcetitle>
<ref-publicationyear first="1999" />
<volisspag>
<volume-issue-number>
<vol-first>126</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>744</first-page>
<last-page>749</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Williams, A., et al.: The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery. 126(4): p. 744–9 (1999); discussion 749–50</ref-fulltext>
<ce:source-text>Williams, A., et al.: The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery. 126(4): p. 744–9 (1999); discussion 749–50</ce:source-text>
</reference>
<reference seq="89">
<ref-info>
<ref-title>
<ref-titletext-english>Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Khal</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle />
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>37</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2196</first-page>
<last-page>2206</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Khal, J., et al.: Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. Int. J. Biochem. Cell Biol. 37(10), 2196–2206 (2005) </ref-fulltext>
<ce:source-text>Khal, J., et al.: Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. Int. J. Biochem. Cell Biol. 37(10), 2196–2206 (2005)
</ce:source-text>
</reference>
<reference seq="90">
<ref-info>
<ref-title>
<ref-titletext-english>Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.A.</ce:initials>
<ce:surname>Stephens</ce:surname>
<ce:given-name>N.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Genome Med</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stephens, N.A., et al.: Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia. Genome Med. 2(1), 1 (2010)</ref-fulltext>
<ce:source-text>Stephens, N.A., et al.: Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia. Genome Med. 2(1), 1 (2010)</ce:source-text>
</reference>
<reference seq="91">
<ref-info>
<ref-title>
<ref-titletext-english>Modeling human cancer-induced
cachexia.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.E.</ce:initials>
<ce:surname>Talbert</ce:surname>
<ce:given-name>E.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Rep</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1612</first-page>
<last-page>1622</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Talbert, E.E., et al.: Modeling human cancer-induced cachexia. Cell Rep. 28(6), 1612–1622 e4 (2019</ref-fulltext>
<ce:source-text>Talbert, E.E., et al.: Modeling human cancer-induced cachexia. Cell Rep. 28(6), 1612–1622 e4 (2019</ce:source-text>
</reference>
<reference seq="92">
<ref-info>
<ref-title>
<ref-titletext-english> C26 cancer-induced muscle wasting is IKKbeta-dependent and NF-kappaB-independent</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.W.</ce:initials>
<ce:surname>Cornwell</ce:surname>
<ce:given-name>E.W.</ce:given-name>
</author>
</ref-authors>
<ref-publicationyear first="2014" />
<ref-text>PLoS One</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Cornwell, E.W., et al.: C26 cancer-induced muscle wasting is IKKbeta-dependent and NF-kappaB-independent. PLoS One. 9(1), e87776 (2014)</ref-fulltext>
<ce:source-text>Cornwell, E.W., et al.: C26 cancer-induced muscle wasting is IKKbeta-dependent and NF-kappaB-independent. PLoS One. 9(1), e87776 (2014)</ce:source-text>
</reference>
<reference seq="93">
<ref-info>
<ref-title>
<ref-titletext-english>Mechanisms of cisplatin-induced muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Sakai</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Toxicol. Appl. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>278</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>190</first-page>
<last-page>199</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sakai, H., et al.: Mechanisms of cisplatin-induced muscle atrophy. Toxicol. Appl. Pharmacol. 278(2), 190–199 (2014)</ref-fulltext>
<ce:source-text>Sakai, H., et al.: Mechanisms of cisplatin-induced muscle atrophy. Toxicol. Appl. Pharmacol. 278(2), 190–199 (2014)</ce:source-text>
</reference>
<reference seq="94">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer and chemotherapy contribute to muscle loss by activating common signaling pathways</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Barreto</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Physiol</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>472</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Barreto, R., et al.: Cancer and chemotherapy contribute to muscle loss by activating common signaling pathways. Front. Physiol. 7, 472 (2016</ref-fulltext>
<ce:source-text>Barreto, R., et al.: Cancer and chemotherapy contribute to muscle loss by activating common signaling pathways. Front. Physiol. 7, 472 (2016</ce:source-text>
</reference>
<reference seq="95">
<ref-info>
<ref-title>
<ref-titletext-english>Chemotherapy-induced muscle wasting: association with NF-kappaB and cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S.</ce:initials>
<ce:surname>Damrauer</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Transl. Myol</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Damrauer, J.S., et al.: Chemotherapy-induced muscle wasting: association with NF-kappaB and cancer cachexia. Eur. J. Transl. Myol. 28(2), 7590 (2018)</ref-fulltext>
<ce:source-text>Damrauer, J.S., et al.: Chemotherapy-induced muscle wasting: association with NF-kappaB and cancer cachexia. Eur. J. Transl. Myol. 28(2), 7590 (2018</ce:source-text>
</reference>
<reference seq="96">
<ref-info>
<ref-title>
<ref-titletext-english>Autophagy: cellular and molecular mechanisms</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Glick</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Barth</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.F.</ce:initials>
<ce:surname>Macleod</ce:surname>
<ce:given-name>K.F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Pathol</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>221</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3</first-page>
<last-page>12</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Glick, D., Barth, S., Macleod, K.F.: Autophagy: cellular and molecular mechanisms. J. Pathol. 221(1),
3–12 (2010</ref-fulltext>
<ce:source-text>Glick, D., Barth, S., Macleod, K.F.: Autophagy: cellular and molecular mechanisms. J. Pathol. 221(1),
3–12 (2010</ce:source-text>
</reference>
<reference seq="97">
<ref-info>
<ref-title>
<ref-titletext-english>The IKK complex contributes to the induction of autophagy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Criollo</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>EMBO J</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>29</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>619</first-page>
<last-page>631</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Criollo, A., et al.: The IKK complex contributes to the induction of autophagy. EMBO J. 29(3), 619–631 (2010</ref-fulltext>
<ce:source-text>Criollo, A., et al.: The IKK complex contributes to the induction of autophagy. EMBO J. 29(3), 619–631 (2010</ce:source-text>
</reference>
<reference seq="98">
<ref-info>
<ref-title>
<ref-titletext-english>IKK-dependent, NF-kappaBindependent control of autophagic gene expression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.C.</ce:initials>
<ce:surname>Comb</ce:surname>
<ce:given-name>W.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
<iss-first>14</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1727</first-page>
<last-page>1732</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Comb, W.C., et al.: IKK-dependent, NF-kappaBindependent control of autophagic gene expression. Oncogene. 30(14), 1727–1732 (2011) </ref-fulltext>
<ce:source-text>Comb, W.C., et al.: IKK-dependent, NF-kappaBindependent control of autophagic gene expression. Oncogene. 30(14), 1727–1732 (2011) </ce:source-text>
</reference>
<reference seq="99">
<ref-info>
<ref-title>
<ref-titletext-english>Autophagic degradation contributes to muscle wasting in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Penna</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Pathol.</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>183</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1367</first-page>
<last-page>1378</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Penna, F., et al.: Autophagic degradation contributes to muscle wasting in cancer cachexia. Am. J. Pathol. 182(4), 1367–1378 (2013)</ref-fulltext>
<ce:source-text>Penna, F., et al.: Autophagic degradation contributes to muscle wasting in cancer cachexia. Am. J. Pathol. 182(4), 1367–1378 (2013)</ce:source-text>
</reference>
<reference seq="100">
<ref-info>
<ref-title>
<ref-titletext-english>Denervation-induced oxidative stress and autophagy signaling in muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.F.</ce:initials>
<ce:surname>O'Leary</ce:surname>
<ce:given-name>M.F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.A.</ce:initials>
<ce:surname>Hood</ce:surname>
<ce:given-name>D.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Autophagy</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>230</first-page>
<last-page>231</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>O'Leary, M.F., Hood, D.A.: Denervation-induced oxidative stress and autophagy signaling in muscle. Autophagy. 5(2), 230–231 (2009</ref-fulltext>
<ce:source-text>O'Leary, M.F., Hood, D.A.: Denervation-induced oxidative stress and autophagy signaling in muscle. Autophagy. 5(2), 230–231 (2009</ce:source-text>
</reference>
<reference seq="101">
<ref-info>
<ref-title>
<ref-titletext-english>Autophagy is required to maintain muscle mass.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Masiero</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>507</first-page>
<last-page>515</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Masiero, E., et al.: Autophagy is required to maintain muscle mass. Cell Metab. 10(6), 507–515 (2009)</ref-fulltext>
<ce:source-text>Masiero, E., et al.: Autophagy is required to maintain muscle mass. Cell Metab. 10(6), 507–515 (2009)</ce:source-text>
</reference>
<reference seq="102">
<ref-info>
<ref-title>
<ref-titletext-english>Autophagy exacerbates muscle wasting in cancer cachexia and impairs mitochondrial function</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Penna</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Mol. Biol</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>431</vol-first>
<iss-first>15</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2674</first-page>
<last-page>2686</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Penna, F., et al.: Autophagy exacerbates muscle wasting in cancer cachexia and impairs mitochondrial function. J. Mol. Biol. 431(15), 2674–2686 (2019)</ref-fulltext>
<ce:source-text>Penna, F., et al.: Autophagy exacerbates muscle wasting in cancer cachexia and impairs mitochondrial function. J. Mol. Biol. 431(15), 2674–2686 (2019)</ce:source-text> 
</reference>
<reference seq="103">
<ref-info>
<ref-title>
<ref-titletext-english>Pax7 is required for the specification of myogenic satellite cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Seale</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2000" />
<volisspag>
<volume-issue-number>
<vol-first>102</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>777</first-page>
<last-page>786</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Seale, P., et al.: Pax7 is required for the specification of myogenic satellite cells. Cell. 102(6), 777–786 (2000)</ref-fulltext>
<ce:source-text>Seale, P., et al.: Pax7 is required for the specification of myogenic satellite cells. Cell. 102(6), 777–786 (2000)</ce:source-text>
</reference>
<reference seq="104">
<ref-info>
<ref-title>
<ref-titletext-english>The molecular regulation of myogenesis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.A.</ce:initials>
<ce:surname>Sabourin</ce:surname>
<ce:given-name>L.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.A.</ce:initials>
<ce:surname>Rudnick</ce:surname>
<ce:given-name>M.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Genet</ref-sourcetitle>
<ref-publicationyear first="2000" />
<volisspag>
<volume-issue-number>
<vol-first>57</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>16</first-page>
<last-page>25</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sabourin, L.A., Rudnicki, M.A.: The molecular regulation of myogenesis. Clin. Genet. 57(1), 16–25 (2000</ref-fulltext>
<ce:source-text>Sabourin, L.A., Rudnicki, M.A.: The molecular regulation of myogenesis. Clin. Genet. 57(1), 16–25 (2000</ce:source-text>
</reference>
<reference seq="105">
<ref-info>
<ref-title>
<ref-titletext-english>Satellite cells and the muscle stem cell niche. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Yin</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Price</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.A.</ce:initials>
<ce:surname>Rudnick</ce:surname>
<ce:given-name>M.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Physiol. Rev</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>93</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>23</first-page>
<last-page>67</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yin, H., Price, F., Rudnicki, M.A.: Satellite cells and the muscle stem cell niche. Physiol. Rev. 93(1), 23–67 (2013)</ref-fulltext>
<ce:source-text>Yin, H., Price, F., Rudnicki, M.A.: Satellite cells and the muscle stem cell niche. Physiol. Rev. 93(1), 23–67 (2013)</ce:source-text>
</reference>
<reference seq="106">
<ref-info>
<ref-title>
<ref-titletext-english>Aging disrupts muscle stem cell function by impairing matricellular WISP1 secretion from fibro-adipogenic progenitors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Lukjanenko</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Stem Cell</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>433</first-page>
<last-page>446</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lukjanenko, L., et al.: Aging disrupts muscle stem cell function by impairing matricellular WISP1 secretion from fibro-adipogenic progenitors. Cell Stem Cell. 24(3), 433–446 e7 (2019) </ref-fulltext>
<ce:source-text>Lukjanenko, L., et al.: Aging disrupts muscle stem cell function by impairing matricellular WISP1 secretion from fibro-adipogenic progenitors. Cell Stem Cell. 24(3), 433–446 e7 (2019) </ce:source-text>
</reference>
<reference seq="107">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle injury activates resident fibro/adipogenic progenitors that facilitate myogenesis. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.W.</ce:initials>
<ce:surname>Joe</ce:surname>
<ce:given-name>A.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>153</first-page>
<last-page>163</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Joe, A.W., et al.: Muscle injury activates resident fibro/adipogenic progenitors that facilitate myogenesis. Nat. Cell Biol. 12(2), 153–163 (2010)</ref-fulltext>
<ce:source-text>Joe, A.W., et al.: Muscle injury activates resident fibro/adipogenic progenitors that facilitate myogenesis. Nat. Cell Biol. 12(2), 153–163 (2010)</ce:source-text>
</reference>
<reference seq="108">
<ref-info>
<ref-title>
<ref-titletext-english> Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Dellavalle</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Cell Biol.</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>255</first-page>
<last-page>267</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dellavalle, A., et al.: Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nat. Cell Biol. 9(3), 255–267 (2007)</ref-fulltext>
<ce:source-text>Dellavalle, A., et al.: Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nat. Cell Biol. 9(3), 255–267 (2007)</ce:source-text>
</reference>
<reference seq="109">
<ref-info>
<ref-title>
<ref-titletext-english>beta-Catenin activation in muscle progenitor cells regulates tissue repair.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Rudolf</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Rep</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1277</first-page>
<last-page>1290</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rudolf, A., et al.: beta-Catenin activation in muscle progenitor cells regulates tissue repair. Cell Rep. 15(6), 1277–1290 (2016)</ref-fulltext>
<ce:source-text>Rudolf, A., et al.: beta-Catenin activation in muscle progenitor cells regulates tissue repair. Cell Rep. 15(6), 1277–1290 (2016)</ce:source-text>
</reference>
<reference seq="110">
<ref-info>
<ref-title>
<ref-titletext-english>Wnt signaling from the dorsal neural tube is required for the formation of the medial dermomyotome</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Ikeya</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Takada</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Development.</ref-sourcetitle>
<ref-publicationyear first="1998" />
<volisspag>
<volume-issue-number>
<vol-first>125</vol-first>
<iss-first>24</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4969</first-page>
<last-page>4976</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ikeya, M., Takada, S.: Wnt signaling from the dorsal neural tube is required for the formation of the medial dermomyotome. Development. 125(24), 4969–4976 (1998)</ref-fulltext>
<ce:source-text>Ikeya, M., Takada, S.: Wnt signaling from the dorsal neural tube is required for the formation of the medial dermomyotome. Development. 125(24), 4969–4976 (1998)</ce:source-text>
</reference>
<reference seq="111">
<ref-info>
<ref-title>
<ref-titletext-english>TGF-beta inhibits muscle differentiation through functional repression of myogenic transcription factors by Smad3</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.L.</ce:initials>
<ce:surname>Black</ce:surname>
<ce:given-name>B.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Derynck</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Genes Dev.</ref-sourcetitle>
<ref-publicationyear first="2001" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>22</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2950</first-page>
<last-page>2966</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Liu, D., Black, B.L., Derynck, R.: TGF-beta inhibits muscle differentiation through functional repression of myogenic transcription factors by Smad3. Genes Dev. 15(22), 2950–2966 (2001)</ref-fulltext>
<ce:source-text>Liu, D., Black, B.L., Derynck, R.: TGF-beta inhibits muscle differentiation through functional repression of myogenic transcription factors by Smad3. Genes Dev. 15(22), 2950–2966 (2001)</ce:source-text>
</reference>
<reference seq="112">
<ref-info>
<ref-title>
<ref-titletext-english>The regulation of Notch signaling controls satellite cell activation and cell fate determination in postnatal myogenesis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.M.</ce:initials>
<ce:surname>Conboy</ce:surname>
<ce:given-name>I.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.A.</ce:initials>
<ce:surname>Rando</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Dev. Cell</ref-sourcetitle>
<ref-publicationyear first="2002" />
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>397</first-page>
<last-page>409</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Conboy, I.M., Rando, T.A.: The regulation of Notch signaling controls satellite cell activation and cell fate determination in postnatal myogenesis. Dev. Cell. 3(3), 397–409 (2002)</ref-fulltext>
<ce:source-text>Conboy, I.M., Rando, T.A.: The regulation of Notch signaling controls satellite cell activation and cell fate determination in postnatal myogenesis. Dev. Cell. 3(3), 397–409 (2002)</ce:source-text>
</reference>
<reference seq="113">
<ref-info>
<ref-title>
<ref-titletext-english>NF-kappaB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.A.</ce:initials>
<ce:surname>He</ce:surname>
<ce:given-name>W.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>123</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4821</first-page>
<last-page>4835</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>He, W.A., et al.: NF-kappaB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia. J. Clin. Invest. 123(11), 4821–4835 (2013)</ref-fulltext>
<ce:source-text>He, W.A., et al.: NF-kappaB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia. J. Clin. Invest. 123(11), 4821–4835 (2013)</ce:source-text>
</reference>
<reference seq="114">
<ref-info>
<ref-title>
<ref-titletext-english>NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.C.</ce:initials>
<ce:surname>Guttridge</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
</ref-authors>
<ref-publicationyear first="2000" />
<volisspag>
<volume-issue-number>
<vol-first>289</vol-first>
<iss-first>5488</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2363</first-page>
<last-page>2366</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Guttridge, D.C., et al.: NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science. 289(5488), 2363–2366 (2000)</ref-fulltext>
<ce:source-text>Guttridge, D.C., et al.: NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science. 289(5488), 2363–2366 (2000)</ce:source-text>
</reference>
<reference seq="115">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle regeneration is disrupted by cancer cachexia without loss of muscle stem cell potential.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Inaba</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>PLoS One</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>13</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Inaba, S., et al.: Muscle regeneration is disrupted by cancer cachexia without loss of muscle stem cell potential. PLoS One. 13(10), e0205467 (2018)</ref-fulltext>
<ce:source-text>Inaba, S., et al.: Muscle regeneration is disrupted by cancer cachexia without loss of muscle stem cell potential. PLoS One. 13(10), e0205467 (2018)</ce:source-text>
</reference>
<reference seq="116">
<ref-info>
<ref-title>
<ref-titletext-english>Satellite cells senescence in limb muscle of severe patients with COPD.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.E.</ce:initials>
<ce:surname>Theriault</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>PLoS One.</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Theriault, M.E., et al.: Satellite cells senescence in limb muscle of severe patients with COPD. PLoS One. 7(6), e39124 (2012)</ref-fulltext>
<ce:source-text>Theriault, M.E., et al.: Satellite cells senescence in limb muscle of severe patients with COPD. PLoS One. 7(6), e39124 (2012)</ce:source-text>
</reference>
<reference seq="117">
<ref-info>
<ref-title>
<ref-titletext-english> Satellite cell dysfunction and impaired IGF-1 signaling cause CKD-induced muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Am. Soc. Nephrol</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>419</first-page>
<last-page>427</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, L., et al.: Satellite cell dysfunction and impaired IGF-1 signaling cause CKD-induced muscle atrophy. J. Am. Soc. Nephrol. 21(3), 419–427 (2010</ref-fulltext>
<ce:source-text>Zhang, L., et al.: Satellite cell dysfunction and impaired IGF-1 signaling cause CKD-induced muscle atrophy. J. Am. Soc. Nephrol. 21(3), 419–427 (2010</ce:source-text>
</reference>
<reference seq="118">
<ref-info>
<ref-title>
<ref-titletext-english>Spontaneous physical activity downregulates Pax7 in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Coletti</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Stem Cells Int</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>2016</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Coletti, D., et al.: Spontaneous physical activity downregulates Pax7 in cancer cachexia. Stem Cells Int. 2016, 6729268 (2016)</ref-fulltext>
<ce:source-text>Coletti, D., et al.: Spontaneous physical activity downregulates Pax7 in cancer cachexia. Stem Cells Int. 2016, 6729268 (2016)</ce:source-text>
</reference>
<reference seq="119">
<ref-info>
<ref-title>
<ref-titletext-english>NF-kappaB regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cell. Biol</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4374</first-page>
<last-page>4387</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, H., et al.: NF-kappaB regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes. Mol. Cell. Biol. 27(12), 4374–4387 (2007)</ref-fulltext>
<ce:source-text>Wang, H., et al.: NF-kappaB regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes. Mol. Cell. Biol. 27(12), 4374–4387 (2007)</ce:source-text>
</reference>
<reference seq="120">
<ref-info>
<ref-title>
<ref-titletext-english>NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> Cancer Cell.</ref-sourcetitle>
<ref-publicationyear first="2008" />
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>369</first-page>
<last-page>381</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, H., et al.: NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell. 14(5), 369–381 (2008)</ref-fulltext>
<ce:source-text>Wang, H., et al.: NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell. 14(5), 369–381 (2008)</ce:source-text>
</reference>
<reference seq="121">
<ref-info>
<ref-title>
<ref-titletext-english> Twist1 activation in muscle progenitor cells causes muscle loss akin to cancer cachexia.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Parajul</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Dev. Cell.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>45</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>712</first-page>
<last-page>725</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Parajuli, P., et al.: Twist1 activation in muscle progenitor cells causes muscle loss akin to cancer cachexia. Dev. Cell. 45(6), 712–725 e6 (2018)</ref-fulltext>
<ce:source-text>Parajuli, P., et al.: Twist1 activation in muscle progenitor cells causes muscle loss akin to cancer cachexia. Dev. Cell. 45(6), 712–725 e6 (2018)</ce:source-text>
</reference>
<reference seq="122">
<ref-info>
<ref-title>
<ref-titletext-english>Epithelial-mesenchymal transition induced by TNF-alpha requires NF-kappaB-mediated transcriptional upregulation of Twist1.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.W.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>C.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>72</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1290</first-page>
<last-page>1300</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Li, C.W., et al.: Epithelial-mesenchymal transition induced by TNF-alpha requires NF-kappaB-mediated transcriptional upregulation of Twist1. Cancer Res. 72(5), 1290–1300 (2012)</ref-fulltext>
<ce:source-text>Li, C.W., et al.: Epithelial-mesenchymal transition induced by TNF-alpha requires NF-kappaB-mediated transcriptional upregulation of Twist1. Cancer Res. 72(5), 1290–1300 (2012)</ce:source-text>
</reference>
<reference seq="123">
<ref-info>
<ref-title>
<ref-titletext-english>The Colon-26 carcinoma tumorbearing mouse as a model for the study of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Vis. Exp</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>117</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Bonetto, A., et al.: The Colon-26 carcinoma tumorbearing mouse as a model for the study of cancer cachexia. J. Vis. Exp. 117 (2016) </ref-fulltext>
<ce:source-text>Bonetto, A., et al.: The Colon-26 carcinoma tumorbearing mouse as a model for the study of cancer cachexia. J. Vis. Exp. 117 (2016) </ce:source-text>
</reference>
<reference seq="124">
<ref-info>
<ref-title>
<ref-titletext-english>Toll-like receptor 4 mediates Lewis lung carcinoma-induced muscle wasting via coordinate activation of protein degradation pathways.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2273</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, G., et al.: Toll-like receptor 4 mediates Lewis lung carcinoma-induced muscle wasting via coordinate activation of protein degradation pathways. Sci. Rep. 7(1), 2273 (2017) </ref-fulltext>
<ce:source-text>Zhang, G., et al.: Toll-like receptor 4 mediates Lewis lung carcinoma-induced muscle wasting via coordinate activation of protein degradation pathways. Sci. Rep. 7(1), 2273 (2017) </ce:source-text>
</reference>
<reference seq="125">
<ref-info>
<ref-title>
<ref-titletext-english>Distinct cachexia profiles in response to human pancreatic tumours in mouse limb and respiratory muscle. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.L.</ce:initials>
<ce:surname>Nosacka</ce:surname>
<ce:given-name>R.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle.</ref-sourcetitle>
<ref-publicationyear first="2020" />
</ref-info>
<ref-fulltext>Nosacka, R.L., et al.: Distinct cachexia profiles in response to human pancreatic tumours in mouse limb and respiratory muscle. J. Cachexia. Sarcopenia Muscle. (2020)</ref-fulltext>
<ce:source-text>Nosacka, R.L., et al.: Distinct cachexia profiles in response to human pancreatic tumours in mouse limb and respiratory muscle. J. Cachexia. Sarcopenia Muscle. (2020)</ce:source-text>
</reference>
<reference seq="126">
<ref-info>
<ref-title>
<ref-titletext-english>MEF2c-dependent downregulation of myocilin mediates cancer-induced muscle wasting and associates with cachexia in patients with cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.M.</ce:initials>
<ce:surname>Judge</ce:surname>
<ce:given-name>S.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>80</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1861</first-page>
<last-page>1874</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Judge, S.M., et al.: MEF2c-dependent downregulation of myocilin mediates cancer-induced muscle wasting and associates with cachexia in patients with cancer. Cancer Res. 80(9), 1861–1874 (2020</ref-fulltext>
<ce:source-text>Judge, S.M., et al.: MEF2c-dependent downregulation of myocilin mediates cancer-induced muscle wasting and associates with cachexia in patients with cancer. Cancer Res. 80(9), 1861–1874 (2020</ce:source-text>
</reference>
<reference seq="127">
<ref-info>
<ref-title>
<ref-titletext-english>Circulating myeloid cells invade the central nervous system to mediate cachexia during pancreatic cancer.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.G.</ce:initials>
<ce:surname>Burfeind</ce:surname>
<ce:given-name>K.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>elife.</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Burfeind, K.G., et al.: Circulating myeloid cells invade the central nervous system to mediate cachexia during pancreatic cancer. elife. 9 (2020)</ref-fulltext>
<ce:source-text>Burfeind, K.G., et al.: Circulating myeloid cells invade the central nervous system to mediate cachexia during pancreatic cancer. elife. 9 (2020)</ce:source-text>
</reference>
<reference seq="128">
<ref-info>
<ref-title>
<ref-titletext-english>Promising models for cancer-induced cachexia drug discovery.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Suzuki</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.H.</ce:initials>
<ce:surname>Von</ce:surname>
<ce:given-name>Haehling</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Springer</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Expert Opin. Drug Discovery.</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>627</first-page>
<last-page>637</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Suzuki, T., Von Haehling, S., Springer, J.: Promising models for cancer-induced cachexia drug discovery. Expert Opin. Drug Discovery. 15(5), 627–637 (2020)</ref-fulltext>
<ce:source-text>Suzuki, T., Von Haehling, S., Springer, J.: Promising models for cancer-induced cachexia drug discovery. Expert Opin. Drug Discovery. 15(5), 627–637 (2020)</ce:source-text>
</reference>
<reference seq="129">
<ref-info>
<ref-title>
<ref-titletext-english>Adipose triglyceride lipase contributes to cancer-associated cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.K.</ce:initials>
<ce:surname>Das</ce:surname>
<ce:given-name>S.K.</ce:given-name>
</author>
</ref-authors>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>333</vol-first>
<iss-first>6039</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>233</first-page>
<last-page>238</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Das, S.K., et al.: Adipose triglyceride lipase contributes to cancer-associated cachexia. Science. 333(6039), 233–238 (2011)</ref-fulltext>
<ce:source-text>Das, S.K., et al.: Adipose triglyceride lipase contributes to cancer-associated cachexia. Science. 333(6039), 233–238 (2011)</ce:source-text>
</reference>
<reference seq="130">
<ref-info>
<ref-title>
<ref-titletext-english>Emerging treatment options for cancerassociated cachexia: a literature review.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Naito</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ther. Clin. Risk Manag</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1253</first-page>
<last-page>1266</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Naito, T.: Emerging treatment options for cancerassociated cachexia: a literature review. Ther. Clin. Risk Manag. 15, 1253–1266 (2019)</ref-fulltext>
<ce:source-text>Naito, T.: Emerging treatment options for cancerassociated cachexia: a literature review. Ther. Clin. Risk Manag. 15, 1253–1266 (2019)</ce:source-text>
</reference>
<reference seq="131">
<ref-info>
<ref-title>
<ref-titletext-english>A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.S.</ce:initials>
<ce:surname>Solheim</ce:surname>
<ce:given-name>T.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>778</first-page>
<last-page>788</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Solheim, T.S., et al.: A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. J. Cachexia. Sarcopenia Muscle. 8(5), 778–788 (2017)</ref-fulltext>
<ce:source-text>Solheim, T.S., et al.: A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. J. Cachexia. Sarcopenia Muscle. 8(5), 778–788 (2017)</ce:source-text>
</reference>
<reference seq="132">
<ref-info>
<ref-title>
<ref-titletext-english>Targeting IKKbeta in cancer: challenges and opportunities for the therapeutic utilisation of IKKbeta inhibitors.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Prescott</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.J.</ce:initials>
<ce:surname>Cook</ce:surname>
<ce:given-name>S.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Prescott, J.A., Cook, S.J.: Targeting IKKbeta in cancer: challenges and opportunities for the therapeutic utilisation of IKKbeta inhibitors. Cell. 7(9) (2018)</ref-fulltext>
<ce:source-text>Prescott, J.A., Cook, S.J.: Targeting IKKbeta in cancer: challenges and opportunities for the therapeutic utilisation of IKKbeta inhibitors. Cell. 7(9) (2018)</ce:source-text>
</reference>
</bibliography>
</tail>
</bibrecord>
<bibrecord>
<item-info>
<status state="new" stage="S300" />
<itemidlist>
<ce:doi>10.1007/978-3-031-09518-4_8</ce:doi>
<itemid idtype="TPB-ID">20232000349315</itemid>
</itemidlist>
</item-info>
<head>
<citation-info>
<citation-type code="ch" />
<citation-language xml:lang="ENG" />
<abstract-language xml:lang="ENG" />
</citation-info>
<citation-title>
<titletext xml:lang="ENG" original="y">Therapy-Induced Toxicities Associated with the Onset of Cachexia</titletext>
</citation-title>
<author-group seq="1">
<author seq="1">
<ce:initials>J.R.</ce:initials>
<ce:surname>Huot</ce:surname>
<ce:given-name>Joshua R.</ce:given-name>
</author>
<affiliation>
<organization>Department of Surgery</organization>
<organization>Indiana University School of Medicine</organization>
<organization>Department of Anatomy, Cell Biology and Physiology</organization>
<city>Indianapolis</city>
<state>IN</state>
<country iso-code="USA" />
<ce:source-text>Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA Department of Anatomy, Cell Biology and Physiology, Indiana University School of Medicine, Indianapolis, IN, USA</ce:source-text>
</affiliation>
</author-group>
<author-group seq="2">
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
<ce:given-name>Fabrizio</ce:given-name>
</author>
<affiliation>
<organization>Department of Anatomy, Cell Biology and Physiology</organization>
<organization>Indiana University School of Medicine</organization>
<city>Indianapolis</city>
<state>IN</state>
<country iso-code="USA" />
<ce:source-text>Department of Anatomy, Cell Biology and Physiology, Indiana University School of Medicine, Indianapolis, IN, USA</ce:source-text>
</affiliation>
</author-group>
<author-group seq="3">
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
<ce:given-name>Andrea</ce:given-name>
<ce:e-address>abonetto@iu.edu</ce:e-address>
</author>
<affiliation>
<organization>Department of Otolaryngology – Head and Neck Surgery</organization>
<organization>Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA</organization>
<organization>Indiana University School of Medicine</organization>
<city>Indianapolis</city>
<state>IN</state>
<country iso-code="USA" />
<ce:source-text>Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA Department of Anatomy, Cell Biology and Physiology, Indiana University School of Medicine, Indianapolis, IN, USA Department of Otolaryngology – Head and Neck Surgery, Indiana University School of Medicine, Indianapolis, IN, USA Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA Indiana Center for Musculoskeletal Health, Indiana University School of Medicine, Indianapolis, IN, USA Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA</ce:source-text>
</affiliation>
</author-group>
<correspondence>
<person>
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
<ce:given-name>Andrea</ce:given-name>
<ce:e-address>abonetto@iu.edu</ce:e-address>
</person>
<affiliation>
<organization>Department of Surgery</organization>
<organization>Indiana University School of Medicine</organization>
<city>Indianapolis</city>
<state>IN</state>
<country iso-code="USA" />
<ce:source-text>Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA Department of Anatomy, Cell Biology and Physiology, Indiana University School of Medicine, Indianapolis, IN, USA Department of Otolaryngology – Head and Neck Surgery, Indiana University School of Medicine, Indianapolis, IN, USA Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA Indiana Center for Musculoskeletal Health, Indiana University School of Medicine, Indianapolis, IN, USA Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA</ce:source-text>
</affiliation>
</correspondence>
<abstracts>
<abstract xml:lang="ENG" original="y">
<publishercopyright>© Springer Nature Switzerland AG 2022.</publishercopyright>
<ce:para>Cancer is the second-leading cause of death worldwide. Notably, 40% of all patients suffer from cachexia, a debilitating muscle wasting syndrome that represents one of the primary causes of death in advanced cancer patients. Despite their known side effects, such as vomiting, anorexia, mucositis, neuropathy, musculoskeletal and metabolic alterations, chemotherapy treatments are the most effective and extensively used strategies against cancer. Moreover, chemotherapeutic agents may participate in and even exacerbate the pathophysiological alterations driving cachexia. Indeed, skeletal muscle atrophy and cardiac abnormalities occurring as a consequence of chemotherapy administration can worsen the response to anticancer therapies, reduce physical activity and severely impede the quality of life in cancer patients. Hence, chemotherapy-induced cachexia has recently emerged as a critical clinical problem impacting outcomes and overall survival in cancer patients. Here, we review some of the mechanism(s) through which chemotherapeutics induce musculoskeletal deficits related to cachexia. Lastly, we discuss different strategies currently under consideration to protect muscle tissue from chemotherapy-related toxicities, including nutritional interventions, mitochondria-targeted molecules, ghrelin, bisphosphonates, ACVR2B antagonists, and physical exercise.</ce:para>
</abstract>
</abstracts>
<source type="book" country="CHE">
<sourcetitle>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle>
<sourcetitle-abbrev>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle-abbrev>
<isbn type="print" length="13">9783031072727</isbn>
<isbn type="electronic" length="13">9783031095184</isbn>
<volisspag>
<page-information>
<pages>
<first-page>139</first-page>
<last-page>153</last-page>
</pages>
</page-information>
</volisspag>
<publicationyear first="2022" />
<publicationdate>
<year>2022</year>
<month>01</month>
<day>01</day>
</publicationdate>
<website type="item">
<ce:e-address type="url">https://link.springer.com/</ce:e-address>
</website>
<publisher>
<publishername>Springer International Publishing</publishername>
</publisher>
</source>
<enhancement>
<classificationgroup>
<classifications type="ASJC">
<classification>
<classification-code>2700</classification-code>
<classification-code>2400</classification-code>
<classification-code>1300</classification-code>
</classification>
</classifications>
</classificationgroup>
</enhancement>
</head>
<tail>
<bibliography refcount="157">
<reference seq="1">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer statistics, 2022</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.L.</ce:initials>
<ce:surname>Siegel</ce:surname>
<ce:given-name>R.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>CA Cancer J. Clin</ref-sourcetitle>
<ref-publicationyear first="2022" />
<volisspag>
<volume-issue-number>
<vol-first>72</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7</first-page>
<last-page>33</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Siegel, R.L., et al.: Cancer statistics, 2022. CA Cancer J. Clin. 72(1), 7–33 (2022)</ref-fulltext>
<ce:source-text>Siegel, R.L., et al.: Cancer statistics, 2022. CA Cancer J. Clin. 72(1), 7–33 (2022)</ce:source-text>
</reference>
<reference seq="2">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer epidemiology: A survey of modifiable risk factors for prevention and survivorship</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Arem</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Loftfield</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Lifestyle Med</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>200</first-page>
<last-page>210</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Arem, H., Loftfield, E.: Cancer epidemiology: A survey of modifiable risk factors for prevention and survivorship. Am. J. Lifestyle Med. 12(3), 200–210 (2018)</ref-fulltext>
<ce:source-text>Arem, H., Loftfield, E.: Cancer epidemiology: A survey of modifiable risk factors for prevention and survivorship. Am. J. Lifestyle Med. 12(3), 200–210 (2018)</ce:source-text>
</reference>
<reference seq="3">
<ref-info>
<ref-title>
<ref-titletext-english>Evolution of cancer pharmacological treatments at the turn of the third millennium</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Falzone</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Salomone</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Libra</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1300</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Falzone, L., Salomone, S., Libra, M.: Evolution of cancer pharmacological treatments at the turn of the third millennium. Front. Pharmacol. 9, 1300 (2018)</ref-fulltext>
<ce:source-text>Falzone, L., Salomone, S., Libra, M.: Evolution of cancer pharmacological treatments at the turn of the third millennium. Front. Pharmacol. 9, 1300 (2018)</ce:source-text>
</reference>
<reference seq="4">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer treatment – objectives and quality of life issues</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.A.</ce:initials>
<ce:surname>Khan</ce:surname>
<ce:given-name>F.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.S.</ce:initials>
<ce:surname>Akhtar</ce:surname>
<ce:given-name>S.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.K.</ce:initials>
<ce:surname>Sheikh</ce:surname>
<ce:given-name>M.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Malays. J. Med. Sci</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3</first-page>
<last-page>5</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Khan, F.A., Akhtar, S.S., Sheikh, M.K.: Cancer treatment – objectives and quality of life issues. Malays. J. Med. Sci. 12(1), 3–5 (2005)</ref-fulltext>
<ce:source-text>Khan, F.A., Akhtar, S.S., Sheikh, M.K.: Cancer treatment – objectives and quality of life issues. Malays. J. Med. Sci. 12(1), 3–5 (2005)</ce:source-text>
</reference>
<reference seq="5">
<ref-info>
<ref-title>
<ref-titletext-english>Assessment of the evolution of cancer treatment therapies</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Arruebo</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancers (Basel)</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3279</first-page>
<last-page>3330</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Arruebo, M., et al.: Assessment of the evolution of cancer treatment therapies. Cancers (Basel). 3(3), 3279–3330 (2011)</ref-fulltext>
<ce:source-text>Arruebo, M., et al.: Assessment of the evolution of cancer treatment therapies. Cancers (Basel). 3(3), 3279–3330 (2011)</ce:source-text>
</reference>
<reference seq="6">
<ref-info>
<ref-title>
<ref-titletext-english>Improving radiotherapy in cancer treatment: Promises and challenges</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.H.W.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>H.H.W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.T.</ce:initials>
<ce:surname>Kuo</ce:surname>
<ce:given-name>M.T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>37</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>62742</first-page>
<last-page>62758</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, H.H.W., Kuo, M.T.: Improving radiotherapy in cancer treatment: Promises and challenges. Oncotarget. 8(37), 62742–62758 (2017)</ref-fulltext>
<ce:source-text>Chen, H.H.W., Kuo, M.T.: Improving radiotherapy in cancer treatment: Promises and challenges. Oncotarget. 8(37), 62742–62758 (2017)</ce:source-text>
</reference>
<reference seq="7">
<ref-info>
<ref-title>
<ref-titletext-english>Radiation oncology in the era of precision medicine. Nat</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Baumann</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>234</first-page>
<last-page>249</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baumann, M., et al.: Radiation oncology in the era of precision medicine. Nat. Rev. Cancer. 16(4), 234–249 (2016)</ref-fulltext>
<ce:source-text>Baumann, M., et al.: Radiation oncology in the era of precision medicine. Nat. Rev. Cancer. 16(4), 234–249 (2016)</ce:source-text>
</reference>
<reference seq="8">
<ref-info>
<ref-title>
<ref-titletext-english>Hormonal therapy for cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S.</ce:initials>
<ce:surname>Jacinta Abraham</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Medicine</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>44</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>30</first-page>
<last-page>33</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Jacinta Abraham, J.S.: Hormonal therapy for cancer. Medicine. 44(1), 30–33 (2016)</ref-fulltext>
<ce:source-text>Jacinta Abraham, J.S.: Hormonal therapy for cancer. Medicine. 44(1), 30–33 (2016)</ce:source-text>
</reference>
<reference seq="9">
<ref-info>
<ref-title>
<ref-titletext-english>Current status and future directions of cancer immunotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1773</first-page>
<last-page>1781</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, H., Chen, J.: Current status and future directions of cancer immunotherapy. J. Cancer. 9(10), 1773–1781 (2018)</ref-fulltext>
<ce:source-text>Zhang, H., Chen, J.: Current status and future directions of cancer immunotherapy. J. Cancer. 9(10), 1773–1781 (2018)</ce:source-text>
</reference>
<reference seq="10">
<ref-info>
<ref-title>
<ref-titletext-english>Delivery strategies of cancer immunotherapy: Recent advances and future perspectives</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Zhao</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Hematol. Oncol</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Zhao, Z., et al.: Delivery strategies of cancer immunotherapy: recent advances and future perspectives. J. Hematol. Oncol. 12(1), 126 (2019)</ref-fulltext>
<ce:source-text>Zhao, Z., et al.: Delivery strategies of cancer immunotherapy: recent advances and future perspectives. J. Hematol. Oncol. 12(1), 126 (2019)</ce:source-text>
</reference>
<reference seq="11">
<ref-info>
<ref-title>
<ref-titletext-english>Alkylating Agents, in Livertox: Clinical and Research Information on Drug-Induced Liver Injury</ref-titletext-english>
</ref-title>
<ref-publicationyear first="2012" />
<ref-text>Bethesda (MD)</ref-text>
</ref-info>
<ref-fulltext>Alkylating Agents, in LiverTox: Clinical and research information on drug-induced liver injury. 2012: Bethesda (MD)</ref-fulltext>
<ce:source-text>Alkylating Agents, in LiverTox: Clinical and research information on drug-induced liver injury. 2012: Bethesda (MD)</ce:source-text>
</reference>
<reference seq="12">
<ref-info>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Lansiaux</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Antimetabolites. Bull. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>98</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1263</first-page>
<last-page>1274</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lansiaux, A.: Antimetabolites. Bull. Cancer. 98(11), 1263–1274 (2011)</ref-fulltext>
<ce:source-text>Lansiaux, A.: Antimetabolites. Bull. Cancer. 98(11), 1263–1274 (2011)</ce:source-text>
</reference>
<reference seq="13">
<ref-info>
<ref-title>
<ref-titletext-english>Topoisomerase I inhibitors: Camptothecins and beyond</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Pommier</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>789</first-page>
<last-page>802</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pommier, Y.: Topoisomerase I inhibitors: Camptothecins and beyond. Nat. Rev. Cancer. 6(10), 789–802 (2006)</ref-fulltext>
<ce:source-text>Pommier, Y.: Topoisomerase I inhibitors: Camptothecins and beyond. Nat. Rev. Cancer. 6(10), 789–802 (2006)</ce:source-text>
</reference>
<reference seq="14">
<ref-info>
<ref-title>
<ref-titletext-english>Vinca alkaloids</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Moudi</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Prev. Med.</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1231</first-page>
<last-page>1235</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Moudi, M., et al.: Vinca alkaloids. Int. J. Prev. Med. 4(11), 1231–1235 (2013)</ref-fulltext>
<ce:source-text>Moudi, M., et al.: Vinca alkaloids. Int. J. Prev. Med. 4(11), 1231–1235 (2013)</ce:source-text>
</reference>
<reference seq="15">
<ref-info>
<ref-title>
<ref-titletext-english>Taxane pathway. Pharmacogenet</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Oshiro</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Genomics</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>979</first-page>
<last-page>983</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Oshiro, C., et al.: Taxane pathway. Pharmacogenet. Genomics. 19(12), 979–983 (2009)</ref-fulltext>
<ce:source-text>Oshiro, C., et al.: Taxane pathway. Pharmacogenet. Genomics. 19(12), 979–983 (2009)</ce:source-text>
</reference>
<reference seq="16">
<ref-info>
<ref-title>
<ref-titletext-english>Editorial: Adverse effects of cancer chemotherapy: Anything new to improve tolerance and reduce sequelae?</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Nurgali</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.T.</ce:initials>
<ce:surname>Jagoe</ce:surname>
<ce:given-name>R.T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Abalo</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Nurgali, K., Jagoe, R.T., Abalo, R.: Editorial: Adverse effects of cancer chemotherapy: Anything new to improve tolerance and reduce sequelae? Front. Pharmacol. 9, 245 (2018)</ref-fulltext>
<ce:source-text>Nurgali, K., Jagoe, R.T., Abalo, R.: Editorial: Adverse effects of cancer chemotherapy: Anything new to improve tolerance and reduce sequelae? Front. Pharmacol. 9, 245 (2018)</ce:source-text>
</reference>
<reference seq="17">
<ref-info>
<ref-title>
<ref-titletext-english>Experiences and consequences of altered taste, flavour and food hedonics during chemotherapy treatment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Boltong</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Keast</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Aranda</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Support Care Cancer</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2765</first-page>
<last-page>2774</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Boltong, A., Keast, R., Aranda, S.: Experiences and consequences of altered taste, flavour and food hedonics during chemotherapy treatment. Support Care Cancer. 20(11), 2765–2774 (2012)</ref-fulltext>
<ce:source-text>Boltong, A., Keast, R., Aranda, S.: Experiences and consequences of altered taste, flavour and food hedonics during chemotherapy treatment. Support Care Cancer. 20(11), 2765–2774 (2012)</ce:source-text>
</reference>
<reference seq="18">
<ref-info>
<ref-title>
<ref-titletext-english>Drug-induced myelosuppression: Diagnosis and management</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.J.</ce:initials>
<ce:surname>Carey</ce:surname>
<ce:given-name>P.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Drug Saf</ref-sourcetitle>
<ref-publicationyear first="2003" />
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>691</first-page>
<last-page>706</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Carey, P.J.: Drug-induced myelosuppression: diagnosis and management. Drug Saf. 26(10), 691–706 (2003)</ref-fulltext>
<ce:source-text>Carey, P.J.: Drug-induced myelosuppression: diagnosis and management. Drug Saf. 26(10), 691–706 (2003)</ce:source-text>
</reference>
<reference seq="19">
<ref-info>
<ref-title>
<ref-titletext-english>Delayed chemotherapy-induced nausea and vomiting: Pathogenesis, incidence, and current management. Front</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.L.</ce:initials>
<ce:surname>Rapoport</ce:surname>
<ce:given-name>B.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>19</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rapoport, B.L.: Delayed chemotherapy-induced nausea and vomiting: Pathogenesis, incidence, and current management. Front. Pharmacol. 8, 19 (2017)</ref-fulltext>
<ce:source-text>Rapoport, B.L.: Delayed chemotherapy-induced nausea and vomiting: Pathogenesis, incidence, and current management. Front. Pharmacol. 8, 19 (2017)</ce:source-text>
</reference>
<reference seq="20">
<ref-info>
<ref-title>
<ref-titletext-english>The role of vagal neurocircuits in the regulation of nausea and vomiting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Babic</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.N.</ce:initials>
<ce:surname>Browning</ce:surname>
<ce:given-name>K.N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>722</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>38</first-page>
<last-page>47</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Babic, T., Browning, K.N.: The role of vagal neurocircuits in the regulation of nausea and vomiting. Eur. J. Pharmacol. 722, 38–47 (2014)</ref-fulltext>
<ce:source-text>Babic, T., Browning, K.N.: The role of vagal neurocircuits in the regulation of nausea and vomiting. Eur. J. Pharmacol. 722, 38–47 (2014)</ce:source-text>
</reference>
<reference seq="21">
<ref-info>
<ref-title>
<ref-titletext-english>GDF15 Induces Anorexia through Nausea and Emesis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Borner</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2020" />
</ref-info>
<ref-fulltext>Borner, T., et al.: GDF15 Induces Anorexia through Nausea and Emesis. Cell Metab. (2020)</ref-fulltext>
<ce:source-text>Borner, T., et al.: GDF15 Induces Anorexia through Nausea and Emesis. Cell Metab. (2020)</ce:source-text>
</reference>
<reference seq="22">
<ref-info>
<ref-title>
<ref-titletext-english>The MIC-1/GDF15-GFRAL pathway in energy homeostasis: Implications for obesity, cachexia, and other associated diseases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.W.W.</ce:initials>
<ce:surname>Tsai</ce:surname>
<ce:given-name>V.W.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>353</first-page>
<last-page>368</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tsai, V.W.W., et al.: The MIC-1/GDF15-GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases. Cell Metab. 28(3), 353–368 (2018)</ref-fulltext>
<ce:source-text>Tsai, V.W.W., et al.: The MIC-1/GDF15-GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases. Cell Metab. 28(3), 353–368 (2018)</ce:source-text>
</reference>
<reference seq="23">
<ref-info>
<ref-title>
<ref-titletext-english>New frontiers in the pathobiology and treatment of cancer regimen-related mucosal injury</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Cinausero</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>354</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cinausero, M., et al.: New frontiers in the pathobiology and treatment of cancer regimen-related mucosal injury. Front. Pharmacol. 8, 354 (2017)</ref-fulltext>
<ce:source-text>Cinausero, M., et al.: New frontiers in the pathobiology and treatment of cancer regimen-related mucosal injury. Front. Pharmacol. 8, 354 (2017)</ce:source-text>
</reference>
<reference seq="24">
<ref-info>
<ref-title>
<ref-titletext-english>Treatment of oral mucositis due to chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Chaveli-Lopez</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.V.</ce:initials>
<ce:surname>Bagan-Sebastian</ce:surname>
<ce:given-name>J.V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J Clin Exp Dent</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>e201</first-page>
<last-page>e209</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chaveli-Lopez, B., Bagan-Sebastian, J.V.: Treatment of oral mucositis due to chemotherapy. J Clin Exp Dent. 8(2), e201–e209 (2016)</ref-fulltext>
<ce:source-text>Chaveli-Lopez, B., Bagan-Sebastian, J.V.: Treatment of oral mucositis due to chemotherapy. J Clin Exp Dent. 8(2), e201–e209 (2016)</ce:source-text>
</reference>
<reference seq="25">
<ref-info>
<ref-title>
<ref-titletext-english>Mechanisms of chemotherapy-induced peripheral neuropathy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Zajaczkowska</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Mol. Sci</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Zajaczkowska, R., et al.: Mechanisms of chemotherapy-induced peripheral neuropathy. Int. J. Mol. Sci. 20(6) (2019)</ref-fulltext>
<ce:source-text>Zajaczkowska, R., et al.: Mechanisms of chemotherapy-induced peripheral neuropathy. Int. J. Mol. Sci. 20(6) (2019)</ce:source-text>
</reference>
<reference seq="26">
<ref-info>
<ref-title>
<ref-titletext-english>The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.A.</ce:initials>
<ce:surname>Kolb</ce:surname>
<ce:given-name>N.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>JAMA Neurol</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>73</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>860</first-page>
<last-page>866</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kolb, N.A., et al.: The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling. JAMA Neurol. 73(7), 860–866 (2016)</ref-fulltext>
<ce:source-text>Kolb, N.A., et al.: The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling. JAMA Neurol. 73(7), 860–866 (2016)</ce:source-text>
</reference>
<reference seq="27">
<ref-info>
<ref-title>
<ref-titletext-english>Chemotherapy, cognitive impairment and hippocampal toxicity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Dietrich</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Prust</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Kaiser</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Neuroscience</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>309</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>224</first-page>
<last-page>232</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dietrich, J., Prust, M., Kaiser, J.: Chemotherapy, cognitive impairment and hippocampal toxicity. Neuroscience. 309, 224–232 (2015)</ref-fulltext>
<ce:source-text>Dietrich, J., Prust, M., Kaiser, J.: Chemotherapy, cognitive impairment and hippocampal toxicity. Neuroscience. 309, 224–232 (2015)</ce:source-text>
</reference>
<reference seq="28">
<ref-info>
<ref-title>
<ref-titletext-english>Longitudinal assessment of chemotherapy-induced changes in brain and cognitive functioning: A systematic review</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Caeyenberghs</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Neurosci. Biobehav. Rev</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>92</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>304</first-page>
<last-page>317</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Li, M., Caeyenberghs, K.: Longitudinal assessment of chemotherapy-induced changes in brain and cognitive functioning: A systematic review. Neurosci. Biobehav. Rev. 92, 304–317 (2018)</ref-fulltext>
<ce:source-text>Li, M., Caeyenberghs, K.: Longitudinal assessment of chemotherapy-induced changes in brain and cognitive functioning: A systematic review. Neurosci. Biobehav. Rev. 92, 304–317 (2018)</ce:source-text>
</reference>
<reference seq="29">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer- and chemotherapy-induced musculoskeletal degradation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.M.</ce:initials>
<ce:surname>Sturgeon</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>JBMR Plus</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Sturgeon, K.M., et al.: Cancer- and chemotherapy-induced musculoskeletal degradation. JBMR Plus. 3(3), e10187 (2019)</ref-fulltext>
<ce:source-text>Sturgeon, K.M., et al.: Cancer- and chemotherapy-induced musculoskeletal degradation. JBMR Plus. 3(3), e10187 (2019)</ce:source-text>
</reference>
<reference seq="30">
<ref-info>
<ref-title>
<ref-titletext-english>Glucocorticoid-induced osteoporosis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.J.</ce:initials>
<ce:surname>Baylink</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>N. Engl. J. Med</ref-sourcetitle>
<ref-publicationyear first="1983" />
<volisspag>
<volume-issue-number>
<vol-first>309</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>306</first-page>
<last-page>308</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baylink, D.J.: Glucocorticoid-induced osteoporosis. N. Engl. J. Med. 309(5), 306–308 (1983)</ref-fulltext>
<ce:source-text>Baylink, D.J.: Glucocorticoid-induced osteoporosis. N. Engl. J. Med. 309(5), 306–308 (1983)</ce:source-text>
</reference>
<reference seq="31">
<ref-info>
<ref-title>
<ref-titletext-english>Myelosuppressive therapies significantly increase pro-inflammatory cytokines and directly cause bone loss</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Quach</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Bone Miner. Res</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>886</first-page>
<last-page>897</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Quach, J.M., et al.: Myelosuppressive therapies significantly increase pro-inflammatory cytokines and directly cause bone loss. J. Bone Miner. Res. 30(5), 886–897 (2015)</ref-fulltext>
<ce:source-text>Quach, J.M., et al.: Myelosuppressive therapies significantly increase pro-inflammatory cytokines and directly cause bone loss. J. Bone Miner. Res. 30(5), 886–897 (2015)</ce:source-text>
</reference>
<reference seq="32">
<ref-info>
<ref-title>
<ref-titletext-english>Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Saarto</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="1997" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1341</first-page>
<last-page>1347</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Saarto, T., et al.: Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients. J. Clin. Oncol. 15(4), 1341–1347 (1997)</ref-fulltext>
<ce:source-text>Saarto, T., et al.: Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients. J. Clin. Oncol. 15(4), 1341–1347 (1997)</ce:source-text>
</reference>
<reference seq="33">
<ref-info>
<ref-title>
<ref-titletext-english>ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Barreto</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Barreto, R., et al.: ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass. Sci. Rep. 7(1), 14470 (2017)</ref-fulltext>
<ce:source-text>Barreto, R., et al.: ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass. Sci. Rep. 7(1), 14470 (2017)</ce:source-text>
</reference>
<reference seq="34">
<ref-info>
<ref-title>
<ref-titletext-english>Chemotherapy-induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.A.</ce:initials>
<ce:surname>Hain</ce:surname>
<ce:given-name>B.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>JCSM Rapid Commun</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Hain, B.A., et al.: Chemotherapy-induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia. JCSM Rapid Commun. 2(1) (2019)</ref-fulltext>
<ce:source-text>Hain, B.A., et al.: Chemotherapy-induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia. JCSM Rapid Commun. 2(1) (2019)</ce:source-text>
</reference>
<reference seq="35">
<ref-info>
<ref-title>
<ref-titletext-english>Bisphosphonate treatment ameliorates chemotherapy-induced bone and muscle abnormalities in young mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.L.</ce:initials>
<ce:surname>Essex</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Endocrinol. (Lausanne).</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Essex, A.L., et al.: Bisphosphonate treatment ameliorates chemotherapy-induced bone and muscle abnormalities in young mice. Front. Endocrinol. (Lausanne). 10, 809 (2019)</ref-fulltext>
<ce:source-text>Essex, A.L., et al.: Bisphosphonate treatment ameliorates chemotherapy-induced bone and muscle abnormalities in young mice. Front. Endocrinol. (Lausanne). 10, 809 (2019)</ce:source-text>
</reference>
<reference seq="36">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer and chemotherapy contribute to muscle loss by activating common signaling pathways</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Barreto</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Physiol</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Barreto, R., et al.: Cancer and chemotherapy contribute to muscle loss by activating common signaling pathways. Front. Physiol. 7, 472 (2016)</ref-fulltext>
<ce:source-text>Barreto, R., et al.: Cancer and chemotherapy contribute to muscle loss by activating common signaling pathways. Front. Physiol. 7, 472 (2016)</ce:source-text>
</reference>
<reference seq="37">
<ref-info>
<ref-title>
<ref-titletext-english>Fatigue and quality of life outcomes of exercise during cancer treatment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.</ce:initials>
<ce:surname>Mock</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Pract</ref-sourcetitle>
<ref-publicationyear first="2001" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>119</first-page>
<last-page>127</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mock, V., et al.: Fatigue and quality of life outcomes of exercise during cancer treatment. Cancer Pract. 9(3), 119–127 (2001)</ref-fulltext>
<ce:source-text>Mock, V., et al.: Fatigue and quality of life outcomes of exercise during cancer treatment. Cancer Pract. 9(3), 119–127 (2001)</ce:source-text>
</reference>
<reference seq="38">
<ref-info>
<ref-title>
<ref-titletext-english>Chemotherapy-induced muscle wasting: Association with NF-kappaB and cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S.</ce:initials>
<ce:surname>Damrauer</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Transl. Myol</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Damrauer, J.S., et al.: Chemotherapy-induced muscle wasting: Association with NF-kappaB and cancer cachexia. Eur. J. Transl. Myol. 28(2), 7590 (2018)</ref-fulltext>
<ce:source-text>Damrauer, J.S., et al.: Chemotherapy-induced muscle wasting: Association with NF-kappaB and cancer cachexia. Eur. J. Transl. Myol. 28(2), 7590 (2018)</ce:source-text>
</reference>
<reference seq="39">
<ref-info>
<ref-title>
<ref-titletext-english>Preservation of muscle mass as a strategy to reduce the toxic effects of cancer chemotherapy on body composition</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.E.</ce:initials>
<ce:surname>Couch</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Opin. Support. Palliat. Care</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>420</first-page>
<last-page>426</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pin, F., Couch, M.E., Bonetto, A.: Preservation of muscle mass as a strategy to reduce the toxic effects of cancer chemotherapy on body composition. Curr. Opin. Support. Palliat. Care. 12(4), 420–426 (2018)</ref-fulltext>
<ce:source-text>Pin, F., Couch, M.E., Bonetto, A.: Preservation of muscle mass as a strategy to reduce the toxic effects of cancer chemotherapy on body composition. Curr. Opin. Support. Palliat. Care. 12(4), 420–426 (2018)</ce:source-text>
</reference>
<reference seq="40">
<ref-info>
<ref-title>
<ref-titletext-english>Negative impact of cancer chemotherapy on protein metabolism in healthy and tumor-bearing rats</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Le Bricon</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Metabolism</ref-sourcetitle>
<ref-publicationyear first="1995" />
<volisspag>
<volume-issue-number>
<vol-first>44</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1340</first-page>
<last-page>1348</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Le Bricon, T., et al.: Negative impact of cancer chemotherapy on protein metabolism in healthy and tumor-bearing rats. Metabolism. 44(10), 1340–1348 (1995)</ref-fulltext>
<ce:source-text>Le Bricon, T., et al.: Negative impact of cancer chemotherapy on protein metabolism in healthy and tumor-bearing rats. Metabolism. 44(10), 1340–1348 (1995)</ce:source-text>
</reference>
<reference seq="41">
<ref-info>
<ref-title>
<ref-titletext-english>Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Crawford</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>68</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Crawford, S.: Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy. Front. Pharmacol. 4, 68 (2013)</ref-fulltext>
<ce:source-text>Crawford, S.: Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy. Front. Pharmacol. 4, 68 (2013)</ce:source-text>
</reference>
<reference seq="42">
<ref-info>
<ref-title>
<ref-titletext-english>Definition and classification of cancer cachexia: An international consensus</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Lancet Oncol</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>489</first-page>
<last-page>495</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fearon, K., et al.: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 12(5), 489–495 (2011)</ref-fulltext>
<ce:source-text>Fearon, K., et al.: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 12(5), 489–495 (2011)</ce:source-text>
</reference>
<reference seq="43">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer statistics, 2012</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Siegel</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Naishadham</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Jemal</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>CA Cancer J. Clin</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>62</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>10</first-page>
<last-page>29</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Siegel, R., Naishadham, D., Jemal, A.: Cancer statistics, 2012. CA Cancer J. Clin. 62(1), 10–29 (2012)</ref-fulltext>
<ce:source-text>Siegel, R., Naishadham, D., Jemal, A.: Cancer statistics, 2012. CA Cancer J. Clin. 62(1), 10–29 (2012)</ce:source-text>
</reference>
<reference seq="44">
<ref-info>
<ref-title>
<ref-titletext-english>Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Thoresen</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>65</first-page>
<last-page>72</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Thoresen, L., et al.: Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results. Clin. Nutr. 32(1), 65–72 (2013)</ref-fulltext>
<ce:source-text>Thoresen, L., et al.: Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results. Clin. Nutr. 32(1), 65–72 (2013)</ce:source-text>
</reference>
<reference seq="45">
<ref-info>
<ref-title>
<ref-titletext-english>Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Barreto</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>28</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>43442</first-page>
<last-page>43460</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Barreto, R., et al.: Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs. Oncotarget. 7(28), 43442–43460 (2016)</ref-fulltext>
<ce:source-text>Barreto, R., et al.: Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs. Oncotarget. 7(28), 43442–43460 (2016)</ce:source-text>
</reference>
<reference seq="46">
<ref-info>
<ref-title>
<ref-titletext-english>Chronic treatment with multi-kinase inhibitors causes differential toxicities on skeletal and cardiac muscles</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.R.</ce:initials>
<ce:surname>Huot</ce:surname>
<ce:given-name>J.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancers (Basel)</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Huot, J.R., et al.: Chronic treatment with multi-kinase inhibitors causes differential toxicities on skeletal and cardiac muscles. Cancers (Basel). 11(4) (2019)</ref-fulltext>
<ce:source-text>Huot, J.R., et al.: Chronic treatment with multi-kinase inhibitors causes differential toxicities on skeletal and cardiac muscles. Cancers (Basel). 11(4) (2019)</ce:source-text>
</reference>
<reference seq="47">
<ref-info>
<ref-title>
<ref-titletext-english>Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>140</first-page>
<last-page>154</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pin, F., et al.: Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism. J. Cachexia. Sarcopenia Muscle. 10(1), 140–154 (2019)</ref-fulltext>
<ce:source-text>Pin, F., et al.: Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism. J. Cachexia. Sarcopenia Muscle. 10(1), 140–154 (2019)</ce:source-text>
</reference>
<reference seq="48">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non-small-cell lung cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Naito</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>BMC Cancer</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>571</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Naito, T., et al.: Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non-small-cell lung cancer. BMC Cancer. 17(1), 571 (2017)</ref-fulltext>
<ce:source-text>Naito, T., et al.: Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non-small-cell lung cancer. BMC Cancer. 17(1), 571 (2017)</ce:source-text>
</reference>
<reference seq="49">
<ref-info>
<ref-title>
<ref-titletext-english>Prognostic value of the six-minute walk in advanced non-small cell lung cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Kasymjanova</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Thorac. Oncol</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>602</first-page>
<last-page>607</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kasymjanova, G., et al.: Prognostic value of the six-minute walk in advanced non-small cell lung cancer. J. Thorac. Oncol. 4(5), 602–607 (2009)</ref-fulltext>
<ce:source-text>Kasymjanova, G., et al.: Prognostic value of the six-minute walk in advanced non-small cell lung cancer. J. Thorac. Oncol. 4(5), 602–607 (2009)</ce:source-text>
</reference>
<reference seq="50">
<ref-info>
<ref-title>
<ref-titletext-english>Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.A.</ce:initials>
<ce:surname>Kurk</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>909</first-page>
<last-page>919</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kurk, S.A., et al.: Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients. J. Cachexia. Sarcopenia Muscle. 9(5), 909–919 (2018)</ref-fulltext>
<ce:source-text>Kurk, S.A., et al.: Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients. J. Cachexia. Sarcopenia Muscle. 9(5), 909–919 (2018)</ce:source-text>
</reference>
<reference seq="51">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle strength in breast cancer patients receiving different treatment regimes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>O.</ce:initials>
<ce:surname>Klassen</ce:surname>
<ce:given-name>O.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>305</first-page>
<last-page>316</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Klassen, O., et al.: Muscle strength in breast cancer patients receiving different treatment regimes. J. Cachexia. Sarcopenia Muscle. 8(2), 305–316 (2017)</ref-fulltext>
<ce:source-text>Klassen, O., et al.: Muscle strength in breast cancer patients receiving different treatment regimes. J. Cachexia. Sarcopenia Muscle. 8(2), 305–316 (2017)</ce:source-text>
</reference>
<reference seq="52">
<ref-info>
<ref-title>
<ref-titletext-english>Weight and body composition changes during and after adjuvant chemotherapy in women with breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.J.</ce:initials>
<ce:surname>Freedman</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Endocrinol. Metab</ref-sourcetitle>
<ref-publicationyear first="2004" />
<volisspag>
<volume-issue-number>
<vol-first>89</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2248</first-page>
<last-page>2253</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Freedman, R.J., et al.: Weight and body composition changes during and after adjuvant chemotherapy in women with breast cancer. J. Clin. Endocrinol. Metab. 89(5), 2248–2253 (2004)</ref-fulltext>
<ce:source-text>Freedman, R.J., et al.: Weight and body composition changes during and after adjuvant chemotherapy in women with breast cancer. J. Clin. Endocrinol. Metab. 89(5), 2248–2253 (2004)</ce:source-text>
</reference>
<reference seq="53">
<ref-info>
<ref-title>
<ref-titletext-english>Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Awad</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>31</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>74</first-page>
<last-page>77</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Awad, S., et al.: Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clin. Nutr. 31(1), 74–77 (2012)</ref-fulltext>
<ce:source-text>Awad, S., et al.: Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clin. Nutr. 31(1), 74–77 (2012)</ce:source-text>
</reference>
<reference seq="54">
<ref-info>
<ref-title>
<ref-titletext-english>A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumab</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Poterucha</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Burnette</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Jatoi</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Med. Oncol</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>29</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1005</first-page>
<last-page>1009</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Poterucha, T., Burnette, B., Jatoi, A.: A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumab. Med. Oncol. 29(2), 1005–1009 (2012)</ref-fulltext>
<ce:source-text>Poterucha, T., Burnette, B., Jatoi, A.: A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumab. Med. Oncol. 29(2), 1005–1009 (2012)</ce:source-text>
</reference>
<reference seq="55">
<ref-info>
<ref-title>
<ref-titletext-english>Mechanisms of cisplatin-induced muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Sakai</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Toxicol. Appl. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>278</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>190</first-page>
<last-page>199</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sakai, H., et al.: Mechanisms of cisplatin-induced muscle atrophy. Toxicol. Appl. Pharmacol. 278(2), 190–199 (2014)</ref-fulltext>
<ce:source-text>Sakai, H., et al.: Mechanisms of cisplatin-induced muscle atrophy. Toxicol. Appl. Pharmacol. 278(2), 190–199 (2014)</ce:source-text>
</reference>
<reference seq="56">
<ref-info>
<ref-title>
<ref-titletext-english>Taurine rescues cisplatin-induced muscle atrophy in vitro: A morphological study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Stacchiotti</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oxidative Med. Cell. Longev</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>2014</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Stacchiotti, A., et al.: Taurine rescues cisplatin-induced muscle atrophy in vitro: A morphological study. Oxidative Med. Cell. Longev. 2014, 840951 (2014)</ref-fulltext>
<ce:source-text>Stacchiotti, A., et al.: Taurine rescues cisplatin-induced muscle atrophy in vitro: A morphological study. Oxidative Med. Cell. Longev. 2014, 840951 (2014)</ce:source-text>
</reference>
<reference seq="57">
<ref-info>
<ref-title>
<ref-titletext-english>Oxaliplatin induces muscle loss and muscle-specific molecular changes in Mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.E.</ce:initials>
<ce:surname>Feather</ce:surname>
<ce:given-name>C.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Muscle Nerve</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>57</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>650</first-page>
<last-page>658</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Feather, C.E., et al.: Oxaliplatin induces muscle loss and muscle-specific molecular changes in Mice. Muscle Nerve. 57(4), 650–658 (2018)</ref-fulltext>
<ce:source-text>Feather, C.E., et al.: Oxaliplatin induces muscle loss and muscle-specific molecular changes in Mice. Muscle Nerve. 57(4), 650–658 (2018)</ce:source-text>
</reference>
<reference seq="58">
<ref-info>
<ref-title>
<ref-titletext-english>BGP-15 protects against oxaliplatin-induced skeletal myopathy and mitochondrial reactive oxygen species production in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.C.</ce:initials>
<ce:surname>Sorensen</ce:surname>
<ce:given-name>J.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>137</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sorensen, J.C., et al.: BGP-15 protects against oxaliplatin-induced skeletal myopathy and mitochondrial reactive oxygen species production in mice. Front. Pharmacol. 8, 137 (2017)</ref-fulltext>
<ce:source-text>Sorensen, J.C., et al.: BGP-15 protects against oxaliplatin-induced skeletal myopathy and mitochondrial reactive oxygen species production in mice. Front. Pharmacol. 8, 137 (2017)</ce:source-text>
</reference>
<reference seq="59">
<ref-info>
<ref-title>
<ref-titletext-english>Zoledronic acid improves muscle function in healthy mice treated with chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.A.</ce:initials>
<ce:surname>Hain</ce:surname>
<ce:given-name>B.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Bone Miner. Res</ref-sourcetitle>
<ref-publicationyear first="2019" />
</ref-info>
<ref-fulltext>Hain, B.A., et al.: Zoledronic acid improves muscle function in healthy mice treated with chemotherapy. J. Bone Miner. Res. (2019)</ref-fulltext>
<ce:source-text>Hain, B.A., et al.: Zoledronic acid improves muscle function in healthy mice treated with chemotherapy. J. Bone Miner. Res. (2019)</ce:source-text>
</reference>
<reference seq="60">
<ref-info>
<ref-title>
<ref-titletext-english>Aerobic exercise, but not metformin, prevents reduction of muscular performance by AMPk activation in mice on doxorubicin chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.A.</ce:initials>
<ce:surname>de Lima</ce:surname>
<ce:given-name>E.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Physiol</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>233</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>9652</first-page>
<last-page>9662</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>de Lima, E.A., et al.: Aerobic exercise, but not metformin, prevents reduction of muscular performance by AMPk activation in mice on doxorubicin chemotherapy. J. Cell. Physiol. 233(12), 9652–9662 (2018)</ref-fulltext>
<ce:source-text>de Lima, E.A., et al.: Aerobic exercise, but not metformin, prevents reduction of muscular performance by AMPk activation in mice on doxorubicin chemotherapy. J. Cell. Physiol. 233(12), 9652–9662 (2018)</ce:source-text>
</reference>
<reference seq="61">
<ref-info>
<ref-title>
<ref-titletext-english>Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.J.</ce:initials>
<ce:surname>Hulmi</ce:surname>
<ce:given-name>J.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>417</first-page>
<last-page>432</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hulmi, J.J., et al.: Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle. J. Cachexia. Sarcopenia Muscle. 9(2), 417–432 (2018)</ref-fulltext>
<ce:source-text>Hulmi, J.J., et al.: Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle. J. Cachexia. Sarcopenia Muscle. 9(2), 417–432 (2018)</ce:source-text>
</reference>
<reference seq="62">
<ref-info>
<ref-title>
<ref-titletext-english>Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.A.</ce:initials>
<ce:surname>Nissinen</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Nissinen, T.A., et al.: Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes. Sci. Rep. 6, 32695 (2016)</ref-fulltext>
<ce:source-text>Nissinen, T.A., et al.: Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes. Sci. Rep. 6, 32695 (2016)</ce:source-text>
</reference>
<reference seq="63">
<ref-info>
<ref-title>
<ref-titletext-english>Endurance exercise protects skeletal muscle against both doxorubicin-induced and inactivity-induced muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.K.</ce:initials>
<ce:surname>Powers</ce:surname>
<ce:given-name>S.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Pflugers Arch</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>471</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>441</first-page>
<last-page>453</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Powers, S.K., et al.: Endurance exercise protects skeletal muscle against both doxorubicin-induced and inactivity-induced muscle wasting. Pflugers Arch. 471(3), 441–453 (2019)</ref-fulltext>
<ce:source-text>Powers, S.K., et al.: Endurance exercise protects skeletal muscle against both doxorubicin-induced and inactivity-induced muscle wasting. Pflugers Arch. 471(3), 441–453 (2019)</ce:source-text>
</reference>
<reference seq="64">
<ref-info>
<ref-title>
<ref-titletext-english>Ibudilast attenuates doxorubicin-induced cytotoxicity by suppressing formation of TRPC3 channel and NADPH oxidase 2 protein complexes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Nishiyama</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>176</vol-first>
<iss-first>18</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3723</first-page>
<last-page>3738</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nishiyama, K., et al.: Ibudilast attenuates doxorubicin-induced cytotoxicity by suppressing formation of TRPC3 channel and NADPH oxidase 2 protein complexes. Br. J. Pharmacol. 176(18), 3723–3738 (2019)</ref-fulltext>
<ce:source-text>Nishiyama, K., et al.: Ibudilast attenuates doxorubicin-induced cytotoxicity by suppressing formation of TRPC3 channel and NADPH oxidase 2 protein complexes. Br. J. Pharmacol. 176(18), 3723–3738 (2019)</ce:source-text>
</reference>
<reference seq="65">
<ref-info>
<ref-title>
<ref-titletext-english>Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.D.</ce:initials>
<ce:surname>Dewys</ce:surname>
<ce:given-name>W.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Med</ref-sourcetitle>
<ref-publicationyear first="1980" />
<volisspag>
<volume-issue-number>
<vol-first>69</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>491</first-page>
<last-page>497</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dewys, W.D., et al.: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am. J. Med. 69(4), 491–497 (1980)</ref-fulltext>
<ce:source-text>Dewys, W.D., et al.: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am. J. Med. 69(4), 491–497 (1980)</ce:source-text>
</reference>
<reference seq="66">
<ref-info>
<ref-title>
<ref-titletext-english>Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Grothey</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Lancet</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>381</vol-first>
<iss-first>9863</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>303</first-page>
<last-page>312</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Grothey, A., et al.: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 381(9863), 303–312 (2013)</ref-fulltext>
<ce:source-text>Grothey, A., et al.: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 381(9863), 303–312 (2013)</ce:source-text>
</reference>
<reference seq="67">
<ref-info>
<ref-title>
<ref-titletext-english>In a ‘real-world’, clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survival</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Shingina</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Can. J. Gastroenterol</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>393</first-page>
<last-page>396</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shingina, A., et al.: In a ‘real-world’, clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survival. Can. J. Gastroenterol. 27(7), 393–396 (2013)</ref-fulltext>
<ce:source-text>Shingina, A., et al.: In a ‘real-world’, clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survival. Can. J. Gastroenterol. 27(7), 393–396 (2013)</ce:source-text>
</reference>
<reference seq="68">
<ref-info>
<ref-title>
<ref-titletext-english>Growth hormone secretagogues hexarelin and JMV2894 protect skeletal muscle from mitochondrial damages in a rat model of cisplatin-induced cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Sirago</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Sirago, G., et al.: Growth hormone secretagogues hexarelin and JMV2894 protect skeletal muscle from mitochondrial damages in a rat model of cisplatin-induced cachexia. Sci. Rep. 7(1), 13017 (2017)</ref-fulltext>
<ce:source-text>Sirago, G., et al.: Growth hormone secretagogues hexarelin and JMV2894 protect skeletal muscle from mitochondrial damages in a rat model of cisplatin-induced cachexia. Sci. Rep. 7(1), 13017 (2017)</ce:source-text>
</reference>
<reference seq="69">
<ref-info>
<ref-title>
<ref-titletext-english>Doxorubicin causes lesions in the electron transport system of skeletal muscle mitochondria that are associated with a loss of contractile function</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.D.</ce:initials>
<ce:surname>Tarpey</ce:surname>
<ce:given-name>M.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>294</vol-first>
<iss-first>51</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>19709</first-page>
<last-page>19722</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tarpey, M.D., et al.: Doxorubicin causes lesions in the electron transport system of skeletal muscle mitochondria that are associated with a loss of contractile function. J. Biol. Chem. 294(51), 19709–19722 (2019)</ref-fulltext>
<ce:source-text>Tarpey, M.D., et al.: Doxorubicin causes lesions in the electron transport system of skeletal muscle mitochondria that are associated with a loss of contractile function. J. Biol. Chem. 294(51), 19709–19722 (2019)</ce:source-text>
</reference>
<reference seq="70">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle weakness and neuromuscular junctions in aging and disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Shigemoto</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Geriatr Gerontol Int</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>S137</first-page>
<last-page>S147</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shigemoto, K., et al.: Muscle weakness and neuromuscular junctions in aging and disease. Geriatr Gerontol Int. 10(Suppl 1), S137–S147 (2010)</ref-fulltext>
<ce:source-text>Shigemoto, K., et al.: Muscle weakness and neuromuscular junctions in aging and disease. Geriatr Gerontol Int. 10(Suppl 1), S137–S147 (2010)</ce:source-text>
</reference>
<reference seq="71">
<ref-info>
<ref-title>
<ref-titletext-english>Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content. Hum. Mol</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.J.</ce:initials>
<ce:surname>de Vos</ce:surname>
<ce:given-name>K.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Genet</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
<iss-first>22</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2720</first-page>
<last-page>2728</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>De Vos, K.J., et al.: Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content. Hum. Mol. Genet. 16(22), 2720–2728 (2007)</ref-fulltext>
<ce:source-text>De Vos, K.J., et al.: Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content. Hum. Mol. Genet. 16(22), 2720–2728 (2007)</ce:source-text>
</reference>
<reference seq="72">
<ref-info>
<ref-title>
<ref-titletext-english>Mitochondrial dynamics and bioenergetic dysfunction is associated with synaptic alterations in mutant SOD1 motor neurons</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Magrane</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Neurosci</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>229</first-page>
<last-page>242</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Magrane, J., et al.: Mitochondrial dynamics and bioenergetic dysfunction is associated with synaptic alterations in mutant SOD1 motor neurons. J. Neurosci. 32(1), 229–242 (2012)</ref-fulltext>
<ce:source-text>Magrane, J., et al.: Mitochondrial dynamics and bioenergetic dysfunction is associated with synaptic alterations in mutant SOD1 motor neurons. J. Neurosci. 32(1), 229–242 (2012)</ce:source-text>
</reference>
<reference seq="73">
<ref-info>
<ref-title>
<ref-titletext-english>Neuromuscular disease: Mitochondrial dysfunction could precipitate motor neuron loss in spinal muscular atrophy. Nat</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Malkki</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Rev. Neurol</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>556</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Malkki, H.: Neuromuscular disease: mitochondrial dysfunction could precipitate motor neuron loss in spinal muscular atrophy. Nat. Rev. Neurol. 12(10), 556 (2016)</ref-fulltext>
<ce:source-text>Malkki, H.: Neuromuscular disease: mitochondrial dysfunction could precipitate motor neuron loss in spinal muscular atrophy. Nat. Rev. Neurol. 12(10), 556 (2016)</ce:source-text>
</reference>
<reference seq="74">
<ref-info>
<ref-title>
<ref-titletext-english>Mitochondrial oxidative stress impairs contractile function but paradoxically increases muscle mass via fibre branching</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Ahn</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>411</first-page>
<last-page>428</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ahn, B., et al.: Mitochondrial oxidative stress impairs contractile function but paradoxically increases muscle mass via fibre branching. J. Cachexia. Sarcopenia Muscle. 10(2), 411–428 (2019)</ref-fulltext>
<ce:source-text>Ahn, B., et al.: Mitochondrial oxidative stress impairs contractile function but paradoxically increases muscle mass via fibre branching. J. Cachexia. Sarcopenia Muscle. 10(2), 411–428 (2019)</ce:source-text>
</reference>
<reference seq="75">
<ref-info>
<ref-title>
<ref-titletext-english>Regulation of nicotinic acetylcholine receptor turnover by MuRF1 connects muscle activity to endo/lysosomal and atrophy pathways</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Rudolf</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Age (Dordr.).</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1663</first-page>
<last-page>1674</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rudolf, R., et al.: Regulation of nicotinic acetylcholine receptor turnover by MuRF1 connects muscle activity to endo/lysosomal and atrophy pathways. Age (Dordr.). 35(5), 1663–1674 (2013)</ref-fulltext>
<ce:source-text>Rudolf, R., et al.: Regulation of nicotinic acetylcholine receptor turnover by MuRF1 connects muscle activity to endo/lysosomal and atrophy pathways. Age (Dordr.). 35(5), 1663–1674 (2013)</ce:source-text>
</reference>
<reference seq="76">
<ref-info>
<ref-title>
<ref-titletext-english>D-methionine ameliorates cisplatin-induced muscle atrophy via inhibition of muscle degradation pathway</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.T.</ce:initials>
<ce:surname>Wu</ce:surname>
<ce:given-name>C.T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Integr. Cancer Ther</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Wu, C.T., et al.: D-methionine ameliorates cisplatin-induced muscle atrophy via inhibition of muscle degradation pathway. Integr. Cancer Ther. 18, 1534735419828832 (2019)</ref-fulltext>
<ce:source-text>Wu, C.T., et al.: D-methionine ameliorates cisplatin-induced muscle atrophy via inhibition of muscle degradation pathway. Integr. Cancer Ther. 18, 1534735419828832 (2019)</ce:source-text>
</reference>
<reference seq="77">
<ref-info>
<ref-title>
<ref-titletext-english>Role of oxidative stress in oxaliplatin-induced enteric neuropathy and colonic dysmotility in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.M.</ce:initials>
<ce:surname>McQuade</ce:surname>
<ce:given-name>R.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>173</vol-first>
<iss-first>24</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3502</first-page>
<last-page>3521</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>McQuade, R.M., et al.: Role of oxidative stress in oxaliplatin-induced enteric neuropathy and colonic dysmotility in mice. Br. J. Pharmacol. 173(24), 3502–3521 (2016)</ref-fulltext>
<ce:source-text>McQuade, R.M., et al.: Role of oxidative stress in oxaliplatin-induced enteric neuropathy and colonic dysmotility in mice. Br. J. Pharmacol. 173(24), 3502–3521 (2016)</ce:source-text>
</reference>
<reference seq="78">
<ref-info>
<ref-title>
<ref-titletext-english>Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.G.</ce:initials>
<ce:surname>Webster</ce:surname>
<ce:given-name>R.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>146</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1027</first-page>
<last-page>1039</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Webster, R.G., et al.: Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br. J. Pharmacol. 146(7), 1027–1039 (2005)</ref-fulltext>
<ce:source-text>Webster, R.G., et al.: Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br. J. Pharmacol. 146(7), 1027–1039 (2005)</ce:source-text>
</reference>
<reference seq="79">
<ref-info>
<ref-title>
<ref-titletext-english>Modification of neuromuscular junction protein expression by exercise and doxorubicin</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.M.</ce:initials>
<ce:surname>Huertas</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Med. Sci. Sports Exerc</ref-sourcetitle>
<ref-publicationyear first="2020" />
</ref-info>
<ref-fulltext>Huertas, A.M., et al.: Modification of neuromuscular junction protein expression by exercise and doxorubicin. Med. Sci. Sports Exerc. (2020)</ref-fulltext>
<ce:source-text>Huertas, A.M., et al.: Modification of neuromuscular junction protein expression by exercise and doxorubicin. Med. Sci. Sports Exerc. (2020)</ce:source-text>
</reference>
<reference seq="80">
<ref-info>
<ref-title>
<ref-titletext-english>Neuromuscular junctions are stable in patients with cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Boehm</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="2019" />
</ref-info>
<ref-fulltext>Boehm, I., et al.: Neuromuscular junctions are stable in patients with cancer cachexia. J. Clin. Invest. (2019)</ref-fulltext>
<ce:source-text>Boehm, I., et al.: Neuromuscular junctions are stable in patients with cancer cachexia. J. Clin. Invest. (2019)</ce:source-text>
</reference>
<reference seq="81">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Penna</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Penna, F., et al.: Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition. PLoS One. 5(10), e13604 (2010)</ref-fulltext>
<ce:source-text>Penna, F., et al.: Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition. PLoS One. 5(10), e13604 (2010)</ce:source-text>
</reference>
<reference seq="82">
<ref-info>
<ref-title>
<ref-titletext-english>p38beta MAPK mediates ULK1-dependent induction of autophagy in skeletal muscle of tumor-bearing mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Stress</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>311</first-page>
<last-page>324</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Liu, Z., et al.: P38beta MAPK mediates ULK1-dependent induction of autophagy in skeletal muscle of tumor-bearing mice. Cell Stress. 2(11), 311–324 (2018)</ref-fulltext>
<ce:source-text>Liu, Z., et al.: P38beta MAPK mediates ULK1-dependent induction of autophagy in skeletal muscle of tumor-bearing mice. Cell Stress. 2(11), 311–324 (2018)</ce:source-text>
</reference>
<reference seq="83">
<ref-info>
<ref-title>
<ref-titletext-english>Selumetinib attenuates skeletal muscle wasting in murine cachexia model through ERK inhibition and AKT activation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Quan-Jun</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cancer Ther</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>334</first-page>
<last-page>343</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Quan-Jun, Y., et al.: Selumetinib attenuates skeletal muscle wasting in murine cachexia model through ERK inhibition and AKT activation. Mol. Cancer Ther. 16(2), 334–343 (2017)</ref-fulltext>
<ce:source-text>Quan-Jun, Y., et al.: Selumetinib attenuates skeletal muscle wasting in murine cachexia model through ERK inhibition and AKT activation. Mol. Cancer Ther. 16(2), 334–343 (2017)</ce:source-text>
</reference>
<reference seq="84">
<ref-info>
<ref-title>
<ref-titletext-english>Ghrelin prevents tumour- and cisplatin-induced muscle wasting: Characterization of multiple mechanisms involved</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>132</first-page>
<last-page>143</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, J.A., et al.: Ghrelin prevents tumour- and cisplatin-induced muscle wasting: Characterization of multiple mechanisms involved. J. Cachexia. Sarcopenia Muscle. 6(2), 132–143 (2015)</ref-fulltext>
<ce:source-text>Chen, J.A., et al.: Ghrelin prevents tumour- and cisplatin-induced muscle wasting: Characterization of multiple mechanisms involved. J. Cachexia. Sarcopenia Muscle. 6(2), 132–143 (2015)</ce:source-text>
</reference>
<reference seq="85">
<ref-info>
<ref-title>
<ref-titletext-english>Dexamethasone exacerbates cisplatin-induced muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Sakai</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Exp. Pharmacol. Physiol</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>46</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>19</first-page>
<last-page>28</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sakai, H., et al.: Dexamethasone exacerbates cisplatin-induced muscle atrophy. Clin. Exp. Pharmacol. Physiol. 46(1), 19–28 (2019)</ref-fulltext>
<ce:source-text>Sakai, H., et al.: Dexamethasone exacerbates cisplatin-induced muscle atrophy. Clin. Exp. Pharmacol. Physiol. 46(1), 19–28 (2019)</ce:source-text>
</reference>
<reference seq="86">
<ref-info>
<ref-title>
<ref-titletext-english>Systemic blockade of ACVR2B ligands protects myocardium from acute ischemia-reperfusion injury</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Magga</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Ther</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>600</first-page>
<last-page>610</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Magga, J., et al.: Systemic blockade of ACVR2B ligands protects myocardium from acute ischemia-reperfusion injury. Mol. Ther. 27(3), 600–610 (2019)</ref-fulltext>
<ce:source-text>Magga, J., et al.: Systemic blockade of ACVR2B ligands protects myocardium from acute ischemia-reperfusion injury. Mol. Ther. 27(3), 600–610 (2019)</ce:source-text>
</reference>
<reference seq="87">
<ref-info>
<ref-title>
<ref-titletext-english>Accelerated cardiomyocyte senescence contributes to late-onset doxorubicin-induced cardiotoxicity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.A.</ce:initials>
<ce:surname>Mitry</ce:surname>
<ce:given-name>M.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Cell Physiol</ref-sourcetitle>
<ref-publicationyear first="2020" />
</ref-info>
<ref-fulltext>Mitry, M.A., et al.: Accelerated cardiomyocyte senescence contributes to late-onset doxorubicin-induced cardiotoxicity. Am. J. Physiol. Cell Physiol. (2020)</ref-fulltext>
<ce:source-text>Mitry, M.A., et al.: Accelerated cardiomyocyte senescence contributes to late-onset doxorubicin-induced cardiotoxicity. Am. J. Physiol. Cell Physiol. (2020)</ce:source-text>
</reference>
<reference seq="88">
<ref-info>
<ref-title>
<ref-titletext-english>Dexrazoxane ameliorates doxorubicin-induced cardiotoxicity by inhibiting both apoptosis and necroptosis in cardiomyocytes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Yu</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochem. Biophys. Res. Commun</ref-sourcetitle>
<ref-publicationyear first="2019" />
</ref-info>
<ref-fulltext>Yu, X., et al.: Dexrazoxane ameliorates doxorubicin-induced cardiotoxicity by inhibiting both apoptosis and necroptosis in cardiomyocytes. Biochem. Biophys. Res. Commun. (2019)</ref-fulltext>
<ce:source-text>Yu, X., et al.: Dexrazoxane ameliorates doxorubicin-induced cardiotoxicity by inhibiting both apoptosis and necroptosis in cardiomyocytes. Biochem. Biophys. Res. Commun. (2019)</ce:source-text>
</reference>
<reference seq="89">
<ref-info>
<ref-title>
<ref-titletext-english>Pravastatin attenuates carboplatin-induced cardiotoxicity via inhibition of oxidative stress associated apoptosis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.F.</ce:initials>
<ce:surname>Cheng</ce:surname>
<ce:given-name>C.F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Apoptosis</ref-sourcetitle>
<ref-publicationyear first="2008" />
<volisspag>
<volume-issue-number>
<vol-first>13</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>883</first-page>
<last-page>894</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cheng, C.F., et al.: Pravastatin attenuates carboplatin-induced cardiotoxicity via inhibition of oxidative stress associated apoptosis. Apoptosis. 13(7), 883–894 (2008)</ref-fulltext>
<ce:source-text>Cheng, C.F., et al.: Pravastatin attenuates carboplatin-induced cardiotoxicity via inhibition of oxidative stress associated apoptosis. Apoptosis. 13(7), 883–894 (2008)</ce:source-text>
</reference>
<reference seq="90">
<ref-info>
<ref-title>
<ref-titletext-english>The effect of rutin on cisplatin-induced oxidative cardiac damage in rats</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Topal</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Anatol. J. Cardiol</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>136</first-page>
<last-page>142</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Topal, I., et al.: The effect of rutin on cisplatin-induced oxidative cardiac damage in rats. Anatol. J. Cardiol. 20(3), 136–142 (2018)</ref-fulltext>
<ce:source-text>Topal, I., et al.: The effect of rutin on cisplatin-induced oxidative cardiac damage in rats. Anatol. J. Cardiol. 20(3), 136–142 (2018)</ce:source-text>
</reference>
<reference seq="91">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia: Understanding the molecular basis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Argiles</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>754</first-page>
<last-page>762</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Argiles, J.M., et al.: Cancer cachexia: understanding the molecular basis. Nat. Rev. Cancer. 14(11), 754–762 (2014)</ref-fulltext>
<ce:source-text>Argiles, J.M., et al.: Cancer cachexia: understanding the molecular basis. Nat. Rev. Cancer. 14(11), 754–762 (2014)</ce:source-text>
</reference>
<reference seq="92">
<ref-info>
<ref-title>
<ref-titletext-english>Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Constantinou</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Mol. Med</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>15</first-page>
<last-page>24</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Constantinou, C., et al.: Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia. Int. J. Mol. Med. 27(1), 15–24 (2011)</ref-fulltext>
<ce:source-text>Constantinou, C., et al.: Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia. Int. J. Mol. Med. 27(1), 15–24 (2011)</ce:source-text>
</reference>
<reference seq="93">
<ref-info>
<ref-title>
<ref-titletext-english>On the origin of cancer cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>O.</ce:initials>
<ce:surname>Warburg</ce:surname>
<ce:given-name>O.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="1956" />
<volisspag>
<volume-issue-number>
<vol-first>123</vol-first>
<iss-first>3191</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>309</first-page>
<last-page>314</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Warburg, O.: On the origin of cancer cells. Science. 123(3191), 309–314 (1956)</ref-fulltext>
<ce:source-text>Warburg, O.: On the origin of cancer cells. Science. 123(3191), 309–314 (1956)</ce:source-text>
</reference>
<reference seq="94">
<ref-info>
<ref-title>
<ref-titletext-english>Understanding the Warburg effect: The metabolic requirements of cell proliferation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.G.</ce:initials>
<ce:surname>Vander Heiden</ce:surname>
<ce:given-name>M.G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.C.</ce:initials>
<ce:surname>Cantley</ce:surname>
<ce:given-name>L.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.B.</ce:initials>
<ce:surname>Thompson</ce:surname>
<ce:given-name>C.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>324</vol-first>
<iss-first>5930</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1029</first-page>
<last-page>1033</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vander Heiden, M.G., Cantley, L.C., Thompson, C.B.: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 324(5930), 1029–1033 (2009)</ref-fulltext>
<ce:source-text>Vander Heiden, M.G., Cantley, L.C., Thompson, C.B.: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 324(5930), 1029–1033 (2009)</ce:source-text>
</reference>
<reference seq="95">
<ref-info>
<ref-title>
<ref-titletext-english>Energy metabolism in cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Rohm</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>EMBO Rep</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rohm, M., et al.: Energy metabolism in cachexia. EMBO Rep. 20, 4 (2019)</ref-fulltext>
<ce:source-text>Rohm, M., et al.: Energy metabolism in cachexia. EMBO Rep. 20, 4 (2019)</ce:source-text>
</reference>
<reference seq="96">
<ref-info>
<ref-title>
<ref-titletext-english>Cachexia: A problem of energetic inefficiency</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Argiles</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>279</first-page>
<last-page>286</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Argiles, J.M., et al.: Cachexia: A problem of energetic inefficiency. J. Cachexia. Sarcopenia Muscle. 5(4), 279–286 (2014)</ref-fulltext>
<ce:source-text>Argiles, J.M., et al.: Cachexia: A problem of energetic inefficiency. J. Cachexia. Sarcopenia Muscle. 5(4), 279–286 (2014)</ce:source-text>
</reference>
<reference seq="97">
<ref-info>
<ref-title>
<ref-titletext-english>A creatine-driven substrate cycle enhances energy expenditure and thermogenesis in beige fat</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Kazak</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>163</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>643</first-page>
<last-page>655</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kazak, L., et al.: A creatine-driven substrate cycle enhances energy expenditure and thermogenesis in beige fat. Cell. 163(3), 643–655 (2015)</ref-fulltext>
<ce:source-text>Kazak, L., et al.: A creatine-driven substrate cycle enhances energy expenditure and thermogenesis in beige fat. Cell. 163(3), 643–655 (2015)</ce:source-text>
</reference>
<reference seq="98">
<ref-info>
<ref-title>
<ref-titletext-english>Lipid metabolism in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.D.</ce:initials>
<ce:surname>Mulligan</ce:surname>
<ce:given-name>H.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.A.</ce:initials>
<ce:surname>Beck</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.J.</ce:initials>
<ce:surname>Tisdale</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="1992" />
<volisspag>
<volume-issue-number>
<vol-first>66</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>57</first-page>
<last-page>61</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mulligan, H.D., Beck, S.A., Tisdale, M.J.: Lipid metabolism in cancer cachexia. Br. J. Cancer. 66(1), 57–61 (1992)</ref-fulltext>
<ce:source-text>Mulligan, H.D., Beck, S.A., Tisdale, M.J.: Lipid metabolism in cancer cachexia. Br. J. Cancer. 66(1), 57–61 (1992)</ce:source-text>
</reference>
<reference seq="99">
<ref-info>
<ref-title>
<ref-titletext-english>Insulin resistance and body composition in cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Dev</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Bruera</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Dalal</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Oncol</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>29</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>ii18</first-page>
<last-page>ii26</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dev, R., Bruera, E., Dalal, S.: Insulin resistance and body composition in cancer patients. Ann. Oncol. 29(suppl_2), ii18–ii26 (2018)</ref-fulltext>
<ce:source-text>Dev, R., Bruera, E., Dalal, S.: Insulin resistance and body composition in cancer patients. Ann. Oncol. 29(suppl_2), ii18–ii26 (2018)</ce:source-text>
</reference>
<reference seq="100">
<ref-info>
<ref-title>
<ref-titletext-english>Hyperglycemia and insulin resistance: Possible mechanisms</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Tomas</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ann. N. Y. Acad. Sci</ref-sourcetitle>
<ref-publicationyear first="2002" />
<volisspag>
<volume-issue-number>
<vol-first>967</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>43</first-page>
<last-page>51</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tomas, E., et al.: Hyperglycemia and insulin resistance: Possible mechanisms. Ann. N. Y. Acad. Sci. 967, 43–51 (2002)</ref-fulltext>
<ce:source-text>Tomas, E., et al.: Hyperglycemia and insulin resistance: Possible mechanisms. Ann. N. Y. Acad. Sci. 967, 43–51 (2002)</ce:source-text>
</reference>
<reference seq="101">
<ref-info>
<ref-title>
<ref-titletext-english>Acute hyperglycemia associated with anti-cancer medication</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Hwangbo</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.K.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>E.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Endocrinol. Metab. (Seoul).</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>23</first-page>
<last-page>29</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hwangbo, Y., Lee, E.K.: Acute hyperglycemia associated with anti-cancer medication. Endocrinol. Metab. (Seoul). 32(1), 23–29 (2017)</ref-fulltext>
<ce:source-text>Hwangbo, Y., Lee, E.K.: Acute hyperglycemia associated with anti-cancer medication. Endocrinol. Metab. (Seoul). 32(1), 23–29 (2017)</ce:source-text>
</reference>
<reference seq="102">
<ref-info>
<ref-title>
<ref-titletext-english>Pathophysiology of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.N.</ce:initials>
<ce:surname>Younes</ce:surname>
<ce:given-name>R.N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Noguchi</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Rev. Hosp. Clin. Fac. Med. Sao Paulo</ref-sourcetitle>
<ref-publicationyear first="2000" />
<volisspag>
<volume-issue-number>
<vol-first>55</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>181</first-page>
<last-page>193</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Younes, R.N., Noguchi, Y.: Pathophysiology of cancer cachexia. Rev. Hosp. Clin. Fac. Med. Sao Paulo. 55(5), 181–193 (2000)</ref-fulltext>
<ce:source-text>Younes, R.N., Noguchi, Y.: Pathophysiology of cancer cachexia. Rev. Hosp. Clin. Fac. Med. Sao Paulo. 55(5), 181–193 (2000)</ce:source-text>
</reference>
<reference seq="103">
<ref-info>
<ref-title>
<ref-titletext-english>Severe recurrent nocturnal hypoglycemia during chemotherapy with 6-mercaptopurine in a child with acute lymphoblastic leukemia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.M.</ce:initials>
<ce:surname>Cho</ce:surname>
<ce:given-name>E.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Pediatr. Endocrinol. Metab</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>23</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>226</first-page>
<last-page>228</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cho, E.M., et al.: Severe recurrent nocturnal hypoglycemia during chemotherapy with 6-mercaptopurine in a child with acute lymphoblastic leukemia. Ann. Pediatr. Endocrinol. Metab. 23(4), 226–228 (2018)</ref-fulltext>
<ce:source-text>Cho, E.M., et al.: Severe recurrent nocturnal hypoglycemia during chemotherapy with 6-mercaptopurine in a child with acute lymphoblastic leukemia. Ann. Pediatr. Endocrinol. Metab. 23(4), 226–228 (2018)</ce:source-text>
</reference>
<reference seq="104">
<ref-info>
<ref-title>
<ref-titletext-english>Regulation of the activity of the pyruvate dehydrogenase complex</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.A.</ce:initials>
<ce:surname>Harris</ce:surname>
<ce:given-name>R.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Adv. Enzym. Regul</ref-sourcetitle>
<ref-publicationyear first="2002" />
<volisspag>
<volume-issue-number>
<vol-first>42</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>249</first-page>
<last-page>259</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Harris, R.A., et al.: Regulation of the activity of the pyruvate dehydrogenase complex. Adv. Enzym. Regul. 42, 249–259 (2002)</ref-fulltext>
<ce:source-text>Harris, R.A., et al.: Regulation of the activity of the pyruvate dehydrogenase complex. Adv. Enzym. Regul. 42, 249–259 (2002)</ce:source-text>
</reference>
<reference seq="105">
<ref-info>
<ref-title>
<ref-titletext-english>PDK4 drives metabolic alterations and muscle atrophy in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>FASEB J</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7778</first-page>
<last-page>7790</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pin, F., et al.: PDK4 drives metabolic alterations and muscle atrophy in cancer cachexia. FASEB J. 33(6), 7778–7790 (2019)</ref-fulltext>
<ce:source-text>Pin, F., et al.: PDK4 drives metabolic alterations and muscle atrophy in cancer cachexia. FASEB J. 33(6), 7778–7790 (2019)</ce:source-text>
</reference>
<reference seq="106">
<ref-info>
<ref-title>
<ref-titletext-english>Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>41</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>43202</first-page>
<last-page>43215</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pin, F., et al.: Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations. Oncotarget. 6(41), 43202–43215 (2015)</ref-fulltext>
<ce:source-text>Pin, F., et al.: Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations. Oncotarget. 6(41), 43202–43215 (2015)</ce:source-text>
</reference>
<reference seq="107">
<ref-info>
<ref-title>
<ref-titletext-english>Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.M.</ce:initials>
<ce:surname>Shum</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Aging (Albany NY)</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>133</first-page>
<last-page>143</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shum, A.M., et al.: Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting. Aging (Albany NY). 4(2), 133–143 (2012)</ref-fulltext>
<ce:source-text>Shum, A.M., et al.: Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting. Aging (Albany NY). 4(2), 133–143 (2012)</ce:source-text>
</reference>
<reference seq="108">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle atrophy and dysfunction in breast cancer patients: Role for chemotherapy-derived oxidant stress</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.A.</ce:initials>
<ce:surname>Guigni</ce:surname>
<ce:given-name>B.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Cell Physiol</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>315</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>C744</first-page>
<last-page>C756</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Guigni, B.A., et al.: Skeletal muscle atrophy and dysfunction in breast cancer patients: role for chemotherapy-derived oxidant stress. Am. J. Physiol. Cell Physiol. 315(5), C744–C756 (2018)</ref-fulltext>
<ce:source-text>Guigni, B.A., et al.: Skeletal muscle atrophy and dysfunction in breast cancer patients: role for chemotherapy-derived oxidant stress. Am. J. Physiol. Cell Physiol. 315(5), C744–C756 (2018)</ce:source-text>
</reference>
<reference seq="109">
<ref-info>
<ref-title>
<ref-titletext-english>Mechanisms for fiber-type specificity of skeletal muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.E.</ce:initials>
<ce:surname>Pessin</ce:surname>
<ce:given-name>J.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Opin. Clin. Nutr. Metab. Care</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>243</first-page>
<last-page>250</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, Y., Pessin, J.E.: Mechanisms for fiber-type specificity of skeletal muscle atrophy. Curr. Opin. Clin. Nutr. Metab. Care. 16(3), 243–250 (2013)</ref-fulltext>
<ce:source-text>Wang, Y., Pessin, J.E.: Mechanisms for fiber-type specificity of skeletal muscle atrophy. Curr. Opin. Clin. Nutr. Metab. Care. 16(3), 243–250 (2013)</ce:source-text>
</reference>
<reference seq="110">
<ref-info>
<ref-title>
<ref-titletext-english>Role of oxidative stress as key regulator of muscle wasting during cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Abrigo</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oxidative Med. Cell. Longev</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>2018</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Abrigo, J., et al.: Role of oxidative stress as key regulator of muscle wasting during cachexia. Oxidative Med. Cell. Longev. 2018, 2063179 (2018)</ref-fulltext>
<ce:source-text>Abrigo, J., et al.: Role of oxidative stress as key regulator of muscle wasting during cachexia. Oxidative Med. Cell. Longev. 2018, 2063179 (2018)</ce:source-text>
</reference>
<reference seq="111">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle atrophy, a link between depression of protein synthesis and increase in degradation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.L.</ce:initials>
<ce:surname>Eley</ce:surname>
<ce:given-name>H.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.J.</ce:initials>
<ce:surname>Tisdale</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>282</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7087</first-page>
<last-page>7097</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Eley, H.L., Tisdale, M.J.: Skeletal muscle atrophy, a link between depression of protein synthesis and increase in degradation. J. Biol. Chem. 282(10), 7087–7097 (2007)</ref-fulltext>
<ce:source-text>Eley, H.L., Tisdale, M.J.: Skeletal muscle atrophy, a link between depression of protein synthesis and increase in degradation. J. Biol. Chem. 282(10), 7087–7097 (2007)</ce:source-text>
</reference>
<reference seq="112">
<ref-info>
<ref-title>
<ref-titletext-english>Impact of antioxidant supplementation on chemotherapeutic toxicity: A systematic review of the evidence from randomized controlled trials</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.I.</ce:initials>
<ce:surname>Block</ce:surname>
<ce:given-name>K.I.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2008" />
<volisspag>
<volume-issue-number>
<vol-first>123</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1227</first-page>
<last-page>1239</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Block, K.I., et al.: Impact of antioxidant supplementation on chemotherapeutic toxicity: A systematic review of the evidence from randomized controlled trials. Int. J. Cancer. 123(6), 1227–1239 (2008)</ref-fulltext>
<ce:source-text>Block, K.I., et al.: Impact of antioxidant supplementation on chemotherapeutic toxicity: A systematic review of the evidence from randomized controlled trials. Int. J. Cancer. 123(6), 1227–1239 (2008)</ce:source-text>
</reference>
<reference seq="113">
<ref-info>
<ref-title>
<ref-titletext-english>PGC1-alpha over-expression prevents metabolic alterations and soleus muscle atrophy in hindlimb unloaded mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Cannavino</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Physiol</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>592</vol-first>
<iss-first>20</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4575</first-page>
<last-page>4589</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cannavino, J., et al.: PGC1-alpha over-expression prevents metabolic alterations and soleus muscle atrophy in hindlimb unloaded mice. J. Physiol. 592(20), 4575–4589 (2014)</ref-fulltext>
<ce:source-text>Cannavino, J., et al.: PGC1-alpha over-expression prevents metabolic alterations and soleus muscle atrophy in hindlimb unloaded mice. J. Physiol. 592(20), 4575–4589 (2014)</ce:source-text>
</reference>
<reference seq="114">
<ref-info>
<ref-title>
<ref-titletext-english>PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Sandri</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>103</vol-first>
<iss-first>44</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>16260</first-page>
<last-page>16265</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sandri, M., et al.: PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc. Natl. Acad. Sci. USA. 103(44), 16260–16265 (2006)</ref-fulltext>
<ce:source-text>Sandri, M., et al.: PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc. Natl. Acad. Sci. USA. 103(44), 16260–16265 (2006)</ce:source-text>
</reference>
<reference seq="115">
<ref-info>
<ref-title>
<ref-titletext-english>Increase in muscle mitochondrial biogenesis does not prevent muscle loss but increased tumor size in a mouse model of acute cancer-induced cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Wang, X., et al.: Increase in muscle mitochondrial biogenesis does not prevent muscle loss but increased tumor size in a mouse model of acute cancer-induced cachexia. PLoS One. 7(3), e33426 (2012)</ref-fulltext>
<ce:source-text>Wang, X., et al.: Increase in muscle mitochondrial biogenesis does not prevent muscle loss but increased tumor size in a mouse model of acute cancer-induced cachexia. PLoS One. 7(3), e33426 (2012)</ce:source-text>
</reference>
<reference seq="116">
<ref-info>
<ref-title>
<ref-titletext-english>Mitofusin-2 prevents skeletal muscle wasting in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Q.L.</ce:initials>
<ce:surname>Xi</ce:surname>
<ce:given-name>Q.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncol. Lett</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4013</first-page>
<last-page>4020</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xi, Q.L., et al.: Mitofusin-2 prevents skeletal muscle wasting in cancer cachexia. Oncol. Lett. 12(5), 4013–4020 (2016)</ref-fulltext>
<ce:source-text>Xi, Q.L., et al.: Mitofusin-2 prevents skeletal muscle wasting in cancer cachexia. Oncol. Lett. 12(5), 4013–4020 (2016)</ce:source-text>
</reference>
<reference seq="117">
<ref-info>
<ref-title>
<ref-titletext-english>The mitochondrial metabolic reprogramming agent trimetazidine as an ‘exercise mimetic’ in cachectic C26-bearing mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Molinari</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>954</first-page>
<last-page>973</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Molinari, F., et al.: The mitochondrial metabolic reprogramming agent trimetazidine as an ‘exercise mimetic’ in cachectic C26-bearing mice. J. Cachexia. Sarcopenia Muscle. 8(6), 954–973 (2017)</ref-fulltext>
<ce:source-text>Molinari, F., et al.: The mitochondrial metabolic reprogramming agent trimetazidine as an ‘exercise mimetic’ in cachectic C26-bearing mice. J. Cachexia. Sarcopenia Muscle. 8(6), 954–973 (2017)</ce:source-text>
</reference>
<reference seq="118">
<ref-info>
<ref-title>
<ref-titletext-english>Moderate exercise improves experimental cancer cachexia by modulating the redox homeostasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Ballaro</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancers (Basel)</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Ballaro, R., et al.: Moderate exercise improves experimental cancer cachexia by modulating the redox homeostasis. Cancers (Basel). 11(3) (2019)</ref-fulltext>
<ce:source-text>Ballaro, R., et al.: Moderate exercise improves experimental cancer cachexia by modulating the redox homeostasis. Cancers (Basel). 11(3) (2019)</ce:source-text>
</reference>
<reference seq="119">
<ref-info>
<ref-title>
<ref-titletext-english>Resistance exercise attenuates skeletal muscle oxidative stress, systemic pro-inflammatory state, and cachexia in Walker-256 tumor-bearing rats</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.S.</ce:initials>
<ce:surname>Padilha</ce:surname>
<ce:given-name>C.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Appl. Physiol. Nutr. Metab</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>42</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>916</first-page>
<last-page>923</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Padilha, C.S., et al.: Resistance exercise attenuates skeletal muscle oxidative stress, systemic pro-inflammatory state, and cachexia in Walker-256 tumor-bearing rats. Appl. Physiol. Nutr. Metab. 42(9), 916–923 (2017)</ref-fulltext>
<ce:source-text>Padilha, C.S., et al.: Resistance exercise attenuates skeletal muscle oxidative stress, systemic pro-inflammatory state, and cachexia in Walker-256 tumor-bearing rats. Appl. Physiol. Nutr. Metab. 42(9), 916–923 (2017)</ce:source-text>
</reference>
<reference seq="120">
<ref-info>
<ref-title>
<ref-titletext-english>Combined exercise training positively affects muscle wasting in tumor-bearing mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Ranjbar</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Med. Sci. Sports Exerc</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>51</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1387</first-page>
<last-page>1395</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ranjbar, K., et al.: Combined exercise training positively affects muscle wasting in tumor-bearing mice. Med. Sci. Sports Exerc. 51(7), 1387–1395 (2019)</ref-fulltext>
<ce:source-text>Ranjbar, K., et al.: Combined exercise training positively affects muscle wasting in tumor-bearing mice. Med. Sci. Sports Exerc. 51(7), 1387–1395 (2019)</ce:source-text>
</reference>
<reference seq="121">
<ref-info>
<ref-title>
<ref-titletext-english>Moderate exercise in mice improves cancer plus chemotherapy-induced muscle wasting and mitochondrial alterations</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Ballaro</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>FASEB J</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5482</first-page>
<last-page>5494</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ballaro, R., et al.: Moderate exercise in mice improves cancer plus chemotherapy-induced muscle wasting and mitochondrial alterations. FASEB J. 33(4), 5482–5494 (2019)</ref-fulltext>
<ce:source-text>Ballaro, R., et al.: Moderate exercise in mice improves cancer plus chemotherapy-induced muscle wasting and mitochondrial alterations. FASEB J. 33(4), 5482–5494 (2019)</ce:source-text>
</reference>
<reference seq="122">
<ref-info>
<ref-title>
<ref-titletext-english>Effect of acute treadmill exercise on cisplatin-induced muscle atrophy in the mouse</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Sakai</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Pflugers Arch</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>469</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1495</first-page>
<last-page>1505</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sakai, H., et al.: Effect of acute treadmill exercise on cisplatin-induced muscle atrophy in the mouse. Pflugers Arch. 469(11), 1495–1505 (2017)</ref-fulltext>
<ce:source-text>Sakai, H., et al.: Effect of acute treadmill exercise on cisplatin-induced muscle atrophy in the mouse. Pflugers Arch. 469(11), 1495–1505 (2017)</ce:source-text>
</reference>
<reference seq="123">
<ref-info>
<ref-title>
<ref-titletext-english>A systematic review of the safety and efficacy of aerobic exercise during cytotoxic chemotherapy treatment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Cave</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Support Care Cancer</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3337</first-page>
<last-page>3351</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cave, J., et al.: A systematic review of the safety and efficacy of aerobic exercise during cytotoxic chemotherapy treatment. Support Care Cancer. 26(10), 3337–3351 (2018)</ref-fulltext>
<ce:source-text>Cave, J., et al.: A systematic review of the safety and efficacy of aerobic exercise during cytotoxic chemotherapy treatment. Support Care Cancer. 26(10), 3337–3351 (2018)</ce:source-text>
</reference>
<reference seq="124">
<ref-info>
<ref-title>
<ref-titletext-english>Highly favorable physiological responses to concurrent resistance and high-intensity interval training during chemotherapy: The OptiTrain breast cancer trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Mijwel</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Breast Cancer Res. Treat</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>169</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>93</first-page>
<last-page>103</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mijwel, S., et al.: Highly favorable physiological responses to concurrent resistance and high-intensity interval training during chemotherapy: The OptiTrain breast cancer trial. Breast Cancer Res. Treat. 169(1), 93–103 (2018)</ref-fulltext>
<ce:source-text>Mijwel, S., et al.: Highly favorable physiological responses to concurrent resistance and high-intensity interval training during chemotherapy: The OptiTrain breast cancer trial. Breast Cancer Res. Treat. 169(1), 93–103 (2018)</ce:source-text>
</reference>
<reference seq="125">
<ref-info>
<ref-title>
<ref-titletext-english>Regulation of muscle growth by multiple ligands signaling through activin type II receptors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.J.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>S.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>102</vol-first>
<iss-first>50</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>18117</first-page>
<last-page>18122</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lee, S.J., et al.: Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc. Natl. Acad. Sci. USA. 102(50), 18117–18122 (2005)</ref-fulltext>
<ce:source-text>Lee, S.J., et al.: Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc. Natl. Acad. Sci. USA. 102(50), 18117–18122 (2005)</ce:source-text>
</reference>
<reference seq="126">
<ref-info>
<ref-title>
<ref-titletext-english>Activin signaling as an emerging target for therapeutic interventions</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Tsuchida</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Commun. Signal</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>15</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tsuchida, K., et al.: Activin signaling as an emerging target for therapeutic interventions. Cell Commun. Signal. 7, 15 (2009)</ref-fulltext>
<ce:source-text>Tsuchida, K., et al.: Activin signaling as an emerging target for therapeutic interventions. Cell Commun. Signal. 7, 15 (2009)</ce:source-text>
</reference>
<reference seq="127">
<ref-info>
<ref-title>
<ref-titletext-english>ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Hatakeyama</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Skelet. Muscle</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>26</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hatakeyama, S., et al.: ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments. Skelet. Muscle. 6, 26 (2016)</ref-fulltext>
<ce:source-text>Hatakeyama, S., et al.: ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments. Skelet. Muscle. 6, 26 (2016)</ce:source-text>
</reference>
<reference seq="128">
<ref-info>
<ref-title>
<ref-titletext-english>Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.A.</ce:initials>
<ce:surname>Nissinen</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>514</first-page>
<last-page>529</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nissinen, T.A., et al.: Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses. J. Cachexia. Sarcopenia Muscle. 9(3), 514–529 (2018)</ref-fulltext>
<ce:source-text>Nissinen, T.A., et al.: Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses. J. Cachexia. Sarcopenia Muscle. 9(3), 514–529 (2018)</ce:source-text>
</reference>
<reference seq="129">
<ref-info>
<ref-title>
<ref-titletext-english>The systemic activin response to pancreatic cancer: Implications for effective cancer cachexia therapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Zhong</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1083</first-page>
<last-page>1101</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhong, X., et al.: The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy. J. Cachexia. Sarcopenia Muscle. 10(5), 1083–1101 (2019)</ref-fulltext>
<ce:source-text>Zhong, X., et al.: The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy. J. Cachexia. Sarcopenia Muscle. 10(5), 1083–1101 (2019)</ce:source-text>
</reference>
<reference seq="130">
<ref-info>
<ref-title>
<ref-titletext-english>Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.E.</ce:initials>
<ce:surname>Benny Klimek</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochem. Biophys. Res. Commun</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>391</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1548</first-page>
<last-page>1554</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Benny Klimek, M.E., et al.: Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem. Biophys. Res. Commun. 391(3), 1548–1554 (2010)</ref-fulltext>
<ce:source-text>Benny Klimek, M.E., et al.: Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem. Biophys. Res. Commun. 391(3), 1548–1554 (2010)</ce:source-text>
</reference>
<reference seq="131">
<ref-info>
<ref-title>
<ref-titletext-english>Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Zhou</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>142</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>531</first-page>
<last-page>543</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhou, X., et al.: Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 142(4), 531–543 (2010)</ref-fulltext>
<ce:source-text>Zhou, X., et al.: Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 142(4), 531–543 (2010)</ce:source-text>
</reference>
<reference seq="132">
<ref-info>
<ref-title>
<ref-titletext-english>Bone and muscle: Interactions beyond mechanical</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Brotto</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Bonewald</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Bone</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>80</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>109</first-page>
<last-page>114</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Brotto, M., Bonewald, L.: Bone and muscle: Interactions beyond mechanical. Bone. 80, 109–114 (2015)</ref-fulltext>
<ce:source-text>Brotto, M., Bonewald, L.: Bone and muscle: Interactions beyond mechanical. Bone. 80, 109–114 (2015)</ce:source-text>
</reference>
<reference seq="133">
<ref-info>
<ref-title>
<ref-titletext-english>Differential bone loss in mouse models of colon cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Physiol</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>679</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bonetto, A., et al.: Differential bone loss in mouse models of colon cancer cachexia. Front. Physiol. 7, 679 (2016)</ref-fulltext>
<ce:source-text>Bonetto, A., et al.: Differential bone loss in mouse models of colon cancer cachexia. Front. Physiol. 7, 679 (2016)</ce:source-text>
</reference>
<reference seq="134">
<ref-info>
<ref-title>
<ref-titletext-english>Growth of ovarian cancer xenografts causes loss of muscle and bone mass: A new model for the study of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>685</first-page>
<last-page>700</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pin, F., et al.: Growth of ovarian cancer xenografts causes loss of muscle and bone mass: A new model for the study of cancer cachexia. J. Cachexia. Sarcopenia Muscle. 9(4), 685–700 (2018)</ref-fulltext>
<ce:source-text>Pin, F., et al.: Growth of ovarian cancer xenografts causes loss of muscle and bone mass: A new model for the study of cancer cachexia. J. Cachexia. Sarcopenia Muscle. 9(4), 685–700 (2018)</ce:source-text>
</reference>
<reference seq="135">
<ref-info>
<ref-title>
<ref-titletext-english>Excess TGF-beta mediates muscle weakness associated with bone metastases in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.L.</ce:initials>
<ce:surname>Waning</ce:surname>
<ce:given-name>D.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Med</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1262</first-page>
<last-page>1271</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Waning, D.L., et al.: Excess TGF-beta mediates muscle weakness associated with bone metastases in mice. Nat. Med. 21(11), 1262–1271 (2015)</ref-fulltext>
<ce:source-text>Waning, D.L., et al.: Excess TGF-beta mediates muscle weakness associated with bone metastases in mice. Nat. Med. 21(11), 1262–1271 (2015)</ce:source-text>
</reference>
<reference seq="136">
<ref-info>
<ref-title>
<ref-titletext-english>Pamidronate attenuates muscle loss after pediatric burn injury</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Borsheim</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Bone Miner. Res</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>29</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1369</first-page>
<last-page>1372</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Borsheim, E., et al.: Pamidronate attenuates muscle loss after pediatric burn injury. J. Bone Miner. Res. 29(6), 1369–1372 (2014)</ref-fulltext>
<ce:source-text>Borsheim, E., et al.: Pamidronate attenuates muscle loss after pediatric burn injury. J. Bone Miner. Res. 29(6), 1369–1372 (2014)</ce:source-text>
</reference>
<reference seq="137">
<ref-info>
<ref-title>
<ref-titletext-english>Molecular mechanisms responsible for the rescue effects of pamidronate on muscle atrophy in pediatric burn patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Endocrinol. (Lausanne).</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>543</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pin, F., et al.: Molecular mechanisms responsible for the rescue effects of pamidronate on muscle atrophy in pediatric burn patients. Front. Endocrinol. (Lausanne). 10, 543 (2019)</ref-fulltext>
<ce:source-text>Pin, F., et al.: Molecular mechanisms responsible for the rescue effects of pamidronate on muscle atrophy in pediatric burn patients. Front. Endocrinol. (Lausanne). 10, 543 (2019)</ce:source-text>
</reference>
<reference seq="138">
<ref-info>
<ref-title>
<ref-titletext-english>RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Bonnet</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>129</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3214</first-page>
<last-page>3223</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bonnet, N., et al.: RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass. J. Clin. Invest. 129(8), 3214–3223 (2019)</ref-fulltext>
<ce:source-text>Bonnet, N., et al.: RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass. J. Clin. Invest. 129(8), 3214–3223 (2019)</ce:source-text>
</reference>
<reference seq="139">
<ref-info>
<ref-title>
<ref-titletext-english>Nutrition interventions to treat low muscle mass in cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.M.</ce:initials>
<ce:surname>Prado</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.A.</ce:initials>
<ce:surname>Purcell</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Laviano</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2020" />
</ref-info>
<ref-fulltext>Prado, C.M., Purcell, S.A., Laviano, A.: Nutrition interventions to treat low muscle mass in cancer. J. Cachexia. Sarcopenia Muscle. (2020)</ref-fulltext>
<ce:source-text>Prado, C.M., Purcell, S.A., Laviano, A.: Nutrition interventions to treat low muscle mass in cancer. J. Cachexia. Sarcopenia Muscle. (2020)</ce:source-text>
</reference>
<reference seq="140">
<ref-info>
<ref-title>
<ref-titletext-english>Alterations of protein turnover underlying disuse atrophy in human skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.M.</ce:initials>
<ce:surname>Phillips</ce:surname>
<ce:given-name>S.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.I.</ce:initials>
<ce:surname>Glover</ce:surname>
<ce:given-name>E.I.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.J.</ce:initials>
<ce:surname>Rennie</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Appl. Physiol. 2009.</ref-sourcetitle>
<ref-publicationyear first="1985" />
<volisspag>
<volume-issue-number>
<vol-first>107</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>645</first-page>
<last-page>654</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Phillips, S.M., Glover, E.I., Rennie, M.J.: Alterations of protein turnover underlying disuse atrophy in human skeletal muscle. J. Appl. Physiol. 2009. 107(3), 645–654 (1985)</ref-fulltext>
<ce:source-text>Phillips, S.M., Glover, E.I., Rennie, M.J.: Alterations of protein turnover underlying disuse atrophy in human skeletal muscle. J. Appl. Physiol. 2009. 107(3), 645–654 (1985)</ce:source-text>
</reference>
<reference seq="141">
<ref-info>
<ref-title>
<ref-titletext-english>Increased amino acid turnover and myofibrillar protein breakdown in advanced cancer are associated with muscle weakness and impaired physical function</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.S.</ce:initials>
<ce:surname>Van der Meij</ce:surname>
<ce:given-name>B.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2399</first-page>
<last-page>2407</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>van der Meij, B.S., et al.: Increased amino acid turnover and myofibrillar protein breakdown in advanced cancer are associated with muscle weakness and impaired physical function. Clin. Nutr. 38(5), 2399–2407 (2019)</ref-fulltext>
<ce:source-text>van der Meij, B.S., et al.: Increased amino acid turnover and myofibrillar protein breakdown in advanced cancer are associated with muscle weakness and impaired physical function. Clin. Nutr. 38(5), 2399–2407 (2019)</ce:source-text>
</reference>
<reference seq="142">
<ref-info>
<ref-title>
<ref-titletext-english>ESPEN guidelines on nutrition in cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Arends</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>11</first-page>
<last-page>48</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Arends, J., et al.: ESPEN guidelines on nutrition in cancer patients. Clin. Nutr. 36(1), 11–48 (2017)</ref-fulltext>
<ce:source-text>Arends, J., et al.: ESPEN guidelines on nutrition in cancer patients. Clin. Nutr. 36(1), 11–48 (2017)</ce:source-text>
</reference>
<reference seq="143">
<ref-info>
<ref-title>
<ref-titletext-english>Whey protein isolate supplementation improves body composition, muscle strength, and treatment tolerance in malnourished advanced cancer patients undergoing chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Cereda</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Med</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>16</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>6923</first-page>
<last-page>6932</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cereda, E., et al.: Whey protein isolate supplementation improves body composition, muscle strength, and treatment tolerance in malnourished advanced cancer patients undergoing chemotherapy. Cancer Med. 8(16), 6923–6932 (2019)</ref-fulltext>
<ce:source-text>Cereda, E., et al.: Whey protein isolate supplementation improves body composition, muscle strength, and treatment tolerance in malnourished advanced cancer patients undergoing chemotherapy. Cancer Med. 8(16), 6923–6932 (2019)</ce:source-text>
</reference>
<reference seq="144">
<ref-info>
<ref-title>
<ref-titletext-english>Whey protein supplementation improves nutritional status, glutathione levels, and immune function in cancer patients: A randomized, double-blind controlled trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Bumrungpert</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Med. Food</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>612</first-page>
<last-page>616</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bumrungpert, A., et al.: Whey protein supplementation improves nutritional status, glutathione levels, and immune function in cancer patients: A randomized, double-blind controlled trial. J. Med. Food. 21(6), 612–616 (2018)</ref-fulltext>
<ce:source-text>Bumrungpert, A., et al.: Whey protein supplementation improves nutritional status, glutathione levels, and immune function in cancer patients: A randomized, double-blind controlled trial. J. Med. Food. 21(6), 612–616 (2018)</ce:source-text>
</reference>
<reference seq="145">
<ref-info>
<ref-title>
<ref-titletext-english>Cysteine-rich protein reverses weight loss in lung cancer patients receiving chemotherapy or radiotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.G.</ce:initials>
<ce:surname>Tozer</ce:surname>
<ce:given-name>R.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Antioxid. Redox Signal</ref-sourcetitle>
<ref-publicationyear first="2008" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>395</first-page>
<last-page>402</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tozer, R.G., et al.: Cysteine-rich protein reverses weight loss in lung cancer patients receiving chemotherapy or radiotherapy. Antioxid. Redox Signal. 10(2), 395–402 (2008)</ref-fulltext>
<ce:source-text>Tozer, R.G., et al.: Cysteine-rich protein reverses weight loss in lung cancer patients receiving chemotherapy or radiotherapy. Antioxid. Redox Signal. 10(2), 395–402 (2008)</ce:source-text>
</reference>
<reference seq="146">
<ref-info>
<ref-title>
<ref-titletext-english>L-leucine dietary supplementation modulates muscle protein degradation and increases pro-inflammatory cytokines in tumour-bearing rats</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Cruz</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Oliveira</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.C.C.</ce:initials>
<ce:surname>Gomes-Marcondes</ce:surname>
<ce:given-name>M.C.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>96</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>253</first-page>
<last-page>260</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cruz, B., Oliveira, A., Gomes-Marcondes, M.C.C.: L-leucine dietary supplementation modulates muscle protein degradation and increases pro-inflammatory cytokines in tumour-bearing rats. Cytokine. 96, 253–260 (2017)</ref-fulltext>
<ce:source-text>Cruz, B., Oliveira, A., Gomes-Marcondes, M.C.C.: L-leucine dietary supplementation modulates muscle protein degradation and increases pro-inflammatory cytokines in tumour-bearing rats. Cytokine. 96, 253–260 (2017)</ce:source-text>
</reference>
<reference seq="147">
<ref-info>
<ref-title>
<ref-titletext-english>Nutritional leucine supplementation attenuates cardiac failure in tumour-bearing cachectic animals</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.T.</ce:initials>
<ce:surname>Toneto</ce:surname>
<ce:given-name>A.T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>577</first-page>
<last-page>586</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Toneto, A.T., et al.: Nutritional leucine supplementation attenuates cardiac failure in tumour-bearing cachectic animals. J. Cachexia. Sarcopenia Muscle. 7(5), 577–586 (2016)</ref-fulltext>
<ce:source-text>Toneto, A.T., et al.: Nutritional leucine supplementation attenuates cardiac failure in tumour-bearing cachectic animals. J. Cachexia. Sarcopenia Muscle. 7(5), 577–586 (2016)</ce:source-text>
</reference>
<reference seq="148">
<ref-info>
<ref-title>
<ref-titletext-english>beta-hydroxy-beta-methylbutyrate (HMB) attenuates muscle and body weight loss in experimental cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Aversa</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Oncol</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>713</first-page>
<last-page>720</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Aversa, Z., et al.: beta-hydroxy-beta-methylbutyrate (HMB) attenuates muscle and body weight loss in experimental cancer cachexia. Int. J. Oncol. 38(3), 713–720 (2011)</ref-fulltext>
<ce:source-text>Aversa, Z., et al.: beta-hydroxy-beta-methylbutyrate (HMB) attenuates muscle and body weight loss in experimental cancer cachexia. Int. J. Oncol. 38(3), 713–720 (2011)</ce:source-text>
</reference>
<reference seq="149">
<ref-info>
<ref-title>
<ref-titletext-english>Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.E.</ce:initials>
<ce:surname>May</ce:surname>
<ce:given-name>P.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Surg</ref-sourcetitle>
<ref-publicationyear first="2002" />
<volisspag>
<volume-issue-number>
<vol-first>183</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>471</first-page>
<last-page>479</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>May, P.E., et al.: Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine. Am. J. Surg. 183(4), 471–479 (2002)</ref-fulltext>
<ce:source-text>May, P.E., et al.: Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine. Am. J. Surg. 183(4), 471–479 (2002)</ce:source-text>
</reference>
<reference seq="150">
<ref-info>
<ref-title>
<ref-titletext-english>Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Gramignano</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nutrition</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>22</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>136</first-page>
<last-page>145</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gramignano, G., et al.: Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. Nutrition. 22(2), 136–145 (2006)</ref-fulltext>
<ce:source-text>Gramignano, G., et al.: Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. Nutrition. 22(2), 136–145 (2006)</ce:source-text>
</reference>
<reference seq="151">
<ref-info>
<ref-title>
<ref-titletext-english>Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.A.</ce:initials>
<ce:surname>Murphy</ce:surname>
<ce:given-name>R.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>117</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1775</first-page>
<last-page>1782</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Murphy, R.A., et al.: Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer. 117(8), 1775–1782 (2011)</ref-fulltext>
<ce:source-text>Murphy, R.A., et al.: Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer. 117(8), 1775–1782 (2011)</ce:source-text>
</reference>
<reference seq="152">
<ref-info>
<ref-title>
<ref-titletext-english>The ghrelin receptor agonist HM01 mimics the neuronal effects of ghrelin in the arcuate nucleus and attenuates anorexia-cachexia syndrome in tumor-bearing rats</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Borner</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Regul. Integr. Comp. Physiol</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>311</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>R89</first-page>
<last-page>R96</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Borner, T., et al.: The ghrelin receptor agonist HM01 mimics the neuronal effects of ghrelin in the arcuate nucleus and attenuates anorexia-cachexia syndrome in tumor-bearing rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 311(1), R89–R96 (2016)</ref-fulltext>
<ce:source-text>Borner, T., et al.: The ghrelin receptor agonist HM01 mimics the neuronal effects of ghrelin in the arcuate nucleus and attenuates anorexia-cachexia syndrome in tumor-bearing rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 311(1), R89–R96 (2016)</ce:source-text>
</reference>
<reference seq="153">
<ref-info>
<ref-title>
<ref-titletext-english>Potentiation of ghrelin signaling attenuates cancer anorexia-cachexia and prolongs survival</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Fujitsuka</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Transl. Psychiatry</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Fujitsuka, N., et al.: Potentiation of ghrelin signaling attenuates cancer anorexia-cachexia and prolongs survival. Transl. Psychiatry. 1, e23 (2011)</ref-fulltext>
<ce:source-text>Fujitsuka, N., et al.: Potentiation of ghrelin signaling attenuates cancer anorexia-cachexia and prolongs survival. Transl. Psychiatry. 1, e23 (2011)</ce:source-text>
</reference>
<reference seq="154">
<ref-info>
<ref-title>
<ref-titletext-english>Oral treatment with the ghrelin receptor agonist HM01 attenuates cachexia in mice bearing Colon-26 (C26) tumors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.O.</ce:initials>
<ce:surname>Villars</ce:surname>
<ce:given-name>F.O.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Mol. Sci</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Villars, F.O., et al.: Oral treatment with the ghrelin receptor agonist HM01 attenuates cachexia in mice bearing Colon-26 (C26) tumors. Int. J. Mol. Sci. 18(5) (2017)</ref-fulltext>
<ce:source-text>Villars, F.O., et al.: Oral treatment with the ghrelin receptor agonist HM01 attenuates cachexia in mice bearing Colon-26 (C26) tumors. Int. J. Mol. Sci. 18(5) (2017)</ce:source-text>
</reference>
<reference seq="155">
<ref-info>
<ref-title>
<ref-titletext-english>Z-505 hydrochloride, an orally active ghrelin agonist, attenuates the progression of cancer cachexia via anabolic hormones in Colon 26 tumor-bearing mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Yoshimura</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>811</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>30</first-page>
<last-page>37</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yoshimura, M., et al.: Z-505 hydrochloride, an orally active ghrelin agonist, attenuates the progression of cancer cachexia via anabolic hormones in Colon 26 tumor-bearing mice. Eur. J. Pharmacol. 811, 30–37 (2017)</ref-fulltext>
<ce:source-text>Yoshimura, M., et al.: Z-505 hydrochloride, an orally active ghrelin agonist, attenuates the progression of cancer cachexia via anabolic hormones in Colon 26 tumor-bearing mice. Eur. J. Pharmacol. 811, 30–37 (2017)</ce:source-text>
</reference>
<reference seq="156">
<ref-info>
<ref-title>
<ref-titletext-english>Z-505 hydrochloride ameliorates chemotherapy-induced anorexia in rodents via activation of the ghrelin receptor, GHSR1a</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Shiomi</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>818</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>148</first-page>
<last-page>157</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shiomi, Y., et al.: Z-505 hydrochloride ameliorates chemotherapy-induced anorexia in rodents via activation of the ghrelin receptor, GHSR1a. Eur. J. Pharmacol. 818, 148–157 (2018)</ref-fulltext>
<ce:source-text>Shiomi, Y., et al.: Z-505 hydrochloride ameliorates chemotherapy-induced anorexia in rodents via activation of the ghrelin receptor, GHSR1a. Eur. J. Pharmacol. 818, 148–157 (2018)</ce:source-text>
</reference>
<reference seq="157">
<ref-info>
<ref-title>
<ref-titletext-english>Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: A prospective, randomized, placebo-controlled phase 2 study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Hiura</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>118</vol-first>
<iss-first>19</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4785</first-page>
<last-page>4794</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hiura, Y., et al.: Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: A prospective, randomized, placebo-controlled phase 2 study. Cancer. 118(19), 4785–4794 (2012)</ref-fulltext>
<ce:source-text>Hiura, Y., et al.: Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: A prospective, randomized, placebo-controlled phase 2 study. Cancer. 118(19), 4785–4794 (2012)</ce:source-text>
</reference>
</bibliography>
</tail>
</bibrecord>
<bibrecord>
<item-info>
<status state="new" stage="S300" />
<itemidlist>
<ce:doi>10.1007/978-3-031-09518-4_9</ce:doi>
<itemid idtype="TPB-ID">20232000349315</itemid>
</itemidlist>
</item-info>
<head>
<citation-info>
<citation-type code="ch" />
<citation-language xml:lang="ENG" />
<abstract-language xml:lang="ENG" />
</citation-info>
<citation-title>
<titletext xml:lang="ENG" original="y">Bone-Muscle Crosstalk in Advanced Cancer and Chemotherapy</titletext>
</citation-title>
<author-group seq="1">
<author seq="1">
<ce:initials>D.L.</ce:initials> 
<ce:surname>Waning</ce:surname>
<ce:given-name>David L.</ce:given-name>
<ce:e-address>dwaning@psu.edu</ce:e-address>
</author>
<affiliation>
<organization>Penn State College of Medicine</organization>
<organization>Penn State Cancer Institute</organization>
<city>Hershey</city>
<state>Pennsylvania</state>
<country iso-code="USA" />
<ce:source-text>Penn State College of Medicine, Hershey, PA, USA Penn State Cancer Institute, Hershey, PA, USA</ce:source-text>
</affiliation>
</author-group>
<correspondence>
<person>
<ce:initials>D.L.</ce:initials> 
<ce:surname>Waning</ce:surname>
<ce:given-name>David L.</ce:given-name>
<ce:e-address>dwaning@psu.edu</ce:e-address>
</person>
<affiliation>
<organization>Penn State College of Medicine</organization>
<organization>Penn State Cancer Institute</organization>
<city>Hershey</city>
<state>Pennsylvania</state>
<country iso-code="USA" />
<ce:source-text>Penn State College of Medicine, Hershey, PA, USA Penn State Cancer Institute, Hershey, PA, USA</ce:source-text>
</affiliation>
</correspondence>
<abstracts>
<abstract xml:lang="ENG" original="y">
<publishercopyright>© Springer Nature Switzerland AG 2022</publishercopyright>
<ce:para>Advanced cancers metastasize to distant sites and bone is a common site for metastases from breast, lung, and prostate cancers. Breast and lung cancer bone metastases typically lead to osteolytic lesions. Osteolytic bone metastases lead to bone pain, nerve compression, hyper- calcemia, increased risk of fractures from falls, and muscle weakness. Bone metastases are incurable, and therapies for osteolytic lesions are aimed at reducing tumor burden and limit- ing bone loss. In addition to growth of tumor cells in bone, systemic effects to the musculo- skeletal system are important in the overall reduction in mobility and increased morbidity. The focus of this chapter will be on the process of breast cancer cell colonization of bone, and bone-muscle crosstalk in breast cancer bone metastases and chemotherapy-induced bone loss. Much progress has been made recently in our understanding of the interplay between bone and muscle in cancer and chemotherapy, and future therapeutic strategies will likely include considerations for both of these tissues in the context of reducing overall tumor bur- den in bone.</ce:para>
</abstract>
</abstracts>
<source type="book" country="USA">
<sourcetitle>The Systemic Effects of Advanced Cancer A Textbook on Cancer-Associated Cachexia</sourcetitle>
<sourcetitle-abbrev>The Systemic Effects of Advanced Cancer A Textbook on Cancer-Associated Cachexia</sourcetitle-abbrev>
<isbn type="print" length="13">9783031072727</isbn>
<isbn type="electronic" length="13">9783031095184</isbn>
<volisspag>
<page-information>
<pages>
<first-page>155</first-page>
<last-page>167</last-page>
</pages>
</page-information>
</volisspag>
<publicationyear first="2022" />
<publicationdate>
<year>2022</year>
<month>01</month>
<day>01</day>
</publicationdate>
<website type="item">
<ce:e-address type="url">https://link.springer.com</ce:e-address>
</website>
<publisher>
<publishername>Springer International Publishing</publishername>
</publisher>
</source>
<enhancement>
<classificationgroup>
<classifications type="ASJC">
<classification>
<classification-code>2700</classification-code>
<classification-code>2400</classification-code>
<classification-code>1300</classification-code>
</classification>
</classifications>
</classificationgroup>
</enhancement>
</head>
<tail>
<bibliography refcount="129">
<reference seq="1">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer statistics, 2018</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.L.</ce:initials>
<ce:surname>Siegel</ce:surname>
<ce:given-name>R.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.D.</ce:initials>
<ce:surname>Miller</ce:surname>
<ce:given-name>K.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Jemal</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>CA Cancer J. Clin.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>68</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7</first-page>
<last-page>30</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Siegel, R.L., Miller, K.D., Jemal, A.: Cancer statistics, 2018. CA Cancer J. Clin. 68(1), 7–30 (2018).</ref-fulltext>
<ce:source-text>Siegel, R.L., Miller, K.D., Jemal, A.: Cancer statistics, 2018. CA Cancer J. Clin. 68(1), 7–30 (2018).</ce:source-text>
</reference>
<reference seq="2">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer and bone.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.A.</ce:initials>
<ce:surname>Guise</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.R.</ce:initials>
<ce:surname>Mundy</ce:surname>
<ce:given-name>G.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Endocr. Rev.</ref-sourcetitle>
<ref-publicationyear first="1998" />
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>18</first-page>
<last-page>54</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Guise, T.A., Mundy, G.R.: Cancer and bone. Endocr. Rev. 19(1), 18–54 (1998).</ref-fulltext>
<ce:source-text>Guise, T.A., Mundy, G.R.: Cancer and bone. Endocr. Rev. 19(1), 18–54 (1998).</ce:source-text>
</reference>
<reference seq="3">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer to bone: a fatal attraction.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.N.</ce:initials>
<ce:surname>Weilbaecher</ce:surname>
<ce:given-name>K.N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.A.</ce:initials>
<ce:surname>Guise</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.K.</ce:initials>
<ce:surname>McCauley</ce:surname>
<ce:given-name>L.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>411</first-page>
<last-page>425</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Weilbaecher, K.N., Guise, T.A., McCauley, L.K.: Cancer to bone: a fatal attraction. Nat. Rev. Cancer. 11(6), 411–425 (2011).</ref-fulltext>
<ce:source-text>Weilbaecher, K.N., Guise, T.A., McCauley, L.K.: Cancer to bone: a fatal attraction. Nat. Rev. Cancer. 11(6), 411–425 (2011).</ce:source-text>
</reference>
<reference seq="4">
<ref-info>
<ref-title>
<ref-titletext-english>The bone extracellular matrix as an ideal milieu for cancer cell metastases.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.D.</ce:initials>
<ce:surname>Kolb</ce:surname>
<ce:given-name>A.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.M.</ce:initials>
<ce:surname>Bussard</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancers (Basel).</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Kolb, A.D., Bussard, K.M.: The bone extracellular matrix as an ideal milieu for cancer cell metastases. Cancers (Basel). 11(7) (2019).</ref-fulltext>
<ce:source-text>Kolb, A.D., Bussard, K.M.: The bone extracellular matrix as an ideal milieu for cancer cell metastases. Cancers (Basel). 11(7) (2019).</ce:source-text>
</reference>
<reference seq="5">
<ref-info>
<ref-title>
<ref-titletext-english>Kinetics of metastatic breast cancer cell trafficking in bone.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.A.</ce:initials>
<ce:surname>Phadke</ce:surname>
<ce:given-name>P.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.R.</ce:initials>
<ce:surname>Mercer</ce:surname>
<ce:given-name>R.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.F.</ce:initials>
<ce:surname>Harms</ce:surname>
<ce:given-name>J.F.</ce:given-name>
</author>
<author seq="4">
<ce:initials>Y.</ce:initials>
<ce:surname>Jia</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="5">
<ce:initials>A.R.</ce:initials>
<ce:surname>Frost</ce:surname>
<ce:given-name>A.R.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.L.</ce:initials>
<ce:surname>Jewell</ce:surname>
<ce:given-name>J.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1431</first-page>
<last-page>1440</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Phadke, P.A., Mercer, R.R., Harms, J.F., Jia, Y., Frost, A.R., Jewell, J.L., et al.: Kinetics of metastatic breast cancer cell trafficking in bone. Clin. Cancer Res. 12(5), 1431–1440 (2006).</ref-fulltext>
<ce:source-text>Phadke, P.A., Mercer, R.R., Harms, J.F., Jia, Y., Frost, A.R., Jewell, J.L., et al.: Kinetics of metastatic breast cancer cell trafficking in bone. Clin. Cancer Res. 12(5), 1431–1440 (2006).</ce:source-text>
</reference>
<reference seq="6">
<ref-info>
<ref-title>
<ref-titletext-english>Bone morphology and organization.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.B.</ce:initials>
<ce:surname>Burr</ce:surname>
<ce:given-name>D.B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>O.</ce:initials>
<ce:surname>Akkus</ce:surname>
<ce:given-name>O.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.R.</ce:initials>
<ce:surname>Allen</ce:surname>
<ce:given-name>M.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Basic and applied bone biology, 2nd edn.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<ref-text>Elsevier</ref-text>
</ref-info>
<ref-fulltext>Burr, D.B., Akkus, O.: Bone morphology and organization. In: Burr, D.B., Allen, M.R. (eds.) Basic and applied bone biology, 2nd edn. Elsevier (2014).</ref-fulltext>
<ce:source-text>Burr, D.B., Akkus, O.: Bone morphology and organization. In: Burr, D.B., Allen, M.R. (eds.) Basic and applied bone biology, 2nd edn. Elsevier (2014).</ce:source-text>
</reference>
<reference seq="7">
<ref-info>
<ref-title>
<ref-titletext-english>Novel techniques to study the bone-tumor microenvironment.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.B.</ce:initials>
<ce:surname>Shupp</ce:surname>
<ce:given-name>A.B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.D.</ce:initials>
<ce:surname>Kolb</ce:surname>
<ce:given-name>A.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.M.</ce:initials>
<ce:surname>Bussard</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Adv. Exp. Med. Biol.</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>1225</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1</first-page>
<last-page>18</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shupp, A.B., Kolb, A.D., Bussard, K.M.: Novel techniques to study the bone-tumor microenvironment. Adv. Exp. Med. Biol. 1225, 1–18 (2020).</ref-fulltext>
<ce:source-text>Shupp, A.B., Kolb, A.D., Bussard, K.M.: Novel techniques to study the bone-tumor microenvironment. Adv. Exp. Med. Biol. 1225, 1–18 (2020).</ce:source-text>
</reference>
<reference seq="8">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer metastases to bone: concepts, mechanisms, and interactions with bone osteoblasts.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.B.</ce:initials>
<ce:surname>Shupp</ce:surname>
<ce:given-name>A.B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.D.</ce:initials>
<ce:surname>Kolb</ce:surname>
<ce:given-name>A.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Mukhopadhyay</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="4">
<ce:initials>K.M.</ce:initials>
<ce:surname>Bussard</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancers (Basel).</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Shupp, A.B., Kolb, A.D., Mukhopadhyay, D., Bussard, K.M.: Cancer metastases to bone: concepts, mechanisms, and interactions with bone osteoblasts. Cancers (Basel). 10(6) (2018).</ref-fulltext>
<ce:source-text>Shupp, A.B., Kolb, A.D., Mukhopadhyay, D., Bussard, K.M.: Cancer metastases to bone: concepts, mechanisms, and interactions with bone osteoblasts. Cancers (Basel). 10(6) (2018).</ce:source-text>
</reference>
<reference seq="9">
<ref-info>
<ref-title>
<ref-titletext-english> Location matters: osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.K.</ce:initials>
<ce:surname>Brown</ce:surname>
<ce:given-name>H.K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.D.</ce:initials>
<ce:surname>Ottewell</ce:surname>
<ce:given-name>P.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.A.</ce:initials>
<ce:surname>Evans</ce:surname>
<ce:given-name>C.A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>I.</ce:initials>
<ce:surname>Holen</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Exp. Metastasis.</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>29</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>927</first-page>
<last-page>938</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Brown, H.K., Ottewell, P.D., Evans, C.A., Holen, I.: Location matters: osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo. Clin. Exp. Metastasis. 29(8), 927–938 (2012).</ref-fulltext>
<ce:source-text>Brown, H.K., Ottewell, P.D., Evans, C.A., Holen, I.: Location matters: osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo. Clin. Exp. Metastasis. 29(8), 927–938 (2012).</ce:source-text>
</reference>
<reference seq="10">
<ref-info>
<ref-title>
<ref-titletext-english>The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Yu</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>X.</ce:initials>
<ce:surname>Gao</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Welte</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="5">
<ce:initials>A.M.</ce:initials>
<ce:surname>Muscarella</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>L.</ce:initials>
<ce:surname>Tian</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell.</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>193</first-page>
<last-page>210</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, H., Yu, C., Gao, X., Welte, T., Muscarella, A.M., Tian, L., et al.: The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell. 27(2), 193–210 (2015).</ref-fulltext>
<ce:source-text>Wang, H., Yu, C., Gao, X., Welte, T., Muscarella, A.M., Tian, L., et al.: The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell. 27(2), 193–210 (2015).</ce:source-text>
</reference>
<reference seq="11">
<ref-info>
<ref-title>
<ref-titletext-english>The osteogenic niche is a calcium reservoir of bone micrometastases and confers unexpected therapeutic vulnerability.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Tian</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Goldstein</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="5">
<ce:initials>I.</ce:initials>
<ce:surname>Bado</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="6">
<ce:initials>W.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>34</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>823</first-page>
<last-page>839</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, H., Tian, L., Liu, J., Goldstein, A., Bado, I., Zhang, W., et al.: The osteogenic niche is a calcium reservoir of bone micrometastases and confers unexpected therapeutic vulnerability. Cancer Cell. 34(5), 823–39 e7 (2018).</ref-fulltext>
<ce:source-text>Wang, H., Tian, L., Liu, J., Goldstein, A., Bado, I., Zhang, W., et al.: The osteogenic niche is a calcium reservoir of bone micrometastases and confers unexpected therapeutic vulnerability. Cancer Cell. 34(5), 823–39 e7 (2018).</ce:source-text>
</reference>
<reference seq="12">
<ref-info>
<ref-title>
<ref-titletext-english>Connexins, connexons, and intercellular communication.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.A.</ce:initials>
<ce:surname>Goodenough</ce:surname>
<ce:given-name>D.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.A.</ce:initials>
<ce:surname>Goliger</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.L.</ce:initials>
<ce:surname>Paul</ce:surname>
<ce:given-name>D.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Annu. Rev. Biochem.</ref-sourcetitle>
<ref-publicationyear first="1996" />
<volisspag>
<volume-issue-number>
<vol-first>65</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>475</first-page>
<last-page>502</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Goodenough, D.A., Goliger, J.A., Paul, D.L.: Connexins, connexons, and intercellular communication. Annu. Rev. Biochem. 65, 475–502 (1996).</ref-fulltext>
<ce:source-text>Goodenough, D.A., Goliger, J.A., Paul, D.L.: Connexins, connexons, and intercellular communication. Annu. Rev. Biochem. 65, 475–502 (1996).</ce:source-text>
</reference>
<reference seq="13">
<ref-info>
<ref-title>
<ref-titletext-english>Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.K.</ce:initials>
<ce:surname>Lim</ce:surname>
<ce:given-name>P.K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.A.</ce:initials>
<ce:surname>Bliss</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.A.</ce:initials>
<ce:surname>Patel</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Taborga</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.A.</ce:initials>
<ce:surname>Dave</ce:surname>
<ce:given-name>M.A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>L.A.</ce:initials>
<ce:surname>Gregory</ce:surname>
<ce:given-name>L.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>71</vol-first>
<iss-first>51</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1550</first-page>
<last-page>1560</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lim, P.K., Bliss, S.A., Patel, S.A., Taborga, M., Dave, M.A., Gregory, L.A., et al.: Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Res. 71(5), 1550–1560 (2011).</ref-fulltext>
<ce:source-text>Lim, P.K., Bliss, S.A., Patel, S.A., Taborga, M., Dave, M.A., Gregory, L.A., et al.: Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Res. 71(5), 1550–1560 (2011).</ce:source-text>
</reference>
<reference seq="14">
<ref-info>
<ref-title>
<ref-titletext-english>Hallmarks of cancer: the next generation.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Hanahan</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.A.</ce:initials>
<ce:surname>Weinberg</ce:surname>
<ce:given-name>R.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell. </ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>144</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>646</first-page>
<last-page>674</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hanahan, D., Weinberg, R.A.: Hallmarks of cancer: the next generation. Cell. 144(5), 646–674 (2011)</ref-fulltext>
<ce:source-text>Hanahan, D., Weinberg, R.A.: Hallmarks of cancer: the next generation. Cell. 144(5), 646–674 (2011)</ce:source-text>
</reference>
<reference seq="15">
<ref-info>
<ref-title>
<ref-titletext-english> Targeting Bcl-2-IP3 receptor interaction to reverse Bcl-2’s inhibition of apoptotic calcium signals.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.P.</ce:initials>
<ce:surname>Rong</ce:surname>
<ce:given-name>Y.P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.S.</ce:initials>
<ce:surname>Aromolaran</ce:surname>
<ce:given-name>A.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>G.</ce:initials>
<ce:surname>Bultynck</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="4">
<ce:initials>F.</ce:initials>
<ce:surname>Zhong</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="5">
<ce:initials>X.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="6">
<ce:initials>K.</ce:initials>
<ce:surname>McColl</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cell.</ref-sourcetitle>
<ref-publicationyear first="2008" />
<volisspag>
<volume-issue-number>
<vol-first>31</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>255</first-page>
<last-page>265</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rong, Y.P., Aromolaran, A.S., Bultynck, G., Zhong, F., Li, X., McColl, K., et al.: Targeting Bcl-2-IP3 receptor interaction to reverse Bcl-2’s inhibition of apoptotic calcium signals. Mol. Cell. 31(2), 255–265 (2008).</ref-fulltext>
<ce:source-text>Rong, Y.P., Aromolaran, A.S., Bultynck, G., Zhong, F., Li, X., McColl, K., et al.: Targeting Bcl-2-IP3 receptor interaction to reverse Bcl-2’s inhibition of apoptotic calcium signals. Mol. Cell. 31(2), 255–265 (2008).</ce:source-text>
</reference>
<reference seq="16">
<ref-info>
<ref-title>
<ref-titletext-english>Crosstalk between calcium and reactive oxygen species signaling in cancer. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Hempel</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Trebak</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Calcium.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>63</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>70</first-page>
<last-page>96</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hempel, N., Trebak, M.: Crosstalk between calcium and reactive oxygen species signaling in cancer. Cell Calcium. 63, 70–96 (2017).</ref-fulltext>
<ce:source-text>Hempel, N., Trebak, M.: Crosstalk between calcium and reactive oxygen species signaling in cancer. Cell Calcium. 63, 70–96 (2017).</ce:source-text>
</reference>
<reference seq="17">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Sethi</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>X.</ce:initials>
<ce:surname>Dai</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.G.</ce:initials>
<ce:surname>Winter</ce:surname>
<ce:given-name>C.G.</ce:given-name>
</author>
<author seq="4">
<ce:initials>Y.</ce:initials>
<ce:surname>Kang</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell.</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>192</first-page>
<last-page>205</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sethi, N., Dai, X., Winter, C.G., Kang, Y.: Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell. 19(2), 192–205 (2011).</ref-fulltext>
<ce:source-text>Sethi, N., Dai, X., Winter, C.G., Kang, Y.: Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell. 19(2), 192–205 (2011).</ce:source-text>
</reference>
<reference seq="18">
<ref-info>
<ref-title>
<ref-titletext-english>Therapeutic antibody targeting tumor- and osteoblastic niche-derived Jagged1 sensitizes bone metastasis to chemotherapy.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Zheng</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Bae</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Kasimir-Bauer</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Tang</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>G.</ce:initials>
<ce:surname>Ren</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>731</first-page>
<last-page>747</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zheng, H., Bae, Y., Kasimir-Bauer, S., Tang, R., Chen, J., Ren, G., et al.: Therapeutic antibody targeting tumor- and osteoblastic niche-derived Jagged1 sensitizes bone metastasis to chemotherapy. Cancer Cell. 32(6), 731–47 e6 (2017).</ref-fulltext>
<ce:source-text>Zheng, H., Bae, Y., Kasimir-Bauer, S., Tang, R., Chen, J., Ren, G., et al.: Therapeutic antibody targeting tumor- and osteoblastic niche-derived Jagged1 sensitizes bone metastasis to chemotherapy. Cancer Cell. 32(6), 731–47 e6 (2017).</ce:source-text>
</reference>
<reference seq="19">
<ref-info>
<ref-title>
<ref-titletext-english>VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Lu</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Mu</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Wei</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Riethdorf</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="5">
<ce:initials>Q.</ce:initials>
<ce:surname>Yang</ce:surname>
<ce:given-name>Q.</ce:given-name>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Yuan</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell.</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>701</first-page>
<last-page>714</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lu, X., Mu, E., Wei, Y., Riethdorf, S., Yang, Q., Yuan, M., et al.: VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell. 20(6), 701–714 (2011).</ref-fulltext>
<ce:source-text>Lu, X., Mu, E., Wei, Y., Riethdorf, S., Yang, Q., Yuan, M., et al.: VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell. 20(6), 701–714 (2011).</ce:source-text>
</reference>
<reference seq="20">
<ref-info>
<ref-title>
<ref-titletext-english>Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Liang</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Wu</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Lou</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="4">
<ce:initials>X.</ce:initials>
<ce:surname>Yu</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="5">
<ce:initials>R.S.</ce:initials>
<ce:surname>Taichman</ce:surname>
<ce:given-name>R.S.</ce:given-name>
</author>
<author seq="6">
<ce:initials>S.K.</ce:initials>
<ce:surname>Lau</ce:surname>
<ce:given-name>S.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2004" />
<volisspag>
<volume-issue-number>
<vol-first>64</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4302</first-page>
<last-page>4308</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Liang, Z., Wu, T., Lou, H., Yu, X., Taichman, R.S., Lau, S.K., et al.: Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res. 64(12), 4302–4308 (2004).</ref-fulltext>
<ce:source-text>Liang, Z., Wu, T., Lou, H., Yu, X., Taichman, R.S., Lau, S.K., et al.: Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res. 64(12), 4302–4308 (2004).</ce:source-text>
</reference>
<reference seq="21">
<ref-info>
<ref-title>
<ref-titletext-english>The role of chemokine receptor CXCR4 in breast cancer metastasis. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Mukherjee</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Zhao</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>46</first-page>
<last-page>57</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mukherjee, D., Zhao, J.: The role of chemokine receptor CXCR4 in breast cancer metastasis. Am. J. Cancer Res. 3(1), 46–57 (2013).</ref-fulltext>
<ce:source-text>Mukherjee, D., Zhao, J.: The role of chemokine receptor CXCR4 in breast cancer metastasis. Am. J. Cancer Res. 3(1), 46–57 (2013).</ce:source-text>
</reference>
<reference seq="22">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.S.</ce:initials>
<ce:surname>Bendre</ce:surname>
<ce:given-name>M.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.C.</ce:initials>
<ce:surname>Montague</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Peery</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="4">
<ce:initials>N.S.</ce:initials>
<ce:surname>Akel</ce:surname>
<ce:given-name>N.S.</ce:given-name>
</author>
<author seq="5">
<ce:initials>D.</ce:initials>
<ce:surname>Gaddy</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="6">
<ce:initials>L.J.</ce:initials>
<ce:surname>Suva</ce:surname>
<ce:given-name>L.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Bone.</ref-sourcetitle>
<ref-publicationyear first="2003" />
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>28</first-page>
<last-page>37</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bendre, M.S., Montague, D.C., Peery, T., Akel, N.S., Gaddy, D., Suva, L.J.: Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone. 33(1), 28–37 (2003).</ref-fulltext>
<ce:source-text>Bendre, M.S., Montague, D.C., Peery, T., Akel, N.S., Gaddy, D., Suva, L.J.: Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone. 33(1), 28–37 (2003).</ce:source-text>
</reference>
<reference seq="23">
<ref-info>
<ref-title>
<ref-titletext-english>Osteoblasts are a major source of inflammatory cytokines in the tumor microenvironment of bone metastatic breast cancer.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.M.</ce:initials>
<ce:surname>Bussard</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.J.</ce:initials>
<ce:surname>Venzon</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.M.</ce:initials>
<ce:surname>Mastro</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Biochem.</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>111</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1138</first-page>
<last-page>1148</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bussard, K.M., Venzon, D.J., Mastro, A.M.: Osteoblasts are a major source of inflammatory cytokines in the tumor microenvironment of bone metastatic breast cancer. J. Cell. Biochem. 111(5), 1138–1148 (2010).</ref-fulltext>
<ce:source-text>Bussard, K.M., Venzon, D.J., Mastro, A.M.: Osteoblasts are a major source of inflammatory cytokines in the tumor microenvironment of bone metastatic breast cancer. J. Cell. Biochem. 111(5), 1138–1148 (2010).</ce:source-text>
</reference>
<reference seq="24">
<ref-info>
<ref-title>
<ref-titletext-english>Osteoblasts are “educated” by crosstalk with metastatic breast cancer cells in the bone tumor microenvironment.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.D.</ce:initials>
<ce:surname>Kolb</ce:surname>
<ce:given-name> A.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.B.</ce:initials>
<ce:surname>Shupp</ce:surname>
<ce:given-name>A.B.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Mukhopadhyay</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="4">
<ce:initials>F.C.</ce:initials>
<ce:surname>Marini</ce:surname>
<ce:given-name>F.C.</ce:given-name>
</author>
<author seq="5">
<ce:initials>K.M.</ce:initials>
<ce:surname>Bussard</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Breast Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>31</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kolb, A.D., Shupp, A.B., Mukhopadhyay, D., Marini, F.C., Bussard, K.M.: Osteoblasts are “educated” by crosstalk with metastatic breast cancer cells in the bone tumor microenvironment. Breast Cancer Res. 21(1), 31 (2019)</ref-fulltext>
<ce:source-text>Kolb, A.D., Shupp, A.B., Mukhopadhyay, D., Marini, F.C., Bussard, K.M.: Osteoblasts are “educated” by crosstalk with metastatic breast cancer cells in the bone tumor microenvironment. Breast Cancer Res. 21(1), 31 (2019)</ce:source-text>
</reference>
<reference seq="25">
<ref-info>
<ref-title>
<ref-titletext-english>Metastatic breast cancer cells overexpress and secrete miR-218 to regulate type I collagen deposition by osteoblasts.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Cao</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Palomares</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>X.</ce:initials>
<ce:surname>Wu</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>W.</ce:initials>
<ce:surname>Yan</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Breast Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>127</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Liu, X., Cao, M., Palomares, M., Wu, X., Li, A., Yan, W., et al.: Metastatic breast cancer cells overexpress and secrete miR-218 to regulate type I collagen deposition by osteoblasts. Breast Cancer Res. 20(1), 127 (2018).</ref-fulltext>
<ce:source-text>Liu, X., Cao, M., Palomares, M., Wu, X., Li, A., Yan, W., et al.: Metastatic breast cancer cells overexpress and secrete miR-218 to regulate type I collagen deposition by osteoblasts. Breast Cancer Res. 20(1), 127 (2018).</ce:source-text>
</reference>
<reference seq="26">
<ref-info>
<ref-title>
<ref-titletext-english>Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>B.</ce:initials>
<ce:surname>Guo</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Liang</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="5">
<ce:initials>L.</ce:initials>
<ce:surname>Dang</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:surname>Lu</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>10872</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Li, D., Liu, J., Guo, B., Liang, C., Dang, L., Lu, C., et al.: Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation. Nat. Commun. 7, 10872 (2016)</ref-fulltext>
<ce:source-text>Li, D., Liu, J., Guo, B., Liang, C., Dang, L., Lu, C., et al.: Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation. Nat. Commun. 7, 10872 (2016)</ce:source-text>
</reference>
<reference seq="27">
<ref-info>
<ref-title>
<ref-titletext-english>Osteoclast-derived microRNA-containing exosomes selectively inhibit osteoblast activity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.</ce:initials>
<ce:surname>Sun</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Zhao</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="4">
<ce:initials>L.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="5">
<ce:initials>G.</ce:initials>
<ce:surname>Nie</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:surname>Peng</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Discov</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>16015</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sun, W., Zhao, C., Li, Y., Wang, L., Nie, G., Peng, J., et al.: Osteoclast-derived microRNA-containing exosomes selectively inhibit osteoblast activity. Cell Discov. 2, 16015 (2016)</ref-fulltext>
<ce:source-text>Sun, W., Zhao, C., Li, Y., Wang, L., Nie, G., Peng, J., et al.: Osteoclast-derived microRNA-containing exosomes selectively inhibit osteoblast activity. Cell Discov. 2, 16015 (2016)</ce:source-text>
</reference>
<reference seq="28">
<ref-info>
<ref-title>
<ref-titletext-english>The roles of bone-derived exosomes and exosomal microRNAs in regulating bone remodelling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Xie</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="4">
<ce:initials>W.</ce:initials>
<ce:surname>Ge</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="5">
<ce:initials>P.</ce:initials>
<ce:surname>Tang</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Mol. Med</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1033</first-page>
<last-page>1041</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xie, Y., Chen, Y., Zhang, L., Ge, W., Tang, P.: The roles of bone-derived exosomes and exosomal microRNAs in regulating bone remodelling. J. Cell. Mol. Med. 21(5), 1033–1041 (2017)</ref-fulltext>
<ce:source-text>Xie, Y., Chen, Y., Zhang, L., Ge, W., Tang, P.: The roles of bone-derived exosomes and exosomal microRNAs in regulating bone remodelling. J. Cell. Mol. Med. 21(5), 1033–1041 (2017)</ce:source-text>
</reference>
<reference seq="29">
<ref-info>
<ref-title>
<ref-titletext-english>Osteoblast-derived extracellular vesicles are biological tools for the delivery of active molecules to bone</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Cappariello</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Loftus</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Muraca</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Maurizi</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="5">
<ce:initials>N.</ce:initials>
<ce:surname>Rucci</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Teti</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Bone Miner. Res</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>517</first-page>
<last-page>533</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cappariello, A., Loftus, A., Muraca, M., Maurizi, A., Rucci, N., Teti, A.: Osteoblast-derived extracellular vesicles are biological tools for the delivery of active molecules to bone. J. Bone Miner. Res. 33(3), 517–533 (2018)</ref-fulltext>
<ce:source-text>Cappariello, A., Loftus, A., Muraca, M., Maurizi, A., Rucci, N., Teti, A.: Osteoblast-derived extracellular vesicles are biological tools for the delivery of active molecules to bone. J. Bone Miner. Res. 33(3), 517–533 (2018)</ce:source-text>
</reference>
<reference seq="30">
<ref-info>
<ref-title>
<ref-titletext-english>Bone-derived extracellular vesicles: Novel players of interorgan crosstalk</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Yin</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Z.</ce:initials>
<ce:surname>Guo</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
<author seq="4">
<ce:initials>H.</ce:initials>
<ce:surname>Lv</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="5">
<ce:initials>Y.</ce:initials>
<ce:surname>Deng</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Endocrinol. (Lausanne).</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>846</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Li, Y., Yin, P., Guo, Z., Lv, H., Deng, Y., Chen, M., et al.: Bone-derived extracellular vesicles: novel players of interorgan crosstalk. Front. Endocrinol. (Lausanne). 10, 846 (2019)</ref-fulltext>
<ce:source-text>Li, Y., Yin, P., Guo, Z., Lv, H., Deng, Y., Chen, M., et al.: Bone-derived extracellular vesicles: novel players of interorgan crosstalk. Front. Endocrinol. (Lausanne). 10, 846 (2019)</ce:source-text>
</reference>
<reference seq="31">
<ref-info>
<ref-title>
<ref-titletext-english>Mesenchymal stem cell-derived exosomes stimulate cycling quiescence and early breast cancer dormancy in bone marrow</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.A.</ce:initials>
<ce:surname>Bliss</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Sinha</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>O.A.</ce:initials>
<ce:surname>Sandiford</ce:surname>
<ce:given-name>O.A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>L.M.</ce:initials>
<ce:surname>Williams</ce:surname>
<ce:given-name>L.M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>D.J.</ce:initials>
<ce:surname>Engelberth</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>K.</ce:initials>
<ce:surname>Guiro</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>76</vol-first>
<iss-first>19</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5832</first-page>
<last-page>5844</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bliss, S.A., Sinha, G., Sandiford, O.A., Williams, L.M., Engelberth, D.J., Guiro, K., et al.: Mesenchymal stem cell-derived exosomes stimulate cycling quiescence and early breast cancer dormancy in bone marrow. Cancer Res. 76(19), 5832–5844 (2016)</ref-fulltext>
<ce:source-text>Bliss, S.A., Sinha, G., Sandiford, O.A., Williams, L.M., Engelberth, D.J., Guiro, K., et al.: Mesenchymal stem cell-derived exosomes stimulate cycling quiescence and early breast cancer dormancy in bone marrow. Cancer Res. 76(19), 5832–5844 (2016)</ce:source-text>
</reference>
<reference seq="32">
<ref-info>
<ref-title>
<ref-titletext-english>Stromal cell extracellular vesicular cargo mediated regulation of breast cancer cell metastasis via ubiquitin conjugating enzyme E2 N pathway</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.C.</ce:initials>
<ce:surname>Vallabhaneni</ce:surname>
<ce:given-name>K.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Penfornis</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:surname>Xing</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="4">
<ce:initials>Y.</ce:initials>
<ce:surname>Hassler</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="5">
<ce:initials>K.V.</ce:initials>
<ce:surname>Adams</ce:surname>
<ce:given-name>K.V.</ce:given-name>
</author>
<author seq="6">
<ce:initials>Y.Y.</ce:initials>
<ce:surname>Mo</ce:surname>
<ce:given-name>Y.Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>66</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>109861</first-page>
<last-page>109876</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vallabhaneni, K.C., Penfornis, P., Xing, F., Hassler, Y., Adams, K.V., Mo, Y.Y., et al.: Stromal cell extracellular vesicular cargo mediated regulation of breast cancer cell metastasis via ubiquitin conjugating enzyme E2 N pathway. Oncotarget. 8(66), 109861–109876 (2017)</ref-fulltext>
<ce:source-text>Vallabhaneni, K.C., Penfornis, P., Xing, F., Hassler, Y., Adams, K.V., Mo, Y.Y., et al.: Stromal cell extracellular vesicular cargo mediated regulation of breast cancer cell metastasis via ubiquitin conjugating enzyme E2 N pathway. Oncotarget. 8(66), 109861–109876 (2017)</ce:source-text>
</reference>
<reference seq="33">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomes and extracellular RNA in muscle and bone aging and crosstalk</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.</ce:initials>
<ce:surname>Qin</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.L.</ce:initials>
<ce:surname>Dallas</ce:surname>
<ce:given-name>S.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Osteoporos. Rep</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>548</first-page>
<last-page>559</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Qin, W., Dallas, S.L.: Exosomes and extracellular RNA in muscle and bone aging and crosstalk. Curr. Osteoporos. Rep. 17(6), 548–559 (2019)</ref-fulltext>
<ce:source-text>Qin, W., Dallas, S.L.: Exosomes and extracellular RNA in muscle and bone aging and crosstalk. Curr. Osteoporos. Rep. 17(6), 548–559 (2019)</ce:source-text>
</reference>
<reference seq="34">
<ref-info>
<ref-title>
<ref-titletext-english>miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.Q.</ce:initials>
<ce:surname>Hassan</ce:surname>
<ce:given-name>M.Q.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Maeda</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Taipaleenmaki</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="4">
<ce:initials>W.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Jafferji</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.A.</ce:initials>
<ce:surname>Gordon</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem.</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>287</vol-first>
<iss-first>50</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>42084</first-page>
<last-page>42092</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hassan, M.Q., Maeda, Y., Taipaleenmaki, H., Zhang, W., Jafferji, M., Gordon, J.A., et al.: miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells. J. Biol. Chem. 287(50), 42084–42092 (2012)</ref-fulltext>
<ce:source-text>Hassan, M.Q., Maeda, Y., Taipaleenmaki, H., Zhang, W., Jafferji, M., Gordon, J.A., et al.: miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells. J. Biol. Chem. 287(50), 42084–42092 (2012)</ce:source-text>
</reference>
<reference seq="35">
<ref-info>
<ref-title>
<ref-titletext-english>miR-148a regulates osteoclastogenesis by targeting V-maf musculoaponeurotic fibrosarcoma oncogene homolog B</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Cheng</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.B.</ce:initials>
<ce:surname>He</ce:surname>
<ce:given-name>H.B.</ce:given-name>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Hu</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="5">
<ce:initials>H.D.</ce:initials>
<ce:surname>Zhou</ce:surname>
<ce:given-name>H.D.</ce:given-name>
</author>
<author seq="6">
<ce:initials>H.</ce:initials>
<ce:surname>Xie</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Bone Miner. Res.</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1180</first-page>
<last-page>1190</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cheng, P., Chen, C., He, H.B., Hu, R., Zhou, H.D., Xie, H., et al.: miR-148a regulates osteoclastogenesis by targeting V-maf musculoaponeurotic fibrosarcoma oncogene homolog B. J. Bone Miner. Res. 28(5), 1180–1190 (2013)</ref-fulltext>
<ce:source-text>Cheng, P., Chen, C., He, H.B., Hu, R., Zhou, H.D., Xie, H., et al.: miR-148a regulates osteoclastogenesis by targeting V-maf musculoaponeurotic fibrosarcoma oncogene homolog B. J. Bone Miner. Res. 28(5), 1180–1190 (2013)</ce:source-text>
</reference>
<reference seq="36">
<ref-info>
<ref-title>
<ref-titletext-english>MicroRNA functions in osteogenesis and dysfunctions in osteoporosis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.J.</ce:initials>
<ce:surname>van Wijnen</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Van de Peppel</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.P.</ce:initials>
<ce:surname>van Leeuwen</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.B.</ce:initials>
<ce:surname>Lian</ce:surname>
<ce:given-name>J.B.</ce:given-name>
</author>
<author seq="5">
<ce:initials>G.S.</ce:initials>
<ce:surname>Stein</ce:surname>
<ce:given-name>G.S.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.J.</ce:initials>
<ce:surname>Westendorf</ce:surname>
<ce:given-name>J.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Osteoporos. Rep</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>72</first-page>
<last-page>82</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>van Wijnen, A.J., van de Peppel, J., van Leeuwen, J.P., Lian, J.B., Stein, G.S., Westendorf, J.J., et al.: MicroRNA functions in osteogenesis and dysfunctions in osteoporosis. Curr. Osteoporos. Rep. 11(2), 72–82 (2013)</ref-fulltext>
<ce:source-text>van Wijnen, A.J., van de Peppel, J., van Leeuwen, J.P., Lian, J.B., Stein, G.S., Westendorf, J.J., et al.: MicroRNA functions in osteogenesis and dysfunctions in osteoporosis. Curr. Osteoporos. Rep. 11(2), 72–82 (2013)</ce:source-text>
</reference>
<reference seq="37">
<ref-info>
<ref-title>
<ref-titletext-english>MicroRNAs in bone metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Hesse</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Taipaleenmaki</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Osteoporos. Rep</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>122</first-page>
<last-page>128</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hesse, E., Taipaleenmaki, H.: MicroRNAs in bone metastasis. Curr. Osteoporos. Rep. 17(3), 122–128 (2019)</ref-fulltext>
<ce:source-text>Hesse, E., Taipaleenmaki, H.: MicroRNAs in bone metastasis. Curr. Osteoporos. Rep. 17(3), 122–128 (2019)</ce:source-text>
</reference>
<reference seq="38">
<ref-info>
<ref-title>
<ref-titletext-english>Targeting of Runx2 by miR-135 and miR-203 impairs progression of breast cancer and metastatic bone disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Taipaleenmaki</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Browne</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Akech</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Zustin</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="5">
<ce:initials>A.J.</ce:initials>
<ce:surname>van Wijnen</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.L.</ce:initials>
<ce:surname>Stein</ce:surname>
<ce:given-name>J.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>75</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1433</first-page>
<last-page>1444</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Taipaleenmaki, H., Browne, G., Akech, J., Zustin, J., van Wijnen, A.J., Stein, J.L., et al.: Targeting of Runx2 by miR-135 and miR-203 impairs progression of breast cancer and metastatic bone disease. Cancer Res. 75(7), 1433–1444 (2015)</ref-fulltext>
<ce:source-text>Taipaleenmaki, H., Browne, G., Akech, J., Zustin, J., van Wijnen, A.J., Stein, J.L., et al.: Targeting of Runx2 by miR-135 and miR-203 impairs progression of breast cancer and metastatic bone disease. Cancer Res. 75(7), 1433–1444 (2015)</ce:source-text>
</reference>
<reference seq="39">
<ref-info>
<ref-title>
<ref-titletext-english>miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.Y.</ce:initials>
<ce:surname>Krzeszinski</ce:surname>
<ce:given-name>J.Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>W.</ce:initials>
<ce:surname>Wei</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Huynh</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="4">
<ce:initials>Z.</ce:initials>
<ce:surname>Jin</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
<author seq="5">
<ce:initials>X.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="6">
<ce:initials>T.C.</ce:initials>
<ce:surname>Chang</ce:surname>
<ce:given-name>T.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>512</vol-first>
<iss-first>7515</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>431</first-page>
<last-page>435</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Krzeszinski, J.Y., Wei, W., Huynh, H., Jin, Z., Wang, X., Chang, T.C., et al.: miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. Nature. 512(7515), 431–435 (2014)</ref-fulltext>
<ce:source-text>Krzeszinski, J.Y., Wei, W., Huynh, H., Jin, Z., Wang, X., Chang, T.C., et al.: miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. Nature. 512(7515), 431–435 (2014)</ce:source-text>
</reference>
<reference seq="40">
<ref-info>
<ref-title>
<ref-titletext-english>miRNA-30 family members inhibit breast cancer invasion, osteomimicry, and bone destruction by directly targeting multiple bone metastasis-associated genes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Croset</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Pantano</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.W.S.</ce:initials>
<ce:surname>Kan</ce:surname>
<ce:given-name>C.W.S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>E.</ce:initials>
<ce:surname>Bonnelye</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="5">
<ce:initials>F.</ce:initials>
<ce:surname>Descotes</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:surname>Alix-Panabieres</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>78</vol-first>
<iss-first>18</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5259</first-page>
<last-page>5273</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Croset, M., Pantano, F., Kan, C.W.S., Bonnelye, E., Descotes, F., Alix-Panabieres, C., et al.: miRNA-30 family members inhibit breast cancer invasion, osteomimicry, and bone destruction by directly targeting multiple bone metastasis-associated genes. Cancer Res. 78(18), 5259–5273 (2018)</ref-fulltext>
<ce:source-text>Croset, M., Pantano, F., Kan, C.W.S., Bonnelye, E., Descotes, F., Alix-Panabieres, C., et al.: miRNA-30 family members inhibit breast cancer invasion, osteomimicry, and bone destruction by directly targeting multiple bone metastasis-associated genes. Cancer Res. 78(18), 5259–5273 (2018)</ce:source-text>
</reference>
<reference seq="41">
<ref-info>
<ref-title>
<ref-titletext-english>Antagonizing miR-218-5p attenuates Wnt signaling and reduces metastatic bone disease of triple negative breast cancer cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Taipaleenmaki</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>N.H.</ce:initials>
<ce:surname>Farina</ce:surname>
<ce:given-name>N.H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.J.</ce:initials>
<ce:surname>van Wijnen</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.L.</ce:initials>
<ce:surname>Stein</ce:surname>
<ce:given-name>J.L.</ce:given-name>
</author>
<author seq="5">
<ce:initials>E.</ce:initials>
<ce:surname>Hesse</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="6">
<ce:initials>G.S.</ce:initials>
<ce:surname>Stein</ce:surname>
<ce:given-name>G.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>48</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>79032</first-page>
<last-page>79046</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Taipaleenmaki, H., Farina, N.H., van Wijnen, A.J., Stein, J.L., Hesse, E., Stein, G.S., et al.: Antagonizing miR-218-5p attenuates Wnt signaling and reduces metastatic bone disease of triple negative breast cancer cells. Oncotarget. 7(48), 79032–79046 (2016)</ref-fulltext>
<ce:source-text>Taipaleenmaki, H., Farina, N.H., van Wijnen, A.J., Stein, J.L., Hesse, E., Stein, G.S., et al.: Antagonizing miR-218-5p attenuates Wnt signaling and reduces metastatic bone disease of triple negative breast cancer cells. Oncotarget. 7(48), 79032–79046 (2016)</ce:source-text>
</reference>
<reference seq="42">
<ref-info>
<ref-title>
<ref-titletext-english>Growth of limb muscle is dependent on skeletal-derived Indian hedgehog. Dev</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Bren-Mattison</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Hausburg</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>B.B.</ce:initials>
<ce:surname>Olwin</ce:surname>
<ce:given-name>B.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biol</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>356</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>486</first-page>
<last-page>495</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bren-Mattison, Y., Hausburg, M., Olwin, B.B.: Growth of limb muscle is dependent on skeletal-derived Indian hedgehog. Dev. Biol. 356(2), 486–495 (2011)</ref-fulltext>
<ce:source-text>Bren-Mattison, Y., Hausburg, M., Olwin, B.B.: Growth of limb muscle is dependent on skeletal-derived Indian hedgehog. Dev. Biol. 356(2), 486–495 (2011)</ce:source-text>
</reference>
<reference seq="43">
<ref-info>
<ref-title>
<ref-titletext-english>The ‘muscle-bone unit’ during the pubertal growth spurt</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Rauch</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.A.</ce:initials>
<ce:surname>Bailey</ce:surname>
<ce:given-name>D.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Baxter-Jones</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Mirwald</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="5">
<ce:initials>R.</ce:initials>
<ce:surname>Faulkner</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Bone</ref-sourcetitle>
<ref-publicationyear first="2004" />
<volisspag>
<volume-issue-number>
<vol-first>34</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>771</first-page>
<last-page>775</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rauch, F., Bailey, D.A., Baxter-Jones, A., Mirwald, R., Faulkner, R.: The ‘muscle-bone unit’ during the pubertal growth spurt. Bone. 34(5), 771–775 (2004)</ref-fulltext>
<ce:source-text>Rauch, F., Bailey, D.A., Baxter-Jones, A., Mirwald, R., Faulkner, R.: The ‘muscle-bone unit’ during the pubertal growth spurt. Bone. 34(5), 771–775 (2004)</ce:source-text>
</reference>
<reference seq="44">
<ref-info>
<ref-title>
<ref-titletext-english>Sarcopenia-consequences, mechanisms, and potential therapies</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.J.</ce:initials>
<ce:surname>Greenlund</ce:surname>
<ce:given-name>L.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.S.</ce:initials>
<ce:surname>Nair</ce:surname>
<ce:given-name>K.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mech. Ageing Dev</ref-sourcetitle>
<ref-publicationyear first="2003" />
<volisspag>
<volume-issue-number>
<vol-first>124</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>287</first-page>
<last-page>299</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Greenlund, L.J., Nair, K.S.: Sarcopenia-consequences, mechanisms, and potential therapies. Mech. Ageing Dev. 124(3), 287–299 (2003)</ref-fulltext>
<ce:source-text>Greenlund, L.J., Nair, K.S.: Sarcopenia-consequences, mechanisms, and potential therapies. Mech. Ageing Dev. 124(3), 287–299 (2003)</ce:source-text>
</reference>
<reference seq="45">
<ref-info>
<ref-title>
<ref-titletext-english>Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Steensberg</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>van Hall</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Osada</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Sacchetti</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>B.</ce:initials>
<ce:surname>Saltin</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="6">
<ce:initials>P.B.</ce:initials>
<ce:surname>Klarlund</ce:surname>
<ce:given-name>P.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Physiol</ref-sourcetitle>
<ref-publicationyear first="2000" />
<volisspag>
<volume-issue-number>
<vol-first>529</vol-first>
<part>Part 1</part>
</volume-issue-number>
<page-information>
<pages>
<first-page>237</first-page>
<last-page>242</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Steensberg, A., van Hall, G., Osada, T., Sacchetti, M., Saltin, B., Klarlund, P.B.: Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J. Physiol. 529(Pt 1), 237–242 (2000)</ref-fulltext>
<ce:source-text>Steensberg, A., van Hall, G., Osada, T., Sacchetti, M., Saltin, B., Klarlund, P.B.: Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J. Physiol. 529(Pt 1), 237–242 (2000)</ce:source-text>
</reference>
<reference seq="46">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.L.</ce:initials>
<ce:surname>Serrano</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Baeza-Raja</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="3">
<ce:initials>E.</ce:initials>
<ce:surname>Perdiguero</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Jardi</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>P.</ce:initials>
<ce:surname>Munoz-Canoves</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2008" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>33</first-page>
<last-page>44</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Serrano, A.L., Baeza-Raja, B., Perdiguero, E., Jardi, M., Munoz-Canoves, P.: Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. Cell Metab. 7(1), 33–44 (2008)</ref-fulltext>
<ce:source-text>Serrano, A.L., Baeza-Raja, B., Perdiguero, E., Jardi, M., Munoz-Canoves, P.: Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. Cell Metab. 7(1), 33–44 (2008)</ce:source-text>
</reference>
<reference seq="47">
<ref-info>
<ref-sourcetitle>The Role of Exercise-Induced Myokines in Muscle Homeostasis and the Defense against Chronic Diseases</ref-sourcetitle>
<ref-publicationyear first="2010" />
</ref-info>
<ref-fulltext>The role of exercise-induced myokines in muscle homeostasis and the defense against chronic diseases, (2010)</ref-fulltext>
<ce:source-text>The role of exercise-induced myokines in muscle homeostasis and the defense against chronic diseases, (2010)</ce:source-text>
</reference>
<reference seq="48">
<ref-info>
<ref-title>
<ref-titletext-english>A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Bostrom</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Wu</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.P.</ce:initials>
<ce:surname>Jedrychowski</ce:surname>
<ce:given-name>M.P.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Korde</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="5">
<ce:initials>L.</ce:initials>
<ce:surname>Ye</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.C.</ce:initials>
<ce:surname>Lo</ce:surname>
<ce:given-name>J.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>481</vol-first>
<iss-first>7382</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>463</first-page>
<last-page>468</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bostrom, P., Wu, J., Jedrychowski, M.P., Korde, A., Ye, L., Lo, J.C., et al.: A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 481(7382), 463–468 (2012)</ref-fulltext>
<ce:source-text>Bostrom, P., Wu, J., Jedrychowski, M.P., Korde, A., Ye, L., Lo, J.C., et al.: A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 481(7382), 463–468 (2012)</ce:source-text>
</reference>
<reference seq="49">
<ref-info>
<ref-title>
<ref-titletext-english>Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Kir</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.P.</ce:initials>
<ce:surname>White</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Kleiner</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>L.</ce:initials>
<ce:surname>Kazak</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="5">
<ce:initials>P.</ce:initials>
<ce:surname>Cohen</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="6">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>513</vol-first>
<iss-first>7516</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>100</first-page>
<last-page>104</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kir, S., White, J.P., Kleiner, S., Kazak, L., Cohen, P., Baracos, V.E., et al.: Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature. 513(7516), 100–104 (2014)</ref-fulltext>
<ce:source-text>Kir, S., White, J.P., Kleiner, S., Kazak, L., Cohen, P., Baracos, V.E., et al.: Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature. 513(7516), 100–104 (2014)</ce:source-text>
</reference>
<reference seq="50">
<ref-info>
<ref-title>
<ref-titletext-english>A switch from white to brown fat increases energy expenditure in cancer-associated cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Petruzzelli</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Schweiger</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Schreiber</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Campos-Olivas</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Tsoli</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:surname>Allen</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>433</first-page>
<last-page>447</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Petruzzelli, M., Schweiger, M., Schreiber, R., Campos-Olivas, R., Tsoli, M., Allen, J., et al.: A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab. 20(3), 433–447 (2014)</ref-fulltext>
<ce:source-text>Petruzzelli, M., Schweiger, M., Schreiber, R., Campos-Olivas, R., Tsoli, M., Allen, J., et al.: A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab. 20(3), 433–447 (2014)</ce:source-text>
</reference>
<reference seq="51">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin-6 induces fat loss in cancer cachexia by promoting white adipose tissue lipolysis and browning</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Han</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Q.</ce:initials>
<ce:surname>Meng</ce:surname>
<ce:given-name>Q.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:surname>Shen</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="4">
<ce:initials>G.</ce:initials>
<ce:surname>Wu</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Lipids Health Dis</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>14</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Han, J., Meng, Q., Shen, L., Wu, G.: Interleukin-6 induces fat loss in cancer cachexia by promoting white adipose tissue lipolysis and browning. Lipids Health Dis. 17(1), 14 (2018)</ref-fulltext>
<ce:source-text>Han, J., Meng, Q., Shen, L., Wu, G.: Interleukin-6 induces fat loss in cancer cachexia by promoting white adipose tissue lipolysis and browning. Lipids Health Dis. 17(1), 14 (2018)</ce:source-text>
</reference>
<reference seq="52">
<ref-info>
<ref-title>
<ref-titletext-english>Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.C.</ce:initials>
<ce:surname>McPherron</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.M.</ce:initials>
<ce:surname>Lawler</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.J.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>S.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="1997" />
<volisspag>
<volume-issue-number>
<vol-first>387</vol-first>
<iss-first>6628</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>83</first-page>
<last-page>90</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>McPherron, A.C., Lawler, A.M., Lee, S.J.: Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 387(6628), 83–90 (1997)</ref-fulltext>
<ce:source-text>McPherron, A.C., Lawler, A.M., Lee, S.J.: Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 387(6628), 83–90 (1997)</ce:source-text>
</reference>
<reference seq="53">
<ref-info>
<ref-title>
<ref-titletext-english>Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>McFarlane</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Plummer</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Thomas</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Hennebry</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Ashby</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>N.</ce:initials>
<ce:surname>Ling</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Physiol</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>209</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>501</first-page>
<last-page>514</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>McFarlane, C., Plummer, E., Thomas, M., Hennebry, A., Ashby, M., Ling, N., et al.: Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism. J. Cell. Physiol. 209(2), 501–514 (2006)</ref-fulltext>
<ce:source-text>McFarlane, C., Plummer, E., Thomas, M., Hennebry, A., Ashby, M., Ling, N., et al.: Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism. J. Cell. Physiol. 209(2), 501–514 (2006)</ce:source-text>
</reference>
<reference seq="54">
<ref-info>
<ref-title>
<ref-titletext-english>Bone and skeletal muscle: Neighbors with close ties</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.J.</ce:initials>
<ce:surname>Digirolamo</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.P.</ce:initials>
<ce:surname>Kiel</ce:surname>
<ce:given-name>D.P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.A.</ce:initials>
<ce:surname>Esser</ce:surname>
<ce:given-name>K.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Bone Miner. Res</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1509</first-page>
<last-page>1518</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>DiGirolamo, D.J., Kiel, D.P., Esser, K.A.: Bone and skeletal muscle: neighbors with close ties. J. Bone Miner. Res. 28(7), 1509–1518 (2013)</ref-fulltext>
<ce:source-text>DiGirolamo, D.J., Kiel, D.P., Esser, K.A.: Bone and skeletal muscle: neighbors with close ties. J. Bone Miner. Res. 28(7), 1509–1518 (2013)</ce:source-text>
</reference>
<reference seq="55">
<ref-info>
<ref-title>
<ref-titletext-english>beta-aminoisobutyric acid, l-BAIBA, is a muscle-derived osteocyte survival factor</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Kitase</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.A.</ce:initials>
<ce:surname>Vallejo</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>W.</ce:initials>
<ce:surname>Gutheil</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="4">
<ce:initials>H.</ce:initials>
<ce:surname>Vemula</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="5">
<ce:initials>K.</ce:initials>
<ce:surname>Jahn</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:surname>Yi</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Rep</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>22</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1531</first-page>
<last-page>1544</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kitase, Y., Vallejo, J.A., Gutheil, W., Vemula, H., Jahn, K., Yi, J., et al.: beta-aminoisobutyric acid, l-BAIBA, is a muscle-derived osteocyte survival factor. Cell Rep. 22(6), 1531–1544 (2018)</ref-fulltext>
<ce:source-text>Kitase, Y., Vallejo, J.A., Gutheil, W., Vemula, H., Jahn, K., Yi, J., et al.: beta-aminoisobutyric acid, l-BAIBA, is a muscle-derived osteocyte survival factor. Cell Rep. 22(6), 1531–1544 (2018)</ce:source-text>
</reference>
<reference seq="56">
<ref-info>
<ref-title>
<ref-titletext-english>Bone anabolic effects of basic fibroblast growth factor in ovariectomized rats</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Liang</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Pun</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.J.</ce:initials>
<ce:surname>Wronski</ce:surname>
<ce:given-name>T.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Endocrinology</ref-sourcetitle>
<ref-publicationyear first="1999" />
<volisspag>
<volume-issue-number>
<vol-first>140</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5780</first-page>
<last-page>5788</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Liang, H., Pun, S., Wronski, T.J.: Bone anabolic effects of basic fibroblast growth factor in ovariectomized rats. Endocrinology. 140(12), 5780–5788 (1999)</ref-fulltext>
<ce:source-text>Liang, H., Pun, S., Wronski, T.J.: Bone anabolic effects of basic fibroblast growth factor in ovariectomized rats. Endocrinology. 140(12), 5780–5788 (1999)</ce:source-text>
</reference>
<reference seq="57">
<ref-info>
<ref-title>
<ref-titletext-english>Circulating levels of IGF-1 directly regulate bone growth and density</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Yakar</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.J.</ce:initials>
<ce:surname>Rosen</ce:surname>
<ce:given-name>C.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>W.G.</ce:initials>
<ce:surname>Beamer</ce:surname>
<ce:given-name>W.G.</ce:given-name>
</author>
<author seq="4">
<ce:initials>C.L.</ce:initials>
<ce:surname>Ackert-Bicknell</ce:surname>
<ce:given-name>C.L.</ce:given-name>
</author>
<author seq="5">
<ce:initials>Y.</ce:initials>
<ce:surname>Wu</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.L.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>J.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="2002" />
<volisspag>
<volume-issue-number>
<vol-first>110</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>771</first-page>
<last-page>781</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yakar, S., Rosen, C.J., Beamer, W.G., Ackert-Bicknell, C.L., Wu, Y., Liu, J.L., et al.: Circulating levels of IGF-1 directly regulate bone growth and density. J. Clin. Invest. 110(6), 771–781 (2002)</ref-fulltext>
<ce:source-text>Yakar, S., Rosen, C.J., Beamer, W.G., Ackert-Bicknell, C.L., Wu, Y., Liu, J.L., et al.: Circulating levels of IGF-1 directly regulate bone growth and density. J. Clin. Invest. 110(6), 771–781 (2002)</ce:source-text>
</reference>
<reference seq="58">
<ref-info>
<ref-title>
<ref-titletext-english>IL-6 contributes to the defective osteogenesis of bone marrow stromal cells from the vertebral body of the glucocorticoid-induced osteoporotic mouse</ref-titletext-english>
</ref-title>
<itemidlist>
<itemid idtype="ARTNUM">e0154677</itemid>
</itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Z.Y.</ce:initials>
<ce:surname>Zhou</ce:surname>
<ce:given-name>Z.Y.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Y.Y.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>Y.Y.</ce:given-name>
</author>
<author seq="4">
<ce:initials>H.L.</ce:initials>
<ce:surname>Yang</ce:surname>
<ce:given-name>H.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Li, X., Zhou, Z.Y., Zhang, Y.Y., Yang, H.L.: IL-6 contributes to the defective osteogenesis of bone marrow stromal cells from the vertebral body of the glucocorticoid-induced osteoporotic mouse. PLoS One. 11(4), e0154677 (2016)</ref-fulltext>
<ce:source-text>Li, X., Zhou, Z.Y., Zhang, Y.Y., Yang, H.L.: IL-6 contributes to the defective osteogenesis of bone marrow stromal cells from the vertebral body of the glucocorticoid-induced osteoporotic mouse. PLoS One. 11(4), e0154677 (2016)</ce:source-text>
</reference>
<reference seq="59">
<ref-info>
<ref-title>
<ref-titletext-english>Myostatin (GDF-8) deficiency increases fracture callus size, Sox-5 expression, and callus bone volume</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Kellum</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Starr</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Arounleut</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="4">
<ce:initials>D.</ce:initials>
<ce:surname>Immel</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Fulzele</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="6">
<ce:initials>K.</ce:initials>
<ce:surname>Wenger</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Bone</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>44</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>17</first-page>
<last-page>23</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kellum, E., Starr, H., Arounleut, P., Immel, D., Fulzele, S., Wenger, K., et al.: Myostatin (GDF-8) deficiency increases fracture callus size, Sox-5 expression, and callus bone volume. Bone. 44(1), 17–23 (2009)</ref-fulltext>
<ce:source-text>Kellum, E., Starr, H., Arounleut, P., Immel, D., Fulzele, S., Wenger, K., et al.: Myostatin (GDF-8) deficiency increases fracture callus size, Sox-5 expression, and callus bone volume. Bone. 44(1), 17–23 (2009)</ce:source-text>
</reference>
<reference seq="60">
<ref-info>
<ref-title>
<ref-titletext-english>Inhibition of GDF8 (Myostatin) accelerates bone regeneration in diabetes mellitus type 2</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Wallner</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Jaurich</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.M.</ce:initials>
<ce:surname>Wagner</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Becerikli</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>K.</ce:initials>
<ce:surname>Harati</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Dadras</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>9878</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wallner, C., Jaurich, H., Wagner, J.M., Becerikli, M., Harati, K., Dadras, M., et al.: Inhibition of GDF8 (Myostatin) accelerates bone regeneration in diabetes mellitus type 2. Sci. Rep. 7(1), 9878 (2017)</ref-fulltext>
<ce:source-text>Wallner, C., Jaurich, H., Wagner, J.M., Becerikli, M., Harati, K., Dadras, M., et al.: Inhibition of GDF8 (Myostatin) accelerates bone regeneration in diabetes mellitus type 2. Sci. Rep. 7(1), 9878 (2017)</ce:source-text>
</reference>
<reference seq="61">
<ref-info>
<ref-title>
<ref-titletext-english>Effects of myokines on bone</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Kaji</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Bonekey Rep</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>826</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kaji, H.: Effects of myokines on bone. Bonekey Rep. 5, 826 (2016)</ref-fulltext>
<ce:source-text>Kaji, H.: Effects of myokines on bone. Bonekey Rep. 5, 826 (2016)</ce:source-text>
</reference>
<reference seq="62">
<ref-info>
<ref-title>
<ref-titletext-english>Increased muscle mass with myostatin deficiency improves gains in bone strength with exercise</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.W.</ce:initials>
<ce:surname>Hamrick</ce:surname>
<ce:given-name>M.W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Samaddar</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Pennington</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>McCormick</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Bone Miner. Res</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>477</first-page>
<last-page>483</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hamrick, M.W., Samaddar, T., Pennington, C., McCormick, J.: Increased muscle mass with myostatin deficiency improves gains in bone strength with exercise. J. Bone Miner. Res. 21(3), 477–483 (2006)</ref-fulltext>
<ce:source-text>Hamrick, M.W., Samaddar, T., Pennington, C., McCormick, J.: Increased muscle mass with myostatin deficiency improves gains in bone strength with exercise. J. Bone Miner. Res. 21(3), 477–483 (2006)</ce:source-text>
</reference>
<reference seq="63">
<ref-info>
<ref-title>
<ref-titletext-english>Pathogenic role of Fgf23 in Hyp mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Zhou</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>W.</ce:initials>
<ce:surname>Tang</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="4">
<ce:initials>X.</ce:initials>
<ce:surname>Jiang</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="5">
<ce:initials>D.W.</ce:initials>
<ce:surname>Rowe</ce:surname>
<ce:given-name>D.W.</ce:given-name>
</author>
<author seq="6">
<ce:initials>L.D.</ce:initials>
<ce:surname>Quarles</ce:surname>
<ce:given-name>L.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Endocrinol. Metab</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>291</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>E38</first-page>
<last-page>E49</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Liu, S., Zhou, J., Tang, W., Jiang, X., Rowe, D.W., Quarles, L.D.: Pathogenic role of Fgf23 in Hyp mice. Am. J. Physiol. Endocrinol. Metab. 291(1), E38–E49 (2006)</ref-fulltext>
<ce:source-text>Liu, S., Zhou, J., Tang, W., Jiang, X., Rowe, D.W., Quarles, L.D.: Pathogenic role of Fgf23 in Hyp mice. Am. J. Physiol. Endocrinol. Metab. 291(1), E38–E49 (2006)</ce:source-text>
</reference>
<reference seq="64">
<ref-info>
<ref-title>
<ref-titletext-english>Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Aono</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Hasegawa</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Yamazaki</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Shimada</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="5">
<ce:initials>T.</ce:initials>
<ce:surname>Fujita</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="6">
<ce:initials>T.</ce:initials>
<ce:surname>Yamashita</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Bone Miner. Res</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>803</first-page>
<last-page>810</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Aono, Y., Hasegawa, H., Yamazaki, Y., Shimada, T., Fujita, T., Yamashita, T., et al.: Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice. J. Bone Miner. Res. 26(4), 803–810 (2011)</ref-fulltext>
<ce:source-text>Aono, Y., Hasegawa, H., Yamazaki, Y., Shimada, T., Fujita, T., Yamashita, T., et al.: Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice. J. Bone Miner. Res. 26(4), 803–810 (2011)</ce:source-text>
</reference>
<reference seq="65">
<ref-info>
<ref-title>
<ref-titletext-english>FGF23 induces left ventricular hypertrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Faul</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.P.</ce:initials>
<ce:surname>Amaral</ce:surname>
<ce:given-name>A.P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>B.</ce:initials>
<ce:surname>Oskouei</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.C.</ce:initials>
<ce:surname>Hu</ce:surname>
<ce:given-name>M.C.</ce:given-name>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Sloan</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>T.</ce:initials>
<ce:surname>Isakova</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>121</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4393</first-page>
<last-page>4408</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Faul, C., Amaral, A.P., Oskouei, B., Hu, M.C., Sloan, A., Isakova, T., et al.: FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 121(11), 4393–4408 (2011)</ref-fulltext>
<ce:source-text>Faul, C., Amaral, A.P., Oskouei, B., Hu, M.C., Sloan, A., Isakova, T., et al.: FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 121(11), 4393–4408 (2011)</ce:source-text>
</reference>
<reference seq="66">
<ref-info>
<ref-title>
<ref-titletext-english>Osteocalcin signaling in myofibers is necessary and sufficient for optimum adaptation to exercise</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Mera</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Laue</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Ferron</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Confavreux</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Wei</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Galan-Diez</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>23</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1078</first-page>
<last-page>1092</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mera, P., Laue, K., Ferron, M., Confavreux, C., Wei, J., Galan-Diez, M., et al.: Osteocalcin signaling in myofibers is necessary and sufficient for optimum adaptation to exercise. Cell Metab. 23(6), 1078–1092 (2016)</ref-fulltext>
<ce:source-text>Mera, P., Laue, K., Ferron, M., Confavreux, C., Wei, J., Galan-Diez, M., et al.: Osteocalcin signaling in myofibers is necessary and sufficient for optimum adaptation to exercise. Cell Metab. 23(6), 1078–1092 (2016)</ce:source-text>
</reference>
<reference seq="67">
<ref-info>
<ref-title>
<ref-titletext-english>Osteocalcin is necessary and sufficient to maintain muscle mass in older mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Mera</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Laue</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.W.</ce:initials>
<ce:surname>Wei</ce:surname>
<ce:given-name>J.W.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.M.</ce:initials>
<ce:surname>Berger</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>G.</ce:initials>
<ce:surname>Karsenty</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Metab</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1042</first-page>
<last-page>1047</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mera, P., Laue, K., Wei, J.W., Berger, J.M., Karsenty, G.: Osteocalcin is necessary and sufficient to maintain muscle mass in older mice. Mol. Metab. 5(10), 1042–1047 (2016)</ref-fulltext>
<ce:source-text>Mera, P., Laue, K., Wei, J.W., Berger, J.M., Karsenty, G.: Osteocalcin is necessary and sufficient to maintain muscle mass in older mice. Mol. Metab. 5(10), 1042–1047 (2016)</ce:source-text>
</reference>
<reference seq="68">
<ref-info>
<ref-title>
<ref-titletext-english>Involvement of activin in the regulation of bone metabolism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Sakai</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Eto</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cell. Endocrinol</ref-sourcetitle>
<ref-publicationyear first="2001" />
<volisspag>
<volume-issue-number>
<vol-first>180</vol-first>
<iss-first>1</iss-first>
<iss-last>2</iss-last>
</volume-issue-number>
<page-information>
<pages>
<first-page>183</first-page>
<last-page>188</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sakai, R., Eto, Y.: Involvement of activin in the regulation of bone metabolism. Mol. Cell. Endocrinol. 180(1–2), 183–188 (2001)</ref-fulltext>
<ce:source-text>Sakai, R., Eto, Y.: Involvement of activin in the regulation of bone metabolism. Mol. Cell. Endocrinol. 180(1–2), 183–188 (2001)</ce:source-text>
</reference>
<reference seq="69">
<ref-info>
<ref-title>
<ref-titletext-english>Quantification of various growth factors in different demineralized bone matrix preparations</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Wildemann</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Kadow-Romacker</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.P.</ce:initials>
<ce:surname>Haas</ce:surname>
<ce:given-name>N.P.</ce:given-name>
</author>
<author seq="4">
<ce:initials>G.</ce:initials>
<ce:surname>Schmidmaier</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biomed. Mater. Res. A</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>81</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>437</first-page>
<last-page>442</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wildemann, B., Kadow-Romacker, A., Haas, N.P., Schmidmaier, G.: Quantification of various growth factors in different demineralized bone matrix preparations. J. Biomed. Mater. Res. A. 81(2), 437–442 (2007)</ref-fulltext>
<ce:source-text>Wildemann, B., Kadow-Romacker, A., Haas, N.P., Schmidmaier, G.: Quantification of various growth factors in different demineralized bone matrix preparations. J. Biomed. Mater. Res. A. 81(2), 437–442 (2007)</ce:source-text>
</reference>
<reference seq="70">
<ref-info>
<ref-title>
<ref-titletext-english>Role of transforming growth factor-beta in bone remodeling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.F.</ce:initials>
<ce:surname>Bonewald</ce:surname>
<ce:given-name>L.F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.R.</ce:initials>
<ce:surname>Mundy</ce:surname>
<ce:given-name>G.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Orthop. Relat. Res</ref-sourcetitle>
<ref-publicationyear first="1990" />
<volisspag>
<volume-issue-number>
<vol-first>250</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>261</first-page>
<last-page>276</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bonewald, L.F., Mundy, G.R.: Role of transforming growth factor-beta in bone remodeling. Clin. Orthop. Relat. Res. 250, 261–276 (1990)</ref-fulltext>
<ce:source-text>Bonewald, L.F., Mundy, G.R.: Role of transforming growth factor-beta in bone remodeling. Clin. Orthop. Relat. Res. 250, 261–276 (1990)</ce:source-text>
</reference>
<reference seq="71">
<ref-info>
<ref-title>
<ref-titletext-english>Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.L.</ce:initials>
<ce:surname>Dallas</ce:surname>
<ce:given-name>S.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.L.</ce:initials>
<ce:surname>Rosser</ce:surname>
<ce:given-name>J.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>G.R.</ce:initials>
<ce:surname>Mundy</ce:surname>
<ce:given-name>G.R.</ce:given-name>
</author>
<author seq="4">
<ce:initials>L.F.</ce:initials>
<ce:surname>Bonewald</ce:surname>
<ce:given-name>L.F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2002" />
<volisspag>
<volume-issue-number>
<vol-first>277</vol-first>
<iss-first>24</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>21352</first-page>
<last-page>21360</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dallas, S.L., Rosser, J.L., Mundy, G.R., Bonewald, L.F.: Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J. Biol. Chem. 277(24), 21352–21360 (2002)</ref-fulltext>
<ce:source-text>Dallas, S.L., Rosser, J.L., Mundy, G.R., Bonewald, L.F.: Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J. Biol. Chem. 277(24), 21352–21360 (2002)</ce:source-text>
</reference>
<reference seq="72">
<ref-info>
<ref-title>
<ref-titletext-english>Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Kang</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>W.</ce:initials>
<ce:surname>He</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Tulley</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>G.P.</ce:initials>
<ce:surname>Gupta</ce:surname>
<ce:given-name>G.P.</ce:given-name>
</author>
<author seq="5">
<ce:initials>I.</ce:initials>
<ce:surname>Serganova</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="6">
<ce:initials>C.R.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>C.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>102</vol-first>
<iss-first>39</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>13909</first-page>
<last-page>13914</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kang, Y., He, W., Tulley, S., Gupta, G.P., Serganova, I., Chen, C.R., et al.: Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc. Natl. Acad. Sci. USA. 102(39), 13909–13914 (2005)</ref-fulltext>
<ce:source-text>Kang, Y., He, W., Tulley, S., Gupta, G.P., Serganova, I., Chen, C.R., et al.: Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc. Natl. Acad. Sci. USA. 102(39), 13909–13914 (2005)</ce:source-text>
</reference>
<reference seq="73">
<ref-info>
<ref-title>
<ref-titletext-english>A multigenic program mediating breast cancer metastasis to bone</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Kang</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.M.</ce:initials>
<ce:surname>Siegel</ce:surname>
<ce:given-name>P.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>W.</ce:initials>
<ce:surname>Shu</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Drobnjak</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>S.M.</ce:initials>
<ce:surname>Kakonen</ce:surname>
<ce:given-name>S.M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:surname>Cordon-Cardo</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2003" />
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>537</first-page>
<last-page>549</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kang, Y., Siegel, P.M., Shu, W., Drobnjak, M., Kakonen, S.M., Cordon-Cardo, C., et al.: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 3(6), 537–549 (2003)</ref-fulltext>
<ce:source-text>Kang, Y., Siegel, P.M., Shu, W., Drobnjak, M., Kakonen, S.M., Cordon-Cardo, C., et al.: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 3(6), 537–549 (2003)</ce:source-text>
</reference>
<reference seq="74">
<ref-info>
<ref-title>
<ref-titletext-english>Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Korpal</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Yan</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>X.</ce:initials>
<ce:surname>Lu</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Xu</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="5">
<ce:initials>D.A.</ce:initials>
<ce:surname>Lerit</ce:surname>
<ce:given-name>D.A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>Y.</ce:initials>
<ce:surname>Kang</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Med</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>960</first-page>
<last-page>966</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Korpal, M., Yan, J., Lu, X., Xu, S., Lerit, D.A., Kang, Y.: Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat. Med. 15(8), 960–966 (2009)</ref-fulltext>
<ce:source-text>Korpal, M., Yan, J., Lu, X., Xu, S., Lerit, D.A., Kang, Y.: Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat. Med. 15(8), 960–966 (2009)</ce:source-text>
</reference>
<reference seq="75">
<ref-info>
<ref-title>
<ref-titletext-english>TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.J.</ce:initials>
<ce:surname>Yin</ce:surname>
<ce:given-name>J.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Selander</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.M.</ce:initials>
<ce:surname>Chirgwin</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Dallas</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>B.G.</ce:initials>
<ce:surname>Grubbs</ce:surname>
<ce:given-name>B.G.</ce:given-name>
</author>
<author seq="6">
<ce:initials>R.</ce:initials>
<ce:surname>Wieser</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="1999" />
<volisspag>
<volume-issue-number>
<vol-first>103</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>197</first-page>
<last-page>206</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yin, J.J., Selander, K., Chirgwin, J.M., Dallas, M., Grubbs, B.G., Wieser, R., et al.: TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103(2), 197–206 (1999)</ref-fulltext>
<ce:source-text>Yin, J.J., Selander, K., Chirgwin, J.M., Dallas, M., Grubbs, B.G., Wieser, R., et al.: TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103(2), 197–206 (1999)</ce:source-text>
</reference>
<reference seq="76">
<ref-info>
<ref-title>
<ref-titletext-english>Excess TGF-beta mediates muscle weakness associated with bone metastases in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.L.</ce:initials>
<ce:surname>Waning</ce:surname>
<ce:given-name>D.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.S.</ce:initials>
<ce:surname>Mohammad</ce:surname>
<ce:given-name>K.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Reiken</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>W.</ce:initials>
<ce:surname>Xie</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="5">
<ce:initials>D.C.</ce:initials>
<ce:surname>Andersson</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>John</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Med</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1262</first-page>
<last-page>1271</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Waning, D.L., Mohammad, K.S., Reiken, S., Xie, W., Andersson, D.C., John, S., et al.: Excess TGF-beta mediates muscle weakness associated with bone metastases in mice. Nat. Med. 21(11), 1262–1271 (2015)</ref-fulltext>
<ce:source-text>Waning, D.L., Mohammad, K.S., Reiken, S., Xie, W., Andersson, D.C., John, S., et al.: Excess TGF-beta mediates muscle weakness associated with bone metastases in mice. Nat. Med. 21(11), 1262–1271 (2015)</ce:source-text>
</reference>
<reference seq="77">
<ref-info>
<ref-title>
<ref-titletext-english>Osteolytic breast cancer causes skeletal muscle weakness in an immunocompetent syngeneic mouse model</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.N.</ce:initials>
<ce:surname>Regan</ce:surname>
<ce:given-name>J.N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Mikesell</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Reiken</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>H.</ce:initials>
<ce:surname>Xu</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="5">
<ce:initials>A.R.</ce:initials>
<ce:surname>Marks</ce:surname>
<ce:given-name>A.R.</ce:given-name>
</author>
<author seq="6">
<ce:initials>K.S.</ce:initials>
<ce:surname>Mohammad</ce:surname>
<ce:given-name>K.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Endocrinol. (Lausanne).</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>358</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Regan, J.N., Mikesell, C., Reiken, S., Xu, H., Marks, A.R., Mohammad, K.S., et al.: Osteolytic breast cancer causes skeletal muscle weakness in an immunocompetent syngeneic mouse model. Front. Endocrinol. (Lausanne). 8, 358 (2017)</ref-fulltext>
<ce:source-text>Regan, J.N., Mikesell, C., Reiken, S., Xu, H., Marks, A.R., Mohammad, K.S., et al.: Osteolytic breast cancer causes skeletal muscle weakness in an immunocompetent syngeneic mouse model. Front. Endocrinol. (Lausanne). 8, 358 (2017)</ce:source-text>
</reference>
<reference seq="78">
<ref-info>
<ref-title>
<ref-titletext-english>Physiology and pathophysiology of excitation-contraction coupling: The functional role of ryanodine receptor</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Santulli</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.R.</ce:initials>
<ce:surname>Lewis</ce:surname>
<ce:given-name>D.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.R.</ce:initials>
<ce:surname>Marks</ce:surname>
<ce:given-name>A.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Muscle Res. Cell Motil</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>37</first-page>
<last-page>45</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Santulli, G., Lewis, D.R., Marks, A.R.: Physiology and pathophysiology of excitation-contraction coupling: The functional role of ryanodine receptor. J. Muscle Res. Cell Motil. 38(1), 37–45 (2017)</ref-fulltext>
<ce:source-text>Santulli, G., Lewis, D.R., Marks, A.R.: Physiology and pathophysiology of excitation-contraction coupling: The functional role of ryanodine receptor. J. Muscle Res. Cell Motil. 38(1), 37–45 (2017)</ce:source-text>
</reference>
<reference seq="79">
<ref-info>
<ref-title>
<ref-titletext-english>Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.C.</ce:initials>
<ce:surname>Andersson</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.J.</ce:initials>
<ce:surname>Betzenhauser</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Reiken</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.C.</ce:initials>
<ce:surname>Meli</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Umanskaya</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>W.</ce:initials>
<ce:surname>Xie</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>196</first-page>
<last-page>207</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Andersson, D.C., Betzenhauser, M.J., Reiken, S., Meli, A.C., Umanskaya, A., Xie, W., et al.: Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging. Cell Metab. 14(2), 196–207 (2011)</ref-fulltext>
<ce:source-text>Andersson, D.C., Betzenhauser, M.J., Reiken, S., Meli, A.C., Umanskaya, A., Xie, W., et al.: Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging. Cell Metab. 14(2), 196–207 (2011)</ce:source-text>
</reference>
<reference seq="80">
<ref-info>
<ref-title>
<ref-titletext-english>Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.M.</ce:initials>
<ce:surname>Bellinger</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Reiken</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Carlson</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Mongillo</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>X.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="6">
<ce:initials>L.</ce:initials>
<ce:surname>Rothman</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Med</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>325</first-page>
<last-page>330</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bellinger, A.M., Reiken, S., Carlson, C., Mongillo, M., Liu, X., Rothman, L., et al.: Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle. Nat. Med. 15(3), 325–330 (2009)</ref-fulltext>
<ce:source-text>Bellinger, A.M., Reiken, S., Carlson, C., Mongillo, M., Liu, X., Rothman, L., et al.: Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle. Nat. Med. 15(3), 325–330 (2009)</ce:source-text>
</reference>
<reference seq="81">
<ref-info>
<ref-title>
<ref-titletext-english>Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Ago</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Kitazono</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Ooboshi</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Iyama</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="5">
<ce:initials>Y.H.</ce:initials>
<ce:surname>Han</ce:surname>
<ce:given-name>Y.H.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:surname>Takada</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Circulation</ref-sourcetitle>
<ref-publicationyear first="2004" />
<volisspag>
<volume-issue-number>
<vol-first>109</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>227</first-page>
<last-page>233</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ago, T., Kitazono, T., Ooboshi, H., Iyama, T., Han, Y.H., Takada, J., et al.: Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation. 109(2), 227–233 (2004)</ref-fulltext>
<ce:source-text>Ago, T., Kitazono, T., Ooboshi, H., Iyama, T., Han, Y.H., Takada, J., et al.: Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation. 109(2), 227–233 (2004)</ce:source-text>
</reference>
<reference seq="82">
<ref-info>
<ref-title>
<ref-titletext-english>Upregulation of the NADPH oxidase NOX4 by TGF-beta in hepatocytes is required for its pro-apoptotic activity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Carmona-Cuenca</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Roncero</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Sancho</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="4">
<ce:initials>L.</ce:initials>
<ce:surname>Caja</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="5">
<ce:initials>N.</ce:initials>
<ce:surname>Fausto</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Fernandez</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Hepatol</ref-sourcetitle>
<ref-publicationyear first="2008" />
<volisspag>
<volume-issue-number>
<vol-first>49</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>965</first-page>
<last-page>976</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Carmona-Cuenca, I., Roncero, C., Sancho, P., Caja, L., Fausto, N., Fernandez, M., et al.: Upregulation of the NADPH oxidase NOX4 by TGF-beta in hepatocytes is required for its pro-apoptotic activity. J. Hepatol. 49(6), 965–976 (2008)</ref-fulltext>
<ce:source-text>Carmona-Cuenca, I., Roncero, C., Sancho, P., Caja, L., Fausto, N., Fernandez, M., et al.: Upregulation of the NADPH oxidase NOX4 by TGF-beta in hepatocytes is required for its pro-apoptotic activity. J. Hepatol. 49(6), 965–976 (2008)</ce:source-text>
</reference>
<reference seq="83">
<ref-info>
<ref-title>
<ref-titletext-english>Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S.</ce:initials>
<ce:surname>Nyman</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.R.</ce:initials>
<ce:surname>Merkel</ce:surname>
<ce:given-name>A.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Uppuganti</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>B.</ce:initials>
<ce:surname>Nayak</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="5">
<ce:initials>B.</ce:initials>
<ce:surname>Rowland</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="6">
<ce:initials>A.J.</ce:initials>
<ce:surname>Makowski</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Bone</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>91</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>81</first-page>
<last-page>91</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nyman, J.S., Merkel, A.R., Uppuganti, S., Nayak, B., Rowland, B., Makowski, A.J., et al.: Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease. Bone. 91, 81–91 (2016)</ref-fulltext>
<ce:source-text>Nyman, J.S., Merkel, A.R., Uppuganti, S., Nayak, B., Rowland, B., Makowski, A.J., et al.: Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease. Bone. 91, 81–91 (2016)</ce:source-text>
</reference>
<reference seq="84">
<ref-info>
<ref-title>
<ref-titletext-english>Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment</ref-titletext-english>
</ref-title>
<itemidlist>
<itemid idtype="ARTNUM">e6896</itemid>
</itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>L.K.</ce:initials>
<ce:surname>Dunn</ce:surname>
<ce:given-name>L.K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.S.</ce:initials>
<ce:surname>Mohammad</ce:surname>
<ce:given-name>K.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>P.G.</ce:initials>
<ce:surname>Fournier</ce:surname>
<ce:given-name>P.G.</ce:given-name>
</author>
<author seq="4">
<ce:initials>C.R.</ce:initials>
<ce:surname>McKenna</ce:surname>
<ce:given-name>C.R.</ce:given-name>
</author>
<author seq="5">
<ce:initials>H.W.</ce:initials>
<ce:surname>Davis</ce:surname>
<ce:given-name>H.W.</ce:given-name>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Niewolna</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Dunn, L.K., Mohammad, K.S., Fournier, P.G., McKenna, C.R., Davis, H.W., Niewolna, M., et al.: Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS One. 4(9), e6896 (2009)</ref-fulltext>
<ce:source-text>Dunn, L.K., Mohammad, K.S., Fournier, P.G., McKenna, C.R., Davis, H.W., Niewolna, M., et al.: Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS One. 4(9), e6896 (2009)</ce:source-text>
</reference>
<reference seq="85">
<ref-info>
<ref-title>
<ref-titletext-english>PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): Defective regulation in failing hearts</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.O.</ce:initials>
<ce:surname>Marx</ce:surname>
<ce:given-name>S.O.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Reiken</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Hisamatsu</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Jayaraman</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="5">
<ce:initials>D.</ce:initials>
<ce:surname>Burkhoff</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="6">
<ce:initials>N.</ce:initials>
<ce:surname>Rosemblit</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2000" />
<volisspag>
<volume-issue-number>
<vol-first>101</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>365</first-page>
<last-page>376</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Marx, S.O., Reiken, S., Hisamatsu, Y., Jayaraman, T., Burkhoff, D., Rosemblit, N., et al.: PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell. 101(4), 365–376 (2000)</ref-fulltext>
<ce:source-text>Marx, S.O., Reiken, S., Hisamatsu, Y., Jayaraman, T., Burkhoff, D., Rosemblit, N., et al.: PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell. 101(4), 365–376 (2000)</ce:source-text>
</reference>
<reference seq="86">
<ref-info>
<ref-title>
<ref-titletext-english>Transforming growth factor-beta induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.L.</ce:initials>
<ce:surname>Mendias</ce:surname>
<ce:given-name>C.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.P.</ce:initials>
<ce:surname>Gumucio</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.E.</ce:initials>
<ce:surname>Davis</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
<author seq="4">
<ce:initials>C.W.</ce:initials>
<ce:surname>Bromley</ce:surname>
<ce:given-name>C.W.</ce:given-name>
</author>
<author seq="5">
<ce:initials>C.S.</ce:initials>
<ce:surname>Davis</ce:surname>
<ce:given-name>C.S.</ce:given-name>
</author>
<author seq="6">
<ce:initials>S.V.</ce:initials>
<ce:surname>Brooks</ce:surname>
<ce:given-name>S.V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Muscle Nerve</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>45</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>55</first-page>
<last-page>59</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mendias, C.L., Gumucio, J.P., Davis, M.E., Bromley, C.W., Davis, C.S., Brooks, S.V.: Transforming growth factor-beta induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis. Muscle Nerve. 45(1), 55–59 (2012)</ref-fulltext>
<ce:source-text>Mendias, C.L., Gumucio, J.P., Davis, M.E., Bromley, C.W., Davis, C.S., Brooks, S.V.: Transforming growth factor-beta induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis. Muscle Nerve. 45(1), 55–59 (2012)</ce:source-text>
</reference>
<reference seq="87">
<ref-info>
<ref-title>
<ref-titletext-english>Inhibition of skeletal muscle satellite cell differentiation by transforming growth factor-beta</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.E.</ce:initials>
<ce:surname>Allen</ce:surname>
<ce:given-name>R.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.K.</ce:initials>
<ce:surname>Boxhorn</ce:surname>
<ce:given-name>L.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Physiol</ref-sourcetitle>
<ref-publicationyear first="1987" />
<volisspag>
<volume-issue-number>
<vol-first>133</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>567</first-page>
<last-page>572</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Allen, R.E., Boxhorn, L.K.: Inhibition of skeletal muscle satellite cell differentiation by transforming growth factor-beta. J. Cell. Physiol. 133(3), 567–572 (1987)</ref-fulltext>
<ce:source-text>Allen, R.E., Boxhorn, L.K.: Inhibition of skeletal muscle satellite cell differentiation by transforming growth factor-beta. J. Cell. Physiol. 133(3), 567–572 (1987)</ce:source-text>
</reference>
<reference seq="88">
<ref-info>
<ref-title>
<ref-titletext-english>Regulation of skeletal muscle satellite cell proliferation and differentiation by transforming growth factor-beta, insulin-like growth factor I, and fibroblast growth factor</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.E.</ce:initials>
<ce:surname>Allen</ce:surname>
<ce:given-name>R.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.K.</ce:initials>
<ce:surname>Boxhorn</ce:surname>
<ce:given-name>L.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Physiol</ref-sourcetitle>
<ref-publicationyear first="1989" />
<volisspag>
<volume-issue-number>
<vol-first>138</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>311</first-page>
<last-page>315</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Allen, R.E., Boxhorn, L.K.: Regulation of skeletal muscle satellite cell proliferation and differentiation by transforming growth factor-beta, insulin-like growth factor I, and fibroblast growth factor. J. Cell. Physiol. 138(2), 311–315 (1989)</ref-fulltext>
<ce:source-text>Allen, R.E., Boxhorn, L.K.: Regulation of skeletal muscle satellite cell proliferation and differentiation by transforming growth factor-beta, insulin-like growth factor I, and fibroblast growth factor. J. Cell. Physiol. 138(2), 311–315 (1989)</ce:source-text>
</reference>
<reference seq="89">
<ref-info>
<ref-title>
<ref-titletext-english>Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.W.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>Y.W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Nagaraju</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Bakay</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>O.</ce:initials>
<ce:surname>McIntyre</ce:surname>
<ce:given-name>O.</ce:given-name>
</author>
<author seq="5">
<ce:initials>R.</ce:initials>
<ce:surname>Rawat</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="6">
<ce:initials>R.</ce:initials>
<ce:surname>Shi</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Neurology</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>65</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>826</first-page>
<last-page>834</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, Y.W., Nagaraju, K., Bakay, M., McIntyre, O., Rawat, R., Shi, R., et al.: Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. Neurology. 65(6), 826–834 (2005)</ref-fulltext>
<ce:source-text>Chen, Y.W., Nagaraju, K., Bakay, M., McIntyre, O., Rawat, R., Shi, R., et al.: Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. Neurology. 65(6), 826–834 (2005)</ce:source-text>
</reference>
<reference seq="90">
<ref-info>
<ref-title>
<ref-titletext-english>Transforming growth factor-beta and myostatin signaling in skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.D.</ce:initials>
<ce:surname>Kollias</ce:surname>
<ce:given-name>H.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.C.</ce:initials>
<ce:surname>McDermott</ce:surname>
<ce:given-name>J.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Appl. Physiol. 2008</ref-sourcetitle>
<ref-publicationyear first="1985" />
<volisspag>
<volume-issue-number>
<vol-first>104</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>579</first-page>
<last-page>587</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kollias, H.D., McDermott, J.C.: Transforming growth factor-beta and myostatin signaling in skeletal muscle. J. Appl. Physiol. 2008, 104(3), 579–587 (1985)</ref-fulltext>
<ce:source-text>Kollias, H.D., McDermott, J.C.: Transforming growth factor-beta and myostatin signaling in skeletal muscle. J. Appl. Physiol. 2008, 104(3), 579–587 (1985)</ce:source-text>
</reference>
<reference seq="91">
<ref-info>
<ref-title>
<ref-titletext-english>Regulation of muscle growth by multiple ligands signaling through activin type II receptors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.J.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>S.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.A.</ce:initials>
<ce:surname>Reed</ce:surname>
<ce:given-name>L.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.V.</ce:initials>
<ce:surname>Davies</ce:surname>
<ce:given-name>M.V.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Girgenrath</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.E.</ce:initials>
<ce:surname>Goad</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
<author seq="6">
<ce:initials>K.N.</ce:initials>
<ce:surname>Tomkinson</ce:surname>
<ce:given-name>K.N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>102</vol-first>
<iss-first>50</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>18117</first-page>
<last-page>18122</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lee, S.J., Reed, L.A., Davies, M.V., Girgenrath, S., Goad, M.E., Tomkinson, K.N., et al.: Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc. Natl. Acad. Sci. USA. 102(50), 18117–18122 (2005)</ref-fulltext>
<ce:source-text>Lee, S.J., Reed, L.A., Davies, M.V., Girgenrath, S., Goad, M.E., Tomkinson, K.N., et al.: Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc. Natl. Acad. Sci. USA. 102(50), 18117–18122 (2005)</ce:source-text>
</reference>
<reference seq="92">
<ref-info>
<ref-title>
<ref-titletext-english>Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Zhou</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.L.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>J.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Lu</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>Y.</ce:initials>
<ce:surname>Song</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="5">
<ce:initials>K.S.</ce:initials>
<ce:surname>Kwak</ce:surname>
<ce:given-name>K.S.</ce:given-name>
</author>
<author seq="6">
<ce:initials>Q.</ce:initials>
<ce:surname>Jiao</ce:surname>
<ce:given-name>Q.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>142</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>531</first-page>
<last-page>543</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhou, X., Wang, J.L., Lu, J., Song, Y., Kwak, K.S., Jiao, Q., et al.: Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 142(4), 531–543 (2010)</ref-fulltext>
<ce:source-text>Zhou, X., Wang, J.L., Lu, J., Song, Y., Kwak, K.S., Jiao, Q., et al.: Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 142(4), 531–543 (2010)</ce:source-text>
</reference>
<reference seq="93">
<ref-info>
<ref-title>
<ref-titletext-english>Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.E.</ce:initials>
<ce:surname>Pistilli</ce:surname>
<ce:given-name>E.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Bogdanovich</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.D.</ce:initials>
<ce:surname>Goncalves</ce:surname>
<ce:given-name>M.D.</ce:given-name>
</author>
<author seq="4">
<ce:initials>R.S.</ce:initials>
<ce:surname>Ahima</ce:surname>
<ce:given-name>R.S.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Lachey</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:surname>Seehra</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Pathol</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>178</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1287</first-page>
<last-page>1297</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pistilli, E.E., Bogdanovich, S., Goncalves, M.D., Ahima, R.S., Lachey, J., Seehra, J., et al.: Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy. Am. J. Pathol. 178(3), 1287–1297 (2011)</ref-fulltext>
<ce:source-text>Pistilli, E.E., Bogdanovich, S., Goncalves, M.D., Ahima, R.S., Lachey, J., Seehra, J., et al.: Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy. Am. J. Pathol. 178(3), 1287–1297 (2011)</ce:source-text>
</reference>
<reference seq="94">
<ref-info>
<ref-title>
<ref-titletext-english>BMP signaling controls muscle mass. Nat</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Sartori</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Schirwis</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>B.</ce:initials>
<ce:surname>Blaauw</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Bortolanza</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Zhao</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>E.</ce:initials>
<ce:surname>Enzo</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Genet</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>45</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1309</first-page>
<last-page>1318</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sartori, R., Schirwis, E., Blaauw, B., Bortolanza, S., Zhao, J., Enzo, E., et al.: BMP signaling controls muscle mass. Nat. Genet. 45(11), 1309–1318 (2013)</ref-fulltext>
<ce:source-text>Sartori, R., Schirwis, E., Blaauw, B., Bortolanza, S., Zhao, J., Enzo, E., et al.: BMP signaling controls muscle mass. Nat. Genet. 45(11), 1309–1318 (2013)</ce:source-text>
</reference>
<reference seq="95">
<ref-info>
<ref-title>
<ref-titletext-english>Regulation and dysregulation of fibrosis in skeletal muscle. Exp</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.L.</ce:initials>
<ce:surname>Serrano</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Munoz-Canoves</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Res</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>316</vol-first>
<iss-first>18</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3050</first-page>
<last-page>3058</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Serrano, A.L., Munoz-Canoves, P.: Regulation and dysregulation of fibrosis in skeletal muscle. Exp. Cell Res. 316(18), 3050–3058 (2010)</ref-fulltext>
<ce:source-text>Serrano, A.L., Munoz-Canoves, P.: Regulation and dysregulation of fibrosis in skeletal muscle. Exp. Cell Res. 316(18), 3050–3058 (2010)</ce:source-text>
</reference>
<reference seq="96">
<ref-info>
<ref-title>
<ref-titletext-english>Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: Insights from genetic models</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Schiaffino</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Mammucari</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Skelet. Muscle</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Schiaffino, S., Mammucari, C.: Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: insights from genetic models. Skelet. Muscle. 1(1), 4 (2011)</ref-fulltext>
<ce:source-text>Schiaffino, S., Mammucari, C.: Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: insights from genetic models. Skelet. Muscle. 1(1), 4 (2011)</ce:source-text>
</reference>
<reference seq="97">
<ref-info>
<ref-title>
<ref-titletext-english>Growth hormone and the insulin-like growth factor system in myogenesis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.R.</ce:initials>
<ce:surname>Florini</ce:surname>
<ce:given-name>J.R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.Z.</ce:initials>
<ce:surname>Ewton</ce:surname>
<ce:given-name>D.Z.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.A.</ce:initials>
<ce:surname>Coolican</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Endocr. Rev</ref-sourcetitle>
<ref-publicationyear first="1996" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>481</first-page>
<last-page>517</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Florini, J.R., Ewton, D.Z., Coolican, S.A.: Growth hormone and the insulin-like growth factor system in myogenesis. Endocr. Rev. 17(5), 481–517 (1996)</ref-fulltext>
<ce:source-text>Florini, J.R., Ewton, D.Z., Coolican, S.A.: Growth hormone and the insulin-like growth factor system in myogenesis. Endocr. Rev. 17(5), 481–517 (1996)</ce:source-text>
</reference>
<reference seq="98">
<ref-info>
<ref-title>
<ref-titletext-english>Evaluation of vitamin D deficiency in breast cancer patients on bisphosphonates</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Wang-Gillam</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.A.</ce:initials>
<ce:surname>Miles</ce:surname>
<ce:given-name>D.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.F.</ce:initials>
<ce:surname>Hutchins</ce:surname>
<ce:given-name>L.F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncologist</ref-sourcetitle>
<ref-publicationyear first="2008" />
<volisspag>
<volume-issue-number>
<vol-first>13</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>821</first-page>
<last-page>827</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang-Gillam, A., Miles, D.A., Hutchins, L.F.: Evaluation of vitamin D deficiency in breast cancer patients on bisphosphonates. Oncologist. 13(7), 821–827 (2008)</ref-fulltext>
<ce:source-text>Wang-Gillam, A., Miles, D.A., Hutchins, L.F.: Evaluation of vitamin D deficiency in breast cancer patients on bisphosphonates. Oncologist. 13(7), 821–827 (2008)</ce:source-text>
</reference>
<reference seq="99">
<ref-info>
<ref-title>
<ref-titletext-english>Swimming behaviour and post-swimming activity in Vitamin D receptor knockout mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.H.</ce:initials>
<ce:surname>Burne</ce:surname>
<ce:given-name>T.H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.N.</ce:initials>
<ce:surname>Johnston</ce:surname>
<ce:given-name>A.N.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.J.</ce:initials>
<ce:surname>McGrath</ce:surname>
<ce:given-name>J.J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Mackay-Sim</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Brain Res. Bull</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>69</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>74</first-page>
<last-page>78</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Burne, T.H., Johnston, A.N., McGrath, J.J., Mackay-Sim, A.: Swimming behaviour and post-swimming activity in Vitamin D receptor knockout mice. Brain Res. Bull. 69(1), 74–78 (2006)</ref-fulltext>
<ce:source-text>Burne, T.H., Johnston, A.N., McGrath, J.J., Mackay-Sim, A.: Swimming behaviour and post-swimming activity in Vitamin D receptor knockout mice. Brain Res. Bull. 69(1), 74–78 (2006)</ce:source-text>
</reference>
<reference seq="100">
<ref-info>
<ref-title>
<ref-titletext-english>Impaired motor performance in mice lacking neurosteroid vitamin D receptors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.V.</ce:initials>
<ce:surname>Kalueff</ce:surname>
<ce:given-name>A.V.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.R.</ce:initials>
<ce:surname>Lou</ce:surname>
<ce:given-name>Y.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>I.</ce:initials>
<ce:surname>Laaksi</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="4">
<ce:initials>P.</ce:initials>
<ce:surname>Tuohimaa</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Brain Res. Bull</ref-sourcetitle>
<ref-publicationyear first="2004" />
<volisspag>
<volume-issue-number>
<vol-first>64</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>25</first-page>
<last-page>29</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kalueff, A.V., Lou, Y.R., Laaksi, I., Tuohimaa, P.: Impaired motor performance in mice lacking neurosteroid vitamin D receptors. Brain Res. Bull. 64(1), 25–29 (2004)</ref-fulltext>
<ce:source-text>Kalueff, A.V., Lou, Y.R., Laaksi, I., Tuohimaa, P.: Impaired motor performance in mice lacking neurosteroid vitamin D receptors. Brain Res. Bull. 64(1), 25–29 (2004)</ce:source-text>
</reference>
<reference seq="101">
<ref-info>
<ref-title>
<ref-titletext-english>Osteomalacic myopathy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Russell</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Muscle Nerve</ref-sourcetitle>
<ref-publicationyear first="1994" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>578</first-page>
<last-page>580</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Russell, J.A.: Osteomalacic myopathy. Muscle Nerve. 17(6), 578–580 (1994)</ref-fulltext>
<ce:source-text>Russell, J.A.: Osteomalacic myopathy. Muscle Nerve. 17(6), 578–580 (1994)</ce:source-text>
</reference>
<reference seq="102">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle weakness in osteomalacia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.D.</ce:initials>
<ce:surname>Schott</ce:surname>
<ce:given-name>G.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.R.</ce:initials>
<ce:surname>Wills</ce:surname>
<ce:given-name>M.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Lancet</ref-sourcetitle>
<ref-publicationyear first="1976" />
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
<iss-first>7960</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>626</first-page>
<last-page>629</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Schott, G.D., Wills, M.R.: Muscle weakness in osteomalacia. Lancet. 1(7960), 626–629 (1976)</ref-fulltext>
<ce:source-text>Schott, G.D., Wills, M.R.: Muscle weakness in osteomalacia. Lancet. 1(7960), 626–629 (1976)</ce:source-text>
</reference>
<reference seq="103">
<ref-info>
<ref-title>
<ref-titletext-english>Antiresorptive therapy in the management of cancer treatment-induced bone loss</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Garg</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Leitzel</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Ali</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Lipton</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Osteoporos. Rep</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>13</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>73</first-page>
<last-page>77</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Garg, A., Leitzel, K., Ali, S., Lipton, A.: Antiresorptive therapy in the management of cancer treatment-induced bone loss. Curr. Osteoporos. Rep. 13(2), 73–77 (2015)</ref-fulltext>
<ce:source-text>Garg, A., Leitzel, K., Ali, S., Lipton, A.: Antiresorptive therapy in the management of cancer treatment-induced bone loss. Curr. Osteoporos. Rep. 13(2), 73–77 (2015)</ce:source-text>
</reference>
<reference seq="104">
<ref-info>
<ref-title>
<ref-titletext-english>Bone loss and fracture risk associated with cancer therapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.A.</ce:initials>
<ce:surname>Guise</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncologist</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1121</first-page>
<last-page>1131</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Guise, T.A.: Bone loss and fracture risk associated with cancer therapy. Oncologist. 11(10), 1121–1131 (2006)</ref-fulltext>
<ce:source-text>Guise, T.A.: Bone loss and fracture risk associated with cancer therapy. Oncologist. 11(10), 1121–1131 (2006)</ce:source-text>
</reference>
<reference seq="105">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer treatment and survivorship statistics, 2016</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.D.</ce:initials>
<ce:surname>Miller</ce:surname>
<ce:given-name>K.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.L.</ce:initials>
<ce:surname>Siegel</ce:surname>
<ce:given-name>R.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.C.</ce:initials>
<ce:surname>Lin</ce:surname>
<ce:given-name>C.C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.B.</ce:initials>
<ce:surname>Mariotto</ce:surname>
<ce:given-name>A.B.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.L.</ce:initials>
<ce:surname>Kramer</ce:surname>
<ce:given-name>J.L.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.H.</ce:initials>
<ce:surname>Rowland</ce:surname>
<ce:given-name>J.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>CA Cancer J. Clin</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>66</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>271</first-page>
<last-page>289</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Miller, K.D., Siegel, R.L., Lin, C.C., Mariotto, A.B., Kramer, J.L., Rowland, J.H., et al.: Cancer treatment and survivorship statistics, 2016. CA Cancer J. Clin. 66(4), 271–289 (2016)</ref-fulltext>
<ce:source-text>Miller, K.D., Siegel, R.L., Lin, C.C., Mariotto, A.B., Kramer, J.L., Rowland, J.H., et al.: Cancer treatment and survivorship statistics, 2016. CA Cancer J. Clin. 66(4), 271–289 (2016)</ce:source-text>
</reference>
<reference seq="106">
<ref-info>
<ref-title>
<ref-titletext-english>Incidence of bone metastases and skeletal-related events in breast cancer patients: A population-based cohort study in Denmark</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.O.</ce:initials>
<ce:surname>Jensen</ce:surname>
<ce:given-name>A.O.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.B.</ce:initials>
<ce:surname>Jacobsen</ce:surname>
<ce:given-name>J.B.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Norgaard</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Yong</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.P.</ce:initials>
<ce:surname>Fryzek</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
<author seq="6">
<ce:initials>H.T.</ce:initials>
<ce:surname>Sorensen</ce:surname>
<ce:given-name>H.T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>BMC Cancer</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>29</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Jensen, A.O., Jacobsen, J.B., Norgaard, M., Yong, M., Fryzek, J.P., Sorensen, H.T.: Incidence of bone metastases and skeletal-related events in breast cancer patients: A population-based cohort study in Denmark. BMC Cancer. 11, 29 (2011)</ref-fulltext>
<ce:source-text>Jensen, A.O., Jacobsen, J.B., Norgaard, M., Yong, M., Fryzek, J.P., Sorensen, H.T.: Incidence of bone metastases and skeletal-related events in breast cancer patients: A population-based cohort study in Denmark. BMC Cancer. 11, 29 (2011)</ce:source-text>
</reference>
<reference seq="107">
<ref-info>
<ref-title>
<ref-titletext-english>Natural history and treatment of bone complications in prostate cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Saad</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:surname>Clarke</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Colombel</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. Urol</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>49</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>429</first-page>
<last-page>440</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Saad, F., Clarke, N., Colombel, M.: Natural history and treatment of bone complications in prostate cancer. Eur. Urol. 49(3), 429–440 (2006)</ref-fulltext>
<ce:source-text>Saad, F., Clarke, N., Colombel, M.: Natural history and treatment of bone complications in prostate cancer. Eur. Urol. 49(3), 429–440 (2006)</ce:source-text>
</reference>
<reference seq="108">
<ref-info>
<ref-title>
<ref-titletext-english>Reversing mitochondrial dysfunction, fatigue and the adverse effects of chemotherapy of metastatic disease by molecular replacement therapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.L.</ce:initials>
<ce:surname>Nicolson</ce:surname>
<ce:given-name>G.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.A.</ce:initials>
<ce:surname>Conklin</ce:surname>
<ce:given-name>K.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Exp. Metastasis</ref-sourcetitle>
<ref-publicationyear first="2008" />
<volisspag>
<volume-issue-number>
<vol-first>25</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>161</first-page>
<last-page>169</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nicolson, G.L., Conklin, K.A.: Reversing mitochondrial dysfunction, fatigue and the adverse effects of chemotherapy of metastatic disease by molecular replacement therapy. Clin. Exp. Metastasis. 25(2), 161–169 (2008)</ref-fulltext>
<ce:source-text>Nicolson, G.L., Conklin, K.A.: Reversing mitochondrial dysfunction, fatigue and the adverse effects of chemotherapy of metastatic disease by molecular replacement therapy. Clin. Exp. Metastasis. 25(2), 161–169 (2008)</ce:source-text>
</reference>
<reference seq="109">
<ref-info>
<ref-title>
<ref-titletext-english>Chemotherapy-induced weakness and fatigue in skeletal muscle: The role of oxidative stress</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.A.</ce:initials>
<ce:surname>Gilliam</ce:surname>
<ce:given-name>L.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.K.</ce:initials>
<ce:surname>St Clair</ce:surname>
<ce:given-name>D.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Antioxid. Redox Signal</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2543</first-page>
<last-page>2563</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gilliam, L.A., St Clair, D.K.: Chemotherapy-induced weakness and fatigue in skeletal muscle: The role of oxidative stress. Antioxid. Redox Signal. 15(9), 2543–2563 (2011)</ref-fulltext>
<ce:source-text>Gilliam, L.A., St Clair, D.K.: Chemotherapy-induced weakness and fatigue in skeletal muscle: The role of oxidative stress. Antioxid. Redox Signal. 15(9), 2543–2563 (2011)</ce:source-text>
</reference>
<reference seq="110">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer treatment-induced bone loss (CTIBL): Pathogenesis and clinical implications</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>D'oronzo</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Stucci</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Tucci</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>F.</ce:initials>
<ce:surname>Silvestris</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Treat. Rev</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>41</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>798</first-page>
<last-page>808</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>D'Oronzo, S., Stucci, S., Tucci, M., Silvestris, F.: Cancer treatment-induced bone loss (CTIBL): Pathogenesis and clinical implications. Cancer Treat. Rev. 41(9), 798–808 (2015)</ref-fulltext>
<ce:source-text>D'Oronzo, S., Stucci, S., Tucci, M., Silvestris, F.: Cancer treatment-induced bone loss (CTIBL): Pathogenesis and clinical implications. Cancer Treat. Rev. 41(9), 798–808 (2015)</ce:source-text>
</reference>
<reference seq="111">
<ref-info>
<ref-title>
<ref-titletext-english>Chemotherapy-induced muscle wasting: Association with NF-kappaB and cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S.</ce:initials>
<ce:surname>Damrauer</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.E.</ce:initials>
<ce:surname>Stadler</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Acharyya</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.S.</ce:initials>
<ce:surname>Baldwin</ce:surname>
<ce:given-name>A.S.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.E.</ce:initials>
<ce:surname>Couch</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
<author seq="6">
<ce:initials>D.C.</ce:initials>
<ce:surname>Guttridge</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Transl. Myol</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7590</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Damrauer, J.S., Stadler, M.E., Acharyya, S., Baldwin, A.S., Couch, M.E., Guttridge, D.C.: Chemotherapy-induced muscle wasting: Association with NF-kappaB and cancer cachexia. Eur. J. Transl. Myol. 28(2), 7590 (2018)</ref-fulltext>
<ce:source-text>Damrauer, J.S., Stadler, M.E., Acharyya, S., Baldwin, A.S., Couch, M.E., Guttridge, D.C.: Chemotherapy-induced muscle wasting: Association with NF-kappaB and cancer cachexia. Eur. J. Transl. Myol. 28(2), 7590 (2018)</ce:source-text>
</reference>
<reference seq="112">
<ref-info>
<ref-title>
<ref-titletext-english>Doxorubicin-mediated bone loss in breast cancer bone metastases is driven by an interplay between oxidative stress and induction of TGFbeta</ref-titletext-english>
</ref-title>
<itemidlist>
<itemid idtype="ARTNUM">e78043</itemid>
</itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Rana</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Chakrabarti</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Freeman</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Biswas</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Rana, T., Chakrabarti, A., Freeman, M., Biswas, S.: Doxorubicin-mediated bone loss in breast cancer bone metastases is driven by an interplay between oxidative stress and induction of TGFbeta. PLoS One. 8(10), e78043 (2013)</ref-fulltext>
<ce:source-text>Rana, T., Chakrabarti, A., Freeman, M., Biswas, S.: Doxorubicin-mediated bone loss in breast cancer bone metastases is driven by an interplay between oxidative stress and induction of TGFbeta. PLoS One. 8(10), e78043 (2013)</ce:source-text>
</reference>
<reference seq="113">
<ref-info>
<ref-title>
<ref-titletext-english>Chemotherapy-induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.A.</ce:initials>
<ce:surname>Hain</ce:surname>
<ce:given-name>B.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Xu</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.R.</ce:initials>
<ce:surname>Wilcox</ce:surname>
<ce:given-name>J.R.</ce:given-name>
</author>
<author seq="4">
<ce:initials>D.</ce:initials>
<ce:surname>Mutua</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="5">
<ce:initials>D.L.</ce:initials>
<ce:surname>Waning</ce:surname>
<ce:given-name>D.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>JCSM Rapid. Communications</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Hain, B.A., Xu, H., Wilcox, J.R., Mutua, D., Waning, D.L.: Chemotherapy-induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia. JCSM Rapid. Communications. 2(1) (2019)</ref-fulltext>
<ce:source-text>Hain, B.A., Xu, H., Wilcox, J.R., Mutua, D., Waning, D.L.: Chemotherapy-induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia. JCSM Rapid. Communications. 2(1) (2019)</ce:source-text>
</reference>
<reference seq="114">
<ref-info>
<ref-title>
<ref-titletext-english>Zoledronic acid improves muscle function in healthy mice treated with chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.A.</ce:initials>
<ce:surname>Hain</ce:surname>
<ce:given-name>B.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Jude</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Xu</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="4">
<ce:initials>D.M.</ce:initials>
<ce:surname>Smuin</ce:surname>
<ce:given-name>D.M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>E.J.</ce:initials>
<ce:surname>Fox</ce:surname>
<ce:given-name>E.J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.C.</ce:initials>
<ce:surname>Elfar</ce:surname>
<ce:given-name>J.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Bone Miner. Res</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>368</first-page>
<last-page>381</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hain, B.A., Jude, B., Xu, H., Smuin, D.M., Fox, E.J., Elfar, J.C., et al.: Zoledronic acid improves muscle function in healthy mice treated with chemotherapy. J. Bone Miner. Res. 35(2), 368–381 (2020)</ref-fulltext>
<ce:source-text>Hain, B.A., Jude, B., Xu, H., Smuin, D.M., Fox, E.J., Elfar, J.C., et al.: Zoledronic acid improves muscle function in healthy mice treated with chemotherapy. J. Bone Miner. Res. 35(2), 368–381 (2020)</ce:source-text>
</reference>
<reference seq="115">
<ref-info>
<ref-title>
<ref-titletext-english>ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass. Sci</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Barreto</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Kitase</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Matsumoto</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="4">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="5">
<ce:initials>K.C.</ce:initials>
<ce:surname>Colston</ce:surname>
<ce:given-name>K.C.</ce:given-name>
</author>
<author seq="6">
<ce:initials>K.E.</ce:initials>
<ce:surname>Couch</ce:surname>
<ce:given-name>K.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Rep</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>14470</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Barreto, R., Kitase, Y., Matsumoto, T., Pin, F., Colston, K.C., Couch, K.E., et al.: ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass. Sci. Rep. 7(1), 14470 (2017)</ref-fulltext>
<ce:source-text>Barreto, R., Kitase, Y., Matsumoto, T., Pin, F., Colston, K.C., Couch, K.E., et al.: ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass. Sci. Rep. 7(1), 14470 (2017)</ce:source-text>
</reference>
<reference seq="116">
<ref-info>
<ref-title>
<ref-titletext-english>Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Barreto</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.L.</ce:initials>
<ce:surname>Waning</ce:surname>
<ce:given-name>D.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Gao</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="4">
<ce:initials>Y.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="5">
<ce:initials>T.A.</ce:initials>
<ce:surname>Zimmers</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>28</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>43442</first-page>
<last-page>43460</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Barreto, R., Waning, D.L., Gao, H., Liu, Y., Zimmers, T.A., Bonetto, A.: Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs. Oncotarget. 7(28), 43442–43460 (2016)</ref-fulltext>
<ce:source-text>Barreto, R., Waning, D.L., Gao, H., Liu, Y., Zimmers, T.A., Bonetto, A.: Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs. Oncotarget. 7(28), 43442–43460 (2016)</ce:source-text>
</reference>
<reference seq="117">
<ref-info>
<ref-title>
<ref-titletext-english>Bisphosphonate treatment ameliorates chemotherapy-induced bone and muscle abnormalities in young mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.L.</ce:initials>
<ce:surname>Essex</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.R.</ce:initials>
<ce:surname>Huot</ce:surname>
<ce:given-name>J.R.</ce:given-name>
</author>
<author seq="4">
<ce:initials>L.F.</ce:initials>
<ce:surname>Bonewald</ce:surname>
<ce:given-name>L.F.</ce:given-name>
</author>
<author seq="5">
<ce:initials>L.I.</ce:initials>
<ce:surname>Plotkin</ce:surname>
<ce:given-name>L.I.</ce:given-name>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Endocrinol. (Lausanne).</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>809</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Essex, A.L., Pin, F., Huot, J.R., Bonewald, L.F., Plotkin, L.I., Bonetto, A.: Bisphosphonate treatment ameliorates chemotherapy-induced bone and muscle abnormalities in young mice. Front. Endocrinol. (Lausanne). 10, 809 (2019)</ref-fulltext>
<ce:source-text>Essex, A.L., Pin, F., Huot, J.R., Bonewald, L.F., Plotkin, L.I., Bonetto, A.: Bisphosphonate treatment ameliorates chemotherapy-induced bone and muscle abnormalities in young mice. Front. Endocrinol. (Lausanne). 10, 809 (2019)</ce:source-text>
</reference>
<reference seq="118">
<ref-info>
<ref-title>
<ref-titletext-english>Doxorubicin acts through tumor necrosis factor receptor subtype 1 to cause dysfunction of murine skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.A.</ce:initials>
<ce:surname>Gilliam</ce:surname>
<ce:given-name>L.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.F.</ce:initials>
<ce:surname>Ferreira</ce:surname>
<ce:given-name>L.F.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.D.</ce:initials>
<ce:surname>Bruton</ce:surname>
<ce:given-name>J.D.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.S.</ce:initials>
<ce:surname>Moylan</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
<author seq="5">
<ce:initials>H.</ce:initials>
<ce:surname>Westerblad</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="6">
<ce:initials>D.K.</ce:initials>
<ce:surname>St Clair</ce:surname>
<ce:given-name>D.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Appl. Physiol. 2009</ref-sourcetitle>
<ref-publicationyear first="1985" />
<volisspag>
<volume-issue-number>
<vol-first>107</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1935</first-page>
<last-page>1942</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gilliam LA, Ferreira LF, Bruton JD, Moylan JS, Westerblad H, St Clair DK, et al. Doxorubicin acts through tumor necrosis factor receptor subtype 1 to cause dysfunction of murine skeletal muscle. J. Appl. Physiol. 2009, 107(6), 1935–1942 (1985)</ref-fulltext>
<ce:source-text>Gilliam LA, Ferreira LF, Bruton JD, Moylan JS, Westerblad H, St Clair DK, et al. Doxorubicin acts through tumor necrosis factor receptor subtype 1 to cause dysfunction of murine skeletal muscle. J. Appl. Physiol. 2009, 107(6), 1935–1942 (1985)</ce:source-text>
</reference>
<reference seq="119">
<ref-info>
<ref-title>
<ref-titletext-english>Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.A.</ce:initials>
<ce:surname>Gilliam</ce:surname>
<ce:given-name>L.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.S.</ce:initials>
<ce:surname>Moylan</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.A.</ce:initials>
<ce:surname>Callahan</ce:surname>
<ce:given-name>L.A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.P.</ce:initials>
<ce:surname>Sumandea</ce:surname>
<ce:given-name>M.P.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.B.</ce:initials>
<ce:surname>Reid</ce:surname>
<ce:given-name>M.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Muscle Nerve</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>43</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>94</first-page>
<last-page>102</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gilliam, L.A., Moylan, J.S., Callahan, L.A., Sumandea, M.P., Reid, M.B.: Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy. Muscle Nerve. 43(1), 94–102 (2011)</ref-fulltext>
<ce:source-text>Gilliam, L.A., Moylan, J.S., Callahan, L.A., Sumandea, M.P., Reid, M.B.: Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy. Muscle Nerve. 43(1), 94–102 (2011)</ce:source-text>
</reference>
<reference seq="120">
<ref-info>
<ref-title>
<ref-titletext-english>An overview of sarcopenia: Facts and numbers on prevalence and clinical impact</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>von Haehling</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.E.</ce:initials>
<ce:surname>Morley</ce:surname>
<ce:given-name>J.E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.D.</ce:initials>
<ce:surname>Anker</ce:surname>
<ce:given-name>S.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>129</first-page>
<last-page>133</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>von Haehling, S., Morley, J.E., Anker, S.D.: An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J. Cachexia. Sarcopenia Muscle. 1(2), 129–133 (2010)</ref-fulltext>
<ce:source-text>von Haehling, S., Morley, J.E., Anker, S.D.: An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J. Cachexia. Sarcopenia Muscle. 1(2), 129–133 (2010)</ce:source-text>
</reference>
<reference seq="121">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle dysfunction in cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.F.</ce:initials>
<ce:surname>Christensen</ce:surname>
<ce:given-name>J.F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.W.</ce:initials>
<ce:surname>Jones</ce:surname>
<ce:given-name>L.W.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.L.</ce:initials>
<ce:surname>Andersen</ce:surname>
<ce:given-name>J.L.</ce:given-name>
</author>
<author seq="4">
<ce:initials>G.</ce:initials>
<ce:surname>Daugaard</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Rorth</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>P.</ce:initials>
<ce:surname>Hojman</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Oncol</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>25</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>947</first-page>
<last-page>958</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Christensen, J.F., Jones, L.W., Andersen, J.L., Daugaard, G., Rorth, M., Hojman, P.: Muscle dysfunction in cancer patients. Ann. Oncol. 25(5), 947–958 (2014)</ref-fulltext>
<ce:source-text>Christensen, J.F., Jones, L.W., Andersen, J.L., Daugaard, G., Rorth, M., Hojman, P.: Muscle dysfunction in cancer patients. Ann. Oncol. 25(5), 947–958 (2014)</ce:source-text>
</reference>
<reference seq="122">
<ref-info>
<ref-title>
<ref-titletext-english>Impact of primary breast cancer therapy on energetic capacity and body composition</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.J.</ce:initials>
<ce:surname>Ballinger</ce:surname>
<ce:given-name>T.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Reddy</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.K.</ce:initials>
<ce:surname>Althouse</ce:surname>
<ce:given-name>S.K.</ce:given-name>
</author>
<author seq="4">
<ce:initials>E.M.</ce:initials>
<ce:surname>Nelson</ce:surname>
<ce:given-name>E.M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>K.D.</ce:initials>
<ce:surname>Miller</ce:surname>
<ce:given-name>K.D.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.S.</ce:initials>
<ce:surname>Sledge</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Breast Cancer Res. Treat</ref-sourcetitle>
<ref-publicationyear first="2018" />
</ref-info>
<ref-fulltext>Ballinger, T.J., Reddy, A., Althouse, S.K., Nelson, E.M., Miller, K.D., Sledge, J.S.: Impact of primary breast cancer therapy on energetic capacity and body composition. Breast Cancer Res. Treat. (2018)</ref-fulltext>
<ce:source-text>Ballinger, T.J., Reddy, A., Althouse, S.K., Nelson, E.M., Miller, K.D., Sledge, J.S.: Impact of primary breast cancer therapy on energetic capacity and body composition. Breast Cancer Res. Treat. (2018)</ce:source-text>
</reference>
<reference seq="123">
<ref-info>
<ref-title>
<ref-titletext-english>Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Hesse</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Schroder</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Brandt</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Pamperin</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="5">
<ce:initials>H.</ce:initials>
<ce:surname>Saito</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="6">
<ce:initials>H.</ce:initials>
<ce:surname>Taipaleenmaki</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>JCI. Insight</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<page-information>
<pages>
<first-page>5</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hesse, E., Schroder, S., Brandt, D., Pamperin, J., Saito, H., Taipaleenmaki, H.: Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness. JCI. Insight. 5 (2019)</ref-fulltext>
<ce:source-text>Hesse, E., Schroder, S., Brandt, D., Pamperin, J., Saito, H., Taipaleenmaki, H.: Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness. JCI. Insight. 5 (2019)</ce:source-text>
</reference>
<reference seq="124">
<ref-info>
<ref-title>
<ref-titletext-english>Bisphosphonates: Mechanism of action and role in clinical practice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.T.</ce:initials>
<ce:surname>Drake</ce:surname>
<ce:given-name>M.T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.L.</ce:initials>
<ce:surname>Clarke</ce:surname>
<ce:given-name>B.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Khosla</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mayo Clin. Proc</ref-sourcetitle>
<ref-publicationyear first="2008" />
<volisspag>
<volume-issue-number>
<vol-first>83</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1032</first-page>
<last-page>1045</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Drake, M.T., Clarke, B.L., Khosla, S.: Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin. Proc. 83(9), 1032–1045 (2008)</ref-fulltext>
<ce:source-text>Drake, M.T., Clarke, B.L., Khosla, S.: Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin. Proc. 83(9), 1032–1045 (2008)</ce:source-text>
</reference>
<reference seq="125">
<ref-info>
<ref-title>
<ref-titletext-english>Romosozumab for the treatment of osteoporosis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Bandeira</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.M.</ce:initials>
<ce:surname>Lewiecki</ce:surname>
<ce:given-name>E.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.P.</ce:initials>
<ce:surname>Bilezikian</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Expert. Opin. Biol. Ther</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>255</first-page>
<last-page>263</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bandeira, L., Lewiecki, E.M., Bilezikian, J.P.: Romosozumab for the treatment of osteoporosis. Expert. Opin. Biol. Ther. 17(2), 255–263 (2017)</ref-fulltext>
<ce:source-text>Bandeira, L., Lewiecki, E.M., Bilezikian, J.P.: Romosozumab for the treatment of osteoporosis. Expert. Opin. Biol. Ther. 17(2), 255–263 (2017)</ce:source-text>
</reference>
<reference seq="126">
<ref-info>
<ref-title>
<ref-titletext-english>The science and practice of bone health in oncology: Managing bone loss and metastasis in patients with solid tumors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Lipton</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Uzzo</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.J.</ce:initials>
<ce:surname>Amato</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>G.K.</ce:initials>
<ce:surname>Ellis</ce:surname>
<ce:given-name>G.K.</ce:given-name>
</author>
<author seq="5">
<ce:initials>B.</ce:initials>
<ce:surname>Hakimian</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="6">
<ce:initials>G.D.</ce:initials>
<ce:surname>Roodman</ce:surname>
<ce:given-name>G.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Natl. Compr. Cancer Netw</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<suppl>Supplement 7</suppl>
</volume-issue-number>
<page-information>
<pages>
<first-page>S1</first-page>
<last-page>S29</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lipton, A., Uzzo, R., Amato, R.J., Ellis, G.K., Hakimian, B., Roodman, G.D., et al.: The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. J. Natl. Compr. Cancer Netw. 7(Suppl 7), S1–29 (2009); quiz S30</ref-fulltext>
<ce:source-text>Lipton, A., Uzzo, R., Amato, R.J., Ellis, G.K., Hakimian, B., Roodman, G.D., et al.: The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. J. Natl. Compr. Cancer Netw. 7(Suppl 7), S1–29 (2009); quiz S30</ce:source-text>
</reference>
<reference seq="127">
<ref-info>
<ref-title>
<ref-titletext-english>Interventions to prevent loss of bone mineral density in women receiving chemotherapy for breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.K.</ce:initials>
<ce:surname>Swenson</ce:surname>
<ce:given-name>K.K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.J.</ce:initials>
<ce:surname>Henly</ce:surname>
<ce:given-name>S.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.C.</ce:initials>
<ce:surname>Shapiro</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>L.M.</ce:initials>
<ce:surname>Schroeder</ce:surname>
<ce:given-name>L.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. J. Oncol. Nurs</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>177</first-page>
<last-page>184</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Swenson, K.K., Henly, S.J., Shapiro, A.C., Schroeder, L.M.: Interventions to prevent loss of bone mineral density in women receiving chemotherapy for breast cancer. Clin. J. Oncol. Nurs. 9(2), 177–184 (2005)</ref-fulltext>
<ce:source-text>Swenson, K.K., Henly, S.J., Shapiro, A.C., Schroeder, L.M.: Interventions to prevent loss of bone mineral density in women receiving chemotherapy for breast cancer. Clin. J. Oncol. Nurs. 9(2), 177–184 (2005)</ce:source-text>
</reference>
<reference seq="128">
<ref-info>
<ref-title>
<ref-titletext-english>American College of Sports M: American College of Sports Medicine Position Stand: Physical activity and bone health. Med. Sci</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.M.</ce:initials>
<ce:surname>Kohrt</ce:surname>
<ce:given-name>W.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.A.</ce:initials>
<ce:surname>Bloomfield</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.D.</ce:initials>
<ce:surname>Little</ce:surname>
<ce:given-name>K.D.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.E.</ce:initials>
<ce:surname>Nelson</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
<author seq="5">
<ce:initials>V.R.</ce:initials>
<ce:surname>Yingling</ce:surname>
<ce:given-name>V.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sports Exerc</ref-sourcetitle>
<ref-publicationyear first="2004" />
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1985</first-page>
<last-page>1996</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kohrt, W.M., Bloomfield, S.A., Little, K.D., Nelson, M.E., Yingling, V.R., American College of Sports M: American College of Sports Medicine Position Stand: Physical activity and bone health. Med. Sci. Sports Exerc. 36(11), 1985–1996 (2004)</ref-fulltext>
<ce:source-text>Kohrt, W.M., Bloomfield, S.A., Little, K.D., Nelson, M.E., Yingling, V.R., American College of Sports M: American College of Sports Medicine Position Stand: Physical activity and bone health. Med. Sci. Sports Exerc. 36(11), 1985–1996 (2004)</ce:source-text>
</reference>
<reference seq="129">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer- and chemotherapy-induced musculoskeletal degradation</ref-titletext-english>
</ref-title>
<itemidlist>
<itemid idtype="ARTNUM">e10187</itemid>
</itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>K.M.</ce:initials>
<ce:surname>Sturgeon</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.M.</ce:initials>
<ce:surname>Mathis</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.J.</ce:initials>
<ce:surname>Rogers</ce:surname>
<ce:given-name>C.J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>K.H.</ce:initials>
<ce:surname>Schmitz</ce:surname>
<ce:given-name>K.H.</ce:given-name>
</author>
<author seq="5">
<ce:initials>D.L.</ce:initials>
<ce:surname>Waning</ce:surname>
<ce:given-name>D.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>JBMR Plus</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Sturgeon, K.M., Mathis, K.M., Rogers, C.J., Schmitz, K.H., Waning, D.L.: Cancer- and chemotherapy-induced musculoskeletal degradation. JBMR Plus. 3(3), e10187 (2019)</ref-fulltext>
<ce:source-text>Sturgeon, K.M., Mathis, K.M., Rogers, C.J., Schmitz, K.H., Waning, D.L.: Cancer- and chemotherapy-induced musculoskeletal degradation. JBMR Plus. 3(3), e10187 (2019)</ce:source-text>
</reference>
</bibliography>
</tail>
</bibrecord>
<bibrecord>
<item-info>
<status state="new" stage="S300" />
<itemidlist>
<ce:doi>10.1007/978-3-031-09518-4_10</ce:doi>
<itemid idtype="TPB-ID">20232000349315</itemid>
</itemidlist>
</item-info>
<head>
<citation-info>
<citation-type code="ch" />
<citation-language xml:lang="ENG" />
<abstract-language xml:lang="ENG" />
</citation-info>
<citation-title>
<titletext xml:lang="ENG" original="y">New Developments in Targeting Cancer Cachexia</titletext>
</citation-title>
<author-group seq="1">
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Miller</ce:surname>
<ce:given-name>Janice</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.I.</ce:initials>
<ce:surname>Ramage</ce:surname>
<ce:given-name>Michael I.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.J.E.</ce:initials>
<ce:surname>Skipworth</ce:surname>
<ce:given-name>Richard J. E.</ce:given-name>
<ce:e-address>richard.skipworth@nhslothian.scot.nhs.uk</ce:e-address>
</author>
<affiliation>
<organization>Royal Infirmary of Edinburgh</organization>
<city>Edinburgh</city>
<country iso-code="GBR" />
<ce:source-text>Clinical Surgery, Royal Infirmary of Edinburgh, Edinburgh, UK</ce:source-text>
</affiliation>
</author-group>
<correspondence>
<person>
<ce:initials>R.J.E.</ce:initials>
<ce:surname>Skipworth</ce:surname>
<ce:given-name>Richard J. E.</ce:given-name>
<ce:e-address>richard.skipworth@nhslothian.scot.nhs.uk</ce:e-address>
</person>
<affiliation>
<organization>Royal Infirmary of Edinburgh</organization>
<city>Edinburgh</city>
<country iso-code="GBR" />
<ce:source-text>Clinical Surgery, Royal Infirmary of Edinburgh, Edinburgh, UK</ce:source-text>
</affiliation>
</correspondence>
<abstracts>
<abstract xml:lang="ENG" original="y">
<publishercopyright>© Springer Nature Switzerland AG 2022.</publishercopyright>
<ce:para>Within the cancer population, 50–80% of patients will develop cachexia, impacting negatively on their ability to tolerate or gain benefit from either curative or palliative treatment. To date, although collaborative management guidelines have been developed, there are no internationally standardised management programmes used in the clinical forum for patients with cancer cachexia. Furthermore, current available treatment strategies have limited efficacy. This chapter considers recent developments in the ability to target cachexia. Such “targeting” comes in two key forms: firstly, the ability to target and recognise new patients with, or at risk of, developing cancer cachexia. Some of the new developments in this field of study relate not just to improvements in patient targeting, but also a better understanding of the inherent pitfalls in this process. The second aspect of targeting relates to the identification of novel therapeutic biological targets for further clinical investigation.</ce:para>
</abstract>
</abstracts>
<source type="book" country="CHE">
<sourcetitle>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle>
<sourcetitle-abbrev>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle-abbrev>
<isbn type="print" length="13">9783031072727</isbn>
<isbn type="electronic" length="13">9783031095184</isbn>
<volisspag>
<page-information>
<pages>
<first-page>171</first-page>
<last-page>192</last-page>
</pages>
</page-information>
</volisspag>
<publicationyear first="2022" />
<publicationdate>
<year>2022</year>
<month>01</month>
<day>01</day>
</publicationdate>
<website type="item">
<ce:e-address type="url">https://link.springer.com/</ce:e-address>
</website>
<publisher>
<publishername>Springer International Publishing</publishername>
</publisher>
</source>
<enhancement>
<classificationgroup>
<classifications type="ASJC">
<classification>
<classification-code>2700</classification-code>
<classification-code>2400</classification-code>
<classification-code>1300</classification-code>
</classification>
</classifications>
</classificationgroup>
</enhancement>
</head>
<tail>
<bibliography refcount="125">
<reference seq="1">
<ref-info>
<ref-title>
<ref-titletext-english>Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.D.</ce:initials>
<ce:surname>Dewys</ce:surname>
<ce:given-name>W.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Begg</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>P.T.</ce:initials>
<ce:surname>Lavin</ce:surname>
<ce:given-name>P.T.</ce:given-name>
</author>
<author seq="4">
<ce:initials>P.R.</ce:initials>
<ce:surname>Band</ce:surname>
<ce:given-name>P.R.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.M.</ce:initials>
<ce:surname>Bennett</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.R.</ce:initials>
<ce:surname>Bertino</ce:surname>
<ce:given-name>J.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Med</ref-sourcetitle>
<ref-publicationyear first="1980" />
<volisspag>
<volume-issue-number>
<vol-first>69</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>491</first-page>
<last-page>497</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dewys, W.D., Begg, C., Lavin, P.T., Band, P.R., Bennett, J.M., Bertino, J.R., et al.: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am. J. Med. 69(4), 491–497 (1980)</ref-fulltext>
<ce:source-text>Dewys, W.D., Begg, C., Lavin, P.T., Band, P.R., Bennett, J.M., Bertino, J.R., et al.: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am. J. Med. 69(4), 491–497 (1980)</ce:source-text>
</reference>
<reference seq="2">
<ref-info>
<ref-title>
<ref-titletext-english>Diagnostic criteria of cancer cachexia: Relation to quality of life, exercise capacity and survival in unselected palliative care patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>O.</ce:initials>
<ce:surname>Wallengren</ce:surname>
<ce:given-name>O.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Lundholm</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="3">
<ce:initials>I.</ce:initials>
<ce:surname>Bosaeus</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Support Care Cancer</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1569</first-page>
<last-page>1577</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wallengren, O., Lundholm, K., Bosaeus, I.: Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients. Support Care Cancer. 21(6), 1569–1577 (2013)</ref-fulltext>
<ce:source-text>Wallengren, O., Lundholm, K., Bosaeus, I.: Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients. Support Care Cancer. 21(6), 1569–1577 (2013)</ce:source-text>
</reference>
<reference seq="3">
<ref-info>
<ref-title>
<ref-titletext-english>Cachexia: Prevalence and impact in medicine</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.H.</ce:initials>
<ce:surname>Tan</ce:surname>
<ce:given-name>B.H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.C.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Opin. Clin. Nutr. Metab. Care</ref-sourcetitle>
<ref-publicationyear first="2008" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>400</first-page>
<last-page>407</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tan, B.H., Fearon, K.C.: Cachexia: Prevalence and impact in medicine. Curr. Opin. Clin. Nutr. Metab. Care. 11(4), 400–407 (2008)</ref-fulltext>
<ce:source-text>Tan, B.H., Fearon, K.C.: Cachexia: Prevalence and impact in medicine. Curr. Opin. Clin. Nutr. Metab. Care. 11(4), 400–407 (2008)</ce:source-text>
</reference>
<reference seq="4">
<ref-info>
<ref-title>
<ref-titletext-english>Definition and classification of cancer cachexia: An international consensus</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Strasser</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.D.</ce:initials>
<ce:surname>Anker</ce:surname>
<ce:given-name>S.D.</ce:given-name>
</author>
<author seq="4">
<ce:initials>I.</ce:initials>
<ce:surname>Bosaeus</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="5">
<ce:initials>E.</ce:initials>
<ce:surname>Bruera</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="6">
<ce:initials>R.L.</ce:initials>
<ce:surname>Fainsinger</ce:surname>
<ce:given-name>R.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Lancet Oncol</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>489</first-page>
<last-page>495</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fearon, K., Strasser, F., Anker, S.D., Bosaeus, I., Bruera, E., Fainsinger, R.L., et al.: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 12(5), 489–495 (2011)</ref-fulltext>
<ce:source-text>Fearon, K., Strasser, F., Anker, S.D., Bosaeus, I., Bruera, E., Fainsinger, R.L., et al.: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 12(5), 489–495 (2011)</ce:source-text>
</reference>
<reference seq="5">
<ref-info>
<ref-title>
<ref-titletext-english>A cross-sectional study examining the prevalence of cachexia and areas of unmet need in patients with cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>O.</ce:initials>
<ce:surname>Vagnildhaug</ce:surname>
<ce:given-name>O.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Balstad</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Almberg</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Bruneli</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Knudsen</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>Kaasa</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Support Care Cancer</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1871</first-page>
<last-page>1880</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vagnildhaug, O., Balstad, T., Almberg, S., Bruneli, C., Knudsen, A., Kaasa, S., et al.: A cross-sectional study examining the prevalence of cachexia and areas of unmet need in patients with cancer. Support Care Cancer. 26(6), 1871–1880 (2017)</ref-fulltext>
<ce:source-text>Vagnildhaug, O., Balstad, T., Almberg, S., Bruneli, C., Knudsen, A., Kaasa, S., et al.: A cross-sectional study examining the prevalence of cachexia and areas of unmet need in patients with cancer. Support Care Cancer. 26(6), 1871–1880 (2017)</ce:source-text>
</reference>
<reference seq="6">
<ref-info>
<ref-title>
<ref-titletext-english>Correlation between the international consensus definition of the Cancer Anorexia-Cachexia Syndrome (CACS) and patient-centered outcomes in advanced non-small cell lung cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Leblanc</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Nipp</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Rushing</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>G.</ce:initials>
<ce:surname>Samsa</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Locke</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Kamal</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Pain Symptom Manag</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>49</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>680</first-page>
<last-page>689</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>LeBlanc, T., Nipp, R., Rushing, C., Samsa, G., Locke, S., Kamal, A., et al.: Correlation between the international consensus definition of the Cancer Anorexia-Cachexia Syndrome (CACS) and patient-centered outcomes in advanced non-small cell lung cancer. J. Pain Symptom Manag. 49(4), 680–689 (2014)</ref-fulltext>
<ce:source-text>LeBlanc, T., Nipp, R., Rushing, C., Samsa, G., Locke, S., Kamal, A., et al.: Correlation between the international consensus definition of the Cancer Anorexia-Cachexia Syndrome (CACS) and patient-centered outcomes in advanced non-small cell lung cancer. J. Pain Symptom Manag. 49(4), 680–689 (2014)</ce:source-text>
</reference>
<reference seq="7">
<ref-info>
<ref-title>
<ref-titletext-english>Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a classification model—a study based on data from an international multicentre project (EPCRC-CSA)</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Blum</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.B.</ce:initials>
<ce:surname>Stene</ce:surname>
<ce:given-name>G.B.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.S.</ce:initials>
<ce:surname>Solheim</ce:surname>
<ce:given-name>T.S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>P.</ce:initials>
<ce:surname>Fayers</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.J.</ce:initials>
<ce:surname>Hjermstad</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Oncol</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>25</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1635</first-page>
<last-page>1642</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Blum, D., Stene, G.B., Solheim, T.S., Fayers, P., Hjermstad, M.J., Baracos, V.E., et al.: Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a classification model—a study based on data from an international multicentre project (EPCRC-CSA). Ann. Oncol. 25(8), 1635–1642 (2014)</ref-fulltext>
<ce:source-text>Blum, D., Stene, G.B., Solheim, T.S., Fayers, P., Hjermstad, M.J., Baracos, V.E., et al.: Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a classification model—a study based on data from an international multicentre project (EPCRC-CSA). Ann. Oncol. 25(8), 1635–1642 (2014)</ce:source-text>
</reference>
<reference seq="8">
<ref-info>
<ref-title>
<ref-titletext-english>Cachexia in cancer: What is in the definition?</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Vanhoutte</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Van de Wiel</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.</ce:initials>
<ce:surname>Wouters</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Sels</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>L.</ce:initials>
<ce:surname>Bartolomeeussen</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="6">
<ce:initials>S.D.</ce:initials>
<ce:surname>Keersmaecker</ce:surname>
<ce:given-name>S.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>BMJ Open Gastroenterol</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Vanhoutte, G., van de Wiel, M., Wouters, K., Sels, M., Bartolomeeussen, L., Keersmaecker, S.D., et al.: Cachexia in cancer: what is in the definition? BMJ Open Gastroenterol. 3(1), e000097 (2016)</ref-fulltext>
<ce:source-text>Vanhoutte, G., van de Wiel, M., Wouters, K., Sels, M., Bartolomeeussen, L., Keersmaecker, S.D., et al.: Cachexia in cancer: what is in the definition? BMJ Open Gastroenterol. 3(1), e000097 (2016)</ce:source-text>
</reference>
<reference seq="9">
<ref-info>
<ref-title>
<ref-titletext-english>Cachexia: A new definition</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.J.</ce:initials>
<ce:surname>Evans</ce:surname>
<ce:given-name>W.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.E.</ce:initials>
<ce:surname>Morley</ce:surname>
<ce:given-name>J.E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Argilés</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Bales</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="5">
<ce:initials>V.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
<author seq="6">
<ce:initials>D.</ce:initials>
<ce:surname>Guttridge</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2008" />
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>793</first-page>
<last-page>799</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Evans, W.J., Morley, J.E., Argilés, J., Bales, C., Baracos, V., Guttridge, D., et al.: Cachexia: A new definition. Clin. Nutr. 27(6), 793–799 (2008)</ref-fulltext>
<ce:source-text>Evans, W.J., Morley, J.E., Argilés, J., Bales, C., Baracos, V., Guttridge, D., et al.: Cachexia: A new definition. Clin. Nutr. 27(6), 793–799 (2008)</ce:source-text>
</reference>
<reference seq="10">
<ref-info>
<ref-title>
<ref-titletext-english>A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Mourtzakis</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.M.M.</ce:initials>
<ce:surname>Prado</ce:surname>
<ce:given-name>C.M.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.R.</ce:initials>
<ce:surname>Lieffers</ce:surname>
<ce:given-name>J.R.</ce:given-name>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Reiman</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="5">
<ce:initials>L.J.</ce:initials>
<ce:surname>McCargar</ce:surname>
<ce:given-name>L.J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Appl. Physiol. Nutr. Metab</ref-sourcetitle>
<ref-publicationyear first="2008" />
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>997</first-page>
<last-page>1006</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mourtzakis, M., Prado, C.M.M., Lieffers, J.R., Reiman, T., McCargar, L.J., Baracos, V.E.: A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl. Physiol. Nutr. Metab. 33(5), 997–1006 (2008)</ref-fulltext>
<ce:source-text>Mourtzakis, M., Prado, C.M.M., Lieffers, J.R., Reiman, T., McCargar, L.J., Baracos, V.E.: A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl. Physiol. Nutr. Metab. 33(5), 997–1006 (2008)</ce:source-text>
</reference>
<reference seq="11">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia in the age of obesity: Skeletal muscle depletion is a powerful prognostic factor, independent of body mass index</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Martin</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Birdsell</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Macdonald</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Reiman</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.T.</ce:initials>
<ce:surname>Clandinin</ce:surname>
<ce:given-name>M.T.</ce:given-name>
</author>
<author seq="6">
<ce:initials>L.J.</ce:initials>
<ce:surname>McCargar</ce:surname>
<ce:given-name>L.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>31</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1539</first-page>
<last-page>1547</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Martin, L., Birdsell, L., MacDonald, N., Reiman, T., Clandinin, M.T., McCargar, L.J., et al.: Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J. Clin. Oncol. 31(12), 1539–1547 (2013)</ref-fulltext>
<ce:source-text>Martin, L., Birdsell, L., MacDonald, N., Reiman, T., Clandinin, M.T., McCargar, L.J., et al.: Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J. Clin. Oncol. 31(12), 1539–1547 (2013)</ce:source-text>
</reference>
<reference seq="12">
<ref-info>
<ref-title>
<ref-titletext-english>Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: A randomised double blind trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.C.H.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.C.H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.F.</ce:initials>
<ce:surname>von Meyenfeldt</ce:surname>
<ce:given-name>M.F.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.G.W.</ce:initials>
<ce:surname>Moses</ce:surname>
<ce:given-name>A.G.W.</ce:given-name>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>van Geenen</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Roy</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>D.J.</ce:initials>
<ce:surname>Gouma</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Gut</ref-sourcetitle>
<ref-publicationyear first="2003" />
<volisspag>
<volume-issue-number>
<vol-first>52</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1479</first-page>
<last-page>1486</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fearon, K.C.H., Von Meyenfeldt, M.F., Moses, A.G.W., Van Geenen, R., Roy, A., Gouma, D.J., et al.: Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: A randomised double blind trial. Gut. 52(10), 1479–1486 (2003)</ref-fulltext>
<ce:source-text>Fearon, K.C.H., Von Meyenfeldt, M.F., Moses, A.G.W., Van Geenen, R., Roy, A., Gouma, D.J., et al.: Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: A randomised double blind trial. Gut. 52(10), 1479–1486 (2003)</ce:source-text>
</reference>
<reference seq="13">
<ref-info>
<ref-title>
<ref-titletext-english>Sarcopenia: European consensus on definition and diagnosis Report of the European Working Group on Sarcopenia in Older People</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.J.</ce:initials>
<ce:surname>Cruz-Jentoft</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.P.</ce:initials>
<ce:surname>Baeyens</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.M.</ce:initials>
<ce:surname>Bauer</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>Y.</ce:initials>
<ce:surname>Boirie</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="5">
<ce:initials>T.</ce:initials>
<ce:surname>Cederholm</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="6">
<ce:initials>F.</ce:initials>
<ce:surname>Landi</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Age Ageing</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>39</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>412</first-page>
<last-page>423</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cruz-Jentoft, A.J., Baeyens, J.P., Bauer, J.M., Boirie, Y., Cederholm, T., Landi, F., et al.: Sarcopenia: European consensus on definition and diagnosis Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 39(4), 412–423 (2010)</ref-fulltext>
<ce:source-text>Cruz-Jentoft, A.J., Baeyens, J.P., Bauer, J.M., Boirie, Y., Cederholm, T., Landi, F., et al.: Sarcopenia: European consensus on definition and diagnosis Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 39(4), 412–423 (2010)</ce:source-text>
</reference>
<reference seq="14">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle wasting and cachexia in heart failure: Mechanisms and therapies</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>von Haehling</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:surname>Ebner</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.R.</ce:initials>
<ce:surname>Dos Santos</ce:surname>
<ce:given-name>M.R.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Springer</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="5">
<ce:initials>S.D.</ce:initials>
<ce:surname>Anker</ce:surname>
<ce:given-name>S.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cardiol</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>323</first-page>
<last-page>341</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>von Haehling, S., Ebner, N., dos Santos, M.R., Springer, J., Anker, S.D.: Muscle wasting and cachexia in heart failure: mechanisms and therapies. Nat. Rev. Cardiol. 14(6), 323–341 (2017)</ref-fulltext>
<ce:source-text>von Haehling, S., Ebner, N., dos Santos, M.R., Springer, J., Anker, S.D.: Muscle wasting and cachexia in heart failure: mechanisms and therapies. Nat. Rev. Cardiol. 14(6), 323–341 (2017)</ce:source-text>
</reference>
<reference seq="15">
<ref-info>
<ref-title>
<ref-titletext-english>Myopenia—a new universal term for muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>W.J.</ce:initials>
<ce:surname>Evans</ce:surname>
<ce:given-name>W.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.D.</ce:initials>
<ce:surname>Anker</ce:surname>
<ce:given-name>S.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1</first-page>
<last-page>3</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fearon, K., Evans, W.J., Anker, S.D.: Myopenia—a new universal term for muscle wasting. J. Cachexia. Sarcopenia Muscle. 2(1), 1–3 (2011)</ref-fulltext>
<ce:source-text>Fearon, K., Evans, W.J., Anker, S.D.: Myopenia—a new universal term for muscle wasting. J. Cachexia. Sarcopenia Muscle. 2(1), 1–3 (2011)</ce:source-text>
</reference>
<reference seq="16">
<ref-info>
<ref-title>
<ref-titletext-english>Validated screening tools for the assessment of cachexia, sarcopenia, and malnutrition: A systematic review</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Miller</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Wells</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>U.</ce:initials>
<ce:surname>Nwulu</ce:surname>
<ce:given-name>U.</ce:given-name>
</author>
<author seq="4">
<ce:initials>D.</ce:initials>
<ce:surname>Currow</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Johnson</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>R.</ce:initials>
<ce:surname>Skipworth</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>108</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1196</first-page>
<last-page>1208</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Miller, J., Wells, L., Nwulu, U., Currow, D., Johnson, M., Skipworth, R.: Validated screening tools for the assessment of cachexia, sarcopenia, and malnutrition: A systematic review. Am. J. Clin. Nutr. 108(6), 1196–1208 (2018)</ref-fulltext>
<ce:source-text>Miller, J., Wells, L., Nwulu, U., Currow, D., Johnson, M., Skipworth, R.: Validated screening tools for the assessment of cachexia, sarcopenia, and malnutrition: A systematic review. Am. J. Clin. Nutr. 108(6), 1196–1208 (2018)</ce:source-text>
</reference>
<reference seq="17">
<ref-info>
<ref-title>
<ref-titletext-english>ESPEN expert group recommendations for action against cancer-related malnutrition</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Arends</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>V.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Bertz</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="4">
<ce:initials>F.</ce:initials>
<ce:surname>Bozzetti</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="5">
<ce:initials>P.</ce:initials>
<ce:surname>Calder</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="6">
<ce:initials>N.E.P.</ce:initials>
<ce:surname>Deutz</ce:surname>
<ce:given-name>N.E.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1187</first-page>
<last-page>1196</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Arends, J., Baracos, V., Bertz, H., Bozzetti, F., Calder, P., Deutz, N.E.P., et al.: ESPEN expert group recommendations for action against cancer-related malnutrition. Clin. Nutr. 36(5), 1187–1196 (2017)</ref-fulltext>
<ce:source-text>Arends, J., Baracos, V., Bertz, H., Bozzetti, F., Calder, P., Deutz, N.E.P., et al.: ESPEN expert group recommendations for action against cancer-related malnutrition. Clin. Nutr. 36(5), 1187–1196 (2017)</ce:source-text>
</reference>
<reference seq="18">
<ref-info>
<ref-title>
<ref-titletext-english>Epidemiology of sarcopenia among the elderly in New Mexico</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.N.</ce:initials>
<ce:surname>Baumgartner</ce:surname>
<ce:given-name>R.N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.M.</ce:initials>
<ce:surname>Koehler</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Gallagher</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="4">
<ce:initials>L.</ce:initials>
<ce:surname>Romero</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="5">
<ce:initials>S.B.</ce:initials>
<ce:surname>Heymsfield</ce:surname>
<ce:given-name>S.B.</ce:given-name>
</author>
<author seq="6">
<ce:initials>R.R.</ce:initials>
<ce:surname>Ross</ce:surname>
<ce:given-name>R.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Epidemiol</ref-sourcetitle>
<ref-publicationyear first="1998" />
<volisspag>
<volume-issue-number>
<vol-first>147</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>755</first-page>
<last-page>763</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baumgartner, R.N., Koehler, K.M., Gallagher, D., Romero, L., Heymsfield, S.B., Ross, R.R., et al.: Epidemiology of sarcopenia among the elderly in New Mexico. Am. J. Epidemiol. 147(8), 755–763 (1998)</ref-fulltext>
<ce:source-text>Baumgartner, R.N., Koehler, K.M., Gallagher, D., Romero, L., Heymsfield, S.B., Ross, R.R., et al.: Epidemiology of sarcopenia among the elderly in New Mexico. Am. J. Epidemiol. 147(8), 755–763 (1998)</ce:source-text>
</reference>
<reference seq="19">
<ref-info>
<ref-title>
<ref-titletext-english>The advantages and limitations of cross-sectional body composition analysis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.J.</ce:initials>
<ce:surname>Macdonald</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.A.</ce:initials>
<ce:surname>Greig</ce:surname>
<ce:given-name>C.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>V.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Opin. Support. Palliat. Care</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>342</first-page>
<last-page>349</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>MacDonald, A.J., Greig, C.A., Baracos, V.: The advantages and limitations of cross-sectional body composition analysis. Curr. Opin. Support. Palliat. Care. 5(4), 342–349 (2011)</ref-fulltext>
<ce:source-text>MacDonald, A.J., Greig, C.A., Baracos, V.: The advantages and limitations of cross-sectional body composition analysis. Curr. Opin. Support. Palliat. Care. 5(4), 342–349 (2011)</ce:source-text>
</reference>
<reference seq="20">
<ref-info>
<ref-title>
<ref-titletext-english>Appendicular skeletal muscle mass: Measurement by dual-photon absorptiometry</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.B.</ce:initials>
<ce:surname>Heymsfield</ce:surname>
<ce:given-name>S.B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Smith</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Aulet</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>B.</ce:initials>
<ce:surname>Bensen</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Lichtman</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="1990" />
<volisspag>
<volume-issue-number>
<vol-first>52</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>214</first-page>
<last-page>218</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Heymsfield, S.B., Smith, R., Aulet, M., Bensen, B., Lichtman, S., Wang, J., et al.: Appendicular skeletal muscle mass: measurement by dual-photon absorptiometry. Am. J. Clin. Nutr. 52(2), 214–218 (1990)</ref-fulltext>
<ce:source-text>Heymsfield, S.B., Smith, R., Aulet, M., Bensen, B., Lichtman, S., Wang, J., et al.: Appendicular skeletal muscle mass: measurement by dual-photon absorptiometry. Am. J. Clin. Nutr. 52(2), 214–218 (1990)</ce:source-text>
</reference>
<reference seq="21">
<ref-info>
<ref-title>
<ref-titletext-english>The epidemiology of obesity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.M.</ce:initials>
<ce:surname>Nguyen</ce:surname>
<ce:given-name>D.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.B.</ce:initials>
<ce:surname>El-Serag</ce:surname>
<ce:given-name>H.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Gastroenterol Clin North Am</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>39</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1</first-page>
<last-page>7</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nguyen, D.M., El-Serag, H.B.: The epidemiology of obesity. Gastroenterol Clin North Am. 39(1), 1–7 (2010)</ref-fulltext>
<ce:source-text>Nguyen, D.M., El-Serag, H.B.: The epidemiology of obesity. Gastroenterol Clin North Am. 39(1), 1–7 (2010)</ce:source-text>
</reference>
<reference seq="22">
<ref-info>
<ref-title>
<ref-titletext-english>Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.M.</ce:initials>
<ce:surname>Flegal</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.D.</ce:initials>
<ce:surname>Carroll</ce:surname>
<ce:given-name>M.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>B.K.</ce:initials>
<ce:surname>Kit</ce:surname>
<ce:given-name>B.K.</ce:given-name>
</author>
<author seq="4">
<ce:initials>C.L.</ce:initials>
<ce:surname>Ogden</ce:surname>
<ce:given-name>C.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>JAMA</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>307</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>491</first-page>
<last-page>497</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Flegal, K.M., Carroll, M.D., Kit, B.K., Ogden, C.L.: Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA. 307(5), 491–497 (2012)</ref-fulltext>
<ce:source-text>Flegal, K.M., Carroll, M.D., Kit, B.K., Ogden, C.L.: Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA. 307(5), 491–497 (2012)</ce:source-text>
</reference>
<reference seq="23">
<ref-info>
<ref-title>
<ref-titletext-english>Risk factor paradox in wasting diseases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Kalantar-Zadeh</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.B.</ce:initials>
<ce:surname>Horwich</ce:surname>
<ce:given-name>T.B.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Oreopoulos</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>C.P.</ce:initials>
<ce:surname>Kovesdy</ce:surname>
<ce:given-name>C.P.</ce:given-name>
</author>
<author seq="5">
<ce:initials>H.</ce:initials>
<ce:surname>Younessi</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="6">
<ce:initials>S.D.</ce:initials>
<ce:surname>Anker</ce:surname>
<ce:given-name>S.D.</ce:given-name>
</author>
<author seq="7">
<ce:initials>J.E.</ce:initials>
<ce:surname>Morley</ce:surname>
<ce:given-name>J.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr Opin Clin Nutr Metab Care</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>433</first-page>
<last-page>442</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kalantar-Zadeh, K., Horwich, T.B., Oreopoulos, A., Kovesdy, C.P., Younessi, H., Anker, S.D., Morley, J.E.: Risk factor paradox in wasting diseases. Curr Opin Clin Nutr Metab Care. 10(4), 433–442 (2007)</ref-fulltext>
<ce:source-text>Kalantar-Zadeh, K., Horwich, T.B., Oreopoulos, A., Kovesdy, C.P., Younessi, H., Anker, S.D., Morley, J.E.: Risk factor paradox in wasting diseases. Curr Opin Clin Nutr Metab Care. 10(4), 433–442 (2007)</ce:source-text>
</reference>
<reference seq="24">
<ref-info>
<ref-title>
<ref-titletext-english>Diagnostic criteria for the classification of cancer-associated weight loss</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Martin</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Senesse</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>I.</ce:initials>
<ce:surname>Gioulbasanis</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Antoun</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="5">
<ce:initials>F.</ce:initials>
<ce:surname>Bozzetti</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:surname>Deans</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="7">
<ce:initials>F.</ce:initials>
<ce:surname>Strasser</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="8">
<ce:initials>L.</ce:initials>
<ce:surname>Thoresen</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="9">
<ce:initials>R.T.</ce:initials>
<ce:surname>Jagoe</ce:surname>
<ce:given-name>R.T.</ce:given-name>
</author>
<author seq="10">
<ce:initials>M.</ce:initials>
<ce:surname>Chasen</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="11">
<ce:initials>K.</ce:initials>
<ce:surname>Lundholm</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="12">
<ce:initials>I.</ce:initials>
<ce:surname>Bosaeus</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="13">
<ce:initials>K.H.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.H.</ce:given-name>
</author>
<author seq="14">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J Clin Oncol</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>90</first-page>
<last-page>99</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Martin, L., Senesse, P., Gioulbasanis, I., Antoun, S., Bozzetti, F., Deans, C., Strasser, F., Thoresen, L., Jagoe, R.T., Chasen, M., Lundholm, K., Bosaeus, I., Fearon, K.H., Baracos, V.E.: Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol. 33(1), 90–99 (2015)</ref-fulltext>
<ce:source-text>Martin, L., Senesse, P., Gioulbasanis, I., Antoun, S., Bozzetti, F., Deans, C., Strasser, F., Thoresen, L., Jagoe, R.T., Chasen, M., Lundholm, K., Bosaeus, I., Fearon, K.H., Baracos, V.E.: Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol. 33(1), 90–99 (2015)</ce:source-text>
</reference>
<reference seq="25">
<ref-info>
<ref-title>
<ref-titletext-english>Health, Aging, and Body: Longitudinal study of muscle strength, quality, and adipose tissue infiltration</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Delmonico</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Harris</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Visser</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Park</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Conroy</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>P.</ce:initials>
<ce:surname>Velasquez-Mieyer</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>90</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1579</first-page>
<last-page>1585</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Delmonico, M., Harris, T., Visser, M., Park, S., Conroy, M., Velasquez-Mieyer, P., et al.: Health, Aging, and Body: longitudinal study of muscle strength, quality, and adipose tissue infiltration. Am. J. Clin. Nutr. 90, 1579–1585 (2009)</ref-fulltext>
<ce:source-text>Delmonico, M., Harris, T., Visser, M., Park, S., Conroy, M., Velasquez-Mieyer, P., et al.: Health, Aging, and Body: longitudinal study of muscle strength, quality, and adipose tissue infiltration. Am. J. Clin. Nutr. 90, 1579–1585 (2009)</ce:source-text>
</reference>
<reference seq="26">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal intramyocellular lipid metabolism and insulin resistance</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Xu</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>X.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="4">
<ce:initials>Z.</ce:initials>
<ce:surname>Yi</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Cichello</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biophys. Rev</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>90</first-page>
<last-page>98</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Li, Y., Xu, S., Zhang, X., Yi, Z., Cichello, S.: Skeletal intramyocellular lipid metabolism and insulin resistance. Biophys. Rev. 1, 90–98 (2015)</ref-fulltext>
<ce:source-text>Li, Y., Xu, S., Zhang, X., Yi, Z., Cichello, S.: Skeletal intramyocellular lipid metabolism and insulin resistance. Biophys. Rev. 1, 90–98 (2015)</ce:source-text>
</reference>
<reference seq="27">
<ref-info>
<ref-title>
<ref-titletext-english>Magnetic resonance imaging with k-means clustering objectively measures whole muscle volume compartments in sarcopenia/cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Gray</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Macgillivray</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Eeley</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>N.</ce:initials>
<ce:surname>Stephens</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="5">
<ce:initials>I.</ce:initials>
<ce:surname>Beggs</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="6">
<ce:initials>K.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>106</first-page>
<last-page>111</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gray, C., MacGillivray, T., Eeley, C., Stephens, N., Beggs, I., Fearon, K., et al.: Magnetic resonance imaging with k-means clustering objectively measures whole muscle volume compartments in sarcopenia/cancer cachexia. Clin. Nutr. 30, 106–111 (2011)</ref-fulltext>
<ce:source-text>Gray, C., MacGillivray, T., Eeley, C., Stephens, N., Beggs, I., Fearon, K., et al.: Magnetic resonance imaging with k-means clustering objectively measures whole muscle volume compartments in sarcopenia/cancer cachexia. Clin. Nutr. 30, 106–111 (2011)</ce:source-text>
</reference>
<reference seq="28">
<ref-info>
<ref-title>
<ref-titletext-english>Intramyocellular lipid droplets increase with progression of cachexia in cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Stephens</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Skipworth</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Macdonald</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Greig</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Ross</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>K.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>111</first-page>
<last-page>117</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stephens, N., Skipworth, R., MacDonald, A., Greig, C., Ross, J., Fearon, K.: Intramyocellular lipid droplets increase with progression of cachexia in cancer patients. J. Cachexia. Sarcopenia Muscle. 2, 111–117 (2011)</ref-fulltext>
<ce:source-text>Stephens, N., Skipworth, R., MacDonald, A., Greig, C., Ross, J., Fearon, K.: Intramyocellular lipid droplets increase with progression of cachexia in cancer patients. J. Cachexia. Sarcopenia Muscle. 2, 111–117 (2011)</ce:source-text>
</reference>
<reference seq="29">
<ref-info>
<ref-title>
<ref-titletext-english>The relationship between muscle protein content and CT-derived muscle radio-density in patients with upper GI cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.I.</ce:initials>
<ce:surname>Ramage</ce:surname>
<ce:given-name>M.I.</ce:given-name>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:surname>Johns</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.D.A.</ce:initials>
<ce:surname>Deans</ce:surname>
<ce:given-name>C.D.A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.A.</ce:initials>
<ce:surname>Ross</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="5">
<ce:initials>T.</ce:initials>
<ce:surname>Preston</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="6">
<ce:initials>R.J.E.</ce:initials>
<ce:surname>Skipworth</ce:surname>
<ce:given-name>R.J.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr. Edinb. Scotl</ref-sourcetitle>
<ref-publicationyear first="2016" />
</ref-info>
<ref-fulltext>Ramage, M.I., Johns, N., Deans, C.D.A., Ross, J.A., Preston, T., Skipworth, R.J.E., et al.: The relationship between muscle protein content and CT-derived muscle radio-density in patients with upper GI cancer. Clin. Nutr. Edinb. Scotl. (2016 Dec 27)</ref-fulltext>
<ce:source-text>Ramage, M.I., Johns, N., Deans, C.D.A., Ross, J.A., Preston, T., Skipworth, R.J.E., et al.: The relationship between muscle protein content and CT-derived muscle radio-density in patients with upper GI cancer. Clin. Nutr. Edinb. Scotl. (2016 Dec 27)</ce:source-text>
</reference>
<reference seq="30">
<ref-info>
<ref-title>
<ref-titletext-english>Subcutaneous adiposity is an independent predictor of mortality in cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Ebadi</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Martin</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Ghosh</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>C.J.</ce:initials>
<ce:surname>Field</ce:surname>
<ce:given-name>C.J.</ce:given-name>
</author>
<author seq="5">
<ce:initials>R.</ce:initials>
<ce:surname>Lehner</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="6">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
<author seq="7">
<ce:initials>V.C.</ce:initials>
<ce:surname>Mazurak</ce:surname>
<ce:given-name>V.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Br J Cancer</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>117</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>148</first-page>
<last-page>155</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ebadi, M., Martin, L., Ghosh, S., Field, C.J., Lehner, R., Baracos, V.E., Mazurak, V.C.: Subcutaneous adiposity is an independent predictor of mortality in cancer patients. Br J Cancer. 117(1), 148–155 (2017)</ref-fulltext>
<ce:source-text>Ebadi, M., Martin, L., Ghosh, S., Field, C.J., Lehner, R., Baracos, V.E., Mazurak, V.C.: Subcutaneous adiposity is an independent predictor of mortality in cancer patients. Br J Cancer. 117(1), 148–155 (2017)</ce:source-text>
</reference>
<reference seq="31">
<ref-info>
<ref-title>
<ref-titletext-english>Imaging body composition in cancer patients: Visceral obesity, sarcopenia and sarcopenic obesity may impact on clinical outcome</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Yip</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Dinkel</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Mahajan</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Siddique</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>G.J.R.</ce:initials>
<ce:surname>Cook</ce:surname>
<ce:given-name>G.J.R.</ce:given-name>
</author>
<author seq="6">
<ce:initials>V.</ce:initials>
<ce:surname>Goh</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Insights Imaging</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>489</first-page>
<last-page>497</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yip, C., Dinkel, C., Mahajan, A., Siddique, M., Cook, G.J.R., Goh, V.: Imaging body composition in cancer patients: visceral obesity, sarcopenia and sarcopenic obesity may impact on clinical outcome. Insights Imaging. 6(4), 489–497 (2015)</ref-fulltext>
<ce:source-text>Yip, C., Dinkel, C., Mahajan, A., Siddique, M., Cook, G.J.R., Goh, V.: Imaging body composition in cancer patients: visceral obesity, sarcopenia and sarcopenic obesity may impact on clinical outcome. Insights Imaging. 6(4), 489–497 (2015)</ce:source-text>
</reference>
<reference seq="32">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle shape consistency and muscle volume prediction of thigh muscles</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Mersmann</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Bohm</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Schroll</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>H.</ce:initials>
<ce:surname>Boeth</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="5">
<ce:initials>G.</ce:initials>
<ce:surname>Duda</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Arampatzis</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Scand. J. Med. Sci. Sports</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>25</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>e208</first-page>
<last-page>e213</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mersmann, F., Bohm, S., Schroll, A., Boeth, H., Duda, G., Arampatzis, A.: Muscle shape consistency and muscle volume prediction of thigh muscles. Scand. J. Med. Sci. Sports. 25(2), e208–e213 (2015)</ref-fulltext>
<ce:source-text>Mersmann, F., Bohm, S., Schroll, A., Boeth, H., Duda, G., Arampatzis, A.: Muscle shape consistency and muscle volume prediction of thigh muscles. Scand. J. Med. Sci. Sports. 25(2), e208–e213 (2015)</ce:source-text>
</reference>
<reference seq="33">
<ref-info>
<ref-title>
<ref-titletext-english>Quantitative muscle MRI as an assessment tool for monitoring disease progression in LGMD2I: A multicentre longitudinal study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.A.</ce:initials>
<ce:surname>Willis</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.G.</ce:initials>
<ce:surname>Hollingsworth</ce:surname>
<ce:given-name>K.G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Coombs</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.L.</ce:initials>
<ce:surname>Sveen</ce:surname>
<ce:given-name>M.L.</ce:given-name>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Andersen</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="6">
<ce:initials>T.</ce:initials>
<ce:surname>Stojkovic</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Plos One [Internet]</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
</volisspag>
<ref-website>
<ce:e-address type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743890/</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Willis, T.A., Hollingsworth, K.G., Coombs, A., Sveen, M.L., Andersen, S., Stojkovic, T., et al.: Quantitative muscle MRI as an assessment tool for monitoring disease progression in LGMD2I: A multicentre longitudinal study. PLoS One [Internet]. (2013 Aug 14) [cited 2016 May 18];8(8). Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743890/</ref-fulltext>
<ce:source-text>Willis, T.A., Hollingsworth, K.G., Coombs, A., Sveen, M.L., Andersen, S., Stojkovic, T., et al.: Quantitative muscle MRI as an assessment tool for monitoring disease progression in LGMD2I: A multicentre longitudinal study. PLoS One [Internet]. (2013 Aug 14) [cited 2016 May 18];8(8). Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743890/</ce:source-text>
</reference>
<reference seq="34">
<ref-info>
<ref-title>
<ref-titletext-english>Automatic and quantitative assessment of regional muscle volume by multi-atlas segmentation using whole-body water–fat MRI</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Karlsson</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Rosander</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Romu</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Tallberg</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Grönqvist</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Borga</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Magn. Reson. Imaging</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>41</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1558</first-page>
<last-page>1569</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Karlsson, A., Rosander, J., Romu, T., Tallberg, J., Grönqvist, A., Borga, M., et al.: Automatic and quantitative assessment of regional muscle volume by multi-atlas segmentation using whole-body water–fat MRI. J. Magn. Reson. Imaging. 41(6), 1558–1569 (2015)</ref-fulltext>
<ce:source-text>Karlsson, A., Rosander, J., Romu, T., Tallberg, J., Grönqvist, A., Borga, M., et al.: Automatic and quantitative assessment of regional muscle volume by multi-atlas segmentation using whole-body water–fat MRI. J. Magn. Reson. Imaging. 41(6), 1558–1569 (2015)</ce:source-text>
</reference>
<reference seq="35">
<ref-info>
<ref-title>
<ref-titletext-english>The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.E.</ce:initials>
<ce:surname>Rollins</ce:surname>
<ce:given-name>K.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:surname>Tewari</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Ackner</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Awwad</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Madhusudan</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="6">
<ce:initials>I.A.</ce:initials>
<ce:surname>Macdonald</ce:surname>
<ce:given-name>I.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr. Edinb. Scotl</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1103</first-page>
<last-page>1109</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rollins, K.E., Tewari, N., Ackner, A., Awwad, A., Madhusudan, S., Macdonald, I.A., et al.: The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma. Clin. Nutr. Edinb. Scotl. 35(5), 1103–1109 (2016)</ref-fulltext>
<ce:source-text>Rollins, K.E., Tewari, N., Ackner, A., Awwad, A., Madhusudan, S., Macdonald, I.A., et al.: The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma. Clin. Nutr. Edinb. Scotl. 35(5), 1103–1109 (2016)</ce:source-text>
</reference>
<reference seq="36">
<ref-info>
<ref-title>
<ref-titletext-english>Morphology, metabolism, microcirculation, and strength of skeletal muscles in cancer-related cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Weber</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Krakowski-Roosen</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:surname>Schroder</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Kinscherf</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Krix</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Kopp-Schneider</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Acta Oncol</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>48</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>116</first-page>
<last-page>124</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Weber, M., Krakowski-Roosen, H., Schroder, L., Kinscherf, R., Krix, M., Kopp-Schneider, A., et al.: Morphology, metabolism, microcirculation, and strength of skeletal muscles in cancer-related cachexia. Acta Oncol. 48(1), 116–124 (2009)</ref-fulltext>
<ce:source-text>Weber, M., Krakowski-Roosen, H., Schroder, L., Kinscherf, R., Krix, M., Kopp-Schneider, A., et al.: Morphology, metabolism, microcirculation, and strength of skeletal muscles in cancer-related cachexia. Acta Oncol. 48(1), 116–124 (2009)</ce:source-text>
</reference>
<reference seq="37">
<ref-info>
<ref-title>
<ref-titletext-english>Assessment of skeletal muscle perfusion using contrast-enhanced ultrasonography</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Krix</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Krakowski-Roosen</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Huttner</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Delorme</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="5">
<ce:initials>H.</ce:initials>
<ce:surname>Kauczor</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="6">
<ce:initials>W.</ce:initials>
<ce:surname>Hildebrandt</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Ultrasound Med</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>431</first-page>
<last-page>441</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Krix, M., Krakowski-Roosen, H., Huttner, H., Delorme, S., Kauczor, H., Hildebrandt, W.: Assessment of skeletal muscle perfusion using contrast-enhanced ultrasonography. J. Ultrasound Med. 24(4), 431–441 (2005)</ref-fulltext>
<ce:source-text>Krix, M., Krakowski-Roosen, H., Huttner, H., Delorme, S., Kauczor, H., Hildebrandt, W.: Assessment of skeletal muscle perfusion using contrast-enhanced ultrasonography. J. Ultrasound Med. 24(4), 431–441 (2005)</ce:source-text>
</reference>
<reference seq="38">
<ref-info>
<ref-title>
<ref-titletext-english>Reliability of bedside ultrasound for measurement of quadriceps muscle thickness in critically ill patients with acute kidney injury</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Sabatino</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Regolistil</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:surname>Bozzoli</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="4">
<ce:initials>F.</ce:initials>
<ce:surname>Fani</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="5">
<ce:initials>R.</ce:initials>
<ce:surname>Antoniotti</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="6">
<ce:initials>U.</ce:initials>
<ce:surname>Maggiore</ce:surname>
<ce:given-name>U.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1710</first-page>
<last-page>1715</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sabatino, A., Regolistil, G., Bozzoli, L., Fani, F., Antoniotti, R., Maggiore, U., et al.: Reliability of bedside ultrasound for measurement of quadriceps muscle thickness in critically ill patients with acute kidney injury. Clin. Nutr. 36(6), 1710–1715 (2017)</ref-fulltext>
<ce:source-text>Sabatino, A., Regolistil, G., Bozzoli, L., Fani, F., Antoniotti, R., Maggiore, U., et al.: Reliability of bedside ultrasound for measurement of quadriceps muscle thickness in critically ill patients with acute kidney injury. Clin. Nutr. 36(6), 1710–1715 (2017)</ce:source-text>
</reference>
<reference seq="39">
<ref-info>
<ref-title>
<ref-titletext-english>Qualitative ultrasound in acute critical illness muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Puthucheary</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Phadke</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Rawal</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>McPhail</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>P.</ce:initials>
<ce:surname>Sidhu</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Rowlerson</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Crit. Care Med</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>43</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1603</first-page>
<last-page>1611</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Puthucheary, Z., Phadke, R., Rawal, J., McPhail, M., Sidhu, P., Rowlerson, A., et al.: Qualitative ultrasound in acute critical illness muscle wasting. Crit. Care Med. 43(8), 1603–1611 (2015)</ref-fulltext>
<ce:source-text>Puthucheary, Z., Phadke, R., Rawal, J., McPhail, M., Sidhu, P., Rowlerson, A., et al.: Qualitative ultrasound in acute critical illness muscle wasting. Crit. Care Med. 43(8), 1603–1611 (2015)</ce:source-text>
</reference>
<reference seq="40">
<ref-info>
<ref-title>
<ref-titletext-english>Sexual dimorphism modulates the impact of cancer cachexia on lower limb muscle mass and function. Clin</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.A.</ce:initials>
<ce:surname>Stephens</ce:surname>
<ce:given-name>N.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Gray</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.J.</ce:initials>
<ce:surname>Macdonald</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>B.H.</ce:initials>
<ce:surname>Tan</ce:surname>
<ce:given-name>B.H.</ce:given-name>
</author>
<author seq="5">
<ce:initials>I.J.</ce:initials>
<ce:surname>Gallagher</ce:surname>
<ce:given-name>I.J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>R.J.E.</ce:initials>
<ce:surname>Skipworth</ce:surname>
<ce:given-name>R.J.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nutr</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>31</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>499</first-page>
<last-page>505</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stephens, N.A., Gray, C., MacDonald, A.J., Tan, B.H., Gallagher, I.J., Skipworth, R.J.E., et al.: Sexual dimorphism modulates the impact of cancer cachexia on lower limb muscle mass and function. Clin. Nutr. 31(4), 499–505 (2012)</ref-fulltext>
<ce:source-text>Stephens, N.A., Gray, C., MacDonald, A.J., Tan, B.H., Gallagher, I.J., Skipworth, R.J.E., et al.: Sexual dimorphism modulates the impact of cancer cachexia on lower limb muscle mass and function. Clin. Nutr. 31(4), 499–505 (2012)</ce:source-text>
</reference>
<reference seq="41">
<ref-info>
<ref-title>
<ref-titletext-english>Interaction of gonadal status with systemic inflammation and opioid use in determining nutritional status and prognosis in advanced pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.J.E.</ce:initials>
<ce:surname>Skipworth</ce:surname>
<ce:given-name>R.J.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Moses</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.</ce:initials>
<ce:surname>Sangster</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Sturgeon</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Voss</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Fallon</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Support Care Cancer</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>391</first-page>
<last-page>401</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Skipworth, R.J.E., Moses, A., Sangster, K., Sturgeon, C., Voss, A., Fallon, M., et al.: Interaction of gonadal status with systemic inflammation and opioid use in determining nutritional status and prognosis in advanced pancreatic cancer. Support Care Cancer. 19(3), 391–401 (2011)</ref-fulltext>
<ce:source-text>Skipworth, R.J.E., Moses, A., Sangster, K., Sturgeon, C., Voss, A., Fallon, M., et al.: Interaction of gonadal status with systemic inflammation and opioid use in determining nutritional status and prognosis in advanced pancreatic cancer. Support Care Cancer. 19(3), 391–401 (2011)</ce:source-text>
</reference>
<reference seq="42">
<ref-info>
<ref-title>
<ref-titletext-english>Sexual dimorphism in the skeletal muscle transcriptome and urinary proteome indicate sex specific pathways involved in regulation of muscularity in cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Stretch</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Rejtar</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Reinker</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Brachat</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="6">
<ce:initials>R.</ce:initials>
<ce:surname>Badur</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>183</first-page>
<last-page>212</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stretch, C., Wang, K., Rejtar, T., Reinker, S., Brachat, S., Badur, R., et al.: Sexual dimorphism in the skeletal muscle transcriptome and urinary proteome indicate sex specific pathways involved in regulation of muscularity in cancer patients. J. Cachexia. Sarcopenia Muscle. 9(1), 183–212 (2018)</ref-fulltext>
<ce:source-text>Stretch, C., Wang, K., Rejtar, T., Reinker, S., Brachat, S., Badur, R., et al.: Sexual dimorphism in the skeletal muscle transcriptome and urinary proteome indicate sex specific pathways involved in regulation of muscularity in cancer patients. J. Cachexia. Sarcopenia Muscle. 9(1), 183–212 (2018)</ce:source-text>
</reference>
<reference seq="43">
<ref-info>
<ref-title>
<ref-titletext-english>Mechanisms of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.J.</ce:initials>
<ce:surname>Tisdale</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Physiol. Rev</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>89</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>381</first-page>
<last-page>410</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tisdale, M.J.: Mechanisms of cancer cachexia. Physiol. Rev. 89(2), 381–410 (2009)</ref-fulltext>
<ce:source-text>Tisdale, M.J.: Mechanisms of cancer cachexia. Physiol. Rev. 89(2), 381–410 (2009)</ce:source-text>
</reference>
<reference seq="44">
<ref-info>
<ref-title>
<ref-titletext-english>New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Johns</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Stretch</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>B.H.L.</ce:initials>
<ce:surname>Tan</ce:surname>
<ce:given-name>B.H.L.</ce:given-name>
</author>
<author seq="4">
<ce:initials>T.S.</ce:initials>
<ce:surname>Solheim</ce:surname>
<ce:given-name>T.S.</ce:given-name>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Sørhaug</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="6">
<ce:initials>N.A.</ce:initials>
<ce:surname>Stephens</ce:surname>
<ce:given-name>N.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J Cachexia Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2016" />
</ref-info>
<ref-fulltext>Johns, N., Stretch, C., Tan, B.H.L., Solheim, T.S., Sørhaug, S., Stephens, N.A., et al.: New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss. J Cachexia Sarcopenia Muscle. (2016 Jan 1);n/a–n/a</ref-fulltext>
<ce:source-text>Johns, N., Stretch, C., Tan, B.H.L., Solheim, T.S., Sørhaug, S., Stephens, N.A., et al.: New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss. J Cachexia Sarcopenia Muscle. (2016 Jan 1);n/a–n/a</ce:source-text>
</reference>
<reference seq="45">
<ref-info>
<ref-title>
<ref-titletext-english>Host cytokine genotype is related to adverse prognosis and systemic inflammation in gastro-oesophageal cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Deans</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Rose-Zerilli</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Wigmore</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Ross</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Howell</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Jackson</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Surg. Oncol</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>329</first-page>
<last-page>339</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Deans, C., Rose-Zerilli, M., Wigmore, S.,Ross, J., Howell, M., Jackson, A., et al.: Host cytokine genotype is related to adverse prognosis and systemic inflammation in gastro-oesophageal cancer. Ann. Surg. Oncol. 14(2), 329–339 (2007)</ref-fulltext>
<ce:source-text>Deans, C., Rose-Zerilli, M., Wigmore, S.,Ross, J., Howell, M., Jackson, A., et al.: Host cytokine genotype is related to adverse prognosis and systemic inflammation in gastro-oesophageal cancer. Ann. Surg. Oncol. 14(2), 329–339 (2007)</ce:source-text>
</reference>
<reference seq="46">
<ref-info>
<ref-title>
<ref-titletext-english>A polymorphism of the interleukin-1 beta gene influences survival in pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Barber</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Powell</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Lynch</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>K.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Ross</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2000" />
<volisspag>
<volume-issue-number>
<vol-first>83</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1443</first-page>
<last-page>1447</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Barber, M., Powell, J., Lynch, S., Fearon, K., Ross, J.: A polymorphism of the interleukin-1 beta gene influences survival in pancreatic cancer. Br. J. Cancer. 83, 1443–1447 (2000)</ref-fulltext>
<ce:source-text>Barber, M., Powell, J., Lynch, S., Fearon, K., Ross, J.: A polymorphism of the interleukin-1 beta gene influences survival in pancreatic cancer. Br. J. Cancer. 83, 1443–1447 (2000)</ce:source-text>
</reference>
<reference seq="47">
<ref-info>
<ref-title>
<ref-titletext-english>Two polymorphisms of the tumour necrosis factor gene do not influence survival in pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Barber</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Powell</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Lynch</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>N.</ce:initials>
<ce:surname>Gough</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="5">
<ce:initials>K.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:surname>Ross</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Exp. Immunol</ref-sourcetitle>
<ref-publicationyear first="1999" />
<volisspag>
<volume-issue-number>
<vol-first>117</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>425</first-page>
<last-page>429</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Barber, M., Powell, J., Lynch, S., Gough, N., Fearon, K., Ross, J.: Two polymorphisms of the tumour necrosis factor gene do not influence survival in pancreatic cancer. Clin. Exp. Immunol. 117, 425–429 (1999)</ref-fulltext>
<ce:source-text>Barber, M., Powell, J., Lynch, S., Gough, N., Fearon, K., Ross, J.: Two polymorphisms of the tumour necrosis factor gene do not influence survival in pancreatic cancer. Clin. Exp. Immunol. 117, 425–429 (1999)</ce:source-text>
</reference>
<reference seq="48">
<ref-info>
<ref-title>
<ref-titletext-english>Cachexia and pancreatic cancer: Are there treatment options? World</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Mueller</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Burmeister</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Bachmann</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Martignoni</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Gastroenterol</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>28</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>9361</first-page>
<last-page>9373</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mueller, T., Burmeister, M., Bachmann, J., Martignoni, M.: Cachexia and pancreatic cancer: Are there treatment options? World J. Gastroenterol. 20(28), 9361–9373 (2014)</ref-fulltext>
<ce:source-text>Mueller, T., Burmeister, M., Bachmann, J., Martignoni, M.: Cachexia and pancreatic cancer: Are there treatment options? World J. Gastroenterol. 20(28), 9361–9373 (2014)</ce:source-text>
</reference>
<reference seq="49">
<ref-info>
<ref-title>
<ref-titletext-english>Relation between hypermetabolism, cachexia and survival in cancer patients: A prospective study in 390 cancer patients before initiation of anticancer therapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Vazeille</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Jouinot</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Durand</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>N.</ce:initials>
<ce:surname>Neveux</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="5">
<ce:initials>P.</ce:initials>
<ce:surname>Boudou-Rouquette</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="6">
<ce:initials>O.</ce:initials>
<ce:surname>Huillard</ce:surname>
<ce:given-name>O.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>105</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1139</first-page>
<last-page>1147</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vazeille, C., Jouinot, A., Durand, J., Neveux, N., Boudou-Rouquette, P., Huillard, O., et al.: Relation between hypermetabolism, cachexia and survival in cancer patients: A prospective study in 390 cancer patients before initiation of anticancer therapy. Am. J. Clin. Nutr. 105(5), 1139–1147 (2017)</ref-fulltext>
<ce:source-text>Vazeille, C., Jouinot, A., Durand, J., Neveux, N., Boudou-Rouquette, P., Huillard, O., et al.: Relation between hypermetabolism, cachexia and survival in cancer patients: A prospective study in 390 cancer patients before initiation of anticancer therapy. Am. J. Clin. Nutr. 105(5), 1139–1147 (2017)</ce:source-text>
</reference>
<reference seq="50">
<ref-info>
<ref-title>
<ref-titletext-english>Tumour-specific and organ-specific protein synthesis rates in patients with pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>van Dijk</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Horstman</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Smeets</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Den Dulk</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>H.</ce:initials>
<ce:surname>Grabsch</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:surname>Dejong</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>van Dijk, D., Horstman, A., Smeets, J., den Dulk, M., Grabsch, H., Dejong, C., et al.: Tumour-specific and organ-specific protein synthesis rates in patients with pancreatic cancer. J. Cachexia. Sarcopenia Muscle. 10(3) (2019)</ref-fulltext>
<ce:source-text>van Dijk, D., Horstman, A., Smeets, J., den Dulk, M., Grabsch, H., Dejong, C., et al.: Tumour-specific and organ-specific protein synthesis rates in patients with pancreatic cancer. J. Cachexia. Sarcopenia Muscle. 10(3) (2019)</ce:source-text>
</reference>
<reference seq="51">
<ref-info>
<ref-title>
<ref-titletext-english>Effects of oral meal feeding on whole body protein breakdown and protein synthesis in cachectic pancreatic cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.P.</ce:initials>
<ce:surname>van Dijk</ce:surname>
<ce:given-name>D.P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.C.</ce:initials>
<ce:surname>Van de Poll</ce:surname>
<ce:given-name>M.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.G.</ce:initials>
<ce:surname>Moses</ce:surname>
<ce:given-name>A.G.</ce:given-name>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Preston</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="5">
<ce:initials>S.W.</ce:initials>
<ce:surname>Olde Damink</ce:surname>
<ce:given-name>S.W.</ce:given-name>
</author>
<author seq="6">
<ce:initials>S.S.</ce:initials>
<ce:surname>Rensen</ce:surname>
<ce:given-name>S.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>212</first-page>
<last-page>221</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>van Dijk, D.P., van de Poll, M.C., Moses, A.G., Preston, T., Olde Damink, S.W., Rensen, S.S., et al.: Effects of oral meal feeding on whole body protein breakdown and protein synthesis in cachectic pancreatic cancer patients. J. Cachexia. Sarcopenia Muscle. 6(3), 212–221 (2015)</ref-fulltext>
<ce:source-text>van Dijk, D.P., van de Poll, M.C., Moses, A.G., Preston, T., Olde Damink, S.W., Rensen, S.S., et al.: Effects of oral meal feeding on whole body protein breakdown and protein synthesis in cachectic pancreatic cancer patients. J. Cachexia. Sarcopenia Muscle. 6(3), 212–221 (2015)</ce:source-text>
</reference>
<reference seq="52">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle protein synthesis in cancer patients can be stimulated with a specially formulated medical food</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.E.P.</ce:initials>
<ce:surname>Deutz</ce:surname>
<ce:given-name>N.E.P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Safar</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Schutzler</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Memelink</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Ferrando</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>H.</ce:initials>
<ce:surname>Spencer</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr. Edinb. Scotl</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>759</first-page>
<last-page>768</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Deutz, N.E.P., Safar, A., Schutzler, S., Memelink, R., Ferrando, A., Spencer, H., et al.: Muscle protein synthesis in cancer patients can be stimulated with a specially formulated medical food. Clin. Nutr. Edinb. Scotl. 30(6), 759–768 (2011)</ref-fulltext>
<ce:source-text>Deutz, N.E.P., Safar, A., Schutzler, S., Memelink, R., Ferrando, A., Spencer, H., et al.: Muscle protein synthesis in cancer patients can be stimulated with a specially formulated medical food. Clin. Nutr. Edinb. Scotl. 30(6), 759–768 (2011)</ce:source-text>
</reference>
<reference seq="53">
<ref-info>
<ref-title>
<ref-titletext-english>A novel oral tracer procedure for measurement of habitual myofibrillar protein synthesis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.J.</ce:initials>
<ce:surname>Macdonald</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.C.</ce:initials>
<ce:surname>Small</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.A.</ce:initials>
<ce:surname>Greig</ce:surname>
<ce:given-name>C.A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>H.</ce:initials>
<ce:surname>Husi</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.A.</ce:initials>
<ce:surname>Ross</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>N.A.</ce:initials>
<ce:surname>Stephens</ce:surname>
<ce:given-name>N.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Rapid. Commun. Mass Spectrom. RCM</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
<iss-first>15</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1769</first-page>
<last-page>1777</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>MacDonald, A.J., Small, A.C., Greig, C.A., Husi, H., Ross, J.A., Stephens, N.A., et al.: A novel oral tracer procedure for measurement of habitual myofibrillar protein synthesis. Rapid. Commun. Mass Spectrom. RCM. 27(15), 1769–1777 (2013)</ref-fulltext>
<ce:source-text>MacDonald, A.J., Small, A.C., Greig, C.A., Husi, H., Ross, J.A., Stephens, N.A., et al.: A novel oral tracer procedure for measurement of habitual myofibrillar protein synthesis. Rapid. Commun. Mass Spectrom. RCM. 27(15), 1769–1777 (2013)</ce:source-text>
</reference>
<reference seq="54">
<ref-info>
<ref-title>
<ref-titletext-english>Habitual myofibrillar protein synthesis is normal in patients with upper GI cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.J.</ce:initials>
<ce:surname>Macdonald</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:surname>Johns</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Stephens</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Greig</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.A.</ce:initials>
<ce:surname>Ross</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>A.C.</ce:initials>
<ce:surname>Small</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. Assoc. Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1734</first-page>
<last-page>1740</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>MacDonald, A.J., Johns, N., Stephens, N., Greig, C., Ross, J.A., Small, A.C., et al.: Habitual myofibrillar protein synthesis is normal in patients with upper GI cancer cachexia. Am. Assoc. Cancer Res. 21(7), 1734–1740 (2015)</ref-fulltext>
<ce:source-text>MacDonald, A.J., Johns, N., Stephens, N., Greig, C., Ross, J.A., Small, A.C., et al.: Habitual myofibrillar protein synthesis is normal in patients with upper GI cancer cachexia. Am. Assoc. Cancer Res. 21(7), 1734–1740 (2015)</ce:source-text>
</reference>
<reference seq="55">
<ref-info>
<ref-title>
<ref-titletext-english>Protein breakdown in muscle wasting: Role of autophagy-lysosome and ubiquitin-proteasome</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Sandri</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Biochem. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>45</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Sandri, M.: Protein breakdown in muscle wasting: role of autophagy-lysosome and ubiquitin-proteasome. Int. J. Biochem. Cell Biol. 45(10) (2013)</ref-fulltext>
<ce:source-text>Sandri, M.: Protein breakdown in muscle wasting: role of autophagy-lysosome and ubiquitin-proteasome. Int. J. Biochem. Cell Biol. 45(10) (2013)</ce:source-text>
</reference>
<reference seq="56">
<ref-info>
<ref-title>
<ref-titletext-english>Coming back: Autophagy in cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Penna</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Baccino</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Costelli</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Opin. Clin. Nutr. Metab. Care</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>241</first-page>
<last-page>246</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Penna, F., Baccino, F., Costelli, P.: Coming back: Autophagy in cachexia. Curr. Opin. Clin. Nutr. Metab. Care. 17(3), 241–246 (2014)</ref-fulltext>
<ce:source-text>Penna, F., Baccino, F., Costelli, P.: Coming back: Autophagy in cachexia. Curr. Opin. Clin. Nutr. Metab. Care. 17(3), 241–246 (2014)</ce:source-text>
</reference>
<reference seq="57">
<ref-info>
<ref-title>
<ref-titletext-english>The impact of autophagy on cell death modalities</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Ryter</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Mizumura</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Choi</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2014" />
</ref-info>
<ref-fulltext>Ryter, S., Mizumura, K., Choi, A.: The impact of autophagy on cell death modalities. Int. J. Cell Biol. (2014)</ref-fulltext>
<ce:source-text>Ryter, S., Mizumura, K., Choi, A.: The impact of autophagy on cell death modalities. Int. J. Cell Biol. (2014)</ce:source-text>
</reference>
<reference seq="58">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signalling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Pettersen</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Andersen</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Degen</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>V.</ce:initials>
<ce:surname>Tadini</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Grosjean</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>Hatakeyama</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2046</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pettersen, K., Andersen, S., Degen, S., Tadini, V., Grosjean, J., Hatakeyama, S., et al.: Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signalling. Sci. Rep. 7, 2046 (2017)</ref-fulltext>
<ce:source-text>Pettersen, K., Andersen, S., Degen, S., Tadini, V., Grosjean, J., Hatakeyama, S., et al.: Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signalling. Sci. Rep. 7, 2046 (2017)</ce:source-text>
</reference>
<reference seq="59">
<ref-info>
<ref-title>
<ref-titletext-english>Clinical classification of cancer cachexia: Phenotypic correlates in human skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Johns</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Hatakeyama</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.A.</ce:initials>
<ce:surname>Stephens</ce:surname>
<ce:given-name>N.A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Degen</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Degen</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="6">
<ce:initials>W.</ce:initials>
<ce:surname>Frieauff</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Johns, N., Hatakeyama, S., Stephens, N.A., Degen, M., Degen, S., Frieauff, W., et al.: Clinical classification of cancer cachexia: Phenotypic correlates in human skeletal muscle. PLoS One. 9(1), e83618 (2014)</ref-fulltext>
<ce:source-text>Johns, N., Hatakeyama, S., Stephens, N.A., Degen, M., Degen, S., Frieauff, W., et al.: Clinical classification of cancer cachexia: Phenotypic correlates in human skeletal muscle. PLoS One. 9(1), e83618 (2014)</ce:source-text>
</reference>
<reference seq="60">
<ref-info>
<ref-title>
<ref-titletext-english>Neuromuscular junctions are stable in patients with cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Boehm</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Miller</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Wishart</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Wigmore</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="5">
<ce:initials>R.</ce:initials>
<ce:surname>Skipworth</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="6">
<ce:initials>R.</ce:initials>
<ce:surname>Jones</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="2019" />
</ref-info>
<ref-fulltext>Boehm, I., Miller, J., Wishart, T., Wigmore, S., Skipworth, R., Jones, R., et al.: Neuromuscular junctions are stable in patients with cancer cachexia. J. Clin. Invest. (2019)</ref-fulltext>
<ce:source-text>Boehm, I., Miller, J., Wishart, T., Wigmore, S., Skipworth, R., Jones, R., et al.: Neuromuscular junctions are stable in patients with cancer cachexia. J. Clin. Invest. (2019)</ce:source-text>
</reference>
<reference seq="61">
<ref-info>
<ref-title>
<ref-titletext-english>Evidence and mechanisms of fat depletion in cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Ebadi</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>V.C.</ce:initials>
<ce:surname>Mazurak</ce:surname>
<ce:given-name>V.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nutrients</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5280</first-page>
<last-page>5297</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ebadi, M., Mazurak, V.C.: Evidence and mechanisms of fat depletion in cancer. Nutrients. 6(11), 5280–5297 (2014)</ref-fulltext>
<ce:source-text>Ebadi, M., Mazurak, V.C.: Evidence and mechanisms of fat depletion in cancer. Nutrients. 6(11), 5280–5297 (2014)</ce:source-text>
</reference>
<reference seq="62">
<ref-info>
<ref-title>
<ref-titletext-english>Lipolysis; not inflammation, cell death, or lipogenesis is involved in adipose tissue loss in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Ryden</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Agustsson</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Laurencikiene</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Britton</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="5">
<ce:initials>E.</ce:initials>
<ce:surname>Sjolin</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="6">
<ce:initials>B.</ce:initials>
<ce:surname>Isaksson</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer</ref-sourcetitle>
<ref-publicationyear first="2008" />
<volisspag>
<volume-issue-number>
<vol-first>113</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1695</first-page>
<last-page>1704</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ryden, M., Agustsson, T., Laurencikiene, J., Britton, T., Sjolin, E., Isaksson, B., et al.: Lipolysis; not inflammation, cell death, or lipogenesis is involved in adipose tissue loss in cancer cachexia. Cancer. 113(7), 1695–1704 (2008)</ref-fulltext>
<ce:source-text>Ryden, M., Agustsson, T., Laurencikiene, J., Britton, T., Sjolin, E., Isaksson, B., et al.: Lipolysis; not inflammation, cell death, or lipogenesis is involved in adipose tissue loss in cancer cachexia. Cancer. 113(7), 1695–1704 (2008)</ce:source-text>
</reference>
<reference seq="63">
<ref-info>
<ref-title>
<ref-titletext-english>Enhanced ZAG production by subcutaneous adipose tissue is linked to weight loss in gastrointestinal cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Mracek</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>N.A.</ce:initials>
<ce:surname>Stephens</ce:surname>
<ce:given-name>N.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Gao</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="4">
<ce:initials>Y.</ce:initials>
<ce:surname>Bao</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.A.</ce:initials>
<ce:surname>Ross</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Rydén</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>104</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>441</first-page>
<last-page>447</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mracek, T., Stephens, N.A., Gao, D., Bao, Y., Ross, J.A., Rydén, M., et al.: Enhanced ZAG production by subcutaneous adipose tissue is linked to weight loss in gastrointestinal cancer patients. Br. J. Cancer. 104(3), 441–447 (2011)</ref-fulltext>
<ce:source-text>Mracek, T., Stephens, N.A., Gao, D., Bao, Y., Ross, J.A., Rydén, M., et al.: Enhanced ZAG production by subcutaneous adipose tissue is linked to weight loss in gastrointestinal cancer patients. Br. J. Cancer. 104(3), 441–447 (2011)</ce:source-text>
</reference>
<reference seq="64">
<ref-info>
<ref-title>
<ref-titletext-english>Loss of visceral adipose tissue precedes subcutaneous adipose tissue and associates with N-6 fatty acid content</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Ebadi</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>V.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
<author seq="3">
<ce:initials>O.</ce:initials>
<ce:surname>Bathe</ce:surname>
<ce:given-name>O.</ce:given-name>
</author>
<author seq="4">
<ce:initials>L.</ce:initials>
<ce:surname>Robinson</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="5">
<ce:initials>V.</ce:initials>
<ce:surname>Mazurak</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1347</first-page>
<last-page>1353</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ebadi, M., Baracos, V., Bathe, O., Robinson, L., Mazurak, V.: Loss of visceral adipose tissue precedes subcutaneous adipose tissue and associates with N-6 fatty acid content. Clin. Nutr. 35(6), 1347–1353 (2016)</ref-fulltext>
<ce:source-text>Ebadi, M., Baracos, V., Bathe, O., Robinson, L., Mazurak, V.: Loss of visceral adipose tissue precedes subcutaneous adipose tissue and associates with N-6 fatty acid content. Clin. Nutr. 35(6), 1347–1353 (2016)</ce:source-text>
</reference>
<reference seq="65">
<ref-info>
<ref-title>
<ref-titletext-english>Not all fat is equal: Differential gene expression and potential therapeutic targets in subcutaneous adipose, visceral adipose, and endometrium of obese women with and without endometrial cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.C.</ce:initials>
<ce:surname>Modesitt</ce:surname>
<ce:given-name>S.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.Y.</ce:initials>
<ce:surname>Hsu</ce:surname>
<ce:given-name>J.Y.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.R.</ce:initials>
<ce:surname>Chowbina</ce:surname>
<ce:given-name>S.R.</ce:given-name>
</author>
<author seq="4">
<ce:initials>R.T.</ce:initials>
<ce:surname>Lawrence</ce:surname>
<ce:given-name>R.T.</ce:given-name>
</author>
<author seq="5">
<ce:initials>K.L.</ce:initials>
<ce:surname>Hoehn</ce:surname>
<ce:given-name>K.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>22</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>732</first-page>
<last-page>741</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Modesitt, S.C., Hsu, J.Y., Chowbina, S.R., Lawrence, R.T., Hoehn, K.L.: Not all fat is equal: differential gene expression and potential therapeutic targets in subcutaneous adipose, visceral adipose, and endometrium of obese women with and without endometrial cancer. Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc. 22(5), 732–741 (2012)</ref-fulltext>
<ce:source-text>Modesitt, S.C., Hsu, J.Y., Chowbina, S.R., Lawrence, R.T., Hoehn, K.L.: Not all fat is equal: differential gene expression and potential therapeutic targets in subcutaneous adipose, visceral adipose, and endometrium of obese women with and without endometrial cancer. Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc. 22(5), 732–741 (2012)</ce:source-text>
</reference>
<reference seq="66">
<ref-info>
<ref-title>
<ref-titletext-english>Adipose triglyceride lipase contributes to cancer-associated cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.K.</ce:initials>
<ce:surname>Das</ce:surname>
<ce:given-name>S.K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Eder</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Schauer</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Diwoky</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="5">
<ce:initials>H.</ce:initials>
<ce:surname>Temmel</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="6">
<ce:initials>B.</ce:initials>
<ce:surname>Guertl</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>333</vol-first>
<iss-first>6039</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>233</first-page>
<last-page>238</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Das, S.K., Eder, S., Schauer, S., Diwoky, C., Temmel, H., Guertl, B., et al.: Adipose triglyceride lipase contributes to cancer-associated cachexia. Science. 333(6039), 233–238 (2011)</ref-fulltext>
<ce:source-text>Das, S.K., Eder, S., Schauer, S., Diwoky, C., Temmel, H., Guertl, B., et al.: Adipose triglyceride lipase contributes to cancer-associated cachexia. Science. 333(6039), 233–238 (2011)</ce:source-text>
</reference>
<reference seq="67">
<ref-info>
<ref-title>
<ref-titletext-english>Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Kir</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.P.</ce:initials>
<ce:surname>White</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Kleiner</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>L.</ce:initials>
<ce:surname>Kazak</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="5">
<ce:initials>P.</ce:initials>
<ce:surname>Cohen</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="6">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>513</vol-first>
<iss-first>7516</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>100</first-page>
<last-page>104</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kir, S., White, J.P., Kleiner, S., Kazak, L., Cohen, P., Baracos, V.E., et al.: Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature. 513(7516), 100–104 (2014)</ref-fulltext>
<ce:source-text>Kir, S., White, J.P., Kleiner, S., Kazak, L., Cohen, P., Baracos, V.E., et al.: Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature. 513(7516), 100–104 (2014)</ce:source-text>
</reference>
<reference seq="68">
<ref-info>
<ref-title>
<ref-titletext-english>Serum parathyroid hormone-related peptide is associated with systemic inflammation and adverse prognosis in gastroesophageal carcinoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Deans</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Wigmore</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Paterson-Brown</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Black</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Ross</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>K.C.H.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.C.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>103</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1810</first-page>
<last-page>1818</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Deans, C., Wigmore, S., Paterson-Brown, S., Black, J., Ross, J., Fearon, K.C.H.: Serum parathyroid hormone-related peptide is associated with systemic inflammation and adverse prognosis in gastroesophageal carcinoma. Cancer. 103(9), 1810–1818 (2005)</ref-fulltext>
<ce:source-text>Deans, C., Wigmore, S., Paterson-Brown, S., Black, J., Ross, J., Fearon, K.C.H.: Serum parathyroid hormone-related peptide is associated with systemic inflammation and adverse prognosis in gastroesophageal carcinoma. Cancer. 103(9), 1810–1818 (2005)</ce:source-text>
</reference>
<reference seq="69">
<ref-info>
<ref-title>
<ref-titletext-english>PTH/PTHrP receptor mediates cachexia in models of kidney failure and cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Kir</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Komaba</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.P.</ce:initials>
<ce:surname>Garcia</ce:surname>
<ce:given-name>A.P.</ce:given-name>
</author>
<author seq="4">
<ce:initials>K.P.</ce:initials>
<ce:surname>Economopoulos</ce:surname>
<ce:given-name>K.P.</ce:given-name>
</author>
<author seq="5">
<ce:initials>W.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="6">
<ce:initials>B.</ce:initials>
<ce:surname>Lanske</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>23</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>315</first-page>
<last-page>323</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kir, S., Komaba, H., Garcia, A.P., Economopoulos, K.P., Liu, W., Lanske, B., et al.: PTH/PTHrP receptor mediates cachexia in models of kidney failure and cancer. Cell Metab. 23(2), 315–323 (2016)</ref-fulltext>
<ce:source-text>Kir, S., Komaba, H., Garcia, A.P., Economopoulos, K.P., Liu, W., Lanske, B., et al.: PTH/PTHrP receptor mediates cachexia in models of kidney failure and cancer. Cell Metab. 23(2), 315–323 (2016)</ce:source-text>
</reference>
<reference seq="70">
<ref-info>
<ref-title>
<ref-titletext-english>TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Chicheportiche</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.R.</ce:initials>
<ce:surname>Bourdon</ce:surname>
<ce:given-name>P.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Xu</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="4">
<ce:initials>Y.M.</ce:initials>
<ce:surname>Hsu</ce:surname>
<ce:given-name>Y.M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>H.</ce:initials>
<ce:surname>Scott</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:surname>Hession</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="1997" />
<volisspag>
<volume-issue-number>
<vol-first>272</vol-first>
<iss-first>51</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>32401</first-page>
<last-page>32410</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chicheportiche, Y., Bourdon, P.R., Xu, H., Hsu, Y.M., Scott, H., Hession, C., et al.: TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J. Biol. Chem. 272(51), 32401–32410 (1997)</ref-fulltext>
<ce:source-text>Chicheportiche, Y., Bourdon, P.R., Xu, H., Hsu, Y.M., Scott, H., Hession, C., et al.: TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J. Biol. Chem. 272(51), 32401–32410 (1997)</ce:source-text>
</reference>
<reference seq="71">
<ref-info>
<ref-title>
<ref-titletext-english>TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Dogra</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Changotra</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Wedhas</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="4">
<ce:initials>X.</ce:initials>
<ce:surname>Qin</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.E.</ce:initials>
<ce:surname>Wergedal</ce:surname>
<ce:given-name>J.E.</ce:given-name>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Kumar</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>FASEB J</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1857</first-page>
<last-page>1869</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dogra, C., Changotra, H., Wedhas, N., Qin, X., Wergedal, J.E., Kumar, A.: TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. FASEB J. 21(8), 1857–1869 (2007)</ref-fulltext>
<ce:source-text>Dogra, C., Changotra, H., Wedhas, N., Qin, X., Wergedal, J.E., Kumar, A.: TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. FASEB J. 21(8), 1857–1869 (2007)</ce:source-text>
</reference>
<reference seq="72">
<ref-info>
<ref-title>
<ref-titletext-english>A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.R.</ce:initials>
<ce:surname>Wiley</ce:surname>
<ce:given-name>S.R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Cassiano</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Lofton</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Davis-Smith</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.A.</ce:initials>
<ce:surname>Winkles</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>V.</ce:initials>
<ce:surname>Lindner</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Immunity</ref-sourcetitle>
<ref-publicationyear first="2001" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>837</first-page>
<last-page>846</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wiley, S.R., Cassiano, L., Lofton, T., Davis-Smith, T., Winkles, J.A., Lindner, V., et al.: A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity. 15(5), 837–846 (2001)</ref-fulltext>
<ce:source-text>Wiley, S.R., Cassiano, L., Lofton, T., Davis-Smith, T., Winkles, J.A., Lindner, V., et al.: A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity. 15(5), 837–846 (2001)</ce:source-text>
</reference>
<reference seq="73">
<ref-info>
<ref-title>
<ref-titletext-english>The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.L.Y.</ce:initials>
<ce:surname>Feng</ce:surname>
<ce:given-name>S.L.Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Guo</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="3">
<ce:initials>V.M.</ce:initials>
<ce:surname>Factor</ce:surname>
<ce:given-name>V.M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.S.</ce:initials>
<ce:surname>Thorgeirsson</ce:surname>
<ce:given-name>S.S.</ce:given-name>
</author>
<author seq="5">
<ce:initials>D.W.</ce:initials>
<ce:surname>Bell</ce:surname>
<ce:given-name>D.W.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.R.</ce:initials>
<ce:surname>Testa</ce:surname>
<ce:given-name>J.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Pathol</ref-sourcetitle>
<ref-publicationyear first="2000" />
<volisspag>
<volume-issue-number>
<vol-first>156</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1253</first-page>
<last-page>1261</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Feng, S.L.Y., Guo, Y., Factor, V.M., Thorgeirsson, S.S., Bell, D.W., Testa, J.R., et al.: The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am. J. Pathol. 156(4), 1253–1261 (2000)</ref-fulltext>
<ce:source-text>Feng, S.L.Y., Guo, Y., Factor, V.M., Thorgeirsson, S.S., Bell, D.W., Testa, J.R., et al.: The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am. J. Pathol. 156(4), 1253–1261 (2000)</ce:source-text>
</reference>
<reference seq="74">
<ref-info>
<ref-title>
<ref-titletext-english>The TWEAK–Fn14 cytokine–receptor axis: Discovery, biology and therapeutic targeting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Winkles</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Drug Discov</ref-sourcetitle>
<ref-publicationyear first="2008" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>411</first-page>
<last-page>425</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Winkles, J.A.: The TWEAK–Fn14 cytokine–receptor axis: discovery, biology and therapeutic targeting. Nat. Rev. Drug Discov. 7(5), 411–425 (2008)</ref-fulltext>
<ce:source-text>Winkles, J.A.: The TWEAK–Fn14 cytokine–receptor axis: discovery, biology and therapeutic targeting. Nat. Rev. Drug Discov. 7(5), 411–425 (2008)</ce:source-text>
</reference>
<reference seq="75">
<ref-info>
<ref-title>
<ref-titletext-english>TWEAK-Fn14 pathway activation after exercise in human skeletal muscle: Insights from two exercise modes and a time course investigation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>U.</ce:initials>
<ce:surname>Raue</ce:surname>
<ce:given-name>U.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Jemiolo</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Yang</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Trappe</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Appl. Physiol</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>118</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>569</first-page>
<last-page>578</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Raue, U., Jemiolo, B., Yang, Y., Trappe, S.: TWEAK-Fn14 pathway activation after exercise in human skeletal muscle: insights from two exercise modes and a time course investigation. J. Appl. Physiol. 118(5), 569–578 (2015)</ref-fulltext>
<ce:source-text>Raue, U., Jemiolo, B., Yang, Y., Trappe, S.: TWEAK-Fn14 pathway activation after exercise in human skeletal muscle: insights from two exercise modes and a time course investigation. J. Appl. Physiol. 118(5), 569–578 (2015)</ce:source-text>
</reference>
<reference seq="76">
<ref-info>
<ref-title>
<ref-titletext-english>TWEAK causes myotube atrophy through coordinated activation of ubiquitin-proteasome system, autophagy, and caspases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Bhatnagar</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Mittal</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.K.</ce:initials>
<ce:surname>Gupta</ce:surname>
<ce:given-name>S.K.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Kumar</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Physiol</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>227</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1042</first-page>
<last-page>1051</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bhatnagar, S., Mittal, A., Gupta, S.K., Kumar, A.: TWEAK causes myotube atrophy through coordinated activation of ubiquitin-proteasome system, autophagy, and caspases. J. Cell. Physiol. 227(3), 1042–1051 (2012)</ref-fulltext>
<ce:source-text>Bhatnagar, S., Mittal, A., Gupta, S.K., Kumar, A.: TWEAK causes myotube atrophy through coordinated activation of ubiquitin-proteasome system, autophagy, and caspases. J. Cell. Physiol. 227(3), 1042–1051 (2012)</ce:source-text>
</reference>
<reference seq="77">
<ref-info>
<ref-title>
<ref-titletext-english>Targeting of Fn14 prevents cancer-induced cachexia and prolongs survival</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.J.</ce:initials>
<ce:surname>Johnston</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.T.</ce:initials>
<ce:surname>Murphy</ce:surname>
<ce:given-name>K.T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:surname>Jenkinson</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="4">
<ce:initials>D.</ce:initials>
<ce:surname>Laine</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="5">
<ce:initials>K.</ce:initials>
<ce:surname>Emmrich</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="6">
<ce:initials>P.</ce:initials>
<ce:surname>Faou</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>162</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1365</first-page>
<last-page>1378</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Johnston, A.J., Murphy, K.T., Jenkinson, L., Laine, D., Emmrich, K., Faou, P., et al.: Targeting of Fn14 prevents cancer-induced cachexia and prolongs survival. Cell. 162(6), 1365–1378 (2015)</ref-fulltext>
<ce:source-text>Johnston, A.J., Murphy, K.T., Jenkinson, L., Laine, D., Emmrich, K., Faou, P., et al.: Targeting of Fn14 prevents cancer-induced cachexia and prolongs survival. Cell. 162(6), 1365–1378 (2015)</ce:source-text>
</reference>
<reference seq="78">
<ref-info>
<ref-title>
<ref-titletext-english>Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Biswas</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>W.</ce:initials>
<ce:surname>Ma</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Kandpal</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>C.</ce:initials>
<ce:surname>Cocker</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="6">
<ce:initials>P.</ce:initials>
<ce:surname>Grandgenett</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Med</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>770</first-page>
<last-page>781</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, G., Biswas, A., Ma, W., Kandpal, M., Cocker, C., Grandgenett, P., et al.: Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle. Nat. Med. 24, 770–781 (2018)</ref-fulltext>
<ce:source-text>Wang, G., Biswas, A., Ma, W., Kandpal, M., Cocker, C., Grandgenett, P., et al.: Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle. Nat. Med. 24, 770–781 (2018)</ce:source-text>
</reference>
<reference seq="79">
<ref-info>
<ref-title>
<ref-titletext-english>Upregulation of ZIP14 and altered zinc homeostasis in muscles in pancreatic cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Shakri</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Zhong</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>W.</ce:initials>
<ce:surname>Ma</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Coker</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Kim</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>Calluori</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancers</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shakri, A., Zhong, T., Ma, W., Coker, C., Kim, S., Calluori, S., et al.: Upregulation of ZIP14 and altered zinc homeostasis in muscles in pancreatic cancer cachexia. Cancers. 18(12), 3 (2019)</ref-fulltext>
<ce:source-text>Shakri, A., Zhong, T., Ma, W., Coker, C., Kim, S., Calluori, S., et al.: Upregulation of ZIP14 and altered zinc homeostasis in muscles in pancreatic cancer cachexia. Cancers. 18(12), 3 (2019)</ce:source-text>
</reference>
<reference seq="80">
<ref-info>
<ref-title>
<ref-titletext-english>The MIC-1/GDF15-GFRAL pathway in energy homeostasis: Implications for obesity, cachexia, and other associated diseases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.</ce:initials>
<ce:surname>Tsai</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Husaini</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Sainsbury</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>D.</ce:initials>
<ce:surname>Brown</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Breit</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>353</first-page>
<last-page>368</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tsai, V., Husaini, Y., Sainsbury, A., Brown, D., Breit, S.: The MIC-1/GDF15-GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases. Cell Metab. 28, 353–368 (2018)</ref-fulltext>
<ce:source-text>Tsai, V., Husaini, Y., Sainsbury, A., Brown, D., Breit, S.: The MIC-1/GDF15-GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases. Cell Metab. 28, 353–368 (2018)</ce:source-text>
</reference>
<reference seq="81">
<ref-info>
<ref-title>
<ref-titletext-english>The role of GDF15 (growth/differentiation factor 15) during prostate carcinogenesis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Sadasivan</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Gupta</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="4">
<ce:initials>K.</ce:initials>
<ce:surname>Taneja</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Maresh</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Gonzalez</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>78</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>421</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sadasivan, S., Chen, Y., Gupta, N., Taneja, K., Maresh, S., Gonzalez, A., et al.: The role of GDF15 (growth/differentiation factor 15) during prostate carcinogenesis. Cancer Res. 78, 421 (2018)</ref-fulltext>
<ce:source-text>Sadasivan, S., Chen, Y., Gupta, N., Taneja, K., Maresh, S., Gonzalez, A., et al.: The role of GDF15 (growth/differentiation factor 15) during prostate carcinogenesis. Cancer Res. 78, 421 (2018)</ce:source-text>
</reference>
<reference seq="82">
<ref-info>
<ref-title>
<ref-titletext-english>GDF15 induces anorexia through nausea and emesis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Borner</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Shaulson</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Ghidewon</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Barnett</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="5">
<ce:initials>C.</ce:initials>
<ce:surname>Horn</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="6">
<ce:initials>R.</ce:initials>
<ce:surname>Doyle</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>31</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>351</first-page>
<last-page>362</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Borner, T., Shaulson, E., Ghidewon, M., Barnett, A., Horn, C., Doyle, R., et al.: GDF15 induces anorexia through nausea and emesis. Cell Metab. 31(2), 351–362 (2020)</ref-fulltext>
<ce:source-text>Borner, T., Shaulson, E., Ghidewon, M., Barnett, A., Horn, C., Doyle, R., et al.: GDF15 induces anorexia through nausea and emesis. Cell Metab. 31(2), 351–362 (2020)</ce:source-text>
</reference>
<reference seq="83">
<ref-info>
<ref-title>
<ref-titletext-english>Blocking extracellular activation of myostatin as a strategy for treating muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Pirruccello-Straub</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Jackson</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Wawersik</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Webster</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="5">
<ce:initials>L.</ce:initials>
<ce:surname>Salta</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="6">
<ce:initials>K.</ce:initials>
<ce:surname>Long</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2292</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pirruccello-Straub, M., Jackson, J., Wawersik, S., Webster, T., Salta, L., Long, K., et al.: Blocking extracellular activation of myostatin as a strategy for treating muscle wasting. Sci. Rep. 8, 2292 (2018)</ref-fulltext>
<ce:source-text>Pirruccello-Straub, M., Jackson, J., Wawersik, S., Webster, T., Salta, L., Long, K., et al.: Blocking extracellular activation of myostatin as a strategy for treating muscle wasting. Sci. Rep. 8, 2292 (2018)</ce:source-text>
</reference>
<reference seq="84">
<ref-info>
<ref-title>
<ref-titletext-english>Specific targeting of TGF-β family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Walton</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Hagg</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Colgan</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>PNAS</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>114</vol-first>
<iss-first>26</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5266</first-page>
<last-page>5275</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, J., Walton, K., Hagg, A., Colgan, T.: Specific targeting of TGF-β family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease. PNAS. 114(26), 5266–5275 (2017)</ref-fulltext>
<ce:source-text>Chen, J., Walton, K., Hagg, A., Colgan, T.: Specific targeting of TGF-β family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease. PNAS. 114(26), 5266–5275 (2017)</ce:source-text>
</reference>
<reference seq="85">
<ref-info>
<ref-title>
<ref-titletext-english>Activin A induces skeletal muscle catabolism via p38 mitogen activated protein kinase</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Ding</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.</ce:initials>
<ce:surname>Sin</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="4">
<ce:initials>Z.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>202</first-page>
<last-page>212</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ding, H., Zhang, G., Sin, K., Liu, Z.: Activin A induces skeletal muscle catabolism via p38 mitogen activated protein kinase. J. Cachexia. Sarcopenia Muscle. 8(2), 202–212 (2017)</ref-fulltext>
<ce:source-text>Ding, H., Zhang, G., Sin, K., Liu, Z.: Activin A induces skeletal muscle catabolism via p38 mitogen activated protein kinase. J. Cachexia. Sarcopenia Muscle. 8(2), 202–212 (2017)</ce:source-text>
</reference>
<reference seq="86">
<ref-info>
<ref-title>
<ref-titletext-english>Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Morvan</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Rondeau</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Zou</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>G.</ce:initials>
<ce:surname>Minetti</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>114</vol-first>
<iss-first>47</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>12448</first-page>
<last-page>12453</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Morvan, F., Rondeau, J., Zou, C., Minetti, G.: Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy. Proc. Natl. Acad. Sci. USA. 114(47), 12448–12453 (2017)</ref-fulltext>
<ce:source-text>Morvan, F., Rondeau, J., Zou, C., Minetti, G.: Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy. Proc. Natl. Acad. Sci. USA. 114(47), 12448–12453 (2017)</ce:source-text>
</reference>
<reference seq="87">
<ref-info>
<ref-title>
<ref-titletext-english>LY2495655, an antimyostatin antibody, in pancreatic cancer: A randomized, phase 2 trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Golan</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Geva</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Richards</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Madhusudan</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>871</first-page>
<last-page>879</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Golan, T., Geva, R., Richards, D., Madhusudan, S.: LY2495655, an antimyostatin antibody, in pancreatic cancer: A randomized, phase 2 trial. J. Cachexia. Sarcopenia Muscle. 9(5), 871–879 (2018)</ref-fulltext>
<ce:source-text>Golan, T., Geva, R., Richards, D., Madhusudan, S.: LY2495655, an antimyostatin antibody, in pancreatic cancer: A randomized, phase 2 trial. J. Cachexia. Sarcopenia Muscle. 9(5), 871–879 (2018)</ce:source-text>
</reference>
<reference seq="88">
<ref-info>
<ref-title>
<ref-titletext-english>Myostatin antibody (LY2495655) in older weak fallers: A proof-of-concept, randomised, phase 2 trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Becker</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Lord</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Studenski</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Warden</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Lancet Diabetes Endocrinol</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>948</first-page>
<last-page>957</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Becker, C., Lord, S., Studenski, S., Warden, S.: Myostatin antibody (LY2495655) in older weak fallers: A proof-of-concept, randomised, phase 2 trial. Lancet Diabetes Endocrinol. 3(12), 948–957 (2015)</ref-fulltext>
<ce:source-text>Becker, C., Lord, S., Studenski, S., Warden, S.: Myostatin antibody (LY2495655) in older weak fallers: A proof-of-concept, randomised, phase 2 trial. Lancet Diabetes Endocrinol. 3(12), 948–957 (2015)</ce:source-text>
</reference>
<reference seq="89">
<ref-info>
<ref-title>
<ref-titletext-english>Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Brink</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Wellen</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Delafontaine</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="1996" />
<volisspag>
<volume-issue-number>
<vol-first>97</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2509</first-page>
<last-page>2516</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Brink, M., Wellen, J., Delafontaine, P.: Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J. Clin. Invest. 97(11), 2509–2516 (1996)</ref-fulltext>
<ce:source-text>Brink, M., Wellen, J., Delafontaine, P.: Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J. Clin. Invest. 97(11), 2509–2516 (1996)</ce:source-text>
</reference>
<reference seq="90">
<ref-info>
<ref-title>
<ref-titletext-english>The effects of enalapril-digoxin-diuretic combination therapy on nutritional and anthropometric indices in chronic congestive heart failure: Preliminary findings in cardiac cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.Q.</ce:initials>
<ce:surname>Adigun</ce:surname>
<ce:given-name>A.Q.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.A.</ce:initials>
<ce:surname>Ajayi</ce:surname>
<ce:given-name>A.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Heart Fail</ref-sourcetitle>
<ref-publicationyear first="2001" />
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>359</first-page>
<last-page>363</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Adigun, A.Q., Ajayi, A.A.: The effects of enalapril-digoxin-diuretic combination therapy on nutritional and anthropometric indices in chronic congestive heart failure: Preliminary findings in cardiac cachexia. Eur. J. Heart Fail. 3(3), 359–363 (2001)</ref-fulltext>
<ce:source-text>Adigun, A.Q., Ajayi, A.A.: The effects of enalapril-digoxin-diuretic combination therapy on nutritional and anthropometric indices in chronic congestive heart failure: Preliminary findings in cardiac cachexia. Eur. J. Heart Fail. 3(3), 359–363 (2001)</ce:source-text>
</reference>
<reference seq="91">
<ref-info>
<ref-title>
<ref-titletext-english>Angiotensin II directly inhibits protein synthesis in murine myotubes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.T.</ce:initials>
<ce:surname>Russell</ce:surname>
<ce:given-name>S.T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.M.</ce:initials>
<ce:surname>Sanders</ce:surname>
<ce:given-name>P.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.J.</ce:initials>
<ce:surname>Tisdale</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Lett</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>231</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>290</first-page>
<last-page>294</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Russell, S.T., Sanders, P.M., Tisdale, M.J.: Angiotensin II directly inhibits protein synthesis in murine myotubes. Cancer Lett. 231(2), 290–294 (2006)</ref-fulltext>
<ce:source-text>Russell, S.T., Sanders, P.M., Tisdale, M.J.: Angiotensin II directly inhibits protein synthesis in murine myotubes. Cancer Lett. 231(2), 290–294 (2006)</ce:source-text>
</reference>
<reference seq="92">
<ref-info>
<ref-title>
<ref-titletext-english>Angiotensin II directly induces muscle protein catabolism through the ubiquitin–proteasome proteolytic pathway and may play a role in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.M.</ce:initials>
<ce:surname>Sanders</ce:surname>
<ce:given-name>P.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.T.</ce:initials>
<ce:surname>Russell</ce:surname>
<ce:given-name>S.T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.J.</ce:initials>
<ce:surname>Tisdale</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>93</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>425</first-page>
<last-page>434</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sanders, P.M., Russell, S.T., Tisdale, M.J.: Angiotensin II directly induces muscle protein catabolism through the ubiquitin–proteasome proteolytic pathway and may play a role in cancer cachexia. Br. J. Cancer. 93(4), 425–434 (2005)</ref-fulltext>
<ce:source-text>Sanders, P.M., Russell, S.T., Tisdale, M.J.: Angiotensin II directly induces muscle protein catabolism through the ubiquitin–proteasome proteolytic pathway and may play a role in cancer cachexia. Br. J. Cancer. 93(4), 425–434 (2005)</ce:source-text>
</reference>
<reference seq="93">
<ref-info>
<ref-title>
<ref-titletext-english>Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: Potential therapeutic targets for cardiac cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Yoshida</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.M.</ce:initials>
<ce:surname>Tabony</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Galvez</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>W.E.</ce:initials>
<ce:surname>Mitch</ce:surname>
<ce:given-name>W.E.</ce:given-name>
</author>
<author seq="5">
<ce:initials>Y.</ce:initials>
<ce:surname>Higashi</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>Sukhanov</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Biochem. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>45</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2322</first-page>
<last-page>2332</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yoshida, T., Tabony, A.M., Galvez, S., Mitch, W.E., Higashi, Y., Sukhanov, S., et al.: Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: Potential therapeutic targets for cardiac cachexia. Int. J. Biochem. Cell Biol. 45(10), 2322–2332 (2013)</ref-fulltext>
<ce:source-text>Yoshida, T., Tabony, A.M., Galvez, S., Mitch, W.E., Higashi, Y., Sukhanov, S., et al.: Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: Potential therapeutic targets for cardiac cachexia. Int. J. Biochem. Cell Biol. 45(10), 2322–2332 (2013)</ce:source-text>
</reference>
<reference seq="94">
<ref-info>
<ref-title>
<ref-titletext-english>Identification of neutrophil-derived proteases and angiotensin II as biomarkers of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.A.</ce:initials>
<ce:surname>Penafuerte</ce:surname>
<ce:given-name>C.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Gagnon</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Sirois</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Murphy</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="5">
<ce:initials>N.</ce:initials>
<ce:surname>Macdonald</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="6">
<ce:initials>M.L.</ce:initials>
<ce:surname>Tremblay</ce:surname>
<ce:given-name>M.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>114</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>680</first-page>
<last-page>687</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Penafuerte, C.A., Gagnon, B., Sirois, J., Murphy, J., MacDonald, N., Tremblay, M.L.: Identification of neutrophil-derived proteases and angiotensin II as biomarkers of cancer cachexia. Br. J. Cancer. 114(6), 680–687 (2016)</ref-fulltext>
<ce:source-text>Penafuerte, C.A., Gagnon, B., Sirois, J., Murphy, J., MacDonald, N., Tremblay, M.L.: Identification of neutrophil-derived proteases and angiotensin II as biomarkers of cancer cachexia. Br. J. Cancer. 114(6), 680–687 (2016)</ce:source-text>
</reference>
<reference seq="95">
<ref-info>
<ref-title>
<ref-titletext-english>Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: An observational study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.D.</ce:initials>
<ce:surname>Anker</ce:surname>
<ce:given-name>S.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Negassa</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.J.</ce:initials>
<ce:surname>Coats</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Afzal</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="5">
<ce:initials>P.A.</ce:initials>
<ce:surname>Poole-Wilson</ce:surname>
<ce:given-name>P.A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.N.</ce:initials>
<ce:surname>Cohn</ce:surname>
<ce:given-name>J.N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Lancet</ref-sourcetitle>
<ref-publicationyear first="2003" />
<volisspag>
<volume-issue-number>
<vol-first>361</vol-first>
<iss-first>9363</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1077</first-page>
<last-page>1083</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Anker, S.D., Negassa, A., Coats, A.J., Afzal, R., Poole-Wilson, P.A., Cohn, J.N., et al.: Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: An observational study. Lancet. 361(9363), 1077–1083 (2003)</ref-fulltext>
<ce:source-text>Anker, S.D., Negassa, A., Coats, A.J., Afzal, R., Poole-Wilson, P.A., Cohn, J.N., et al.: Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: An observational study. Lancet. 361(9363), 1077–1083 (2003)</ce:source-text>
</reference>
<reference seq="96">
<ref-info>
<ref-title>
<ref-titletext-english>Role of exosomal Micro-RNAs and myomiRs in the development of cancer cachexia-associated muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Marinho</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Alcantara</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Ottoch</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Seelaender</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Nutr</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>69</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Marinho, R., Alcantara, P., Ottoch, J., Seelaender, M.: Role of exosomal Micro-RNAs and myomiRs in the development of cancer cachexia-associated muscle wasting. Front. Nutr. 4, 69 (2017)</ref-fulltext>
<ce:source-text>Marinho, R., Alcantara, P., Ottoch, J., Seelaender, M.: Role of exosomal Micro-RNAs and myomiRs in the development of cancer cachexia-associated muscle wasting. Front. Nutr. 4, 69 (2017)</ce:source-text>
</reference>
<reference seq="97">
<ref-info>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Miller</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Characterisation and Mechanisms of Altered Body Composition and Tissue Wasting in Cancer Cachexia</ref-sourcetitle>
<ref-publicationyear first="2020" />
<ref-text>University of Edinburgh</ref-text>
</ref-info>
<ref-fulltext>Miller, J.: Characterisation and mechanisms of altered body composition and tissue wasting in cancer cachexia. University of Edinburgh (2020)</ref-fulltext>
<ce:source-text>Miller, J.: Characterisation and mechanisms of altered body composition and tissue wasting in cancer cachexia. University of Edinburgh (2020)</ce:source-text>
</reference>
<reference seq="98">
<ref-info>
<ref-title>
<ref-titletext-english>Insights into the potential use of microRNAs as biomarker in cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Anindo</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Yaqinuddin</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Surg</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>443</first-page>
<last-page>449</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Anindo, M., Yaqinuddin, A.: Insights into the potential use of microRNAs as biomarker in cancer. Int. J. Surg. 10(9), 443–449 (2012)</ref-fulltext>
<ce:source-text>Anindo, M., Yaqinuddin, A.: Insights into the potential use of microRNAs as biomarker in cancer. Int. J. Surg. 10(9), 443–449 (2012)</ce:source-text>
</reference>
<reference seq="99">
<ref-info>
<ref-title>
<ref-titletext-english>MicroRNAs as potential biomarkers in cancer: Opportunities and challenges</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Lan</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Lu</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>X.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="4">
<ce:initials>H.</ce:initials>
<ce:surname>Jin</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biomed. Res. Int</ref-sourcetitle>
</ref-info>
<ref-fulltext>Lan, H., Lu, H., Wang, X., Jin, H.: MicroRNAs as potential biomarkers in cancer: opportunities and challenges. Biomed. Res. Int. 125094</ref-fulltext>
<ce:source-text>Lan, H., Lu, H., Wang, X., Jin, H.: MicroRNAs as potential biomarkers in cancer: opportunities and challenges. Biomed. Res. Int. 125094</ce:source-text>
</reference>
<reference seq="100">
<ref-info>
<ref-title>
<ref-titletext-english>Small RNAome profiling from human skeletal muscle: Novel miRNAs and their targets associated with cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Narasimhan</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Ghosh</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Stretch</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Greiner</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="5">
<ce:initials>O.</ce:initials>
<ce:surname>Bathe</ce:surname>
<ce:given-name>O.</ce:given-name>
</author>
<author seq="6">
<ce:initials>V.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>405</first-page>
<last-page>416</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Narasimhan, A., Ghosh, S., Stretch, C., Greiner, R., Bathe, O., Baracos, V., et al.: Small RNAome profiling from human skeletal muscle: novel miRNAs and their targets associated with cancer cachexia. J. Cachexia. Sarcopenia Muscle. 8(3), 405–416 (2017)</ref-fulltext>
<ce:source-text>Narasimhan, A., Ghosh, S., Stretch, C., Greiner, R., Bathe, O., Baracos, V., et al.: Small RNAome profiling from human skeletal muscle: novel miRNAs and their targets associated with cancer cachexia. J. Cachexia. Sarcopenia Muscle. 8(3), 405–416 (2017)</ce:source-text>
</reference>
<reference seq="101">
<ref-info>
<ref-title>
<ref-titletext-english>Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.</ce:initials>
<ce:surname>He</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Calore</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Londhe</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Canella</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="5">
<ce:initials>D.</ce:initials>
<ce:surname>Guttridge</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:surname>Croce</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>111</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4525</first-page>
<last-page>4529</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>He, W., Calore, F., Londhe, P., Canella, A., Guttridge, D., Croce, C.: Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7. Proc. Natl. Acad. Sci. USA. 111(12), 4525–4529 (2014)</ref-fulltext>
<ce:source-text>He, W., Calore, F., Londhe, P., Canella, A., Guttridge, D., Croce, C.: Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7. Proc. Natl. Acad. Sci. USA. 111(12), 4525–4529 (2014)</ce:source-text>
</reference>
<reference seq="102">
<ref-info>
<ref-title>
<ref-titletext-english>IL-6, cancer and cachexia: Metabolic dysfunction creates the perfect storm</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>White</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Transl Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>280</first-page>
<last-page>285</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>White, J.: IL-6, cancer and cachexia: metabolic dysfunction creates the perfect storm. Transl Cancer Res. 6(2), 280–285 (2017)</ref-fulltext>
<ce:source-text>White, J.: IL-6, cancer and cachexia: metabolic dysfunction creates the perfect storm. Transl Cancer Res. 6(2), 280–285 (2017)</ce:source-text>
</reference>
<reference seq="103">
<ref-info>
<ref-title>
<ref-titletext-english>Can serum IL-6 be a sentinel biomarker for cancer cachexia in gynaecologic cancer patients? Gynaecol</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Yoshikwa</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Takano</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Kouta</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Horikoshi</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>T.</ce:initials>
<ce:surname>Asakawa</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="6">
<ce:initials>K.</ce:initials>
<ce:surname>Kudoh</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
<iss-first>15</iss-first>
<suppl>Supplement</suppl>
</volume-issue-number>
<page-information>
<pages>
<first-page>e17544</first-page>
<last-page>e17544</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yoshikwa, T., Takano, M., Kouta, H., Horikoshi, M., Asakawa, T., Kudoh, K.: Can serum IL-6 be a sentinel biomarker for cancer cachexia in gynaecologic cancer patients? Gynaecol. Cancer. 36(15_suppl), e17544–e17544 (2018)</ref-fulltext>
<ce:source-text>Yoshikwa, T., Takano, M., Kouta, H., Horikoshi, M., Asakawa, T., Kudoh, K.: Can serum IL-6 be a sentinel biomarker for cancer cachexia in gynaecologic cancer patients? Gynaecol. Cancer. 36(15_suppl), e17544–e17544 (2018)</ce:source-text>
</reference>
<reference seq="104">
<ref-info>
<ref-title>
<ref-titletext-english>Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Miller</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>McLeod</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Alhayyani</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Szczepny</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="5">
<ce:initials>D.</ce:initials>
<ce:surname>Watkins</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="6">
<ce:initials>W.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
<iss-first>21</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3059</first-page>
<last-page>3066</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Miller, A., McLeod, L., Alhayyani, S., Szczepny, A., Watkins, D., Chen, W., et al.: Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma. Oncogene. 36(21), 3059–66 (2017)</ref-fulltext>
<ce:source-text>Miller, A., McLeod, L., Alhayyani, S., Szczepny, A., Watkins, D., Chen, W., et al.: Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma. Oncogene. 36(21), 3059–66 (2017)</ce:source-text>
</reference>
<reference seq="105">
<ref-info>
<ref-title>
<ref-titletext-english>Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Ramsey</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Talbert</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Ahn</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Bekaii-Saab</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="5">
<ce:initials>N.</ce:initials>
<ce:surname>Badi</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="6">
<ce:initials>P.</ce:initials>
<ce:surname>Bloomston</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Pancreatology</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>80</first-page>
<last-page>87</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ramsey, M., Talbert, E., Ahn, D., Bekaii-Saab, T., Badi, N., Bloomston, P., et al.: Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. Pancreatology. 19(1), 80–87 (2019)</ref-fulltext>
<ce:source-text>Ramsey, M., Talbert, E., Ahn, D., Bekaii-Saab, T., Badi, N., Bloomston, P., et al.: Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. Pancreatology. 19(1), 80–87 (2019)</ce:source-text>
</reference>
<reference seq="106">
<ref-info>
<ref-title>
<ref-titletext-english>A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Bayliss</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Smith</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Schuster</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>K.</ce:initials>
<ce:surname>Dragnev</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Rigas</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Expert. Opin. Biol. Ther</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1663</first-page>
<last-page>1668</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bayliss, T., Smith, J., Schuster, M., Dragnev, K., Rigas, J.: A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert. Opin. Biol. Ther. 11(12), 1663–1668 (2011)</ref-fulltext>
<ce:source-text>Bayliss, T., Smith, J., Schuster, M., Dragnev, K., Rigas, J.: A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert. Opin. Biol. Ther. 11(12), 1663–1668 (2011)</ce:source-text>
</reference>
<reference seq="107">
<ref-info>
<ref-title>
<ref-titletext-english>Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Tournadre</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Pereira</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:surname>Dutheil</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Giraud</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="5">
<ce:initials>D.</ce:initials>
<ce:surname>Courteix</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="6">
<ce:initials>V.</ce:initials>
<ce:surname>Sapin</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>639</first-page>
<last-page>646</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tournadre, A., Pereira, B., Dutheil, F., Giraud, C., Courteix, D., Sapin, V., et al.: Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis. J. Cachexia. Sarcopenia Muscle. 8, 639–646 (2017)</ref-fulltext>
<ce:source-text>Tournadre, A., Pereira, B., Dutheil, F., Giraud, C., Courteix, D., Sapin, V., et al.: Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis. J. Cachexia. Sarcopenia Muscle. 8, 639–646 (2017)</ce:source-text>
</reference>
<reference seq="108">
<ref-info>
<ref-title>
<ref-titletext-english>IL-8 released from human pancreatic cancer and tumor-associated stromal cells signals through a CXCR2-ERK1/2 axis to induce muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Callaway</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Delitto</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>D’Lugos</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Patel</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="5">
<ce:initials>R.</ce:initials>
<ce:surname>Nosacka</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="6">
<ce:initials>D.</ce:initials>
<ce:surname>Delitto</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancers</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1863</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Callaway, C., Delitto, A., D’Lugos, A., Patel, R., Nosacka, R., Delitto, D., et al.: IL-8 released from human pancreatic cancer and tumor-associated stromal cells signals through a CXCR2-ERK1/2 axis to induce muscle atrophy. Cancers. 11(12), 1863 (2019)</ref-fulltext>
<ce:source-text>Callaway, C., Delitto, A., D’Lugos, A., Patel, R., Nosacka, R., Delitto, D., et al.: IL-8 released from human pancreatic cancer and tumor-associated stromal cells signals through a CXCR2-ERK1/2 axis to induce muscle atrophy. Cancers. 11(12), 1863 (2019)</ce:source-text>
</reference>
<reference seq="109">
<ref-info>
<ref-title>
<ref-titletext-english>Exercise training as therapy for cancer-induced cardiac cachexia. Trends Mol</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Antunes</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Ferreira</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Moreira-Goncalves</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Med</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>709</first-page>
<last-page>727</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Antunes, J., Ferreira, R., Moreira-Goncalves, D.: Exercise training as therapy for cancer-induced cardiac cachexia. Trends Mol. Med. 24(8), 709–727 (2018)</ref-fulltext>
<ce:source-text>Antunes, J., Ferreira, R., Moreira-Goncalves, D.: Exercise training as therapy for cancer-induced cardiac cachexia. Trends Mol. Med. 24(8), 709–727 (2018)</ce:source-text>
</reference>
<reference seq="110">
<ref-info>
<ref-title>
<ref-titletext-english>The AMPK agonist 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), but not metformin, prevents inflammation-associated cachectic muscle wasting. EMBO Mol</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Hall</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Griss</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Ma</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>B.</ce:initials>
<ce:surname>Sanchez</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Sadek</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Tremblay</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Med</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Hall, D., Griss, T., Ma, J., Sanchez, B., Sadek, J., Tremblay, A., et al.: The AMPK agonist 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), but not metformin, prevents inflammation-associated cachectic muscle wasting. EMBO Mol. Med. 10(7), e8307 (2018)</ref-fulltext>
<ce:source-text>Hall, D., Griss, T., Ma, J., Sanchez, B., Sadek, J., Tremblay, A., et al.: The AMPK agonist 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), but not metformin, prevents inflammation-associated cachectic muscle wasting. EMBO Mol. Med. 10(7), e8307 (2018)</ce:source-text>
</reference>
<reference seq="111">
<ref-info>
<ref-title>
<ref-titletext-english>Disrupted skeletal muscle mitochondrial dynamics, mitophagy and biogenesis during cancer cachexia: A role for inflammation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Vanderveen</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Fix</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Carson</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oxidative Med. Cell. Longev</ref-sourcetitle>
<ref-publicationyear first="2017" />
</ref-info>
<ref-fulltext>VanderVeen, B., Fix, D., Carson, J.: Disrupted skeletal muscle mitochondrial dynamics, mitophagy and biogenesis during cancer cachexia: A role for inflammation. Oxidative Med. Cell. Longev. 2017;Article ID 3292087</ref-fulltext>
<ce:source-text>VanderVeen, B., Fix, D., Carson, J.: Disrupted skeletal muscle mitochondrial dynamics, mitophagy and biogenesis during cancer cachexia: A role for inflammation. Oxidative Med. Cell. Longev. 2017;Article ID 3292087</ce:source-text>
</reference>
<reference seq="112">
<ref-info>
<ref-title>
<ref-titletext-english>Novel molecular targets of muscle wasting in cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Miller</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Skipworth</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Opin. Clin. Nutr. Metab. Care</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>22</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>196</first-page>
<last-page>204</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Miller, J., Skipworth, R.: Novel molecular targets of muscle wasting in cancer patients. Curr. Opin. Clin. Nutr. Metab. Care. 22(3), 196–204 (2019)</ref-fulltext>
<ce:source-text>Miller, J., Skipworth, R.: Novel molecular targets of muscle wasting in cancer patients. Curr. Opin. Clin. Nutr. Metab. Care. 22(3), 196–204 (2019)</ce:source-text>
</reference>
<reference seq="113">
<ref-info>
<ref-title>
<ref-titletext-english>Loss of oxidative defense and potential blockade of satellite cell maturation in the skeletal muscle of patients with cancer but not in the healthy elderly</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Brzeszczynska</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:surname>Johns</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Schlib</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Degen</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="5">
<ce:initials>R.</ce:initials>
<ce:surname>Langen</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Schols</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Aging</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1690</first-page>
<last-page>1702</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Brzeszczynska, J., Johns, N., Schlib, A., Degen, S., Langen, R., Schols, A., et al.: Loss of oxidative defense and potential blockade of satellite cell maturation in the skeletal muscle of patients with cancer but not in the healthy elderly. Aging. 8(8), 1690–1702 (2016)</ref-fulltext>
<ce:source-text>Brzeszczynska, J., Johns, N., Schlib, A., Degen, S., Langen, R., Schols, A., et al.: Loss of oxidative defense and potential blockade of satellite cell maturation in the skeletal muscle of patients with cancer but not in the healthy elderly. Aging. 8(8), 1690–1702 (2016)</ce:source-text>
</reference>
<reference seq="114">
<ref-info>
<ref-title>
<ref-titletext-english>Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): Results from two randomised, double-blind, phase 3 trials</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S.</ce:initials>
<ce:surname>Temel</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.P.</ce:initials>
<ce:surname>Abernethy</ce:surname>
<ce:given-name>A.P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.C.</ce:initials>
<ce:surname>Currow</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Friend</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="5">
<ce:initials>E.M.</ce:initials>
<ce:surname>Duus</ce:surname>
<ce:given-name>E.M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>Y.</ce:initials>
<ce:surname>Yan</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Lancet Oncol</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>519</first-page>
<last-page>531</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Temel, J.S., Abernethy, A.P., Currow, D.C., Friend, J., Duus, E.M., Yan, Y., et al.: Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 17(4), 519–531 (2016)</ref-fulltext>
<ce:source-text>Temel, J.S., Abernethy, A.P., Currow, D.C., Friend, J., Duus, E.M., Yan, Y., et al.: Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 17(4), 519–531 (2016)</ce:source-text>
</reference>
<reference seq="115">
<ref-info>
<ref-title>
<ref-titletext-english>ROMANA 3: A phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Currow</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.S.</ce:initials>
<ce:surname>Temel</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Abernethy</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Milanowski</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Friend</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>K.C.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Oncol. Off. J. Eur. Soc. Med. Oncol</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1949</first-page>
<last-page>1956</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Currow, D., Temel, J.S., Abernethy, A., Milanowski, J., Friend, J., Fearon, K.C.: ROMANA 3: A phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 28(8), 1949–1956 (2017)</ref-fulltext>
<ce:source-text>Currow, D., Temel, J.S., Abernethy, A., Milanowski, J., Friend, J., Fearon, K.C.: ROMANA 3: A phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 28(8), 1949–1956 (2017)</ce:source-text>
</reference>
<reference seq="116">
<ref-info>
<ref-title>
<ref-titletext-english>Enobosarm and lean body mass in patients with non-small cell lung cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Crawford</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.A.</ce:initials>
<ce:surname>Johnston</ce:surname>
<ce:given-name>M.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.P.</ce:initials>
<ce:surname>Taylor</ce:surname>
<ce:given-name>R.P.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.T.</ce:initials>
<ce:surname>Dalton</ce:surname>
<ce:given-name>J.T.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.S.</ce:initials>
<ce:surname>Steiner</ce:surname>
<ce:given-name>M.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol. [Internet]</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<page-information>
<pages>
<first-page>32</first-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">http://meetinglibrary.asco.org/content/128938-144</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Crawford, J., Johnston, M.A., Taylor, R.P., Dalton, J.T., Steiner, M.S.: Enobosarm and lean body mass in patients with non-small cell lung cancer. J. Clin. Oncol. [Internet]. (2014) [cited 2017 May 15];32, 5s(suppl; abstr 9618). Available from: http://meetinglibrary.asco.org/content/128938-144</ref-fulltext>
<ce:source-text>Crawford, J., Johnston, M.A., Taylor, R.P., Dalton, J.T., Steiner, M.S.: Enobosarm and lean body mass in patients with non-small cell lung cancer. J. Clin. Oncol. [Internet]. (2014) [cited 2017 May 15];32, 5s(suppl; abstr 9618). Available from: http://meetinglibrary.asco.org/content/128938-144</ce:source-text>
</reference>
<reference seq="117">
<ref-info>
<ref-authors>
<collaboration seq="1">
<ce:text>ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US)</ce:text>
</collaboration>
</ref-authors>
<ref-sourcetitle>2000 Feb 29 – Identifier NCT02330926 Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy – 05-Jan-2015</ref-sourcetitle>
<ref-publicationyear first="2015" />
<ref-website>
<ce:e-address type="url">https://clinicaltrials.gov/ct2/show/NCT02330926</ce:e-address>
</ref-website>
<ref-text>Cited 04-Sept-2016 [Internet]. ClinicalTrials.gov</ref-text>
</ref-info>
<ref-fulltext>ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 – Identifier NCT02330926 Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy – 05-Jan-2015, Cited 04-Sept-2016 [Internet]. ClinicalTrials.gov. 2015 [cited 2016 Sep 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT02330926</ref-fulltext>
<ce:source-text>ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 – Identifier NCT02330926 Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy – 05-Jan-2015, Cited 04-Sept-2016 [Internet]. ClinicalTrials.gov. 2015 [cited 2016 Sep 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT02330926</ce:source-text>
</reference>
<reference seq="118">
<ref-info>
<ref-title>
<ref-titletext-english>A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.S.</ce:initials>
<ce:surname>Solheim</ce:surname>
<ce:given-name>T.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.J.A.</ce:initials>
<ce:surname>Laird</ce:surname>
<ce:given-name>B.J.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.R.</ce:initials>
<ce:surname>Balstad</ce:surname>
<ce:given-name>T.R.</ce:given-name>
</author>
<author seq="4">
<ce:initials>G.B.</ce:initials>
<ce:surname>Stene</ce:surname>
<ce:given-name>G.B.</ce:given-name>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Bye</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>N.</ce:initials>
<ce:surname>Johns</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2017" />
</ref-info>
<ref-fulltext>Solheim, T.S., Laird, B.J.A., Balstad, T.R., Stene, G.B., Bye, A., Johns, N., et al.: A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. J. Cachexia. Sarcopenia Muscle. (2017) Jun 14</ref-fulltext>
<ce:source-text>Solheim, T.S., Laird, B.J.A., Balstad, T.R., Stene, G.B., Bye, A., Johns, N., et al.: A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. J. Cachexia. Sarcopenia Muscle. (2017) Jun 14</ce:source-text>
</reference>
<reference seq="119">
<ref-info>
<ref-title>
<ref-titletext-english>D3-Creatine dilution and the importance of accuracy in the assessment of skeletal muscle mass</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.J.</ce:initials>
<ce:surname>Evans</ce:surname>
<ce:given-name>W.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Hellerstein</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>E.</ce:initials>
<ce:surname>Orwoll</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Cummings</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="5">
<ce:initials>P.M.</ce:initials>
<ce:surname>Cawthon</ce:surname>
<ce:given-name>P.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>14</first-page>
<last-page>21</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Evans, W.J., Hellerstein, M., Orwoll, E., Cummings, S., Cawthon, P.M.: D3-Creatine dilution and the importance of accuracy in the assessment of skeletal muscle mass. J. Cachexia. Sarcopenia Muscle. 10(1), 14–21 (2019)</ref-fulltext>
<ce:source-text>Evans, W.J., Hellerstein, M., Orwoll, E., Cummings, S., Cawthon, P.M.: D3-Creatine dilution and the importance of accuracy in the assessment of skeletal muscle mass. J. Cachexia. Sarcopenia Muscle. 10(1), 14–21 (2019)</ce:source-text>
</reference>
<reference seq="120">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia induces morphological and inflammatory changes in the intestinal mucosa</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Costa</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Caro</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>E.</ce:initials>
<ce:surname>de Matos-Neto</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Lima</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="5">
<ce:initials>K.</ce:initials>
<ce:surname>Radloff</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Alves</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1116</first-page>
<last-page>1127</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Costa, R., Caro, P., de Matos-Neto, E., Lima, J., Radloff, K., Alves, M., et al.: Cancer cachexia induces morphological and inflammatory changes in the intestinal mucosa. J. Cachexia. Sarcopenia Muscle. 10(5), 1116–1127 (2019)</ref-fulltext>
<ce:source-text>Costa, R., Caro, P., de Matos-Neto, E., Lima, J., Radloff, K., Alves, M., et al.: Cancer cachexia induces morphological and inflammatory changes in the intestinal mucosa. J. Cachexia. Sarcopenia Muscle. 10(5), 1116–1127 (2019)</ce:source-text>
</reference>
<reference seq="121">
<ref-info>
<ref-title>
<ref-titletext-english>Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Morrison</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Preston</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Gut Microbes</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>189</first-page>
<last-page>200</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Morrison, D., Preston, T.: Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 7, 189–200 (2016)</ref-fulltext>
<ce:source-text>Morrison, D., Preston, T.: Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 7, 189–200 (2016)</ce:source-text>
</reference>
<reference seq="122">
<ref-info>
<ref-title>
<ref-titletext-english>The immunological regulation of cancer cachexia and its therapeutic implications</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Miller</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Laird</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Skipworth</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cancer Metastasis Treat</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>68</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Miller, J., Laird, B., Skipworth, R.: The immunological regulation of cancer cachexia and its therapeutic implications. J. Cancer Metastasis Treat. 5, 68 (2019)</ref-fulltext>
<ce:source-text>Miller, J., Laird, B., Skipworth, R.: The immunological regulation of cancer cachexia and its therapeutic implications. J. Cancer Metastasis Treat. 5, 68 (2019)</ce:source-text>
</reference>
<reference seq="123">
<ref-info>
<ref-title>
<ref-titletext-english>Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Roberts</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Deonarine</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Jones</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Denton</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="5">
<ce:initials>C.</ce:initials>
<ce:surname>Feig</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>Lyons</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Exp. Med</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>210</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1137</first-page>
<last-page>1157</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Roberts, E., Deonarine, A., Jones, J., Denton, A., Feig, C., Lyons, S., et al.: Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia. J. Exp. Med. 3(210), 1137–1157 (2013)</ref-fulltext>
<ce:source-text>Roberts, E., Deonarine, A., Jones, J., Denton, A., Feig, C., Lyons, S., et al.: Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia. J. Exp. Med. 3(210), 1137–1157 (2013)</ce:source-text>
</reference>
<reference seq="124">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Z.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Ding</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="4">
<ce:initials>Y.</ce:initials>
<ce:surname>Zhou</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="5">
<ce:initials>H.</ce:initials>
<ce:surname>Doan</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="6">
<ce:initials>K.</ce:initials>
<ce:surname>Sin</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>589</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, G., Liu, Z., Ding, H., Zhou, Y., Doan, H., Sin, K., et al.: Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90. Nat. Commun. 8(589) (2017)</ref-fulltext>
<ce:source-text>Zhang, G., Liu, Z., Ding, H., Zhou, Y., Doan, H., Sin, K., et al.: Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90. Nat. Commun. 8(589) (2017)</ce:source-text>
</reference>
<reference seq="125">
<ref-info>
<ref-title>
<ref-titletext-english>TRIF is a key inflammatory mediator of acute sickness behavior and cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Burfeind</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>X.</ce:initials>
<ce:surname>Zhu</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Levasseur</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="4">
<ce:initials>K.</ce:initials>
<ce:surname>Michaelis</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Norgard</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>D.</ce:initials>
<ce:surname>Marks</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Brain Behav. Immun</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>73</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>364</first-page>
<last-page>374</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Burfeind, K., Zhu, X., Levasseur, P., Michaelis, K., Norgard, M., Marks, D.: TRIF is a key inflammatory mediator of acute sickness behavior and cancer cachexia. Brain Behav. Immun. 73, 364–374 (2018)</ref-fulltext>
<ce:source-text>Burfeind, K., Zhu, X., Levasseur, P., Michaelis, K., Norgard, M., Marks, D.: TRIF is a key inflammatory mediator of acute sickness behavior and cancer cachexia. Brain Behav. Immun. 73, 364–374 (2018)</ce:source-text>
</reference>
</bibliography>
</tail>
</bibrecord>
<bibrecord>
<item-info>
<status state="new" stage="S300" />
<itemidlist>
<ce:doi>10.1007/978-3-031-09518-4_11</ce:doi>
<itemid idtype="TPB-ID">20232000349315</itemid>
</itemidlist>
</item-info>
<head>
<citation-info>
<citation-type code="ch" />
<citation-language xml:lang="ENG" />
<abstract-language xml:lang="ENG" />
</citation-info>
<citation-title>
<titletext xml:lang="ENG" original="y">Exercise: A Critical Component of Cachexia Prevention and Therapy in Cancer</titletext>
</citation-title>
<author-group seq="1">
<author seq="1">
<ce:initials>E.E.</ce:initials> 
<ce:surname>Pistilli</ce:surname>
<ce:given-name>Emidio E.</ce:given-name>
<ce:e-address>epistilli2@hsc.wvu.ed</ce:e-address>
</author>
<affiliation>
<organization>Division of Exercise Physiology</organization>
<organization>Department of Human Performance</organization>
<organization>West Virginia University School of Medicine</organization>
<city>Morgantown</city>
<state>West Virginia</state>
<country iso-code="USA" />
<ce:source-text>Division of Exercise Physiology, Department of Human Performance, West Virginia University School of Medicine, Morgantown, WV, USA Cancer Institute, West Virginia University School of Medicine, Morgantown, WV, USA Department of Microbiology, Immunology, and Cell Biology, West Virginia University School of Medicine, Morgantown, WV, USA West Virginia Clinical and Translational Sciences Institute, West Virginia University School of Medicine, Morgantown, WV, USA.</ce:source-text>
</affiliation>
</author-group>
<author-group seq="2">
<author seq="1">
<ce:initials>H.E.</ce:initials> 
<ce:surname>Wilson</ce:surname>
<ce:given-name>Hannah E.</ce:given-name>
<ce:e-address />
</author>
<affiliation>
<organization>Cancer Institute</organization>
<organization>West Virginia University School of Medicine</organization>
<city>Morgantown</city>
<state>West Virginia</state>
<country iso-code="USA" />
<ce:source-text>Cancer Institute, West Virginia University School of Medicine, Morgantown, WV, USA.</ce:source-text>
</affiliation>
</author-group>
<author-group seq="3">
<author seq="1">
<ce:initials>D.A.</ce:initials> 
<ce:surname>Stanton</ce:surname>
<ce:given-name> David A.</ce:given-name>
</author>
<affiliation>
<organization>Division of Exercise Physiology</organization>
<organization>Department of Human Performance</organization>
<organization>West Virginia University School of
Medicine</organization>
<city>Morgantown</city>
<state>West Virginia</state>
<country iso-code="USA" />
<ce:source-text>Clinical Surgery, Royal Infirmary of Edinburgh, Edinburgh, UK</ce:source-text>
</affiliation>
</author-group>
<correspondence>
<person>
<ce:initials>E.E.</ce:initials>
<ce:surname>Pistilli</ce:surname>
<ce:given-name>Emidio E.</ce:given-name>
<ce:e-address>epistilli2@hsc.wvu.edu</ce:e-address>
</person>
<affiliation>
<organization>Division of Exercise Physiology</organization>
<organization>Department of Human Performance</organization>
<organization>West Virginia University School of Medicine</organization>
<city>Morgantown</city>
<state>WV</state>
<country iso-code="USA" />
<ce:source-text>Division of Exercise Physiology, Department of Human Performance, West Virginia University School of Medicine, Cancer Institute, West Virginia University School of Medicine, Department of Microbiology, Immunology, and Cell Biology, West Virginia University School of Medicine, West Virginia Clinical and Translational Sciences Institute, West Virginia University School of Medicine, Morgantown, WV, USA</ce:source-text>
</affiliation>
</correspondence>
<abstracts>
<abstract xml:lang="ENG" original="y">
<publishercopyright>© Springer Nature Switzerland AG 2022</publishercopyright>
<ce:para>Cachexia is a condition characterized by loss of body weight as a result of chronic disease. In the setting of cancer, cachexia is more com- monly observed in late stage and metastatic disease and the loss of body weight is attributed to varying combinations of muscle wasting and loss of adipose tissue. Cancer cachexia is a clinically relevant medical issue and is estimated to account for up to 20% of cancer mortality. Additionally, cachexia in cancer patients is associated with reduced tol- erance to tumor-directed therapies.</ce:para>
</abstract>
</abstracts>
<source type="book" country="USA">
<sourcetitle>The Systemic Effects of Advanced Cancer A Textbook on Cancer-Associated Cachexia</sourcetitle>
<sourcetitle-abbrev>The Systemic Effects of Advanced Cancer A Textbook on Cancer-Associated Cachexia</sourcetitle-abbrev>
<isbn type="print" length="13">9783031072727</isbn>
<isbn type="electronic" length="13">9783031095184</isbn>
<volisspag>
<page-information>
<pages>
<first-page>193</first-page>
<last-page>203</last-page>
</pages>
</page-information>
</volisspag>
<publicationyear first="2022" />
<publicationdate>
<year>2022</year>
<month>01</month>
<day>01</day>
</publicationdate>
<website type="item">
<ce:e-address type="url">https://link.springer.com</ce:e-address>
</website>
<publisher>
<publishername>Springer International Publishing</publishername>
</publisher>
</source>
<enhancement>
<classificationgroup>
<classifications type="ASJC">
<classification>
<classification-code>2700</classification-code>
<classification-code>2400</classification-code>
<classification-code>1300</classification-code>
</classification>
</classifications>
</classificationgroup>
</enhancement>
</head>
<tail>
<bibliography refcount="80">
<reference seq="1">
<ref-info>
<ref-title>
<ref-titletext-english>Fundamentals of cancer metabolism</ref-titletext-english>
</ref-title>
<itemidlist>
<itemid idtype="ARTNUM">e1600200</itemid>
</itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>R.J.</ce:initials>
<ce:surname>Deberardinis</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>N.S.</ce:initials>
<ce:surname>Chandel</ce:surname>
<ce:given-name>N.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Adv</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>DeBerardinis, R.J., Chandel, N.S.: Fundamentals of cancer metabolism. Sci. Adv. 2, e1600200 (2016)</ref-fulltext>
<ce:source-text>DeBerardinis, R.J., Chandel, N.S.: Fundamentals of cancer metabolism. Sci. Adv. 2, e1600200 (2016)</ce:source-text>
</reference>
<reference seq="2">
<ref-info>
<ref-title>
<ref-titletext-english>The hallmarks of cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Hanahan</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.A.</ce:initials>
<ce:surname>Weinberg</ce:surname>
<ce:given-name>R.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2000" />
<volisspag>
<volume-issue-number>
<vol-first>100</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>57</first-page>
<last-page>70</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hanahan, D., Weinberg, R.A.: The hallmarks of cancer. Cell. 100, 57–70 (2000)</ref-fulltext>
<ce:source-text>Hanahan, D., Weinberg, R.A.: The hallmarks of cancer. Cell. 100, 57–70 (2000)</ce:source-text>
</reference>
<reference seq="3">
<ref-info>
<ref-title>
<ref-titletext-english>Chemical and elemental analysis of humans in vivo using improved body composition models</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.B.</ce:initials>
<ce:surname>Heymsfield</ce:surname>
<ce:given-name>S.B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Waki</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Kehayias</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Lichtman</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="5">
<ce:initials>F.A.</ce:initials>
<ce:surname>Dilmanian</ce:surname>
<ce:given-name>F.A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>Y.</ce:initials>
<ce:surname>Kamen</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="7">
<ce:initials>J.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="8">
<ce:initials>R.N.</ce:initials>
<ce:surname>Pierson</ce:surname>
<ce:given-name>R.N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Phys</ref-sourcetitle>
<ref-publicationyear first="1991" />
<volisspag>
<volume-issue-number>
<vol-first>261</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>E190</first-page>
<last-page>E198</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Heymsfield, S.B., Waki, M., Kehayias, J., Lichtman, S., Dilmanian, F.A., Kamen, Y., Wang, J., Pierson Jr., R.N.: Chemical and elemental analysis of humans in vivo using improved body composition models. Am. J. Phys. 261, E190–E198 (1991)</ref-fulltext>
<ce:source-text>Heymsfield, S.B., Waki, M., Kehayias, J., Lichtman, S., Dilmanian, F.A., Kamen, Y., Wang, J., Pierson Jr., R.N.: Chemical and elemental analysis of humans in vivo using improved body composition models. Am. J. Phys. 261, E190–E198 (1991)</ce:source-text>
</reference>
<reference seq="4">
<ref-info>
<ref-title>
<ref-titletext-english>Multi-component body composition models: Recent advances and future directions</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Pietrobelli</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.B.</ce:initials>
<ce:surname>Heymsfield</ce:surname>
<ce:given-name>S.B.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Z.M.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>Z.M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>D.</ce:initials>
<ce:surname>Gallagher</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2001" />
<volisspag>
<volume-issue-number>
<vol-first>55</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>69</first-page>
<last-page>75</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pietrobelli, A., Heymsfield, S.B., Wang, Z.M., Gallagher, D.: Multi-component body composition models: recent advances and future directions. Eur. J. Clin. Nutr. 55, 69–75 (2001)</ref-fulltext>
<ce:source-text>Pietrobelli, A., Heymsfield, S.B., Wang, Z.M., Gallagher, D.: Multi-component body composition models: recent advances and future directions. Eur. J. Clin. Nutr. 55, 69–75 (2001)</ce:source-text>
</reference>
<reference seq="5">
<ref-info>
<ref-title>
<ref-titletext-english>Cachexia: The last illness</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Lok</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>528</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>182</first-page>
<last-page>183</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lok, C.: Cachexia: The last illness. Nature. 528, 182–183 (2015)</ref-fulltext>
<ce:source-text>Lok, C.: Cachexia: The last illness. Nature. 528, 182–183 (2015)</ce:source-text>
</reference>
<reference seq="6">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-associated cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Martin</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Korc</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>D.C.</ce:initials>
<ce:surname>Guttridge</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
<author seq="5">
<ce:initials>K.C.H.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.C.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Dis. Primers</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>17105</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baracos, V.E., Martin, L., Korc, M., Guttridge, D.C., Fearon, K.C.H.: Cancer-associated cachexia. Nat. Rev. Dis. Primers. 4, 17105 (2018)</ref-fulltext>
<ce:source-text>Baracos, V.E., Martin, L., Korc, M., Guttridge, D.C., Fearon, K.C.H.: Cancer-associated cachexia. Nat. Rev. Dis. Primers. 4, 17105 (2018)</ce:source-text>
</reference>
<reference seq="7">
<ref-info>
<ref-title>
<ref-titletext-english>Diseases of the heart in the works of Hippocrates</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.M.</ce:initials>
<ce:surname>Katz</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.B.</ce:initials>
<ce:surname>Katz</ce:surname>
<ce:given-name>P.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Br. Heart J</ref-sourcetitle>
<ref-publicationyear first="1962" />
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>257</first-page>
<last-page>264</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Katz, A.M., Katz, P.B.: Diseases of the heart in the works of Hippocrates. Br. Heart J. 24, 257–264 (1962)</ref-fulltext>
<ce:source-text>Katz, A.M., Katz, P.B.: Diseases of the heart in the works of Hippocrates. Br. Heart J. 24, 257–264 (1962)</ce:source-text>
</reference>
<reference seq="8">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia: Understanding the molecular basis. Nat</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Argiles</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Busquets</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>B.</ce:initials>
<ce:surname>Stemmler</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="4">
<ce:initials>F.J.</ce:initials>
<ce:surname>Lopez-Soriano</ce:surname>
<ce:given-name>F.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>754</first-page>
<last-page>762</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Argiles, J.M., Busquets, S., Stemmler, B., Lopez-Soriano, F.J.: Cancer cachexia: understanding the molecular basis. Nat. Rev. Cancer. 14, 754–762 (2014)</ref-fulltext>
<ce:source-text>Argiles, J.M., Busquets, S., Stemmler, B., Lopez-Soriano, F.J.: Cancer cachexia: understanding the molecular basis. Nat. Rev. Cancer. 14, 754–762 (2014)</ce:source-text>
</reference>
<reference seq="9">
<ref-info>
<ref-title>
<ref-titletext-english>Cachexia: A new definition</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.J.</ce:initials>
<ce:surname>Evans</ce:surname>
<ce:given-name>W.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.E.</ce:initials>
<ce:surname>Morley</ce:surname>
<ce:given-name>J.E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Argiles</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Bales</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="5">
<ce:initials>V.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
<author seq="6">
<ce:initials>D.</ce:initials>
<ce:surname>Guttridge</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="7">
<ce:initials>A.</ce:initials>
<ce:surname>Jatoi</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="8">
<ce:initials>K.</ce:initials>
<ce:surname>Kalantar-Zadeh</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="9">
<ce:initials>H.</ce:initials>
<ce:surname>Lochs</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="10">
<ce:initials>G.</ce:initials>
<ce:surname>Mantovani</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="11">
<ce:initials>D.</ce:initials>
<ce:surname>Marks</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="12">
<ce:initials>W.E.</ce:initials>
<ce:surname>Mitch</ce:surname>
<ce:given-name>W.E.</ce:given-name>
</author>
<author seq="13">
<ce:initials>M.</ce:initials>
<ce:surname>Muscaritoli</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="14">
<ce:initials>A.</ce:initials>
<ce:surname>Najand</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="15">
<ce:initials>P.</ce:initials>
<ce:surname>Ponikowski</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="16">
<ce:initials>F.</ce:initials>
<ce:surname>Rossi Fanelli</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="17">
<ce:initials>M.</ce:initials>
<ce:surname>Schambelan</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="18">
<ce:initials>A.</ce:initials>
<ce:surname>Schols</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="19">
<ce:initials>M.</ce:initials>
<ce:surname>Schuster</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="20">
<ce:initials>D.</ce:initials>
<ce:surname>Thomas</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="21">
<ce:initials>R.</ce:initials>
<ce:surname>Wolfe</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="22">
<ce:initials>S.D.</ce:initials>
<ce:surname>Anker</ce:surname>
<ce:given-name>S.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2008" />
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>793</first-page>
<last-page>799</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Evans, W.J., Morley, J.E., Argiles, J., Bales, C., Baracos, V., Guttridge, D., Jatoi, A., Kalantar-Zadeh, K., Lochs, H., Mantovani, G., Marks, D., Mitch, W.E., Muscaritoli, M., Najand, A., Ponikowski, P., Rossi Fanelli, F., Schambelan, M., Schols, A., Schuster, M., Thomas, D., Wolfe, R., Anker, S.D.: Cachexia: A new definition. Clin. Nutr. 27, 793–799 (2008)</ref-fulltext>
<ce:source-text>Evans, W.J., Morley, J.E., Argiles, J., Bales, C., Baracos, V., Guttridge, D., Jatoi, A., Kalantar-Zadeh, K., Lochs, H., Mantovani, G., Marks, D., Mitch, W.E., Muscaritoli, M., Najand, A., Ponikowski, P., Rossi Fanelli, F., Schambelan, M., Schols, A., Schuster, M., Thomas, D., Wolfe, R., Anker, S.D.: Cachexia: A new definition. Clin. Nutr. 27, 793–799 (2008)</ce:source-text>
</reference>
<reference seq="10">
<ref-info>
<ref-title>
<ref-titletext-english>Definition and classification of cancer cachexia: An international consensus</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Strasser</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.D.</ce:initials>
<ce:surname>Anker</ce:surname>
<ce:given-name>S.D.</ce:given-name>
</author>
<author seq="4">
<ce:initials>I.</ce:initials>
<ce:surname>Bosaeus</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="5">
<ce:initials>E.</ce:initials>
<ce:surname>Bruera</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="6">
<ce:initials>R.L.</ce:initials>
<ce:surname>Fainsinger</ce:surname>
<ce:given-name>R.L.</ce:given-name>
</author>
<author seq="7">
<ce:initials>A.</ce:initials>
<ce:surname>Jatoi</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="8">
<ce:initials>C.</ce:initials>
<ce:surname>Loprinzi</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="9">
<ce:initials>N.</ce:initials>
<ce:surname>Macdonald</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="10">
<ce:initials>G.</ce:initials>
<ce:surname>Mantovani</ce:surname>
<ce:given-name>G.</ce:given-name><ce:givenname>G.</ce:givenname>
</author>
<author seq="11">
<ce:initials>M.</ce:initials>
<ce:surname>Davis</ce:surname>
<ce:given-name>M.</ce:given-name><ce:givenname>M.</ce:givenname>
</author>
<author seq="12">
<ce:initials>M.</ce:initials>
<ce:surname>Muscaritoli</ce:surname>
<ce:given-name>M.</ce:given-name><ce:givenname>M.</ce:givenname>
</author>
<author seq="13">
<ce:initials>F.</ce:initials>
<ce:surname>Ottery</ce:surname>
<ce:given-name>F.</ce:given-name><ce:givenname>F.</ce:givenname>
</author>
<author seq="14">
<ce:initials>L.</ce:initials>
<ce:surname>Radbruch</ce:surname>
<ce:given-name>L.</ce:given-name><ce:givenname>L.</ce:givenname>
</author>
<author seq="15">
<ce:initials>P.</ce:initials>
<ce:surname>Ravasco</ce:surname>
<ce:given-name>P.</ce:given-name><ce:givenname>P.</ce:givenname>
</author>
<author seq="16">
<ce:initials>D.</ce:initials>
<ce:surname>Walsh</ce:surname>
<ce:given-name>D.</ce:given-name><ce:givenname>D.</ce:givenname>
</author>
<author seq="17">
<ce:initials>A.</ce:initials>
<ce:surname>Wilcock</ce:surname>
<ce:given-name>A.</ce:given-name><ce:givenname>A.</ce:givenname>
</author>
<author seq="18">
<ce:initials>S.</ce:initials>
<ce:surname>Kaasa</ce:surname>
<ce:given-name>S.</ce:given-name><ce:givenname>S.</ce:givenname>
</author>
<author seq="19">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name><ce:givenname>V.E.</ce:givenname>
</author>
</ref-authors>
<ref-sourcetitle>Lancet Oncol</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>489</first-page>
<last-page>495</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fearon, K., Strasser, F., Anker, S.D., Bosaeus, I., Bruera, E., Fainsinger, R.L., Jatoi, A., Loprinzi, C., MacDonald, N., Mantovani, G., Davis, M., Muscaritoli, M., Ottery, F., Radbruch, L., Ravasco, P., Walsh, D., Wilcock, A., Kaasa, S., Baracos, V.E.: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 12, 489–495 (2011)</ref-fulltext>
<ce:source-text>Fearon, K., Strasser, F., Anker, S.D., Bosaeus, I., Bruera, E., Fainsinger, R.L., Jatoi, A., Loprinzi, C., MacDonald, N., Mantovani, G., Davis, M., Muscaritoli, M., Ottery, F., Radbruch, L., Ravasco, P., Walsh, D., Wilcock, A., Kaasa, S., Baracos, V.E.: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 12, 489–495 (2011)</ce:source-text>
</reference>
<reference seq="11">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle reprogramming by breast cancer regardless of treatment history or tumor molecular subtype</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.E.</ce:initials>
<ce:surname>Wilson</ce:surname>
<ce:given-name>H.E.</ce:given-name><ce:givenname>H.E.</ce:givenname>
</author>
<author seq="2">
<ce:initials>D.A.</ce:initials>
<ce:surname>Stanton</ce:surname>
<ce:given-name>D.A.</ce:given-name><ce:givenname>D.A.</ce:givenname>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Montgomery</ce:surname>
<ce:given-name>C.</ce:given-name><ce:givenname>C.</ce:givenname>
</author>
<author seq="4">
<ce:initials>A.M.</ce:initials>
<ce:surname>Infante</ce:surname>
<ce:given-name>A.M.</ce:given-name><ce:givenname>A.M.</ce:givenname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Taylor</ce:surname>
<ce:given-name>M.</ce:given-name><ce:givenname>M.</ce:givenname>
</author>
<author seq="6">
<ce:initials>H.</ce:initials>
<ce:surname>Hazard-Jenkins</ce:surname>
<ce:given-name>H.</ce:given-name><ce:givenname>H.</ce:givenname>
</author>
<author seq="7">
<ce:initials>E.N.</ce:initials>
<ce:surname>Pugacheva</ce:surname>
<ce:given-name>E.N.</ce:given-name><ce:givenname>E.N.</ce:givenname>
</author>
<author seq="8">
<ce:initials>E.E.</ce:initials>
<ce:surname>Pistilli</ce:surname>
<ce:given-name>E.E.</ce:given-name><ce:givenname>E.E.</ce:givenname>
</author>
</ref-authors>
<ref-sourcetitle>NPJ Breast Cancer</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>18</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wilson, H.E., Stanton, D.A., Montgomery, C., Infante, A.M., Taylor, M., Hazard-Jenkins, H., Pugacheva, E.N., Pistilli, E.E.: Skeletal muscle reprogramming by breast cancer regardless of treatment history or tumor molecular subtype. NPJ Breast Cancer. 6, 18 (2020)</ref-fulltext>
<ce:source-text>Wilson, H.E., Stanton, D.A., Montgomery, C., Infante, A.M., Taylor, M., Hazard-Jenkins, H., Pugacheva, E.N., Pistilli, E.E.: Skeletal muscle reprogramming by breast cancer regardless of treatment history or tumor molecular subtype. NPJ Breast Cancer. 6, 18 (2020)</ce:source-text>
</reference>
<reference seq="12">
<ref-info>
<ref-title>
<ref-titletext-english>A clinically applicable muscular index predicts long-term survival in resectable pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Delitto</ce:surname>
<ce:given-name>D.</ce:given-name><ce:givenname>D.</ce:givenname>
</author>
<author seq="2">
<ce:initials>S.M.</ce:initials>
<ce:surname>Judge</ce:surname>
<ce:given-name>S.M.</ce:given-name><ce:givenname>S.M.</ce:givenname>
</author>
<author seq="3">
<ce:initials>T.J.</ce:initials>
<ce:surname>George</ce:surname>
<ce:given-name>T.J.</ce:given-name><ce:givenname>T.J.</ce:givenname>
</author>
<author seq="4">
<ce:initials>G.A.</ce:initials>
<ce:surname>Sarosi</ce:surname>
<ce:given-name>G.A.</ce:given-name><ce:givenname>G.A.</ce:givenname>
</author>
<author seq="5">
<ce:initials>R.M.</ce:initials>
<ce:surname>Thomas</ce:surname>
<ce:given-name>R.M.</ce:given-name><ce:givenname>R.M.</ce:givenname>
</author>
<author seq="6">
<ce:initials>K.E.</ce:initials>
<ce:surname>Behrns</ce:surname>
<ce:given-name>K.E.</ce:given-name><ce:givenname>K.E.</ce:givenname>
</author>
<author seq="7">
<ce:initials>S.J.</ce:initials>
<ce:surname>Hughes</ce:surname>
<ce:given-name>S.J.</ce:given-name><ce:givenname>S.J.</ce:givenname>
</author>
<author seq="8">
<ce:initials>A.R.</ce:initials>
<ce:surname>Judge</ce:surname>
<ce:given-name>A.R.</ce:given-name><ce:givenname>A.R.</ce:givenname>
</author>
<author seq="9">
<ce:initials>J.G.</ce:initials>
<ce:surname>Trevino</ce:surname>
<ce:given-name>J.G.</ce:given-name><ce:givenname>J.G.</ce:givenname>
</author>
</ref-authors>
<ref-sourcetitle>Surgery</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>161</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>930</first-page>
<last-page>938</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Delitto, D., Judge, S.M., George Jr., T.J., Sarosi, G.A., Thomas, R.M., Behrns, K.E., Hughes, S.J., Judge, A.R., Trevino, J.G.: A clinically applicable muscular index predicts long-term survival in resectable pancreatic cancer. Surgery. 161, 930–938 (2017)</ref-fulltext>
<ce:source-text>Delitto, D., Judge, S.M., George Jr., T.J., Sarosi, G.A., Thomas, R.M., Behrns, K.E., Hughes, S.J., Judge, A.R., Trevino, J.G.: A clinically applicable muscular index predicts long-term survival in resectable pancreatic cancer. Surgery. 161, 930–938 (2017)</ce:source-text>
</reference>
<reference seq="13">
<ref-info>
<ref-title>
<ref-titletext-english>Cachexia in cancer: What is in the definition?</ref-titletext-english>
</ref-title>
<itemidlist>
<itemid idtype="ARTNUM">e000097</itemid>
</itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Vanhoutte</ce:surname>
<ce:given-name>G.</ce:given-name><ce:givenname>G.</ce:givenname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Van de Wiel</ce:surname>
<ce:given-name>M.</ce:given-name><ce:givenname>M.</ce:givenname>
</author>
<author seq="3">
<ce:initials>K.</ce:initials>
<ce:surname>Wouters</ce:surname>
<ce:given-name>K.</ce:given-name><ce:givenname>K.</ce:givenname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Sels</ce:surname>
<ce:given-name>M.</ce:given-name><ce:givenname>M.</ce:givenname>
</author>
<author seq="5">
<ce:initials>L.</ce:initials>
<ce:surname>Bartolomeeussen</ce:surname>
<ce:given-name>L.</ce:given-name><ce:givenname>L.</ce:givenname>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>de Keersmaecker</ce:surname>
<ce:given-name>S.</ce:given-name><ce:givenname>S.</ce:givenname>
</author>
<author seq="7">
<ce:initials>C.</ce:initials>
<ce:surname>Verschueren</ce:surname>
<ce:given-name>C.</ce:given-name><ce:givenname>C.</ce:givenname>
</author>
<author seq="8">
<ce:initials>V.</ce:initials>
<ce:surname>de Vroey</ce:surname>
<ce:given-name>V.</ce:given-name><ce:givenname>V.</ce:givenname>
</author>
<author seq="9">
<ce:initials>A.</ce:initials>
<ce:surname>de Wilde</ce:surname>
<ce:given-name>A.</ce:given-name><ce:givenname>A.</ce:givenname>
</author>
<author seq="10">
<ce:initials>E.</ce:initials>
<ce:surname>Smits</ce:surname>
<ce:given-name>E.</ce:given-name><ce:givenname>E.</ce:givenname>
</author>
<author seq="11">
<ce:initials>K.J.</ce:initials>
<ce:surname>Cheung</ce:surname>
<ce:given-name>K.J.</ce:given-name>
</author>
<author seq="12">
<ce:initials>L.</ce:initials>
<ce:surname>de Clerck</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="13">
<ce:initials>P.</ce:initials>
<ce:surname>Aerts</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="14">
<ce:initials>D.</ce:initials>
<ce:surname>Baert</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="15">
<ce:initials>C.</ce:initials>
<ce:surname>Vandoninck</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="16">
<ce:initials>S.</ce:initials>
<ce:surname>Kindt</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="17">
<ce:initials>S.</ce:initials>
<ce:surname>Schelfhaut</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="18">
<ce:initials>M.</ce:initials>
<ce:surname>Vankerkhoven</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="19">
<ce:initials>A.</ce:initials>
<ce:surname>Troch</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="20">
<ce:initials>L.</ce:initials>
<ce:surname>Ceulemans</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="21">
<ce:initials>H.</ce:initials>
<ce:surname>Vandenbergh</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="22">
<ce:initials>S.</ce:initials>
<ce:surname>Leys</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="23">
<ce:initials>T.</ce:initials>
<ce:surname>Rondou</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="24">
<ce:initials>E.</ce:initials>
<ce:surname>Dewitte</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="25">
<ce:initials>K.</ce:initials>
<ce:surname>Maes</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="26">
<ce:initials>P.</ce:initials>
<ce:surname>Pauwels</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="27">
<ce:initials>B.</ce:initials>
<ce:surname>de Winter</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="28">
<ce:initials>L.</ce:initials>
<ce:surname>van Gaal</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="29">
<ce:initials>D.</ce:initials>
<ce:surname>Ysebaert</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="30">
<ce:initials>M.</ce:initials>
<ce:surname>Peeters</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>BMJ Open Gastroenterol</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Vanhoutte, G., van de Wiel, M., Wouters, K., Sels, M., Bartolomeeussen, L., De Keersmaecker, S., Verschueren, C., De Vroey, V., De Wilde, A., Smits, E., Cheung, K.J., De Clerck, L., Aerts, P., Baert, D., Vandoninck, C., Kindt, S., Schelfhaut, S., Vankerkhoven, M., Troch, A., Ceulemans, L., Vandenbergh, H., Leys, S., Rondou, T., Dewitte, E., Maes, K., Pauwels, P., De Winter, B., Van Gaal, L., Ysebaert, D., Peeters, M.: Cachexia in cancer: what is in the definition? BMJ Open Gastroenterol. 3, e000097 (2016)</ref-fulltext>
<ce:source-text>Vanhoutte, G., van de Wiel, M., Wouters, K., Sels, M., Bartolomeeussen, L., De Keersmaecker, S., Verschueren, C., De Vroey, V., De Wilde, A., Smits, E., Cheung, K.J., De Clerck, L., Aerts, P., Baert, D., Vandoninck, C., Kindt, S., Schelfhaut, S., Vankerkhoven, M., Troch, A., Ceulemans, L., Vandenbergh, H., Leys, S., Rondou, T., Dewitte, E., Maes, K., Pauwels, P., De Winter, B., Van Gaal, L., Ysebaert, D., Peeters, M.: Cachexia in cancer: what is in the definition? BMJ Open Gastroenterol. 3, e000097 (2016)</ce:source-text>
</reference>
<reference seq="14">
<ref-info>
<ref-title>
<ref-titletext-english>Physiological basis of fatigue</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.J.</ce:initials>
<ce:surname>Evans</ce:surname>
<ce:given-name>W.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.P.</ce:initials>
<ce:surname>Lambert</ce:surname>
<ce:given-name>C.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Phys. Med. Rehabil</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>86</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>S29</first-page>
<last-page>S46</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Evans, W.J., Lambert, C.P.: Physiological basis of fatigue. Am. J. Phys. Med. Rehabil. 86, S29–S46 (2007)</ref-fulltext>
<ce:source-text>Evans, W.J., Lambert, C.P.: Physiological basis of fatigue. Am. J. Phys. Med. Rehabil. 86, S29–S46 (2007)</ce:source-text>
</reference>
<reference seq="15">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle mass as a target to reduce fatigue in patients with advanced cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.C.W.</ce:initials>
<ce:surname>Neefjes</ce:surname>
<ce:given-name>E.C.W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.M.</ce:initials>
<ce:surname>Van den Hurk</ce:surname>
<ce:given-name>R.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Blauwhoff-Buskermolen</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Van der Vorst</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Becker-Commissaris</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>M.A.E.</ce:initials>
<ce:surname>De van der Schueren</ce:surname>
<ce:given-name>M.A.E.</ce:given-name>
</author>
<author seq="7">
<ce:initials>L.M.</ce:initials>
<ce:surname>Buffart</ce:surname>
<ce:given-name>L.M.</ce:given-name>
</author>
<author seq="8">
<ce:initials>H.M.W.</ce:initials>
<ce:surname>Verheul</ce:surname>
<ce:given-name>H.M.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>623</first-page>
<last-page>629</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Neefjes, E.C.W., van den Hurk, R.M., Blauwhoff-Buskermolen, S., van der Vorst, M., Becker-Commissaris, A., de van der Schueren, M.A.E., Buffart, L.M., Verheul, H.M.W.: Muscle mass as a target to reduce fatigue in patients with advanced cancer. J. Cachexia. Sarcopenia Muscle. 8, 623–629 (2017)</ref-fulltext>
<ce:source-text>Neefjes, E.C.W., van den Hurk, R.M., Blauwhoff-Buskermolen, S., van der Vorst, M., Becker-Commissaris, A., de van der Schueren, M.A.E., Buffart, L.M., Verheul, H.M.W.: Muscle mass as a target to reduce fatigue in patients with advanced cancer. J. Cachexia. Sarcopenia Muscle. 8, 623–629 (2017)</ce:source-text>
</reference>
<reference seq="16">
<ref-info>
<ref-title>
<ref-titletext-english>Fatigue in breast cancer survivors: Occurrence, correlates, and impact on quality of life</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.E.</ce:initials>
<ce:surname>Bower</ce:surname>
<ce:given-name>J.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.A.</ce:initials>
<ce:surname>Ganz</ce:surname>
<ce:given-name>P.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.A.</ce:initials>
<ce:surname>Desmond</ce:surname>
<ce:given-name>K.A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.H.</ce:initials>
<ce:surname>Rowland</ce:surname>
<ce:given-name>J.H.</ce:given-name>
</author>
<author seq="5">
<ce:initials>B.E.</ce:initials>
<ce:surname>Meyerowitz</ce:surname>
<ce:given-name>B.E.</ce:given-name>
</author>
<author seq="6">
<ce:initials>T.R.</ce:initials>
<ce:surname>Belin</ce:surname>
<ce:given-name>T.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2000" />
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>743</first-page>
<last-page>753</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bower, J.E., Ganz, P.A., Desmond, K.A., Rowland, J.H., Meyerowitz, B.E., Belin, T.R.: Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J. Clin. Oncol. 18, 743–753 (2000)</ref-fulltext>
<ce:source-text>Bower, J.E., Ganz, P.A., Desmond, K.A., Rowland, J.H., Meyerowitz, B.E., Belin, T.R.: Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J. Clin. Oncol. 18, 743–753 (2000)</ce:source-text>
</reference>
<reference seq="17">
<ref-info>
<ref-title>
<ref-titletext-english>Fatigue in cancer patients compared with fatigue in the general United States population</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Cella</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.S.</ce:initials>
<ce:surname>Lai</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.H.</ce:initials>
<ce:surname>Chang</ce:surname>
<ce:given-name>C.H.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Peterman</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Slavin</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer</ref-sourcetitle>
<ref-publicationyear first="2002" />
<volisspag>
<volume-issue-number>
<vol-first>94</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>528</first-page>
<last-page>538</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cella, D., Lai, J.S., Chang, C.H., Peterman, A., Slavin, M.: Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 94, 528–538 (2002)</ref-fulltext>
<ce:source-text>Cella, D., Lai, J.S., Chang, C.H., Peterman, A., Slavin, M.: Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 94, 528–538 (2002)</ce:source-text>
</reference>
<reference seq="18">
<ref-info>
<ref-title>
<ref-titletext-english>The impact of fatigue on patients with cancer: Overview of FATIGUE 1 and 2</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.A.</ce:initials>
<ce:surname>Curt</ce:surname>
<ce:given-name>G.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncologist</ref-sourcetitle>
<ref-publicationyear first="2000" />
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<suppl>Supplement 2</suppl>
</volume-issue-number>
<page-information>
<pages>
<first-page>9</first-page>
<last-page>12</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Curt, G.A.: The impact of fatigue on patients with cancer: overview of FATIGUE 1 and 2. Oncologist. 5(Suppl 2), 9–12 (2000)</ref-fulltext>
<ce:source-text>Curt, G.A.: The impact of fatigue on patients with cancer: overview of FATIGUE 1 and 2. Oncologist. 5(Suppl 2), 9–12 (2000)</ce:source-text>
</reference>
<reference seq="19">
<ref-info>
<ref-title>
<ref-titletext-english>Dysregulation of metabolic-associated pathways in muscle of breast cancer patients: Preclinical evaluation of interleukin-15 targeting fatigue</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Bohlen</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.L.</ce:initials>
<ce:surname>McLaughlin</ce:surname>
<ce:given-name>S.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Hazard-Jenkins</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.M.</ce:initials>
<ce:surname>Infante</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>C.</ce:initials>
<ce:surname>Montgomery</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Davis</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="7">
<ce:initials>E.E.</ce:initials>
<ce:surname>Pistilli</ce:surname>
<ce:given-name>E.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>701</first-page>
<last-page>714</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bohlen, J., McLaughlin, S.L., Hazard-Jenkins, H., Infante, A.M., Montgomery, C., Davis, M., Pistilli, E.E.: Dysregulation of metabolic-associated pathways in muscle of breast cancer patients: Preclinical evaluation of interleukin-15 targeting fatigue. J. Cachexia. Sarcopenia Muscle. 9, 701–714 (2018)</ref-fulltext>
<ce:source-text>Bohlen, J., McLaughlin, S.L., Hazard-Jenkins, H., Infante, A.M., Montgomery, C., Davis, M., Pistilli, E.E.: Dysregulation of metabolic-associated pathways in muscle of breast cancer patients: Preclinical evaluation of interleukin-15 targeting fatigue. J. Cachexia. Sarcopenia Muscle. 9, 701–714 (2018)</ce:source-text>
</reference>
<reference seq="20">
<ref-info>
<ref-title>
<ref-titletext-english>Human breast cancer xenograft model implicates peroxisome proliferator-activated receptor signaling as driver of cancer-induced muscle fatigue</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.E.</ce:initials>
<ce:surname>Wilson</ce:surname>
<ce:given-name>H.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.K.</ce:initials>
<ce:surname>Rhodes</ce:surname>
<ce:given-name>K.K.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Rodriguez</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="4">
<ce:initials>I.</ce:initials>
<ce:surname>Chahal</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="5">
<ce:initials>D.A.</ce:initials>
<ce:surname>Stanton</ce:surname>
<ce:given-name>D.A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:surname>Bohlen</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="7">
<ce:initials>M.</ce:initials>
<ce:surname>Davis</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="8">
<ce:initials>A.M.</ce:initials>
<ce:surname>Infante</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
<author seq="9">
<ce:initials>H.</ce:initials>
<ce:surname>Hazard-Jenkins</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="10">
<ce:initials>D.J.</ce:initials>
<ce:surname>Klinke</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
<author seq="11">
<ce:initials>E.N.</ce:initials>
<ce:surname>Pugacheva</ce:surname>
<ce:given-name>E.N.</ce:given-name>
</author>
<author seq="12">
<ce:initials>E.E.</ce:initials>
<ce:surname>Pistilli</ce:surname>
<ce:given-name>E.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>25</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2336</first-page>
<last-page>2347</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wilson, H.E., Rhodes, K.K., Rodriguez, D., Chahal, I., Stanton, D.A., Bohlen, J., Davis, M., Infante, A.M., Hazard-Jenkins, H., Klinke, D.J., Pugacheva, E.N., Pistilli, E.E.: Human breast cancer xenograft model implicates peroxisome proliferator-activated receptor signaling as driver of cancer-induced muscle fatigue. Clin. Cancer Res. 25, 2336–2347 (2019)</ref-fulltext>
<ce:source-text>Wilson, H.E., Rhodes, K.K., Rodriguez, D., Chahal, I., Stanton, D.A., Bohlen, J., Davis, M., Infante, A.M., Hazard-Jenkins, H., Klinke, D.J., Pugacheva, E.N., Pistilli, E.E.: Human breast cancer xenograft model implicates peroxisome proliferator-activated receptor signaling as driver of cancer-induced muscle fatigue. Clin. Cancer Res. 25, 2336–2347 (2019)</ce:source-text>
</reference>
<reference seq="21">
<ref-info>
<ref-title>
<ref-titletext-english>Understanding sex differences in the regulation of cancer-induced muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.N.</ce:initials>
<ce:surname>Montalvo</ce:surname>
<ce:given-name>R.N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.R.</ce:initials>
<ce:surname>Counts</ce:surname>
<ce:given-name>B.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.A.</ce:initials>
<ce:surname>Carson</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Opin. Support. Palliat. Care</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>394</first-page>
<last-page>403</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Montalvo, R.N., Counts, B.R., Carson, J.A.: Understanding sex differences in the regulation of cancer-induced muscle wasting. Curr. Opin. Support. Palliat. Care. 12, 394–403 (2018)</ref-fulltext>
<ce:source-text>Montalvo, R.N., Counts, B.R., Carson, J.A.: Understanding sex differences in the regulation of cancer-induced muscle wasting. Curr. Opin. Support. Palliat. Care. 12, 394–403 (2018)</ce:source-text>
</reference>
<reference seq="22">
<ref-info>
<ref-title>
<ref-titletext-english>The landscape of sex-differential transcriptome and its consequent selection in human adults</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Gershoni</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Pietrokovski</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>BMC Biol</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gershoni, M., Pietrokovski, S.: The landscape of sex-differential transcriptome and its consequent selection in human adults. BMC Biol. 15, 7 (2017)</ref-fulltext>
<ce:source-text>Gershoni, M., Pietrokovski, S.: The landscape of sex-differential transcriptome and its consequent selection in human adults. BMC Biol. 15, 7 (2017)</ce:source-text>
</reference>
<reference seq="23">
<ref-info>
<ref-title>
<ref-titletext-english>Sex differences in muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.J.</ce:initials>
<ce:surname>Anderson</ce:surname>
<ce:given-name>L.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.M.</ce:initials>
<ce:surname>Garcia</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Adv. Exp. Med. Biol</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>1043</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>153</first-page>
<last-page>197</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Anderson, L.J., Liu, H., Garcia, J.M.: Sex differences in muscle wasting. Adv. Exp. Med. Biol. 1043, 153–197 (2017)</ref-fulltext>
<ce:source-text>Anderson, L.J., Liu, H., Garcia, J.M.: Sex differences in muscle wasting. Adv. Exp. Med. Biol. 1043, 153–197 (2017)</ce:source-text>
</reference>
<reference seq="24">
<ref-info>
<ref-title>
<ref-titletext-english>Loss of muscle mass in the end of life in patients with advanced cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>O.</ce:initials>
<ce:surname>Wallengren</ce:surname>
<ce:given-name>O.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.M.</ce:initials>
<ce:surname>Iresjo</ce:surname>
<ce:given-name>B.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.</ce:initials>
<ce:surname>Lundholm</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="4">
<ce:initials>I.</ce:initials>
<ce:surname>Bosaeus</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Support Care Cancer</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>23</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>79</first-page>
<last-page>86</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wallengren, O., Iresjo, B.M., Lundholm, K., Bosaeus, I.: Loss of muscle mass in the end of life in patients with advanced cancer. Support Care Cancer. 23, 79–86 (2015)</ref-fulltext>
<ce:source-text>Wallengren, O., Iresjo, B.M., Lundholm, K., Bosaeus, I.: Loss of muscle mass in the end of life in patients with advanced cancer. Support Care Cancer. 23, 79–86 (2015)</ce:source-text>
</reference>
<reference seq="25">
<ref-info>
<ref-title>
<ref-titletext-english>Sexual dimorphism modulates the impact of cancer cachexia on lower limb muscle mass and function</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.A.</ce:initials>
<ce:surname>Stephens</ce:surname>
<ce:given-name>N.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Gray</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.J.</ce:initials>
<ce:surname>Macdonald</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>B.H.</ce:initials>
<ce:surname>Tan</ce:surname>
<ce:given-name>B.H.</ce:given-name>
</author>
<author seq="5">
<ce:initials>I.J.</ce:initials>
<ce:surname>Gallagher</ce:surname>
<ce:given-name>I.J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>R.J.</ce:initials>
<ce:surname>Skipworth</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
<author seq="7">
<ce:initials>J.A.</ce:initials>
<ce:surname>Ross</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="8">
<ce:initials>K.C.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.C.</ce:given-name>
</author>
<author seq="9">
<ce:initials>C.A.</ce:initials>
<ce:surname>Greig</ce:surname>
<ce:given-name>C.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>31</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>499</first-page>
<last-page>505</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stephens, N.A., Gray, C., MacDonald, A.J., Tan, B.H., Gallagher, I.J., Skipworth, R.J., Ross, J.A., Fearon, K.C., Greig, C.A.: Sexual dimorphism modulates the impact of cancer cachexia on lower limb muscle mass and function. Clin. Nutr. 31, 499–505 (2012)</ref-fulltext>
<ce:source-text>Stephens, N.A., Gray, C., MacDonald, A.J., Tan, B.H., Gallagher, I.J., Skipworth, R.J., Ross, J.A., Fearon, K.C., Greig, C.A.: Sexual dimorphism modulates the impact of cancer cachexia on lower limb muscle mass and function. Clin. Nutr. 31, 499–505 (2012)</ce:source-text>
</reference>
<reference seq="26">
<ref-info>
<ref-title>
<ref-titletext-english>Evidence against a sexual dimorphism in glucose and fatty acid metabolism in skeletal muscle cultures from age-matched men and post-menopausal women</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Rune</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Salehzadeh</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:surname>Szekeres</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="4">
<ce:initials>I.</ce:initials>
<ce:surname>Kuhn</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.E.</ce:initials>
<ce:surname>Osler</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
<author seq="6">
<ce:initials>L.</ce:initials>
<ce:surname>Al-Khalili</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Acta Physiol (Oxf.).</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>197</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>207</first-page>
<last-page>215</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rune, A., Salehzadeh, F., Szekeres, F., Kuhn, I., Osler, M.E., Al-Khalili, L.: Evidence against a sexual dimorphism in glucose and fatty acid metabolism in skeletal muscle cultures from age-matched men and post-menopausal women. Acta Physiol (Oxf.). 197, 207–215 (2009)</ref-fulltext>
<ce:source-text>Rune, A., Salehzadeh, F., Szekeres, F., Kuhn, I., Osler, M.E., Al-Khalili, L.: Evidence against a sexual dimorphism in glucose and fatty acid metabolism in skeletal muscle cultures from age-matched men and post-menopausal women. Acta Physiol (Oxf.). 197, 207–215 (2009)</ce:source-text>
</reference>
<reference seq="27">
<ref-info>
<ref-title>
<ref-titletext-english>Gender dimorphism in the exercise-naive murine skeletal muscle proteome</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.A.</ce:initials>
<ce:surname>Metskas</ce:surname>
<ce:given-name>L.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Kulp</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.P.</ce:initials>
<ce:surname>Scordilis</ce:surname>
<ce:given-name>S.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell. Mol. Biol. Lett</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>507</first-page>
<last-page>516</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Metskas, L.A., Kulp, M., Scordilis, S.P.: Gender dimorphism in the exercise-naive murine skeletal muscle proteome. Cell. Mol. Biol. Lett. 15, 507–516 (2010)</ref-fulltext>
<ce:source-text>Metskas, L.A., Kulp, M., Scordilis, S.P.: Gender dimorphism in the exercise-naive murine skeletal muscle proteome. Cell. Mol. Biol. Lett. 15, 507–516 (2010)</ce:source-text>
</reference>
<reference seq="28">
<ref-info>
<ref-title>
<ref-titletext-english>State of the epidemiological evidence on physical activity and cancer prevention</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.M.</ce:initials>
<ce:surname>Friedenreich</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.K.</ce:initials>
<ce:surname>Neilson</ce:surname>
<ce:given-name>H.K.</ce:given-name>
</author>
<author seq="3">
<ce:initials>B.M.</ce:initials>
<ce:surname>Lynch</ce:surname>
<ce:given-name>B.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>46</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2593</first-page>
<last-page>2604</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Friedenreich, C.M., Neilson, H.K., Lynch, B.M.: State of the epidemiological evidence on physical activity and cancer prevention. Eur. J. Cancer. 46, 2593–2604 (2010)</ref-fulltext>
<ce:source-text>Friedenreich, C.M., Neilson, H.K., Lynch, B.M.: State of the epidemiological evidence on physical activity and cancer prevention. Eur. J. Cancer. 46, 2593–2604 (2010)</ce:source-text>
</reference>
<reference seq="29">
<ref-info>
<ref-title>
<ref-titletext-english>Lifestyle factors associated with cancer incidence, recurrence and survival</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.K.</ce:initials>
<ce:surname>Neilson</ce:surname>
<ce:given-name>H.K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.M.</ce:initials>
<ce:surname>Friedenreich</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>ACSM’s Guide to Exercise and Cancer Survivorship</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<page-information>
<pages>
<first-page>29</first-page>
<last-page>47</last-page>
</pages>
</page-information>
</volisspag>
<ref-text>Irwin, M.L. (ed.), Human Kinetics, Illinois</ref-text>
</ref-info>
<ref-fulltext>Neilson, H.K., Friedenreich, C.M.: Lifestyle factors associated with cancer incidence, recurrence and survival. In: Irwin, M.L. (ed.) ACSM’s guide to exercise and cancer survivorship, pp. 29–47. Human Kinetics, Illinois (2012)</ref-fulltext>
<ce:source-text>Neilson, H.K., Friedenreich, C.M.: Lifestyle factors associated with cancer incidence, recurrence and survival. In: Irwin, M.L. (ed.) ACSM’s guide to exercise and cancer survivorship, pp. 29–47. Human Kinetics, Illinois (2012)</ce:source-text>
</reference>
<reference seq="30">
<ref-info>
<ref-title>
<ref-titletext-english>Physical activity and cancer risk: Dose-response and cancer, all sites and site-specific</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Thune</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.S.</ce:initials>
<ce:surname>Furberg</ce:surname>
<ce:given-name>A.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Med. Sci. Sports Exerc</ref-sourcetitle>
<ref-publicationyear first="2001" />
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>S530</first-page>
<last-page>S550</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Thune, I., Furberg, A.S.: Physical activity and cancer risk: dose-response and cancer, all sites and site-specific. Med. Sci. Sports Exerc. 33, S530–50 (2001); discussion S609–10</ref-fulltext>
<ce:source-text>Thune, I., Furberg, A.S.: Physical activity and cancer risk: dose-response and cancer, all sites and site-specific. Med. Sci. Sports Exerc. 33, S530–50 (2001); discussion S609–10</ce:source-text>
</reference>
<reference seq="31">
<ref-info>
<ref-title>
<ref-titletext-english>Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.C.</ce:initials>
<ce:surname>Moore</ce:surname>
<ce:given-name>S.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>I.M.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>I.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>E.</ce:initials>
<ce:surname>Weiderpass</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="4">
<ce:initials>P.T.</ce:initials>
<ce:surname>Campbell</ce:surname>
<ce:given-name>P.T.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.N.</ce:initials>
<ce:surname>Sampson</ce:surname>
<ce:given-name>J.N.</ce:given-name>
</author>
<author seq="6">
<ce:initials>C.M.</ce:initials>
<ce:surname>Kitahara</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
<author seq="7">
<ce:initials>S.K.</ce:initials>
<ce:surname>Keadle</ce:surname>
<ce:given-name>S.K.</ce:given-name>
</author>
<author seq="8">
<ce:initials>H.</ce:initials>
<ce:surname>Arem</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="9">
<ce:initials>A.</ce:initials>
<ce:surname>Berrington de Gonzalez</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="10">
<ce:initials>P.</ce:initials>
<ce:surname>Hartge</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="11">
<ce:initials>H.O.</ce:initials>
<ce:surname>Adami</ce:surname>
<ce:given-name>H.O.</ce:given-name>
</author>
<author seq="12">
<ce:initials>C.K.</ce:initials>
<ce:surname>Blair</ce:surname>
<ce:given-name>C.K.</ce:given-name>
</author>
<author seq="13">
<ce:initials>K.B.</ce:initials>
<ce:surname>Borch</ce:surname>
<ce:given-name>K.B.</ce:given-name>
</author>
<author seq="14">
<ce:initials>E.</ce:initials>
<ce:surname>Boyd</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="15">
<ce:initials>D.P.</ce:initials>
<ce:surname>Check</ce:surname>
<ce:given-name>D.P.</ce:given-name>
</author>
<author seq="16">
<ce:initials>A.</ce:initials>
<ce:surname>Fournier</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="17">
<ce:initials>N.D.</ce:initials>
<ce:surname>Freedman</ce:surname>
<ce:given-name>N.D.</ce:given-name>
</author>
<author seq="18">
<ce:initials>M.</ce:initials>
<ce:surname>Gunter</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="19">
<ce:initials>M.</ce:initials>
<ce:surname>Johannson</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="20">
<ce:initials>K.T.</ce:initials>
<ce:surname>Khaw</ce:surname>
<ce:given-name>K.T.</ce:given-name>
</author>
<author seq="21">
<ce:initials>M.S.</ce:initials>
<ce:surname>Linet</ce:surname>
<ce:given-name>M.S.</ce:given-name>
</author>
<author seq="22">
<ce:initials>N.</ce:initials>
<ce:surname>Orsini</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="23">
<ce:initials>Y.</ce:initials>
<ce:surname>Park</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="24">
<ce:initials>E.</ce:initials>
<ce:surname>Riboli</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="25">
<ce:initials>K.</ce:initials>
<ce:surname>Robien</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="26">
<ce:initials>C.</ce:initials>
<ce:surname>Schairer</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="27">
<ce:initials>H.</ce:initials>
<ce:surname>Sesso</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="28">
<ce:initials>M.</ce:initials>
<ce:surname>Spriggs</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="29">
<ce:initials>R.</ce:initials>
<ce:surname>van Dusen</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="30">
<ce:initials>A.</ce:initials>
<ce:surname>Wolk</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="31">
<ce:initials>C.E.</ce:initials>
<ce:surname>Matthews</ce:surname>
<ce:given-name>C.E.</ce:given-name>
</author>
<author seq="32">
<ce:initials>A.V.</ce:initials>
<ce:surname>Patel</ce:surname>
<ce:given-name>A.V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>JAMA Intern. Med</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>176</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>816</first-page>
<last-page>825</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Moore, S.C., Lee, I.M., Weiderpass, E., Campbell, P.T., Sampson, J.N., Kitahara, C.M., Keadle, S.K., Arem, H., Berrington de Gonzalez, A., Hartge, P., Adami, H.O., Blair, C.K., Borch, K.B., Boyd, E., Check, D.P., Fournier, A., Freedman, N.D., Gunter, M., Johannson, M., Khaw, K.T., Linet, M.S., Orsini, N., Park, Y., Riboli, E., Robien, K., Schairer, C., Sesso, H., Spriggs, M., Van Dusen, R., Wolk, A., Matthews, C.E., Patel, A.V.: Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults. JAMA Intern. Med. 176, 816–825 (2016)</ref-fulltext>
<ce:source-text>Moore, S.C., Lee, I.M., Weiderpass, E., Campbell, P.T., Sampson, J.N., Kitahara, C.M., Keadle, S.K., Arem, H., Berrington de Gonzalez, A., Hartge, P., Adami, H.O., Blair, C.K., Borch, K.B., Boyd, E., Check, D.P., Fournier, A., Freedman, N.D., Gunter, M., Johannson, M., Khaw, K.T., Linet, M.S., Orsini, N., Park, Y., Riboli, E., Robien, K., Schairer, C., Sesso, H., Spriggs, M., Van Dusen, R., Wolk, A., Matthews, C.E., Patel, A.V.: Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults. JAMA Intern. Med. 176, 816–825 (2016)</ce:source-text>
</reference>
<reference seq="32">
<ref-info>
<ref-title>
<ref-titletext-english>Effect of physical activity and body size on survival after diagnosis with colorectal cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.M.</ce:initials>
<ce:surname>Haydon</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.J.</ce:initials>
<ce:surname>Macinnis</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.R.</ce:initials>
<ce:surname>English</ce:surname>
<ce:given-name>D.R.</ce:given-name>
</author>
<author seq="4">
<ce:initials>G.G.</ce:initials>
<ce:surname>Giles</ce:surname>
<ce:given-name>G.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Gut</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>55</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>62</first-page>
<last-page>67</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Haydon, A.M., Macinnis, R.J., English, D.R., Giles, G.G.: Effect of physical activity and body size on survival after diagnosis with colorectal cancer. Gut. 55, 62–67 (2006)</ref-fulltext>
<ce:source-text>Haydon, A.M., Macinnis, R.J., English, D.R., Giles, G.G.: Effect of physical activity and body size on survival after diagnosis with colorectal cancer. Gut. 55, 62–67 (2006)</ce:source-text>
</reference>
<reference seq="33">
<ref-info>
<ref-title>
<ref-titletext-english>Physical activity and survival after diagnosis of invasive breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.N.</ce:initials>
<ce:surname>Holick</ce:surname>
<ce:given-name>C.N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.A.</ce:initials>
<ce:surname>Newcomb</ce:surname>
<ce:given-name>P.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Trentham-Dietz</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>L.</ce:initials>
<ce:surname>Titus-Ernstoff</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="5">
<ce:initials>A.J.</ce:initials>
<ce:surname>Bersch</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
<author seq="6">
<ce:initials>M.J.</ce:initials>
<ce:surname>Stampfer</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
<author seq="7">
<ce:initials>J.A.</ce:initials>
<ce:surname>Baron</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="8">
<ce:initials>K.M.</ce:initials>
<ce:surname>Egan</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
<author seq="9">
<ce:initials>W.C.</ce:initials>
<ce:surname>Willett</ce:surname>
<ce:given-name>W.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Epidemiol. Biomark. Prev</ref-sourcetitle>
<ref-publicationyear first="2008" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>379</first-page>
<last-page>386</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Holick, C.N., Newcomb, P.A., Trentham-Dietz, A., Titus-Ernstoff, L., Bersch, A.J., Stampfer, M.J., Baron, J.A., Egan, K.M., Willett, W.C.: Physical activity and survival after diagnosis of invasive breast cancer. Cancer Epidemiol. Biomark. Prev. 17, 379–386 (2008)</ref-fulltext>
<ce:source-text>Holick, C.N., Newcomb, P.A., Trentham-Dietz, A., Titus-Ernstoff, L., Bersch, A.J., Stampfer, M.J., Baron, J.A., Egan, K.M., Willett, W.C.: Physical activity and survival after diagnosis of invasive breast cancer. Cancer Epidemiol. Biomark. Prev. 17, 379–386 (2008)</ce:source-text>
</reference>
<reference seq="34">
<ref-info>
<ref-title>
<ref-titletext-english>Physical activity and gynecologic cancer prevention</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.E.</ce:initials>
<ce:surname>Cust</ce:surname>
<ce:given-name>A.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Recent Results Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>186</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>159</first-page>
<last-page>185</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cust, A.E.: Physical activity and gynecologic cancer prevention. Recent Results Cancer Res. 186, 159–185 (2011)</ref-fulltext>
<ce:source-text>Cust, A.E.: Physical activity and gynecologic cancer prevention. Recent Results Cancer Res. 186, 159–185 (2011)</ce:source-text>
</reference>
<reference seq="35">
<ref-info>
<ref-title>
<ref-titletext-english>Weight training and risk of 10 common types of cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.M.</ce:initials>
<ce:surname>Mazzilli</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.E.</ce:initials>
<ce:surname>Matthews</ce:surname>
<ce:given-name>C.E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>E.A.</ce:initials>
<ce:surname>Salerno</ce:surname>
<ce:given-name>E.A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.C.</ce:initials>
<ce:surname>Moore</ce:surname>
<ce:given-name>S.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Med. Sci. Sports Exerc</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>51</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1845</first-page>
<last-page>1851</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mazzilli, K.M., Matthews, C.E., Salerno, E.A., Moore, S.C.: Weight training and risk of 10 common types of cancer. Med. Sci. Sports Exerc. 51, 1845–1851 (2019)</ref-fulltext>
<ce:source-text>Mazzilli, K.M., Matthews, C.E., Salerno, E.A., Moore, S.C.: Weight training and risk of 10 common types of cancer. Med. Sci. Sports Exerc. 51, 1845–1851 (2019)</ce:source-text>
</reference>
<reference seq="36">
<ref-info>
<ref-title>
<ref-titletext-english>Influence of pre- and postdiagnosis physical activity on mortality in breast cancer survivors: The health, eating, activity, and lifestyle study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.L.</ce:initials>
<ce:surname>Irwin</ce:surname>
<ce:given-name>M.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.W.</ce:initials>
<ce:surname>Smith</ce:surname>
<ce:given-name>A.W.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>McTiernan</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Ballard-Barbash</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="5">
<ce:initials>K.</ce:initials>
<ce:surname>Cronin</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="6">
<ce:initials>F.D.</ce:initials>
<ce:surname>Gilliland</ce:surname>
<ce:given-name>F.D.</ce:given-name>
</author>
<author seq="7">
<ce:initials>R.N.</ce:initials>
<ce:surname>Baumgartner</ce:surname>
<ce:given-name>R.N.</ce:given-name>
</author>
<author seq="8">
<ce:initials>K.B.</ce:initials>
<ce:surname>Baumgartner</ce:surname>
<ce:given-name>K.B.</ce:given-name>
</author>
<author seq="9">
<ce:initials>L.</ce:initials>
<ce:surname>Bernstein</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2008" />
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3958</first-page>
<last-page>3964</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Irwin, M.L., Smith, A.W., McTiernan, A., Ballard-Barbash, R., Cronin, K., Gilliland, F.D., Baumgartner, R.N., Baumgartner, K.B., Bernstein, L.: Influence of pre- and postdiagnosis physical activity on mortality in breast cancer survivors: The health, eating, activity, and lifestyle study. J. Clin. Oncol. 26, 3958–3964 (2008)</ref-fulltext>
<ce:source-text>Irwin, M.L., Smith, A.W., McTiernan, A., Ballard-Barbash, R., Cronin, K., Gilliland, F.D., Baumgartner, R.N., Baumgartner, K.B., Bernstein, L.: Influence of pre- and postdiagnosis physical activity on mortality in breast cancer survivors: The health, eating, activity, and lifestyle study. J. Clin. Oncol. 26, 3958–3964 (2008)</ce:source-text>
</reference>
<reference seq="37">
<ref-info>
<ref-title>
<ref-titletext-english>Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: Findings from CALGB 89803</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Meyerhardt</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Heseltine</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Niedzwiecki</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="4">
<ce:initials>D.</ce:initials>
<ce:surname>Hollis</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="5">
<ce:initials>L.B.</ce:initials>
<ce:surname>Saltz</ce:surname>
<ce:given-name>L.B.</ce:given-name>
</author>
<author seq="6">
<ce:initials>R.J.</ce:initials>
<ce:surname>Mayer</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
<author seq="7">
<ce:initials>J.</ce:initials>
<ce:surname>Thomas</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="8">
<ce:initials>H.</ce:initials>
<ce:surname>Nelson</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="9">
<ce:initials>R.</ce:initials>
<ce:surname>Whittom</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="10">
<ce:initials>A.</ce:initials>
<ce:surname>Hantel</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="11">
<ce:initials>R.L.</ce:initials>
<ce:surname>Schilsky</ce:surname>
<ce:given-name>R.L.</ce:given-name>
</author>
<author seq="12">
<ce:initials>C.S.</ce:initials>
<ce:surname>Fuchs</ce:surname>
<ce:given-name>C.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3535</first-page>
<last-page>3541</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Meyerhardt, J.A., Heseltine, D., Niedzwiecki, D., Hollis, D., Saltz, L.B., Mayer, R.J., Thomas, J., Nelson, H., Whittom, R., Hantel, A., Schilsky, R.L., Fuchs, C.S.: Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J. Clin. Oncol. 24, 3535–3541 (2006)</ref-fulltext>
<ce:source-text>Meyerhardt, J.A., Heseltine, D., Niedzwiecki, D., Hollis, D., Saltz, L.B., Mayer, R.J., Thomas, J., Nelson, H., Whittom, R., Hantel, A., Schilsky, R.L., Fuchs, C.S.: Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J. Clin. Oncol. 24, 3535–3541 (2006)</ce:source-text>
</reference>
<reference seq="38">
<ref-info>
<ref-title>
<ref-titletext-english>Physical activity and survival after breast cancer diagnosis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.D.</ce:initials>
<ce:surname>Holmes</ce:surname>
<ce:given-name>M.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>W.Y.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>W.Y.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Feskanich</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="4">
<ce:initials>C.H.</ce:initials>
<ce:surname>Kroenke</ce:surname>
<ce:given-name>C.H.</ce:given-name>
</author>
<author seq="5">
<ce:initials>G.A.</ce:initials>
<ce:surname>Colditz</ce:surname>
<ce:given-name>G.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>JAMA</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>293</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2479</first-page>
<last-page>2486</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Holmes, M.D., Chen, W.Y., Feskanich, D., Kroenke, C.H., Colditz, G.A.: Physical activity and survival after breast cancer diagnosis. JAMA. 293, 2479–2486 (2005)</ref-fulltext>
<ce:source-text>Holmes, M.D., Chen, W.Y., Feskanich, D., Kroenke, C.H., Colditz, G.A.: Physical activity and survival after breast cancer diagnosis. JAMA. 293, 2479–2486 (2005)</ce:source-text>
</reference>
<reference seq="39">
<ref-info>
<ref-title>
<ref-titletext-english>Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.A.</ce:initials>
<ce:surname>Kenfield</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.J.</ce:initials>
<ce:surname>Stampfer</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>E.</ce:initials>
<ce:surname>Giovannucci</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.M.</ce:initials>
<ce:surname>Chan</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>29</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>726</first-page>
<last-page>732</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kenfield, S.A., Stampfer, M.J., Giovannucci, E., Chan, J.M.: Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J. Clin. Oncol. 29, 726–732 (2011)</ref-fulltext>
<ce:source-text>Kenfield, S.A., Stampfer, M.J., Giovannucci, E., Chan, J.M.: Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J. Clin. Oncol. 29, 726–732 (2011)</ce:source-text>
</reference>
<reference seq="40">
<ref-info>
<ref-title>
<ref-titletext-english>Physical activity levels among breast cancer survivors. Med. Sci</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.L.</ce:initials>
<ce:surname>Irwin</ce:surname>
<ce:given-name>M.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>McTiernan</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:surname>Bernstein</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="4">
<ce:initials>F.D.</ce:initials>
<ce:surname>Gilliland</ce:surname>
<ce:given-name>F.D.</ce:given-name>
</author>
<author seq="5">
<ce:initials>R.</ce:initials>
<ce:surname>Baumgartner</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="6">
<ce:initials>K.</ce:initials>
<ce:surname>Baumgartner</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="7">
<ce:initials>R.</ce:initials>
<ce:surname>Ballard-Barbash</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sports Exerc</ref-sourcetitle>
<ref-publicationyear first="2004" />
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1484</first-page>
<last-page>1491</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Irwin, M.L., McTiernan, A., Bernstein, L., Gilliland, F.D., Baumgartner, R., Baumgartner, K., Ballard-Barbash, R.: Physical activity levels among breast cancer survivors. Med. Sci. Sports Exerc. 36, 1484–1491 (2004)</ref-fulltext>
<ce:source-text>Irwin, M.L., McTiernan, A., Bernstein, L., Gilliland, F.D., Baumgartner, R., Baumgartner, K., Ballard-Barbash, R.: Physical activity levels among breast cancer survivors. Med. Sci. Sports Exerc. 36, 1484–1491 (2004)</ce:source-text>
</reference>
<reference seq="41">
<ref-info>
<ref-title>
<ref-titletext-english>State variation in meeting the 2008 federal guidelines for both aerobic and muscle-strengthening activities through leisure-time physical activity among adults aged 18–64: United States, 2010–2015</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.L.</ce:initials>
<ce:surname>Blackwell</ce:surname>
<ce:given-name>D.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.C.</ce:initials>
<ce:surname>Clarke</ce:surname>
<ce:given-name>T.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Natl Health Stat Report</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<page-information>
<pages>
<first-page>1</first-page>
<last-page>22</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Blackwell, D.L., Clarke, T.C.: State variation in meeting the 2008 federal guidelines for both aerobic and muscle-strengthening activities through leisure-time physical activity among adults aged 18–64: United States, 2010–2015. Natl Health Stat Report, 1–22 (2018)</ref-fulltext>
<ce:source-text>Blackwell, D.L., Clarke, T.C.: State variation in meeting the 2008 federal guidelines for both aerobic and muscle-strengthening activities through leisure-time physical activity among adults aged 18–64: United States, 2010–2015. Natl Health Stat Report, 1–22 (2018)</ce:source-text>
</reference>
<reference seq="42">
<ref-info>
<ref-title>
<ref-titletext-english>Lifetime recreational exercise activity and breast cancer risk among black women and white women</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Bernstein</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.V.</ce:initials>
<ce:surname>Patel</ce:surname>
<ce:given-name>A.V.</ce:given-name>
</author>
<author seq="3">
<ce:initials>G.</ce:initials>
<ce:surname>Ursin</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Sullivan-Halley</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.F.</ce:initials>
<ce:surname>Press</ce:surname>
<ce:given-name>M.F.</ce:given-name>
</author>
<author seq="6">
<ce:initials>D.</ce:initials>
<ce:surname>Deapen</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="7">
<ce:initials>J.A.</ce:initials>
<ce:surname>Berlin</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="8">
<ce:initials>J.R.</ce:initials>
<ce:surname>Daling</ce:surname>
<ce:given-name>J.R.</ce:given-name>
</author>
<author seq="9">
<ce:initials>J.A.</ce:initials>
<ce:surname>McDonald</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="10">
<ce:initials>S.A.</ce:initials>
<ce:surname>Norman</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
<author seq="11">
<ce:initials>K.E.</ce:initials>
<ce:surname>Malone</ce:surname>
<ce:given-name>K.E.</ce:given-name>
</author>
<author seq="12">
<ce:initials>B.L.</ce:initials>
<ce:surname>Strom</ce:surname>
<ce:given-name>B.L.</ce:given-name>
</author>
<author seq="13">
<ce:initials>J.</ce:initials>
<ce:surname>Liff</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="14">
<ce:initials>S.G.</ce:initials>
<ce:surname>Folger</ce:surname>
<ce:given-name>S.G.</ce:given-name>
</author>
<author seq="15">
<ce:initials>M.S.</ce:initials>
<ce:surname>Simon</ce:surname>
<ce:given-name>M.S.</ce:given-name>
</author>
<author seq="16">
<ce:initials>R.T.</ce:initials>
<ce:surname>Burkman</ce:surname>
<ce:given-name>R.T.</ce:given-name>
</author>
<author seq="17">
<ce:initials>P.A.</ce:initials>
<ce:surname>Marchbanks</ce:surname>
<ce:given-name>P.A.</ce:given-name>
</author>
<author seq="18">
<ce:initials>L.K.</ce:initials>
<ce:surname>Weiss</ce:surname>
<ce:given-name>L.K.</ce:given-name>
</author>
<author seq="19">
<ce:initials>R.</ce:initials>
<ce:surname>Spirtas</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Natl. Cancer Inst</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>97</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1671</first-page>
<last-page>1679</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bernstein, L., Patel, A.V., Ursin, G., Sullivan-Halley, J., Press, M.F., Deapen, D., Berlin, J.A., Daling, J.R., McDonald, J.A., Norman, S.A., Malone, K.E., Strom, B.L., Liff, J., Folger, S.G., Simon, M.S., Burkman, R.T., Marchbanks, P.A., Weiss, L.K., Spirtas, R.: Lifetime recreational exercise activity and breast cancer risk among black women and white women. J. Natl. Cancer Inst. 97, 1671–1679 (2005)</ref-fulltext>
<ce:source-text>Bernstein, L., Patel, A.V., Ursin, G., Sullivan-Halley, J., Press, M.F., Deapen, D., Berlin, J.A., Daling, J.R., McDonald, J.A., Norman, S.A., Malone, K.E., Strom, B.L., Liff, J., Folger, S.G., Simon, M.S., Burkman, R.T., Marchbanks, P.A., Weiss, L.K., Spirtas, R.: Lifetime recreational exercise activity and breast cancer risk among black women and white women. J. Natl. Cancer Inst. 97, 1671–1679 (2005)</ce:source-text>
</reference>
<reference seq="43">
<ref-info>
<ref-title>
<ref-titletext-english>Prospective cohort study of lifetime physical activity and breast cancer survival</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.M.</ce:initials>
<ce:surname>Friedenreich</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Gregory</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.A.</ce:initials>
<ce:surname>Kopciuk</ce:surname>
<ce:given-name>K.A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.R.</ce:initials>
<ce:surname>Mackey</ce:surname>
<ce:given-name>J.R.</ce:given-name>
</author>
<author seq="5">
<ce:initials>K.S.</ce:initials>
<ce:surname>Courneya</ce:surname>
<ce:given-name>K.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>124</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1954</first-page>
<last-page>1962</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Friedenreich, C.M., Gregory, J., Kopciuk, K.A., Mackey, J.R., Courneya, K.S.: Prospective cohort study of lifetime physical activity and breast cancer survival. Int. J. Cancer. 124, 1954–1962 (2009)</ref-fulltext>
<ce:source-text>Friedenreich, C.M., Gregory, J., Kopciuk, K.A., Mackey, J.R., Courneya, K.S.: Prospective cohort study of lifetime physical activity and breast cancer survival. Int. J. Cancer. 124, 1954–1962 (2009)</ce:source-text>
</reference>
<reference seq="44">
<ref-info>
<ref-title>
<ref-titletext-english>Women’s Health Initiative Cohort, S.: Recreational physical activity and the risk of breast cancer in postmenopausal women: The Women’s Health Initiative Cohort Study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>McTiernan</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Kooperberg</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>E.</ce:initials>
<ce:surname>White</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Wilcox</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="5">
<ce:initials>R.</ce:initials>
<ce:surname>Coates</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="6">
<ce:initials>L.L.</ce:initials>
<ce:surname>Adams-Campbell</ce:surname>
<ce:given-name>L.L.</ce:given-name>
</author>
<author seq="7">
<ce:initials>N.</ce:initials>
<ce:surname>Woods</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="8">
<ce:initials>J.</ce:initials>
<ce:surname>Ockene</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>JAMA</ref-sourcetitle>
<ref-publicationyear first="2003" />
<volisspag>
<volume-issue-number>
<vol-first>290</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1331</first-page>
<last-page>1336</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>McTiernan, A., Kooperberg, C., White, E., Wilcox, S., Coates, R., Adams-Campbell, L.L., Woods, N., Ockene, J., Women’s Health Initiative Cohort, S.: Recreational physical activity and the risk of breast cancer in postmenopausal women: The Women’s Health Initiative Cohort Study. JAMA. 290, 1331–1336 (2003)</ref-fulltext>
<ce:source-text>McTiernan, A., Kooperberg, C., White, E., Wilcox, S., Coates, R., Adams-Campbell, L.L., Woods, N., Ockene, J., Women’s Health Initiative Cohort, S.: Recreational physical activity and the risk of breast cancer in postmenopausal women: The Women’s Health Initiative Cohort Study. JAMA. 290, 1331–1336 (2003)</ce:source-text>
</reference>
<reference seq="45">
<ref-info>
<ref-title>
<ref-titletext-english>Recreational physical activity and ovarian cancer risk and survival</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.G.</ce:initials>
<ce:surname>Moorman</ce:surname>
<ce:given-name>P.G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.W.</ce:initials>
<ce:surname>Jones</ce:surname>
<ce:given-name>L.W.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:surname>Akushevich</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.M.</ce:initials>
<ce:surname>Schildkraut</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Epidemiol</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>178</first-page>
<last-page>187</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Moorman, P.G., Jones, L.W., Akushevich, L., Schildkraut, J.M.: Recreational physical activity and ovarian cancer risk and survival. Ann. Epidemiol. 21, 178–187 (2011)</ref-fulltext>
<ce:source-text>Moorman, P.G., Jones, L.W., Akushevich, L., Schildkraut, J.M.: Recreational physical activity and ovarian cancer risk and survival. Ann. Epidemiol. 21, 178–187 (2011)</ce:source-text>
</reference>
<reference seq="46">
<ref-info>
<ref-authors>
<collaboration seq="1">
<ce:text>Committee, P. A. G. A</ce:text>
</collaboration>
</ref-authors>
<ref-sourcetitle>Physical Activity Guidelines Advisory Committee Report</ref-sourcetitle>
<ref-publicationyear first="2008" />
<ref-text>US Department of Health and Human Services</ref-text>
</ref-info>
<ref-fulltext>Committee, P. A. G. A.: Physical activity guidelines advisory committee report: US Department of Health and Human Services (2008)</ref-fulltext>
<ce:source-text>Committee, P. A. G. A.: Physical activity guidelines advisory committee report: US Department of Health and Human Services (2008)</ce:source-text>
</reference>
<reference seq="47">
<ref-info>
<ref-title>
<ref-titletext-english>American College of Sports, M: American College of Sports Medicine roundtable on exercise guidelines for cancer survivors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.H.</ce:initials>
<ce:surname>Schmitz</ce:surname>
<ce:given-name>K.H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.S.</ce:initials>
<ce:surname>Courneya</ce:surname>
<ce:given-name>K.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Matthews</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>W.</ce:initials>
<ce:surname>Demark-Wahnefried</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="5">
<ce:initials>D.A.</ce:initials>
<ce:surname>Galvao</ce:surname>
<ce:given-name>D.A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>B.M.</ce:initials>
<ce:surname>Pinto</ce:surname>
<ce:given-name>B.M.</ce:given-name>
</author>
<author seq="7">
<ce:initials>M.L.</ce:initials>
<ce:surname>Irwin</ce:surname>
<ce:given-name>M.L.</ce:given-name>
</author>
<author seq="8">
<ce:initials>K.Y.</ce:initials>
<ce:surname>Wolin</ce:surname>
<ce:given-name>K.Y.</ce:given-name>
</author>
<author seq="9">
<ce:initials>R.J.</ce:initials>
<ce:surname>Segal</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
<author seq="10">
<ce:initials>A.</ce:initials>
<ce:surname>Lucia</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="11">
<ce:initials>C.M.</ce:initials>
<ce:surname>Schneider</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
<author seq="12">
<ce:initials>V.E.</ce:initials>
<ce:surname>von Gruenigen</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
<author seq="13">
<ce:initials>A.L.</ce:initials>
<ce:surname>Schwartz</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Med. Sci. Sports Exerc.</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>42</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1409</first-page>
<last-page>1426</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Schmitz, K.H., Courneya, K.S., Matthews, C., Demark-Wahnefried, W., Galvao, D.A., Pinto, B.M., Irwin, M.L., Wolin, K.Y., Segal, R.J., Lucia, A., Schneider, C.M., von Gruenigen, V.E., Schwartz, A.L., American College of Sports, M: American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med. Sci. Sports Exerc. 42, 1409–1426 (2010)</ref-fulltext>
<ce:source-text>Schmitz, K.H., Courneya, K.S., Matthews, C., Demark-Wahnefried, W., Galvao, D.A., Pinto, B.M., Irwin, M.L., Wolin, K.Y., Segal, R.J., Lucia, A., Schneider, C.M., von Gruenigen, V.E., Schwartz, A.L., American College of Sports, M: American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med. Sci. Sports Exerc. 42, 1409–1426 (2010)</ce:source-text>
</reference>
<reference seq="48">
<ref-info>
<ref-title>
<ref-titletext-english>Adaptations to aerobic endurance training programs</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Swank</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Sharp</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Essentials of Strength Training and Conditioning</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<page-information>
<pages>
<first-page>115</first-page>
<last-page>133</last-page>
</pages>
</page-information>
</volisspag>
<ref-text>Haff, G.G., Triplett, N.T. (eds.), Human Kinetics, Illinois</ref-text>
</ref-info>
<ref-fulltext>Swank, A., Sharp, C.: Adaptations to aerobic endurance training programs. In: Haff, G.G., Triplett, N.T. (eds.) Essentials of strength training and conditioning, pp. 115–133. Human Kinetics, Illinois (2016)</ref-fulltext>
<ce:source-text>Swank, A., Sharp, C.: Adaptations to aerobic endurance training programs. In: Haff, G.G., Triplett, N.T. (eds.) Essentials of strength training and conditioning, pp. 115–133. Human Kinetics, Illinois (2016)</ce:source-text>
</reference>
<reference seq="49">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle enzymes and fiber composition in male and female track athletes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.L.</ce:initials>
<ce:surname>Costill</ce:surname>
<ce:given-name>D.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Daniels</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>W.</ce:initials>
<ce:surname>Evans</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="4">
<ce:initials>W.</ce:initials>
<ce:surname>Fink</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="5">
<ce:initials>G.</ce:initials>
<ce:surname>Krahenbuhl</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="6">
<ce:initials>B.</ce:initials>
<ce:surname>Saltin</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Appl. Physiol</ref-sourcetitle>
<ref-publicationyear first="1976" />
<volisspag>
<volume-issue-number>
<vol-first>40</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>149</first-page>
<last-page>154</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Costill, D.L., Daniels, J., Evans, W., Fink, W., Krahenbuhl, G., Saltin, B.: Skeletal muscle enzymes and fiber composition in male and female track athletes. J. Appl. Physiol. 40, 149–154 (1976)</ref-fulltext>
<ce:source-text>Costill, D.L., Daniels, J., Evans, W., Fink, W., Krahenbuhl, G., Saltin, B.: Skeletal muscle enzymes and fiber composition in male and female track athletes. J. Appl. Physiol. 40, 149–154 (1976)</ce:source-text>
</reference>
<reference seq="50">
<ref-info>
<ref-title>
<ref-titletext-english>A randomized pilot study with daily walking during adjuvant chemotherapy for patients with breast and colorectal cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Backman</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Wengstrom</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="3">
<ce:initials>B.</ce:initials>
<ce:surname>Johansson</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="4">
<ce:initials>I.</ce:initials>
<ce:surname>Skoldengen</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Borjesson</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>Tarnbro</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="7">
<ce:initials>A.</ce:initials>
<ce:surname>Berglund</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Acta Oncol</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>53</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>510</first-page>
<last-page>520</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Backman, M., Wengstrom, Y., Johansson, B., Skoldengen, I., Borjesson, S., Tarnbro, S., Berglund, A.: A randomized pilot study with daily walking during adjuvant chemotherapy for patients with breast and colorectal cancer. Acta Oncol. 53, 510–520 (2014)</ref-fulltext>
<ce:source-text>Backman, M., Wengstrom, Y., Johansson, B., Skoldengen, I., Borjesson, S., Tarnbro, S., Berglund, A.: A randomized pilot study with daily walking during adjuvant chemotherapy for patients with breast and colorectal cancer. Acta Oncol. 53, 510–520 (2014)</ce:source-text>
</reference>
<reference seq="51">
<ref-info>
<ref-title>
<ref-titletext-english>Exercise intervention in breast cancer patients with aromatase inhibitor-associated arthralgia: A pilot study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.A.</ce:initials>
<ce:surname>Denysschen</ce:surname>
<ce:given-name>C.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Burton</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:surname>Ademuyiwa</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="4">
<ce:initials>E.</ce:initials>
<ce:surname>Levine</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Tetewsky</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="6">
<ce:initials>T.</ce:initials>
<ce:surname>O’Connor</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Cancer Care (Engl)</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>23</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>493</first-page>
<last-page>501</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>DeNysschen, C.A., Burton, H., Ademuyiwa, F., Levine, E., Tetewsky, S., O’Connor, T.: Exercise intervention in breast cancer patients with aromatase inhibitor-associated arthralgia: A pilot study. Eur. J. Cancer Care (Engl). 23, 493–501 (2014)</ref-fulltext>
<ce:source-text>DeNysschen, C.A., Burton, H., Ademuyiwa, F., Levine, E., Tetewsky, S., O’Connor, T.: Exercise intervention in breast cancer patients with aromatase inhibitor-associated arthralgia: A pilot study. Eur. J. Cancer Care (Engl). 23, 493–501 (2014)</ce:source-text>
</reference>
<reference seq="52">
<ref-info>
<ref-title>
<ref-titletext-english>Evaluation of a 12-week home-based walking intervention for breast cancer survivors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.E.</ce:initials>
<ce:surname>Matthews</ce:surname>
<ce:given-name>C.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Wilcox</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.L.</ce:initials>
<ce:surname>Hanby</ce:surname>
<ce:given-name>C.L.</ce:given-name>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>der Ananian</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="5">
<ce:initials>S.P.</ce:initials>
<ce:surname>Heiney</ce:surname>
<ce:given-name>S.P.</ce:given-name>
</author>
<author seq="6">
<ce:initials>T.</ce:initials>
<ce:surname>Gebretsadik</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="7">
<ce:initials>A.</ce:initials>
<ce:surname>Shintani</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Support Care Cancer</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>203</first-page>
<last-page>211</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Matthews, C.E., Wilcox, S., Hanby, C.L., Der Ananian, C., Heiney, S.P., Gebretsadik, T., Shintani, A.: Evaluation of a 12-week home-based walking intervention for breast cancer survivors. Support Care Cancer. 15, 203–211 (2007)</ref-fulltext>
<ce:source-text>Matthews, C.E., Wilcox, S., Hanby, C.L., Der Ananian, C., Heiney, S.P., Gebretsadik, T., Shintani, A.: Evaluation of a 12-week home-based walking intervention for breast cancer survivors. Support Care Cancer. 15, 203–211 (2007)</ce:source-text>
</reference>
<reference seq="53">
<ref-info>
<ref-title>
<ref-titletext-english>Effect of a vigorous aerobic regimen on physical performance in breast cancer patients – a randomized controlled pilot trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Nikander</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Sievanen</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.</ce:initials>
<ce:surname>Ojala</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Oivanen</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="5">
<ce:initials>P.L.</ce:initials>
<ce:surname>Kellokumpu-Lehtinen</ce:surname>
<ce:given-name>P.L.</ce:given-name>
</author>
<author seq="6">
<ce:initials>T.</ce:initials>
<ce:surname>Saarto</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Acta Oncol</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>46</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>181</first-page>
<last-page>186</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nikander, R., Sievanen, H., Ojala, K., Oivanen, T., Kellokumpu-Lehtinen, P.L., Saarto, T.: Effect of a vigorous aerobic regimen on physical performance in breast cancer patients – a randomized controlled pilot trial. Acta Oncol. 46, 181–186 (2007)</ref-fulltext>
<ce:source-text>Nikander, R., Sievanen, H., Ojala, K., Oivanen, T., Kellokumpu-Lehtinen, P.L., Saarto, T.: Effect of a vigorous aerobic regimen on physical performance in breast cancer patients – a randomized controlled pilot trial. Acta Oncol. 46, 181–186 (2007)</ce:source-text>
</reference>
<reference seq="54">
<ref-info>
<ref-title>
<ref-titletext-english>Effects of Tai Chi Chuan on insulin and cytokine levels in a randomized controlled pilot study on breast cancer survivors. Clin</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.C.</ce:initials>
<ce:surname>Janelsins</ce:surname>
<ce:given-name>M.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.G.</ce:initials>
<ce:surname>Davis</ce:surname>
<ce:given-name>P.G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:surname>Wideman</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.A.</ce:initials>
<ce:surname>Katula</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="5">
<ce:initials>L.K.</ce:initials>
<ce:surname>Sprod</ce:surname>
<ce:given-name>L.K.</ce:given-name>
</author>
<author seq="6">
<ce:initials>L.J.</ce:initials>
<ce:surname>Peppone</ce:surname>
<ce:given-name>L.J.</ce:given-name>
</author>
<author seq="7">
<ce:initials>O.G.</ce:initials>
<ce:surname>Palesh</ce:surname>
<ce:given-name>O.G.</ce:given-name>
</author>
<author seq="8">
<ce:initials>C.E.</ce:initials>
<ce:surname>Heckler</ce:surname>
<ce:given-name>C.E.</ce:given-name>
</author>
<author seq="9">
<ce:initials>J.P.</ce:initials>
<ce:surname>Williams</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
<author seq="10">
<ce:initials>G.R.</ce:initials>
<ce:surname>Morrow</ce:surname>
<ce:given-name>G.R.</ce:given-name>
</author>
<author seq="11">
<ce:initials>K.M.</ce:initials>
<ce:surname>Mustian</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Breast Cancer</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>161</first-page>
<last-page>170</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Janelsins, M.C., Davis, P.G., Wideman, L., Katula, J.A., Sprod, L.K., Peppone, L.J., Palesh, O.G., Heckler, C.E., Williams, J.P., Morrow, G.R., Mustian, K.M.: Effects of Tai Chi Chuan on insulin and cytokine levels in a randomized controlled pilot study on breast cancer survivors. Clin. Breast Cancer. 11, 161–170 (2011)</ref-fulltext>
<ce:source-text>Janelsins, M.C., Davis, P.G., Wideman, L., Katula, J.A., Sprod, L.K., Peppone, L.J., Palesh, O.G., Heckler, C.E., Williams, J.P., Morrow, G.R., Mustian, K.M.: Effects of Tai Chi Chuan on insulin and cytokine levels in a randomized controlled pilot study on breast cancer survivors. Clin. Breast Cancer. 11, 161–170 (2011)</ce:source-text>
</reference>
<reference seq="55">
<ref-info>
<ref-title>
<ref-titletext-english>Exercise improves body fat, lean mass, and bone mass in breast cancer survivors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.L.</ce:initials>
<ce:surname>Irwin</ce:surname>
<ce:given-name>M.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Alvarez-Reeves</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:surname>Cadmus</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="4">
<ce:initials>E.</ce:initials>
<ce:surname>Mierzejewski</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="5">
<ce:initials>S.T.</ce:initials>
<ce:surname>Mayne</ce:surname>
<ce:given-name>S.T.</ce:given-name>
</author>
<author seq="6">
<ce:initials>H.</ce:initials>
<ce:surname>Yu</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="7">
<ce:initials>G.G.</ce:initials>
<ce:surname>Chung</ce:surname>
<ce:given-name>G.G.</ce:given-name>
</author>
<author seq="8">
<ce:initials>B.</ce:initials>
<ce:surname>Jones</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="9">
<ce:initials>M.T.</ce:initials>
<ce:surname>Knobf</ce:surname>
<ce:given-name>M.T.</ce:given-name>
</author>
<author seq="10">
<ce:initials>L.</ce:initials>
<ce:surname>Dipietro</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Obesity (Silver Spring)</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1534</first-page>
<last-page>1541</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Irwin, M.L., Alvarez-Reeves, M., Cadmus, L., Mierzejewski, E., Mayne, S.T., Yu, H., Chung, G.G., Jones, B., Knobf, M.T., DiPietro, L.: Exercise improves body fat, lean mass, and bone mass in breast cancer survivors. Obesity (Silver Spring). 17, 1534–1541 (2009)</ref-fulltext>
<ce:source-text>Irwin, M.L., Alvarez-Reeves, M., Cadmus, L., Mierzejewski, E., Mayne, S.T., Yu, H., Chung, G.G., Jones, B., Knobf, M.T., DiPietro, L.: Exercise improves body fat, lean mass, and bone mass in breast cancer survivors. Obesity (Silver Spring). 17, 1534–1541 (2009)</ce:source-text>
</reference>
<reference seq="56">
<ref-info>
<ref-title>
<ref-titletext-english>A randomised controlled trial to evaluate the efficacy of a 6-month dietary and physical activity intervention for patients receiving androgen deprivation therapy for prostate cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.F.</ce:initials>
<ce:surname>O'neill</ce:surname>
<ce:given-name>R.F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Haseen</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.J.</ce:initials>
<ce:surname>Murray</ce:surname>
<ce:given-name>L.J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.M.</ce:initials>
<ce:surname>O'sullivan</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.M.</ce:initials>
<ce:surname>Cantwell</ce:surname>
<ce:given-name>M.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cancer Surviv</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>431</first-page>
<last-page>440</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>O'Neill, R.F., Haseen, F., Murray, L.J., O'Sullivan, J.M., Cantwell, M.M.: A randomised controlled trial to evaluate the efficacy of a 6-month dietary and physical activity intervention for patients receiving androgen deprivation therapy for prostate cancer. J. Cancer Surviv. 9, 431–440 (2015)</ref-fulltext>
<ce:source-text>O'Neill, R.F., Haseen, F., Murray, L.J., O'Sullivan, J.M., Cantwell, M.M.: A randomised controlled trial to evaluate the efficacy of a 6-month dietary and physical activity intervention for patients receiving androgen deprivation therapy for prostate cancer. J. Cancer Surviv. 9, 431–440 (2015)</ce:source-text>
</reference>
<reference seq="57">
<ref-info>
<ref-title>
<ref-titletext-english>Endurance training improves insulin sensitivity and body composition in prostate cancer patients treated with androgen deprivation therapy. Endocr. Relat</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Hvid</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Winding</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Rinnov</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Dejgaard</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="5">
<ce:initials>C.</ce:initials>
<ce:surname>Thomsen</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="6">
<ce:initials>P.</ce:initials>
<ce:surname>Iversen</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="7">
<ce:initials>K.</ce:initials>
<ce:surname>Brasso</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="8">
<ce:initials>K.J.</ce:initials>
<ce:surname>Mikines</ce:surname>
<ce:given-name>K.J.</ce:given-name>
</author>
<author seq="9">
<ce:initials>G.</ce:initials>
<ce:surname>van Hall</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="10">
<ce:initials>B.</ce:initials>
<ce:surname>Lindegaard</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="11">
<ce:initials>T.P.</ce:initials>
<ce:surname>Solomon</ce:surname>
<ce:given-name>T.P.</ce:given-name>
</author>
<author seq="12">
<ce:initials>B.K.</ce:initials>
<ce:surname>Pedersen</ce:surname>
<ce:given-name>B.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>621</first-page>
<last-page>632</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hvid, T., Winding, K., Rinnov, A., Dejgaard, T., Thomsen, C., Iversen, P., Brasso, K., Mikines, K.J., van Hall, G., Lindegaard, B., Solomon, T.P., Pedersen, B.K.: Endurance training improves insulin sensitivity and body composition in prostate cancer patients treated with androgen deprivation therapy. Endocr. Relat. Cancer. 20, 621–632 (2013)</ref-fulltext>
<ce:source-text>Hvid, T., Winding, K., Rinnov, A., Dejgaard, T., Thomsen, C., Iversen, P., Brasso, K., Mikines, K.J., van Hall, G., Lindegaard, B., Solomon, T.P., Pedersen, B.K.: Endurance training improves insulin sensitivity and body composition in prostate cancer patients treated with androgen deprivation therapy. Endocr. Relat. Cancer. 20, 621–632 (2013)</ce:source-text>
</reference>
<reference seq="58">
<ref-info>
<ref-title>
<ref-titletext-english>A prospective, multicenter pilot study to investigate the feasibility and safety of a 1-year controlled exercise training after adjuvant chemotherapy in colorectal cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Piringer</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Fridrik</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Fridrik</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Leiherer</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Zabernigg</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="6">
<ce:initials>R.</ce:initials>
<ce:surname>Greil</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="7">
<ce:initials>W.</ce:initials>
<ce:surname>Eisterer</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="8">
<ce:initials>J.</ce:initials>
<ce:surname>Tschmelitsch</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="9">
<ce:initials>A.</ce:initials>
<ce:surname>Lang</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="10">
<ce:initials>S.</ce:initials>
<ce:surname>Frantal</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="11">
<ce:initials>S.</ce:initials>
<ce:surname>Burgstaller</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="12">
<ce:initials>M.</ce:initials>
<ce:surname>Gnant</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="13">
<ce:initials>J.</ce:initials>
<ce:surname>Thaler</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="14">
<ce:initials>B.</ce:initials>
<ce:surname>Austrian</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="15">
<ce:initials>G.</ce:initials>
<ce:surname>Colorectal Cancer Study</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Support Care Cancer</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1345</first-page>
<last-page>1352</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Piringer, G., Fridrik, M., Fridrik, A., Leiherer, A., Zabernigg, A., Greil, R., Eisterer, W., Tschmelitsch, J., Lang, A., Frantal, S., Burgstaller, S., Gnant, M., Thaler, J., Austrian, B., Colorectal Cancer Study, G: A prospective, multicenter pilot study to investigate the feasibility and safety of a 1-year controlled exercise training after adjuvant chemotherapy in colorectal cancer patients. Support Care Cancer. 26, 1345–1352 (2018)</ref-fulltext>
<ce:source-text>Piringer, G., Fridrik, M., Fridrik, A., Leiherer, A., Zabernigg, A., Greil, R., Eisterer, W., Tschmelitsch, J., Lang, A., Frantal, S., Burgstaller, S., Gnant, M., Thaler, J., Austrian, B., Colorectal Cancer Study, G: A prospective, multicenter pilot study to investigate the feasibility and safety of a 1-year controlled exercise training after adjuvant chemotherapy in colorectal cancer patients. Support Care Cancer. 26, 1345–1352 (2018)</ce:source-text>
</reference>
<reference seq="59">
<ref-info>
<ref-title>
<ref-titletext-english>A walk-and-eat intervention improves outcomes for patients with esophageal cancer undergoing neoadjuvant chemoradiotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.J.</ce:initials>
<ce:surname>Xu</ce:surname>
<ce:given-name>Y.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.C.</ce:initials>
<ce:surname>Cheng</ce:surname>
<ce:given-name>J.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.M.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>P.M.</ce:initials>
<ce:surname>Huang</ce:surname>
<ce:given-name>P.M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>G.H.</ce:initials>
<ce:surname>Huang</ce:surname>
<ce:given-name>G.H.</ce:given-name>
</author>
<author seq="6">
<ce:initials>C.C.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>C.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncologist</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1216</first-page>
<last-page>1222</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xu, Y.J., Cheng, J.C., Lee, J.M., Huang, P.M., Huang, G.H., Chen, C.C.: A walk-and-eat intervention improves outcomes for patients with esophageal cancer undergoing neoadjuvant chemoradiotherapy. Oncologist. 20, 1216–1222 (2015)</ref-fulltext>
<ce:source-text>Xu, Y.J., Cheng, J.C., Lee, J.M., Huang, P.M., Huang, G.H., Chen, C.C.: A walk-and-eat intervention improves outcomes for patients with esophageal cancer undergoing neoadjuvant chemoradiotherapy. Oncologist. 20, 1216–1222 (2015)</ce:source-text>
</reference>
<reference seq="60">
<ref-info>
<ref-title>
<ref-titletext-english>Exercise-dependent regulation of NK cells in cancer protection. Trends Mol</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Idorn</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Hojman</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Med</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>22</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>565</first-page>
<last-page>577</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Idorn, M., Hojman, P.: Exercise-dependent regulation of NK cells in cancer protection. Trends Mol. Med. 22, 565–577 (2016)</ref-fulltext>
<ce:source-text>Idorn, M., Hojman, P.: Exercise-dependent regulation of NK cells in cancer protection. Trends Mol. Med. 22, 565–577 (2016)</ce:source-text>
</reference>
<reference seq="61">
<ref-info>
<ref-title>
<ref-titletext-english>The muscular system: The control of muscle mass</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Tsika</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Farrell, P.A., Joyner, M.J., Caiozzo, V.J</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<page-information>
<pages>
<first-page>152</first-page>
<last-page>170</last-page>
</pages>
</page-information>
</volisspag>
<ref-text>(eds.) ACSMs advanced exercise physiology, Lippincot Williams and Wilkens</ref-text>
</ref-info>
<ref-fulltext>Tsika, R.: The muscular system: The control of muscle mass. In: Farrell, P.A., Joyner, M.J., Caiozzo, V.J. (eds.) ACSMs advanced exercise physiology, pp. 152–170. Lippincot Williams and Wilkens (2012)</ref-fulltext>
<ce:source-text>Tsika, R.: The muscular system: The control of muscle mass. In: Farrell, P.A., Joyner, M.J., Caiozzo, V.J. (eds.) ACSMs advanced exercise physiology, pp. 152–170. Lippincot Williams and Wilkens (2012)</ce:source-text>
</reference>
<reference seq="62">
<ref-info>
<ref-title>
<ref-titletext-english>Adaptations to anaerobic training programs</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>French</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Essentials of Strength Training and Conditioning</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<page-information>
<pages>
<first-page>87</first-page>
<last-page>113</last-page>
</pages>
</page-information>
</volisspag>
<ref-text>Haff, G.G., Triplett, N.T. (eds.), Human Kinetics, Illinois</ref-text>
</ref-info>
<ref-fulltext>French, D.: Adaptations to anaerobic training programs. In: Haff, G.G., Triplett, N.T. (eds.) Essentials of strength training and conditioning, pp. 87–113. Human Kinetics, Illinois (2016)</ref-fulltext>
<ce:source-text>French, D.: Adaptations to anaerobic training programs. In: Haff, G.G., Triplett, N.T. (eds.) Essentials of strength training and conditioning, pp. 87–113. Human Kinetics, Illinois (2016)</ce:source-text>
</reference>
<reference seq="63">
<ref-info>
<ref-title>
<ref-titletext-english>Resistance exercise in men receiving androgen deprivation therapy for prostate cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.J.</ce:initials>
<ce:surname>Segal</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.D.</ce:initials>
<ce:surname>Reid</ce:surname>
<ce:given-name>R.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.S.</ce:initials>
<ce:surname>Courneya</ce:surname>
<ce:given-name>K.S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.C.</ce:initials>
<ce:surname>Malone</ce:surname>
<ce:given-name>S.C.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.B.</ce:initials>
<ce:surname>Parliament</ce:surname>
<ce:given-name>M.B.</ce:given-name>
</author>
<author seq="6">
<ce:initials>C.G.</ce:initials>
<ce:surname>Scott</ce:surname>
<ce:given-name>C.G.</ce:given-name>
</author>
<author seq="7">
<ce:initials>P.M.</ce:initials>
<ce:surname>Venner</ce:surname>
<ce:given-name>P.M.</ce:given-name>
</author>
<author seq="8">
<ce:initials>H.A.</ce:initials>
<ce:surname>Quinney</ce:surname>
<ce:given-name>H.A.</ce:given-name>
</author>
<author seq="9">
<ce:initials>L.W.</ce:initials>
<ce:surname>Jones</ce:surname>
<ce:given-name>L.W.</ce:given-name>
</author>
<author seq="10">
<ce:initials>M.E.</ce:initials>
<ce:surname>D'angelo</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
<author seq="11">
<ce:initials>G.A.</ce:initials>
<ce:surname>Wells</ce:surname>
<ce:given-name>G.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2003" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1653</first-page>
<last-page>1659</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Segal, R.J., Reid, R.D., Courneya, K.S., Malone, S.C., Parliament, M.B., Scott, C.G., Venner, P.M., Quinney, H.A., Jones, L.W., D'Angelo, M.E., Wells, G.A.: Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J. Clin. Oncol. 21, 1653–1659 (2003)</ref-fulltext>
<ce:source-text>Segal, R.J., Reid, R.D., Courneya, K.S., Malone, S.C., Parliament, M.B., Scott, C.G., Venner, P.M., Quinney, H.A., Jones, L.W., D'Angelo, M.E., Wells, G.A.: Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J. Clin. Oncol. 21, 1653–1659 (2003)</ce:source-text>
</reference>
<reference seq="64">
<ref-info>
<ref-title>
<ref-titletext-english>Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: A randomized controlled trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.A.</ce:initials>
<ce:surname>Galvao</ce:surname>
<ce:given-name>D.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.R.</ce:initials>
<ce:surname>Taaffe</ce:surname>
<ce:given-name>D.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Spry</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="4">
<ce:initials>D.</ce:initials>
<ce:surname>Joseph</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="5">
<ce:initials>R.U.</ce:initials>
<ce:surname>Newton</ce:surname>
<ce:given-name>R.U.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>340</first-page>
<last-page>347</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Galvao, D.A., Taaffe, D.R., Spry, N., Joseph, D., Newton, R.U.: Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: A randomized controlled trial. J. Clin. Oncol. 28, 340–347 (2010)</ref-fulltext>
<ce:source-text>Galvao, D.A., Taaffe, D.R., Spry, N., Joseph, D., Newton, R.U.: Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: A randomized controlled trial. J. Clin. Oncol. 28, 340–347 (2010)</ce:source-text>
</reference>
<reference seq="65">
<ref-info>
<ref-title>
<ref-titletext-english>Exercise improves V O2max and body composition in androgen deprivation therapy-treated prostate cancer patients. Med. Sci</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.A.</ce:initials>
<ce:surname>Wall</ce:surname>
<ce:given-name>B.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.A.</ce:initials>
<ce:surname>Galvão</ce:surname>
<ce:given-name>D.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Fatehee</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="4">
<ce:initials>D.R.</ce:initials>
<ce:surname>Taaffe</ce:surname>
<ce:given-name>D.R.</ce:given-name>
</author>
<author seq="5">
<ce:initials>N.</ce:initials>
<ce:surname>Spry</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="6">
<ce:initials>D.</ce:initials>
<ce:surname>Joseph</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="7">
<ce:initials>J.J.</ce:initials>
<ce:surname>Hebert</ce:surname>
<ce:given-name>J.J.</ce:given-name>
</author>
<author seq="8">
<ce:initials>R.U.</ce:initials>
<ce:surname>Newton</ce:surname>
<ce:given-name>R.U.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sports Exerc</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>49</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1503</first-page>
<last-page>1510</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wall, B.A., Galvão, D.A., Fatehee, N., Taaffe, D.R., Spry, N., Joseph, D., Hebert, J.J., Newton, R.U.: Exercise improves V O2max and body composition in androgen deprivation therapy-treated prostate cancer patients. Med. Sci. Sports Exerc. 49, 1503–1510 (2017)</ref-fulltext>
<ce:source-text>Wall, B.A., Galvão, D.A., Fatehee, N., Taaffe, D.R., Spry, N., Joseph, D., Hebert, J.J., Newton, R.U.: Exercise improves V O2max and body composition in androgen deprivation therapy-treated prostate cancer patients. Med. Sci. Sports Exerc. 49, 1503–1510 (2017)</ce:source-text>
</reference>
<reference seq="66">
<ref-info>
<ref-title>
<ref-titletext-english>Combined aerobic and resistance training in breast cancer survivors: A randomized, controlled pilot trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Herrero</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.F.</ce:initials>
<ce:surname>San Juan</ce:surname>
<ce:given-name>A.F.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.J.</ce:initials>
<ce:surname>Fleck</ce:surname>
<ce:given-name>S.J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Balmer</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Perez</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>Canete</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="7">
<ce:initials>C.P.</ce:initials>
<ce:surname>Earnest</ce:surname>
<ce:given-name>C.P.</ce:given-name>
</author>
<author seq="8">
<ce:initials>C.</ce:initials>
<ce:surname>Foster</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="9">
<ce:initials>A.</ce:initials>
<ce:surname>Lucia</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Sports Med</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>573</first-page>
<last-page>580</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Herrero, F., San Juan, A.F., Fleck, S.J., Balmer, J., Perez, M., Canete, S., Earnest, C.P., Foster, C., Lucia, A.: Combined aerobic and resistance training in breast cancer survivors: A randomized, controlled pilot trial. Int. J. Sports Med. 27, 573–580 (2006)</ref-fulltext>
<ce:source-text>Herrero, F., San Juan, A.F., Fleck, S.J., Balmer, J., Perez, M., Canete, S., Earnest, C.P., Foster, C., Lucia, A.: Combined aerobic and resistance training in breast cancer survivors: A randomized, controlled pilot trial. Int. J. Sports Med. 27, 573–580 (2006)</ce:source-text>
</reference>
<reference seq="67">
<ref-info>
<ref-title>
<ref-titletext-english>The effects of an individualized exercise intervention on body composition in breast cancer patients undergoing treatment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Battaglini</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Bottaro</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Dennehy</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>L.</ce:initials>
<ce:surname>Rae</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="5">
<ce:initials>E.</ce:initials>
<ce:surname>Shields</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="6">
<ce:initials>D.</ce:initials>
<ce:surname>Kirk</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="7">
<ce:initials>A.C.</ce:initials>
<ce:surname>Hackney</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sao Paulo Med. J</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>125</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>22</first-page>
<last-page>28</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Battaglini, C., Bottaro, M., Dennehy, C., Rae, L., Shields, E., Kirk, D., Hackney, A.C.: The effects of an individualized exercise intervention on body composition in breast cancer patients undergoing treatment. Sao Paulo Med. J. 125, 22–28 (2007)</ref-fulltext>
<ce:source-text>Battaglini, C., Bottaro, M., Dennehy, C., Rae, L., Shields, E., Kirk, D., Hackney, A.C.: The effects of an individualized exercise intervention on body composition in breast cancer patients undergoing treatment. Sao Paulo Med. J. 125, 22–28 (2007)</ce:source-text>
</reference>
<reference seq="68">
<ref-info>
<ref-title>
<ref-titletext-english>Effects of exercise dose and type during breast cancer chemotherapy: Multicenter randomized trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.S.</ce:initials>
<ce:surname>Courneya</ce:surname>
<ce:given-name>K.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.C.</ce:initials>
<ce:surname>McKenzie</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.R.</ce:initials>
<ce:surname>Mackey</ce:surname>
<ce:given-name>J.R.</ce:given-name>
</author>
<author seq="4">
<ce:initials>K.</ce:initials>
<ce:surname>Gelmon</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="5">
<ce:initials>C.M.</ce:initials>
<ce:surname>Friedenreich</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
<author seq="6">
<ce:initials>Y.</ce:initials>
<ce:surname>Yasui</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="7">
<ce:initials>R.D.</ce:initials>
<ce:surname>Reid</ce:surname>
<ce:given-name>R.D.</ce:given-name>
</author>
<author seq="8">
<ce:initials>D.</ce:initials>
<ce:surname>Cook</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="9">
<ce:initials>D.</ce:initials>
<ce:surname>Jespersen</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="10">
<ce:initials>C.</ce:initials>
<ce:surname>Proulx</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="11">
<ce:initials>L.B.</ce:initials>
<ce:surname>Dolan</ce:surname>
<ce:given-name>L.B.</ce:given-name>
</author>
<author seq="12">
<ce:initials>C.C.</ce:initials>
<ce:surname>Forbes</ce:surname>
<ce:given-name>C.C.</ce:given-name>
</author>
<author seq="13">
<ce:initials>E.</ce:initials>
<ce:surname>Wooding</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="14">
<ce:initials>L.</ce:initials>
<ce:surname>Trinh</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="15">
<ce:initials>R.J.</ce:initials>
<ce:surname>Segal</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Natl. Cancer Inst</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>105</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1821</first-page>
<last-page>1832</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Courneya, K.S., McKenzie, D.C., Mackey, J.R., Gelmon, K., Friedenreich, C.M., Yasui, Y., Reid, R.D., Cook, D., Jespersen, D., Proulx, C., Dolan, L.B., Forbes, C.C., Wooding, E., Trinh, L., Segal, R.J.: Effects of exercise dose and type during breast cancer chemotherapy: multicenter randomized trial. J. Natl. Cancer Inst. 105, 1821–1832 (2013)</ref-fulltext>
<ce:source-text>Courneya, K.S., McKenzie, D.C., Mackey, J.R., Gelmon, K., Friedenreich, C.M., Yasui, Y., Reid, R.D., Cook, D., Jespersen, D., Proulx, C., Dolan, L.B., Forbes, C.C., Wooding, E., Trinh, L., Segal, R.J.: Effects of exercise dose and type during breast cancer chemotherapy: multicenter randomized trial. J. Natl. Cancer Inst. 105, 1821–1832 (2013)</ce:source-text>
</reference>
<reference seq="69">
<ref-info>
<ref-title>
<ref-titletext-english>A pilot study of group exercise training (GET) for women with primary breast cancer: Feasibility and health benefits</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.G.</ce:initials>
<ce:surname>Kolden</ce:surname>
<ce:given-name>G.G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.J.</ce:initials>
<ce:surname>Strauman</ce:surname>
<ce:given-name>T.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Ward</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Kuta</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="5">
<ce:initials>T.E.</ce:initials>
<ce:surname>Woods</ce:surname>
<ce:given-name>T.E.</ce:given-name>
</author>
<author seq="6">
<ce:initials>K.L.</ce:initials>
<ce:surname>Schneider</ce:surname>
<ce:given-name>K.L.</ce:given-name>
</author>
<author seq="7">
<ce:initials>E.</ce:initials>
<ce:surname>Heerey</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="8">
<ce:initials>L.</ce:initials>
<ce:surname>Sanborn</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="9">
<ce:initials>C.</ce:initials>
<ce:surname>Burt</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="10">
<ce:initials>L.</ce:initials>
<ce:surname>Millbrandt</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="11">
<ce:initials>N.H.</ce:initials>
<ce:surname>Kalin</ce:surname>
<ce:given-name>N.H.</ce:given-name>
</author>
<author seq="12">
<ce:initials>J.A.</ce:initials>
<ce:surname>Stewart</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="13">
<ce:initials>B.</ce:initials>
<ce:surname>Mullen</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Psychooncology</ref-sourcetitle>
<ref-publicationyear first="2002" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>447</first-page>
<last-page>456</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kolden, G.G., Strauman, T.J., Ward, A., Kuta, J., Woods, T.E., Schneider, K.L., Heerey, E., Sanborn, L., Burt, C., Millbrandt, L., Kalin, N.H., Stewart, J.A., Mullen, B.: A pilot study of group exercise training (GET) for women with primary breast cancer: feasibility and health benefits. Psychooncology. 11, 447–456 (2002)</ref-fulltext>
<ce:source-text>Kolden, G.G., Strauman, T.J., Ward, A., Kuta, J., Woods, T.E., Schneider, K.L., Heerey, E., Sanborn, L., Burt, C., Millbrandt, L., Kalin, N.H., Stewart, J.A., Mullen, B.: A pilot study of group exercise training (GET) for women with primary breast cancer: feasibility and health benefits. Psychooncology. 11, 447–456 (2002)</ce:source-text>
</reference>
<reference seq="70">
<ref-info>
<ref-title>
<ref-titletext-english>Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: A multicenter randomized controlled trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.S.</ce:initials>
<ce:surname>Courneya</ce:surname>
<ce:given-name>K.S.</ce:given-name><ce:givenname>K.S.</ce:givenname>
</author>
<author seq="2">
<ce:initials>R.J.</ce:initials>
<ce:surname>Segal</ce:surname>
<ce:given-name>R.J.</ce:given-name><ce:givenname>R.J.</ce:givenname>
</author>
<author seq="3">
<ce:initials>J.R.</ce:initials>
<ce:surname>Mackey</ce:surname>
<ce:given-name>J.R.</ce:given-name><ce:givenname>J.R.</ce:givenname>
</author>
<author seq="4">
<ce:initials>K.</ce:initials>
<ce:surname>Gelmon</ce:surname>
<ce:given-name>K.</ce:given-name><ce:givenname>K.</ce:givenname>
</author>
<author seq="5">
<ce:initials>R.D.</ce:initials>
<ce:surname>Reid</ce:surname>
<ce:given-name>R.D.</ce:given-name><ce:givenname>R.D.</ce:givenname>
</author>
<author seq="6">
<ce:initials>C.M.</ce:initials>
<ce:surname>Friedenreich</ce:surname>
<ce:given-name>C.M.</ce:given-name><ce:givenname>C.M.</ce:givenname>
</author>
<author seq="7">
<ce:initials>A.B.</ce:initials>
<ce:surname>Ladha</ce:surname>
<ce:given-name>A.B.</ce:given-name><ce:givenname>A.B.</ce:givenname>
</author>
<author seq="8">
<ce:initials>C.</ce:initials>
<ce:surname>Proulx</ce:surname>
<ce:given-name>C.</ce:given-name><ce:givenname>C.</ce:givenname>
</author>
<author seq="9">
<ce:initials>J.K.</ce:initials>
<ce:surname>Vallance</ce:surname>
<ce:given-name>J.K.</ce:given-name><ce:givenname>J.K.</ce:givenname>
</author>
<author seq="10">
<ce:initials>K.</ce:initials>
<ce:surname>Lane</ce:surname>
<ce:given-name>K.</ce:given-name><ce:givenname>K.</ce:givenname>
</author>
<author seq="11">
<ce:initials>Y.</ce:initials>
<ce:surname>Yasui</ce:surname>
<ce:given-name>Y.</ce:given-name><ce:givenname>Y.</ce:givenname>
</author>
<author seq="12">
<ce:initials>D.C.</ce:initials>
<ce:surname>McKenzie</ce:surname>
<ce:given-name>D.C.</ce:given-name><ce:givenname>D.C.</ce:givenname>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>25</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4396</first-page>
<last-page>4404</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Courneya, K.S., Segal, R.J., Mackey, J.R., Gelmon, K., Reid, R.D., Friedenreich, C.M., Ladha, A.B., Proulx, C., Vallance, J.K., Lane, K., Yasui, Y., McKenzie, D.C.: Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: A multicenter randomized controlled trial. J. Clin. Oncol. 25, 4396–4404 (2007)</ref-fulltext>
<ce:source-text>Courneya, K.S., Segal, R.J., Mackey, J.R., Gelmon, K., Reid, R.D., Friedenreich, C.M., Ladha, A.B., Proulx, C., Vallance, J.K., Lane, K., Yasui, Y., McKenzie, D.C.: Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: A multicenter randomized controlled trial. J. Clin. Oncol. 25, 4396–4404 (2007)</ce:source-text>
</reference>
<reference seq="71">
<ref-info>
<ref-title>
<ref-titletext-english>Effects of resistance exercise on fatigue and quality of life in breast cancer patients undergoing adjuvant chemotherapy: A randomized controlled trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.E.</ce:initials>
<ce:surname>Schmidt</ce:surname>
<ce:given-name>M.E.</ce:given-name><ce:givenname>M.E.</ce:givenname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Wiskemann</ce:surname>
<ce:given-name>J.</ce:given-name><ce:givenname>J.</ce:givenname>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Armbrust</ce:surname>
<ce:given-name>P.</ce:given-name><ce:givenname>P.</ce:givenname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Schneeweiss</ce:surname>
<ce:given-name>A.</ce:given-name><ce:givenname>A.</ce:givenname>
</author>
<author seq="5">
<ce:initials>C.M.</ce:initials>
<ce:surname>Ulrich</ce:surname>
<ce:given-name>C.M.</ce:given-name><ce:givenname>C.M.</ce:givenname>
</author>
<author seq="6">
<ce:initials>K.</ce:initials>
<ce:surname>Steindorf</ce:surname>
<ce:given-name>K.</ce:given-name><ce:givenname>K.</ce:givenname>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>137</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>471</first-page>
<last-page>480</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Schmidt, M.E., Wiskemann, J., Armbrust, P., Schneeweiss, A., Ulrich, C.M., Steindorf, K.: Effects of resistance exercise on fatigue and quality of life in breast cancer patients undergoing adjuvant chemotherapy: A randomized controlled trial. Int. J. Cancer. 137, 471–480 (2015)</ref-fulltext>
<ce:source-text>Schmidt, M.E., Wiskemann, J., Armbrust, P., Schneeweiss, A., Ulrich, C.M., Steindorf, K.: Effects of resistance exercise on fatigue and quality of life in breast cancer patients undergoing adjuvant chemotherapy: A randomized controlled trial. Int. J. Cancer. 137, 471–480 (2015)</ce:source-text>
</reference>
<reference seq="72">
<ref-info>
<ref-title>
<ref-titletext-english>Randomized, controlled trial of resistance training in breast cancer patients receiving adjuvant radiotherapy: Results on cancer-related fatigue and quality of life</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Steindorf</ce:surname>
<ce:given-name>K.</ce:given-name><ce:givenname>K.</ce:givenname>
</author>
<author seq="2">
<ce:initials>M.E.</ce:initials>
<ce:surname>Schmidt</ce:surname>
<ce:given-name>M.E.</ce:given-name><ce:givenname>M.E.</ce:givenname>
</author>
<author seq="3">
<ce:initials>O.</ce:initials>
<ce:surname>Klassen</ce:surname>
<ce:given-name>O.</ce:given-name><ce:givenname>O.</ce:givenname>
</author>
<author seq="4">
<ce:initials>C.M.</ce:initials>
<ce:surname>Ulrich</ce:surname>
<ce:given-name>C.M.</ce:given-name><ce:givenname>C.M.</ce:givenname>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Oelmann</ce:surname>
<ce:given-name>J.</ce:given-name><ce:givenname>J.</ce:givenname>
</author>
<author seq="6">
<ce:initials>N.</ce:initials>
<ce:surname>Habermann</ce:surname>
<ce:given-name>N.</ce:given-name><ce:givenname>N.</ce:givenname>
</author>
<author seq="7">
<ce:initials>P.</ce:initials>
<ce:surname>Beckhove</ce:surname>
<ce:given-name>P.</ce:given-name><ce:givenname>P.</ce:givenname>
</author>
<author seq="8">
<ce:initials>R.</ce:initials>
<ce:surname>Owen</ce:surname>
<ce:given-name>R.</ce:given-name><ce:givenname>R.</ce:givenname>
</author>
<author seq="9">
<ce:initials>J.</ce:initials>
<ce:surname>Debus</ce:surname>
<ce:given-name>J.</ce:given-name><ce:givenname>J.</ce:givenname>
</author>
<author seq="10">
<ce:initials>J.</ce:initials>
<ce:surname>Wiskemann</ce:surname>
<ce:given-name>J.</ce:given-name><ce:givenname>J.</ce:givenname>
</author>
<author seq="11">
<ce:initials>K.</ce:initials>
<ce:surname>Potthoff</ce:surname>
<ce:given-name>K.</ce:given-name><ce:givenname>K.</ce:givenname>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Oncol</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>25</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2237</first-page>
<last-page>2243</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Steindorf, K., Schmidt, M.E., Klassen, O., Ulrich, C.M., Oelmann, J., Habermann, N., Beckhove, P., Owen, R., Debus, J., Wiskemann, J., Potthoff, K.: Randomized, controlled trial of resistance training in breast cancer patients receiving adjuvant radiotherapy: results on cancer-related fatigue and quality of life. Ann. Oncol. 25, 2237–2243 (2014)</ref-fulltext>
<ce:source-text>Steindorf, K., Schmidt, M.E., Klassen, O., Ulrich, C.M., Oelmann, J., Habermann, N., Beckhove, P., Owen, R., Debus, J., Wiskemann, J., Potthoff, K.: Randomized, controlled trial of resistance training in breast cancer patients receiving adjuvant radiotherapy: results on cancer-related fatigue and quality of life. Ann. Oncol. 25, 2237–2243 (2014)</ce:source-text>
</reference>
<reference seq="73">
<ref-info>
<ref-title>
<ref-titletext-english>Effect of a multimodal high intensity exercise intervention in cancer patients undergoing chemotherapy: Randomised controlled trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Adamsen</ce:surname>
<ce:given-name>L.</ce:given-name><ce:givenname>L.</ce:givenname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Quist</ce:surname>
<ce:given-name>M.</ce:given-name><ce:givenname>M.</ce:givenname>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Andersen</ce:surname>
<ce:given-name>C.</ce:given-name><ce:givenname>C.</ce:givenname>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Moller</ce:surname>
<ce:given-name>T.</ce:given-name><ce:givenname>T.</ce:givenname>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Herrstedt</ce:surname>
<ce:given-name>J.</ce:given-name><ce:givenname>J.</ce:givenname>
</author>
<author seq="6">
<ce:initials>D.</ce:initials>
<ce:surname>Kronborg</ce:surname>
<ce:given-name>D.</ce:given-name><ce:givenname>D.</ce:givenname>
</author>
<author seq="7">
<ce:initials>M.T.</ce:initials>
<ce:surname>Baadsgaard</ce:surname>
<ce:given-name>M.T.</ce:given-name><ce:givenname>M.T.</ce:givenname>
</author>
<author seq="8">
<ce:initials>K.</ce:initials>
<ce:surname>Vistisen</ce:surname>
<ce:given-name>K.</ce:given-name><ce:givenname>K.</ce:givenname>
</author>
<author seq="9">
<ce:initials>J.</ce:initials>
<ce:surname>Midtgaard</ce:surname>
<ce:given-name>J.</ce:given-name><ce:givenname>J.</ce:givenname>
</author>
<author seq="10">
<ce:initials>B.</ce:initials>
<ce:surname>Christiansen</ce:surname>
<ce:given-name>B.</ce:given-name><ce:givenname>B.</ce:givenname>
</author>
<author seq="11">
<ce:initials>M.</ce:initials>
<ce:surname>Stage</ce:surname>
<ce:given-name>M.</ce:given-name><ce:givenname>M.</ce:givenname>
</author>
<author seq="12">
<ce:initials>M.T.</ce:initials>
<ce:surname>Kronborg</ce:surname>
<ce:given-name>M.T.</ce:given-name><ce:givenname>M.T.</ce:givenname>
</author>
<author seq="13">
<ce:initials>M.</ce:initials>
<ce:surname>Rorth</ce:surname>
<ce:given-name>M.</ce:given-name><ce:givenname>M.</ce:givenname>
</author>
</ref-authors>
<ref-sourcetitle>BMJ</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-text>b3410</vol-text>
</volume-issue-number>
<page-information>
<pages>
<first-page>339</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Adamsen, L., Quist, M., Andersen, C., Moller, T., Herrstedt, J., Kronborg, D., Baadsgaard, M.T., Vistisen, K., Midtgaard, J., Christiansen, B., Stage, M., Kronborg, M.T., Rorth, M.: Effect of a multimodal high intensity exercise intervention in cancer patients undergoing chemotherapy: randomised controlled trial. BMJ. 339, b3410 (2009)</ref-fulltext>
<ce:source-text>Adamsen, L., Quist, M., Andersen, C., Moller, T., Herrstedt, J., Kronborg, D., Baadsgaard, M.T., Vistisen, K., Midtgaard, J., Christiansen, B., Stage, M., Kronborg, M.T., Rorth, M.: Effect of a multimodal high intensity exercise intervention in cancer patients undergoing chemotherapy: randomised controlled trial. BMJ. 339, b3410 (2009)</ce:source-text>
</reference>
<reference seq="74">
<ref-info>
<ref-title>
<ref-titletext-english>The pathophysiology of lymphedema</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.S.</ce:initials>
<ce:surname>Mortimer</ce:surname>
<ce:given-name>P.S.</ce:given-name><ce:givenname>P.S.</ce:givenname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer</ref-sourcetitle>
<ref-publicationyear first="1998" />
<volisspag>
<volume-issue-number>
<vol-first>83</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2798</first-page>
<last-page>2802</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mortimer, P.S.: The pathophysiology of lymphedema. Cancer. 83, 2798–2802 (1998)</ref-fulltext>
<ce:source-text>Mortimer, P.S.: The pathophysiology of lymphedema. Cancer. 83, 2798–2802 (1998)</ce:source-text>
</reference>
<reference seq="75">
<ref-info>
<ref-title>
<ref-titletext-english>Breast cancer-related lymphedema and resistance exercise: A systematic review</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.L.</ce:initials>
<ce:surname>Nelson</ce:surname>
<ce:given-name>N.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Strength Cond. Res</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2656</first-page>
<last-page>2665</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nelson, N.L.: Breast cancer-related lymphedema and resistance exercise: A systematic review. J. Strength Cond. Res. 30, 2656–2665 (2016)</ref-fulltext>
<ce:source-text>Nelson, N.L.: Breast cancer-related lymphedema and resistance exercise: A systematic review. J. Strength Cond. Res. 30, 2656–2665 (2016)</ce:source-text>
</reference>
<reference seq="76">
<ref-info>
<ref-title>
<ref-titletext-english>Physiologic aspects of lymphatic contractile function: Current perspectives</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>A.A.</ce:initials>
<ce:surname>Gashev</ce:surname>
<ce:given-name>A.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ann. N. Y. Acad. Sci.</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>979</vol-first>
</volume-issue-number>
<page-information>
<pages>
<page-text>178–87, 188–96</page-text>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gashev, A.A.: Physiologic aspects of lymphatic contractile function: Current perspectives. Ann. N. Y. Acad. Sci. 979, 178–87 (2002); discussion 188–96</ref-fulltext>
<ce:source-text>Gashev, A.A.: Physiologic aspects of lymphatic contractile function: Current perspectives. Ann. N. Y. Acad. Sci. 979, 178–87 (2002); discussion 188–96</ce:source-text>
</reference>
<reference seq="77">
<ref-info>
<ref-title>
<ref-titletext-english>Randomized controlled trial of weight training and lymphedema in breast cancer survivors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.L.</ce:initials>
<ce:surname>Ahmed</ce:surname>
<ce:given-name>R.L.</ce:given-name><ce:givenname>R.L.</ce:givenname>
</author>
<author seq="2">
<ce:initials>W.</ce:initials>
<ce:surname>Thomas</ce:surname>
<ce:given-name>W.</ce:given-name><ce:givenname>W.</ce:givenname>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Yee</ce:surname>
<ce:given-name>D.</ce:given-name><ce:givenname>D.</ce:givenname>
</author>
<author seq="4">
<ce:initials>K.H.</ce:initials>
<ce:surname>Schmitz</ce:surname>
<ce:given-name>K.H.</ce:given-name><ce:givenname>K.H.</ce:givenname>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2765</first-page>
<last-page>2772</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ahmed, R.L., Thomas, W., Yee, D., Schmitz, K.H.: Randomized controlled trial of weight training and lymphedema in breast cancer survivors. J. Clin. Oncol. 24, 2765–2772 (2006)</ref-fulltext>
<ce:source-text>Ahmed, R.L., Thomas, W., Yee, D., Schmitz, K.H.: Randomized controlled trial of weight training and lymphedema in breast cancer survivors. J. Clin. Oncol. 24, 2765–2772 (2006)</ce:source-text>
</reference>
<reference seq="78">
<ref-info>
<ref-title>
<ref-titletext-english>Weight lifting in women with breast-cancer-related lymphedema</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.H.</ce:initials>
<ce:surname>Schmitz</ce:surname>
<ce:given-name>K.H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.L.</ce:initials>
<ce:surname>Ahmed</ce:surname>
<ce:given-name>R.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Troxel</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Cheville</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="5">
<ce:initials>R.</ce:initials>
<ce:surname>Smith</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="6">
<ce:initials>L.</ce:initials>
<ce:surname>Lewis-Grant</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="7">
<ce:initials>C.J.</ce:initials>
<ce:surname>Bryan</ce:surname>
<ce:given-name>C.J.</ce:given-name>
</author>
<author seq="8">
<ce:initials>C.T.</ce:initials>
<ce:surname>Williams-Smith</ce:surname>
<ce:given-name>C.T.</ce:given-name>
</author>
<author seq="9">
<ce:initials>Q.P.</ce:initials>
<ce:surname>Greene</ce:surname>
<ce:given-name>Q.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>N. Engl. J. Med</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>361</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>664</first-page>
<last-page>673</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Schmitz, K.H., Ahmed, R.L., Troxel, A., Cheville, A., Smith, R., Lewis-Grant, L., Bryan, C.J., Williams-Smith, C.T., Greene, Q.P.: Weight lifting in women with breast-cancer-related lymphedema. N. Engl. J. Med. 361, 664–673 (2009)</ref-fulltext>
<ce:source-text>Schmitz, K.H., Ahmed, R.L., Troxel, A., Cheville, A., Smith, R., Lewis-Grant, L., Bryan, C.J., Williams-Smith, C.T., Greene, Q.P.: Weight lifting in women with breast-cancer-related lymphedema. N. Engl. J. Med. 361, 664–673 (2009)</ce:source-text>
</reference>
<reference seq="79">
<ref-info>
<ref-title>
<ref-titletext-english>Weight lifting for women at risk for breast cancer-related lymphedema: A randomized trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.H.</ce:initials>
<ce:surname>Schmitz</ce:surname>
<ce:given-name>K.H.</ce:given-name><ce:givenname>K.H.</ce:givenname>
</author>
<author seq="2">
<ce:initials>R.L.</ce:initials>
<ce:surname>Ahmed</ce:surname>
<ce:given-name>R.L.</ce:given-name><ce:givenname>R.L.</ce:givenname>
</author>
<author seq="3">
<ce:initials>A.B.</ce:initials>
<ce:surname>Troxel</ce:surname>
<ce:given-name>A.B.</ce:given-name><ce:givenname>A.B.</ce:givenname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Cheville</ce:surname>
<ce:given-name>A.</ce:given-name><ce:givenname>A.</ce:givenname>
</author>
<author seq="5">
<ce:initials>L.</ce:initials>
<ce:surname>Lewis-Grant</ce:surname>
<ce:given-name>L.</ce:given-name><ce:givenname>L.</ce:givenname>
</author>
<author seq="6">
<ce:initials>R.</ce:initials>
<ce:surname>Smith</ce:surname>
<ce:given-name>R.</ce:given-name><ce:givenname>R.</ce:givenname>
</author>
<author seq="7">
<ce:initials>C.J.</ce:initials>
<ce:surname>Bryan</ce:surname>
<ce:given-name>C.J.</ce:given-name><ce:givenname>C.J.</ce:givenname>
</author>
<author seq="8">
<ce:initials>C.T.</ce:initials>
<ce:surname>Williams-Smith</ce:surname>
<ce:given-name>C.T.</ce:given-name><ce:givenname>C.T.</ce:givenname>
</author>
<author seq="9">
<ce:initials>J.</ce:initials>
<ce:surname>Chittams</ce:surname>
<ce:given-name>J.</ce:given-name><ce:givenname>J.</ce:givenname>
</author>
</ref-authors>
<ref-sourcetitle>JAMA</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>304</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2699</first-page>
<last-page>2705</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Schmitz, K.H., Ahmed, R.L., Troxel, A.B., Cheville, A., Lewis-Grant, L., Smith, R., Bryan, C.J., Williams-Smith, C.T., Chittams, J.: Weight lifting for women at risk for breast cancer-related lymphedema: A randomized trial. JAMA. 304, 2699–2705 (2010)</ref-fulltext>
<ce:source-text>Schmitz, K.H., Ahmed, R.L., Troxel, A.B., Cheville, A., Lewis-Grant, L., Smith, R., Bryan, C.J., Williams-Smith, C.T., Chittams, J.: Weight lifting for women at risk for breast cancer-related lymphedema: A randomized trial. JAMA. 304, 2699–2705 (2010)</ce:source-text>
</reference>
<reference seq="80">
<ref-info>
<ref-title>
<ref-titletext-english>Obesity is a risk factor for developing postoperative lymphedema in breast cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.K.</ce:initials>
<ce:surname>Helyer</ce:surname>
<ce:given-name>L.K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Varnic</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.W.</ce:initials>
<ce:surname>Le</ce:surname>
<ce:given-name>L.W.</ce:given-name>
</author>
<author seq="4">
<ce:initials>W.</ce:initials>
<ce:surname>Leong</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="5">
<ce:initials>D.</ce:initials>
<ce:surname>McCready</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Breast J.</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>48</first-page>
<last-page>54</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Helyer, L.K., Varnic, M., Le, L.W., Leong, W., McCready, D.: Obesity is a risk factor for developing postoperative lymphedema in breast cancer patients. Breast J. 16, 48–54 (2010)</ref-fulltext>
<ce:source-text>Helyer, L.K., Varnic, M., Le, L.W., Leong, W., McCready, D.: Obesity is a risk factor for developing postoperative lymphedema in breast cancer patients. Breast J. 16, 48–54 (2010)</ce:source-text>
</reference>
</bibliography>
</tail>
</bibrecord>
</unit-content>
</unit>
</units>